{"version":3,"sources":["src/icon.png","src/overlay.ts","src/components/twitt.tsx","src/data/index.ts","src/data/output/guidelineList.ts","src/data/output/changeList.ts","src/feed.tsx","src/data/output/filelist.js","src/message.tsx","src/components/notificationTwitt.tsx","src/changes.tsx","src/all.tsx","src/notifications.tsx","src/bottomTabs.tsx","src/components/detailedTwitt.tsx","src/details.tsx","src/stack.tsx","src/context/preferencesContext.ts","src/drawerContent.tsx","src/rootNavigator.tsx","src/main.tsx","App.tsx","web-build/register-service-worker.js"],"names":["module","exports","overlay","elevation","surfaceColor","DarkTheme","colors","surface","Animated","Value","inputRange","interpolate","outputRange","map","calculateColor","overlayTransparency","elevationOverlayTransparency","color","mix","hex","1","2","3","4","5","6","7","8","9","10","11","12","13","14","15","16","17","18","19","20","21","22","23","24","Twitt","props","useTheme","onPress","id","style","styles","container","View","leftColumn","MaterialCommunityIcons","name","size","rightColumn","topRow","StyleSheet","create","flexDirection","paddingTop","paddingRight","width","marginRight","alignItems","flex","twitts","notificationTweets","renderItem","item","keyExtractor","Feed","theme","data3","twittProps","navigation","push","data","Object","values","datum","lowerCaseName","toLowerCase","sort","a","b","useState","query","setQuery","debounceQuery","value","delay","debounceValue","setDebounceValue","useEffect","timer","setTimeout","clearTimeout","useDebounce","filteredData","setFilteredData","lowerCaseQuery","newData","filter","includes","rank","indexOf","placeholder","onChangeText","FlatList","contentContainerStyle","backgroundColor","background","ItemSeparatorComponent","height","hairlineWidth","Message","htmlString","setHtmlString","htmlFile","ScrollView","scrollViewContent","html","imagesMaxWidth","Dimensions","get","paddingHorizontal","NotificationTwitt","marginBottom","paddingBottom","AllChanges","AllNotifications","centerText","Linking","button","mode","labelStyle","justifyContent","textAlign","marginTop","initialLayout","All","Mentions","Notifications","React","index","setIndex","key","title","routes","renderScene","SceneMap","all","mentions","tabBarColor","dark","rippleColor","lighten","darken","Fragment","navigationState","onIndexChange","renderTabBar","indicatorStyle","primary","shadowColor","text","pressColor","Tab","createMaterialBottomTabNavigator","BottomTabs","route","state","useSafeArea","useIsFocused","Navigator","initialRouteName","backBehavior","shifting","activeColor","inactiveColor","alpha","rgb","string","sceneAnimationEnabled","Screen","component","options","tabBarIcon","tabBarLabel","DetailedTwitt","file","fileList","Details","params","Stack","createStackNavigator","StackNavigator","headerMode","screenOptions","header","scene","previous","descriptor","undefined","headerTitle","Header","BackAction","goBack","TouchableOpacity","marginLeft","openDrawer","Image","source","require","Content","subtitle","titleStyle","fontSize","fontWeight","subtitleStyle","console","log","PreferencesContext","createContext","rtl","toggleTheme","toggleRTL","DrawerContent","paperTheme","useContext","translateX","progress","DrawerContentScrollView","drawerContent","transform","userInfoSection","toggleDrawer","caption","Section","preference","pointerEvents","paddingLeft","lineHeight","row","section","paragraph","drawerSection","paddingVertical","Drawer","createDrawerNavigator","RootNavigator","navigationTheme","DefaultTheme","NavigationContainer","Main","colorScheme","useColorScheme","setTheme","preferences","useMemo","Provider","App","navigator","window","addEventListener","serviceWorker","register","scope","then","info","catch","error"],"mappings":"yEAAAA,EAAOC,QAAU,IAA0B,kC,iPCI5B,SAASC,IAGrB,IAFDC,EAEA,uDAFqC,EACrCC,EACA,uDADuBC,YAAUC,OAAOC,QAExC,GAAIJ,aAAqBK,IAASC,MAAO,CACvC,IAAMC,EAAa,CAAC,EAAG,EAAG,EAAG,EAAG,EAAG,IACnC,OAAOP,EAAUQ,YAAY,CAC3BD,aACAE,YAAaF,EAAWG,KAAI,SAAAV,GAC1B,OAAOW,EAAeV,EAAcD,QAI1C,OAAOW,EAAeV,EAAcD,GAEtC,SAASW,EAAeV,EAAsBD,GAC5C,IAAIY,EAQJ,OANEA,EADEZ,GAAa,GAAKA,GAAa,GACXa,EAA6Bb,GAC1CA,EAAY,GACCa,EAA6B,IAE7BA,EAA6B,GAE9CC,IAAMb,GACVc,IAAID,IAAM,SAAgC,IAAtBF,GACpBI,MAEL,IAAMH,EAAyD,CAC7DI,EAAG,EACHC,EAAG,EACHC,EAAG,EACHC,EAAG,EACHC,EAAG,GACHC,EAAG,GACHC,EAAG,KACHC,EAAG,GACHC,EAAG,KACHC,GAAI,GACJC,GAAI,KACJC,GAAI,GACJC,GAAI,MACJC,GAAI,KACJC,GAAI,MACJC,GAAI,GACJC,GAAI,MACJC,GAAI,MACJC,GAAI,MACJC,GAAI,MACJC,GAAI,KACJC,GAAI,MACJC,GAAI,MACJC,GAAI,I,gCCtCOC,EAAQ,SAACC,GACNC,qBAEd,OACE,kBAAC,kBAAD,CAAiBC,QAAS,kBAAMF,EAAME,QAAQF,EAAMG,MAClD,kBAAC,UAAD,CAASC,MAAOC,EAAOC,WACrB,kBAACC,EAAA,EAAD,CAAMH,MAAOC,EAAOG,YAClB,kBAACC,EAAA,EAAD,CACEC,KAAK,mBACLC,KAAM,GACNvC,MAAM,aAGV,kBAACmC,EAAA,EAAD,CAAMH,MAAOC,EAAOO,aAClB,kBAACL,EAAA,EAAD,CAAMH,MAAOC,EAAOQ,QAClB,kBAAC,QAAD,KAAQb,EAAMU,WAQpBL,EAASS,IAAWC,OAAO,CAC/BT,UAAW,CACTU,cAAe,MACfC,WAAY,GACZC,aAAc,IAEhBV,WAAY,CACVW,MAAO,GACPC,YAAa,GACbC,WAAY,YAEdT,YAAa,CACXU,KAAM,GAERT,OAAQ,CACNG,cAAe,MACfK,WAAY,cClDHE,ECPE,CACf,CAAEpB,GAAI,MAAOO,KAAM,uBACnB,CAAEP,GAAI,MAAOO,KAAM,0BACnB,CAAEP,GAAI,MAAOO,KAAM,qBACnB,CAAEP,GAAI,MAAOO,KAAM,gBACnB,CAAEP,GAAI,MAAOO,KAAM,mBACnB,CAAEP,GAAI,MAAOO,KAAM,UACnB,CAAEP,GAAI,MAAOO,KAAM,wCACnB,CAAEP,GAAI,MAAOO,KAAM,iBACnB,CAAEP,GAAI,MAAOO,KAAM,cACnB,CAAEP,GAAI,MAAOO,KAAM,0CACnB,CAAEP,GAAI,MAAOO,KAAM,0BACnB,CAAEP,GAAI,MAAOO,KAAM,4BACnB,CAAEP,GAAI,MAAOO,KAAM,gBACnB,CAAEP,GAAI,MAAOO,KAAM,QACnB,CAAEP,GAAI,MAAOO,KAAM,kDACnB,CAAEP,GAAI,MAAOO,KAAM,wCACnB,CAAEP,GAAI,MAAOO,KAAM,4DACnB,CAAEP,GAAI,MAAOO,KAAM,0BACnB,CAAEP,GAAI,MAAOO,KAAM,mCACnB,CAAEP,GAAI,MAAOO,KAAM,2EACnB,CAAEP,GAAI,MAAOO,KAAM,4BACnB,CAAEP,GAAI,MAAOO,KAAM,SACnB,CAAEP,GAAI,MAAOO,KAAM,gDACnB,CAAEP,GAAI,MAAOO,KAAM,cACnB,CAAEP,GAAI,MAAOO,KAAM,uBACnB,CAAEP,GAAI,MAAOO,KAAM,qBACnB,CAAEP,GAAI,MAAOO,KAAM,OACnB,CAAEP,GAAI,MAAOO,KAAM,aACnB,CAAEP,GAAI,MAAOO,KAAM,YACnB,CAAEP,GAAI,MAAOO,KAAM,yBACnB,CAAEP,GAAI,MAAOO,KAAM,gBACnB,CAAEP,GAAI,MAAOO,KAAM,YACnB,CAAEP,GAAI,MAAOO,KAAM,0BACnB,CAAEP,GAAI,MAAOO,KAAM,mBACnB,CAAEP,GAAI,MAAOO,KAAM,qBACnB,CAAEP,GAAI,MAAOO,KAAM,YACnB,CAAEP,GAAI,MAAOO,KAAM,wBACnB,CAAEP,GAAI,MAAOO,KAAM,6BACnB,CAAEP,GAAI,MAAOO,KAAM,OACnB,CAAEP,GAAI,MAAOO,KAAM,OACnB,CAAEP,GAAI,MAAOO,KAAM,gBACnB,CAAEP,GAAI,MAAOO,KAAM,8BACnB,CAAEP,GAAI,MAAOO,KAAM,oCACnB,CAAEP,GAAI,MAAOO,KAAM,iDACnB,CAAEP,GAAI,MAAOO,KAAM,oCACnB,CAAEP,GAAI,MAAOO,KAAM,kBACnB,CAAEP,GAAI,MAAOO,KAAM,0BACnB,CAAEP,GAAI,MAAOO,KAAM,wDACnB,CAAEP,GAAI,MAAOO,KAAM,wBACnB,CAAEP,GAAI,MAAOO,KAAM,kCACnB,CAAEP,GAAI,MAAOO,KAAM,iBACnB,CAAEP,GAAI,MAAOO,KAAM,mBACnB,CAAEP,GAAI,MAAOO,KAAM,OACnB,CAAEP,GAAI,MAAOO,KAAM,WACnB,CAAEP,GAAI,MAAOO,KAAM,gBACnB,CAAEP,GAAI,MAAOO,KAAM,cACnB,CAAEP,GAAI,MAAOO,KAAM,qBACnB,CAAEP,GAAI,MAAOO,KAAM,sBACnB,CAAEP,GAAI,MAAOO,KAAM,kBACnB,CAAEP,GAAI,MAAOO,KAAM,gBACnB,CAAEP,GAAI,MAAOO,KAAM,oBACnB,CAAEP,GAAI,MAAOO,KAAM,mBACnB,CAAEP,GAAI,MAAOO,KAAM,WACnB,CAAEP,GAAI,MAAOO,KAAM,2BACnB,CAAEP,GAAI,MAAOO,KAAM,YACnB,CAAEP,GAAI,MAAOO,KAAM,oBACnB,CAAEP,GAAI,MAAOO,KAAM,uBACnB,CAAEP,GAAI,MAAOO,KAAM,aACnB,CAAEP,GAAI,MAAOO,KAAM,4BACnB,CAAEP,GAAI,MAAOO,KAAM,OACnB,CAAEP,GAAI,MAAOO,KAAM,UACnB,CAAEP,GAAI,MAAOO,KAAM,MACnB,CAAEP,GAAI,MAAOO,KAAM,+BACnB,CAAEP,GAAI,MAAOO,KAAM,UACnB,CAAEP,GAAI,MAAOO,KAAM,sCACnB,CAAEP,GAAI,MAAOO,KAAM,QDjENc,EEXE,CACf,CAAErB,GAAI,EAAGO,KAAM,uEACf,CAAEP,GAAI,EAAGO,KAAM,iMACf,CAAEP,GAAI,EAAGO,KAAM,kN,ikBCyBf,SAASe,EAAT,GAAqD,IAA/BC,EAA8B,EAA9BA,KACpB,OAAO,kBAAC,EAAUA,GAGpB,SAASC,EAAaD,GACpB,OAAOA,EAAKvB,GAOP,IAAMyB,EAAO,SAAC5B,GACnB,IAAM6B,EAAQ5B,qBAER6B,EAAQP,EAAOvD,KAAI,SAAA+D,GAAU,cAC9BA,GAD8B,IAEjC7B,QAAS,kBACPF,EAAMgC,YACNhC,EAAMgC,WAAWC,KAAK,UAAtB,KACKF,UAIHG,EAAOC,OAAOC,OAAON,GACxB9D,KAAI,SAAAqE,GAAK,cACLA,GADK,IAERC,cAAeD,EAAM3B,KAAK6B,mBAE3BC,MAAK,SAACC,EAAGC,GAAJ,OAAUD,EAAE/B,KAAOgC,EAAEhC,QAjBO,EAmBViC,mBAAS,IAnBC,WAmB7BC,EAnB6B,KAmBtBC,EAnBsB,KAoB9BC,EAnDY,SAACC,EAAYC,GAAmB,IAAD,EACPL,mBAASI,GADF,WAC1CE,EAD0C,KAC3BC,EAD2B,KAajD,OAVAC,qBAAU,WACR,IAAMC,EAAQC,YAAW,WACvBH,EAAiBH,KAChBC,GAEH,OAAO,WACLM,aAAaF,MAEd,CAACL,EAAOC,IAEJC,EAsCeM,CAAYX,EAAO,KApBL,EAqBID,mBAAST,GArBb,WAqB7BsB,EArB6B,KAqBfC,EArBe,KAoCpC,OAbAN,qBAAU,WACR,IAAMO,EAAiBZ,EAAcP,cAC/BoB,EAAUzB,EACb0B,QAAO,SAACvB,GAAD,OAAWA,EAAMC,cAAcuB,SAASH,MAC/C1F,KAAI,SAACqE,GAAD,cACAA,GADA,IAEHyB,KAAMzB,EAAMC,cAAcyB,QAAQL,QAEnClB,MAAK,SAACC,EAAGC,GAAJ,OAAUD,EAAEqB,KAAOpB,EAAEoB,QAE7BL,EAAgBE,KACf,CAACb,IAGF,kBAACvC,EAAA,EAAD,KACI,kBAAC,YAAD,CACIyD,YAAY,oBACZC,aAAcpB,EACdE,MAAOH,IAEX,kBAACsB,EAAA,EAAD,CACEC,sBAAuB,CAAEC,gBAAiBvC,EAAMpE,OAAO4G,YACvDjE,MAAO,CAAEgE,gBAAiBvC,EAAMpE,OAAO4G,YACvCnC,KAAMsB,EACN/B,WAAYA,EACZE,aAAcA,EACd2C,uBAAwB,kBACtB,kBAAC/D,EAAA,EAAD,CAAMH,MAAO,CAAEmE,OAAQzD,IAAW0D,sB,yBC1F/B,GACf,MAAO,6wxBACP,MAAO,i9xBACP,MAAO,2q/BACP,MAAO,ozlBACP,MAAO,o79EACP,MAAO,q2iCACP,MAAO,qjqBACP,MAAO,wwrBACP,MAAO,wk0BACP,MAAO,8oyCACP,MAAO,2l6FACP,MAAO,mwzBACP,MAAO,uluBACP,MAAO,ugrBACP,MAAO,wg6BACP,MAAO,0z8BACP,MAAO,+/4BACP,MAAO,wqyBACP,MAAO,souEACP,MAAO,yqpQACP,MAAO,spjIACP,MAAO,qn4DACP,MAAO,mn2BACP,MAAO,wh2BACP,MAAO,2i8CACP,MAAO,ugmCACP,MAAO,ym8BACP,MAAO,wgyEACP,MAAO,+riFACP,MAAO,i/iBACP,MAAO,kkgBACP,MAAO,+qmCACP,MAAO,gpqBACP,MAAO,m8sIACP,MAAO,gvhBACP,MAAO,qyuBACP,MAAO,83uBACP,MAAO,ou3BACP,MAAO,ouqBACP,MAAO,2hqBACP,MAAO,2voGACP,MAAO,i0pBACP,MAAO,sjlBACP,MAAO,kquBACP,MAAO,4wwBACP,MAAO,iqpGACP,MAAO,8o9BACP,MAAO,+oqBACP,MAAO,uhpBACP,MAAO,sm/BACP,MAAO,m/gCACP,MAAO,w7wEACP,MAAO,+8yBACP,MAAO,8kyBACP,MAAO,mrlJACP,MAAO,o15BACP,MAAO,6irBACP,MAAO,28sBACP,MAAO,+4mBACP,MAAO,w3oBACP,MAAO,ym1BACP,MAAO,qteACP,MAAO,y6tBACP,MAAO,6mrBACP,MAAO,kmkBACP,MAAO,g+oBACP,MAAO,i81BACP,MAAO,+8qBACP,MAAO,4r8BACP,MAAO,+iwBACP,MAAO,ojzBACP,MAAO,u7mBACP,MAAO,wutBACP,MAAO,+rzBACP,MAAO,y2jBACP,MAAO,gj2BC/DMC,EAAU,WAGGpH,EAAQ,EAFlB4C,qBAE2BxC,OAAOC,SAFhD,IAD2B,EAMSiF,mBADvB,2BALc,WAMpB+B,EANoB,KAMRC,EANQ,KAc3B,OANAxB,qBAAU,WAGRwB,EADoBC,EADL,WAMX,kBAACC,EAAA,EAAD,CAAYV,sBAAwB9D,EAAOyE,mBAChD,kBAAC,IAAD,CAAMC,KAAML,EAAYM,eAAiBC,IAAWC,IAAI,UAAU/D,UAM/Dd,EAASS,IAAWC,OAAO,CAC/B+D,kBAAmB,CACjBK,kBAAmB,M,0BC1BVC,EAAoB,SAACpF,GAClBC,qBAEd,OACE,kBAAC,UAAD,CAASG,MAAOC,EAAOC,WACrB,kBAACC,EAAA,EAAD,CAAMH,MAAOC,EAAOG,YAClB,kBAACC,EAAA,EAAD,CACEC,KAAK,mBACLC,KAAM,GACNvC,MAAM,aAGV,kBAACmC,EAAA,EAAD,CAAMH,MAAOC,EAAOO,aAClB,kBAAC,OAAD,CAAMR,MAAO,CAAEiF,aAAc,KAC1BrF,EAAMU,SAOXL,EAASS,IAAWC,OAAO,CAC/BT,UAAW,CACTU,cAAe,MACfC,WAAY,GACZC,aAAc,GACdoE,cAAe,IAEjB9E,WAAY,CACVW,MAAO,GACPC,YAAa,GACbC,WAAY,YAEdT,YAAa,CACXU,KAAM,GAERT,OAAQ,CACNG,cAAe,MACfK,WAAY,SACZgE,aAAc,MCzClB,SAAS5D,EAAT,GAAiE,IAA3CC,EAA0C,EAA1CA,KACpB,OAAO,kBAAC,EAAsBA,GAGhC,SAASC,EAAaD,GACpB,OAAOA,EAAKvB,GAGP,IAAMoF,EAAa,WACxB,IAAM1D,EAAQ5B,qBAEd,OACE,kBAACiE,EAAA,EAAD,CACEC,sBAAuB,CAAEC,gBAAiBvC,EAAMpE,OAAO4G,YACvDjE,MAAO,CAAEgE,gBAAiBvC,EAAMpE,OAAO4G,YACvCnC,KAAMV,EACNC,WAAYA,EACZE,aAAcA,EACd2C,uBAAwB,kBACtB,kBAAC/D,EAAA,EAAD,CAAMH,MAAO,CAAEmE,OAAQzD,IAAW0D,qB,SCrB7BgB,GAAmB,WAC9B,IAEMpB,EAAkB/G,EAAQ,EAFlB4C,qBAE2BxC,OAAOC,SAMhD,OACE,kBAACmH,EAAA,EAAD,CACEzE,MAAO,CAAEgE,mBACTD,sBAAuB,CAAC9D,GAAOyE,kBAAmB,CAAEV,qBAEpD,kBAAC,WAAD,CAAUhE,MAAOC,GAAOoF,YAAxB,6CAGA,kBAAC,UAAD,CAASrF,MAAOC,GAAOoF,YAAvB,oLACoL,KADpL,6KACoW,KADpW,oDAGA,kBAAC,SAAD,CACEvF,QAhBe,WACnBwF,UAAgB,0BAgBZtF,MAAOC,GAAOsF,OACdC,KAAK,YACLC,WAAY,CAAEzH,MAAO,UAJvB,gBAYAiC,GAASS,IAAWC,OAAO,CAC/B+D,kBAAmB,CACjBxD,KAAM,EACN6D,kBAAmB,GACnBW,eAAgB,SAChBzE,WAAY,UAEdoE,WAAY,CACVM,UAAW,UAEbJ,OAAQ,CACNK,UAAW,MCxCTC,GAAgB,CAAE9E,MAAO8D,IAAWC,IAAI,UAAU/D,OAElD+E,GAAM,kBAAM,kBAAC,GAAD,OAEZC,GAAW,kBAAM,kBAAC,EAAD,OAEVC,GAAgB,WAAO,IAAD,EACPC,IAAM1D,SAAS,GADR,WAC1B2D,EAD0B,KACnBC,EADmB,OAEhBF,IAAM1D,SAAS,CAC9B,CAAE6D,IAAK,MAAOC,MAAO,SACrB,CAAED,IAAK,WAAYC,MAAO,gBAFrBC,EAF0B,YAO3B7E,EAAQ5B,qBAER0G,EAAcC,YAAS,CAC3BC,IAAKX,GACLY,SAAUX,KAGNY,EAAclF,EAAMmF,KACrB3J,EAAQ,EAAGwE,EAAMpE,OAAOC,SACzBmE,EAAMpE,OAAOC,QAEXuJ,EAAcpF,EAAMmF,KACtB5I,IAAM2I,GAAaG,QAAQ,IAC3B9I,IAAM2I,GAAaI,OAAO,IAY9B,OACE,kBAAC,IAAMC,SAAP,KACE,kBAAC,IAAD,CACEC,gBAAiB,CAAEf,QAAOI,UAC1BC,YAAaA,EACbW,cAAef,EACfN,cAAeA,GACfsB,aAjBe,SAAAvH,GAAK,OACxB,kBAAC,IAAD,OACMA,EADN,CAEEwH,eAAgB,CAAEpD,gBAAiBvC,EAAMpE,OAAOgK,SAChDrH,MAAO,CAAEgE,gBAAiB2C,EAAaW,YAAa7F,EAAMpE,OAAOkK,MACjE9B,WAAY,CAAEzH,MAAOyD,EAAMpE,OAAOgK,SAClCG,WAAYX,UC/BZY,GAAMC,cAMCC,GAAa,SAAC/H,GACPA,EAAMgI,MAAMC,OAC1BjI,EAAMgI,MAAMC,MAAMvB,OAAO1G,EAAMgI,MAAMC,MAAM3B,OAAO5F,KADtD,IAIMmB,EAAQ5B,qBAIR8G,GAHWmB,cACCC,yBAEEtG,EAAMmF,KACrB3J,EAAQ,EAAGwE,EAAMpE,OAAOC,SACzBmE,EAAMpE,OAAOC,SAEjB,OACE,kBAAC,IAAM0J,SAAP,KACE,kBAACS,GAAIO,UAAL,CACEC,iBAAiB,WACjBC,aAAa,eACbC,UAAU,EACVC,YAAa3G,EAAMpE,OAAOgK,QAC1BgB,cAAerK,IAAMyD,EAAMpE,OAAOkK,MAC/Be,MAAM,IACNC,MACAC,SACHC,uBAAuB,GAEvB,kBAAChB,GAAIiB,OAAL,CACEpI,KAAK,WACLqI,UAAWtE,EACXuE,QAAS,CACPC,WAAY,eACZC,YAAa,OACbnC,iBAGJ,kBAACc,GAAIiB,OAAL,CACEpI,KAAK,OACLqI,UAAWnH,EACXoH,QAAS,CACPC,WAAY,yBACZC,YAAa,SACbnC,iBAGJ,kBAACc,GAAIiB,OAAL,CACEpI,KAAK,gBACLqI,UAAW3C,GACX4C,QAAS,CACPC,WAAY,sBACZC,YAAa,OACbnC,oBCvDCoC,GAAgB,SAACnJ,GACdC,qBAAd,IACMmJ,EAAOpJ,EAAMG,GACbuE,EAAa2E,EAASD,GAC5B,OACM,kBAACvE,EAAA,EAAD,CAAYV,sBAAwB9D,GAAOyE,mBAChD,kBAAC,IAAD,CAAMC,KAAML,EAAYM,eAAiBC,IAAWC,IAAI,UAAU/D,UAK/Dd,GAASS,IAAWC,OAAO,CAC/B+D,kBAAmB,CACjBK,kBAAmB,MCjBVmE,GAAU,SAACtJ,GACtB,OAAO,kBAAC,GAAkBA,EAAMgI,MAAMuB,SCAlCC,GAAQC,cAEDC,GAAiB,WAC5B,IAAM7H,EAAQ5B,qBAEd,OACE,kBAACuJ,GAAMpB,UAAP,CACEC,iBAAiB,WACjBsB,WAAW,SACXC,cAAe,CACbC,OAAQ,YAAsC,IAAnCC,EAAkC,EAAlCA,MAAOC,EAA2B,EAA3BA,SAAU/H,EAAiB,EAAjBA,WAClBgH,EAAYc,EAAME,WAAlBhB,aAEkBiB,IAAxBjB,EAAQkB,YACJlB,EAAQkB,iBACUD,IAAlBjB,EAAQvC,MACRuC,EAAQvC,MACRqD,EAAM9B,MAAMtH,KAElB,OACE,kBAAC,SAAOyJ,OAAR,CACEtI,MAAO,CAAEpE,OAAQ,CAAEgK,QAAS5F,EAAMpE,OAAOC,WAExCqM,EACC,kBAAC,SAAOK,WAAR,CACElK,QAAS8B,EAAWqI,OACpBjM,MAAOyD,EAAMpE,OAAOgK,UAGtB,kBAAC6C,EAAA,EAAD,CACElK,MAAO,CAAEmK,WAAY,IACrBrK,QAAS,WACL8B,EAAgDwI,eAGpD,kBAAC,SAAOC,MAAR,CACE9J,KAAM,GACN+J,OAAQC,EAAQ,QAItB,kBAAC,SAAOC,QAAR,CACEnE,MACI,iBAEJoE,SACI,+BAEJC,WAAY,CACVC,SAAU,GACVC,WAAY,OACZ5M,MAAOyD,EAAMpE,OAAOgK,SAEtBwD,cAAe,CACbF,SAAU,GACVC,WAAY,OACZ5M,MAAOyD,EAAMpE,OAAOkK,YAQhC,kBAAC6B,GAAMV,OAAP,CACEpI,KAAK,WACLqI,UAAWhB,GACXiB,QAAS,YAAgB,IAAbhB,EAAY,EAAZA,MAKV,OAJAkD,QAAQC,IAAI,cAAe,CAAEnD,UAItB,CAAEkC,YAHSlC,EAAMC,MACpBD,EAAMC,MAAMvB,OAAOsB,EAAMC,MAAM3B,OAAO5F,KACtC,WAIR,kBAAC8I,GAAMV,OAAP,CACEpI,KAAK,UACLqI,UAAWO,GACXN,QAAS,CAAEkB,YAAa,a,mBChFnBkB,GAAqB/E,IAAMgF,cAAsC,CAC5EC,IAAK,OACLzJ,MAAO,QACP0J,YAAa,aACbC,UAAW,eCaN,SAASC,GAAczL,GAC5B,IAAM0L,EAAazL,qBADuB,EAEXoG,IAAMsF,WACnCP,IADMvJ,EAFkC,EAElCA,MAAO0J,EAF2B,EAE3BA,YAITK,EAAajO,KAASG,YAAYkC,EAAM6L,SAAU,CACtDhO,WAAY,CAAC,EAAG,GAAK,GAAK,GAAK,GAC/BE,YAAa,EAAE,KAAM,IAAK,IAAK,GAAI,KAGrC,OACE,kBAAC+N,GAAA,EAA4B9L,EAC3B,kBAAC,KAASO,KAAV,CAEEH,MAAO,CACLC,GAAO0L,cACP,CACE3H,gBAAiBsH,EAAWjO,OAAOC,QACnCsO,UAAW,CAAC,CAAEJ,kBAIlB,kBAACrL,EAAA,EAAD,CAAMH,MAAOC,GAAO4L,iBAClB,kBAAC3B,EAAA,EAAD,CACElK,MAAO,CAAEmK,WAAY,IACrBrK,QAAS,WACPF,EAAMgC,WAAWkK,iBAGnB,kBAAC,SAAOzB,MAAR,CACEC,OAAQC,EAAQ,KAChBhK,KAAM,MAGV,kBAAC,QAAD,CAAOP,MAAOC,GAAOoG,OAArB,kBACA,kBAAC,UAAD,CAASrG,MAAOC,GAAO8L,SAAvB,2BAEF,kBAAC,SAAOC,QAAR,CAAgB3F,MAAM,eACpB,kBAAC,kBAAD,CAAiBvG,QAASqL,GACxB,kBAAChL,EAAA,EAAD,CAAMH,MAAOC,GAAOgM,YAClB,kBAAC,OAAD,mBACA,kBAAC9L,EAAA,EAAD,CAAM+L,cAAc,QAClB,kBAAC,SAAD,CAAQvJ,MAAiB,SAAVlB,UAU/B,IAAMxB,GAASS,IAAWC,OAAO,CAC/BgL,cAAe,CACbzK,KAAM,GAER2K,gBAAiB,CACfM,YAAa,IAEf9F,MAAO,CACLT,UAAW,GACXgF,WAAY,QAEdmB,QAAS,CACPpB,SAAU,GACVyB,WAAY,IAEdC,IAAK,CACHzG,UAAW,GACXhF,cAAe,MACfK,WAAY,UAEdqL,QAAS,CACP1L,cAAe,MACfK,WAAY,SACZD,YAAa,IAEfuL,UAAW,CACT3B,WAAY,OACZ5J,YAAa,GAEfwL,cAAe,CACb5G,UAAW,IAEbqG,WAAY,CACVrL,cAAe,MACf8E,eAAgB,gBAChB+G,gBAAiB,GACjB1H,kBAAmB,MC1GjB2H,GAASC,cAEFC,GAAgB,WAC3B,IACMC,EADQhN,qBACgB+G,KAAOxJ,IAAY0P,IAEjD,OACE,kBAACC,EAAA,EAAD,CAAqBtL,MAAOoL,GAC1B,kBAACH,GAAO1E,UAAR,CAAkB2D,cAAe,SAAA/L,GAAK,OAAI,kBAACyL,GAAkBzL,KAC3D,kBAAC8M,GAAOhE,OAAR,CAAepI,KAAK,OAAOqI,UAAWW,Q,qkBCNvC,IAAM0D,GAAO,WAClB,IAAMC,EAAcC,2BADI,EAEEjH,IAAM1D,SACd,SAAhB0K,EAAyB,OAAS,SAHZ,WAEjBxL,EAFiB,KAEV0L,EAFU,KAMxB,SAAShC,IACPgC,GAAS,SAAA1L,GAAK,MAAe,UAAVA,EAAoB,OAAS,WAGlD,IAAM2L,EAAcnH,IAAMoH,SACxB,iBAAO,CACLlC,cACA1J,WAEF,CAACA,IAGH,OACE,kBAACuJ,GAAmBsC,SAApB,CAA6B3K,MAAOyK,GAClC,kBAAC,WAAD,CACE3L,MACY,UAAVA,EAAA,SAESqL,gBAFT,IAGMzP,OAAO,SAAMyP,eAAazP,QAApB,IAA4BgK,QAAS,cAHjD,SAMSjK,aANT,IAOMC,OAAO,SAAMD,YAAUC,QAAjB,IAAyBgK,QAAS,eAIhD,kBAAC,GAAD,SCvCO,SAASkG,KACtB,OACE,kBAAC,IAAD,KACE,kBAAC,qBAAD,KACE,kBAAC,GAAD,U,+DCRJ,kBAAmBC,WACrBC,OAAOC,iBAAiB,QAAQ,WAC9BF,UAAUG,cACPC,SAAS,0BAA2B,CAAEC,MAAO,MAC7CC,MAAK,SAAUC,OAGfC,OAAM,SAAUC,GACfnD,QAAQiD,KAAK,oCAAqCE,U","file":"static/js/app.90599352.chunk.js","sourcesContent":["module.exports = __webpack_public_path__ + \"static/media/icon.0f0f045d.png\";","import color from 'color';\r\nimport { Animated } from 'react-native';\r\nimport { DarkTheme } from 'react-native-paper';\r\n\r\nexport default function overlay(\r\n  elevation: number | Animated.Value = 1,\r\n  surfaceColor: string = DarkTheme.colors.surface\r\n) {\r\n  if (elevation instanceof Animated.Value) {\r\n    const inputRange = [0, 1, 2, 3, 8, 24];\r\n    return elevation.interpolate({\r\n      inputRange,\r\n      outputRange: inputRange.map(elevation => {\r\n        return calculateColor(surfaceColor, elevation);\r\n      }),\r\n    });\r\n  }\r\n  return calculateColor(surfaceColor, elevation);\r\n}\r\nfunction calculateColor(surfaceColor: string, elevation: number) {\r\n  let overlayTransparency: number;\r\n  if (elevation >= 1 && elevation <= 24) {\r\n    overlayTransparency = elevationOverlayTransparency[elevation];\r\n  } else if (elevation > 24) {\r\n    overlayTransparency = elevationOverlayTransparency[24];\r\n  } else {\r\n    overlayTransparency = elevationOverlayTransparency[1];\r\n  }\r\n  return color(surfaceColor)\r\n    .mix(color('white'), overlayTransparency * 0.01)\r\n    .hex();\r\n}\r\nconst elevationOverlayTransparency: { [id: number]: number } = {\r\n  1: 5,\r\n  2: 7,\r\n  3: 8,\r\n  4: 9,\r\n  5: 10,\r\n  6: 11,\r\n  7: 11.5,\r\n  8: 12,\r\n  9: 12.5,\r\n  10: 13,\r\n  11: 13.5,\r\n  12: 14,\r\n  13: 14.25,\r\n  14: 14.5,\r\n  15: 14.75,\r\n  16: 15,\r\n  17: 15.12,\r\n  18: 15.24,\r\n  19: 15.36,\r\n  20: 15.48,\r\n  21: 15.6,\r\n  22: 15.72,\r\n  23: 15.84,\r\n  24: 16,\r\n};\r\n","import React from 'react';\r\nimport { StyleSheet, View, TouchableOpacity } from 'react-native';\r\nimport {\r\n  Surface,\r\n  Title,\r\n  Text,\r\n  TouchableRipple,\r\n  useTheme,\r\n} from 'react-native-paper';\r\nimport { MaterialCommunityIcons } from '@expo/vector-icons';\r\nimport color from 'color';\r\n\r\ntype Props = {\r\n  id: string;\r\n  name: string;\r\n  onPress: (id: number) => void;\r\n};\r\n\r\nexport const Twitt = (props: Props) => {\r\n  const theme = useTheme();\r\n  \r\n  return (\r\n    <TouchableRipple onPress={() => props.onPress(props.id)}>\r\n      <Surface style={styles.container}>\r\n        <View style={styles.leftColumn}>\r\n          <MaterialCommunityIcons\r\n            name=\"star-four-points\"\r\n            size={30}\r\n            color=\"#8d38e8\"\r\n          />\r\n        </View>\r\n        <View style={styles.rightColumn}>\r\n          <View style={styles.topRow}>\r\n            <Title>{props.name}</Title>\r\n          </View>\r\n        </View>\r\n      </Surface>\r\n    </TouchableRipple>\r\n  );\r\n};\r\n\r\nconst styles = StyleSheet.create({\r\n  container: {\r\n    flexDirection: 'row',\r\n    paddingTop: 15,\r\n    paddingRight: 15,\r\n  },\r\n  leftColumn: {\r\n    width: 40,\r\n    marginRight: 10,\r\n    alignItems: 'flex-end',\r\n  },\r\n  rightColumn: {\r\n    flex: 1,\r\n  },\r\n  topRow: {\r\n    flexDirection: 'row',\r\n    alignItems: 'baseline',\r\n  },\r\n});\r\n","import { Twitt } from '../components/twitt';\r\nimport { NotificationTwitt } from '../components/notificationTwitt';\r\nimport changeList from './output/changeList.ts';\r\nimport guidelineList from './output/guidelineList.ts';\r\n\r\ntype TwittProps = React.ComponentProps<typeof Twitt>;\r\n\r\nexport const twitts: Omit<TwittProps, 'onPress'>[] = guidelineList;\r\n\r\ntype NotificationTwittProps = React.ComponentProps<typeof NotificationTwitt>;\r\n\r\nexport const notificationTweets: Array<NotificationTwittProps> = changeList;\r\n","export default [\n{ id: \"071\", name: \"Acute kidney injury\", },\n{ id: \"048\", name: \"Acute rheumatic fever \", },\n{ id: \"077\", name: \"Anaemia in adults\", },\n{ id: \"049\", name: \"Animal bites\", },\n{ id: \"081\", name: \"Anticoagulation\", },\n{ id: \"001\", name: \"Asthma\", },\n{ id: \"050\", name: \"Bone and joint infections guidelines\", },\n{ id: \"069\", name: \"Bronchiolitis\", },\n{ id: \"051\", name: \"Cellulitis\", },\n{ id: \"052\", name: \"Chest pain and Acute Coronary Syndrome\", },\n{ id: \"053\", name: \"Chronic kidney disease\", },\n{ id: \"039\", name: \"Congenital heart disease\", },\n{ id: \"003\", name: \"Constipation\", },\n{ id: \"032\", name: \"COPD\", },\n{ id: \"083\", name: \"COVID-19 Adults with mild or moderate COVID-19\", },\n{ id: \"084\", name: \"COVID-19 Adults with severe COVID-19\", },\n{ id: \"082\", name: \"COVID-19 Children with Suspected  or Confirmed Infection\", },\n{ id: \"089\", name: \"COVID-19 Communication\", },\n{ id: \"086\", name: \"COVID-19 Infection in Pregnancy\", },\n{ id: \"085\", name: \"COVID-19 Neonates born to mothers with confirmed or suspected infection\", },\n{ id: \"088\", name: \"COVID-19 Palliative care\", },\n{ id: \"059\", name: \"Croup\", },\n{ id: \"055\", name: \"Deep venous thombosis and pulmonary embolism\", },\n{ id: \"075\", name: \"Depression\", },\n{ id: \"054\", name: \"Developmental delay\", },\n{ id: \"004\", name: \"Diabetes Mellitus\", },\n{ id: \"021\", name: \"DKA\", },\n{ id: \"034\", name: \"Dyspepsia\", },\n{ id: \"070\", name: \"Ear pain\", },\n{ id: \"078\", name: \"Endoscopy indications\", },\n{ id: \"063\", name: \"Epiglottitis\", },\n{ id: \"056\", name: \"Epilepsy\", },\n{ id: \"057\", name: \"Fungal Skin Infections\", },\n{ id: \"033\", name: \"Gastroenteritis\", },\n{ id: \"007\", name: \"General Body Pain\", },\n{ id: \"045\", name: \"Headache\", },\n{ id: \"040\", name: \"Heart failure adults\", },\n{ id: \"091\", name: \"Hepatitis B and Fibroscan\", },\n{ id: \"046\", name: \"HHS\", },\n{ id: \"035\", name: \"HIV\", },\n{ id: \"010\", name: \"Hypertension\", },\n{ id: \"027\", name: \"Hyperthyroidism and goitre\", },\n{ id: \"074\", name: \"Hypocalcaemia and hypercalcaemia\", },\n{ id: \"073\", name: \"Hypokalaemia, hyperkalaemia, hypermagnesaemia\", },\n{ id: \"072\", name: \"Hyponatraemia and hypernatraemia\", },\n{ id: \"036\", name: \"Hypothyroidism\", },\n{ id: \"058\", name: \"Infective Endocarditis\", },\n{ id: \"041\", name: \"Inflammatory arthritis and connective tissue disease\", },\n{ id: \"009\", name: \"Intestinal helminths\", },\n{ id: \"047\", name: \"Introduction and abbreviations\", },\n{ id: \"031\", name: \"Liver disease\", },\n{ id: \"022\", name: \"Lower back pain\", },\n{ id: \"011\", name: \"LRI\", },\n{ id: \"012\", name: \"Malaria\", },\n{ id: \"037\", name: \"Malnutrition\", },\n{ id: \"028\", name: \"Meningitis\", },\n{ id: \"060\", name: \"Neonatal jaundice\", },\n{ id: \"061\", name: \"Nephrotic Syndrome\", },\n{ id: \"042\", name: \"Osteoarthritis\", },\n{ id: \"023\", name: \"Otitis media\", },\n{ id: \"064\", name: \"Palliative Care \", },\n{ id: \"015\", name: \"Rectal prolapse\", },\n{ id: \"029\", name: \"Red eye\", },\n{ id: \"065\", name: \"Rheumatic heart disease\", },\n{ id: \"066\", name: \"Scabies \", },\n{ id: \"043\", name: \"Sepsis in adults\", },\n{ id: \"076\", name: \"Sickle cell disease\", },\n{ id: \"062\", name: \"Sinusitis\", },\n{ id: \"067\", name: \"Stevens-Johnson syndrome\", },\n{ id: \"038\", name: \"STI\", },\n{ id: \"020\", name: \"Stroke\", },\n{ id: \"044\", name: \"TB\", },\n{ id: \"024\", name: \"Tonsillitis and pharyngitis\", },\n{ id: \"068\", name: \"Trauma\", },\n{ id: \"018\", name: \"Upper respiratory tract infections\", },\n{ id: \"019\", name: \"UTI\", },\n ]","export default [\n{ id: 1, name: \"18th May 2020: App changed to Expo framework from Cordova/Phonegap.\", },\n{ id: 2, name: \"20th May 2020: This version of the app features a new bright look with a more user-friendly updating system. We have added the current guidelines for management of COVID-19 in the Unit.\\r\\n\", },\n{ id: 3, name: \"21st May 2020: If you can read this, it just means that we have succesfully performed continuous delivery and continuous integration with Github Actions and Expo! You can safely ignore the tech babble!\\r\\n\", },\n ]","import React, { useState, useEffect } from 'react';\r\nimport { FlatList, View, StyleSheet } from 'react-native';\r\nimport { StackNavigationProp } from '@react-navigation/stack';\r\nimport { useTheme, Searchbar } from 'react-native-paper';\r\n\r\nimport { Twitt } from './components/twitt';\r\nimport { twitts } from './data';\r\nimport { StackNavigatorParamlist } from './types';\r\n\r\nconst useDebounce = (value: any, delay: number) => {\r\n  const [debounceValue, setDebounceValue] = useState(value);\r\n\r\n  useEffect(() => {\r\n    const timer = setTimeout(() => {\r\n      setDebounceValue(value);\r\n    }, delay);\r\n\r\n    return () => {\r\n      clearTimeout(timer);\r\n    };\r\n  }, [value, delay]);\r\n\r\n  return debounceValue;\r\n};\r\n\r\n\r\ntype TwittProps = React.ComponentProps<typeof Twitt>;\r\n\r\nfunction renderItem({ item }: { item: TwittProps }) {\r\n  return <Twitt {...item} />;\r\n}\r\n\r\nfunction keyExtractor(item: TwittProps) {\r\n  return item.id;\r\n}\r\n\r\ntype Props = {\r\n  navigation?: StackNavigationProp<StackNavigatorParamlist>;\r\n};\r\n\r\nexport const Feed = (props: Props) => {\r\n  const theme = useTheme();\r\n\r\n  const data3 = twitts.map(twittProps => ({\r\n    ...twittProps,\r\n    onPress: () =>\r\n      props.navigation &&\r\n      props.navigation.push('Details', {\r\n        ...twittProps,\r\n      }),\r\n  }))\r\n  \r\n  const data = Object.values(data3)\r\n    .map(datum => ({\r\n      ...datum,\r\n      lowerCaseName: datum.name.toLowerCase(),\r\n    }))\r\n    .sort((a, b) => a.name > b.name);\r\n    \r\n  const [query, setQuery] = useState('');\r\n  const debounceQuery = useDebounce(query, 200);\r\n  const [filteredData, setFilteredData] = useState(data);\r\n\r\n  useEffect(() => {\r\n    const lowerCaseQuery = debounceQuery.toLowerCase();\r\n    const newData = data\r\n      .filter((datum) => datum.lowerCaseName.includes(lowerCaseQuery))\r\n      .map((datum) => ({\r\n        ...datum,\r\n        rank: datum.lowerCaseName.indexOf(lowerCaseQuery),\r\n      }))\r\n      .sort((a, b) => a.rank - b.rank);\r\n\r\n    setFilteredData(newData);\r\n  }, [debounceQuery]);\r\n  \r\n  return (\r\n    <View>\r\n        <Searchbar\r\n            placeholder=\"Search Guidelines\"\r\n            onChangeText={setQuery}\r\n            value={query}\r\n        />\r\n        <FlatList\r\n          contentContainerStyle={{ backgroundColor: theme.colors.background }}\r\n          style={{ backgroundColor: theme.colors.background }}\r\n          data={filteredData}\r\n          renderItem={renderItem}\r\n          keyExtractor={keyExtractor}\r\n          ItemSeparatorComponent={() => (\r\n            <View style={{ height: StyleSheet.hairlineWidth }} />\r\n          )}\r\n        />\r\n    </View>\r\n  );\r\n};\r\n","export default {\n\"071\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>Acute kidney injury MeG-CLS-071</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"acute-kidney-injury\\\">Acute Kidney Injury </h1>\\r\\n<h2 id=\\\"executive-summary\\\"><em>Executive summary</em></h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<p>Acute kidney injury (AKI) is an abrupt decline in renal function usually taking place over hours to days. It is defined by a reduction in urine output and / or a laboratory diagnosis of a decline in renal function i.e. increased serum creatinine (Cr) or reduced glomerular filtration rate (GFR). Acute kidney is a significant risk factor for morbidity and mortality – a moderate elevation of serum creatinine is an independent risk factor for mortality. The causes of AKI in adults are not significantly different from the causes in children, however, different criteria are used to determine the severity of AKI in each age group. AKI may progress to chronic kidney disease(CKD) and may occur in the presence of CKD. It is important to distinguish between the two conditions as interventions and prognosis are very different. The difference is usually temporal.</p>\\r\\n<h3 id=\\\"target-user\\\">Target User</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doctors</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nurses</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"target-area-of-use\\\">Target area of use </h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ward</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Outpatient department</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"key-areas-of-focus\\\">Key areas of focus </h3>\\r\\n<p>The main focus of this guideline is to stimulate doctors to recognize and manage AKI promptly. It is necessary to follow up the patients with AKI and those at risk of AKI to reduce morbidity. Furosemide use in the management of AKI is restricted to patients with signs of fluid overload.</p>\\r\\n<h3 id=\\\"limitations\\\">Limitations </h3>\\r\\n<h2 id=\\\"management-of-stage-3-aki-an-indication-for-renal-replacement-therapy-is-not-available-at-csd.-these-patients-must-be-referred-to-efsth.-patients-at-keneba-who-are-suspected-to-have-aki-should-be-referred-for-adequate-management.\\\">Management of stage 3 AKI (an indication for renal replacement therapy) is not available at CSD. These patients must be referred to EFSTH. Patients at Keneba who are suspected to have AKI should be referred for adequate management.</h2>\\r\\n<h2 id=\\\"common-causes\\\">Common causes: </h2>\\r\\n<p>The following are common causes of AKI in this region.</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Gastroenteritis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Sepsis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Malaria</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Haemorrhage</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Glomerulonephritis, especially in children</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Use of nephrotoxins – NSAIDs, aminoglycosides, ACEi / ARBs, diuretics overuse, metformin, herbal medications, contrast dyes</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Heart failure</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Liver failure</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Urinary tract obstruction - stones, tumours</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"risk-factors-for-aki\\\">Risk factors for AKI </h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Patients older than 65 years of age</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>CKD</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Heart failure</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Liver disease</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Diabetes</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Haematological malignancy</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>History of AKI</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Neurological/cognitive impairment</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Reliance on carers for fluids</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs\\\">Presenting symptoms and signs</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Reduced urine volume or absent urine</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Features suggestive of uraemia including epigastric pain, haematemesis, haematochezia, chest pain, confusion, obtundation, loss of consciousness, increased somnolence, dyspnea, abnormal bleeding and bruising, generalised body weakness</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Features of the underlying causes: fever, vomiting, diarrhoea, haematuria</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"examination-findings\\\">Examination findings</h2>\\r\\n<p>This includes features of AKI (oliguria or anuria) as well as those of the underlying cause or complications.</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Oliguria or anuria</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Fever or hypothermia</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Pallor</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Dehydration</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Jaundice</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Oedema</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"investigations\\\">Investigations</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Urinalysis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Urine microscopy</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Serum electrolytes, urea, creatinine, calcium and phosphate</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>FBC and blood film</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Renal ultrasound</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p><strong>Diagnosis of AKI</strong></p>\\r\\n<p>The diagnosis of AKI is made if any <span class=\\\"underline\\\">ONE</span> of the following criteria is fulfilled:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Increase in Cr by 26.5 µmol/l within 48 hours; or</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Increase in Cr ≥ 1.5 times baseline, which is known or presumed to have occurred within the prior 7 days; or</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Urine volume of ˂ 0.5 ml/kg/h for 6 hours (adults) or 8 hours (children); or</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>25% of greater fall in eGFR in children within past 7 days.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>The staging of AKI severity is determined by creatinine levels in adults and by creatinine clearance in children as well as urine output in both age groups</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Stage</strong></th>\\r\\n<th><strong>Children</strong></th>\\r\\n<th><strong>Adults</strong></th>\\r\\n<th></th>\\r\\n<th></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td></td>\\r\\n<td><strong>eGFR criteria</strong></td>\\r\\n<td><strong>Urine output criteria</strong></td>\\r\\n<td><strong>Creatinine criteria</strong></td>\\r\\n<td><strong>Urine output criteria</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>1</td>\\r\\n<td>eGFR decreased by 25%</td>\\r\\n<td>&lt; 0.5ml/kg/hr x 8 hours</td>\\r\\n<td><p>1.5 – 1.9 times base line Cr OR</p>\\r\\n<p>Cr ≥ 26.5µmol from base line</p></td>\\r\\n<td>&lt; 0.5 ml/kg/hr x 6 hours</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>2</td>\\r\\n<td>eGFR decreased by 50%</td>\\r\\n<td>&lt;0.5ml/kg/hr x16 hours</td>\\r\\n<td>2.0-2.9 times baseline Cr</td>\\r\\n<td>&lt;0.5 ml/kg/hr x12 hours</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>3</td>\\r\\n<td><p>eGFR decreased by 75% OR</p>\\r\\n<p>eGFR &lt; 35 ml/min/1.73m<sup>2</sup></p></td>\\r\\n<td>&lt;0.3 ml/kg/hr x 24 hours OR anuria (≤100ml) for 12 hours</td>\\r\\n<td><p>≥ 3.0 times baseline Cr</p>\\r\\n<p>OR</p>\\r\\n<p>Cr ≥ 353.6µmol/L</p>\\r\\n<p>OR</p>\\r\\n<p>Initiation of renal replacement therapy</p></td>\\r\\n<td>&lt;0.3 ml/kg/hr x 24 hours or anuria (≤100 ml) for 12 hours</td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<p>For children, the eGFR is calculated using the Bedside Schwartz formula which can be found on this link <a href=\\\"http://nephron.com/bedside_peds_nic.cgi\\\"><span data-custom-style=\\\"Hyperlink\\\">http://nephron.com/bedside_peds_nic.cgi</span></a>.</p>\\r\\n<h2 id=\\\"management\\\">Management </h2>\\r\\n<p>Management of AKI is similar for both adults and children</p>\\r\\n<h3 id=\\\"patients-at-risk\\\">Patients at risk:</h3>\\r\\n<p>Serum creatinine levels should be done at baseline and this should be repeated periodically. While on admission, creatinine levels should be done at least on a weekly basis (more often depending on the patient’s clinical status). Urine output should be monitored throughout admission.</p>\\r\\n<h3 id=\\\"conservative-management\\\">Conservative management: </h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Treat underlying cause e.g. antibiotics for sepsis, antimalarials for malaria etc.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Replace fluid losses (insensible water loss plus fluid loss from vomiting or diarrhea) with colloids, preferably containing saline.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Monitor input and output. Use urethral catheter only if it will be difficult to estimate urine volume or if a urethral obstruction is suspected.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ensure patient is feeding well: High caloric intake with low to normal protein.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Manage electrolyte disturbances such as hyperkalaemia and metabolic acidosis using the guidelines on the management of electrolyte disturbances.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><span class=\\\"underline\\\">Note</span>: The use of diuretics is restricted to conditions in which there is fluid overload e.g. peripheral and pulmonary oedema. They should not be used routinely.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"indications-for-renal-replacement-therapy-referral-to-efsth\\\">Indications for renal replacement therapy (referral to EFSTH):</h3>\\r\\n<p><strong>Biochemical</strong></p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Refractory hyperkalaemia of ≥ 6.5 mmol/L or 6 mmol/L with ECG changes or a daily rise of 1 mmol/L/ day</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Refractory metabolic acidosis : Bicarbonate levels ≤ 12 mmol/L</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Urea level of &gt; 25 mmol/L or increase of &gt;10 mmol/L/day</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Stage 3 AKI (Serum creatinine ≥ 353.6 µmol/L) or daily rise of ≥ 100 mmol/L/ day</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p><strong>Clinical</strong></p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Refractory pulmonary oedema</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Uraemic gastritis with persistent symptoms</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Uraemic pericarditis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Uraemic encephalopathy</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Bleeding diathesis</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"follow-up\\\">Follow up:</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Counsel patient on the prognosis of AKI and the need for follow up care.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Serum creatinine levels should be measured at least 90 days after recovery from AKI. Monitoring can be as frequent as monthly</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Follow up in clinic may be extended to the next 2-3 years to check for progression of the disease, even if creatinine levels are normal and stabilised.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"key-issues-for-nursing-care\\\">Key Issues for Nursing care</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Strict monitoring of patient’s input and output on the fluid balance chart with escalation of care where necessary.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ensure adherence to the management protocol<strong>.</strong></p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Restrict potassium-rich foods e.g. bananas, oranges, cooked spinach and potatoes.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<p>KDIGO A. K. I. Work Group (2012). KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl, 2(1), 1-138.</p>\\r\\n<p>Soler, Y. A., Nieves-Plaza, M., Prieto, M., García-De Jesús, R., &amp; Suárez-Rivera, M. (2013). pRIFLE (Pediatric Risk, Injury, Failure, Loss, End Stage Renal Disease) score identifies Acute Kidney Injury and predicts mortality in critically ill children: a prospective study. Pediatric critical care medicine: a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies, 14(4), e189.</p>\\r\\n<p><a href=\\\"https://www.nice.org.uk/guidance/cg169/evidence/acute-kidney-injury-full-guideline-pdf-191530621\\\"><span data-custom-style=\\\"Hyperlink\\\">https://www.nice.org.uk/guidance/cg169/evidence/acute-kidney-injury-full-guideline-pdf-191530621</span></a></p>\\r\\n<p>Rahman, M., Shad, F., &amp; Smith, M. C. (2012). Acute kidney injury: a guide to diagnosis and management. American family physician, 86(7).</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Orighomisan Agboghoroma</th>\\r\\n<th>Date: 04 April 2019</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Karen Forrest</td>\\r\\n<td>Date: 07 May 2019</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td>31 May 2021</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"048\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>Acute rheumatic fever  MeG-CLS-048</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h2 id=\\\"acute-rheumatic-fever\\\">Acute Rheumatic Fever</h2>\\r\\n<h2 id=\\\"executive-summary\\\"><em>Executive summary</em></h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<h1 id=\\\"acute-rheumatic-fever-arf-is-an-auto-immune-consequence-of-infection-with-the-bacterium-group-a-streptococcus-gas.-the-symptoms-usually-appear-2-4-weeks-following-infection.-it-causes-an-acute-generalised-inflammatory-response-and-an-illness-that-affects-only-certain-parts-of-the-body-mainly-the-heart-joints-brain-and-skin.\\\">Acute rheumatic fever (ARF) is an auto-immune consequence of infection with the bacterium group A streptococcus (GAS). The symptoms usually appear 2-4 weeks following infection. It causes an acute generalised inflammatory response and an illness that affects only certain parts of the body, mainly the heart, joints, brain and skin. </h1>\\r\\n<h1 id=\\\"arf-leaves-no-lasting-damage-to-the-brain-joints-or-skin.-however-the-damage-to-the-heart-or-more-specifically-the-mitral-andor-aortic-valves-may-remain-once-the-acute-episode-has-resolved-and-these-long-term-changes-are-termed-rheumatic-heart-disease-rhd.-because-of-its-high-prevalence-in-developing-countries-rhd-is-the-most-common-form-of-paediatric-heart-disease-globally.-in-many-countries-it-is-the-most-common-cause-of-cardiac-mortality-in-children-and-adults-aged-less-than-40-years.\\\">ARF leaves no lasting damage to the brain, joints or skin. However, the damage to the heart, or more specifically the mitral and/or aortic valves, may remain once the acute episode has resolved and these long term changes are termed rheumatic heart disease (RHD). Because of its high prevalence in developing countries, RHD is the most common form of paediatric heart disease globally. In many countries, it is the most common cause of cardiac mortality in children and adults aged less than 40 years.</h1>\\r\\n<h3 id=\\\"target-users\\\">Target users</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doctors</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nurses</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"target-area-of-use\\\">Target area of use </h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Gate clinic</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>OPD</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ward</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"key-areas-of-focus-new-additions-changes\\\">Key areas of focus / New additions / Changes </h3>\\r\\n<h2 id=\\\"this-guideline-is-intended-to-support-clinicians-in-the-diagnosis-and-management-of-acute-rheumatic-fever-in-adults-and-children-who-present-to-csd.\\\">This guideline is intended to support clinicians in the diagnosis and management of acute rheumatic fever in adults and children who present to CSD.</h2>\\r\\n<h2 id=\\\"limitations\\\">Limitations</h2>\\r\\n<p>We do not currently have access to streptococcal antibody tests (Anti-DNAse B and Anti-Streptolysin Titre) which are highly useful investigations in acute rheumatic fever.</p>\\r\\n<p>There is limited use of intramuscular Benzathine Penicillin G due to historical cases of severe adverse drug reaction. Throat culture is not routinely available at Keneba.</p>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs\\\">Presenting symptoms and signs</h2>\\r\\n<p>WHO criteria for the diagnosis of rheumatic fever are based on the revised Jones criteria:</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Diagnostic category</strong></th>\\r\\n<th><strong>Criteria</strong></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Primary episode of ARF</td>\\r\\n<td><p>2 major OR 1 major and 2 minor manifestations <strong>PLUS</strong></p>\\r\\n<p>Evidence of a preceding GAS infection</p></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Recurrent attack of ARF in a patient <strong>without</strong> established rheumatic heart disease</td>\\r\\n<td><p>2 major OR 1 major and 2 minor manifestations <strong>PLUS</strong></p>\\r\\n<p>Evidence of a preceding GAS infection</p></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Recurrent attack of ARF in a patient <strong>with</strong> established rheumatic heart disease</td>\\r\\n<td><p>2 minor manifestations <strong>PLUS</strong></p>\\r\\n<p>Evidence of a preceding GAS infection</p></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>MAJOR MANIFESTATIONS</strong></th>\\r\\n<th><strong>POINTS FOR DIAGNOSIS</strong></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Arthritis</td>\\r\\n<td><p>Most common presenting feature of ARF</p>\\r\\n<p>Polyarthritis is usually asymmetrical and migratory</p>\\r\\n<p>Monoarthritis may also be a presenting feature</p>\\r\\n<p>Large joints are usually affected, especially the knees and ankles</p>\\r\\n<p>Usually responds within 3 days of starting NSAID therapy</p></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Chorea</td>\\r\\n<td><p>Consists of jerky, uncoordinated movements especially affecting the hands, feet, tongue and face</p>\\r\\n<p>Disappears during sleep</p></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Carditis</td>\\r\\n<td>Usually presents as a pansystolic murmur over the apex or an early diastolic murmur at the left sternal edge</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Subcutaneous nodules</td>\\r\\n<td>Present as crops of small, round, painless nodules over the elbows, wrists, knees, occiput and spinal processes</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Erythema marginatum</td>\\r\\n<td>Occurs as circular patterns of bright pink macules or papules on the trunk and proximal extremities</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>MINOR MANIFESTATIONS</strong></td>\\r\\n<td><strong>POINTS FOR DIAGNOSIS</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Arthralgia</td>\\r\\n<td>Migratory, asymmetrical and affecting large joints</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Fever</td>\\r\\n<td><p>Most manifestations of ARF are accompanied by fever</p>\\r\\n<p>A fever of ≥ 38 degrees meets this criteria</p></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Elevated acute phase reactants</td>\\r\\n<td>ESR (or CRP) ≥ 30 meets this criteria</td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<h2 id=\\\"differential-diagnosis\\\">Differential diagnosis</h2>\\r\\n<p>The following table outlines the features that can help differentiate between pharyngitis caused by GAS from that caused by a viral illness.</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>GAS infection</strong></th>\\r\\n<th><strong>Viral infection</strong></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Sudden onset of sore throat</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Fever</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Headache</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nausea, vomiting, abdominal pain</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Tonsillopharyngeal inflammation</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Tonsillopharyngeal exudates</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Palatal petechiae</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Enlarged anterior cervical lymph nodes</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Scarlatiniform rash</p>\\r\\n</div></li>\\r\\n</ul></td>\\r\\n<td><ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Conjunctivitis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Coryza</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Cough</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Diarrhoea</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hoarseness</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ulcerative stomatitis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Viral exanthema</p>\\r\\n</div></li>\\r\\n</ul></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<h2 id=\\\"investigations\\\">Investigations</h2>\\r\\n<p>Patients should have the following:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Bloods: FBC, ESR, blood culture</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Throat swab</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>ECG</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Echocardiogram</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>CXR (if carditis suspected)</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Evidence of preceding GAS infection includes:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Elevated P-R interval on ECG: &gt; 0.16s (3-12 years), &gt; 0.18s (13-16 years), &gt;20s (≥ 17 years)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Elevated streptococcal antibodies</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Positive throat culture</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Recent scarlet fever</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"management\\\">Management</h2>\\r\\n<h3 id=\\\"primary-prevention-of-arf\\\">Primary prevention of ARF </h3>\\r\\n<ul>\\r\\n<li><h1 id=\\\"all-patients-presenting-with-a-sore-throat-should-have-their-throat-examined.\\\">All patients presenting with a sore throat should have their throat examined.</h1></li>\\r\\n<li><h1 id=\\\"all-children-aged-4-15-years-who-present-with-a-fever-should-have-their-throat-examined-unless-clear-alternative-source-of-their-fever.\\\">All children aged 4-15 years who present with a fever should have their throat examined (unless clear alternative source of their fever).</h1></li>\\r\\n<li><h1 id=\\\"any-patient-who-has-features-suggestive-of-gas-and-all-children-aged-4-15-years-who-have-evidence-of-pharyngeal-inflammationexudate-should-be-treated-with-antibiotics-for-suspected-gas-infection.\\\">Any patient who has features suggestive of GAS and all children aged 4-15 years who have evidence of pharyngeal inflammation/exudate should be treated with antibiotics for suspected GAS infection.</h1></li>\\r\\n<li><h1 id=\\\"a-throat-swab-should-be-sent-for-culture-in-all-patients-who-are-being-treated-with-antibiotics-for-suspected-gas-infection.\\\">A throat swab should be sent for culture in all patients who are being treated with antibiotics for suspected GAS infection.</h1></li>\\r\\n</ul>\\r\\n<h3 id=\\\"antibiotic-therapy-for-gas-infection\\\">Antibiotic therapy for GAS infection</h3>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><h1 id=\\\"for-patients-without-penicillin-allergy\\\">For patients without penicillin allergy</h1></th>\\r\\n<th></th>\\r\\n<th></th>\\r\\n<th></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><p>Penicillin V</p>\\r\\n<p>(Phenoxymethylpenicillin)</p></td>\\r\\n<td>Oral</td>\\r\\n<td>7.5 mg/kg (max dose 500 mg) QDS</td>\\r\\n<td>10 days</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Amoxicillin</td>\\r\\n<td>Oral</td>\\r\\n<td>50 mg/kg (max dose 1000 mg) OD</td>\\r\\n<td>10 days</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Benzathine penicillin G</td>\\r\\n<td>Intramuscular</td>\\r\\n<td><p>Weight &lt; 30 kg: 450 mg (600,000 units)</p>\\r\\n<p>Weight ≥ 30 kg: 900 mg (1,200,000 units)</p></td>\\r\\n<td>One dose</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>For patients with penicillin allergy</strong></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Erythromycin</td>\\r\\n<td>Oral</td>\\r\\n<td>20 mg/kg (max 500 mg) BD</td>\\r\\n<td>10 days</td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<h3 id=\\\"treatment-of-arf\\\">Treatment of ARF</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Antibiotics:</strong> All patients diagnosed with ARF should receive a course of antibiotics to treat GAS infection (see above on antibiotics).</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Analgesia/anti-inflammatories</strong>: Paracetamol may be sufficient for fever and mild arthralgia. Ibuprofen (10 mg/kg, maximum 500 mg, TDS) may be given for arthralgia or Aspirin (50-60 mg/kg/day, increased if needed to 80-100 mg/kg/day, given in 4-5 divided doses). Ibuprofen and aspirin may be used for more severe arthritis and pain but should only be started after a diagnosis of ARF has been made as they may mask the manifestations used to make the diagnosis.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Chorea:</strong> Can use carbamazepine (2-3 mg/kg TDS) for severe symptoms.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Carditis/heart failure:</strong> Diuretics and fluid restriction, use of ACE inhibitor and Digoxin if atrial fibrillation present.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"secondary-prevention-of-arf\\\">Secondary prevention of ARF</h3>\\r\\n<p>Patients who develop recurrent episodes of ARF are at increased risk of worsening rheumatic heart disease. Therefore antibiotic prophylaxis is used in all patients who have had an episode of ARF to minimise the risk of recurrent episodes of GAS infection.</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><div data-custom-style=\\\"Normal (Web)\\\">\\r\\n<p><strong>For patients without penicillin allergy</strong></p>\\r\\n</div></th>\\r\\n<th></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><p>Oral Penicillin V</p>\\r\\n<p>(Phenoxymethylpenicillin)</p></td>\\r\\n<td>7.5 mg/kg (max dose 500 mg) BD</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><div data-custom-style=\\\"Normal (Web)\\\">\\r\\n<p><strong>For patients with penicillin allergy</strong></p>\\r\\n</div></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Oral Erythromycin</td>\\r\\n<td>20 mg/kg (max dose 500 mg) BD</td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<p>New Zealand Guidelines for Rheumatic Fever- Diagnosis, Management and Secondary Prevention of Acute Rheumatic Fever and Rheumatic Heart Disease: 2014 Update</p>\\r\\n<p>The Australian Guideline for prevention, diagnosis and management of acute rheumatic fever and rheumatic heart disease (second edition)</p>\\r\\n<p>AHA Guidelines on Prevention of Rheumatic Fever and Diagnosis and Treatment of Acute Streptococcal Pharyngitis</p>\\r\\n<p>NICE guidelines: Sore throat (acute): antimicrobial prescribing, January 2018</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Lucy Affleck</th>\\r\\n<th>Date: 20 November 2018</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Baderinwa Abatan</td>\\r\\n<td>Date: 28 February 2019</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td>31 May 2021</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"077\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>Anaemia in adults MeG-CLS-077</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"anaemia-in-adults\\\">Anaemia in adults</h1>\\r\\n<h2 id=\\\"executive-summary\\\"><em>Executive summary</em></h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<p>Anaemia is a condition in which the number of the red blood cells or their oxygen carrying capacity is insufficient to meet physiological needs, or the number of red blood cells or haemoglobin concentration is reduced below normal value for age. It varies according to age, sex, altitude, smoking and pregnancy status.</p>\\r\\n<p>Having a correct number of red blood cells and prevention of anaemia requires cooperation between the kidneys, the bone marrow and the nutrients within the body.</p>\\r\\n<p>Anaemia is actually a sign of a disease process rather than being a disease itself.</p>\\r\\n<p>Red blood cells have a life span of 90 – 100 days so the body is constantly trying to replace them.</p>\\r\\n<p>Young women are twice as likely to have anaemia as young men because of regular menstrual bleeding.</p>\\r\\n<h2 id=\\\"target-users\\\">Target users</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doctors</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nurses</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"target-area-of-use\\\">Target area of use </h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ward</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Outpatient department</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"key-areas-of-focus-new-additions-changes\\\">Key areas of focus / New additions / Changes </h2>\\r\\n<p>This addresses the investigation and management of anaemia – focussing on adults.</p>\\r\\n<h2 id=\\\"limitations\\\">Limitations</h2>\\r\\n<p>Blood transfusion services are not available at Keneba.</p>\\r\\n<h2 id=\\\"causes-of-anaemia\\\">Causes of anaemia</h2>\\r\\n<p>The causes of anaemia can be acquired or inherited. Where possible the cause should be identified as different types of anaemia need different treatment. If the cause cannot be identified, there should still be an attempt to classify which group the cause is likely to fall into.</p>\\r\\n<ol type=\\\"1\\\">\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Malaria</strong></p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Iron deficiency anaemia (Microcytic hypochromic)</strong> is the most common type of anaemia worldwide.</p>\\r\\n</div></li>\\r\\n</ol>\\r\\n<div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Causes include:</p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>reduced intake of iron examples of foods rich in iron include meat, eggs, leafy green vegetables and iron fortified foods;</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>reduced absorption of iron - such as occurs in celiac disease atrophic gastritis and post gastrectomy;</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>increased iron requirements as in pregnancy, growth spurts and chronic haemolysis;</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>blood loss – gastrointestinal diseases like peptic ulcer, malignancy, angiodysplasia and hookworm infestation, menstruation, hematuria and drugs e.g. NSAID; frequent blood donation .</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<ol start=\\\"3\\\" type=\\\"1\\\">\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Normocytic anaemia</strong> – anaemia with normal sized red blood cells seen in</p>\\r\\n</div></li>\\r\\n</ol>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>anaemia of chronic disease seen in chronic kidney disease, rheumatoid diseases, polymyalgia rheumatica;</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>combined deficiencies – iron and folate deficiencies in coeliac disease;</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>haematological malignancies – acute or chronic leukaemia, myelodysplasia;</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>acute blood loss – haemorrhage;</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>organ failure – kidney, liver, thyroid and pituitary.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<ol start=\\\"4\\\" type=\\\"1\\\">\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Macrocytic anaemia</strong> – the red blood cells are large but have low haemoglobin concentration. Causes include:</p>\\r\\n</div></li>\\r\\n</ol>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Vit B12 deficiency due to:</p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>reduced intake, seen in vegetarians and folate deficiency in elderly &amp; alcoholics</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>reduced absorption in pernicious anaemia, post gastrectomy, post-ileal resection in Crohn’s disease, stagnant loops, fish tapeworm infestation</p>\\r\\n</div></li>\\r\\n</ul></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Folate deficiency due to:</p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>increased requirements – folate deficiency seen in pregnancy, chronic hemolysis, dialysis and exfoliative dermatitis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>reduced absorption in coeliac disease, tropical sprue, Crohn’s disease and stagnant loops</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>drugs which affect absorption: phenytoin, sodium valproate, combined oral contraceptive</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>drugs which oppose folate: methotrexate, septrin</p>\\r\\n</div></li>\\r\\n</ul></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Drugs which directly cause megaloblastic anaemia: alcohol; hydroxycarbamide (hydroxyurea), azathioprine, azidothymidine (AZT), cytosine – arabinoside</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<ol start=\\\"5\\\" type=\\\"1\\\">\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Haemolytic anaemia</strong>: where red blood cells are destroyed faster than they can be made, due to:</p>\\r\\n</div></li>\\r\\n</ol>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>inherited conditions such as sickle cell disease or thalassemia</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>stressors such as infections, drugs, snake and spider venom, and certain foods</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>autoimmune disease such as haemolytic disease of the new born</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>direct damage to red blood cells by vascular grafts, prosthetic heart values; tumours; severe burns; exposure to certain chemicals.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<ol start=\\\"6\\\" type=\\\"1\\\">\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Aplastic anaemia:</strong> occurs when the bone fails producing enough new blood cells. Causes include: Idiopathic causes, infections causes such as hepatitis, viruses, Epstein – Barr (EBV) virus, HIV, parvovirus and mycobacteria; exposure to radiation.</p>\\r\\n</div></li>\\r\\n</ol>\\r\\n<h2 id=\\\"grading-of-anaemia\\\">Grading of anaemia</h2>\\r\\n<p>Anaemia can be graded clinically or according to the haemoglobin.</p>\\r\\n<h3 id=\\\"clinical-grading\\\">Clinical grading:</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Mild – pale conjunctiva and mucous membranes</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Moderate – mild plus pale skin</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Severe – moderate plus pale palms.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"lab-based-grading\\\">Lab-based grading:</h3>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Grade</strong></th>\\r\\n<th></th>\\r\\n<th><strong>Haemoglobin</strong></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1</td>\\r\\n<td>mild</td>\\r\\n<td>10-10.9</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>2</td>\\r\\n<td>moderate</td>\\r\\n<td>7-9.9</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>3</td>\\r\\n<td>severe</td>\\r\\n<td>5-6.9</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>4</td>\\r\\n<td>life threatening</td>\\r\\n<td>≤ 5</td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs\\\">Presenting symptoms and signs</h2>\\r\\n<p>Patients may complain of easy fatigue, loss of energy and strength, headache, dizziness, lack of sleep, difficulty in concentrating, shortness of breath particularly with exercise, rapid heartbeat especially with exercise, pale skin and palms, cramps in the limbs, chest pain, blackouts.</p>\\r\\n<h2 id=\\\"examination-findings\\\">Examination findings</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Pallor, lethargy, tachypnoea.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Tachycardia and hypotension may suggest a recent bleed.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Jaundice may indicate haemolysis.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Do not forget rectal examination.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"management-at-the-gate-clinic\\\">Management at the Gate Clinic</h2>\\r\\n<p>Mild anaemias with Hb of 10-10.9 g/dl or PCV 30-32.7% can be managed at the Gate Clinic.</p>\\r\\n<p>Take a brief history with relevant past medical history and examination; send the patient to the lab and look for malaria parasites and the PCV or Hb.</p>\\r\\n<p>Treat malaria appropriately if present.</p>\\r\\n<p>Deworm with mebendazole 100 mg BD for 3 days or albendazole 400 mg single dose if the individual has not received anthelminthic in the past 4 - 6 months.</p>\\r\\n<p>Give adult patients ferrous sulphate 200 mg OD for 1 month.</p>\\r\\n<p>Refer patients to the OPD if</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hb &lt; 10 g/dl,</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>active blood loss,</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>the patient is very sick,</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>history of recurrent blood transfusions</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>any concerning history or examination findings.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"management-at-the-opd\\\">Management at the OPD</h2>\\r\\n<p>Take a proper history including dietary history, blood loss, gastrointestinal symptoms, menstrual cycle, menorrhagia, use of drugs and alcohol consumption.</p>\\r\\n<p>The past medical history of previous admissions and blood transfusion, blood loss or anaemia, surgical procedures and family history of anaemia is important.</p>\\r\\n<h3 id=\\\"examination-findings-1\\\">Examination findings</h3>\\r\\n<p>A general examination and complete systemic examination is important to identify any underlying condition, which can affect any system.</p>\\r\\n<p>Take care to note tachycardia, tachypnoea, hypotension, heart murmurs, jaundice, abdominal tenderness and organ enlargement and never forget digital rectal examination and, where relevant, vaginal examination.</p>\\r\\n<h3 id=\\\"investigations\\\">Investigations</h3>\\r\\n<p>At first consultation request a FBC and blood film comment to classify the kind of anaemia. Malaria blood film is also important during the transmission season.</p>\\r\\n<p>Further investigations may be indicated depending on the initial findings. These include:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Direct Coombs test, reticulocyte count, Hb genotype, ESR (but beware that this will be raised by severe anaemia itself).</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Biochemistry – electrolytes, urea and creatinine, liver function tests, bone profile.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Radiology to look for evidence of myeloma, metastases or bony malignancy.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ultrasound studies to look for other malignancies.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Gastrointestinal investigations including faecal occult blood, upper and lower gastrointestinal endoscopy and barium studies of the bowel.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Other tests that would be useful, but are usually not available to us include:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Serum iron ferritin and total iron binding capacity</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Serum B12 and folate.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Bone marrow aspirate or biopsy studies (this is sometimes available at EFSTH).</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"treatment\\\">Treatment</h3>\\r\\n<p>Moderate anaemia in haemodynamically stable patients can be treated in the OPD. Patient with the following problems should be admitted to the ward (<em>Fajara</em>) or referred emergently to Bwiam (<em>Keneba</em>):</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Severe to life threatening anaemia.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Signs of heart failure, tachycardia, tachypnoea and hepatomegaly.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Severe malaria with anaemia.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Acute massive blood loss.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Extensive severe burns.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>The treatment of anaemia depends on the suspected cause:</p>\\r\\n<p><strong>Iron deficiency anaemia:</strong> Ferrous sulphate 200 mg OD. The efficiency of iron absorption is reduced as the dose increases. Where the Hb is &lt; 8 g/dl, increasing frequency will increased absorption somewhat, but the side effects may become more prominent. Greater absorption is achieved when you prescribe the iron TDS on alternate days rather than giving it BD every day. Iron should be continued until the Hb has returned to normal and then for a further 3 months after this.</p>\\r\\n<p><strong>Normocytic anaemia:</strong> The main priority is to treat any identifiable underlying cause or abnormality and stop any precipitating drugs. This may reflect mixed iron and folate deficiency, so if no other cause is identified, a trial of treatment is indicated.</p>\\r\\n<p><strong>Macrocytic anaemia:</strong> correct any haematinic deficiency and treat any underlying cause.</p>\\r\\n<p>Vitamin B12 deficiency – give im cyanocobalamin 1 mg alternate days until 10 doses have been given, then monthly until the full blood count is normal. Continue treatment every three months, unless a clear cause for the deficiency was identified.</p>\\r\\n<p>Folate deficiency: give folic acid 5 mg orally once daily. Do not start folate supplements until the initial 10 doses of vitamin B12 have been given. Folate replacement in B12 deficiency can precipitate neurological problems.</p>\\r\\n<p><strong>Haemolytic anaemia:</strong> this usually requires further investigation to rule out underlying lymphoproliferative disorders and the identify the exact cause for the haemolysis. Refer to the haematologist whenever possible. If this is not possible, then consider treatment with prednisolone at a dose of 1 mg/kg OD to see if the patient responds. Note that this may initially be effective even in the presence of lymphoma, so the patient must be kept under review.</p>\\r\\n<p><strong>Aplastic anaemia:</strong> again this diagnosis require further investigation to identify the underlying cause. In some cases, the patient will gradually recover and can be given transfusions until this occurs. In others, the patient will be permanently transfusion dependent. If possible, refer to a haematologist.</p>\\r\\n<h2 id=\\\"management-on-the-ward\\\">Management on the ward</h2>\\r\\n<p>Take a proper and detailed history.</p>\\r\\n<p>Do a complete physical examination – general and systemic.</p>\\r\\n<p>Arrange investigations as for outpatients. Consider adding:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>blood, urine and stool MC&amp;S</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>faecal occult blood</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>X-ray and ultrasound investigations</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>endoscopic investigations.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"treatment-on-the-ward\\\">Treatment on the ward</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Treat malaria if present</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Treat any infections</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Treat the underlying cause of the anaemia.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Consider transfusion in severe or life-threatening anaemia.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"indications-for-blood-transfusion\\\">Indications for blood transfusion </h3>\\r\\n<ol type=\\\"1\\\">\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Whole blood transfusion: give 20 ml/kg over 4 hours.</p>\\r\\n</div></li>\\r\\n</ol>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Haemorrhage – sudden loss of ≥ 25% of blood volume.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Patients undergoing exchange transfusion (this is not routinely offered here).</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Patients who continue to bleed after receiving 4 units of packed red blood cells.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<ol start=\\\"2\\\" type=\\\"1\\\">\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Packed cell transfusion</strong>: one unit of packed cell typically increases the level of haemoglobin by 1 g/dl and haematocrit by 3%. They should be used when whole blood might overload the circulation. Give 15 ml/kg over 4 hours.</p>\\r\\n</div></li>\\r\\n</ol>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Symptomatic chronic anaemia without haemorrhage</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Acute sickle cell crises</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Cardiac failure</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Acute blood loss (30% or more)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Preoperative anaemia</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Note that the target post-transfusion Hb in most conditions is 7 g/dl.</p>\\r\\n<h3 id=\\\"when-to-refer-to-the-teaching-hospital\\\">When to refer to the Teaching Hospital:</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Acute massive or ongoing uncontrolled blood loss.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Unavailability of a compatible blood donor</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"key-issues-for-nursing-care\\\">Key Issues for Nursing care</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Regular vital signs while patients are on blood transfusion.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Watch for any sign of reaction. If present stop the transfusion and inform the senior nurse / doctor on duty.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Transfuse blood over the period recommended.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Teach patients how to prevent further iron deficiency anaemia</p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Sleep under insecticide treated mosquito nets.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Avoid drinking tea or coffee with meals as they can affect iron absorption.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Eat plenty of iron rich foods such as green leafy vegetables, lean red meat, beans, iron fortified cereals, liver, seafood and fish.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Eat / drink Vitamin C rich foods.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Daily prophylactic iron and folate is recommended in pregnancy.</p>\\r\\n</div></li>\\r\\n</ul></li>\\r\\n</ul>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<p>Anemia - Diagnosis and treatment - Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/anemia/diagnosis-treatment/drc-20351366 (accessed Aug 30, 2019).Haematology and Oncology. Blackwell Science, 2001.How Anemia Is Diagnosed and Treated. WebMD. https://www.webmd.com/a-to-z-guides/understanding-anemia-treatment (accessed Aug 30, 2019).Anemia - American Family Physician. https://www.aafp.org/afp/topicModules/viewTopicModule. htm?topicModuleId=2 (accessed Aug 30, 2019).Anemia. 2018; published online Aug 1. /Patients/Anemia/ (accessed Aug 30, 2019).Mabey D, Gill G, Parry E, Weber MW, Whitty CJM. Principles of Medicine in Africa. Cambridge University Press, 2013.</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Danlami Garba</th>\\r\\n<th>Date:</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Karen Forrest</td>\\r\\n<td>Date: 15 July 2019</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td>30 August 2021</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"049\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>Animal bites MeG-CLS-049</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"animal-bites\\\">Animal bites</h1>\\r\\n<h2 id=\\\"executive-summary\\\"><em>Executive summary</em></h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<p>Patients may present with bites from other people as well as a number of different animals. The most common sources include dogs, monkeys and snakes.</p>\\r\\n<p>All bites can be associated with bacterial infections – often with very virulent bacteria. Human bites, then cat bites, are the most likely to lead to serious infections. Mammal bites raise the possibility of exposure to rabies. Snake bites may also be venomous (but up to 2/3 of all bites contain no venom).</p>\\r\\n<h3 id=\\\"target-users\\\">Target users</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doctors</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nurses</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"target-area-of-use\\\">Target area of use </h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Outpatients</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ward</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"key-areas-of-focus-new-additions-changes\\\">Key areas of focus / New additions / Changes </h3>\\r\\n<p>This guidelines summarises in clinical format the management of animal bites, including human, other mammals and snake bites. There are formal SOPs (SOP-CLS-009 and SOP-CLS-020) giving more detail about how to manage rabies-prone exposures and snake bites.</p>\\r\\n<h2 id=\\\"limitations\\\">Limitations</h2>\\r\\n<p>We do not have rabies immunoglobulin available. There is no anti-venom manufactured for neurotoxic snake bites in this region.</p>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs\\\">Presenting symptoms and signs</h2>\\r\\n<p>The history is very important. What animal bit the patient? What was happening at the time? Was the bite unprovoked or was there something that triggered the bite? If it was unprovoked, was there any other indication that the animal was unwell or mad? Does the animal belong to someone? Has it been vaccinated? Has the patient been vaccinated against rabies?</p>\\r\\n<p>For snake bites, did they see the snake? What did it look like?</p>\\r\\n<p>Beware that traditional healers often diagnose swollen legs as being due to snake bite even when there is no history of this. They then “remove the fangs,” reinforcing their diagnosis. Patients who later present to a clinic will report that they were bitten by a snake, but on further questioning cannot remember when this happened.</p>\\r\\n<p>For all patients with bites, ask what treatment has been given so far. How long ago did the bite happen?</p>\\r\\n<h2 id=\\\"examination-findings\\\">Examination findings</h2>\\r\\n<p>Look at the bite. Is it deep? Which part of the body is it on? Does it already look infected?</p>\\r\\n<p>Check the observations (GCS, HR, BP, RR, O<sub>2</sub> saturations) and look at the general state of the patient.</p>\\r\\n<p>For snake bites, look for signs of envenomation – local swelling, tender lymph nodes, bleeding, signs of shock (cold, cyanosis, sweating, reduced GCS) and signs of neurotoxicity (blurred vision, heavy eyes, drowsiness, shortness of breath, restlessness).</p>\\r\\n<h2 id=\\\"investigations\\\">Investigations</h2>\\r\\n<p>No investigations are needed for mammal bites.</p>\\r\\n<p>For snake bites, with signs of envenomation, check FBC, blood film, INR, APTT. Also put 2 ml blood in a clean dry glass tube and leave it for 20 minutes, then look for clotting.</p>\\r\\n<h2 id=\\\"management\\\">Management </h2>\\r\\n<h3 id=\\\"mammal-including-human-bites\\\">Mammal (including human) bites</h3>\\r\\n<p>For bites with a risk of rabies exposure, which present acutely, wash the wound with soap and water for at least 15 minutes. If it looks dirty, scrub away the dirt with a brush. Apply iodine or 40-70% alcohol to the wound and dress it with a sterile dressing.</p>\\r\\n<p><strong>Never</strong> suture an animal bite.</p>\\r\\n<p>Give tetanus toxoid and start antibiotics – co-amoxiclav is the best choice. Prescribe by amoxicillin dose (30 mg/kg up to 500 mg TDS – where the dose of amoxicillin is greater than 250 mg use 1 co-amoxiclav tablet and make the rest of the dose up with amoxicillin tablets). Alternatives include doxycycline 100 mg BD and metronidazole 500 mg TDS (non-pregnant adults only), ceftriaxone 80 mg/kg OD or ciprofloxacin 20 mg/kg up to 500 mg BD and clindamycin 10 mg/kg up to 450 mg TDS. All courses of antibiotics are for 5 days.</p>\\r\\n<p>Where there is concern about rabies, consider the possibility of rabies vaccine. Patients must pay the full cost of this. See SOP-CLS-009. Rabies vaccine will only be effective if given within 72 hours of the bite. We do not have access to human rabies immunoglobulin, so if a patient has a high risk bite, especially on a proximal site of the body, they would need to travel immediately to Dakar. High risk bites are those where carnivore saliva has contacted the mucous membranes, has entered a transdermal bite or has been licked onto broken skin.</p>\\r\\n<h3 id=\\\"snake-bites\\\">Snake bites</h3>\\r\\n<p>Management is very variable depending on whether the bite contained venom or not and on the type of snake that bit the patient.</p>\\r\\n<p>If there is evidence of hypovolaemia or shock, manage the airway, breathing and circulation as necessary. Start fluid resuscitation as soon as possible.</p>\\r\\n<p>Give paracetamol and / or codeine if necessary for pain.</p>\\r\\n<p>If there is evidence of bleeding, organize a whole blood transfusion.</p>\\r\\n<p>Clean all wounds with antiseptic – alcohol, potassium permanganate, iodine or GV are all suitable. Immobilise the limb in a comfortable position level with the patient (neither elevate nor hold it down).</p>\\r\\n<p>Where there is local tissue damage or swelling:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Do not open blisters.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>If there is necrotic tissue, debride it.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Watch for signs of compartment syndrome and arrange surgical intervention if present.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Treat with cloxacillin if there are signs of bacterial wound infection.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>If the bite was from a puff adder or a spitting cobra with signs of envenomation, then anti-venom is indicated and should be available for staff and staff relatives only. Make it up as instructed, dilute it in normal saline and infuse over 30 minutes. Admit any patient given anti-venom to the ward. Monitor the patient closely for evidence of anti-venom reaction including anaphylaxis, fever and late reactions. See SOP-CLS-020 for more details on management of snake bite.</p>\\r\\n<p>There is no anti-venom available for bites by mambas or neurotoxic biting cobras.</p>\\r\\n<h2 id=\\\"key-issues-for-nursing-care\\\">Key Issues for Nursing care</h2>\\r\\n<h2 id=\\\"keep-the-patient-calm.\\\">Keep the patient calm.</h2>\\r\\n<p>Wash the wound as described above. Dress the wound only after it has been reviewed by a doctor (or take a photograph before dressing it, if you are away from Fajara and need to dress it before transferring the patient there).</p>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<p>World Health Organisation 2010. Guidelines for the Prevention and Clinical Management of Snakebite in Africa.</p>\\r\\n<p>World Health Organisation, ‘Rabies: Local treatment of wounds’ published 2012 cited 24/07/12 found at: <a href=\\\"http://www.who.int/rabies/vaccines/treatment_wound/en/index.html\\\"><span data-custom-style=\\\"Hyperlink\\\">http://www.who.int/rabies/vaccines/treatment_wound/en/index.html</span></a></p>\\r\\n<p>World Health Organisation. Rabies: Guide to post exposure prophylaxis, published WHO 2012, cited 25/07/12, found at: <a href=\\\"http://www.who.int/rabies/human/postexp/en/index.html\\\"><span data-custom-style=\\\"Hyperlink\\\">http://www.who.int/rabies/human/postexp/en/index.html</span></a></p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Karen Forrest</th>\\r\\n<th>Date: 31 October 2018</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Fatai Akemokwe</td>\\r\\n<td>Date: 14 November 2018</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td>31 January 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>1.1</td>\\r\\n<td>Executive summary added</td>\\r\\n<td>31 January 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"081\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>Anticoagulation MeG-CLS-081</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"anticoagulation\\\">Anticoagulation</h1>\\r\\n<h2 id=\\\"executive-summary\\\"><em>Executive summary</em></h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<p>Anticoagulation is the use of drugs to reduce the ability of the blood to coagulate. It is indicated in the treatment of venous thromboembolic disease, after cardiac surgery involving implantation of a metal valve and in the prevention of complications from atrial fibrillation and other conditions leading to thrombosis in the ventricles of the heart.</p>\\r\\n<p>When a decision is made to anticoagulate a patient, the indications, target INR range and expected length of treatment must be recorded clearly in the notes and communicated to the patient. The risks involved must be clearly communicated to the patient and their relatives along with recommendations for how they should respond to unexpected events.</p>\\r\\n<p>When a patient on anticoagulation presents with an INR outside their target range, the patient should see a doctor familiar with the use of warfarin, to ensure that the patient is quickly treated and the INR is returned to the target range.</p>\\r\\n<h2 id=\\\"target-users\\\">Target users</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doctors</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nurses</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"target-area-of-use\\\">Target area of use </h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Outpatient department</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ward</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"key-areas-of-focus-new-additions-changes\\\">Key areas of focus / New additions / Changes </h2>\\r\\n<p>This guideline outlines the use of anticoagulants in our practice, focusing on the decision to initiate treatment, the process of initiating treatment, ongoing adjustments to keep the patient in the target range and the response to a raised INR.</p>\\r\\n<h2 id=\\\"limitations\\\">Limitations</h2>\\r\\n<p>We do not have out-of-hours access to APTT or INR measurements, limiting our ability to safely use unfractionated heparin. Low molecular weight heparin (LMWH) is outside our budget for drugs for the general public. Modern direct oral anticoagulants (DOACs) are outside our budget for all patients.</p>\\r\\n<h2 id=\\\"indications-for-anticoagulation\\\">Indications for anticoagulation</h2>\\r\\n<p>Anticoagulation is indicated in 3 groups of conditions:</p>\\r\\n<ol type=\\\"1\\\">\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Venous thrombo-embolic disease (pulmonary embolism (PE) and deep vein thrombosis (DVT))</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Metal artificial heart valves</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Atrial fibrillation and intracardiac thrombosis</p>\\r\\n</div></li>\\r\\n</ol>\\r\\n<p>Warfarin is contraindicated in pregnancy.</p>\\r\\n<h3 id=\\\"venous-thrombo-embolic-disease\\\">Venous thrombo-embolic disease</h3>\\r\\n<p>A separate guideline (Deep vein thrombosis and pulmonary embolism MeG-CLS-055) provides guidance on making the diagnosis. Once a diagnosis of DVT or PE has been made anticoagulation is an essential part of treatment. It should be continued for at least 3 months for patients with DVT and for at least 6 months for those with PE. The target INR range is 2.0-3.0.</p>\\r\\n<h3 id=\\\"metal-artificial-heart-valve\\\">Metal artificial heart valve</h3>\\r\\n<p>These patients need lifelong anticoagulation. They will usually return to us from surgery already established on warfarin treatment and with advice from the surgeons about the INR range. If there is no advice then an INR range of 3.0-4.0 is appropriate. When their INR is raised, great care should be taken to avoid lowering it too far or making it difficult to anticoagulate them in the medium term (see section on treatment of raised INR).</p>\\r\\n<h3 id=\\\"atrial-fibrillation-and-ventricular-thrombosis\\\">Atrial fibrillation and ventricular thrombosis</h3>\\r\\n<p>Anticoagulation is indicated to reduce the risk of stroke when a thrombosis is visible on ECHO or in a patient with atrial fibrillation who scores for this on a risk score such as CHA<sub>2</sub>DS<sub>2</sub>-Vasc score. This score has been validated in developed countries and patients where anticoagulation is widely available and relatively safe and patients are expected to be treated for life. This should be offset against the risk of bleeding, which can be estimated through scores such as HAS-BLED score.</p>\\r\\n<p>In our setting, where we are the only centre able to safely manage anticoagulation and where access to services to treat complications such as gastrointestinal bleeding and intracerebral bleeding are limited, a careful risk benefit analysis must be made if anticoagulation is considered. This should take into account where the patient lives and their commitment to returning to the clinic frequently for INR checks as well as the more clinical aspects. In general, we are not able to commit to lifelong anticoagulation for most of these patients.</p>\\r\\n<p>If the patient is able to pay for a regular supply of a direct acting oral anticoagulant, this may be a viable option. If you wish to calculate the CHA<sub>2</sub>DS<sub>2</sub>-Vasc score, you can find a calculator here: <span class=\\\"underline\\\"><a href=\\\"https://www.mdcalc.com/cha2ds2-vasc-score-atrial-fibrillation-stroke-risk\\\">https://www.mdcalc.com/cha2ds2-vasc-score-atrial-fibrillation-stroke-risk</a>;</span> HASBLED is available here: <span class=\\\"underline\\\"> https://www.mdcalc.com/has-bled-score-major-bleeding-risk</span></p>\\r\\n<h2 id=\\\"initiating-anticoagulation\\\">Initiating anticoagulation</h2>\\r\\n<p>Patients with PE or DVT and those with visible thrombosis in their ventricle will require rapid anticoagulation with heparin treatment, bridging to warfarin treatment for the longer term.</p>\\r\\n<p>Heparin can cause heparin induced thrombocytopenia (HIT), which is a life-threatening complication, when given for more than 4 days. The platelet count should be monitored before treatment and again at 4 days, then every 2-3 days until day 14 or the heparin is stopped (if earlier). HIT is very rare in obstetric patients given heparin and, in all groups, usually presents before day 15.</p>\\r\\n<h3 id=\\\"unfractionated-heparin\\\">Unfractionated heparin</h3>\\r\\n<p>This can be given subcutaneously at a dose of 250 units/kg up to 15,000 units BD. The APTT should be monitored daily whilst on this treatment.</p>\\r\\n<p>This is a compromise. This treatment is effective for DVT, but has not been shown to be effective in other conditions. However, iv heparin is not safe without regular APTT measurements 4 times each 24 hour period and this is not available to us.</p>\\r\\n<h3 id=\\\"lmwh\\\">LMWH</h3>\\r\\n<p>Enoxaparin is available for staff and study participants. It is available in local pharmacies at about D1000 per injection if other patients would prefer to use it. Give 1.5 mg/kg enoxaparin sc OD.</p>\\r\\n<h3 id=\\\"warfarin\\\">Warfarin</h3>\\r\\n<p>Patients receiving warfarin for a metal valve will usually have been started on warfarin before returning to our care. This section does not address their care.</p>\\r\\n<p>Use a 10 mg starting dose for adults starting on warfarin for DVT, PE or AF. This requires fewer INR measurements and more rapidly achieves anticoagulation compared to 5 mg starting dose regimens. Give 10 mg warfarin on days 1 and 2, then check the INR on day 3. The doses are given at 8 pm and the INR is checked in the morning. Warfarin should be prescribed both on the drug chart and on the green warfarin chart.</p>\\r\\n<p>Use a lower starting dose for older patients or those who are frail with altered metabolism.</p>\\r\\n<p>Use the figure on the next page to calculate the doses for days 3 and 4. Recheck the INR on day 5 and use the figure to calculate the dose for days 5, 6 and 7. The INR should be rechecked on day 8 and further dosing is according to the next section of the guideline.</p>\\r\\n<p>Continue heparin for at least 5 days or until the INR is 2.0 or above – whichever is latest. This is because warfarin is associated with an initial hypercoagulability which reduces by day 5.</p>\\r\\n<h2 id=\\\"section\\\"><img src=\\\"data:image/png;base64,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\\\" style=\\\"width:4.10417in;height:4.40172in\\\" /></h2>\\r\\n<h2 id=\\\"ongoing-treatment-with-warfarin\\\">Ongoing treatment with warfarin</h2>\\r\\n<p>The adjustment of warfarin doses to maintain a steady INR is as much an art as it is a science. This is partly because the patient also has to contribute to their ongoing care, by taking the warfarin dose at about the same time every day and by having regular habits with regard to diet.</p>\\r\\n<h3 id=\\\"patient-counselling\\\">Patient counselling</h3>\\r\\n<p>Patients need to understand the risks and benefits of warfarin treatment. Counsel them on the importance of eating regularly and taking their medications every day – ideally in the evening at a similar time. For those without watches, they can take it as the sun goes down or when they hear the evening call to prayer. Alternatively, encourage them to set an alarm on their phone.</p>\\r\\n<p>Some foods, which contain a lot of vitamin K, can interfere with warfarin treatment. These include green leafy vegetables, liver and alcohol. They can take these, but should do so on regular basis – taking about the same amount each week. If they suddenly increase or decrease what they take, then the INR will change accordingly. Similarly certain drugs can increase the INR. These include regular paracetamol, ciprofloxacin, macrolides, mebendazole and related medications, statins, NSAIDs and some herbal medications. Patients should tell any doctor prescribing medication for them that they are on warfarin.</p>\\r\\n<p>Patients should also be warned that they may need to come to the clinic more frequently than usual or even be admitted for a few days, if their INR goes out of range or is unstable.</p>\\r\\n<h3 id=\\\"checking-the-inr-and-responding-to-the-result\\\">Checking the INR and responding to the result</h3>\\r\\n<p>The INR should initially be checked on a weekly basis, increasing to 2 weekly, then monthly as the result stabilizes. If the result is found to be outside range, then the frequency will need to be increased again.</p>\\r\\n<p>The INR must be interpreted in the context of recent results and any changes of warfarin dose. If the INR has remained within range but has tended either to rise or fall, you will need to adjust the warfarin dose accordingly to change this trend. Also if the result has drifted just out of range, don’t make big adjustments to the dose, small adjustments should be adequate</p>\\r\\n<p>When the INR is outside range, think about why this has happened. Has the patient missed doses or stopped taking the medication? Have they changed their diet? Were they given concomitant medications? Has something else changed?</p>\\r\\n<p>For larger deviations, leading to the INR being outside range, the table below can be used to make bigger changes to the dose. Repeat the INR in a week or less (but not less than 48 hours) when you use the table.</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>INR (target range 2.0-3.0)</strong></th>\\r\\n<th><strong>INR (target range 3.0-4.0)</strong></th>\\r\\n<th><strong>Dose change</strong></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><em>&lt;1.5</em></td>\\r\\n<td><em>&lt;2.5</em></td>\\r\\n<td><em>Increase by 20%</em></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><em>1.6-1.9</em></td>\\r\\n<td><em>2.5-2.9</em></td>\\r\\n<td><em>Increase by 10%</em></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><em>3.1-3.4</em></td>\\r\\n<td><em>4.1-4.4</em></td>\\r\\n<td><em>Decrease by 10% (or repeat after no change)</em></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><em>3.5-3.9</em></td>\\r\\n<td><em>4.5-4.9</em></td>\\r\\n<td><em>Decrease by 20%, consider holding one dose</em></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><em>4.0-4.9</em></td>\\r\\n<td><em>5.0-5.9</em></td>\\r\\n<td><em>Hold until INR returns to range then decrease by 20-30%</em></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<p>If the patient has a low INR and a metal valve, then use either subcutaneous unfractionated heparin or LMWH at therapeutic doses as described in the initiating anticoagulation section. (Note that we do usually provide LMWH to the cardiac children on warfarin when needed).</p>\\r\\n<h2 id=\\\"treatment-of-raised-inr\\\">Treatment of raised INR</h2>\\r\\n<p>The risk of bleeding increases with rising INR. When the INR is very high or the patient is bleeding consider how strong the indication is for anticoagulation. Patients in whom the indication is not strong may be best served by stopping the treatment. On the other hand, those with metal valves must be managed with great care, so that they do not fall below the therapeutic range. These patients must be admitted to hospital and you should be prepared to give them heparin until their INR is in range if this occurs.</p>\\r\\n<p>INRs up to 10, where the patient is not bleeding, can be managed without vitamin K. Warfarin should be stopped and the INR monitored closely until it is in range. It is important to try and identify why the INR has risen so high. This will help determine your response and how you counsel the patient.</p>\\r\\n<p>If the INR is above 10 and there is no bleeding, consider the use of 1 mg vitamin K given orally as a single dose. This should be discussed with a consultant and only used if absolutely necessary, especially in patients with a metal valve.</p>\\r\\n<p>If the patient is actively bleeding, treatment will depend upon the INR and the type of bleeding. Use the table below.</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Type of bleeding</strong></th>\\r\\n<th><strong>INR</strong></th>\\r\\n<th><strong>Intervention</strong></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Major life-threatening bleeding</td>\\r\\n<td>Any</td>\\r\\n<td><p>Omit warfarin</p>\\r\\n<p>Give 5 mg iv vitamin K</p>\\r\\n<p>Use fresh whole blood for transfusions</p></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Minor bleeding from mucosa (including gums, nose, rectum, anus, urinary tract)</td>\\r\\n<td>Above 6.0</td>\\r\\n<td><p>Omit warfarin for 1-2 and reintroduce when bleeding is under control and INR &lt; 5.0.</p>\\r\\n<p>Use vitamin K only if INR above 10 and if you are prepared to admit the patient and give heparin if the INR falls below the therapeutic range.</p></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td></td>\\r\\n<td>Above range but less than 6.0</td>\\r\\n<td><p>Reduce dose of warfarin by 10%. Consider holding for a few days as per guidance above.</p>\\r\\n<p>Monitor INR closely.</p></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td></td>\\r\\n<td>Within range</td>\\r\\n<td>Continue warfarin unless indications are weak. Look for cause of bleeding.</td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<h2 id=\\\"measuring-inr\\\">Measuring INR</h2>\\r\\n<p>INRs can be measured either at the bedside using a point-of-care test or in the laboratory. In general, we prefer the point-of-care test as it allows us to obtain an immediate result. Unfortunately, we have had trouble maintaining the machines and they are often not working.</p>\\r\\n<p>An accurate lab INR requires that the tube is filled full. Whenever possible, ask the patient to attend the lab for the sample to be taken. Request the result urgently. Make a decision about what you will do with the warfarin assuming that the result is well in range. Take the patient’s phone number. Check the result the next day and if the result deviates from your expectation, call the patient to inform them what to do. If you are unsure, bring them back to clinic as soon as possible.</p>\\r\\n<h2 id=\\\"key-issues-for-nursing-care\\\">Key Issues for Nursing care</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Make sure patients understand why they are prescribed anticoagulation.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Counsel patients on the importance of a regular diet and lifestyle and the importance of taking every dose of medication. Help them think through how to schedule doses and to identify reminders to take the medicine (such as the evening call to prayer or a reminder alarm on their phone). Explain the importance of telling anyone who gives them a drug that they are on warfarin.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Explain why patients need to return for INR checks and how the frequency of this may change over time.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Make sure patients know what to do if they start bleeding.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<p>Anticoagulation in patients with heart valve replacements - Guideline for primary and secondary care. 2019; published online March 19. http://www.wales.nhs.uk/sites3/Documents/814/ABUHB_Clinical_0780%20AnticoagulationForHeartValveReplacementsMarch2019.pdf.Keeling D, Shapiro S, Curry N, Price V, Mulholland L. Oxford Haemophilia and Thrombosis Centre Protocols for outpatient oral anticoagulation with vitamin K antagonists. 2017; published online May. https://www.ouh.nhs.uk/services/referrals/specialist-medicine/documents/anticoagulant-protocols.pdf.Tideman PA, Tirimacco R, St John A, Roberts GW. How to manage warfarin therapy. <em>Aust Prescr</em> 2015; <strong>38</strong>: 44–8.Ebell MH. Evidence-Based Initiation of Warfarin (Coumadin). <em>Am Fam Physician</em> 2005; <strong>71</strong>: 763.Camm AJ, Lip GYH, De Caterina R, <em>et al.</em> 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. <em>Eur Heart J</em> 2012; <strong>33</strong>: 2719–47.</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Karen Forrest</th>\\r\\n<th>Date: 03 December 2019</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Behzad Nadjm</td>\\r\\n<td>Date: 04 February 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"001\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>Asthma MeG-CLS-001</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"asthma\\\">Asthma</h1>\\r\\n<h2 id=\\\"executive-summary\\\"><em>Executive summary</em></h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<p><strong>Asthma</strong> is a very common, <a href=\\\"https://en.wikipedia.org/wiki/Chronic_(medicine)\\\"><span data-custom-style=\\\"Hyperlink\\\">long-term</span></a>, <a href=\\\"https://en.wikipedia.org/wiki/Inflammation\\\"><span data-custom-style=\\\"Hyperlink\\\">inflammatory</span></a> disease of the <a href=\\\"https://en.wikipedia.org/wiki/Bronchi\\\"><span data-custom-style=\\\"Hyperlink\\\">airways</span></a> of the lungs, characterized by variable and recurring symptoms, inflammation, reversible <a href=\\\"https://en.wikipedia.org/wiki/Airway_obstruction\\\"><span data-custom-style=\\\"Hyperlink\\\">airflow obstruction</span></a>, and <a href=\\\"https://en.wikipedia.org/wiki/Bronchospasm\\\"><span data-custom-style=\\\"Hyperlink\\\">bronchospasm</span></a>. Symptoms include episodes of <a href=\\\"https://en.wikipedia.org/wiki/Wheezing\\\"><span data-custom-style=\\\"Hyperlink\\\">wheezing</span></a>, <a href=\\\"https://en.wikipedia.org/wiki/Coughing\\\"><span data-custom-style=\\\"Hyperlink\\\">coughing</span></a>, chest tightness, and <a href=\\\"https://en.wikipedia.org/wiki/Shortness_of_breath\\\"><span data-custom-style=\\\"Hyperlink\\\">shortness of breath</span></a>. These episodes may occur a few times a day or a few times per week. Depending on the person, they may become worse at night or with exercise.</p>\\r\\n<p>It is thought to be caused by a combination of <a href=\\\"https://en.wikipedia.org/wiki/Genetics\\\"><span data-custom-style=\\\"Hyperlink\\\">genetic</span></a> and <a href=\\\"https://en.wikipedia.org/wiki/Environmental_factor\\\"><span data-custom-style=\\\"Hyperlink\\\">environmental factors</span></a> (e.g. exposure to <a href=\\\"https://en.wikipedia.org/wiki/Air_pollution\\\"><span data-custom-style=\\\"Hyperlink\\\">air pollution</span></a> and <a href=\\\"https://en.wikipedia.org/wiki/Allergen\\\"><span data-custom-style=\\\"Hyperlink\\\">allergens</span></a>). Other potential triggers include medications such as <a href=\\\"https://en.wikipedia.org/wiki/Aspirin\\\"><span data-custom-style=\\\"Hyperlink\\\">aspirin</span></a> and <a href=\\\"https://en.wikipedia.org/wiki/Beta_blockers\\\"><span data-custom-style=\\\"Hyperlink\\\">beta blockers</span></a>. Diagnosis is usually based on the pattern of symptoms, response to therapy over time, and <a href=\\\"https://en.wikipedia.org/wiki/Spirometry\\\"><span data-custom-style=\\\"Hyperlink\\\">spirometry</span></a> or peak flow</p>\\r\\n<p>There is no cure for asthma. Symptoms can be prevented by avoiding triggers, such as <a href=\\\"https://en.wikipedia.org/wiki/Allergens\\\"><span data-custom-style=\\\"Hyperlink\\\">allergens</span></a> and <a href=\\\"https://en.wikipedia.org/wiki/Irritation\\\"><span data-custom-style=\\\"Hyperlink\\\">irritants</span></a>, and by the use of inhaled <span data-custom-style=\\\"Hyperlink\\\"><a href=\\\"https://en.wikipedia.org/wiki/Corticosteroid\\\">corticosteroids</a>.</span></p>\\r\\n<h2 id=\\\"target-users\\\">Target users</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doctors</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nurses</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"target-area-of-use\\\">Target area of use </h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Gate clinic</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Outpatients</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ward</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"key-areas-of-focus-new-additions-changes\\\">Key areas of focus / New additions / Changes </h3>\\r\\n<p>This guideline addresses the management of both acute and chronic asthma. It gives guidance on the immediate management of the acutely ill patient in gate clinic and the ongoing management of such patients on the ward.</p>\\r\\n<p>It provides an asthma management plan to encourage literate patients to self-manage their asthma.</p>\\r\\n<p>It advocates the use of inhalers rather than oral medications – given the increased effectiveness and reduced side-effects associated with this treatment.</p>\\r\\n<h2 id=\\\"limitations\\\">Limitations</h2>\\r\\n<p>There is no access to arterial blood gases or to intubation for severely ill patients with asthma.</p>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs\\\">Presenting symptoms and signs</h2>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th></th>\\r\\n<th><strong>Life threatening</strong></th>\\r\\n<th><strong>Acute severe</strong></th>\\r\\n<th><strong>Moderately exacerbated</strong></th>\\r\\n<th><strong>Mild</strong></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Dyspnoea</strong></td>\\r\\n<td>At rest</td>\\r\\n<td>At rest</td>\\r\\n<td>When talking</td>\\r\\n<td>With activity</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Speech</strong></td>\\r\\n<td>Mute</td>\\r\\n<td>Difficult</td>\\r\\n<td>Difficulty completing sentences</td>\\r\\n<td>Can complete sentences</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Body position</strong></td>\\r\\n<td>Unable to recline</td>\\r\\n<td>Unable to recline, restless</td>\\r\\n<td>Sitting up</td>\\r\\n<td>Able to recline</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Respiratory rate</strong></td>\\r\\n<td>&gt;30 /min – feeble effort</td>\\r\\n<td>Often &gt; 25 /min</td>\\r\\n<td>Increased</td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Use of accessory muscles</strong></td>\\r\\n<td>Paradoxical thoraco-abdominal movements</td>\\r\\n<td>Increased use</td>\\r\\n<td>Yes</td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Breath sounds</strong></td>\\r\\n<td>Near silent or silent chest</td>\\r\\n<td>Loud inspiratory and expiratory wheeze</td>\\r\\n<td>Loud expiratory wheeze</td>\\r\\n<td>Moderate wheeze at mid to end expiration</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Heart rate</strong></td>\\r\\n<td>Relative bradycardia &lt; 50/min</td>\\r\\n<td>Tachycardia &gt; 110 /minute</td>\\r\\n<td>&gt; 100 /min</td>\\r\\n<td>&lt; 100 /min</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Blood pressure</strong></td>\\r\\n<td>Hypotension</td>\\r\\n<td>Normotensive in most cases</td>\\r\\n<td>Normotensive</td>\\r\\n<td>Normotensive</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Mental status</strong></td>\\r\\n<td>Confused or drowsy</td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>PEFR (% of predicted)</strong></td>\\r\\n<td>&lt; 33%</td>\\r\\n<td>33-50%</td>\\r\\n<td>50-80%</td>\\r\\n<td>&gt; 80%</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Oxygen saturation</strong></td>\\r\\n<td>&lt; 92%</td>\\r\\n<td>≥ 92%</td>\\r\\n<td>&gt; 95%</td>\\r\\n<td>&gt; 95%</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>ECG</strong></td>\\r\\n<td>Arrhythmia</td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<h3 id=\\\"brittle-asthma\\\">Brittle asthma</h3>\\r\\n<p>Defined by either:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Wide peak flow variability (&gt; 40% diurnal variation for more than 50% of the time over a period of &gt; 150 days) despite intense therapy</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Sudden severe attacks on a background of apparently well-controlled asthma</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"investigations-of-acute-severe-asthma\\\">Investigations of acute severe asthma</h2>\\r\\n<p><strong>Peak flow</strong> – when expressed as a percentage of the patient’s previous best value is most useful clinically</p>\\r\\n<p><strong>Pulse Oximetry</strong> – measurement of oxygen saturation with a pulse oximeter is necessary to determine the adequacy of oxygen therapy</p>\\r\\n<p><strong>Chest x-ray</strong> – recommended in patients with:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Suspected pneumomediastinum or pneumothorax</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Suspected consolidation</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Life-threatening asthma</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Failure to respond to treatment satisfactorily</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Requirement for ventilation.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Arterial blood gases are desirable but not currently available.</p>\\r\\n<h2 id=\\\"management-in-gate-clinic\\\">Management in Gate Clinic </h2>\\r\\n<p>Anyone with saturations below 92%, very little air entry, poor respiratory effort, reduced conscious level, reduced blood pressure, arrhythmia has life-threatening asthma and <em><strong>the doctor should be called to see them immediately</strong></em>.</p>\\r\\n<p>Look out for common symptoms and signs of asthma: cough, difficulty with breathing, dyspnea, difficulty speaking in full sentences, sitting up/unable to recline.</p>\\r\\n<p>Once you suspect asthma, examine for auscultatory wheeze (if life threatening, chest may be silent).</p>\\r\\n<p>Nebulize immediately if there is anything other than mild asthma with Salbutamol 2.5 mg in children, 5 mg in adults, double diluted with water for injection. Nebulization can be done back to back till the patient feels relief.</p>\\r\\n<p>Give a course of steroids to all patients with a clear diagnosis of asthma, who do not have signs of severe asthma and who improve after nebulization. Give prednisolone 40 mg OD for 5 days to adults and 2 mg/kg (max 40 mg) OD for 3 days to children.</p>\\r\\n<p>Also give these patients a salbutamol inhaler with a spacer. Ensure that the patient and their family understand when to use the inhaler and how to use it. Advise them to use the inhaler whenever they are short of breath. Explain that they should always use the spacer to ensure the full dose of medication reaches their lungs and that they do not suffer side effects. If they need to use it more than 3 times in a day, then they should seek medical help. Also advise them to take 10 puffs of the inhaler via the spacer if they become acutely breathless. They should then seek medical help.</p>\\r\\n<h3 id=\\\"refer-to-the-doctor-if\\\">Refer to the doctor if:</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>you are unsure of the diagnosis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>there is any of fever, weight loss, general body pain, failure to thrive, any unexplained clinical findings, vomiting or chronic productive cough.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>the patient has not improved after nebulization.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"management-in-opd\\\">Management in OPD</h2>\\r\\n<p>Look out for common symptoms and signs of asthma: cough, difficulty with breathing, dyspnea, difficulty speaking in full sentences, sitting up/unable to recline.</p>\\r\\n<p>Once you suspect asthma, do a quick assessment: including a quick general examination and a quick respiratory exam (including pulse oximetry).</p>\\r\\n<p>Send for nebulization and/or admission as necessary. If stable after nebulization, consider managing as outpatient with short follow-up period.</p>\\r\\n<h3 id=\\\"stable-asthma-management\\\">Stable asthma management</h3>\\r\\n<p>For patients with stable asthma use the asthma action plan to help them manage their asthma in the long run.</p>\\r\\n<p>Give these patients a salbutamol inhaler with a spacer. Ensure that the patient and their family understand when to use the inhaler and how to use it. Advise them to use the inhaler whenever they are short of breath. Explain that they should always use the spacer to ensure the full dose of medication reaches their lungs and that they do not suffer side effects. If they need to use it more than 3 times in a day, then they should seek medical help. Also advise them to take 10 puffs of the inhaler via the spacer if they become acutely breathless. They should then seek medical help.</p>\\r\\n<h2 id=\\\"management-on-the-ward\\\">Management on the ward</h2>\\r\\n<p>Admit the patient if:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Respiratory fatigue and suspected airway infection</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Presence of pneumothorax</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hypotensive</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>History of status epilepticus</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Persisting or worsening hypoxia</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Drowsiness and confusion</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Exhaustion, feeble respiratory effort</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>ECG abnormalities (supraventricular arrhythmias, multifocal atria tachycardia, conduction disturbances, ventricular ectopics).</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Move to acute care room or emergency bed and give continuous humidified oxygen.</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Every 15 minutes monitor pulse oximetry and vital signs electronically.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Rehydrate if dehydrated or hypotensive using 0.9% Normal Saline at maintenance level.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nebulise with Salbutamol (5 mg in 5 mls of Normal saline or 2.5 mg for children).</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>IV Hydrocortisone 200 mg 6 hourly or Oral Prednisolone 30-50 mg PO.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Consider giving a single dose of IV Magnesium Sulphate (1.2-2 g IV MgSO<sub>4</sub> in 100ml 0.9% saline over 20 minutes) for patients with acute severe asthma that have not had a good initial <em>response to inhaled bronchodilator therapy or have life</em> <em>threatening</em> or near fatal asthma.</p>\\r\\n<p>Subcutaneous adrenaline (1: 10,000 solution) 0.1 – 0.3 ml in the young and 1 ml in the adult can be used for those that do not respond despite all the measures above.</p>\\r\\n<p>Remember to exclude anaphylaxis and tension pneumothorax.</p>\\r\\n<h3 id=\\\"intravenous-aminophylline\\\">Intravenous aminophylline</h3>\\r\\n<p>In acute asthma, the use of aminophylline is not likely to result in any additional bronchodilation compared to standard immediate treatment with nebulised ß<sub>2</sub>-agonist bronchodilators and oral steroids. Some patients with near fatal asthma or life threatening asthma with a poor response to initial therapy may gain additional benefit from iv aminophylline.</p>\\r\\n<p>Give a single iv dose of aminophylline 5 mg/kg over 30 minutes only if the patient has not received oral theophylline or aminophylline within the last 24 hours.</p>\\r\\n<p>Add 500 mg aminophylline (20 ml volume to 500 ml 0.9% saline after removing 20 ml from the bag of saline (concentration: 500 mg in 500ml = 1 mg/ml). Run the infusion for 30 minutes.</p>\\r\\n<p>Do not use a maintenance infusion unless it is absolutely necessary as we cannot measure aminophylline levels.</p>\\r\\n<p>Consider intubation if in <strong>impending respiratory failure</strong> – no sedation to be given</p>\\r\\n<p><strong>ASTHMA ACTION PLAN</strong></p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Name:</strong></th>\\r\\n<th><strong>My Asthma Severity:</strong></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><p><img src=\\\"data:image/png;base64,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\\\" style=\\\"width:0.38547in;height:0.36463in\\\" /></p>\\r\\n<p><strong>GO</strong></p>\\r\\n<p>I feel good</p>\\r\\n<p>No cough or wheeze</p>\\r\\n<p>I can work, sleep &amp; play without symptoms</p>\\r\\n<p>My peak flow number is above __________</p></td>\\r\\n<td><p><strong>Green Zone</strong> : Asthma in good Control</p>\\r\\n<ol type=\\\"1\\\">\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Take your asthma preventer inhaler everyday: <strong>Seretide/ Beclomethasone</strong> inhaler 2 puffs twice a day (gargle with warm water after)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Avoid your triggers as much as possible</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>If you are about to something really physically demanding, use <strong>Salbutamol</strong> inhaler 2 puffs 15 minutes before starting and 2 puffs during the activity if you have symptoms.</p>\\r\\n</div></li>\\r\\n</ol></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><p><img src=\\\"data:image/png;base64,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\\\" style=\\\"width:0.42714in;height:0.40631in\\\" /></p>\\r\\n<p><strong>SLOW</strong></p>\\r\\n<p>I have any one of these:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>I do not feel good</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Cough or wheeze</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Chest feels tight</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Waking up at night</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Difficulty working, playing or sleeping</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>My peak flow number is between __________ and __________</p></td>\\r\\n<td><p><strong>Yellow Zone</strong>: Asthma is getting worse</p>\\r\\n<ol type=\\\"1\\\">\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Keep taking your green zone inhalers.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Start your reliever/rescue inhaler <strong>Salbutamol Inhaler</strong> 2 puffs every 20 minutes for up to one hour. Then every 4 hours for 24-48 hours.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>If you do not return to the green zone in 12 hours, or you get worse, start taking <strong>Prednisolone</strong> 40 mg once daily for 5 days.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>If you stay in yellow zone for more than 12 hours, go to the clinic ASAP.</p>\\r\\n</div></li>\\r\\n</ol></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><p><img src=\\\"data:image/png;base64,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\\\" style=\\\"width:0.36463in;height:0.31254in\\\" /></p>\\r\\n<p><strong>STOP</strong></p>\\r\\n<p>I have any one of the following:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Very short of breath. Cannot sleep, walk, work, talk or play</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Severe wheezing, coughing hard</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Chest tightness</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Blueness of skin of lips, tiredness due to effort of breathing</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>My peak flow number is less than ___________</p></td>\\r\\n<td><p><strong>Red Zone</strong>-Medical Alert- Get Help FAST!!</p>\\r\\n<ol type=\\\"1\\\">\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Take reliever immediately or get nebulised every 10-15 minutes.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Get to health facility FAST.</p>\\r\\n</div></li>\\r\\n</ol></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<p><span data-custom-style=\\\"cit-article-title\\\"><em>Asthma: diagnosis, monitoring and chronic asthma management, NICE NG80, November 2017</em></span><span data-custom-style=\\\"HTML Cite\\\">.</span> <a href=\\\"https://www.nice.org.uk/guidance/ng80\\\"><span data-custom-style=\\\"Hyperlink\\\"><em>https://www.nice.org.uk/guidance/ng80</em></span></a> <span data-custom-style=\\\"HTML Cite\\\">(</span><span data-custom-style=\\\"cit-comment\\\"><em>accessed 4 June 2018</em></span><span data-custom-style=\\\"HTML Cite\\\">).</span></p>\\r\\n<p><span data-custom-style=\\\"HTML Cite\\\">National Asthma Education and Prevention Program Expert Panel Report 3: Guidelines for the diagnosis and management of Asthma.</span> <a href=\\\"https://www.nhlbi.nih.gov/sites/default/files/media/docs/asthsumm.pdf\\\"><span data-custom-style=\\\"Hyperlink\\\">https://www.nhlbi.nih.gov/sites/default/files/media/docs/asthsumm.pdf</span></a></p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Babatunde Awokola</th>\\r\\n<th>Date: 29 June 2018</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Karen Forrest</td>\\r\\n<td>Date: 25 July 2018</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>2.0</td>\\r\\n<td>Rewritten to expand relevance beyond gate clinic</td>\\r\\n<td>31 July 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>2.1</td>\\r\\n<td>Executive summary added</td>\\r\\n<td>31 July 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"050\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>Bone and joint infections guidelines MeG-CLS-050</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"bone-and-joint-infections\\\">Bone and Joint infections</h1>\\r\\n<h2 id=\\\"executive-summary\\\"><em>Executive summary</em></h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<p>Bone and joint infections are serious conditions requiring prompt diagnosis and treatment to prevent disability and mortality. They consist of osteomyelitis (OM) and septic arthritis (SA). Both are bacterial infections that occur by a hematogenous spread from other parts of the body. They may result in sepsis and bone loss. These infections frequently occur in the lower limbs but can occur in the upper limbs and vertebrae.</p>\\r\\n<p>The most common causative organism is <em>Staphylococcus aureus</em> in all ages. <em>Hemophilus influenza</em> is also common in children aged less than 5 years. In sexually active adults and adolescents, <em>Neisseria gonorrhoea</em> could be suspected. Bone and joint infections in sickle cell disease patients may be caused by <em>Salmonella spp</em></p>\\r\\n<p>Osteomyelitis is an infection of the bone that may be acute or chronic. Acute osteomyelitis is a medical emergency requiring a long duration of treatment with intravenous antibiotics. A chronic OM is managed by the orthopaedic surgeons and its presentation is insidious in onset, occurring over weeks and with draining sinuses on the skin.</p>\\r\\n<p>Septic arthritis is an acute bacterial joint infection and an orthopedic emergency requiring arthrocentesis and intravenous antibiotics to prevent joint deformity and disability.</p>\\r\\n<h2 id=\\\"target-users\\\">Target users</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doctors</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nurses</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"target-area-of-use\\\">Target area of use </h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Outpatients</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ward</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"key-areas-of-focus-new-additions-changes\\\">Key areas of focus / New additions / Changes </h2>\\r\\n<p>This guideline outlines the diagnosis and management of bone and joint infections.</p>\\r\\n<h2 id=\\\"limitations\\\">Limitations</h2>\\r\\n<p>Patients with suspected septic arthritis must be referred to the orthopaedic surgeons as soon as possible.</p>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs\\\">Presenting symptoms and signs</h2>\\r\\n<p>The symptoms and signs of OM and SA are of an acute onset (usually within days) and include:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Fever (some babies may be apyrexial)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Swelling of the limb or joint</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Limping or refusal to use affected limb</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Movement restriction at the joint(s) – OA</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Malaise</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>There may be no preceding history of trauma or penetrative injury to the affected limb.</p>\\r\\n<h2 id=\\\"examination-findings\\\">Examination findings:</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Fever</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Tender joint or limb swelling, non-pitting with differential warmth</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Joint movement restriction</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Painful gait</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"differential-diagnoses\\\">Differential diagnoses :</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Acute OM</p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Traumatic or stress fracture</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Cellulitis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Pyomyositis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Septicaemia (newborns)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Thrombophlebitis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Sickle cell infarction</p>\\r\\n</div></li>\\r\\n</ul></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>SA</p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Viral arthritis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Reactive arthritis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Juvenile idiopathic arthritis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Tuberculosis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Slipped capital femoral epiphysis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Vaso-occlusive crisis in sickle cell anaemia</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Arthralgia</p>\\r\\n</div></li>\\r\\n</ul></li>\\r\\n</ul>\\r\\n<h2 id=\\\"investigations\\\">Investigations</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>ESR</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>FBC</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Blood culture</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>X-ray to rule out fracture, chronic OM</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>MRI for Acute OM</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Joint aspiration for microscopy, culture and sensitivity – should be done before commencement of empirical antibiotic therapy</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>US scan of the joints may be done in children</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"management\\\">Management</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Empirical antibiotic therapy is based on the commonest organisms responsible for infections – <em>Staph. aureus</em> in adults and children over 5 years and <em>Haemophilus influenza</em> for children aged under 5 years.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>For SA, antibiotic therapy is given for 2-3 weeks. If patient improves on IV antibiotics after 4-6 days, oral antibiotics can be used and continued until the end of 3 weeks.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>For OM, parenteral antibiotics should be given for at least 2 weeks before continuing on oral therapy. Duration of therapy for children is between 3-4 weeks and for adults 4–6 weeks.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Empirical antibiotic therapy should be changed if antibiotic sensitivity results are different from current therapy.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Serial arthrocentesis, arthroscopy or arthrotomy may be needed in SA.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p><strong>Empirical antibiotic therapy</strong></p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Age</strong></th>\\r\\n<th><strong>OM</strong></th>\\r\\n<th><strong>SA</strong></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Children under 5 years</td>\\r\\n<td>IV Cloxacillin 25-50 mg/kg QDS <em>plus</em> Ceftriaxone 50-75 mg/kg OD for 4 -6 days <em>followed by</em> oral Amoxicillin 15 mg/kg + clavulanic acid (maximum 500 mg) orally every 8 hours to complete the treatment course.</td>\\r\\n<td>IV Cloxacillin 25-50 mg/kg QDS <em>plus</em> Ceftriaxone 50-75 mg /kg OD for 4-6 days <em>followed by</em> oral Cloxacillin 12.5 mg/kg QDS for the duration of treatment.</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><em>Children aged 5 years and above</em></td>\\r\\n<td><p>IV Cloxacillin 25–50 mg/kg (maximum 2 g) QDS for 4-6 days (or until clinical improvement occurs), followed by cloxacillin 25 mg/kg (maximum 500 mg) orally every 6 hours to complete the treatment course</p>\\r\\n<p>OR</p>\\r\\n<p>IV Ceftriaxone 50–75 mg/kg (maximum 1 g) OD for 4-6 days (or until clinical improvement occurs), followed by oral Cloxacillin 25 mg/kg (maximum 500 mg) orally QDS to complete the treatment course.</p></td>\\r\\n<td>IV Cloxacillin 25-50 mg/kg QDS plus IV Ceftriaxone 25-50 mg/kg OD</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><em>Adults</em></td>\\r\\n<td>IV Cloxacillin 2 g QDS for at least the initial 14 days, but preferably the entire treatment course of 4-6 weeks (if the duration of parenteral therapy is less than 4-6 weeks, the treatment course should be completed with cloxacillin 1 g orally QDS)</td>\\r\\n<td>IV Cloxacillin 2 g QDS plus IV Ceftriaxone 1-2 g OD</td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>On suspicion of septic arthritis, the orthopaedic surgeon at the teaching hospital should be informed and patient should be referred.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>All patients with bone and joint infections should be informed of the seriousness of the condition and the need for adherence to the long course of antibiotic therapy.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p><strong>Key Issues for Nursing care</strong></p>\\r\\n<p>Patients suspected of having bone or joint infections should see a doctor immediately, as this is an emergency.</p>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<p>Coakley G, Mathews C, Field M, Jones A, Kingsley G, Walker D, Phillips M, Bradish C, McLachlan A, Mohammed R, Weston V. BSR &amp; BHPR, BOA, RCGP and BSAC guidelines for management of the hot swollen joint in adults. Rheumatology. 2006 Jul 6;45(8):1039-41.</p>\\r\\n<p>Saavedra-Lozano J, Falup-Pecurariu O, Faust SN, Girschick H, Hartwig N, Kaplan S, Lorrot M, Mantadakis E, Peltola H, Rojo P, Zaoutis T. Bone and joint infections. The Pediatric infectious disease journal. 2017 Aug 1;36(8):788-99</p>\\r\\n<p>Korean Orthopaedic Association. Clinical guidelines for the antimicrobial treatment of bone and joint infections in Korea. Infection &amp; chemotherapy. 2014 Jun 1;46(2):125-38.</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Orighomisan Agboghoroma</th>\\r\\n<th>Date: 13 November 2018</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Karen Forrest</td>\\r\\n<td>Date: 16 November 2018</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td>31 January 2021</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>1.1</td>\\r\\n<td>Executive summary added</td>\\r\\n<td>31 January 2021</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"069\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>Bronchiolitis MeG-CLS-069</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"bronchiolitis\\\">Bronchiolitis</h1>\\r\\n<h2 id=\\\"executive-summary\\\"><em>Executive summary</em></h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<p>Bronchiolitis is a common viral infection that affects infants from birth to 2 years old but seen mostly in those less than 6 months old. They present with persistent cough, wheeze and varying degrees of respiratory distress. Fever, poor feeding and irritability is a common presentation. Bronchiolitis is a clinical diagnosis. No investigation is required. Those with severe respiratory distress with/and poor feeding and dehydration should be admitted. Management is supportive and minimal handling is recommended. Oxygen therapy, suctioning and nasogastric tube feeding should be given when required. Chest x-rays, blood investigations, antibiotics and nebulisations are not recommended. Oxygen saturations, respiratory rates and efforts should be monitored.</p>\\r\\n<h2 id=\\\"target-users\\\">Target users</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doctors</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nurses</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"target-area-of-use\\\">Target area of use </h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Outpatient department</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ward</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"key-areas-of-focus-new-additions-changes\\\">Key areas of focus / New additions / Changes </h2>\\r\\n<p>This guideline addresses the diagnosis and management of bronchiolitis.</p>\\r\\n<h2 id=\\\"limitations\\\">Limitations</h2>\\r\\n<p>Respiratory support via mechanical ventilation is not available in our setting.</p>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs\\\">Presenting symptoms and signs</h2>\\r\\n<p>Bronchiolitis typically begins with an acute upper respiratory tract infection lasting 1 to 3 days followed by</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Persistent cough</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Tachypnoea or chest recessions (or both)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Wheeze or crackles on chest auscultations (or both).</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>It may also present with</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Fever (may be present but usually less than 39 <sup>O</sup>C)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Poor feeding</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Increasing coryza and congestion</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Irritability</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Cyanosis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Apnoea may be the first presentation and this tends to occur in infants under 6 weeks of age.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Symptoms usually peak between 3 and 5 days and cough resolves in 90% of infants within 3 weeks.</p>\\r\\n<p>Bronchiolitis is a clinical diagnosis based on typical history and examination.</p>\\r\\n<h2 id=\\\"differential-diagnosis\\\">Differential diagnosis</h2>\\r\\n<ol type=\\\"1\\\">\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Pneumonia:</strong> consider this if the infant has</p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>high fever (over 39 <sup>O</sup>C ) and/or</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>persistently focal crackles</p>\\r\\n</div></li>\\r\\n</ul></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Viral-induced wheeze or early-onset-asthma</strong>: consider in infants with</p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>persistent wheeze without crackles</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>recurrent episodic wheeze</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>a personal or family history of atopy</p>\\r\\n</div></li>\\r\\n</ul></li>\\r\\n</ol>\\r\\n<p>Other differential diagnoses include:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Cardiac disease/ congenital heart disease</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Croup</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Aspiration syndromes</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Gastroesophageal reflux</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Tracheal ring</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Vascular ring</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Branchial cleft cyst</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Bronchomalacia.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"investigations\\\">Investigations</h2>\\r\\n<p>In most children with bronchiolitis no investigations are required, therefore investigations should only be undertaken when there is diagnostic uncertainty eg cardiac murmur with signs of congestive cardiac failure.</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Chest X-ray is not routinely indicated and may lead to unnecessary treatment with antibiotics<strong>.</strong></p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Blood tests (including blood gas, full blood count (FBC), blood cultures) have no role in management<strong>.</strong></p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Virological testing (nasopharyngeal swab or aspirate) has no role in management of individual patients<strong>.</strong></p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"management\\\">Management</h2>\\r\\n<p>Management is directed towards <strong>symptomatic relief</strong>. Apart from oxygen, no pharmacological therapy is proven to change the course of bronchiolitis. Thus medications should be avoided.</p>\\r\\n<p>In management of bronchiolitis do <strong>not</strong> give the following:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Antibiotics</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hypertonic saline</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Salbutamol</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Systemic or inhaled corticosteroids</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Chest physiotherapy (except in children with underlying respiratory conditions).</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Admit to the ward if a child has any of the following:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Apnoea (observed or reported)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Persistent oxygen saturation of less than 92% in room air</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Inadequate oral fluid intake</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Clinically dehydrated</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Severe respiratory distress eg grunting, marked chest recession, respiratory rates above 70 breaths/minute.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Risk factors for more serious illness include:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Chronological age at presentation less than 10 weeks</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Chronic lung disease</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Congenital heart disease</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Chronic neurological conditions</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Immunodeficiency<strong>.</strong></p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Suspect impending respiratory failure if any of the following are present:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>signs of exhaustion, for example listlessness or decreased respiratory effort</strong></p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>recurrent apnoea</strong></p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>failure to maintain adequate oxygen saturation despite oxygen supplementation.</strong></p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Supportive care for patients with bronchiolitis may include the following:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Supplemental (humidified) oxygen:</strong> consider CPAP in impending respiratory failure.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Ensure adequate hydration</strong>: give fluids by nasogastric tube if they cannot take enough by mouth.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Give <strong>intravenous isotonic fluids</strong> to children who do not tolerate nasogastric fluids or have impending respiratory failure.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Nasal and oral suctioning</strong> in children who have respiratory distress or feeding difficulties because of upper airway secretions and children who have apnoea.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Apnoea and cardiorespiratory monitoring.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Mechanical ventilation in respiratory failure.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"key-issues-for-nursing-care\\\">Key Issues for Nursing care</h2>\\r\\n<p>Minimal handling is recommended in the care of children with bronchiolitis. Oxygen saturation and respiratory rate and efforts and able to tolerate oral feeds should be monitored closely to enable timely escalation or weaning oxygen therapy. Very young children with bronchiolitis are at risk of apnoea and this should be looked out for.</p>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<p>Nizar F Maraqa et al. (2018). Bronchiolitis. Medscape @ emedicine. Retrieved from <a href=\\\"https://emedicine.medscape.com/article/961963-differential\\\"><span data-custom-style=\\\"Hyperlink\\\">https://emedicine.medscape.com/article/961963-differential</span></a></p>\\r\\n<p>Bronchiolitis in children: diagnosis and management. National institute for Health and Care Excellence. Retrieved from <a href=\\\"https://www.nice.org.uk/guidance/ng9/chapter/1-Recommendations#assessment-and-diagnosis\\\"><span data-custom-style=\\\"Hyperlink\\\">https://www.nice.org.uk/guidance/ng9/chapter/1-Recommendations#assessment-and-diagnosis</span></a> on 28<sup>th</sup> May, 2019.</p>\\r\\n<p>Friedman JN et al. (2018). Bronchiolitis: Recommendations for diagnosis, monitoring and management of children one to 24 months of age. Canadian Paediatric society. Retrieved from <a href=\\\"https://www.cps.ca/en/documents/position/bronchiolitis#TABLE3\\\"><span data-custom-style=\\\"Hyperlink\\\">https://www.cps.ca/en/documents/position/bronchiolitis#TABLE3</span></a> om 3<sup>rd</sup> June, 2019.</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Fatoumata Sawaneh</th>\\r\\n<th>Date: 3 June 2019</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Baderinwa Abatan</td>\\r\\n<td>Date: 12 June 2019</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td>30 August 2021</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"051\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>Cellulitis MeG-CLS-051</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h2 id=\\\"cellulitis\\\">Cellulitis</h2>\\r\\n<h2 id=\\\"executive-summary\\\"><em>Executive summary</em></h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<p>The term cellulitis is commonly used to indicate a non-necrotizing inflammation of the skin and subcutaneous tissues, usually from acute infection. Cellulitis usually follows a breach in the skin, although a portal of entry may not be obvious; the breach may involve microscopic skin changes or invasive qualities of certain bacteria.</p>\\r\\n<h2 id=\\\"target-users\\\">Target Users</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doctors</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nurses</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"target-area-of-use\\\">Target area of use </h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ward</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Outpatient department</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Gate clinic</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"key-areas-of-focusnew-additionschanges\\\">Key areas of focus/new additions/changes</h2>\\r\\n<p>These guidelines addresses the management of cellulitis in adults and children.</p>\\r\\n<h2 id=\\\"limitations\\\">Limitations</h2>\\r\\n<p>Patient with complicated cellulitis associated with compartment syndrome or necrosis must be referred to a surgeon.</p>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs\\\">Presenting symptoms and signs</h2>\\r\\n<p>Nonpurulent cellulitis is associated with the 4 cardinal signs of infections, as follows:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Erythema</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Pain</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Swelling</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Warmth</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>The follow findings suggest severe infection:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Malaise</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Chills</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Fever and toxicity</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Circumferential cellulitis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Lymphangitic spread (red lines streaking away from the area of infection)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Crepitus</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Pain disproportionate to examination findings</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"examination-findings\\\">Examination findings</h2>\\r\\n<p>The involved site(s) is/are red, hot, swollen and tender. The leg is the most common site. Tinea pedis lesions may be the sites of entry</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Regional lymphadenopathy may be present</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Malaise, chills, fever, and toxicity may be present</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Skin infections without associated drainage, penetrating trauma, eschar, or abscess is most likely caused by streptococci; on the other hand<strong>, <em>S aureus</em></strong>, often community acquired methicillin-resistant <em>S aureus</em> (MRSA), is the most likely pathogen when these factors are present.</p>\\r\\n<p>Perianal cellulitis is usually observed in children with perianal fissures; it is characterized by <strong>perianal erythema</strong> and <strong>pruritis, purulent secretions</strong>, <strong>painful defecation</strong> and <strong>blood in stools</strong></p>\\r\\n<p>Cellulitis characterized by violet colour and bullae suggests more serious or systemic infection with organisms such as <em>V. vulnificus</em> or <em>S. pneumoniae.</em></p>\\r\\n<p>Lymphangitic spread (red lines streaking away from area of infection), crepitus, .and hemodynamic instability are indications of severe infection, requiring more aggressive treatment.</p>\\r\\n<p>Circumferential cellulitis or pain that is disproportional to examination findings should prompt consideration of severe soft tissue infection</p>\\r\\n<p><strong><a href=\\\"https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540402/all/Orbital_Cellulitis\\\">Periorbital</a> (preseptal) cellulitis</strong> is potentially serious and merits an ophthalmology consultation and a CT scan to exclude an orbital infection</p>\\r\\n<p><strong><span class=\\\"underline\\\">Indication for referral for emergent surgical evaluation</span></strong> are as follows:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Violaceous bullae</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Cutaneous haemorrhage</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Skin sloughing</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Skin anaesthesia</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Rapid progression</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Gas in the tissue (crepitus)</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"differential-diagnoses\\\">Differential Diagnoses</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Erysipelas (more superficial with sharply demarcated borders)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Thrombophlebitis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><a href=\\\"https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540378/all/Necrotizing_Fasciitis\\\">Necrotizing fasciitis</a></p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Erythroderma</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Panniculitis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Pyoderma</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Dermatitis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Allergic reactions</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Drug reaction</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"investigations\\\">Investigations</h2>\\r\\n<p>Generally no work-up is required in uncomplicated cases of cellulitis.</p>\\r\\n<p>For patients with cellulitis who have signs and symptoms of systemic inflammatory response, do:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>FBC</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Creatinine and Bicarbonate</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Aspirate gram stain and culture (purulent cellulitis only)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Blood culture should be performed for serious infections to pinpoint the etiology</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Blood cultures are only positive in 5-15 % of patients with cellulitis)</p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"List Paragraph\\\">\\r\\n<blockquote>\\r\\n<p>Blood cultures are also indicated in special populations (immunosuppressed, severe post-surgical wounds).</p>\\r\\n</blockquote>\\r\\n</div>\\r\\n<h2 id=\\\"management\\\">Management </h2>\\r\\n<h3 id=\\\"management-at-the-gate-clinic\\\">Management at the Gate Clinic</h3>\\r\\n<p>Patients with cellulitis should be referred to OPD for evaluation by a doctor.</p>\\r\\n<h3 id=\\\"management-in-opd-or-on-the-ward\\\">Management in OPD or on the ward</h3>\\r\\n<p>Management of cellulitis should include elevation of the affected area and treatment of underlying conditions.</p>\\r\\n<p>Many patients with cellulitis have underlying conditions that predispose them to developing recurrent cellulitis (these include tinea pedis, lymphedema, and chronic venous insufficiency). In such patients, treatment should be directed at both the infection and the predisposing condition if modifiable. As an example, patients with oedema may benefit from treatment with compressive stockings and diuretic therapy.</p>\\r\\n<p>Consider in-patient care when there is:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>An elevated creatinine level</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>A low serum bicarbonate level</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Systemic signs of toxicity (e.g. fever &gt; 38°C, hypotension, or sustained tachycardia)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Rapid progression of erythema</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Progression of clinical findings after 48 hours of oral antibiotic therapy</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Inability to tolerate oral therapy</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Proximity of the lesion to an indwelling medical device (e.g. prosthetic joint or vascular graft)</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"nonpurulent-cellulitis\\\">Nonpurulent cellulitis</h3>\\r\\n<p>Patients with nonpurulent cellulitis (e.g. cellulitis with no purulent drainage or exudate and no associated abscess) should be managed with empiric therapy for infection due to beta-hemolytic streptococci and methicillin-susceptible <span data-custom-style=\\\"Emphasis\\\">Staphylococcus aureus</span>. Common options for mild infections are:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Cloxacillin 25 mg/kg/dose (max. 500 mg) PO QDS</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Amoxicillin/Clavulanate 625 – 875 mg PO BD</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>For patients with penicillin allergies:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Azithromycin 10 mg/kg (max. 500 mg) PO OD for 3 days, or</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Clindamycin 150 – 300 mg PO QDS (3 – 6 mg/kg/dose in children)</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>In patients with moderately severe infection, intravenous antibiotics options include:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>IV Cloxacillin 1 – 2 g QDS</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>For severe infections:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>IV Ceftriaxone 1 – 2 g OD (children 50 – 80 mg/kg OD)</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"purulent-infection\\\"><span data-custom-style=\\\"h23\\\"><strong>Purulent infection</strong></span></h3>\\r\\n<p>Purulent infection refers to presence of a drainable abscess <span data-custom-style=\\\"Strong\\\">or</span> cellulitis associated with purulent drainage in the absence of drainable abscess. Any infection involving purulence is potentially attributable to <span data-custom-style=\\\"Emphasis\\\">MRSA</span>, which should be reflected in the choice of empiric antimicrobial therapy.</p>\\r\\n<p><strong>Incision and drainage</strong> of abscess is indicated for all purulent infections and is sufficient for <strong>mild infections.</strong></p>\\r\\n<p>For moderate infections, options for oral antibiotics include the following:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doxycycline 100 mg PO BD (non-pregnant adults only), or</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Trimethoprim-sulfamethoxazole 24 mg/kg/dose (max. 960 mg) PO BD</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Once microorganisms are identified based on cultures, treatment is tailored to the patient’s need. The most common organism are staphylococcal and streptococcal strains.</p>\\r\\n<h3 id=\\\"duration-of-therapy\\\">Duration of therapy</h3>\\r\\n<p>The appropriate duration of therapy for treatment of skin and soft tissue infection depends on the nature of the clinical presentation, and the clinical response should guide duration of therapy.</p>\\r\\n<p>Patients with mild infection who receive outpatient management with oral antibiotic therapy should have repeat evaluation after 48 hours to verify clinical response.</p>\\r\\n<p>Patients with MRSA responsive to oral therapy are typically treated for 5 days; treatment may be extended up to 14 days where there is severe infection, slow response to therapy, or immunosuppression. Lack of response may be due to infection with resistant organism(s), inadequate adherence, or presence of a deeper, more serious infection than previously realized.</p>\\r\\n<p>Patients with infection warranting parenteral therapy (in the absence of bacteraemia or involvement beyond soft tissue) are typically treated for a total duration of 5 to 14 days. Once there are signs of clinical improvement with no evidence of systemic toxicity, antibiotics may be transitioned from parenteral to oral therapy.</p>\\r\\n<p>For patients with abscess that was detected radiographically, follow-up imaging may be useful for assessing response to therapy.</p>\\r\\n<h2 id=\\\"key-issues-for-nursing-care\\\">Key Issues for Nursing care</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ensure that patient get adequate bed rest: Passive exercise can reduce the associated complications</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Limb elevation is important to reduce oedema</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Pressure area care</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Cleaning any skin breaks carefully and monitoring for signs of infection</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Advise on basic skin care and avoidance of predisposing factors where possible</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Advise on avoidance of skin damage by wearing appropriate protective equipment when taking part in work or sport.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<p><a href=\\\"https://www.uptodate.com/contents/cellulitis-and-skin-abscess-in-adults-treatment/abstract/1\\\">Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.</a></p>\\r\\n<p><a href=\\\"https://www.uptodate.com/contents/cellulitis-and-skin-abscess-in-adults-treatment/abstract/2\\\">Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. Clin Infect Dis 2014; 59:147.</a></p>\\r\\n<p><a href=\\\"https://www.uptodate.com/contents/cellulitis-and-skin-abscess-in-adults-treatment/abstract/3\\\">Raff AB, Kroshinsky D. Cellulitis: A Review. JAMA 2016; 316:325.</a></p>\\r\\n<p><a href=\\\"https://www.uptodate.com/contents/cellulitis-and-skin-abscess-in-adults-treatment/abstract/4\\\">Halilovic J, Heintz BH, Brown J. Risk factors for clinical failure in patients hospitalized with cellulitis and cutaneous abscess. J Infect 2012; 65:128.</a></p>\\r\\n<p>Herchline TE. Cellulitis. Medscape 2018. Available from: <a href=\\\"https://emedicine.medscape.com/article/214222-overview\\\"><span data-custom-style=\\\"Hyperlink\\\">https://emedicine.medscape.com/article/214222-overview</span></a></p>\\r\\n<p>John Hopkins ABX guide for cellulitis</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Amie Secka</th>\\r\\n<th>Date: 26 November 2018</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Fatai Akemokwe</td>\\r\\n<td>Date: 28 January 2019</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td>31 January 2021</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>1.1</td>\\r\\n<td>Executive summary added</td>\\r\\n<td>31 January 2021</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"052\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>Chest pain and Acute Coronary Syndrome MeG-CLS- 052</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"chest-pain-and-acute-coronary-syndromes\\\">Chest Pain And Acute Coronary Syndromes </h1>\\r\\n<h2 id=\\\"executive-summary\\\"><em>Executive summary</em></h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<p>Cardiovascular disease represents the leading cause of morbidity and mortality worldwide. Chest pain secondary to myocardial ischaemia in the forms of stable angina and acute coronary syndromes (ACS), often referred to as a ‘heart attack’, represent perhaps the most well-known presentations of cardiovascular disease (table 1). The prevalence of cardiovascular disease and resultant ACS continues to rise in low-income settings. Despite this cardiac chest pain and ACS are understudied and have poor outcomes in Sub-Saharan Africa<em>.</em></p>\\r\\n<h2 id=\\\"target-users\\\">Target users</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nurses</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doctors</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"target-area-of-use\\\">Target area of use </h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Outpatient department</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ward</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"key-areas-of-focus-new-additions-changes\\\">Key areas of focus / New additions / Changes </h2>\\r\\n<p>This guideline discusses how to identify cardiac chest pain, how to classify severity and the management of both chronic cardiac chest pain and acute coronary syndromes.</p>\\r\\n<h2 id=\\\"limitations\\\">Limitations</h2>\\r\\n<p>None</p>\\r\\n<h2 id=\\\"background-and-definitions\\\">Background and definitions</h2>\\r\\n<p>Chest pain is an extremely common presenting complaint, present in approximately 20% of medical admissions to hospital<em>.</em> It is a distressing symptom and can be concerning for both patients and health care professionals – often due to worries about potentially life threatening aetiologies such as ACS. The majority of chest pain is not cardiac in origin though (table 2) and can be managed as an outpatient. The wide variety of possible differential diagnoses (table 3) can make the task of identifying the underlying cause of chest pain and treating it appropriately extremely daunting. The key to the management of these patients is a thorough assessment to help identifying the underlying cause and early recognition of signs of possible life threatening aetiologies.</p>\\r\\n<p>Table 1: Important terms in chest pain related to cardiovascular disease</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Term</strong></th>\\r\\n<th><strong>Explanation</strong></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Ischaemic Heart Disease</td>\\r\\n<td>Also referred to as coronary heart disease, is present when a patient has one or more symptoms, signs, or complications from an inadequate supply of blood to the myocardium. This is most commonly due to obstruction of the epicardial coronary arteries due to atherosclerosis.</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Angina</td>\\r\\n<td>Occurs when myocardial oxygen demand exceeds oxygen supply; the clinical manifestation is often chest discomfort.</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Stable Angina</td>\\r\\n<td>Refers to chest discomfort that occurs predictably and reproducibly at a certain level of exertion and is relieved with rest or nitrates. Most patients with ischaemic heart disease will experience angina as part of the clinical manifestations of the disease.</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Acute Coronary Syndrome (ACS)</td>\\r\\n<td>Applied to patients in whom there is a suspicion or confirmation of acute myocardial ischaemia or infarction. Non-ST elevation myocardial infarction (NSTEMI), unstable angina (UA), and ST-elevation myocardial infarction (STEMI) are the three types of ACS.</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>STEMI</td>\\r\\n<td>Myocardial ischaemia with raised markers of myocardial injury (troponin, CK-MB) and characteristic ECG changes (predominantly ST elevation).</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>NSTEMI</td>\\r\\n<td>Myocardial ischemia with raised markers of myocardial injury without the characteristic ECG changes of STEMI.</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Unstable Angina</td>\\r\\n<td>Myocardial ischemia without raised markers of myocardial injury.</td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<p>Table 2: Aetiology of chest pain</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th></th>\\r\\n<th><strong>Percentage of Patients Presenting</strong></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Musculoskeletal</td>\\r\\n<td>30 – 50%</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Gastro-intestinal</td>\\r\\n<td>10 – 20%</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Stable Angina</td>\\r\\n<td>10%</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Respiratory Conditions</td>\\r\\n<td>5%</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Acute Coronary Syndromes</td>\\r\\n<td>2 – 4%</td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<p>Table 3: Differential diagnoses of chest pain</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Cardiac</strong></th>\\r\\n<th></th>\\r\\n<th></th>\\r\\n<th></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Ischaemic</strong></td>\\r\\n<td>Stable Angina</td>\\r\\n<td><strong>Non</strong>-<strong>Ischaemic</strong></td>\\r\\n<td>Aortic Dissection</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td></td>\\r\\n<td>Acute Coronary Syndrome</td>\\r\\n<td></td>\\r\\n<td>Heart Failure</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n<td>Pericarditis/Myocarditis</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Pulmonary</strong></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td></td>\\r\\n<td>Pulmonary Embolism</td>\\r\\n<td>Asthma and COPD</td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td></td>\\r\\n<td>Pneumonia</td>\\r\\n<td>Pulmonary Hypertension</td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td></td>\\r\\n<td>Malignancy</td>\\r\\n<td>Pulmonary Tuberculosis</td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Gastro-intestinal</strong></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td></td>\\r\\n<td>Oesophagitis</td>\\r\\n<td>Gastroesophageal reflux disease </td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td></td>\\r\\n<td>Oesophageal rupture/perforation</td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Musculoskeletal</strong></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td></td>\\r\\n<td>Isolated musculoskeletal pain – i.e. costochrondritis</td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td></td>\\r\\n<td>Trauma</td>\\r\\n<td>Inflammatory Conditions</td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Psychiatric</strong></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td></td>\\r\\n<td>Panic Attacks/Disorder</td>\\r\\n<td>Factitious Disorder</td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Other</strong></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td></td>\\r\\n<td>Referred Pain</td>\\r\\n<td>Herpes Zoster</td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs\\\">Presenting symptoms and Signs</h2>\\r\\n<p>Given the variety of possible diagnoses underlying chest pain, thorough history taking is of the utmost importance.</p>\\r\\n<p>Early assessment should focus on symptoms and signs of chest pain with possible life-threatening aetiologies. Any patients in whom there are concerns for life-threatening causes of chest pain should be referred urgently to the ward for further assessment:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Unstable vital signs.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Abrupt onset of chest pain and/or clinical concern for life-threatening aetiology (e.g. pulmonary embolism, aortic dissection, esophageal rupture, tension pneumothorax).</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Concern for acute coronary syndrome (ACS) based on symptoms (anginal symptoms at rest, prolonged, or progressing episodes).</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Assess patients presenting with chest pain for typical signs of angina (table 4). Classic symptoms of stable angina include:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>A pressure, heaviness, tightness, or constriction in the center or left of the chest that is precipitated by exertion and relieved by rest.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Provocation with emotional stress or cold</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Radiation (to the neck, jaw, and shoulder)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Dyspnoea</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nausea and vomiting</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Sweating</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Severity of pain is not a useful differentiating factor and it is important to note no symptom alone or in combination identifies a group of patients in whom the diagnosis can be entirely excluded.</p>\\r\\n<p>The clinical presentation of myocardial ischemia varies by population. Women, diabetics, and older adult patients are more likely to present without chest pain but have symptoms of dyspnoea, weakness, nausea and vomiting, palpitations, or syncope<em>.</em> Compared with older patients, younger patients are less likely to have stable angina and have a higher incidence of ACS<em>.</em></p>\\r\\n<p>Patients who present with ACS have:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Anginal symptoms at rest (usually greater than 20 minutes)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>New-onset angina that is not stable and predictable</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Progressive symptoms (angina that is more frequent, longer in duration, or occurs with less exertion than previously).</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>These patients should be admitted urgently.</p>\\r\\n<p>Table 4: Assessment of chest pain</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Stratification of Chest Pain</strong></th>\\r\\n<th></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Typical Angina</strong></td>\\r\\n<td>Presence of three of the three features of anginal chest pain</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Atypical Angina</strong></td>\\r\\n<td>Presence of two of the features anginal chest pain</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Non-Anginal Chest Pain</strong></td>\\r\\n<td>Presence of one or none of the features of anginal chest pain</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Features of Anginal Chest Pain</strong></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Constricting discomfort in the front of the chest, or in the neck, shoulders, jaw or arm</td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Precipitated by physical exertion</td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Relieved by rest or GTN within about 5 minutes</td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Features Suggestive of Non-Anginal Chest Pain</strong></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Pleuritic pain, sharp or knife-like pain related to respiratory movements or cough</td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Primary or sole location in the mid or lower abdominal region</td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Any discomfort localized with one finger</td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Any discomfort reproduced by movement or palpation</td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Constant pain lasting for days</td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Fleeting pains lasting for a few seconds or less</td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Pain radiating into the lower extremities or above the mandible</td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<h2 id=\\\"examination\\\">Examination </h2>\\r\\n<p>A focused examination of the patient with chest pain should include a cardiovascular, respiratory and abdominal examination, thereby broadly assessing the most likely underlying aetiologies. In many cases there may be few findings on examination and further investigation will be warranted.</p>\\r\\n<h2 id=\\\"investigations\\\">Investigations</h2>\\r\\n<p>Patients with typical signs of stable angina and no other concerning features should be commenced on anginal therapy, but investigations (table 5) may be warranted if there are concerns about other possible causes.</p>\\r\\n<p>ECGs may be limited in the outpatient setting due to the cost to patients, but should be used if they will help make a diagnosis or change management plans. Concerns over ACS should prompt referral to the ward where an ECG can be performed as an in-patient.</p>\\r\\n<p>Patients with atypical cardiac chest pain should be investigated further. If there is no other clear cause, and especially in patients with a high number of cardiac risk factors (age, smoking, hypertension, diabetes, dyslipidaemia, family history of coronary heart disease, etc) they should be commenced on anginal treatment and monitored closely for response to therapy.</p>\\r\\n<p>Patients with non-anginal chest pain should be investigated further unless a clear diagnosis of a non-life threatening aetiology can be made clinically. For example clear musculoskeletal chest pain or a clear (low risk) pneumonia may not require any further investigation.</p>\\r\\n<p>Patients admitted to the ward with chest pain should have urgent bloods (full blood count, urea and electrolytes, Creatine kinase MB (CK-MB) if concerns over cardiac pain), an ECG and a chest x-ray. Other investigations may also be required depending on the clinical situation.</p>\\r\\n<p>Table 5: Investigation of patients with chest pain</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Investigation</strong></th>\\r\\n<th><strong>Role and Interpretation</strong></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>ECG</strong></td>\\r\\n<td><p>A standard 12-lead electrocardiogram (ECG) should be obtained for all patients presenting with chest pain that may be from an ACS.</p>\\r\\n<p>ECG remains the best immediately available test for detecting ACS but its sensitivity for acute myocardial infarction (AMI) is low. The initial ECG is often <span data-custom-style=\\\"Strong\\\">NOT</span> diagnostic in patients with ACS and can be repeated as frequently as every 10 minutes if the initial ECG is not diagnostic but the patient remains symptomatic and there remains high clinical suspicion for AMI. Prior ECGs are important for determining whether abnormalities are new. The presence of a left bundle branch block makes it difficult to determine the presence of ischemic ECG changes.</p>\\r\\n<p>Findings consistent with ST elevation myocardial infarction (STEMI): New ST elevation at the J point in two anatomically contiguous leads using the following diagnostic thresholds: ≥0.1 mV (1 mm) in all leads other than V2-V3, where the following diagnostic thresholds apply: ≥0.2 mV (2 mm) in men ≥ 40 years; ≥0.25 mV (2.5 mm) in men &lt;40 years, or ≥0.15 mV (1.5 mm) in women.</p>\\r\\n<p>Findings consistent with Non ST elevation myocardial infarction or unstable angina: New horizontal or down-sloping ST depression ≥0.05 mV (0.5 mm) in two anatomically contiguous leads and/or T inversion ≥0.1 mV (1 mm) in two anatomically contiguous leads with prominent R wave or R/S ratio &gt;1.</p></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Chest X-Ray (CXR)</strong></td>\\r\\n<td><p>A CXR should be performed in all patients unless a probable underlying cause that does not require imaging has already been identified in a stable patient.</p>\\r\\n<p>A nondiagnostic CXR is typical in patients with <span data-custom-style=\\\"Strong\\\">ACS and stable angina.or pulmonary embolus (PE)</span></p>\\r\\n<p>Approximately 90 percent of patients with <span data-custom-style=\\\"Strong\\\">acute aortic dissection</span> will have some CXR abnormality</p>\\r\\n<p>Pneumonia and pneumothorax are often diagnosed by CXR.</p>\\r\\n<p>Acute heart failure is suggested by pulmonary vascular congestion and cardiomegaly. In patients with severe vomiting or recent instrumentation of the oesophagus, mediastinal emphysema and pleural effusion suggest o<span data-custom-style=\\\"Strong\\\">esophageal rupture</span>.</p></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Blood Tests</strong></th>\\r\\n<th></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>CK-MB</strong></td>\\r\\n<td><p>Creatine kinase MB (CK-MB) isoform levels rise to twice normal at six hours and peak within approximately 24 hours post myocardial injury. Note should be made of the time pain started and when the test was taken. An initial test should be performed on admission for anyone who may have ACS and a repeat after 6-9 hours to assess for ongoing changes,</p>\\r\\n<p>Although it is no longer recommended for most patients being evaluated for ACS due to the higher accuracy of troponin assays, it is the available option here at present.</p></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Full Blood Count</strong></td>\\r\\n<td>The white blood cell count may be elevated in any of the inflammatory or infectious etiologies of chest pain. Anaemia in a patient with exertional chest pain is suggestive of myocardial ischemia, but also consistent with aortic rupture.</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Urea and Electrolytes</strong></td>\\r\\n<td>Raised urea and other markers indicating dehydration and acute kidney injury may accompany many forms of chest pain. Abnormalities in these tests often indicates a poorer prognosis.</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Further Possible Investigations</strong></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Transthoracic Echocardiogram</strong></td>\\r\\n<td><p>May show regional wall abnormalities in patients with acute coronary syndromes or prior myocardial injury.</p>\\r\\n<p>May show signs of right heart strain and features of raised pulmonary pressure in pulmonary embolism.</p>\\r\\n<p>Will demonstrate significant valvular disease and left ventricular dysfunction if present.</p></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>USS Doppler (lower legs)</strong></td>\\r\\n<td>Can be used as a surrogate investigation if there are concerns over a (non-massive) pulmonary embolism.</td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<h2 id=\\\"management\\\">Management </h2>\\r\\n<p>Non-cardiac causes of chest pain such as pneumonia and musculoskeletal pain should be managed as described in their separate guidance. The following will focus on the management of stable angina and ACS.</p>\\r\\n<h3 id=\\\"management-of-stable-angina\\\">Management of stable angina</h3>\\r\\n<p><em>Anti-anginal therapy</em>:</p>\\r\\n<ol type=\\\"1\\\">\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Beta-blockers</strong></p>\\r\\n</div></li>\\r\\n</ol>\\r\\n<div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>First line therapy to reduce anginal episodes and improve exercise tolerance. The only antianginal drugs proven to prevent reinfarction and to improve survival in patients who have sustained a myocardial infarction</p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Bisoprolol: Start at 1.25 mg OD immediately and uptitrate to 10 mg daily, as tolerated and according to symptomatic response (can be given in divided doses).</p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Dose can be increased in 1.25-2.5 mg steps, aiming to double every 2 weeks until target dose is reached.</p>\\r\\n</div>\\r\\n<ol start=\\\"2\\\" type=\\\"1\\\">\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Calcium</strong> <strong>Channel Blockers</strong></p>\\r\\n</div></li>\\r\\n</ol>\\r\\n<div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Used in combination with beta blockers when initial treatment with beta blockers is not successful or as a substitute for a beta blocker when beta blockers are contraindicated or cause side effects.</p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Amlodipine: Start at 5 mg OD and uptitrate to 10 mg OD as tolerated and according to symptomatic response.</p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>This should be initiated following maximal uptitration of a beta-blocker.</p>\\r\\n</div>\\r\\n<ol start=\\\"3\\\" type=\\\"1\\\">\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Nitrates</strong></p>\\r\\n</div></li>\\r\\n</ol>\\r\\n<div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>First-line therapy for the treatment of acute anginal symptoms. Usually in the form of a sublingual preparation&gt; Patients should be instructed to use them at the onset of angina. They may also be recommended for the prophylaxis of anginal episodes.</p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>GTN sublingual tablets: 300-500 micrograms as required. Up to three times with 5 minute intervals for relief of acute anginal pain.</p>\\r\\n</div>\\r\\n<p><em>Anti-platelet therapy:</em></p>\\r\\n<ol type=\\\"1\\\">\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Aspirin</strong></p>\\r\\n</div></li>\\r\\n</ol>\\r\\n<div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>In the absence of a contraindication, all patients with definite angina should be treated with aspirin. Patients who have a gastrointestinal bleed on low-dose aspirin should, after the episode is controlled, be treated with aspirin plus a proton pump inhibitor. </p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Aspirin: 75 mg OD.</p>\\r\\n</div>\\r\\n<ol start=\\\"2\\\" type=\\\"1\\\">\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Clopidogrel</strong></p>\\r\\n</div></li>\\r\\n</ol>\\r\\n<div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Can be given as an <strong>alternative</strong> to aspirin in stable angina if the patient has aspirin intolerance. Available from CSD pharmacy only for staff.</p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Clopidogrel: 75 mg OD.</p>\\r\\n</div>\\r\\n<p><em>Preventative therapy:</em></p>\\r\\n<ol type=\\\"1\\\">\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Statins</strong></p>\\r\\n</div></li>\\r\\n</ol>\\r\\n<div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Reduce cholesterol and prevent future cardiovascular disease.</p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Atorvastatin: 40-80 mg Nocte.</p>\\r\\n</div>\\r\\n<ol start=\\\"2\\\" type=\\\"1\\\">\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Risk factor reduction</strong></p>\\r\\n</div></li>\\r\\n</ol>\\r\\n<div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>A central component of the management of patients with stable angina. This includes treatment of hypertension, cessation of smoking, weight reduction, glycaemic control in diabetics and participation in regular physical activity.</p>\\r\\n</div>\\r\\n<h3 id=\\\"management-of-nstemi-unstable-angina\\\">Management of NSTEMI / unstable angina:</h3>\\r\\n<p><em>Anti-thrombotic therapy:</em></p>\\r\\n<ol type=\\\"1\\\">\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Anti-platelet agents</strong></p>\\r\\n</div></li>\\r\\n</ol>\\r\\n<div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Aspirin 300 mg AND clopidogrel 300 mg given as a stat dose as soon as possible.</p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ideally aspirin 75 mg and clopidogrel 75 mg OD to continue for 1 year following this.</p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Aspirin can be used as a monotherapy in the absence of clopidogrel, though with lower efficacy.</p>\\r\\n</div>\\r\\n<ol start=\\\"2\\\" type=\\\"1\\\">\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Anticoagulation</strong></p>\\r\\n</div></li>\\r\\n</ol>\\r\\n<div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Enoxaparin should be started immediately and given for 5 days post ACS (1 mg/kg 12 hourly): Available for members of staff only – patients should be encouraged to buy this if they can.</p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Unfractionated heparin can be used as an alternative to enoxaparin, but has worse clinical outcomes. We cannot measure APTT out-of-hours, so are not able to use it iv. If there is no alternative then sc heparin can be given at a dose of 15,000 units BD, as this is likely to be better than nothing.</p>\\r\\n</div>\\r\\n<p><em>Anti-ischaemic and analgesic therapy:</em></p>\\r\\n<ol type=\\\"1\\\">\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Oxygen</strong></p>\\r\\n</div></li>\\r\\n</ol>\\r\\n<div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Administer supplemental oxygen to ACS patients with an arterial saturation less than 90 percent.</p>\\r\\n</div>\\r\\n<ol start=\\\"2\\\" type=\\\"1\\\">\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>GTN</strong></p>\\r\\n</div></li>\\r\\n</ol>\\r\\n<div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Sublingual GTN (300-500microgams): Consider intravenous GTN in patients with persistent pain after three sublingual GTN tablets, hypertension, or heart failure.</p>\\r\\n</div>\\r\\n<ol start=\\\"3\\\" type=\\\"1\\\">\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Morphine</strong></p>\\r\\n</div></li>\\r\\n</ol>\\r\\n<div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>IV morphine should be avoided if possible and reserved for patients with an unacceptable level of pain. If needed give intravenous morphine 2 to 4 mg, with increments of 2 to 8 mg repeated at 5- to 15-minute intervals.</p>\\r\\n</div>\\r\\n<p><em>Further inpatient management:</em></p>\\r\\n<p>Initiation of anti-anginal medications as per stable angina.</p>\\r\\n<p>A beta-blocker should be started in the first 24 hours if able.</p>\\r\\n<p>When stable an ACE inhibitor may be started if there is evidence of heart failure, hypertension or chronic kidney disease.</p>\\r\\n<h3 id=\\\"management-of-stemi\\\">Management of STEMI</h3>\\r\\n<ol type=\\\"1\\\">\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Fibrinolytic therapy</strong></p>\\r\\n</div></li>\\r\\n</ol>\\r\\n<div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Streptokinase 1500000 units (15 million units) to be initiated as soon as possible and within 12 hours of symptom onset as an infusion over 60 minutes. Outside of 12 hours, there is limited evidence for benefit.</p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Assess for bleeding risk prior to make a risk-benefit decision. Streptokinase is antigenic, and can cause immunologic sensitization and allergic reactions, particularly with repeat administration</p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Consultant input is advised.</p>\\r\\n</div>\\r\\n<ol start=\\\"2\\\" type=\\\"1\\\">\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Anti-thrombotic therapy</strong></p>\\r\\n</div></li>\\r\\n</ol>\\r\\n<div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Aspirin 300 mg and clopidogrel 300 mg should be given as a stat dose as soon as possible and continued as 75 mg OD following this for 1 year. Aspirin monotherapy can be continued after this.</p>\\r\\n</div>\\r\\n<ol start=\\\"3\\\" type=\\\"1\\\">\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Anticoagulant Therapy</strong></p>\\r\\n</div></li>\\r\\n</ol>\\r\\n<div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>As per NSTEMI protocol. Anticoagulate with enoxaparin or unfractionated heparin for 5 days.</p>\\r\\n</div>\\r\\n<ol start=\\\"4\\\" type=\\\"1\\\">\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Further inpatient management</strong></p>\\r\\n</div></li>\\r\\n</ol>\\r\\n<div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>As per NSTEMI protocol. Early initiation of a beta-blocker (1<sup>st</sup> 24 hours) is recommended.</p>\\r\\n</div>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<p>Bösner, S., Becker, A., Haasenritter, J., Hani, M. A., Keller, H., Sönnichsen, A. C., Donner-Banzhoff, N. (2009). Chest pain in primary care: Epidemiology and pre-work-up probabilities. European Journal of General Practice, 15(3), 141-146. doi:10.3109/13814780903329528.</p>\\r\\n<p><em>European Society of Cardiology Clinical Practice Guidelines (2013). Management of Stable Coronary Artery Disease.  Eur Heart J 2013;34:2949–3003 - doi:10.1093/eurheartj/eht296</em></p>\\r\\n<p><em>European Society of Cardiology Clinical Practice Guidelines (2015). Management of Acute Coronary Syndromes (ACS) in patients presenting without persistent ST-segment elevation. European Heart Journal, doi/10.1093/eurheartj/ehv320.</em></p>\\r\\n<p><em>European Society of Cardiology Clinical Practice Guidelines (2017). Management of Acute Myocardial Infarction in patients presenting with ST-segment elevation. Available at: https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Acute-Myocardial-Infarction-in-patients-presenting-with-ST-segment-elevation-Ma.</em></p>\\r\\n<p>Launbjerg J, Fruergaard P, Hesse B, et al. Long-term risk of death, cardiac events and recurrent chest pain in patients with acute chest pain of different origin. Cardiology 1996; 87:60.</p>\\r\\n<p>National Institute for Health and Care Excellence (2016<em>) </em><span data-custom-style=\\\"Emphasis\\\">Chest pain of recent onset: assessment and diagnosis</span> (NICE Guideline CG95). Available at: https://www.nice.org.uk/guidance/cg95/evidence</p>\\r\\n<p>McCaig, L, Burt, C. National Hospital Ambulatory Medical Care Survey: 2003 Emergency Department Summary. In: Advance Data from Vital and Health Statistics. Centers for disease control and prevention, Atlanta, GA 2005.</p>\\r\\n<p>Thygesen K, Alpert JS, Jaffe AS, et al. Fourth Universal Definition of Myocardial Infarction (2018). J Am Coll Cardiol 2018; 72:2231.</p>\\r\\n<p>Panju AA, Hemmelgarn BR, Guyatt GH, Simel DL. The rational clinical examination. Is this patient having a myocardial infarction? JAMA 1998; 280:1256.</p>\\r\\n<p>Poon S, Goodman SG, Yan RT, et al. Bridging the gender gap: Insights from a contemporary analysis of sex-related differences in the treatment and outcomes of patients with acute coronary syndromes. Am Heart J 2012; 163:66.</p>\\r\\n<p>Pope JH, Aufderheide TP, Ruthazer R, et al. Missed diagnoses of acute cardiac ischemia in the emergency department. N Engl J Med 2000; 342:1163.</p>\\r\\n<p>Varwani, M., Jeilan, M., Ngunga, M., Barasa, A. (2018). Outcomes in patients with acute coronary syndrome in a referral hospital in sub-Saharan Africa. Cardiovascular journal of Africa, 29, 1-5. doi: 10.5830/CVJA-2018-066.</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Ben Dowsing</th>\\r\\n<th>Date: 03 December 2018</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Orighomisan Agboghoroma</td>\\r\\n<td>Date: 31 December 2018</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td>31 January 2021</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>1.1</td>\\r\\n<td>Executive summary added</td>\\r\\n<td>31 January 2021</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"053\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>Chronic kidney disease MeG-CLS-053</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"chronic-kidney-disease\\\">Chronic kidney disease</h1>\\r\\n<h2 id=\\\"executive-summary\\\"><em>Executive summary</em></h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<p>Chronic kidney disease (CKD) is a process that may progress over years and the end point of this process is renal failure. Early detection and management of CKD improves mortality, and morbidity and delays the point where dialysis is necessary which incur significant cost to the patient in terms of life expectancy, quality of life and finances. Most patients with CKD have a stable glomerular filtration rate (GFR), but an important minority deteriorate to end stage kidney failure. The early stage of CKD is usually asymptomatic, therefore must be detected by opportunistic testing of at-risk groups or acting on incidental findings. Preventive measures may be taken to slow the progression and minimise nephrotoxicity.</p>\\r\\n<h2 id=\\\"target-users\\\">Target users</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doctors</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nurses</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"target-area-of-use\\\">Target area of use </h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Outpatients</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ward</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"key-areas-of-focus-new-additions-changes\\\">Key areas of focus / New additions / Changes </h2>\\r\\n<p>This guideline aims to address both management of the patient in chronic kidney failure, and the early detection of CKD and minimising modifiable risks for progression.</p>\\r\\n<p>Conservative management can be provided in accordance with the patient and with consulting the palliative care guidelines for additional advice.</p>\\r\\n<h3 id=\\\"aims-for-csd\\\">Aims for CSD</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Identification of patients at risk of CKD.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Classification of patients according to estimated GFR (or eGFR) with serum creatinine.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Urine reagent strip (dipstick) analysis for broad quantification of kidney damage.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Monitoring progression of CKD.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Optimisation of pharmacotherapy and hypertension management.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Early referral to nephrologists (at stage G4 or G3a with 3+ of protein on urine dipstick analysis)</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"limitations\\\">Limitations</h2>\\r\\n<p>We cannot offer Renal Replacement Therapy (RRT) and patients must be referred to the EFSTH hospital early, in anticipation of deteriorating renal function, and at end stage renal failure.</p>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs\\\">Presenting symptoms and signs</h2>\\r\\n<p>Chronic kidney disease is asymptomatic in most patients until end-stage renal failure occurs.</p>\\r\\n<h2 id=\\\"examination-findings\\\">Examination findings</h2>\\r\\n<div data-custom-style=\\\"Body Text\\\">\\r\\n<p>Signs and symptoms of (end stage) kidney failure:</p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"Body Text\\\">\\r\\n<p>Acid-base or electrolyte abnormalities</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"Body Text\\\">\\r\\n<p>Pruritis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"Body Text\\\">\\r\\n<p>Serositis (pericarditis, pleuritis)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"Body Text\\\">\\r\\n<p>Inability to control volume status or blood pressure (severe hypertension, pulmonary oedema)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"Body Text\\\">\\r\\n<p>Progressive deterioration in nutritional status refractory to dietary intervention</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"Body Text\\\">\\r\\n<p>Cognitive impairment</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"Body Text\\\">\\r\\n<p>Anaemia</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"Body Text\\\">\\r\\n<p>Bone pains</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"Body Text\\\">\\r\\n<p>Gastritis</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"management\\\">Management </h2>\\r\\n<h3 id=\\\"define-at-risk-patient-groups\\\">Define ‘at risk’ patient groups:</h3>\\r\\n<p>Patients with the following conditions should be screened for chronic kidney disease with serum creatinine and urine dipstick:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hypertension</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Diabetes mellitus</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Cardiovascular disease</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Heart failure</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Peripheral vascular disease</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ischaemic heart disease</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Cerebral vascular disease</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Acute kidney injury</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Family history of kidney disease</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Incidental findings of haematuria</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Multisystem disease that involves the kidney (e.g. SLE).</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Current evidence does not support the screening of unselected populations.</p>\\r\\n<h2 id=\\\"investigations\\\">Investigations</h2>\\r\\n<h3 id=\\\"serum-urea-electrolytes-and-creatinine\\\">Serum Urea, Electrolytes and Creatinine:</h3>\\r\\n<p>Serum creatinine levels are useful for estimating glomerular filtration rate. The CKD-EPI calculation gives better estimations in the early stages of CKD. There are reliable online calculators available e.g. <a href=\\\"https://www.mdcalc.com/ckd-epi-equations-glomerular-filtration-rate-gfr\\\"><span data-custom-style=\\\"Hyperlink\\\">https://www.mdcalc.com/ckd-epi-equations-glomerular-filtration-rate-gfr</span></a></p>\\r\\n<p>CKD is classified into 5 stages. Stages 1 and 2 are defined by good GFR, but with markers of kidney damage e.g. albuminuria, abnormalities in urine sediment, histological abnormalities, structural abnormalities detected by imaging, history of kidney transplant, and electrolyte disorders that are due to tubular disorders.</p>\\r\\n<p>Stages 3a, 3b, 4 and 5 are defined by GFR of less than 60 ml/min/1.73m<sup>2</sup> with or without the evidence of kidney damage.</p>\\r\\n<p>This diagnosis must be made from at least 3 instances of investigations with at least 90 days between the first and last tests.</p>\\r\\n<table>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><h3 id=\\\"gfr-categories\\\"><br />\\r\\nGFR categories</h3></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>GFR category</strong></td>\\r\\n<td><strong>GFR (ml/min/1.73 m<sup>2</sup>)</strong></td>\\r\\n<td><strong>Terms</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>G1</td>\\r\\n<td>&gt;90</td>\\r\\n<td>Normal or high</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>G2</td>\\r\\n<td>60–89</td>\\r\\n<td>Mildly decreased</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>G3a</td>\\r\\n<td>45–59</td>\\r\\n<td>Mildly to moderately decreased</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>G3b</td>\\r\\n<td>30–44</td>\\r\\n<td>Moderately to severely decreased</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>G4</td>\\r\\n<td>15–29</td>\\r\\n<td>Severely decreased (<strong>R</strong>)</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>G5</td>\\r\\n<td>&lt;15</td>\\r\\n<td>Kidney failure (<strong>R</strong>)</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Abbreviations: CKD, chronic kidney disease; GFR, glomerular filtration rate, <strong>R</strong>- refer to EFSTH</td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<p>Progression of CKD is the sustained decrease in GFR of 25% or more with a change in GFR category within 12 months, <strong>or</strong> a sustained decrease in GFR of 15 ml/min/1.73 m<sup>2</sup> per year.</p>\\r\\n<h3 id=\\\"dipstick-urinalysis\\\">Dipstick Urinalysis</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Proteinuria</strong>: Test for proteinuria in patients in the at-risk groups, and patients with abnormal serum creatinine. Urine dipstick testing should occur at each appointment in patients in groups G3a –G5 (eGFR &lt; 60 ml/min). Although urine albumin-creatinine ratio is the ideal test for proteinuria, dipstick testing of random urine samples is most practical for the OPD.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Haematuria</strong>: The presence of 1+ or more of blood in urine is considered significant and should be investigated further. Urine microscopy is not required to test or confirm diagnosis. Invisible haematuria is confirmed with 2 out of 3 positive urine analysis dipstick tests in separate clinic appointments. Investigate patients with persistent invisible haematuria for urinary tract malignancy in the appropriate age groups. Patients with invisible haematuria with proteinuria should be followed up with annual repeat testing for as long as the haematuria continues</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"haemoglobin\\\">Haemoglobin</h3>\\r\\n<p>Check the haemoglobin level in people with a GFR of less than 45 ml/min/1.73 m<sup>2</sup> to identify anaemia (haemoglobin less than 11 g/dl).</p>\\r\\n<h3 id=\\\"serum-calcium-and-phosphate\\\">Serum calcium and phosphate</h3>\\r\\n<p>Low calcium and high phosphate levels may be seen in patients in end stage renal disease.</p>\\r\\n<h3 id=\\\"renal-ultrasound\\\">Renal ultrasound</h3>\\r\\n<p>Perform renal ultrasound if there is:</p>\\r\\n<ul>\\r\\n<li><p>accelerated progression of CKD</p></li>\\r\\n<li><p>Haematuria or persisting invisible haematuria</p></li>\\r\\n<li><p>Urinary tract obstruction</p></li>\\r\\n<li><p>Family history of polycystic kidney disease</p></li>\\r\\n<li><p>GFR of &lt;30 ml/min/1.73m<sup>2</sup> (G4 or G5)</p></li>\\r\\n</ul>\\r\\n<h2 id=\\\"treatment\\\">Treatment</h2>\\r\\n<p>At all stages, it is important to involve the patient in shared decision making, discussing the implications of diagnosis and prognosis, as well as preference for invasive treatment or conservative management</p>\\r\\n<h3 id=\\\"hypertension\\\">Hypertension</h3>\\r\\n<p>Control systolic blood pressure in the target range of 120 - 139 mmHg and keep diastolic blood pressure below 90 mmHg. In those with diabetes, aim for tighter blood pressure control with target systolic BP of 120 – 130 mmHg and diastolic BP of &lt; 80 mmHg. Refer to the CSD hypertension guideline for more information on controlling blood pressure.</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Single renin - angiotensin system antagonists may be used (do not combine renin - angiotensin system antagonists): these include ACE inhibitors and spironolactone.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Monitor potassium levels and withhold treatment if Potassium &gt;6 mmol/l.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Check GFR when starting or increasing dose of renin - angiotensin system antagonist. A deterioration of less than 25% is acceptable. If the eGFR change is 25% or more, or the change in serum creatinine is 30% or more, investigate other causes of deterioration in renal function, such as volume depletion or concurrent medication (for example, NSAIDs).If no other cause for the deterioration in renal function is found, stop the renin–angiotensin system antagonist or reduce the dose to a previously tolerated lower dose, and add an alternative antihypertensive medication if required.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"reduce-nephrotoxic-medication-burden\\\">Reduce nephrotoxic medication burden:</h3>\\r\\n<p>Avoid giving the following drugs if possible:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Antimicrobials: Vancomycin, Quinolones, Aminoglycosides</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>NSAIDS, Methotrexate</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>ACE- Inhibitors, Angiotensin Receptor Blocker, Renin Inhibitor</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Statins - Offer atorvastatin 20 mg for the primary or secondary prevention of CVD to people with CKD. Increase the dose if less than 40% reduction in non‑HDL cholesterol is achieved and eGFR is 30 ml/min/1.73 m<sup>2</sup> or more. Do not give in patients with eGFR &lt; 30 ml/min/1.73 m<sup>2</sup>.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"lifestyle-advice\\\">Lifestyle advice:</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Encourage exercise, aim for healthy weight, stop smoking.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Dietary advice regarding calorie, salt, potassium and phosphate levels appropriate to the severity of CKD.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Low protein diet should <strong>not</strong> be recommended.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"acute-kidney-injury-aki\\\">Acute Kidney Injury (AKI):</h3>\\r\\n<p>Patients with CKD are more likely to develop AKI than the normal population. AKI may also lead to progression of CKD</p>\\r\\n<p>AKI in the background of CKD should not be managed with diuretics</p>\\r\\n<p>The prognosis is poor for patients with AKI in end stage kidney disease. This is an emergency and should lead to an urgent referral of the patient to EFSTH following stabilisation, or conservative management.</p>\\r\\n<h3 id=\\\"anaemia\\\">Anaemia</h3>\\r\\n<p>Iron replacement therapy is often effective in anaemia of CKD. Erythropoietin may be needed in later stages.</p>\\r\\n<h3 id=\\\"hypocalcaemia\\\">Hypocalcaemia</h3>\\r\\n<p>Hypocalcaemia in patients with GFR &lt; 30 ml/min/1.73m<sup>2</sup> (stage G4 or G5) should be treated with cholecalciferol as hypocalcaemia results from Vitamin D deficiency.</p>\\r\\n<h2 id=\\\"referral-to-efsth\\\">Referral to EFSTH</h2>\\r\\n<p>Referral criteria include:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>GFR &lt; 60 ml/min/1.73m<sup>2</sup> AND visible/persistent invisible haematuria</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>GFR &lt; 45 ml/min/1.73m<sup>2</sup> with at least 1+ proteinuria</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>GFR &lt; 30 ml/min/1.73m<sup>2</sup> (category G4/G5)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Sustained decrease in GFR of &gt; 15 ml/min/1.73m<sup>2</sup> over 12 months</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Sustained decrease of 25% in GFR and a change in GFR category within 12 months</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Suspected genetic or rare causes of CKD</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Suspected renal artery stenosis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>AKI with a background of End Stage CKD (emergency)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Uraemic features such as gastritis, pericarditis, pleuritis and encephalopathy</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>CKD and Hypertension refractory to treatment with 4 or more antihypertensive agents</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nephrolithiasis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Persistent abnormalities in serum potassium.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Referral should be made to EFSTH Nephrologist via the Accident and Emergency Department.</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Stabilise medical conditions such as hyperkalaemia, uraemic symptoms, acidosis and fluid overload before ambulance transfer.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>If possible, address correspondence to EFSTH renal physicians for referral and long-term management plan.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p><img src=\\\"data:image/png;base64,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\\\" style=\\\"width:6in;height:5.34444in\\\" /></p>\\r\\n<h2 id=\\\"key-issues-for-nursing-care\\\">Key Issues for Nursing care</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Monitoring of urine output is essential.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Daily review of fluid management.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Oral intake is encouraged.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Good skin care should be practiced in patients with peripheral oedema.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Patient mobility and self-care should be actively encouraged.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Patients should continue to eat a balanced diet, and certain foods containing high amounts of potassium, such as bananas should be avoided.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<p>Kerr M, Bray B, Medcalf J et al. (2012) Estimating the financial cost of chronic kidney disease to the NHS in England. Nephrology Dialysis Transplantation. 27 (Suppl. 3): iii73–80]</p>\\r\\n<p>National Institute for Health and Care Excellence (2015) <em>Chronic kidney disease in adults: assessment and management</em> Clinical guideline [CG182] (available at <a href=\\\"https://www.nice.org.uk/guidance/cg182%20accessed%201/11/18\\\"><span data-custom-style=\\\"Internet Link\\\">https://www.nice.org.uk/guidance/cg182 accessed 1/11/18</span></a>)</p>\\r\\n<p>Kidney disease improving global outcomes (KDIGO): 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. (available at <a href=\\\"http://www.kdigo.org/clinical_practice_guidelines/pdf/CKD/KDIGO_2012_CKD_GL.pdf\\\"><span data-custom-style=\\\"Internet Link\\\">http://www.kdigo.org/clinical_practice_guidelines/pdf/CKD/KDIGO_2012_CKD_GL.pdf</span></a> (accessed 1/11/18)</p>\\r\\n<p>Rule AD, Larson TS, Bergstralh EJ, et al; Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease. Ann Intern Med. 2004 Dec 21;141(12):929-37.</p>\\r\\n<p>Levey AS et al; A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009 May 5;150(9):604-12.</p>\\r\\n<p>Inker LA et al; Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012 Jul 5;367(1):20-9. doi: 10.1056/NEJMoa1114248.</p>\\r\\n<p>Boulware LE, Jaar BG, Tarver-Carr ME et al. Screening for proteinuria in US adults: a cost-effectiveness analysis. JAMA 2003; 290: 3101–3114.</p>\\r\\n<p>White SL, Yu R, Craig JC et al. Diagnostic accuracy of urine dipsticks for detection of albuminuria in the general community. Am J Kidney Dis 2011; 58: 19–28.</p>\\r\\n<p>Lamb EJ, MacKenzie F, Stevens PE. How should proteinuria be detected and measured? Ann Clin Biochem 2009; 46: 205–217.</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Thomas Sammut</th>\\r\\n<th>Date: 29 November 2018</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Fatai Akemokwe</td>\\r\\n<td>Date: 04 February 2019</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td>31 May 2021</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<h2 id=\\\"section\\\"></h2>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"039\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>Congenital heart disease MeG-CLS-039</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"congenital-heart-disease\\\">Congenital heart disease</h1>\\r\\n<h2 id=\\\"executive-summary\\\"><em>Executive summary</em></h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<p>Congenital heart defects (CHD) are problems with the structure of the heart that are present at birth. It is caused by abnormal formation of the heart during foetal development. In most cases when a baby is born with a congenital heart defect, there is no known cause for it. CHD are classified into two broad categories, acyanotic (ACHD) and cyanotic lesions (CCHD). The most common acyanotic lesions are ventricular septal defect (VSD), atrial septal defect (ASD), atrioventricular canal defects and patent ductus arteriosus (PDA). In patients with Cyanotic congenital heart defects, the blood that is pumped around the body contains less than normal levels of oxygen causing the child to have bluish tinge to the skin and mucous membranes. Tetralogy of Fallot is the most common cyanotic heart defect but may not always become apparent immediately after birth.</p>\\r\\n<p>CHDs are the most common cause of infant death due to birth defects. Approximately 25% of children born with a CHD will need heart surgery or other interventions to survive. MRCG has an ongoing collaboration with the Chain of Hope charity which assist in management of children with CHD, by making arrangements for surgical treatment overseas for those children who will benefit. Please review the current SOP or discuss with a consultant if you need more advice about how to ensure children with CHD are included in this programme.</p>\\r\\n<h2 id=\\\"target-users\\\">Target users</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doctors</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nurses</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"target-area-of-use\\\">Target area of use </h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Outpatient department</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ward</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"key-areas-of-focus-new-additions-changes\\\">Key areas of focus / New additions / Changes </h2>\\r\\n<p>This guideline outlines the diagnosis and management of congenital heart defects.</p>\\r\\n<h2 id=\\\"limitations\\\">Limitations</h2>\\r\\n<p>Patients with congenital heart disease need to be referred overseas for surgical repair. This is best achieved through ongoing care at our clinic and attendance at our periodic screening clinic (about once per year) run by Chain of Hope, who can arrange sponsorship for eligible children.</p>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs\\\">Presenting symptoms and signs</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Failure to thrive (Small for age)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Feeding difficulties</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Diaphoresis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Respiratory distress</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Cyanosis (in cyanotic CHD)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Cardiac murmurs</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Detection of a heart murmur - need to differentiate innocent from pathological</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Shock - when duct closes in severe left heart obstruction</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"examination-findings\\\">Examination findings</h2>\\r\\n<p>Full cardiac and respiratory examination is important, including basic observations, inspection, palpation and auscultation.</p>\\r\\n<p>Pulse oximetry is helpful to identify oxygen saturations.</p>\\r\\n<h2 id=\\\"investigations\\\">Investigations</h2>\\r\\n<p>ECHO is the gold standard for making the diagnosis.</p>\\r\\n<p>Other tests that might be helpful include:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>CXR – to see if the heart is enlarged or if there are signs of left heart failure.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>ECG – to identify rhythm problems.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Cardiac catheterization is not available in Gambia – but can help determine the function of the heart valves and chambers.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"management\\\">Management</h2>\\r\\n<p>The management of CHD depends on the exact problem identified – these are described below.</p>\\r\\n<h3 id=\\\"asymptomatic-child-with-a-systolic-murmur\\\">Asymptomatic Child With a Systolic Murmur </h3>\\r\\n<p>When murmur is identified in an asymptomatic child 2 years of age or older, the child should be evaluated with full history, examination, CXR (and perhaps ECG).</p>\\r\\n<p>ECHO is reserved for selected cases where the history and physical findings are atypical for an innocent murmur. Once a murmur is determined to be innocent, further cardiac evaluation is unnecessary.</p>\\r\\n<h3 id=\\\"ventricular-septal-defect\\\">Ventricular Septal Defect</h3>\\r\\n<h4 id=\\\"small-vsd\\\">Small VSD</h4>\\r\\n<p>In most patients, a small VSD is a relatively benign condition. It is important to monitor these patients to detect and manage the relatively rare but important complications of endocarditis, arrhythmias, aortic regurgitation and subvalvular pulmonary stenosis and discrete subaortic stenosis.</p>\\r\\n<p>Clinical examination and ECHO are adequate to establish the diagnosis.</p>\\r\\n<p>Children with a small VSD are often asymptomatic and have an excellent long-term prognosis. Neither medical therapy nor surgical therapy is indicated. Prophylactic antibiotic therapy against endocarditis is no longer indicated in most cases.</p>\\r\\n<h4 id=\\\"moderate-to-large-vsd\\\">Moderate to large VSD</h4>\\r\\n<p>In moderate or large VSDs, medical therapy is indicated to manage symptomatic congestive heart failure (CHF). This may include:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Increase feeds to ensure adequate weight gain. Occasionally, oral feeds must be supplemented with nasogastric tube feedings, because a baby in CHF may be unable to consume adequate calories for appropriate weight gain.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Furosemide to relieve pulmonary congestion – give 1-3 mg/kg/day divided into 2 or 3 doses. Long-term furosemide treatment may result in hypercalciuria, renal damage, and electrolyte disturbances.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>ACE inhibitors (eg captopril and ramipril) reduce both the systemic and pulmonary pressures (the former to a greater degree), thereby reducing the left-to-right shunt.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Uncontrolled CHF with growth failure and recurrent respiratory infection is an indication for immediate surgical repair. Neither the age nor the size of the patient is prohibitive in considering surgery.Ideally, surgery is performed at 3 – 6 months of age to prevent permanent lung damage from pulmonary hypertension.</p>\\r\\n<h3 id=\\\"patent-ductus-arteriosus-pda\\\">Patent Ductus Arteriosus (PDA)</h3>\\r\\n<p>In most cases, Doppler ECHO is adequate to confirm the diagnosis. Cardiac catheterization is necessary only in atypical cases.</p>\\r\\n<p>Treatment is by elective closure of the PDA.</p>\\r\\n<p>When the duct is large complications include infective arteritis, aneurysm of the ductus, congestive heart failure, pulmonary vascular obstructive disease, and calcification of the ductus.</p>\\r\\n<h3 id=\\\"atrial-septal-defect-asd\\\">Atrial Septal Defect (ASD)</h3>\\r\\n<p>There are two main types of ASD – secundum ASD (80% of ASD) and partial atrioventricular septal defect AVSD or primum ASD. Both present with similar symptoms and signs but their anatomy is different.</p>\\r\\n<p>Patient may have no symptoms or may present with recurrent chest infections and wheeze. ECHO is the mainstay of diagnosis.</p>\\r\\n<p>Once an ASD is found at ECHO, an assessment of shunt size is made.</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Small shunt: Absence of diastolic flow rumble, normal chest X-ray, ECHO evidence of normal right ventricular size and normal interventricular septal motion or a pulmonary to systemic flow ratio (QP/QS) &lt;1.5.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Large shunt: Presence of a diastolic flow rumble or ECG evidence of right ventricular hypertrophy, CXR evidence of cardiomegaly or increased pulmonary vascular markings, or ECHO evidence of right ventricular enlargement or paradoxical septal motion or a QP/QS 1.5.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Many small ASDs close spontaneously below the age of 2 years and some up to the age of 4 years, therefore conservative treatment is indicated if the patient is under age 4 years and asymptomatic. Even those with symptoms and a large left-to-right shunt can be observed up to the age of 5 years.</p>\\r\\n<p>If the ASD does not close spontaneously, then surgical closure is indicated at 3-5 years of age in order to prevent right heart failure and arrhythmias in later life.</p>\\r\\n<h3 id=\\\"tetralogy-of-fallot-tof\\\">Tetralogy of Fallot (TOF)</h3>\\r\\n<p>TOF is the most frequent cyanotic congenital heart disease. The four cardinal anatomic features are a large VSD, overriding of the aorta, subpulmonary stenosis causing right ventricular outflow tract obstruction (RVOTO) and right ventricular hypertrophy. The severity of RVOTO determines the extent of R-L shunting on ventricular level and therefore the extent of cyanosis.</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Severe RVOTO</strong> results in deep cyanosis due to a large R-L shunt.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Mild RVOTO</strong> does not cause cyanosis (“pink Fallot”) and may result in heart failure due to large L-R shunting on ventricular level</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p><em>Examination findings</em></p>\\r\\n<p>Central cyanosis and a systolic murmur, caused by PS with the intensity inversely correlated with severity of PS. The VSD is not associated with a murmur!</p>\\r\\n<p><em>Investigations</em></p>\\r\\n<p>Echocardiography is the cornerstone for the diagnosis. Chest X-ray and ECG may be helpful.</p>\\r\\n<p>Pulse oximetry at each clinical visit. If O<sub>2</sub> saturations repeatedly &lt; 80%, treatment is mandatory.</p>\\r\\n<p><em>Management of cyanotic spells</em></p>\\r\\n<p>These are caused by acute obstruction of RVOT or acute decrease of peripheral resistance.</p>\\r\\n<p>They present with:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Increase of cyanosis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Tachycardia</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Auscultation decreased intensity of systolic heart murmur due to reduced flow into PA</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Seizures (neurological sequelae)</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Older untreated children have signs of chronic hypoxaemia including digital clubbing. They are at risk of endocarditis and brain abscess and these risks increase with age, raised Hb and iron deficiency.</p>\\r\\n<p><em>Emergency treatment</em></p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Increase peripheral resistance by encouraging knee-to-chin position</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Administer oxygen</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Sedation: Morphine sc or iv 0.1-0.2 mg/kg OR Midazolam iv 0.1 mg/kg OR Midazolam Rectal 0.5 mg/kg OR Ketamine iv 1-2 mg/kg OR Ketamine im 5 mg/kg.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Give fluid: iv bolus of 10 ml/kg of normal saline which can be repeated.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Give betablocker: iv propranolol 15-20 mcg/kg – repeat up to a maximum of 100 mcg/kg. Once child is improving, continue with doses of 15-20 mcg/kg up to 6 hourly until able to take it orally.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p><em><br />\\r\\n</em></p>\\r\\n<p><em>Ongoing treatment</em></p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Oral propranolol 2-6 mg/kg/day in divided doses.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Iron replacement as despite the plethora, children with TOF are often iron deficient.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Surgical repair involves enlargement of RVOT and VSD closure.</p>\\r\\n<h3 id=\\\"children-who-have-had-surgery-for-chd\\\">Children who have had surgery for CHD</h3>\\r\\n<p>Review patients in clinic about 3 months after surgery. Check for resolution of all post-operative problems. Examine the patient fully.</p>\\r\\n<p>Look for important complications such as arrhythmia and pulmonary valve insufficiency.</p>\\r\\n<p>ECHO to confirm successful treatment is usually done by the surgeons, but may need to be repeated here.</p>\\r\\n<p>ECG, CXR and other tests to assess the patient may be needed if there are any abnormal clinical findings.</p>\\r\\n<h3 id=\\\"antibiotic-prophylaxis-for-dental-procedures\\\">Antibiotic prophylaxis for dental procedures</h3>\\r\\n<p>Many patients with congenital cardiac defects require prophylaxis for bacterial endocarditis when undergoing certain surgical and dental procedures. Antibiotics before dental procedures are only recommended for patients with the highest risk of infective endocarditis:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>A prosthetic heart valve or who have had a heart valve repaired with prosthetic material.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>A history of endocarditis.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>A heart transplant with abnormal heart valve function</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Certain congenital heart defects including:</p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>CCHD that has not been fully repaired, including children who have had a surgical shunts and conduits.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>CHD that&#39;s been completely repaired with prosthetic material or a device for the first six months after the repair procedure.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Repaired CHD with residual defects, such as persisting leaks or abnormal flow at or adjacent to a prosthetic patch or prosthetic device.</p>\\r\\n</div></li>\\r\\n</ul></li>\\r\\n</ul>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<h2 id=\\\"lissauer-t.-carroll-w.-craft-a.-2018.-illustrated-textbook-of-paediatrics.-fifth-edition.-elsevier\\\">Lissauer, T., Carroll, W., &amp; Craft, A. (2018). <em>Illustrated textbook of paediatrics</em>. Fifth Edition. Elsevier</h2>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Baderinwa Abatan</th>\\r\\n<th>Date: 31 July 2018</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Karen Forrest</td>\\r\\n<td>Date: 31 July 2018</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td>31 July 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>1.1</td>\\r\\n<td>Executive summary added</td>\\r\\n<td>31 July 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"003\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>Constipation MeG-CLS-003</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"constipation\\\">Constipation</h1>\\r\\n<h2 id=\\\"executive-summary\\\"><em>Executive summary</em></h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<p>Constipation is infrequent and difficult defecation of hard stools and a sensation of incomplete evacuation or straining. Constipation may also refer to a decrease in the volume or weight of stool, and the need for enemas, suppositories, or laxatives to maintain bowel regularity. However there is no objective definition of constipation because of great individual variation in normal bowel habits.</p>\\r\\n<p>Constipation can be divided into:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Normal­transit constipation (most common)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Functional constipation (slow transit)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>IBS (constipation dominant)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Outlet obstruction (sudden onset)</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"target-users\\\">Target users</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doctors</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nurses</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"target-area-of-use\\\">Target area of use </h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Gate clinic</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Outpatient department</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ward</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"key-areas-of-focus-new-additions-changes\\\">Key areas of focus / New additions / Changes </h2>\\r\\n<p>This guideline provides advice on lifestyle and dietary modifications to treat constipation as well as add-on medications where needed. It also provides advice on when to be concerned about the presentation of constipation and who should be referred to a doctor.</p>\\r\\n<h2 id=\\\"limitations\\\">Limitations</h2>\\r\\n<p>None</p>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs\\\">Presenting symptoms and signs</h2>\\r\\n<p>Constipation itself is a symptom.</p>\\r\\n<p>Always ascertain what the patient means by constipation. Patients may use the term constipation to mean that their faeces are too hard, they do not defaecate often enough, defaecation causes straining or there is a sense of incomplete evacuation. Some may need digital manipulation to facilitate evacuation.</p>\\r\\n<p><em><strong>When associated with inability to pass flatus, severe abdominal pain, or vomiting there may be the need for urgent referral to a surgeon.</strong></em></p>\\r\\n<p>Ask about other symptoms including:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hard, pebbly, rocklike stools</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Painful defecation</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Abdominal pain</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Weight loss</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Blood in stools</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"examination-findings\\\">Examination findings</h2>\\r\\n<p>Consider looking for anaemia, hypothyroidism, malnutrition, hernias, spinal abnormalities.</p>\\r\\n<p>Examine abdomen for altered bowel sounds, tenderness, masses and organomegaly.</p>\\r\\n<p>Do a rectal examination to identify masses, anal conditions and to confirm impaction or faecal loading.</p>\\r\\n<h2 id=\\\"management-in-gate-clinic\\\">Management in Gate Clinic</h2>\\r\\n<p><strong><span class=\\\"underline\\\">What to look out for</span></strong></p>\\r\\n<p>The following features may indicate a more serious condition and these patients should be <em>referred</em> to the doctor:</p>\\r\\n<p>For children:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Symptoms began at birth or soon after</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>There was delayed passage of meconium more than 48 hours</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ribbon stools</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Weakness in legs</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Abdominal swelling and vomiting</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>For adults</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Change of calibre of stools</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Blood mixed in stools</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>New onset of symptoms</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Rectal prolapse</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Abdominal swelling and vomiting</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Failure to pass flatus</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Weight loss</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Weakness in legs</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Refer other children who do not respond to lifestyle advice and other adults who do not respond to either lifestyle advice or lactulose.</p>\\r\\n<h3 id=\\\"management\\\">Management</h3>\\r\\n<p>When the patient is first seen, recommend simple lifestyle advice:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Increase fluid intake (minimum 10 cups of water a day for a healthy teenager and adult)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Increase intake of food rich in fibers such as: fruits and vegetables,</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Advise to visit the toilet immediately he/she has the urge and usually after eating.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>If the symptoms persist despite this, then all children should be referred to the doctor. Adults may be prescribed lactulose 15 ml BD for 3-5 days.</p>\\r\\n<p>Patients with symptoms persisting despite this should be referred to the doctor.</p>\\r\\n<h2 id=\\\"management-in-opd\\\">Management in OPD</h2>\\r\\n<p>Treatment objectives are:</p>\\r\\n<ol type=\\\"1\\\">\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>To identify more complex causes of constipation.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>To arrange necessary investigations.</p>\\r\\n</div></li>\\r\\n</ol>\\r\\n<p>Consider other causes:</p>\\r\\n<h4 id=\\\"medical-causes\\\">‘Medical&#39; causes</h4>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Diet deficient in roughage</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ignoring the urge to defaecate e.g. due to immobility</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Myxoedema</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Irritable bowel syndrome</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hypercalcaemia</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Drugs e.g. atropine, codeine phosphate, morphine, tricyclic antidepressants, disopyramide</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Lazy bowel from chronic laxative use including &#39;herbal&#39; preparations</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Lack of exercise</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h4 id=\\\"surgical-causes\\\">‘Surgical&#39; causes</h4>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Anal fissure and other painful perianal lesions</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Carcinoma of the rectum and sigmoid colon</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Foreign body in the gut</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Pelvic mass e.g. fibroid, foetus</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Any gastrointestinal obstruction</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Aganglionic and acquired megacolon</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h4 id=\\\"other-diagnoses\\\">Other diagnoses</h4>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hypothyroidism</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Psychosocial dysfunction</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Neurological disorders including multiple sclerosis or spinal cord injury</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Diabetes (chronic dysmotility)</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"investigations\\\">Investigations</h3>\\r\\n<p>No tests are required for unless there is reason to consider an underlying diagnosis.</p>\\r\\n<p>In those circumstances, tests which may be considered include:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>FBC</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>TSH</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Potassium and calcium</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Urine dipstick</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Barium enema or flexible sigmoidoscopy (check guideline before requesting this)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Stool for occult blood.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"management-of-simple-constipation\\\">Management of simple constipation</h3>\\r\\n<p>Check the patient is following the lifestyle advice above.</p>\\r\\n<p>Medication should be given according to the probable cause. In all cases, it should only be given on a long term basis if there is a clear irreversible reason for problem. Most other patients will be able to taken medicine intermittently for 3-5 days at a time when they have problems.</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Lactulose</strong> – is first line option – it is not absorbed, so is safe in pregnancy and diabetes. Start with 15 ml BD for adults (dose is age dependent in children – see BNF or EMRS).</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Bisacodyl</strong> – should only be used when you suspect motility problems. It is first-line when the patient is taking opiates. 5-10 mg nocte (max of 5 mg per day below age of 10 years).</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Glycerine</strong> suppositories – useful where the cause is an underlying neurological problem. 1 nocte.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Docusate</strong> liquid – preferred for children. Give 12.5-25 mg OD (max of 12.5 mg per day below age of 6 months).</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Patients with surgical causes will usually require referral to the surgeons.</p>\\r\\n<h3 id=\\\"management-of-constipation-in-pregnancy\\\">Management of constipation in pregnancy</h3>\\r\\n<p>Constipation is very common in pregnancy secondary to progesterone and the enlarging uterus.</p>\\r\\n<p>Constipation that results from iron supplementation can be avoided by increasing the intake of fluid and high­fibre foods, and increasing physical activity such as walking.</p>\\r\\n<p>Bulking agents and lactulose will not enter breast milk. Senna, in large doses, will enter breast milk and may cause diarrhoea and colic in infants.</p>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<p>Suares NC, Ford AC. Prevalence of, and risk factors for, chronic idiopathic constipation in the community: systematic review and meta-analysis. Am J Gastroenterol 2011;106:1582-91.</p>\\r\\n<p>Brandt LJ, Prather CM, Quigley EM et al. Systematic review on the management of chronic constipation in North America. Am J Gastroenterol 2005;100(Suppl 1):S5-S21.</p>\\r\\n<p>Ford A, Moayyedi P, Lacy B, Lembo A, Saito Y et. Al. American College of Gastroenterology Monograph on the Management of Irritable Bowel Syndrome and Chronic Idiopathic Constipation. The American Journal of Gastroenterology 2014:109(S1)pp:S2-S26.</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Chibuike Okpara</th>\\r\\n<th>Date: 8 July 2018</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Karen Forrest</td>\\r\\n<td>Date: 25 July 2018</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>2.0</td>\\r\\n<td>Adapted from previous version to expand relevance beyond gate clinic.</td>\\r\\n<td>31 July 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>2.1</td>\\r\\n<td>Executive summary added</td>\\r\\n<td>31 July 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"032\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>COPD MeG-CLS-032</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"chronic-obstructive-pulmonary-disease-copd\\\">Chronic obstructive pulmonary disease (COPD)</h1>\\r\\n<h2 id=\\\"executive-summary\\\"><em>Executive summary</em></h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<p>COPD is a chronic lung condition characterised by air-flow limitation that is not fully reversible. It usually progresses over time – either gradually or in a step-wise fashion. It is most commonly associated with smoking, but may also be associated with cooking over wood fires, exposure to dust or a history of TB.</p>\\r\\n<p>COPD is not easy to diagnose. There is no single test and the diagnosis will depend on a good history and examination. Tests are at best suggestive of COPD. It is not curable but can be treated. Adequate treatment can slow the rate of progression.</p>\\r\\n<h2 id=\\\"target-users\\\">Target users</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doctors</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nurses</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"target-area-of-use\\\">Target area of use </h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Outpatients department</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ward</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"key-areas-of-focus-new-additions-changes\\\">Key areas of focus / New additions / Changes </h2>\\r\\n<p>This guideline outlines the diagnosis and management of COPD in our setting.</p>\\r\\n<h2 id=\\\"limitations\\\">Limitations</h2>\\r\\n<p>Diagnosis is difficult in the absence of access to spirometry.</p>\\r\\n<h2 id=\\\"diagnosis\\\">Diagnosis</h2>\\r\\n<h3 id=\\\"presenting-symptoms-and-signs\\\">Presenting symptoms and signs</h3>\\r\\n<p>Patients complain of shortness of breath on exertion, chronic cough, often productive of sputum, wheeze and recurrent chest infections.</p>\\r\\n<p>The exact degree of exertion required to bring on symptoms will vary from patient to patient. Some patients will not experience much shortness of breath but will have limited their activity levels to avoid exertion. This leads to most patients being overweight – however, patients with very severe disease can develop cachexia.</p>\\r\\n<p>Most patients will give a history of smoking or other environmental exposure. A few patients may have a history of asthma which has evolved into COPD.</p>\\r\\n<p>Symptoms commonly vary in severity over the day or from week to week. They are most often worse in the mornings.</p>\\r\\n<h3 id=\\\"examination-findings\\\">Examination findings</h3>\\r\\n<p>Patients may be using their accessory respiratory muscles. They may purse their lips on expiration. The lungs may be over-distended, with very reduced air entry and a long expiratory phase. There may be wheeze on auscultation.</p>\\r\\n<p>Patients may have signs of right heart failure in established disease. Mild ankle oedema may be seen even in the absence of heart failure. Clubbing is not typical of COPD and suggests another diagnosis.</p>\\r\\n<p>The saturations should be measured. Levels below 92% on air are abnormal.</p>\\r\\n<h3 id=\\\"investigation\\\">Investigation</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hb – anaemia commonly coexists with COPD and treatment can reduce symptoms.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Blood glucose, renal profile and electrolytes are all useful to exclude alternative causes of shortness of breath. If the renal function is normal, but the bicarbonate is raised, this is an indication of chronic under-ventilation. This is very important to note in hypoxic patients.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Spirometry is not available here. PEFR can be measured instead, but it often underestimates the degree of airflow obstruction in COPD.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Chest X-ray is important to exclude other diagnoses. About half of patients with COPD have a normal X-ray. Features supportive of a diagnosis of COPD are: increased radiolucency of the lung, flat diaphragm, long, narrow heart shadow, bullae and evidence of right heart failure.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>ECG may show right axis deviation, incomplete right bundle branch block, low voltage across all leads, persistent S waves in the precordial leads or prominent peaked P waves in leads II, III and aVF.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"differential-diagnoses\\\">Differential diagnoses</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Bronchial Asthma</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Central airway obstruction may be caused by a malignancy or by TB lymph nodes.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Bronchiectasis is very difficult to differentiate from COPD – it is suggested by daily purulent sputum production.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Heart failure usually presents with a large heart on CXR along with signs of pulmonary oedema.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>TB usually causes consolidation or other CXR signs. However, it can co-exist with COPD and about 30% of former TB patients will later develop some degree of airflow obstruction.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Rarer lung diseases that can cause progressive shortness of breath include pulmonary fibrosis and bronchiolitis obliterans.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"management\\\">Management</h2>\\r\\n<h3 id=\\\"management-in-opd\\\">Management in OPD</h3>\\r\\n<p><em>This is only for stable COPD</em></p>\\r\\n<p>The management of COPD is difficult in our setting – we have access neither to the investigations we need to guide treatment nor to the best treatments.</p>\\r\\n<p>The most important intervention is to encourage the patient to avoid any possible causes of COPD. Smokers should be encouraged to stop and women who cook over wood fires should try to avoid this.</p>\\r\\n<p>Bronchodilators have been shown to improve symptoms and exercise capacity. Short-acting bronchodilators such as salbutamol are best administered via inhaler with a spacer. A spacer can be made from a plastic bottle. They work quickly and are particularly helpful to patients with mild intermittent symptoms. They are most effective and safest when used on an as-needed basis. Salbutamol can be prescribed orally but is more likely to cause serious side effects such as cardiac arrhythmias. As COPD is by definition not fully reversible, the benefits may not outweigh the risks.</p>\\r\\n<p>If further treatment is required long-acting bronchodilators (either salmeterol or tiotropium) would be recommended next. Inhaled steroids, if prescribed, should be given with these agents.</p>\\r\\n<p>In the absence of access to bronchodilators, aminophylline can be used. It is controversial, but there is some evidence of an improvement in lung function and improved exercise tolerance. It is toxic in overdose.</p>\\r\\n<p>Oral steroids have no place in the management of stable COPD.</p>\\r\\n<h3 id=\\\"management-on-the-ward\\\">Management on the ward</h3>\\r\\n<p><em>Patients with exacerbations of COPD are managed as inpatients on the ward.</em></p>\\r\\n<p>Exacerbations are characterised by increase in cough, increased sputum production and increased shortness of breath.</p>\\r\\n<p>Note that 70% of exacerbations are thought to be caused by infections (bacterial or viral). Most of the remaining cases are caused by pulmonary emboli.</p>\\r\\n<p>Patients with an exacerbation should be investigated with saturations, chest X-ray (to exclude pneumonia, pneumothorax, pulmonary oedema and pleural effusion), FBC, electrolytes, renal profile and glucose. Those with hypoxia (saturations &lt; 92%) or who remain breathless after a nebuliser will need admission to hospital.</p>\\r\\n<p>All patients will benefit from inhaled salbutamol during an acute exacerbation.</p>\\r\\n<p>Oral steroids may help a little – give prednisolone 40 mg OD for 5 days in outpatients. Courses can be extended to 14 days for those ill enough to be admitted.</p>\\r\\n<p>Patients who have 2 of these symptoms will benefit from antibiotics</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>increased shortness of breath,</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>increased sputum production,</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>increased sputum purulence.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Those who are under age 65, without heart disease and who have less than 3 exacerbations per year can be given azithromycin, doxycycline or co-trimoxazole. Other patients should be treated with ciprofloxacin or co-amoxiclav. The antibiotics should be cycled to prevent resistance – especially in those receiving regular courses.</p>\\r\\n<p>Oxygen should be used in all patients with saturations &lt; 88%. It should be given via nasal prongs at an initial rate of 2 litres per minute and increased up to a rate of 6 litres per minute if necessary. The aim is to keep the saturations between 88 and 92%. Higher levels than this are associated with hypercapnia and increased mortality.</p>\\r\\n<h2 id=\\\"key-issues-for-nursing-care\\\">Key Issues for Nursing care</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Check the O<sub>2</sub> saturation. Provide oxygen via nasal prongs if O<sub>2</sub> saturation is less than 88% but do not allow to be more than 92%.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Give salbutamol nebuliser if very short of breath.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Sit patient upright – in the acute phase they will be most comfortable sitting with their arms resting on a pillow on a table. This position provides the most support to the intercostal muscles.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Encourage mobilisation.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Give patient advice to discontinue smoking and/or avoid cooking over an open wood fire.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p><strong>References</strong></p>\\r\\n<p>Han, Dransfield and Martinez 2017. Chronic obstructive pulmonary disease: Disease, clinical manifestations, diagnosis, and staging. UpToDate Aug 2017.</p>\\r\\n<p>Ferguson and Make 2017. Management of stable chronic obstructive pulmonary disease. UpToDate June 2017</p>\\r\\n<p>Stoller 2017. Management of exacerbations of chronic obstructive pulmonary disease. UpToDate Aug 2017.</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Babatunde Awokola</th>\\r\\n<th>Date: 2 July 2018</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Karen Forrest</td>\\r\\n<td>Date: 25 July 2018</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>2.0</td>\\r\\n<td>Transferred to new template</td>\\r\\n<td>31 July 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>2.1</td>\\r\\n<td>Executive summary added</td>\\r\\n<td>31 July 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"083\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>COVID-19 Adults with mild or moderate COVID-19 MeG-CLS-083</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"adults-with-mild-or-moderate-covid-19\\\">Adults with mild or moderate COVID-19</h1>\\r\\n<div data-custom-style=\\\"paragraph\\\">\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\"><em><strong>Executive summary</strong></em></span></p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"paragraph\\\">\\r\\n<p><strong><span data-custom-style=\\\"normaltextrun\\\">Introduction</span><span data-custom-style=\\\"eop\\\"> </span></strong></p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"paragraph\\\">\\r\\n<p>In late December 2019, the World Health Organization (WHO) China Country Office was informed of cases of pneumonia of unknown cause detected in Wuhan City, China. On 7 January 2020, the causative pathogen was identified as a novel coronavirus (SARS-CoV-2). The disease (COVID-19) can range from an symptomatic or mild flu-like illness to a severe pneumonia requiring critical care. It was declared a pandemic by WHO on 11<sup>th</sup> March 2020.</p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"paragraph\\\">\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\"><strong>Target User</strong></span></p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\">Doctors</span></p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\">Nurses</span></p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<div data-custom-style=\\\"paragraph\\\">\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\"><strong>Target area of use</strong></span></p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Outpatient department</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\">Ward</span></p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"key-areas-of-focus-new-additions-changes\\\">Key areas of focus / New additions / Changes  </h2>\\r\\n<div data-custom-style=\\\"paragraph\\\">\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\">These guidelines</span> addresses the diagnosis and management of low risk adults with COVID-19 who are mainly those under the age of 60 with no serious underlying health conditions.</p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"paragraph\\\">\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\"><strong>Limitations</strong></span></p>\\r\\n</div>\\r\\n<p>We lack access to HDU/ICU level care and cannot ventilate patients.</p>\\r\\n<p>We have only two negative pressure ward side rooms.</p>\\r\\n<h2 id=\\\"section\\\"></h2>\\r\\n<h2 id=\\\"management-in-the-gate-clinic-or-at-registration-to-opd\\\">Management in the Gate clinic or at registration to OPD</h2>\\r\\n<p>Patients should be asked as a group and individually at registration if they have a history of travel to areas with local transmission of SARS-CoV-2 in the last four weeks and if they have a fever, cough or shortness of breath.</p>\\r\\n<p>When the number of people having a dry cough in the gate clinic and OPD waiting areas are more than usual, please have a heightened index of suspicion. The travel history inquiry must be repeated before consultation starts in the gate clinic and also during vital signs assessment at the OPD by the nurses. If the answer to both questions is yes, do not touch the patient. Give them a surgical mask and take them to a place 2 metres from other people. Immediately inform a doctor or senior nurse who will wear a mask, goggles and gloves and verbally screen the patient from a safe distance. If the risk for COVID-19 is significant, a call is immediately placed to the COVID-19 national number on 1025. A health worker in facemask and gloves must be left watching over the patient. If there is no risk for COVID-19, the patient is taken care of in the usual manner.</p>\\r\\n<p><span class=\\\"underline\\\">Epidemiological criteria-</span> <em><strong>Please note that this is dynamic and it changes everyday</strong></em></p>\\r\\n<p>Those that have travelled from the countries with ongoing presumed community transmission of COVID-19 disease in the 4 weeks prior to onset of symptoms. (See WHO website for the latest list of relevant countries:</p>\\r\\n<p><a href=\\\"https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports\\\"><span data-custom-style=\\\"Hyperlink\\\">https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports</span></a>)</p>\\r\\n<p>OR</p>\\r\\n<p>Contact with a confirmed case of COVID-19</p>\\r\\n<p>OR</p>\\r\\n<p>Patient has worked or attended a heath care facility where patients with COVID-19 acute respiratory disease patients were being treated.</p>\\r\\n<p><span class=\\\"underline\\\">Clinical criteria</span></p>\\r\\n<p>Severe acute respiratory infection requiring hospital admission with radiological/clinical signs of pneumonia or respiratory distress syndrome</p>\\r\\n<p>OR</p>\\r\\n<p>Acute respiratory infection with cough or shortness of breath (with or without fever)</p>\\r\\n<p>OR</p>\\r\\n<p>Fever with no other symptoms.</p>\\r\\n<p>AND with no other aetiology that fully explains the clinical presentation</p>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs\\\">Presenting symptoms and signs</h2>\\r\\n<p>Early recognition of suspected patients allows timely initiation of infection prevention and control (IPC) measures. Most (80%) symptomatic patients develop mild disease, an estimated 15% develop severe disease (with hypoxaemia, dyspnoea and tachypnoea) while 5% become critically ill (with respiratory failure, septic shock and/or multiorgan dysfunction). The proportion of asymptomatic carriers is currently unknown.</p>\\r\\n<p><strong>The most common presenting symptoms have been:</strong></p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>fever (~90%, but only present in 44% on admission)</strong></p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>cough (68%)</strong></p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>fatigue (38%)</strong></p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>sputum production (34%)</strong></p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>shortness of breath (19%)</strong></p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>myalgia or arthralgia (15%)</strong></p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>sore throat (14%)</strong></p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>headache (13.6%)</strong></p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>chills (12%).</strong></p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p><strong>Gastrointestinal symptoms such as nausea or vomiting (5.0%) and diarrhoea (3.8%) appear to be uncommon.</strong></p>\\r\\n<p><strong>There have been recent reports of people with COVID-19 presenting with loss of smell (anosmia) and loss of taste (ageusia)</strong></p>\\r\\n<p><strong>The vast majority of cases will make a full recovery, particularly the low risk adults.</strong></p>\\r\\n<h2 id=\\\"examination-findings\\\">Examination findings</h2>\\r\\n<p>Examinations are non-specific and may range from none other than fever to severe respiratory distress, shock and multi organ failure.</p>\\r\\n<h3 id=\\\"important-things-to-look-for\\\">Important things to look for</h3>\\r\\n<h2 id=\\\"travel-history-of-anyone-meeting-the-clinical-criteria-is-key.\\\">Travel history of anyone meeting the clinical criteria is key.</h2>\\r\\n<h2 id=\\\"management-at-the-opd-and-ward\\\">Management at the OPD and Ward</h2>\\r\\n<p>Diagnostic criteria, symptoms, signs and examination findings are as above.</p>\\r\\n<p>As soon as a possible case is identified the nurse and doctor in charge should be called. Possible cases should be given a surgical mask to wear as soon as it is clear that they are a possible case.</p>\\r\\n<p>They should then be transferred as soon as possible into the negative pressure ward side room using the rear corridor (avoiding transit through the ward). If the two side rooms are occupied, the Gambian MOH must be promptly informed on 1025 so that the patient can be evacuated after nasopharyngeal and throat samples are taken for COVID-19. However, if the patient is eligible for admission into the MRCG CSD, admit to the COVID-19 bay on Fajara ward and or the COVID-19 ward at Keneba.</p>\\r\\n<p>For emphasis, the public health authorities (Gambian MOH, 1025) should be alerted that the unit has a possible case. They have the duty to follow things up and inform the WHO if the results turn out to be positive.</p>\\r\\n<p>Where there is a delay in transit and the patient is well, they should be taken to chairs behind the seminar room to wait for the side room to be made ready. If they are unwell one of the OPD rooms should be vacated for them and access to this room strictly limited.</p>\\r\\n<p>Once a patient has been identified as a possible case, 2 staff should get changed into the appropriate PPE. See SOP-AIR-001 and 002 for Donning/Doffing PPE for COVID-19.</p>\\r\\n<h2 id=\\\"investigations\\\">Investigations </h2>\\r\\n<p>Investigations should be discussed with the laboratories prior to sampling so that they can be sure that they are prepared. ALL samples should be clearly labelled with a sticker and marked as “suspected Coronavirus”</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nasopharyngeal and oropharyngeal swab, sputum – For PCR detection of SARS-CoV-2 after discussion with the molecular lab.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>FBC – Lymphopenia is common, seen in ~80% of patients (Guan et al ,Yang et al). Mild thrombocytopenia is common (but platelets are rarely &lt;100). Lower platelet count is a poor prognostic sign (Ruan et al 3/3). Also look for signs of other diseases or coinfection.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>U&amp;Es – renal failure can be a complication of sepsis.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>LFTs – may give signs of alternative diagnosis (eg biliary sepsis).</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Malaria RDT &amp; slide – looking for signs of other diseases or coinfection. Note that it is safe to do an RDT at the bedside using a capillary blood sample.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Blood sugar – it is safe to do blood sugar at the bedside using a capillary sample.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>HIV – looking for signs of other diseases or coinfection.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Chest X-ray – should NOT be performed until COVID-19 has been ruled out as there is a risk of contamination. If/when available, the portable Xray machine will be used for all chest X-rays.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>ECG – if there is arrhythmia.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>USS – bedside USS may be helpful in the absence of CXR. Remember that the probe and all parts that enter the negative pressure room must be decontaminated after use.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Other tests that are clinically indicated.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p><strong>Treatment on the Ward</strong></p>\\r\\n<p>There is no specific treatment for COVID-19.</p>\\r\\n<p>Patient with confirmed COVID-19 with <strong>mild disease</strong> such as fever, cough, sore throat, fatigue, headache, muscle pain and nasal congestion may be managed at home with strict instructions to self-isolate at home where they will be followed up by public health officials and be given appropriate advice about reducing possible transmission to others. See guidance on Self-isolation for Coronavirus issued by MRCG at LSHTM.</p>\\r\\n<p>Currently in the Gambia however, people with mild disease are being admitted to ensure isolation and decrease the probability of community/local transmission. This might however change as the pandemic unfolds locally.</p>\\r\\n<p>Confirmed patients with <strong>moderate</strong> to <strong>severe</strong> cases with pneumonia manifestations who meet any of the following criteria: respiratory rate ≥ 30 breaths/min; oxygen saturation ≤ 93% at a rest state; Heart rate &gt; 120 bpm, temperature &gt; 39 and altered mental state must be hospitalized to receive supportive therapy. This is covered in another guideline.</p>\\r\\n<p>All patients must be assessed for severity and a decision made about plans for treatment escalation at the time of admission. This is covered in another guideline.</p>\\r\\n<p><strong>Give supplemental oxygen therapy immediately to patients with low oxygen saturation.</strong></p>\\r\\n<p>Oxygen therapy is likely to be the single most effective supportive measure in COVID-19 patients overall. Target SpO2 ≥90% in non-pregnant adults and SpO2 ≥92-95 % in pregnant patients. Titrate oxygen therapy up and down to reach targets by means of nasal cannula, a simple face mask or a face mask with reservoir bag, as appropriate.</p>\\r\\n<p><strong>Use conservative fluid management in patients with SARS when there is no evidence of shock.</strong> Aggressive fluid resuscitation may worsen oxygenation, especially in settings where there is limited availability of mechanical ventilation.</p>\\r\\n<p><strong>If a clinical suspicion for co-infection exists, consider empiric antimicrobials to treat co-pathogens causing the syndrome, particularly in severe cases</strong>. This may include conventional and atypical bacterial pathogens, malaria, influenza and PCP.</p>\\r\\n<p>Although there is no clinical evidence for effective antiviral drugs, lopinavir-ritonavir combination as well as antibacterial, azithromycin and antimalarial drug, hydroxychloroquine are being studied at the moment. Use of antiviral or anti-inflammatory medications should be used only as part of a clinical trial.</p>\\r\\n<p>Closely monitor patients for signs of clinical deterioration, such as rapidly progressive respiratory failure and sepsis, and apply supportive care interventions.</p>\\r\\n<p><strong>Differential diagnosis</strong></p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Influenza (remembering the seasonality in patients from the northern hemisphere differs from those of the southern hemisphere)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Both conventional and atypical bacterial pneumonias,</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>In patients with HIV and a CD4 count &lt;200 cells/mm3 (or equivalent immunosuppression), <em>Pneumocystis jiroveci</em> pneumonia.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p><strong>Discharge and deisolation criteria</strong></p>\\r\\n<p>Patients with COVID-19 can be discharged home from OPD or isolation room provided the meet ALL of the following criteria:</p>\\r\\n<p>1. There are no medical indications for admission.</p>\\r\\n<p>2. The patient’s symptoms have improved or resolved. (Note: full recovery can take several weeks, especially in severe cases. It is not necessary for every symptoms to have completely resolved prior to discharge, only that there has been improvement).</p>\\r\\n<p>3. The patient has two consecutive negative combined nasopharyngeal and oropharyngeal RT-PCR tests, performed at least 24-48 hours apart.</p>\\r\\n<p>Patients with mild disease who were managed at home from the outset can be deisolated using the same criteria.</p>\\r\\n<h2 id=\\\"key-issues-for-nursing-care\\\">Key Issues for Nursing care</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>All patients being seen in Gate clinic or OPD with any one of cough, shortness of breath or fever starting in the last 14 days MUST be asked about travel.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>All nursing staff entering a side room containing a patient, or caring for a patient in another setting, with suspected or proven COVID-19 must wear PPE as outlined in the SOP.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>All staff that have contact with the patient must enter the details into the log book provided.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<p>Handbook of COVID-19 prevention and treatment <a href=\\\"https://video-intl.alicdn.com/Handbook%20of%20COVID-19%20Prevention%20and%20Treatment%20%28Standard%29.pdf?spm=a3c0i.14138300.8102420620.download.6df3647ft8yaHa&amp;file=Handbook%20of%20COVID-19%20Prevention%20and%20Treatment%20%28Standard%29.pdf\\\"><span data-custom-style=\\\"Hyperlink\\\">https://video-intl.alicdn.com/Handbook%20of%20COVID-19%20Prevention%20and%20Treatment%20%28Standard%29.pdf?spm=a3c0i.14138300.8102420620.download.6df3647ft8yaHa&amp;file=Handbook%20of%20COVID-19%20Prevention%20and%20Treatment%20%28Standard%29.pdf</span></a></p>\\r\\n<p>Clinical management of suspected or confirmed COVID-19 disease <a href=\\\"http://www.health.gov.za/index.php/component/phocadownload/category/628\\\"><span data-custom-style=\\\"Hyperlink\\\">http://www.health.gov.za/index.php/component/phocadownload/category/628</span></a></p>\\r\\n<p>WHO technical guidance for 2019-nCoV. <a href=\\\"https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance\\\"><span data-custom-style=\\\"Hyperlink\\\">https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance</span></a></p>\\r\\n<p>Novel Coronavirus (2019-nCov) Guidance for Health professionals collection. <a href=\\\"https://www.gov.uk/government/collections/wuhan-novel-coronavirus\\\"><span data-custom-style=\\\"Hyperlink\\\">https://www.gov.uk/government/collections/wuhan-novel-coronavirus</span></a></p>\\r\\n<p>Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020.</p>\\r\\n<p>Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, Ji R, Wang H, Wang Y, Zhou Y, Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis, International Journal of Infectious Diseases (2020), doi: <a href=\\\"https://doi.org/10.1016/j.ijid.2020.03.017\\\"><span data-custom-style=\\\"Hyperlink\\\">https://doi.org/10.1016/j.ijid.2020.03.017</span></a></p>\\r\\n<p>Ruan, Q., Yang, K., Wang, W. <em>et al.</em> Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. <em>Intensive Care Med</em> (2020). https://doi.org/10.1007/s00134-020-05991-x</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Amie Secka</th>\\r\\n<th>Date: 25 March 2020</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Babatunde Awokola</td>\\r\\n<td>Date: 10 April 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td>10 April 2022</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"084\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>COVID-19 Adults with severe COVID-19 MeG-CLS-084</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<div data-custom-style=\\\"Heading\\\">\\r\\n<p>Adults with severe COVID-19</p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"paragraph\\\">\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\"><em><strong>Executive summary</strong></em></span></p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"paragraph\\\">\\r\\n<p><strong><span data-custom-style=\\\"normaltextrun\\\">Introduction</span><span data-custom-style=\\\"eop\\\"> </span></strong></p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"paragraph\\\">\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\">This guideline assumes that an adult patient has been diagnosed with COVID-19 or that the clinical picture is highly suspicious for COVID-19. A small group of patients who contract COVID-19 will become very unwell with it.</span></p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"paragraph\\\">\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\"><strong>Target User</strong></span></p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\">Nurses</span></p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\">Doctors</span></p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<div data-custom-style=\\\"paragraph\\\">\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\"><strong>Target area of use</strong></span></p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\">Ward</span></p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"key-areas-of-focus-new-additions-changes\\\">Key areas of focus / New additions / Changes  </h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"paragraph\\\">\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\">Identification of those who may become unwell.</span></p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"paragraph\\\">\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\">Management of complications</span></p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"paragraph\\\">\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\">The importance of PPE in all circumstances</span></p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<div data-custom-style=\\\"paragraph\\\">\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\"><strong>Limitations</strong></span></p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"paragraph\\\">\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\">We lack access to HDU/ITU level care and cannot ventilate patients.</span></p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"paragraph\\\">\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\">We have two negative pressure rooms.</span></p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs\\\">Presenting symptoms and signs</h2>\\r\\n<p>There are two groups of patients to think about as high risk in the COVID-19 outbreak:</p>\\r\\n<ol type=\\\"1\\\">\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Those who have become very unwell with COVID-19 as their only problem.</strong> This group seems to present to hospital 5-12 days after the start of symptoms. They can develop Acute Respiratory Distress Syndrome (ARDS) and become very unwell. They comprise patients who have diabetes, chronic respiratory conditions (including severe asthma and COPD), chronic heart conditions (including uncontrolled hypertension) and immunosuppression (which in our setting is HIV/AIDS, steroids and methotrexate use). Also, lymphopenia, especially when progressively worsening seems to be a marker of likely poorer prognosis.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Those patients who have another medical condition that has been complicated by contracting COVID-19</strong>.</p>\\r\\n</div></li>\\r\\n</ol>\\r\\n<h3 id=\\\"clinical-presentation-of-covid-19-pneumonia-severe-critical-covid-19\\\">Clinical presentation of COVID-19 Pneumonia (severe &amp; critical COVID-19)</h3>\\r\\n<p>Clinically apparent COVID-19 primarily presents as a febrile, flu-like illness with recovery in approximately 80 % of cases.</p>\\r\\n<p>In around 20% of cases this flu-like illness progresses to a pneumonia over a period of 5-12 days from symptom onset and in a small number of cases (approximately 5% of total clinically apparent cases) this progresses further to ARDS, multi-organ failure, circulatory collapse &amp; death. COVID with hypoxia, tachypnoea, or widespread CXR changes (&gt; 50% lungs on CXR) is considered severe disease, whilst the presence of ARDS, multi-organ failure or circulatory collapse would constitute critical disease.</p>\\r\\n<p>Fever can be prolonged, lasting up to 14 days even in relatively uncomplicated cases, though persistence of fever after 7 days suggests that a more severe course may be developing.</p>\\r\\n<p>As disease become more common, more atypical presentations may present including acute abdominal pain, diarrhoea, delirium etc.</p>\\r\\n<h3 id=\\\"differentiating-covid-19-from-bacterial-pneumonia-cap\\\">Differentiating COVID-19 from bacterial pneumonia (CAP)</h3>\\r\\n<p>The following are suggestive of COVID-19 rather than CAP:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Travel from outside the Gambia</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>A history of close contact with confirmed / suspected case(s) of COVID-19</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Household contacts with acute cough, fever, breathlessness</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>High rapidly spiking fever (peaks &gt; 37.8<sup>0</sup>C)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Several days history before respiratory deterioration</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>History of loss of sense of smell / taste is highly suggestive and should be sought in all patients</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>History of myalgia and /or headache</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Bilateral respiratory signs</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Bilateral infiltrates on the chest X ray, with a non-lobar, lower zone and peripheral predominance</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Normal WCC with relative lymphopenia and absence of neutrophilia.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Significant pleural effusion is uncommon in COVID-19</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p><span class=\\\"underline\\\"><br />\\r\\n</span></p>\\r\\n<div data-custom-style=\\\"List Paragraph\\\">\\r\\n<blockquote>\\r\\n<p><span class=\\\"underline\\\">Other laboratory features commonly seen:</span></p>\\r\\n</blockquote>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Slightly elevated liver enzymes (ALT/AST)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Low platelets</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Raised LDH</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Raised troponin</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Currently COVID-19 can only be confirmed by a viral PCR, usually of a throat or nasopharyngeal swab sample. Estimates of the sensitivity of the vary from 80-90%, probably worse later in disease when the virus is predominantly in the lungs. Specificity is good. Therefore remember two things:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Imaging changes (CXR or US in our context) with symptoms and lab tests suggestive of COVID-19 with a negative test can still be COVID-19. This is particularly true at the time when pneumonia becomes a predominant feature, and also becomes more of a problem as the disease spreads (pre-test probability rises and the test performs worse).</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>If someone has COVID-19, they can still have another infection or health problem complicating their presentation.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"management\\\">Management </h2>\\r\\n<p>All patients must be assessed for severity and a decision made about plans for treatment escalation at the time of admission. This is covered in another guideline.</p>\\r\\n<div data-custom-style=\\\"Body\\\">\\r\\n<p>Currently, the management of COVD-19 is <strong>supportive</strong>.</p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"Body\\\">\\r\\n<p>There have been several treatments suggested that may be of benefit. At this moment, <strong>only patients enrolled in a clinical trial</strong> should receive therapy directed at COVID-19. This group of medicines include high dose corticosteroids (in the absence of bronchoconstriction), hydroxychloroquine, azithromycin and anti-retroviral medications such as Lopinavir/ritonavir.</p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"Body\\\">\\r\\n<p><strong>In all circumstances</strong>, appropriate PPE must be worn. If a patient becomes critically unwell, then staff should still take the time to don the PPE in a safe and proper manner.</p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"Body\\\">\\r\\n<p>Decisions on whether patients with COVID-19 need admission are likely to vary depending on the state of the epidemic at the time and the public health strategy. Where containment is the objective public health authorities may request the admission of all patients. If resources and beds become scarce, this may change to those meeting specific criteria (eg at risk of deterioration, needing oxygen or palliation).</p>\\r\\n</div>\\r\\n<p><strong><span class=\\\"underline\\\">Respiratory support</span></strong>: Give oxygen to patients with SARI and resp distress, hypoxaemia, seizures or shock and target SpO2 &gt; or equal to 94%. Once stable, target saturation is &gt; 90% in non-pregnant and 92 – 95% in pregnant patients. (This is not a guide on how many litres of oxygen to give them but a target for the optimum saturations once the oxygen is started. Oxygen should be turned down if saturations are consistently 99-100%).</p>\\r\\n<div data-custom-style=\\\"Body\\\">\\r\\n<p>It may help in all patients, to lie them in a prone position i.e. on their front.</p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"Body\\\">\\r\\n<p>BiPAP or CPAP are indicated when patients are classed as critically ill. If BiPAP or CPAP are available, they are likely to be the ceiling of care for many patients in The Gambia. CPAP and BiPAP are aerosol generating so should ideally be deployed in a neutral or negative pressure room. It may become necessary to cohort (place together) patients with proven or suspected COVID-19 and COVID-19 patients on CPAP or BiPAP.</p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"Body\\\">\\r\\n<p>Intubation and ventilation may be available in a few cases offsite, but the feasibility of this is currently unknown. With mortality in well-resourced settings of 66% for selected patients put on a ventilator with COVID-19, it will be necessary to select specific patients that may benefit from this resource intensive procedure. Intubation should be done by the most skilled operative using strict PPE.</p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"Body\\\">\\r\\n<p><strong><span class=\\\"underline\\\">Fever</span></strong>: Give due consideration as to why the fever is being treated. Generally, bringing down a patient&#39;s fever will likely make them feel better but not necessarily change how long they are unwell for. The exception to this is in patients with haemodynamic instability where reducing fever may reduce the risk of hypoxic tissue damage.</p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"Body\\\">\\r\\n<p>There is currently no evidence that NSAIDs are associated with extra morbidity and mortality in COVID-19. There is some evidence from other respiratory infections that NSAIDS will increase stroke and heart disease risk in susceptible patients. We recommend the use paracetamol first and then ibuprofen at as little a quantity as possible, for as short a time as possible.</p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"Body\\\">\\r\\n<p><strong><span class=\\\"underline\\\">Pain</span></strong>: Please, see above under fever above. If unresponsive to paracetamol, then use the WHO pain ladder.</p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"Body\\\">\\r\\n<p><strong><span class=\\\"underline\\\">Underlying medical conditions</span></strong>: Individual decisions should be made about each patient as they come, to manage their underlying condition alongside their acute COVID-19 as needed. There are a few areas of controversy to address:</p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>ACEi/ARB:</strong> There is no current evidence to support that patients will either gain protection or come to harm from these medications. Continuing the medication where it is needed while the patient is unwell is reasonable. However, given that these patients are likely to be acutely unwell, they are likely to be at risk of hypotension and renal injury. In such a situation, consideration should be given to stopping them during the infection and re-starting these medications after recovery.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Asthma/COPD/Post TB lung</strong>: These patients may benefit from steroids. Endeavour to use the lowest effective dose and where possible reduce the dose to less than 20mg for adults. However, given our limited therapy for bronchoconstriction, higher doses of steroids may still be needed.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<div data-custom-style=\\\"Body\\\">\\r\\n<p><strong><span class=\\\"underline\\\">Secondary bacterial infection</span></strong>: Patients who worsen unexpectedly, whose cough becomes productive, who have neutrophil leucocytosis or who have new lateralising signs and symptoms should be considered for treatment with antibiotics aimed at bacterial pneumonia. It may be necessary for some patients (eg. critical cases with unclear aetiology) to start antibiotics when they are unwell and then stop them if the test for COVID-19 comes back and explains their presentation.</p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"Body\\\">\\r\\n<p><strong><span class=\\\"underline\\\">Pressure area care</span></strong>: Ensure that patients who become bed bound are turned regularly (2-3 hourly) by nursing staff to stop pressure area damage.</p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"Body\\\">\\r\\n<p><strong><span class=\\\"underline\\\">Fluid and nutrition</span></strong>: Patients should be encouraged to eat but anorexia and anosmia are a common feature. Food intake is not vital and people will recover an appetite and their lost weight after recovery.</p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"Body\\\">\\r\\n<p>Fluid should be encouraged orally and then given NG first and ultimately intravenously if that does not work. If iv fluids are given, the aim is to maintain euvolaemia, taking into account insensible losses. Boluses should only be used if a patient is obviously shocked.</p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"Body\\\">\\r\\n<p><strong><span class=\\\"underline\\\">Monitoring</span></strong>: Hospitalised patients should be monitored regularly to identify deterioration. Saturations are particularly important. Early warning scores or specific severity scores should be used according to current practice.</p>\\r\\n</div>\\r\\n<h2 id=\\\"key-issues-for-nursing-care\\\">Key Issues for Nursing care</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Regular monitoring of a potential unstable group of patients</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Adhering to PPE to ensure staff and wider public safety</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Communication with patients and families</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<div data-custom-style=\\\"Default\\\">\\r\\n<p>Aronson J, Ferner R. Angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers in COVID-19 - CEBM [Internet]. CEBM. 2020 [cited 24 March 2020]. Available from: <a href=\\\"https://www.cebm.net/angiotensin-converting-enzyme-ace-inhibitors-and-angiotensin-receptor-blockers-in-covid-19/\\\"><span data-custom-style=\\\"Hyperlink.0\\\">https://www.cebm.net/angiotensin-converting-enzyme-ace-inhibitors-and-angiotensin-receptor-blockers-in-covid-19/</span></a></p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"Default\\\">\\r\\n<p>De Simone G. Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angi [Internet]. Escardio.org. 2020 [cited 24 March 2020]. Available from: <a href=\\\"https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang\\\"><span data-custom-style=\\\"Hyperlink.0\\\">https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang</span></a></p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"Default\\\">\\r\\n<p>Ramsay M. Contraindications and special considerations [Internet]. Assets.publishing.service.gov.uk. 2020 [cited 25 March 2020]. Available from: <a href=\\\"https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf\\\"><span data-custom-style=\\\"Hyperlink.0\\\">https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf</span></a></p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"Default\\\">\\r\\n<p>Heneghan C, Brassey J. NSAIDs in Acute Respiratory Infection - CEBM [Internet]. CEBM. 2020 [cited 25 March 2020]. Available from: <a href=\\\"https://www.cebm.net/oxford-covid-19/nsaids-in-acute-respiratory-infection/\\\"><span data-custom-style=\\\"Hyperlink.0\\\">https://www.cebm.net/oxford-covid-19/nsaids-in-acute-respiratory-infection/</span></a></p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"Default\\\">\\r\\n<p>Clinical management of persons admitted to hospital with suspected COVID-19 infection [Internet]. England.nhs.uk. 2020 [cited 25 March 2020]. Available from: <a href=\\\"https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2020/03/clinical-management-of-persons-admitted-to-hospita-v1-19-march-2020.pdf\\\"><span data-custom-style=\\\"Hyperlink.0\\\">https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2020/03/clinical-management-of-persons-admitted-to-hospita-v1-19-march-2020.pdf</span></a></p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"Default\\\">\\r\\n<p>Myth busters [Internet]. Who.int. 2020 [cited 25 March 2020]. Available from: <a href=\\\"https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public/myth-busters\\\"><span data-custom-style=\\\"Hyperlink.0\\\">https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public/myth-busters</span></a></p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"Default\\\">\\r\\n<p>Kalil A. Treating COVID-19—Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics. JAMA [Internet]. 2020 [cited 25 March 2020];. Available from: <a href=\\\"https://jamanetwork.com/journals/jama/fullarticle/2763802?utm_source=twitter&amp;utm_campaign=content-shareicons&amp;utm_content=article_engagement&amp;utm_medium=social&amp;utm_term=032420#.XnprLOb6jWY.twitter\\\"><span data-custom-style=\\\"Hyperlink.0\\\">https://jamanetwork.com/journals/jama/fullarticle/2763802?utm_source=twitter&amp;utm_campaign=content-shareicons&amp;utm_content=article_engagement&amp;utm_medium=social&amp;utm_term=032420#.XnprLOb6jWY.twitter</span></a></p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"Default\\\">\\r\\n<p>Self-isolation advice - Coronavirus (COVID-19) [Internet]. nhs.uk. 2020 [cited 25 March 2020]. Available from: <a href=\\\"https://www.nhs.uk/conditions/coronavirus-covid-19/self-isolation-advice/\\\"><span data-custom-style=\\\"Hyperlink.0\\\">https://www.nhs.uk/conditions/coronavirus-covid-19/self-isolation-advice/</span></a></p>\\r\\n</div>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Will Taylor</th>\\r\\n<th>Date: 30 March 2020</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Babatunde Awokola</td>\\r\\n<td>Date: 07 April 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: <span data-custom-style=\\\"normaltextrun\\\">Behzad Nadjm</span></td>\\r\\n<td>Date: 10 April 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td>10 April 2022</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"082\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>COVID-19 Children with Suspected  or Confirmed Infection MeG-CLS-082</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"children-with-suspected-or-confirmed-covid-19-infection\\\">Children with Suspected or Confirmed COVID-19 Infection</h1>\\r\\n<div data-custom-style=\\\"paragraph\\\">\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\"><em><strong>Executive summary</strong></em></span></p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"paragraph\\\">\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\"><strong>Introduction</strong></span></p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"paragraph\\\">\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\">Children appear to have a similar likelihood of contracting COVID-19 as adults do but the infection is associated with a less severe illness. Children with pre-existing medical conditions such as immunocompromise, heart disease, chronic kidney disease or respiratory problems may be more severely affected. Children may also have a mixed infection with another respiratory virus or a secondary bacterial infection. Most children should, however, recover 1-2 weeks after the onset of symptoms.</span></p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"paragraph\\\">\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\"><strong>Target User</strong></span></p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\">Doctors</span></p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\">Nurses</span></p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<div data-custom-style=\\\"paragraph\\\">\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\"><strong>Target area of use</strong></span></p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\">Ward</span></p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"key-areas-of-focus-new-additions-changes\\\">Key areas of focus / New additions / Changes  </h2>\\r\\n<div data-custom-style=\\\"paragraph\\\">\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\">Clinical care of patients under 16 years old with confirmed or suspected COVID-19 infection. Please see separate guideline for care of neonates, pregnant women and adults with COVID-19 as well as palliative care.</span></p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"paragraph\\\">\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\"><strong>Limitations</strong></span></p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"paragraph\\\">\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\">The evidence base for managing COVID-19 infections is growing exponentially as we see more cases. For the most up to date information please see the links in the reference section below as our understanding and response to this disease will change over time. Currently we have no facilities for dedicated paediatric intensive care in The Gambia.</span></p>\\r\\n</div>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs\\\">Presenting symptoms and signs</h2>\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\">Children will most often present with fever and cough. Other less common symptoms include rhinitis, dyspnoea, cyanosis, fatigue, headache, poor feeding and diarrhoea. Diarrhoea appears to be more common in children. Most children will be asymptomatic or just have mild symptoms and not require admission to hospital. In severe cases it may present as pneumonia, bronchiolitis or sepsis.</span></p>\\r\\n<h3 id=\\\"pneumonia\\\">Pneumonia</h3>\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\">Pneumonia is defined as: cough or difficulty breathing AND fast breathing</span></p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Definition of fast breathing as per WHO</strong></th>\\r\\n<th></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>&lt;2 months old</td>\\r\\n<td>≥ 60 breaths/min</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>2-11 months old</td>\\r\\n<td>≥ 50 breaths/min</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1-5 years old</td>\\r\\n<td>≥ 40 breaths/min</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>&gt; 5 years old</td>\\r\\n<td>&gt;20 breaths/min</td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\">Severe pneumonia is defined as:</span></p>\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\">Cough or difficulty breathing plus at least one of the following:</span></p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Central cyanosis or SpO2 &lt; 90%</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Severe respiratory distress (grunting or severe chest indrawing)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Inability to breastfeed or drink</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Lethargic or unconscious</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Convulsions</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"septic-shock\\\">Septic shock </h3>\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\">Septic shock is defined in children as:</span></p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hypotension (systolic blood pressure [SBP] &lt; 5th centile or &gt; 2 SD below normal for age)</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\">OR</span></p>\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\">Two or more of the following:</span></p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Altered mental state</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Bradycardia or tachycardia (HR &lt; 90 bpm or &gt; 160 bpm in infants and HR &lt; 70 bpm or &gt; 150 bpm in children</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Prolonged capillary refill (&gt; 2 sec) or feeble pulses</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Tachypnoea</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Mottled or cold skin or petechial or purpuric rash</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Increased lactate (not available at MRC lab)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Oliguria</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hyperthermia or hypothermia.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"examination-findings\\\">Examination findings</h2>\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\">Do not routinely examine ANY children’s throats during the COVID-19 pandemic as there are likely to be asymptomatic patients with pharyngeal carriage which increases exposure for healthcare professionals. It is reasonable to prescribe antibiotics for a possible streptococcal infection on the basis of history alone at this time</span>.</p>\\r\\n<p>Although most children will only have mild symptoms, it is important to specifically assess their:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Breathing: Respiratory rate, work of breathing, presence of severe chest indrawing, SpO2 level</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Circulation: Heart rate, central capillary re-fill time, BP if available</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hydration: Skin turgor, anterior fontanelle, mucous membranes</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Temperature and features of sepsis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Blood glucose level if history of poor feeding or vomiting</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"investigations\\\">Investigations</h2>\\r\\n<p>Please see SOP-AIR-007 for how to do nasopharyngeal and throat swabs to confirm infection.</p>\\r\\n<h3 id=\\\"well-child\\\">Well child</h3>\\r\\n<p>There is no need to do any investigations for a child with confirmed COVID-19 who is well with mild symptoms.</p>\\r\\n<h3 id=\\\"unwell-child\\\">Unwell child </h3>\\r\\n<p>If the child looks unwell (specifically with persistent fever, dehydration or suspected sepsis, signs of liver dysfunction or respiratory failure) then they should be investigated with full blood count, blood culture and renal function tests.</p>\\r\\n<p>In COVID-19 you would typically see normal or reduced white cell count with low neutrophil and/or lymphocyte counts. Some patients will also have low platelets too. In severe cases there may be elevated liver enzymes, if these persist then check coagulation as this may also be deranged. Liver function tests should not routinely be checked.</p>\\r\\n<p>Radiological changes in children may be non-specific. Chest X-rays may show bilateral patchy airspace consolidation at the periphery of the lungs, peribronchial thickening and ground-glass opacities. Chest CT shows airspace consolidations and ground-glass opacities.</p>\\r\\n<h2 id=\\\"management\\\">Management </h2>\\r\\n<p>The majority of children with confirmed COVID-19 can be managed at home with good advice on hand hygiene, self-isolation and staying well hydrated. Hospital admission should be avoided wherever possible and is only indicated if the child requires oxygen therapy, feeding or fluid support or has a suspected bacterial infection.</p>\\r\\n<h3 id=\\\"respiratory-care\\\">Respiratory Care</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Oxygen therapy should be given if SpO2 &lt; 90%.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>If signs of severe pneumonia, shock, coma or convulsion aim for SpO2 ≥ 94%.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Infants and young children can use nasal prongs or cannula (maximum flow rate 2L/min). Older children and adolescents should receive oxygen via a face mask. Face masks with reservoir bags should be reserved for those with severe disease to deliver 10 – 15 L/min. Head boxes or other devices to maximise oxygen delivery should be used where possible.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>CPAP is not currently available for children with confirmed or suspected COVID-19.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Children with asthma should be treated as usual but with salbutamol given via a spacer rather than nebulized to reduce the risk of aerosolisation of COVID-19. Oral steroids should be used as normal for children with asthma.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Diagnosis of Acute Respiratory Distress Syndrome (ARDS) is based on ventilatory or oxygen requirements, which is not available in our setting.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"supportive-care\\\">Supportive Care</h3>\\r\\n<p>Feeding and hydration are very important. If a child is not feeding well then nasogastric feeds or fluids should be considered before IV fluids.</p>\\r\\n<p>If IV fluids are required for fluid resuscitation of a child or infant with COVID-19 and sepsis then Ringer’s Lactate given at maintenance volume would be first choice unless there is hypotension or poor perfusion. If hypotension or poor perfusion is present then Ringers Lactate should be given cautiously at 10-20 ml/kg over 30-60 minutes to a maximum of 40 ml/kg. If Ringers Lactate is unavailable then 0.9% normal saline, 0.9%/5% dextrose saline or 5% dextrose could be used depending on availability. There are concerns about liberal fluid use in severe COVID-19 being associated with poorer outcomes.</p>\\r\\n<p>Maintenance Fluids for Infants and Children</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>100 ml/kg/day for the first 10 kg of weight</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>50 ml/kg/day for the second 10 kg of weight</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>20 ml/kg/day for the weight over 20 kg</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Over a 24 hour period, females are unlikely to need more than 2000 ml and males 2500 ml</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Infants and children of mothers with COVID-19 should continue to breastfeed freely, if clinically able.</p>\\r\\n<p>Children with significant respiratory compromise should be fluid restricted to 2/3rds maintenance to reduce the risk of ARDS.</p>\\r\\n<h3 id=\\\"fevers\\\">Fevers</h3>\\r\\n<p>First line antipyretic for children with a fever should be paracetamol. There is currently no significant evidence that ibuprofen is associated with worse outcomes in COVID-19 infection. If ibuprofen is prescribed regularly for a pre-existing medical condition (e.g. for rheumatoid arthritis) then this should be continued. Tepid sponging is not recommended.</p>\\r\\n<h3 id=\\\"bacterial-infection\\\">Bacterial infection</h3>\\r\\n<p>Children who have signs and symptoms of sepsis at any stage in their illness, or if they are not clinically improving by day 3, should be assessed for possible bacterial infection and started on IV ceftriaxone following blood cultures within an hour of assessment. Duration of antibiotics should be guided by clinical course and blood culture results.</p>\\r\\n<h3 id=\\\"monitoring-of-children-with-covid-19-infection\\\">Monitoring of children with COVID-19 infection</h3>\\r\\n<p>Hospitalised children need regular vital signs to identify deterioration.</p>\\r\\n<h3 id=\\\"treatments-to-avoid\\\">Treatments to avoid</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Although recommended in some papers for adults, the following medical treatments are not routinely recommended in children and may, in fact, have more side effects than potential beneficial effects: bronchodilators, steroids, antibiotics, antivirals and diuretics.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Angiotensin converting enzyme (ACE) inhibitors have not yet been shown to be harmful to children with COVID-19 infections. Patients taking ACE inhibitors for a pre-existing condition should continue them.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>There is no evidence at the time of writing (March 2020) to support any specific treatment for COVID-19 in children. The use of anti-virals is not currently recommended in children</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"research\\\">Research</h3>\\r\\n<p>Clinical trials for COVID-19 are ongoing so please consider whether each patient might be eligible.</p>\\r\\n<h3 id=\\\"palliative\\\">Palliative</h3>\\r\\n<p>Please see separate guideline for advice on symptom-control and other considerations for the dying patient.</p>\\r\\n<h3 id=\\\"discharge\\\">Discharge</h3>\\r\\n<p>Self-isolation of a child will need to follow Ministry of Health guidance where possible but this may need to be adjusted on a case-by-case basis.</p>\\r\\n<h2 id=\\\"additional-information\\\">Additional Information</h2>\\r\\n<p>For the most current case definition and details of countries with transmission, please see <a href=\\\"https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports\\\">https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports</a></p>\\r\\n<h3 id=\\\"for-the-who-guidance-for-managing-covid-19-see-httpsapps.who.intirishandle10665331446\\\">For the WHO guidance for managing COVID-19 see: <a href=\\\"https://apps.who.int/iris/handle/10665/331446\\\"><span data-custom-style=\\\"Hyperlink\\\">https://apps.who.int/iris/handle/10665/331446</span></a></h3>\\r\\n<h2 id=\\\"online-resources\\\">Online Resources:</h2>\\r\\n<p><a href=\\\"https://www.ncbi.nlm.nih.gov/research/coronavirus/\\\">https://www.ncbi.nlm.nih.gov/research/coronavirus/</a></p>\\r\\n<p><a href=\\\"https://foamid.com/2020/03/17/covid-19-ultimate-resource-list/\\\">https://foamid.com/2020/03/17/covid-19-ultimate-resource-list/</a></p>\\r\\n<h2 id=\\\"key-issues-for-nursing-care\\\">Key Issues for Nursing care</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>All the routine precautions for caring for patients with COVID-19 apply, see relevant guidelines.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Given increased demand on staffing and for the comfort of the children, it will still be important for children 15 years and under to have an escort present even if their escort is confirmed negative or asymptomatic.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Adults and children will be cohorted together on the same wards. Where possible, all children should be grouped together and be near to the nurses station to maintain their safety.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<p>Bi Q, Wu Y, Mei S, et al. Epidemiology and transmission of COVID-19 in Shenzhen China: analysis of 391 cases and 1,286 of their close contacts. medRxiv 2020. Available at: https://doi.org/10.1101/2020.03.03.20028423.</p>\\r\\n<p>Chen ZM, Fu JF, Shu Q, et al. Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus. World Pediatr. 2020. [Epub ahead of print]</p>\\r\\n<p>Zimmermann P and Curtis N. Coronavirus Infections in Children Including COVID-19</p>\\r\\n<p>An Overview of the Epidemiology, Clinical Features, Diagnosis, Treatment and Prevention Options in Children. The Pediatric Infectious Disease Journal. 2020. [Epub ahead of print]</p>\\r\\n<p>Lu D, Wang H, Yu R et al. Integrated infection control strategy to minimize nosocomial infection of corona virus disease 2019 among ENT healthcare workers. J Hosp Infect 2020 https://www.rcpch.ac.uk/sites/default/files/2020-03/bprs_management_of_children_admitted_to_hospital_with_covid19_-_20200319.pdf</p>\\r\\n<p>Sinha I (2020) British Paediatric Respiratory Society. https://www.rcpch.ac.uk/sites/default/files/2020-03/bprs_management_of_children_admitted_to_hospital_with_covid19_-_20200319.pdf</p>\\r\\n<p>Weiss SL, Peters MJ, Alhazzani W, et al. Management of Paediatric Septic Shock Surviving sepsis campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in children. Intensive Care Med. 2020 Feb;46(Suppl 1):10-67. doi: 10.1007/s00134-019-05878-6.</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Daisy Taylor</th>\\r\\n<th>Date: 25 March 2020</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Baderinwa Abatan</td>\\r\\n<td>Date: 01 April 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Helen Brotherton</td>\\r\\n<td>Date: 10 April 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td>10 April 2022</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"089\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>COVID-19 Communication MeG-CLS-089</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"covid-19-communication-guideline\\\">COVID-19 Communication Guideline</h1>\\r\\n<h2 id=\\\"executive-summary\\\"><em>Executive summary</em></h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<p>COVID-19 is likely to bring us a range of difficult communication scenarios that we have to address with patients and relatives. The staff working in the Clinical Services Department (CSD) will have a varied amount of training in communication skills previously so this guideline will provide a simple overview to support staff. It will also detail the specific communication processes in place for COVID-19 during a surge in capacity where patients will be cohorted and relatives’ access to patients and communication with clinical staff will be restricted.</p>\\r\\n<h2 id=\\\"target-user\\\">Target User</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>All CSD staff</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"target-area-of-use\\\">Target area of use</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ward</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"key-areas-of-focus-new-additions-changes\\\">Key areas of focus / New additions / Changes  </h2>\\r\\n<p>This guidelines provides generic communication tools and examples of phrasing for difficult conversations and information about the Family Liaison Team who will support communication with relatives.</p>\\r\\n<h2 id=\\\"limitations\\\">Limitations</h2>\\r\\n<p>COVID-19 is a rapidly evolving situation and processes on CSD may have to adapt depending on what stage of the pandemic we are in as well as staffing levels.</p>\\r\\n<h2 id=\\\"generic-communication-tools\\\">Generic Communication Tools</h2>\\r\\n<p>When approaching a patient or relative to break bad news or discuss a sensitive topic, there are some simple tools which can help. ‘SPIKES’ was developed and validated as a tool for disclosing unfavourable information to cancer patients about their illness initially, but has been used since then more broadly for breaking bad news. There have been a number of alternative mnemonics discussed in the literature but they are mostly quite similar to SPIKES which is clear and easy to understand.</p>\\r\\n<blockquote>\\r\\n<p><strong>S</strong> Setting and situation: choose the most private and comfortable setting available, sit down if possible.</p>\\r\\n<p><strong>P</strong> Perceptions: uncover what the patient and/or family think is happening.</p>\\r\\n<p><strong>I</strong> Invitation: ask the patient and/or family what they would like to know.</p>\\r\\n<p><strong>K</strong> Knowledge: explain the disease and care options in simple language, address any concerns.</p>\\r\\n<p><strong>E</strong> Empathy: respect feelings and respond with empathy.</p>\\r\\n<p><strong>S</strong> Summary and strategy: summarise and decide plan for what is next.</p>\\r\\n</blockquote>\\r\\n<h3 id=\\\"examples-of-phrasing\\\">Examples of phrasing</h3>\\r\\n<p>When communicating with relatives and patients you should use <strong>simple language</strong> with <strong>no medical jargon</strong>. <strong>Speak slowly</strong> and <strong>use pauses</strong> to give people a chance to process what they are hearing. Ensure you <strong>listen</strong> to what the relatives or patients are saying, acknowledge that you have heard them and show <strong>empathy</strong> when appropriate. Always check that people have understood what you have said by asking them to <strong>summarise</strong> back to you what they have understood from your conversation.</p>\\r\\n<p>Below are some examples of how you might phrase some conversations. It is important to find phrasing that feels natural to you and to focus on positives where possible. Instead of saying things such as ‘there’s nothing more that we can do’, try saying ‘we are doing everything we can to make your relative feel more comfortable’. It can also be useful to deflect some negativity on COVID-19 itself so instead of saying ‘it is MRC’s policy that we don’t allow visitors on the ward’ you could say ‘I’m so sorry you can’t visit your relative but this disease is so infectious and dangerous that you need to stay safe at home.’</p>\\r\\n<table>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Despite all our best treatments, your Dad is continuing to get more tired. He is in God’s hands now.</td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th>The breathing machine we have tried with your Mum is not helping her and I’m worried that it is making her more uncomfortable. We are going to take it off and give her our best treatment to help her breathlessness.</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th>I know that this is a really scary situation and I can see how worried you are about your Mum. I can see that she is very tired and unwell and we will do everything we can to make her feel more comfortable</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<table>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>I know it’s hard not to have visitors but the risk of spreading this disease is too high. They would be in danger if they came in. I wish things were different. You can use your phone but I know that’s not the same.</td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<h2 id=\\\"family-liaison-team\\\">Family Liaison Team</h2>\\r\\n<p>The Family Liaison Team will consist MRC staff who are not working on the front line but are senior in cultural authority. They will be focused on assisting with communicating to families during the COVID-19 response.</p>\\r\\n<p>They will have 4 main roles:</p>\\r\\n<ol type=\\\"1\\\">\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>To counsel families as their relative is admitted on the communication procedures of CSD (See appendix 1).</p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>One family member is to be nominated as the primary point of contact and their name and contact details to be taken and uploaded onto EMRS.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>One family member to be identified as the person to contact for a patient visit if their relative becomes very tired and is deteriorating rapidly.</p>\\r\\n</div></li>\\r\\n</ul></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>To give telephone updates daily to families of patients who are very unwell or unconscious.</p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doctors and nurses to allocate an ‘update status’ for each patient daily when on the ward round which the Family Liaison Team can use. See below for full details.</p>\\r\\n</div></li>\\r\\n</ul></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>To call families when their relative is identified as becoming very tired and deteriorating rapidly for the nominated family member to attend for a visit for up to one hour each day.</p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Family Liaison Team will advise relative to bring a bag with a towel and soap.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>They will then brief the relative on PPE and what to expect. The relative will put on cotton scrubs and give their bag with belongings to the Family Liaison Team member with a name label on.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>They will help the relative to don PPE then wait for them to complete their visit on the ward.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>They will then advise them from 2 m away on the process of doffing PPE then escort them back to the changing room with their bag of belongings so they can shower then get dressed back in their own clothes.</p>\\r\\n</div></li>\\r\\n</ul></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>To receive calls from relatives and respond to any questions or concerns surrounding routine care of patients with COVID-19. The team will have a ‘Frequently Asked Questions’ document with scripted responses to cover topics such as what COVID-19 is, how COVID-19 progresses etc.</p>\\r\\n</div></li>\\r\\n</ol>\\r\\n<p><strong>Daily Update Status</strong></p>\\r\\n<p>Clinical staff will document daily for each patient on their clinical category as follows:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Improving</strong></p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Patient is improving and will be ready for discharge soon.</p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Stable</strong></p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Patient is stable – neither improving nor getting worse, but we are not concerned about them at present.</p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Concern</strong></p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Patient is not making progress or responding well to medical interventions, we are concerned they may deteriorate despite maximal treatment.</p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Deteriorating</strong></p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Patient is getting worse despite receiving all possible treatments. They may not survive.</p>\\r\\n</div>\\r\\n<p>A member of the Family Liaison Team will then ring the allocated primary contact relative to update them using the script detailed in Appendix 2. When the relative has been successfully contacted then this will be documented in EMRS.</p>\\r\\n<p>The contacts for the Family Liaison Team will be made available in the clinical area when they are needed.</p>\\r\\n<h2 id=\\\"key-issues-for-nursing-care\\\">Key Issues for Nursing care</h2>\\r\\n<p>Liaise with the Family Liaison Team when necessary and ensure a relative’s contact details are appropriately recorded on EMRS.</p>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<p>Baile, W.F., Buckman, R., Lenzi, R., Glober, G., Beale, E.A. and Kudelka, A.P. (2000), SPIKES—A Six‐Step Protocol for Delivering Bad News: Application to the Patient with Cancer. The Oncologist, 5: 302-311. doi:<a href=\\\"https://doi.org/10.1634/theoncologist.5-4-302\\\"><span data-custom-style=\\\"Hyperlink\\\">10.1634/theoncologist.5-4-302</span></a></p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Daisy Taylor</th>\\r\\n<th>Date: 29 April 2020</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Karen Forrest, Helen Brotherton, Effua Usuf</td>\\r\\n<td>Date: 08 May 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td>08 May 2022</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<h2 id=\\\"appendix-2-family-liaison-team-checklist-for-a-new-patient\\\">Appendix 2 – Family Liaison Team Checklist for a New Patient</h2>\\r\\n<p>When a new admission arrives on the ward, please ensure the following details are taken and added to EMRS.</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th>Name of patient &amp; MRC number</th>\\r\\n<th></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Name of primary point of contact for family</td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Relationship to patient</td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Telephone numbers of primary point of contact</td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Name of escort who will visit the ward in case of deterioration</td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Telephone numbers of escort who will visit the ward in case of deterioration</td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<p>Please also explain to the relatives the following procedures.</p>\\r\\n<ol type=\\\"1\\\">\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Relatives can bring in a small bag for the patient containing a mobile phone, charger, change of clothes and any other small items that they may require. The bag should have a label with the patient’s name on it.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Explain daily update status procedures.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Give primary point of contact for the family the contact details for the Family Liaison Team.</p>\\r\\n</div></li>\\r\\n</ol>\\r\\n<h2 id=\\\"appendix-2-family-liaison-team-script-for-the-daily-update-status\\\">Appendix 2 – Family Liaison Team script for the daily update status</h2>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th></th>\\r\\n<th><p><strong>Greeting</strong></p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Confirm identity of relative</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Confirm identity of the patient with relative</p>\\r\\n</div></li>\\r\\n</ul></th>\\r\\n<th></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>↓</strong></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><p><strong>Give Background Statement</strong></p>\\r\\n<p>“This is your daily update on your relative’s condition. I am contacting you because the doctors and nurses are very busy looking after the patients on the ward. The information I will give you has been provided by the doctors and nurses looking after your relative so I will not be able to answer specific questions.”</p></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>↓</strong></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><p><strong>Care Update</strong></p>\\r\\n<p><strong>Improving</strong></p>\\r\\n<p>Your relative is improving. We hope they will be ready for discharge soon.</p>\\r\\n<p><strong>Stable</strong></p>\\r\\n<p>Your relative is stable at the moment. They are neither improving nor getting worse, but the doctors and nurses are not concerned about them at present.</p>\\r\\n<p><strong>Concern</strong></p>\\r\\n<p>The doctors and nurses are very concerned about your relative because they are not making the progress that we hoped for. They are receiving all appropriate treatment and will be reviewed by the doctors and nurses regularly.</p>\\r\\n<p><strong>Deteriorating</strong></p>\\r\\n<p>Your relative is becoming very tired despite receiving all appropriate treatments. We would like to invite their nominated escort to come straight away to visit for 1 hour. Please remember to bring a bag with some soap and a towel. They will have to wear protective clothing while visiting and we will provide this for them. I will meet them at the ward and explain the process to them. My name is….please ask the security guards to inform the ward on arrival.</p></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"086\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>COVID-19 Infection in Pregnancy MeG-CLS-086</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"covid-19-infection-in-pregnancy\\\">COVID-19 Infection in Pregnancy</h1>\\r\\n<h2 id=\\\"executive-summary\\\"><em>Executive summary</em></h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\">Current evidence suggests that pregnant women are not at a greater risk of contracting SARS-CoV-2 infection than the general population. However, if they do, they can be at an increased risk of severe illness like pneumonia, hypoxia and ARDS, especially at later gestations. Despite this increased risk, most will have</span> no symptoms or a mild cold/flu-like illness from which they will make a full recovery<span data-custom-style=\\\"normaltextrun\\\">.</span></p>\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\">There is also unclear evidence of vertical transmission in limited studies. Hence, it is important to take further precautions against this.</span> At present, there are no known effective treatments for COVID19 and antiviral medications should only be given as part of a clinical trial.</p>\\r\\n<h2 id=\\\"target-users\\\">Target users</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doctors</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nurses</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"target-area-of-use\\\">Target area of use </h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>OPD</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ward</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"key-areas-of-focus-new-additions-changes\\\">Key areas of focus / New additions / Changes </h2>\\r\\n<h2 id=\\\"limitations\\\">Limitations</h2>\\r\\n<h2 id=\\\"risks-of-covid-19-in-pregnancy\\\">Risks of COVID-19 in pregnancy</h2>\\r\\n<h3 id=\\\"effect-on-mother\\\">Effect on mother</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Potential for increased risk <span data-custom-style=\\\"normaltextrun\\\">of severe illness, especially after 28 weeks’ gestation (third trimester).</span></p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\">There is accumulating evidence that COVID19 results in an increased risk of preterm delivery for maternal medical reasons.</span></p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"effect-on-foetus\\\"><span data-custom-style=\\\"normaltextrun\\\">Effect on foetus</span></h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\">From limited evidence, no increased risk of miscarriage or early pregnancy loss.</span></p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\">No current evidence for intrauterine infection, abnormal foetal development or teratogenicity.</span></p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\">In at least one report, foetal compromise and prelabour preterm rupture of membranes although this association is not established.</span></p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"general-advice-for-patients\\\"><span data-custom-style=\\\"normaltextrun\\\">General Advice for patients:</span></h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\">Strict observation of social distancing, especially when above 28 weeks’ gestation. Avoid any social mixing in the community, e.g. having friends and family visiting the house, avoid public transport and work from home.</span></p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\">Identify the escort for delivery early and identify a primary support person for the puerperal period (6-8 weeks), ideally the same person.</span></p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\">Should it be necessary to seek care, firstly use the telephone to contact health services instead of visiting in person.</span></p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\">Avoid contact with confirmed COVID-19 cases or those with possible symptoms, especially when above 28 weeks’ gestation.</span></p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\">Do not reduce the number of antenatal visits without first discussing and agreeing with your maternity team.</span></p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\">Do not bring children when you attend appointments.</span></p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\">Defer appointments until 7 days after the start of symptoms, unless the symptoms persevere (aside from persistent cough).</span></p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\">Defer appointments for 14 days if self-isolating because someone in your household has possible COVID-19 symptoms.</span></p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Even if previous tests were negative for COVID-19, if you re-present with symptoms, COVID-19 should be tested for again</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"general-management-of-all-pregnant-women-with-covid-19\\\">General management of all pregnant women with COVID-19</h2>\\r\\n<h3 id=\\\"antepartum\\\">Antepartum</h3>\\r\\n<p>See flowchart for outpatient assessment. Avoid admission if possible:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Prescribe symptomatic treatment e.g. paracetamol.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Initiate self-isolation at home.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\">Defer appointments until 7 days after the start of symptoms, unless the symptoms persevere (aside from persistent cough).</span></p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\"><br />\\r\\n</span></p>\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\">Advise:</span></p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\">to seek urgent care if symptoms deteriorate.</span></p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\">on what to do once labour sets in or membranes rupture (how and when to come to the health facility).</span></p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Once COVID-19 is confirmed, arrange for ultrasound to monitor foetal growth. Although there is no evidence for foetal growth restriction (FGR), two thirds of pregnancies with SARS had FGR and placental abruption occurred in a MERS case.</p>\\r\\n<h3 id=\\\"intrapartum\\\">Intrapartum</h3>\\r\\n<p>In labour and vaginal delivery, PPE is required by all healthcare professionals caring for woman with suspected or proven COVID-19 to prevent droplet spread – gloves, apron, gown, fluid resistant surgical mask (FRSM) with visor to protect eyes as per SOP-AIR-001.</p>\\r\\n<p>The mode of birth is as per obstetric presentation. It is not influenced by presence of COVID-19, except for avoiding water birth. All obstetric complications can be managed as per standard practice, taking precautions for aerosolising techniques and wearing appropriate PPE.</p>\\r\\n<p>Women should stay at home during early (latent phase) of labour, contact health facility. They should deliver at an obstetric unit, in an isolation room.</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Delivery escort/partner</strong></p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>If asymptomatic: wear a facemask and wash hands frequently.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>If symptomatic: to remain in self-isolation and cannot attend the health facility</p>\\r\\n</div></li>\\r\\n</ul></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Admission</strong></p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Inform obstetrician, anaesthetist, midwife-in-charge, neonatologist and infection control team.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>PPE required by all healthcare professionals caring for woman.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Take woman and escort to isolation room/delivery room.</p>\\r\\n</div></li>\\r\\n</ul></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Monitoring</strong></p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Open partogram.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Frequent temperature, respiratory rate, SpO<sub>2</sub> aim &gt; 94% - if possible hourly.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Foetal heart rate - CTG if possible or done after every contraction.</p>\\r\\n</div></li>\\r\\n</ul></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Epidural or spinal analgesia is possible.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Delayed cord clamping is recommended.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Third stage of labour is proceeded as per normal protocols i.e. active management with controlled cord traction and prophylactic uterotonics e.g. 10 units IV oxytocin or 1 ml syntometrine intramuscularly or ergometrine.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Recommendations for conducting Caesarean Sections:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>General anaesthesia – all staff in theatre should wear PPE, including FFP3 mask before GA is commenced, with scrub team scrubbed up.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Regional anaesthesia – all staff not required for siting of the regional anaesthesia should stay outside the theatre till the block is effective, then don PPE with FRSM.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Number of staff in the operating theatre should be kept to a minimum, and all must wear appropriate PPE.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>For elective caesarean sections and planned inductions of labour, make an individual assessment on whether it is safe to delay the appointment to minimise transmission to other women, healthcare workers and postnatally, to her infant.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"postpartum\\\">Postpartum</h3>\\r\\n<p>Keep women and well infants together. Advise hand washing before usual mother-baby interactions e.g. feeding, changing nappy, holding.</p>\\r\\n<p>Breastfeeding is advised as the benefits outweigh the potential risks of close contact with mother. There is no current evidence of presence of virus in breastmilk and stopping breastfeeding is a risk to the newborn.</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Avoid coughing or sneezing on the baby.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Consider wearing a face mask while breastfeeding.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Consider asking well escort to feed expressed milk to the baby.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>For babies &lt; 2000 g, encourage KMC unless there is a clinical reason to stop.</p>\\r\\n<h2 id=\\\"management-of-pregnant-women-with-moderatesevere-covid-19\\\">Management of pregnant women with moderate/severe COVID-19</h2>\\r\\n<h3 id=\\\"antepartum-1\\\">Antepartum</h3>\\r\\n<p>Admit to an obstetric unit in an isolation room.</p>\\r\\n<p><span class=\\\"underline\\\">Monitoring and diagnostics:</span></p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>frequent temperature, respiratory rate, SpO<sub>2</sub> – if possible hourly.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Consider cardiotocogram (CTG) if &gt;34 weeks. The frequency and suitability of CTG should be considered on an individual basis, taking into concern the maternal condition and gestational age of foetus.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Perform Chest X-ray once if indicated e.g. acute respiratory symptoms, hyoxia or suspected pulmonary embolism, and not to be delayed due to foetal concerns. Abdominal shielding can be used as per normal protocols to protect foetus.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p><span class=\\\"underline\\\">Treatment:</span></p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>If hypotensive, cautious trial of 250-500mls IV fluid bolus before proceeding with further fluids.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>No changes to usual indications for antenatal steroids, magnesium sulfate, tocolytics. There is no evidence that steroids for foetal lung maturation cause any harm in the context of COVID-19 and should still be given to women in preterm labour, if available.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p><span class=\\\"underline\\\">Before discharge:</span></p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Following an initial period of improvement in the woman’s condition, consider observation for 24-48 hours further as she may rapidly deteriorate.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>After resolution of symptoms, arrange ultrasound for foetal growth.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Advise to return if she becomes more unwell.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"intrapartum-1\\\">Intrapartum</h3>\\r\\n<p>Maternal stabilisation before delivery is essential, as in other obstetric emergencies.</p>\\r\\n<p>If delivery is anticipated or indicated, transfer should be made to the closest obstetric unit with surgical capacity. They should be notified in advance to allow for adequate preparation.</p>\\r\\n<p>In addition to the general advice:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Open fluid input/output chart – hourly, if possible.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Consider instrumental delivery if women is becoming exhausted or hypoxic.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>If the woman’s symptoms are deteriorating, proceed to emergency CS, if the delivery would be quicker than vaginal, to assist efforts to resuscitate her.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"post-partum\\\">Post partum</h3>\\r\\n<p>In addition to the general advice:</p>\\r\\n<p>Encourage and support mother and baby to be together. Consider separating mother and baby partially or completely (e.g. discharging baby home before unwell mother) only after taking into account limited local capacity, disease severity, psychological wellbeing, parental preferences, if method exists to feed baby e.g. bottle or cup feeding.</p>\\r\\n<h2 id=\\\"advice-for-pregnant-healthcare-workers\\\">Advice for pregnant healthcare workers</h2>\\r\\n<p>At any gestation, they should be offered the choice of whether or not they wish to work in direct patient-facing roles and should discuss work arrangements with their line manager.</p>\\r\\n<p>Less than 28 weeks pregnant and without underlying health conditions e.g. heart or lung disease:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Practice social distancing</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Where possible, avoid caring for patients with suspected or confirmed COVID-19</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>More than 28 weeks pregnant, or have underlying health conditions:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Recommended to work from home</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Avoid patient contact in general</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Avoid contact with anyone with symptoms of COVID-19</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Significantly reduce unnecessary social contact</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<p>Royal College of Obstetricians and Gynaecologists. <em>Coronavirus (COVID-19) Infection in Pregnancy</em>. Information for healthcare professionals. London; RCOG, 26 March 2020.</p>\\r\\n<p>MB, Fontijin J, Ochsenbein-Kölble N et al. COVID-19 in pregnant women. The Lancet Infectious Diseases. 2020; (published online March 17.) DOI: 10.1016/S1437-3099(20)30175-4</p>\\r\\n<p>American College of Obstetricians and Gynecologists. Outpatient Assessment and Management of Pregnant Women with Suspected or Confirmed Novel Coronavirus (COVID-19). March 2020</p>\\r\\n<p>World Health Organization. Clinical Management of severe acute respiratory infections (SARI) when COVID-19 disease is suspected. Interim guidance. 13 March 2020</p>\\r\\n<p>Swartz D, Graham A. Potential Maternal and Infant Outcomes from Coronavirus 2019-nCoV (SARS-CoV-2) Infecting Pregnant Women: Lessons from SARS, MERS, and Other Human Coronavirus Infections. Viruses 2020:1-16.</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Caryssa Yan</th>\\r\\n<th>Date: 10 April 2020</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Hawanatu Jah</td>\\r\\n<td>Date: 12 April 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td>12 April 2022</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<h2 id=\\\"outpatient-assessment-of-pregnant-women-with-suspected-or-confirmed-covid-19\\\">Outpatient Assessment of Pregnant Women with Suspected or Confirmed COVID-19</h2>\\r\\n<p><img src=\\\"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAuEAAANMCAYAAADytXMWAAAAAXNSR0ICQMB9xQAAAAlwSFlzAAAOxAAADsQBlSsOGwAAABl0RVh0U29mdHdhcmUATWljcm9zb2Z0IE9mZmljZX/tNXEAAICtSURBVHja7d1P6DVXft95LRrcmA4IYrtt0+AmaaJsBA0hLROH5Fk0IovWIC9Cg8HkWQkxC9PQC3WgQW0YGC0EmlUWgkFLLUzGgzYmC9Gz02IW7mE206tGqyDCYIFJjGHgmS51Sn11VX++3/On/t3XGz48z/3dW1WnTp06933rnlvnuT//8z9/TkREjpEXXnjhr58+ffrszTffFBGRC+YHP/jBs9/5nd/5L970REQOJuE//elPnwEArskvfvELEi4iQsIBAFtCwkVESDgAYGNIuIgICQcAbAwJFxEh4QCAjSHhIiIkHACwMSRcROTiEv7cc899KUfgKOVQB333b9zHvfY1st3IubF2Dq1tZ6oeas/Nuddveb4/ynncoy5JuIjIA0j4Ed4477dJwq9dB2f5sBdpl5G/lUp4ab1lPgz0PBaPcB732kcSLiJNMnRSmb/LvhK+x5snCX8sgTmDhEfOjczy2fWVnptL3y6Q8PPsIwkXkWYSPiXcJPw8Er729fXaV/HZZW9FomSbURGa+/p/SWymlomWLbJftXUQvXob/Qq95NgulX3teM/JaG3dTy1XIuHR1+wl4WvHPbu+yDEubcM1/UaL8y3z4X+u3a6dfyS8cd54443nnzx58hORubz22mvfdq58WbbvpZuEn0PCMyKbXXbpdTVlyC4Xed2SAEbLmnnDLq2DmuOVqb+a/SyR9tq6Xytjiexml685d7KSF91+zfGPCnxJ+2nVRnv3I66Eb5w//uM/fvriiy/+/ZtvvvlM5D6vvvrqs+985zt/4VzJS/jtVQX1dk0JL3kjbSWSkautPbffUi6i22lx9a9Ufkrqr7W4tvwAUls/rc6dGgm/FdOSbwOy53ar86S0T8uM6e9ZDyWQ8AUJ/5M/+ZO/fQZM8N5775HwhWEnkf+7Sn4+CV+640LrYSORbS69yW4h4XNlay3ha9uJLHM1CV9ri6X7V1s/2X2Nnpuld2RpfYxLz+uafqPF+UbCSTguBAkn4Y9+Jbx2e722uZWEb/E1e3Q7tT/EO/uV8Oy6as+NzPItJLz02PU4xq3byBbtcO14tKqHEkg4CUcBJHxZwueGp5Dw40j4VkLaa5tbrD+6zz2vhK+Nzy2t6xbH9grDUaKvr7kv+NLfe3yAarn/LSW81XlSup7e9VACCSfhKICEk/CzSXhkaELPu6OUvnlmv66uWV/pcJS1N+xWw1FK1r3F3VGyj1vWfavJalpM1rO2T1N/32KynmwfEW1ftedJaRstPd9a3IEls64IJJyEowASvi7h499I+P4SDgCPzhHvZ07CSTgKIOExCZ8Tb3dHIeEAsCUk/MIS3mtGupKvp87S+M5YxhESLiQcAI5PK4/qAQlvKOGtp4ptIfCt1tXrxDgrSxI+TvT08ssv/8C5JCQcADAFCW98Jbzl4H0SflymJHyU79/4jd/4m2Hfhv87l4SEAwCmIOE7SHj2V9hz61q6X+zcbFkldz6I3l8zs+7o/q2VZy+Rv5Xwe/keQ8KFhAMA5iDhHcaEt5oAo+X9Y7O3Bltbd2k5bx/X3Jt276v8g4T/s3/2z/73Kfke8/zzz//im9/85k9FSvKbv/mbf/sf/+N/9C61Az36lDN/89di33v9bmqv43HkccZL5Z16/8zOrhq96La0LH4FCb+QhEfL1GLdmc6tZDKJVjNw9YKECwm/LkeX8LPJ31H2pdXFmyPUf+sJfSLrzd7f/Wjv20eEhHe6O0p0eMqRJHzpk3Jk/7M3+99qSujsJ/0IhqOI4SjXhYRvt98kvG5/SsuypYQf7VuQI0HCSXjRiVdaztL9OeKVcD/MFBK+DUsf8Gtmv1zrp0tnMCz9LUt02bkLJT1mO41euFgb6rD2/pH5PVLp7J7Z30m1aIs1M39Gfo9V005r3+uX/nb0G0McBRLeScLXOpVI4zzLcJTM2PS1jrWkPEeR8HsZd4tCIeH1tLrAsfQ1+ZKgZ/qYrX6Xky1v77629v0je2xavM/ViOJW9VvyASFS162mdS89L/BrSHhHCZ/7e+bKQvQEWPsQUHPXlsyJmVl37d1R9jzBTdYjJHwbSsRv7XHNsiVl3bu8pZLc6sNHy2VbXciqeR/pcTOC2nbX67dba68pXQ6/goQ3knA8FiRcSPg2nEnCx9eWDkvoVd6138TUDkfZWsKj+7KlhEe2W7rcWltrcV6R8H0g4SQcBZBwIeHbcDYJ77HN1lfCS+q79Fj0vhLeq05Ly7z0+tLlss/Vts3MNmsknJyTcBKOIki4kPBt2GtM+NLjbFlblrf14yOMCc8s2+q4bjkcpWRf1sqUuetX9jdj0f1udW48MiSchKMAEi4kfDtKhlHcP19yd5To42hZ19aRWTYrlHvcHWWtriLHKLOtyHHN/k5qbvvZeirdlx7nUM0V+Zpb/Zqs58uQcBKOAki4kPDr0OL2btAugCwknISjABIuJPy81H41Ts4es50ArSHhjSS8x6yMOofjQsKFhJ8bX40D2BsS3lDCM38vwZvFcSDhQsIBADWQcBKOAki4kHAAQA0kfAcJL/n1/P0yU7+Mj94lILIvJRM6zO3DFb/yJeFCwgEANZDwjSW81b1gs9O/R8q69NrsLbOy2z0bJFxIOACgBhLeUMIjP8zsJeHR5aYeR5/LrpOEi5BwAMA0JLzTlfAWM4u1lPDoXVsyM3StLbfl3WK2hoQLCQcA1EDCOw5HOeqV8Ox+lG7jyj8kJeGyhYQ/ffr02ZtvvikiIhfMD37wAxL+aBJeOyY8cyX8qlJOwqV3XnvttW8/efLkJyKPkj/4gz/4P37jN37jb9SFPFK+//3vv+pNr4OEL8np0pjxtbuTZCV8bZvR185tf23/3R1FRETWMgjJ888//wt1IY8WlVAp4XgsSLiICAkXIeEkHCRcRISEi5BwEg4SLiIiJFyEhJNwkHARERIuQsJJOEi4iIiQcCHhcifhL7744t+7j6VM5dVXXyXhIiIkXISEt85bb7311e9+97s/cg9LmcsPf/jDbzpXRERIuAgJFxERERIuQsJFRERESLgICRcREZGHkPBhtubM30VIuIiIiJDwDiJOwIWEi4iIiJBwIeEqQURERK4l4bfivTQ8ZUzmORESLiIiIiS8QMKXrpS7ii4kXEREREh4AxGvkXAREi4iIiIkvJGE32fuecdJSLiIiIiQ8EYSXrsOERIuIiIiJLxCwo0JFxIuIiIiJLyzhI/PuTuKkHAREREh4SIkXERERISEi5BwERERIeEiJFxERESEhIuQcBERESHhIiRcREREhISLkHARERHZLS+88MJfTs1YOeRrX/vaf37rrbe+qp6EhIuIiIg0zGuvvfbtOQl/+eWXf6COhISLiIiIdMjU1XBXwYWEi4iIiHTM1NVwV8GFhIuIiIh0zu3VcFfBhYSLiIiIbJDbq+GuggsJFxEREdkow9VwV8GFhIuIiIhsmOFquKvgQsJFRGSz/Nt/+2//xxdeeOGvRUTksfLv/t2/+x+8EYqI7JShI37nnXee/fSnPxURkQfJj370o2ff+c53/sIboYjIjhI+dMgAgMfhvffeI+EiIiQcALAlJFxEhIQDADaGhIuIkHAAwMaQcBEREg4A2BgSLiJCwgEAG0PCRURIOABgY0i4iAgJn+S55577Qqae36IMOB4tjktkHXsc//t2f9/+a59fO7ei+zx3Xj56uzoTJFxEhISH3gz3kG4Sfl3Wju1ex762XHPPj3+PnFtHrZu9637vOmi9TRIuIkLCw280vd/4SPjj8KgS3qLdk3ASLiIiDybhU6+LCMTSsJal19xuo2a92cdLwwTmhh9E9ymyXyX7Gd3m1OOlYzn1XLTOMuWJlHWruu7xfPbDbcl+lpwn0baVbf9r610630vqoHY/om2vpYiTcBGRk0l4jzeDnhJeK19zb9KZN+ysjM49t/Y4s52lZVvWX0l5MuWt2WaLdtCyru/Pr8h47pp2uCappW2ixfGZq5cW5+aS6GaOU6v9KK3LWki4iMiJJHxNAFoQ/RFZ5EpqS4msfeNd+rfF9nqVvUbOauQi+vrSsrf+9qJVXbd4PnueZn+DUSOoW5ybpdtZ6kcy+9irbZFwERESvqmEZ0Rs7WvplkNHSta7tYRHPsCUiF30tTVy0UrCo3XQSpQyxy1brhbPR5cpGb5SUs89zs1Im60ZUpI9N3u1pVpIuIgICS96Ayu9Ep7Zdqs3xCNcCd/itaWi0kvCWw5HadVOtrgS3uKc6/WN0R7nZmacdkk9k3AREeku4eMbQe97BJcMKykdk72XXNWI55ZiGP0RaM021+qixZjwI14JLxHTHs+3lPDMty5bnJuZb2WMCRcRkUNL+FZkJ+vJ3vmk1Rtk6V0vSu+ykVlf6bqW6qV0OMrSMV2ri4j0rG0zIzR713XP5yPnVrZ+1tpIy7ujZM/NzPFq8UPR2rujrJ0n7o4iIkLCgU3Z+r7Mj3yPePfHf4y6JeEiIiQcWJUVEm7f1W1bSLiICAkHZoWl9+8PziJM9ln9toaEi4iQcADAxpBwERESDgDYGBIuIkLCD88jfUXfal9b3a86s+wew1d63kJu6+N+9PIbKtMWEi4iQsJPISj29Vxl3mo/tv6w8UjHfO8f514dEi4iQsIPDwm3Hy23Q8LLykXC20LCRURI+OSb79LEJ5kJctYm+8lO8tJrOyUz59VOHlRSxzWTq2Rm3Mwe64xYzq07W3dzZV7a5+jfWhyPaJ3PTVpTW8aatrhWrpJzqeZ8uSIkXESEhKfks+Wsh5Gp0Gumas9sJ/tczcyMpXVcM919ZLnSYx3Zx7VjUtKuWhzbPdpPpD3UlrHFedqyLmpnMr0iJFxEhIRXvSm3WG9rgSndTs1yNWXuXS/R49TrWNces5L66VH/rdpPyza8VX3WvHbP3wwcGRIuIkLCu0jg+HzNcI+oRJRu5375GvlaK8fS6zPbjW6j1XCUrDRFhz9sJY3ROm7VDlodq56PW52H0ba59M2L4SgkXESEhDd4U24lCq2uKtesa8srezXbLamX6HCU7P6VinovaYy8bqtvUlrWxxmuhPdqO1eChIuIkPBmb8pLy51hOEpLCe8hPluPCc9IUk/pLKm7kte1bKeGo7Q7X64KCRcRIeGTb5Atfky1dIeTmiEC0fJmt7O03tZfr7cePhPZ717DUaaGIrSUztLjslTHc/Ld8njUHKvWbby0LZb8QDTzoc9wFBIuIkLCAQCbQcJFREg4AGBjSLiICAkHAGwMCRcRIeEAgI0h4SIiJBwAsDEkXESEhAMANoaEi4iQcADAxpBwERES/gUiE7m03l52Rr3ae1bXvGaLexq3mokxU78tynY1HvX+1dgGEi4iQsJD4tFDSEpnWWw9JXt2G3sdg7Ov52x1ScLRExIuIkLCQ+JBwvc/Bmdfz9nqkoSjJyRcRISEh8Sj9XTd0WnH1/5fUv5eEh6ZWnytzjL7t7TOyDCb6DFZm9a9dJ+z9bc0JXpkX7P7EDkOc/XVYt+y5ZtrG7XbQR9IuIjIySS89xtliaBGn1vb1tEkPDMmPLIvkf2JfHiJrLOmfqN1X7PPmfpbe670tdntru1bST31PGattoM+kHARkRNJ+BY/Eqy9SnwECW/1w8yW9djjg0utWJUc015i10PQI/vYok56Hd+t6qVFe0ceEi4iQsJDb8Ylwx0yV3UzUlF795BWr1k7Pr0lrUS05spIwuvaWeSqdPScWWpXNfVSuh30gYSLiJDwkAyVimFmW2eW8F7DCjJ1vYUEk/A22y2po8y+117pJuL9IeEiIieS8PHNsffVqj2EMrPeo0v4ka+E1wrdVhLeY0z1EYej9Go3LdsG+kDCRUROJuFbUXMnhegHhbVl95bw7GQ9a3cRWXucHcJTIlKlwx5q7o4SrffWQzLWyp5dd43ERvat9phFPnC4O8pxIOEiIiQcALAxJFxEhIQDADaGhIuIkHAAwMaQcBEREg4A2BgSLiJCwgEAG0PCRURIOABgY0i4iAgJn8Wtys5Tx0c/VrW3ley1/9r4sdvMlY/PooQ/ffr0yfDmICJSku9973v/nmSfV8LX7q386HJwxHUdeb9772fNTK249jl2VBYl/MmTJz/5pYg/G94cREQyeeedd54NckmySThBuI5skHCc8Rw7KqsS/uabb2oJANIMUknCry3ha7Mrlsx6ODXr39JMjCUzdi4tWzPjZGa2wdIZKCN1GFl/Sd3VHO+ldpStg8zMmZHylswAmpkNduq4lB7b6PlRej5kly+tw+jMs5ljurYPR4SEA+gCCe8n4VtMLV0yJffa66LSOPd4qg6y26ldtrR+Mvtdup0l6WtZd9nyzJWjtJ1Et1daztK2M3eetqrLTLvJbqd0+ewH2dLzpKQcZ4CEA+gCCe8j4bcC3vONp1Qya97Ma7bf6s389nHLdfaqh0i596i7mu20qruS5Y5Sdz3aRcmyJceqpmyt6ucskHAAXSDh55XwqW1Er7wdRcKX6ujoEr52fEuGBvSsu2gbaTEcJduGokN3WrW71m14j3JE+oSlZdfacLT/IuEkHEAhJPzcEr729yNLeKt1HeFKeOZYtZDwLSW05LkjDEdptf9nkfBse+3VJkg4AAQh4eccE17yY7PI32uem3scEamaH19m6mmv4SilY8Ij26/5FqGmTlqPCXclvJ2ER6+El7avVvVzFppK+FZjFWt5lIkRtqzPaF20vq1X9Gu0XsdMG5iHhJ/z7iglb8i97mwReVxyV45WEt7i7igl62l1d5Slx2t3vSg53nvdHaX0uR7jnVsc22w5svu01t6j34i1vmNOpn7OQnMJLzm4W0PCt6vLXidK6f1gHbPtIOHXmDHzrH3P0dd/pboCUEZ3CT9iB0DCt6tLEv64kHASvmffc/T1b1l2/R5wTHaT8NIbuZd+3TdVntptRG7aX/qL8a32M3L8lvajdN/3uIn/3D63untCpj2slesKkHAS3pOet2a8wvl49GGhAHaS8F4/3Mlso3aihrX1LD3e6ocftRMFlByTyLKt6r6kjK1/JFZa34/w5kjCSTgAYJ5TS3hJWWq2n92vpdcv/Sih5qvEkivuLeur17Fvtd4a0V67gt36hzRnh4STcADAPIeU8JpfjUdeWztRQnS/ptZ3/9qSG91nt7FWvqVjF6mvTJvYqu5J+P6Q8PNKeIu7He1xxyQAOBOHvxJesr211/bafu39XFuX4exXwnusl4RvBwl/rCvhpe2ZhKsr4FHZ5RaFRxgT3nsbU+ttMQZ76bWlUwa3ni2rpo561X3p9npNpmBMuJDwuuUeEXUFXIvdJus5wt1Rlh5n7o4y9/h2XdHX1+zn/TpbSXimLpfK1rPuo2UsmRQj+rimPbg7Cgk/6nCUpbv+3D/X4k5EW7xXtHxurn5qJmSpHYoJ4ByYth46dfXeBRJ+HQnvebehrb/RbP3cmnzXfEPmft/AtSHh0LHvVM8kXM50JXztuZphdC3KVbLtFuus/S1Ii9vIAjgnJPyB8dXmfnX+CPVOwkn4XNvP/q6k5G5ZkWVarLNmuGOruRwAnBMSDqALJJyElzw397rsa0u2V7LOrSZfy5YdwPEh4QC6QMJJ+Nz/SyQ8OyPtVs8ZjgKgFBIOoAsk/PEkPHJ3lLX1T5VlSXiPcneU6OOlbUSHsgC4BiQcQBdIuGnrAQDzkHAAXSDhJBwAMA8JB9AFEk7CAQDzkHAAXSDhJBwAMA8JB9AFEk7CAQDzkHAAXSDhJBwAMA8JB9AFEk7CAQDzkHAAXSDhJBwAMA8Jv2FuEoQrT46wx76VzgJnkopzQcJJOABgHhJ+w9Ek/KrSWbpfNfVB4LeHhJNwAMA8JPwGEn7s/SLh54KEk3AAwDwk/IaohM89vv13aV1Tz8+t4/Z1c8tGtr223Uz5SoT2drleZVhaLvP3tecQg4TH8+KLL/6n2zYnIiKPkT/6oz/6D6eQ8N5itFRJUQm/l+aozK9tJyqu2WUzr1t67Vq9ttjP0n0sORZLrwUJF5H2GZzj+eef/4W6kEfL4SV8TYxbbSP696mrui3Fr/e6a2S9RsKz62pVvlb1BRIuIiRchISfUMLn9iEi4SVX56eWP7qER+uotn7WXm84CgkXERIuQsIveCU8uo2I9La4unwECW/1XE39RNsFSLiIkHCRy0v4vYj3Wn/N32vHhGckvIfYHk3Cs1fCS7fZcl9BwkWEhItcTsK3kPxaCZ+SxylRj4heyd1R1j4gtHxdtJ7u15v5kenSkJNo3c4dE3dHIeEiQsJFSPgFpP3RhY2w4hYSLiIkXISEbyKdJJyE49eQcBEh4SIkvLlsZodjAI8GCRcREi5CwgFsDAkXERIuQsIBbAwJFxESLkLCAWwMCRcREi5CwgFsDAkXERIuQsJTrN0jessfYJZs66g/ED3bD1ezM5yedT97QcJFhISLkPBi8TrjXVC2Kl92O1eS8CvtZy9IuIiQcBESXiVPZ7sfOAnftx5J+K8g4SJCwkVIeFN5Wpqefmq69dvXZqe6j05bn13n2nCbSFmz07rf78vac5EyRo5bZH8i7WGt/FPry+zL2oe9s8k9CRcREi5yEQkvEb9eEj4nZFmZWlrXmtSXli8jepmytpTw0tdmRTq6bFTIp8peWv8kXERIuAgJP5SA9xLx7JXwiDjVilb0am8vsWsphSVSW/K45lhF636rfSk5/iRcREi4CAkn4QeU8LV6nHv+ESU8OkyoZl+WjgcJF5Gri/c3v/nNnw4ZBPwrX/nK342Pv/Wtb/3VW2+99VX1JCT8gSW8ZgjBESW81bKPciW8pry147xJuIhcOa+99tq3p97fh7z00kvvqCMh4Qeh95jwqCQdQcJbiWersdl7SXjtmPCjSfgZb4lJwkWkJr/sJ/7yXsCHK+JvvPHG76ofIeEPRnaynojYld4Bo+buKEuPS+48snRHkNIPB6XDXlreHaWFwLfYlyNMDkXCReQIV8NdBRcSbtp6JNlDGK9+X24SLiKPdDXcVXAh4SQcBxXGs9+674h12gMSLiIlV8NdBRcSTsJxcDHt/fuAo+zjWSHhIpK9Gu4quJBwEg6gEhKey7/+1//6f527S4SIiFwz/+Sf/JP/k4QDaAoJT18F/OuhzgAAj8EvfvGLZ7/zO7/zX0j4BI829hhoCQkn4QCAeUj4AqQbKGcvCR/O28zfSTgAYA9I+AIkHChnTwmfEm4SDgA4EiT8jqVJYKIT50Qnw8ku+wh3BMF12PtK+L10k3AAwJEg4TesTYcelfO552qWNT4dZ+PoEn77oZaEAwC2hoTfEBXm7NTs0W22XC+wN0cYEx75/1GukpNwAHgsSPgN2avWc1fL7zO1ncjy2fUCR4KE95XwpfvOnqmfPdr6rkimXfSqz9Iy9CwPsDckfOGkjF59znQYmSvaW3REQC+OcneUqeEpV5HwkueO1s8ebX1Xo+V70lbHyHsfHgUSvtBR9B4Tfn9lwJhwXAkSvp+EH7mPIOHHqm8SDuwHCZ84+ZeGhEy9bmkdS9uY6mDcHQVX4Uj3Cb//AeajSXhkuErNMLqSfrTltmrWF/2GM9P/lu5/pCyZ7ZUc0x7HJ1u2tTpZWmek7uaWy97ZzIcF1ELCAXTh6JP1nP3uKBk5XVt27TVRuYmuq0S6lvazZn1r+1FSntL9L5Hw0v1bagstj09te8ssm/n2OtMmo/UEZCHhALpg2vprS3htuTLbqpHQyDKtpbNm/2rusFVy7Hp+IGuxjRbLRv9WU2agBBIOoAsk/FwSvnaXlezdLWqvlEeHPGSHIGSvepbegaZ0yMQZJDxbHyQcmIaEA+gCCT/3lfCl9dbIeMur7qX7VzKkoaZMpcIXlf2a+ux9fGq3UbrsWp2ScBwBEg6gCyT8mhJeskyLMdqZcpT+WK9F3bQoDwkn4XgMSDiALixJ+FtvvfXV11577Q/Jd//7hB/xh5mttlWyvpqhMiXlKbmDx9kk/EjDUaJts/Yc8cNMtICEJ0/c28elvzpfG1N3xlnwgHumJHyQ75dffvkHX/va1/7zt7/97ffI9zYzZh7xFoWZvjLbb6/d+jV7F5Ka8eD3620h+rX1na2bmuOztM7WtyiMHMfMNmqPK7AGCU+euLePW/4Cv+bvwBG5lfBb+R7fxEh4nYTj2ujvHSNcHxIeOKGyn9LXlsku64THGfnvEv5/3cv3mG9961t/9fTp0yfyq/yyPv5vEo4R/f3xj4djhFpIeOCEIuFAnkEof+u3fuu/rQ3Dkl/l937v9z4m4TD88PjHxjFCK04l4b0bf3SMZc3tr9b+tlQO4EysXQk3HMVwFAB4ZE4j4VtIaelV7a3GfhNxnAljwkk4AGAeEn63jcjfM/eYzay39O/AEXF3FBIOAJiHhN9tI/J3Eg6s4z7hJBwAMI8x4Xfrj/y9dqKHkvWsrQs4GmbMJOEAgHncHeWGI0m4H2bi7JBwEg4AmIeEA+gCCSfhAIB5SDiALpBwEg4AmIeEA+gCCSfhAIB5SDiALpBwEg4AmIeEA+gCCSfhAIB5SDiALpBwEg4AmIeEz1B7S0C3FMSjQ8JJ+Fof6XasZfV21nI4tsAXIeELHUW2w7h9vc4Gjw4JJ+HR/hLb1FtmWccH6A8Jn4CEA/WQcBIe7S+xTb2RcOBYkPAJ1iR86mvT+7/d/rs0k+bceiLbBI4MCSfhkX422hfX9JNzffpUnx3pcyP9+1I5InUQ2Zea96i1bcy9ny3ty9p7VLaOS+rQeyXOxKkkfIuTq+SEn/t/pMOKvD7TcQNHgYSfW8J797eRMeGt+sk1mYv012v9d7QcS+st2Zea96jSbbbYr9L1tSgHcBROI+Fb/Xin9spF6XpKtwMcFRJ+Xgnfor/NXAmPPM48V7Oukm1NvTZ7xbi0bC3Ws1Z/0fYRXaZX3QBHg4SvbCPyVV1JZ1DzFZuOBWeAhJPwtW1kXxO5Wjt3RT2z7sh7wNKykX3qKZrR96joPvaQ8KVyRvchu0/A0SDhCyd3pINp8VVfpGOJlgc4CiSchJf0t636ybVttRDpmmW3utobfY+KLleyrtJjlN1/7404G8aEB0/epR/vZDuK7OPID5KAo0HCjQmv6XNr+sm159b61d4XTVpK/lZjwtfqL7J/xoQDX8TdUYIna+YX5ZHOoHQ4io4FZ4GEuzvKWp8a+WFmST+ZkcKau6Nky7FWnui+RNa/9h4V2cel95y97o6yVgeGouBMkHAAXSDhJPxMbCltBBHAAAkH0AUSTsKPzJ5DF0g4gAESDqALJJyEH52thy4YJgHgFhIOoAsknIQDAOYh4QC6QMJJOABgHhIOoAsknIQDAOYh4TdEZ8vste0er927PvG4kHAS3qt/aDE5DADsDQm/oWSCgd7brn0tsBcknIT36sdIOIArQMJvIOFAO0g4Ce/Vj5FwAFeAhN9QOtVuyYxft88vbTvy2rVpfDPlK509LjJ0x0xmjwUJJ+GZ/va27ymZ1n2pDyqdlXHtfUBfBqCGU0l4b4nLjgkvfW7qtdGpfqOyW1q+zPozz+05MQb2gYSfW8K36G+nthfpIzJ9UGmfVNNnA0CE00j4mhy32sba33tI+NK2o6+dEu/MOiPLRPazdJ9wPUj4eSV8j/62pk8s6YdrJRwAaiHhd9tY+/uZJPy+3rL7ulT/JdvoffxwLEg4Cc/0t7V94tLwutZ9tP4LQAtI+N021v5+NgmPli+y7mxZDUd5bEg4Cc/0ty36ma36aP0XgBYYE363/rW/H1XCs9uIjiOfWq52TLgr4Y8BCTcmPNPftvqwT8IBnAV3R7mhZLKeFndHid4NILK+TBkiX9/evzZTB0s/vPImdn1IuLujrPVpmcclfctav1naR+u/ALSAhF8Ibww4EiSchAMA5iHhF4KE40iQcBIOAJiHhF8AY6xxREg4CQcAzEPCAXSBhJNwAMA8JBxAF0g4CQcAzEPCAXSBhJNwAMA8JBxAF0g4CV8iOiHQ2n3AW9729Cq/rSndD78tOs9xfJRj1XM/j/B7OhK+cGBaHSAd22Od2PgVJJyEZ8/BFpOWtSrTmfuIaNmJ3Hn3YetJC7WJPpDwwIEhbEAeEk7Cl8hMOjb1dxKer9vS1121rZ15H0j4NfaThAcPChEHcpBwEr5ERrbvv5mMzGKZmcn3/v/R9S/tW3aWzvtt378+8tpMXaztY2Qb0aFAmW+WS2c4Xau/bPuIzqRasp/RNhlpjzV1FWn32ePesu1n22S0Xda0idaQ8ESnmj1RM42oVadcWt6aE6e0A4/sd6vOeakDW2sDLYcmPRIk/NwS3rvdZ694l/Q/Nc9l+9gW2157HHmuZV1E6iYibZF6qylrprw1+13TPjN1MrXOXvu7tmy0nvZoa5l1lh6DyLpqOJWE7/WmkD0BMg0329HWnHQly/Y4qbL73aOMJW/sa8cZX4SEn1fCoz+a7NHf9pDwkuXWLh60eh8p6Xu2/kCS3X7Jca+pu73qtuR1c21pTbx77kOLc2ft9T3OyZr361Z1UstpJHzPN4WWB/soHUdpZ7tXJ9CqjEvLZ7eLZUg4CS/pb0l4+9fOHcutJDzTliJDBVpcqCmpk7V2m93PpX+3ah+tzp3Isa49diR8R0j4PhLe4sRp0eAjHXDJcJS5zm/LdndVSDgJL+lvSXjf17bYRkvZibaRmnHWveSsdL+m2tIVJLyHF5FwEr5ZYzvKSdf6xGnR4Ft/3Vl6JRxxSLgx4dnzNCO+W48Jj/YJvcR2jzHh0XqqGUfcou5a123Jdko+bJzBBzLHstX47R5j+1vWfUuMCQ90sLXDFK40HGWrMeGtOufaDtNwlHJIuLujRPvzyGQ9JX1c5NuxrFz2usNHjx++R7bZ4ndG0SEmmde2uuPHXD2VHodIfZbeIrL1D0ajd3jJymvk2+NsO1w6TiXHZq2t1ZybLXF3lETjzJ6opR1byWvXyt3qDStzIi+d0NGTrnUZS4+foSh5SDgJvyJH6AeO1hfpG50LR2w/Z2iXJBy7NH6d9vUh4ST8Efu2RyiDbwi1/ZbHvdd6SDicrJ1POhwXEk7Cr9anHaXfOsoHAd8QPu550PK4t17XmdolCUe3E3Wrkw7HhISTcADAPCQcQBdIOAkHAMxDwgF0gYST8FKu+E2ZcdTtbjV7pLZ39iE5W99tDl+EhO/Q0Le+xzna1qe6jkHCSTi27Tf26Jt6ifWW+1L6/nzW94Kt7oHtvXIdEr5Do9e4z10H6j4GCSfh2LbfIOH1+0DCz90ezwYJ36HRa9znrgN1H4OEk/DIuRSdoKP0Xv5ry0fmNIhOejL33NT2s/MqRPajdgKZkvkWSibCiZQnMpdEi/ku7v8eLePa/Bi1baR20qCluou2y6XtRh5H6rJFWzkzJDxw0Ft3wLUdR3TymdKGHe20Szr3uZM6u53MG8Jc55idfa2kg31kSDgJj/S3U49bTz8dnQEw0le32ofSabtbTcVdejxq6mjtfStzXHrOPl0yjXttuUpmxCzdh5rtZJap2afMcTgzJHzlpG8x22VpJ7/XdPJrJ2DmdZHOc+2YROs40zlu1VE+MiSchGf738i5ne2LapZvJeG9+vOWdVHaL7csX2l99Vx37f5s8eGmZdu7/Vtk3+f+7b0PV4GEV3RgLU6uHh1f60+9pZ1Pi5MpI/d7H0t8ERJOwiPn99o3e3tL+FwZ156/moSX7mer8kTEMXOstqjvmjYSvbDUuu3d/m0LCW/Rrs4MCa/owFqcXD06vtoOJjK8Yq3DK+1417a1tF/RTra2kzIcJQYJJ+Gl/e1Rr4SvLdujjzmChG8praXHZYtjUbI/veq11/7e/m3rK+E15/FZIeEVHViLk2vrMXq1b1AlJ0TLk2mrN+pWnfIjQ8JJeOZcNhwl1s/tPSa81xX/muNSW4dHGI7Sekx4TV1GzpvaMrZsK2eGhO/QgFp0vnuMMyt5XaQDLD0mRxyOQsJ/DQkn4ZHze+0KWou7etT2+7U/zq8Vv+gP27e4O0qkTy/9RrKk7mrLH3mutO20KlfJHV9q29MWEt6qrZwZEt6pAS2dQK1uX1Rzd5TSfSrZRk0nt7ad0rudZF8fHWuIX0PCSTjao59xbLWz60DC4eRGF0g4CUf7/lL/+TjHWlmuDwnH5iezk/sxIOEkHG3wbdvjHOejtDVsAwnHpie2k/txIOEkHAAwDwkH0AUSTsIBAPOQcABdIOEkHAAwDwkH0AUSTsJ7UzrnAgAcARIOoAsknIT3Jns/cQA4EiQcQBdIOAnvDQkHcGZIOIAukHASPkfpDH8tZykumcEQAFpCwgF0gYST8DkyEp6V68gy0XWQcAA9IeEAukDCSfgS91ebo1efI1e4o8tkngOA1qxK+NOnTz97MxURyeSdd94h4SR8loyE3w5HWbtyTcIBnIVFCf+lgD8Z3hj2yO/93u/9v78s2N/utX2J5Q/+4A8+fv7555+pC5nK9773vX9PsEn4FFEJ7zEcpeQ5AGjNooTvmW9/+9vvffOb3/ypN+dj54//+I+fDm9U6kKEhGeJSG/peO6ldUSeMyYcQG9IuJBwERK+C9Erz3N3LKn9AefcY3dHAbAFJFxIuAgJxwQkHEBPSLiQcBESjmfGhAPYFhIuJFyEhOO/s3SXFQBoCQkXEi5CwgEAG0PChYSLkHAAwMaQcCHhIiQcALAxJFxIuAgJ3429xmAvbe/RxoMfqe4xf45k67FHPTt2bSHhQsJFSPhucrHXG/wjy8Te9R7ZHtlbrwcSfn5IuJBwERJ+GLnY6k2ehO9X5yS8TTsl4eeHhAsJFyHhh5KLqddOXUGtmf3y9u+R2TaXruBGZ9mcW9fScIOl8s3t71oZprZfW47s8cwe77V9W3q+tPyl28zWy9J61ra/Vv7aOsq0b+Qh4ULCRUh4WkBarL/kdaVT1S8JembZtW1GBDhbhuj+ROu3tC6ydVNz7KNlqG0jJfvdsl5qj2PJ+dDyPEIdJFxIuAgJn3xz7yniW0p4jbjVrKdGuDLP9SzH0rKlw1paS3hm2Rb1X7vs0dtTi2OMGEUSPiddLWWMhJ9XwrdoHyIkvB8k/JwSHj1mpcN6Mldea4/93FCUyHCK6DAMEt52X5CnWMKnhIqEk/C5tkDARUh45M18C7HILHvWK+GZut9a0GqvhGf3Z8/207JN7HEcSXhfqq6E9xQtEk7CRUj4fmxx/+7IG3zPMeHRZTPLXW04Sun4+MxxX3tNy/HYW40J73EstmpPJHw7ukv4bUdOwh9HwpfaSaRtlLYbERJ+Lkrv6DH1XMndUSLiuSYh2bujZB5HPkBk6nJNPpfK0UrQMncMie7b2rHe4+4o0f1da9+R5ba4O4ofZranekz43P9rr4aS8GtL+FLbcBVdSDha4/7jcKxwNEi4dJPwtavgUQkXIeGoFaytbrVI7M7bRoCtaXJ3lOjwFBJOwqeGm0wNOzEcRUg4WkjWFl+h+6r+vO0D2BMSLoe4Ep5pbyIkHABwdprdJ3zuaiYJJ+G1w1FIuJBwAMDV6D5Zj7ujkPCl59wdRYSEA8AjYtp66SrhIkLCp4hO1nOGMvdabo+6Ofo46S3Ld4Yx41v83uGKdXOU8pNwIeEiJHyXN8jamR8foY62rput7iJTuuyW0qktnrtuzlBGEi4kXISE7/YG6RZ/cYkg4ST8KO2RhLeBhAsJFyHhu71BZmakrJlWfGq7NTMhRtZTs9zSPpfO8NhiG2vbmVtn6ayo939vcfyiy7XaVrR9bNUmS2aPLamb0mOcLetaX1Jbb9EZcUm4kHAREt5Mknve+7p0mviSaejn3lBLhSSynqV1lCy3tmzJVOkRYSmtn7XnaqSwpnzZD0ytthX5ALJVm6xZf8n+tTyPo+XJnC+lr2sBCRcSLkLCJ9+8eop4rYRPvZFHrlbVyGqp9LZYrkaAI+su2eZaGfbYz9Lyta7Tlse5Z5tcO3d6fejrcTxbfLio3c8sJFxIuAgJ/9IbzZYSviYBc2XpJeFr26uRrJ4SnjlmNVK0tJ3IsIna/SwtXw8Jj27rqG2ShJNwEk7CRUg4Ce8mEj3e9I9+JTxb/6X1Uyq0W4lXtuy9rroftU2ScBJOwkm4CAl/4DHh99ts9Sa9tF/RN+BHGY7Seozu2nN7i1eLY1UzfnzvNhl9/Ra/QWhxPLN9R0m7NSZcSLgICb8EmUlAau6eMPf6yJ0oWknIFnK2Vk9L668ZghF9rvTuKEvHI1u+qISXbKtF+9iyTWb2r7Rusm0jcmeYkrujrNVVzR1YaiHhQsJFSPjD4N7P0CbV41G2QcKFhIuQcG/UgDZ56nrb8rcrrSDhQsJFSDjhAbTJU9Zdz9+u9N4GCRcSLkLCAQAbQ8KFhIuQcADAxpBwIeEiJBwAsDEkXEi4CAnfnMwtCluuv/V2WpZpy+1vUc9bHUvgrJBwIeEiJHxzzirhNeU7koSfaXskHFeFhAsJFyHhm0PCj1PnR98eCcdVIeFCwkVI+OZEJXxtNsG12REzM22WzuoYvYVZzYyXpfs5t70eMw9G1hO91VvJekrK3fv2dsASJFxIuAgJD0tfy/VH/r40rfqaZGVeGylbVvSWlq0V3eh+Rta5tL5M2Urrf62crY5jab0BvSDhQsJFSPiXZOU+PbYR+fvektujfNEr8z3LXlpXpevJtKEWoj33b0m9Ab0g4ULCRUj4l4TkLBI+V86Sq6LRISmlMhcdbjK1L6X7ubTPNXVeup7aYTskHFeChEs6f/Znf/ZPnz59+mTIv/yX//J/Hjqv8fGQN95443n1JELCM6JVK4ClspYVsK2u1Jc+d2QJb7FPJBxXgoRLOt///vdfnXqTHvK1r33tP7/11ltfVU8i55XwUUp6/2gtIkIZATzLcJSW5TvqmPBedVzbZkrKA/SChEtRvv71r//1lIS//PLLP1A/IueX8K1Yk/3oEIcpWVsb/pEpx9T2SpYtLcOed0dZqs/o8KBMPdWuh4TjLJBwaXY13FVwERKObdlyqBCAtpBwaXY13FVwERKObSHhwHkh4dLkarir4CIkHNtDwoHzQsKlydVwV8FFSDgAIA4Jl+qr4a6Ci5BwAEAOEi7V+dM//dN/ox5ESDgAIA4Jn8lwZfe73/3uj548efITEclnmE2VXJPwJdYmBTra2OTMfdNrJgCqKV/LfQXQFxI+k0EgXnzxxb9/8803n4lIPv/gH/yDv//hD3/4TYJNwqeI3uP56OVt8fojSDjpBraHhC9I+J/8yZ/8rSYClPH7v//7f0vCSfgcJLz9PpNw4FyQcBIOdIGEk/AlorMm3j+emx3z/vmpdWVmxJybfTOy7FLZl2ZvzE4ZH62Tkv2Llj8zYyeAL0LCSTjQBRJ+bgnPTDHeaxtzUjgnkVOvjTyOvC47JXy2PEv72qJOsvuXeS5TTwB+DQkn4UAXSPh5JXztB5M9t3n/t6n/Z56berxUhug2apYtfVwj1Wtl7lX3AOYh4SQc6AIJJ+Gl2177f+a5qX2KbHttG9llM3eB6Snhc+Ug4cD2kHASDnSBhJPwtW2s/b2XCPYejtJy2dvHtRLeazhKpu4B/BoSTsI/Z+kqTe0b8dF/tDMlHW+//fazTz/9tHgfHv2HSiTcmPC19a/9PTP+eWndW48JX1u2pHy1Ul1ThyQc6AMJJ+Gfc/um+/Of//yzvw3/nkHCP/7448+kuVX5xv1+9913i/eBhJNwd0eJ9znRYRpLdwKZe3y/rWiZ1ta5tj/R7ZdK+NI2114/VYc1d0fJ1BOAX0HCSfjnjB3sK6+88uzDDz/87G/Dv8Pjo0t4j/Jd/ep/b0g4Ce/dX9lfAGeGhJPwz7kdhjFeVR7/PyWUH3zwweeCPvz/nmG5119//dnPfvazyeWHq8zj3++Xvy3Lj3/848/+9sknn3yhLMO676/UZ7Yxtb2lv90+HsoylOu2nMPf5pYf6+D9999/mPZEwkl46/5p6fGj7T+A80PCSfjnjNI4XP2+/bpyfHz7JjD+7aOPPvos4+tGBtkcnx//f7v87fOjoN4ufz8sZmCQ3vHxILzjVfvb19+yto2pfR8Z92luOMrwAeBWyIf/jx8W7l8/Pv9IAj5Awkl4rz7qkYTUJDjAdSHhJPxzxs5+GF89/DuK6/j49o3gVkLHZYe/jYxXyO/XvfT87fJzbzxDWYYr2rdXoedev7aNqX2//2Hm1Gtu1z2UY6inpXUOr70X9EeAhJNwAMA8JJyEf8691N6KdmSGupLHSz8qupfq8UPBcHV6vLq8Nt1z9FZrt8+NHzrmrmyPZbkdKz/8/17G77c7rPeRIOEkHAAwDwkn4Z8zNdxivHLc+0r4Ulnm/pa9Eh7d94FxuM3tOPKpbQzDY8ZhL+PQmPvXjx8eHu1qOAkn4QCAeUg4Cf+cW8kcxXIcx1wzJnxqTPnt8+NV7bXhKKNUD68ft7kk4WvbmNv3++2N9wq/fc04HGZY7/D81LpvXz/I/NKY9CtCwkn4Wn8DdRfZ1633V9vEVpBwEj7Z2Y2SO/w71xGOd0cZMnd3lHGYxpIkT91dZG44yu32pu4+cn+1eWkbc/s+Mn54GMeG375mEO/bO68M2126O8rAIOlD2W8nALoyJJyEr/U3wBHbiLaJrSDhJBzoAgkn4UsQHRy1jWib2AoSTsKBLpBwEr5E6cyVa89nZsa8L0fJNpeGxEXKWrLsVNnn6jRzW8dIOUuXX5stdOnH+3P7l91O9Mf5JBxbQcJJONAFEn5uCe99T+61H2aXPM5M6FMieHPbLF1P6bLR/c3WR7ScmeWj4jy33UwZS54r2VegFSSchANdIOHnlfDorT1rtxF9LiqTmXK2Etia9bTY5tLV25YSXno8t6qfHh/qgN6QcBIOdIGEk/C1bdRsv9VwlNpt9pTMyDbXJDx6HM8u4dE2sTTcJrO/QAtIOAkHukDCSfjaNkqey7y+5upodJu9JXxtm5kr4Zk6PKOEl5afhGMvSDgJB7pAwo0JX1t/9LleY8JbbbPHOOYW+7nncJQtPqT0GBMe3V+gBSSchANdIOHujrLE1NX22juVRJa7fV10nUvPt7g7SrZMJT9AbXF3lJrl1+6OMvU4MsQms53oMSLh2AoSTsKBLpBwEv4IEDYApZBwEg50gYST8EeAhAMohYSTcKALJJyEPwIkHEApJJyEA10g4SQcADAPCSfhQBdIOAkHAMxDwkk40AUSTsIBAPOQcBIOdIGEk3AAwDwk/EQSvsUsdj3KjMeEhJNwAMA8JPwkEl4yLfORynnU9aIfJJyEAwDmIeEkfJNyHnW96AcJJ+EAgHlI+MklfOp1pdP2Tm0vs67o9Mpr0xdnp6+OvCYzlXVJ/ZXsV+9juDcknIQDAOYh4Y0kfAs5iojm3OOl55a2lV1XTRky24zud2bf99ivnsdwb0g4CQcAzEPCG0j4Hj+YnNpOawmPvr6lrEaXbVX2kn1suV+ZMp1tSA4JJ+EAgHlI+Ekl/HbbkXJkyxi9uhsZfhItQ42Er+1b7XCULSV8rY4MRyHhAIDzQ8JPIuGRIRSZK7nZ7fUYjlKzzehyNXWxxRX+mn0xHOVa+c53vvMXU32JiIhcN9/4xjf+HxJ+8DHhJRK+xZjw7JXwUlnNDIc54pjwErHO1C0JF5Gz58mTJz95/vnnf6Eu5NFCwislfAsiV9y3vjtKiTiu3UUkKteR8mT3vefdUUo+ABmOIiIkXISEk/AHwn25QcJFhISLkHASTsJBwkWEhIuQcBJOwgESLiIkXISEk3CAhIsICRch4SQcIOE6WBEh4SIknIQnWLrbyNTrjlDWo9YhCRcRIeEiJJyENxXJUtFsKag109qDhIsICRch4SSchJNwEi4iJFyEhJPwI4nw0kQtrSeauR+OkpmMJjq5Ts1kNCWT2kz9PTLRzlpdROomOgHSVT4kkHARIeEiJPwSEl46VXrtcy2npo+WObNsr7qJyHa2buZee7Yp6Um4iJBwERL+MBJe+jgjwlPPtZTaHhJeItYt6nWrD0MkXERIeFBmftl3Zv4uQsJJeFcJHx/XDkeJyuR99pDwpTKUvra3hEfrjYSLCAmPizgBFxJOwneV8JLnWlwJb7lPrcpQ+treEn41SLiIkHAREn4JCd9zTHiLbe0l4YajkHAReRwJvxXvpeEpYzLPiZDwB5XwKRmfEvUed0eJ3EEksq2lDxaZZdfKFdnf6Gu3kPDsvpNwESHhZRK+dKXcVXQh4SR8VQYBEi4iJHxdxGskXISEk3ASDhIuIiS8kYTfZ+55x0VIOAkn4SDhIkLCG0l47TpESPgDSThAwkWEhLeXcGPChYSTcICEiwgJ7yzh43PujiIknISfhi2GxKzd/WXt/yDhIkLCRUg4CSfkndZJwkm4iJBwERJOwkk4CQcJFxESLkLCryjh2Ql3IrMwRibqmfpbybbWyro2UU1kOMrapEatJzQCCRcREi5Cwi8s4SUzMdbO7thyuveS/SiV8OjY8UeeUp6EiwgJFyHhJLxAwrNim52Sfe31S8/XlrVWwluINukm4SJCwkVIOAn/XAbnrlDfJyrha8tdTcLn9nepfteeAwkXkbJ897vf/dHwXj9kEPCvfOUrfzc+/ta3vvVXb7311lfVk5BwEn4osldxI1fC15672pXw6LYyz4GEi0g8r7322renLpAMeemll95RR0LCSfihpDsjnkvS2Ho4Slak95ZwY8JJuIjsnxdeeOEv7wV8uCL+xhtv/K76ERJOwg8j4qV39siuMyLh2W2VbLOlhNfWoeEoJFxE2mfqarir4ELCSbj7hBd8UABIuIhkcns13FVwIeEknISTcJBwEdkgt1fDXQUXEk7CSXhSvgk4SLiIlGa4Gu4quJBwEk7CARIuIhtmuBruKriQcBJOwgESLr/M06dPnwyTqIhskX/1r/7V/6Qe5JHy8ssv/4CEk3CAhMuX8p3vfOcvXn311WdvvvmmiIg0zmfDeUn4OSR87VZ5JZPTtBjLbTx4+2NMwuUoEv7ee+85MQGgAyT8JBKevZf3nmVDWV1dqR5JOAkHACxDwk8g4SWzXh6hfMjVFQkXEg4AjwMJP7GEL71u6v+RmSpLZo6MzHbZeqbK1s/N1VGr9dSUa207R4SEk3AAwDIkvIGE957WvIWE1077nnluqew9ttfquZI6y9R1TV2tbedokHASDgBYhoRXSvitgPcSo1ZXwrOvK9lWq+VaiX2LdZbWZ+RxqzIcDRJOwgEAy5BwEh7eztx+li53/9zScpk6bzGkJnIVOlIXJJzIknA8Ikt989rfsuvNvP8Mefvtt599+umnm5UBWGxLJPycEl4q1yUS3mM4SnQ/M9trtc5e+0vC5Uh5/vnnfzH0dyQcrTmahI/8/Oc//+zxu+++u1kZgMW2RMKPPSZ83MbS4/u/tZDwkjHma2U68pjwaH0bjrIOCT9HxnNyTsZJOEppIdzR9W5dDhKOpucJCa+T8K07texkPVlpXBvKsbaO6HLR7W15d5TM49L1RL/ZyGznaJDwc0n4nIyTcJRScyV8GC7yyiuvPPvwww9nfzT/s5/97LPXDBn+X1OO28effPLJsx//+MdfGLoy/G1u+WHbw//ff/99Bx1l5wkJP4eEA2fht3/7t/+/b3zjGx8N57EcN1PD6W5lnISjlLm2tSbEg8wOjz/66KPP/z8lzMNzgxwP/3/99ddXyzEyrHdpOMqwrlshH/4/SPnUOsfnCTiqzhMSTsKBlnz961//+5deeul/efLkyU/kuJmTpKEPHr7JIOEopfRK+HBlO3v72LVhflM/zJwrw7j9QbznrrCPrx9eey/oQPo8IeEkHGiJ4SjnHI4yyrfhKKilVMJrHy+V4+OPP168sj0wDnO5Fe17Gb8/b4b1AsXnCQkn4UBLSPi5JPxevkk4ajnalfCRcZz5Bx98sLiO4S4q43CYoUxT6xzHg7sajqrzhISTcKAlJPwcmZNvEo5aSiU8OiZ8aZ1r2xxFf7xX+O1rxh9lDuO9h+enxpzfvn6Q+eH/g9wDRecJCSfhQEtI+DVCwlFK7d1RBvEdrzS3lvDxavg4Nvz2NYN4Dz/aHP82SPnS3VEGhrIOYn87ARAQPk9IOAkfGwMcgxaQcBIOtOoTvTfh0u2bhJPwFg0JGNlLwod2mPm7kHAci+GK8jAUZWC8BeDt7QSBK0HCSXizhgSM7Hkl/F64ewj4o0g9CcfWDD+IHO/VPTdZDnAVSPgJJLzlbJO364rMpBnZ5tokDEtlmNr21ONe+52to6XyR14f3XbNvh4BEk7CAQDLkPCTSHhmevS15yLT27fcZu26e+13dN8j97VdK2PpMSit773Ze0z4KMlTsnz74WVu2ZLn15Yj4QCAW0j4ia6EL/1tSdBKlotIXY2EL60vU/7SbbZ6bevHLY7jETiqhNc+rl2OhAMARkj4iSX8PnPPL60rK4Bz2yThbR5njuPS8d+bI9wdZe4qeAt5JuEAgFpI+EWuhEeXr5HwXpJ7/3cSnj+OR+PIEn6f7HAUEg4AaAEJf4DhKC3GI2fWky3f2r622u/MevaScmPCt70SXvoDTBIOAKiFhJ9Uwj8/eJ3vjjK33qnXlw6JiT7XYr8jj6N3R8mUKbvtmn09AlcZjkLCSTgA9IKEn0DCWx9w5Tt3HZ2Bo0p4i7uj3L7G3VEAAKWQcBKufCerozNg2noSDgBYhoST8OM0xIOUjYTXQ8JJOABgGRL+YBIObAEJJ+EAgGVIOAkHmkPCSfgWb144fh2d4Tgt/fB9r31vUW9nPkf2rrst95OEH1zC9z4Z974/dY9tPnoH1xsSTsK36BOcg/V3mzpL/91zX3rd8lX73KfuSudR2Ws/SfgDXAk/86fKI49jxzQknIRvce45B0l4j3WT8GO365bLknASfqkGfbSyP2K5jsDVJfxKtyG8ooQvzRdQet/97Drn5hso2f7auiKzEJfMYZCpn6nXzq0zexxq6j7bl0f2M1L+pfqNtIkWbTe6X2vtJNumSs6jVu0me9yz51SPvoyEn2g4SuRkmWtYmY53aVKe7MkYOSkikwiVvJFkJu+pnQAIv8aV8GvIe1bCt3gDK52Iq9WMupl1lsxWvNQ/RZaNLhd9L8i8bq0Oao5DzazHtW2qpPxLHxqyx7W2zmraV6ZNtZwtuuWy0WO/x3s8CT+hhJc0+h5TuGc6kIiEl2wnus89Ozh8GRL+eBJ+K+A9RbyVSB5pna3kJVuGpf4ycwxq6rLVvtT0zTXy1eo4Zt6jsseitlx7tOOWy7Y6fr36MxJ+wivhNW8WvTqGmsZcu67Ih40WHTYJj7GXhI+Seyu7JTNk3q5narm5166tMzPT5tx6t5T6o0n41DaywxTW/l7yjVj2yt1UX7K2PyX9UEsJjx7bR5DwubroJeFL7SzSBreU8Oh5WVJ3pctGjz0JJ+HVjYSE598gW3W4+DV7SnhGWpfEN7qe7Guj5VkS80eW8MzfS/vEFuVoKY17S3grSeu5L1tJeK+ruTV1sbaOva6E15ynLdtctEwknIQ37dh7dBRnk/CS/ejV0T8Se18JL31cKsvRMrVY79QV8kcYE575XUnm7zV9YssxzC365Ez/Vdo/b3klvNeHmtJ6WquLrYaj9BgTXrL/Pdux4Sgk/BISXjsmvEXH0GJMeMkbSe/9IOHzHEnC75MZjlIqy3PbvLqEb9UPRvrJo9wdJfO45sfna2WuvZVh9of2pXW9Vs8t6j773pGpi9JhRZH3pd53R4nsf007zuxHTbspuetPtPw9+jUSfiEJn2tEmY5i6fnSX/S3uDvK2glVc2eTklsfkfB5jnolvGRMeeshJiQcR0NfBu17v7KR8INL+COcBC1OEm8kx+Gsw1FKx4S3GC+eGeay1V1WSLj+GdC++5aNhJPw7o2ehD8WR5HwLe+OMvcD0ciPLSM/wiTh6NFP6zeBnc9BEk7CuzWuxAxrtdvBcTj7fcKPfj9vEg4A54eEk3CgOSSchAMAliHhJBxoDgnvV64ty0bCAaAfJJyEhxvKGdaJY2Da+mvk6BLe+7ckR+ijjthPHq1MVx+SePR9i9xOcqvjWDIfyJ7tkISTcJ0JmkPCSfgV+pMrS3jt73AepQ0cfR/32P8e5TnKDLtbt0MSTsJ1mGgOCb/GEBkSTsKP3o+TcBKeXScJJ+FlB6piNrW1qd7XZmCbmwq3ZMazyExj0bLW1l/NdMBLExGtbe/qX5+ScFfCe/eF2T5k7vnsJGPZuz7V9gOR12ZnGYzU01ofX7P9VnUZXb5mtslsG2t1/COT3dXUSfQ4R9Z/v54WEwzWHre5/5eWsVWdT66PhB9bwqONeKkBrr3ZzD2e+3/NLJqly5WO74qWqeR1JWL/CLNuknAS3rsvzL6RRs/n0nM70+9k+oGa/cw8V7rNHs9l67K0/88coy2P/1o5WtTpWjl6Hdfo1ekW22/hKa3a4eIxIOHXlPCaRl7TgHusM9u5lKyr5YebVp3kWdlTwpcmv1mbfGdq0p7orJr3z0XLlN1udH9a3EnlyBLe4421ZT+0hYBmt9Nrmy22v5WER1+b/da5Zt296rvnB5SSeqsZxlLSrjI/0qx1KBJ+cQm/T7QRLy3X+6p1yVdFLTqlko4z8rVs6f6T8P3GTS9J8ZS0Lj0ueW5t29ntRtfZaiz52SQ809+16NuOIuFr+52pj9L+ONLfbVGX0b69pOyZMmfWTcJz/kLCSfiubzxLr2l5orf+mqp0nSWdS8m6el0Jb7UfZ+JI09ZHJTwjztHnaoU5KuGZfXmUK+HRfrTVuV1T1l5XpTP72uK9oWYbWx/3kvVudfxJeJt2RcJJeBNajAnf6kp4yQ88W3dKpSd36Tgww1G+DAnvK+HRYTe1Q1KuPBylx4WLHv1Ar+FvPcaEtxpLXlOXpctGr4SXlPnRr4S3KEvPMeE96ivTp5HwB7g7SsvOPPMjypLnSjq/0l/Hlw5Vqb07Su2Je3RIeH8JL3ndle6Okr2bwtzzmeF0kW207geiQxFL71Y1t76l17Ts11vXZWn9rL3P1ZQ5+x4aPe5Tx6jk7iiRc2Ftm5F6y5SltF2V3FyiRVsi4ReXcOQ6ky3XfeVbDZZyxjHhNeO49x6O8ihjwnH+/hTalDJ+cZsknIQ7wRPrfpSr2TWc9e4oGcmN/AgzeneUlsNRrnx3FJy/P4U2pYxf3CYJJ+GYOzkafCX5iFz5PuEth3scPST8cfs+oFVbOnp72rOMJJyEA80h4SQcALAMCSfhQHNIOAkHACxDwkk40BzT1pPwXm9YR+YsvxdpUa7MHTu0j8fCccjVFQkn4U46NIWEk3D94GPu6551cIT6f8T3Qu//dXVHwi8q4Xvetg+PDQkn4Y8ICSfhJBzZuiPhJNxJh6aQcBLeu9+Zm1BmaSKNkjseRSauiUyIVrOeaFnvtzP179zf5h5nJjbJTqLUan9LJgpaWjY7mU7p/i8du2hdlbbbkuMS3eeWZbw6JPwkEp6ddSx6Yjjp0AMSTsJ79YP3fczS48hzkb6xdBa+VuuJljVSL2v9fUkdZcsX3ddMGXsd45J1ldRbtg333KeSbZU+12Lq9zNDwk8g4T0av5MOPSHhJLx3X9hTjHr1saXrKX1/mFtX5AJMdjst6qRlG+gp0q3aZabuIt9G9NqHXsfBxHck/JQS3qMzcNKhJSSchPfuC1tL+H1arbdHvzhX1ui6ohKe2U6v952lckQu+JTUU3Y4SvRb4ZpvOSJl6LUPtcehVbu/IiT8YsNRWku4kw4lkHAS3qsfbNG/9bo6uUW/WHOFd2nbLdbb6n2nR532Oq41x7KmTD3bScur7nxg/ZiT8JP9MHOLqzROOtRAwkn4nn3f1Gv3kOeS9WSulra4Eh55zZ5XwkuP417jp3uOCc/Udcm3BqXtgQ/U9Wkk/CJjwltfCXfSoRQSTsJ794Ul/VvNnSKWHkeWzfygMjocJVsP2X44s5217WVEPluO0ruSlK53adned0fJ1m2Lu8Nk9zl7o4Zse7gSJPxCw1GynYGTDr0g4ST8aP2n8uLodd6yDNrQedodCT/ZcBTg6JBwEn60N7ozlY9APWYbIeGP2e5IOAkHmkLCSfjR3ujOUEbzJzx2GyHhj9nuSDgJB5pCwkk4AGAZEk7CgeaQcBIOAFiGhJNwoDkknIQDAJYh4SQcaA4JJ+Fd3qxmgvL67H2sMsf0/rm1ZadeV9s+sjOHnu2YZ+r4im3+aNsh4SQcaA4JJ+FHeZPbY31Hp+f+1t5PPFrGzP3LS+5H3mJ9j3Tcj3he7bV9Ek7CgV0h4ST8KG9ye6zv6PS8Ah75e2ZG0OxrMtI/9TwJv855RcJPKuHf//73X/2t3/qtv3vppZf+Rr6cf/7P//l//eUxeqYuZC5f+9rX/u6NN974XSJLwrd+k4vOkng/o2BU0jKPMzMZ1szmmRkmkZ1dMjqLZ0Y+jijhmfWlJWtlor1Wz61NrFczq2xmRteSdhY5Jpn6iExKuFbH2W2S8IZ57bXX/vDp06dP5Mv5F//iX7w1NBx1IXP5sz/7s39KYh9PwrcaN1t6xbWlYJZOUb8m39ntZIZwtNjGlhLe4nGPummxrl7Pzb12bajN2rKt9z97TCJla/VczTZJuGwyXGdoOOpChIRPCXhvEW8l4aWCNvdvqzf/VutqJeG1x+XMEn7ftrN1UlKvpfXTqy1t0c5q1tNjn0q3WXLOkHAh4SJyCQlfK0Pka+qjSfjcPj2ChC/Vc4mER4YrtdrPqeNHwvusJ3t+tPiwV3pnHxIuJFxELn8lPCvVR5XwUjk5ioTX7FNrCW8h2D2Go7Q45o8o4T2Ho7RadrXfJOFCwkWkRsI/f0O56JjwzBvuow5HqZXiEjHt8UPKloJ1f26cUSyPMCa8pGxb1JUr4ULCReQQEr4VLe+O0los1spRIial68rUX4uv1qPHYOp12bvTLNVBz8l6SutirayZbWaOVXTYROaHirX3XS+9O0q2bC3ujlJSHyRcSLiIXFbCAeyHWWrb1iUJl2YSnv37keKDhQgJB/BlUVx6jLq6JeHSVMKnnru64BJ4IeEArspWv/d4yHol4dL6Svj98yRchIQDAH4NCZfdJPz2k3VEcG9ft7bs3PO361oqY2abJX+f2x6pFxIOAI8BCZcuEp6VzCXpvBfZ7LqmRDpS3lbbXFs3CRcSDgCPBwmXU0h4zeOMHEcluFbCM98iiJBwALgeJFy6SfiSWNaK833mrp6XyvHaOkm4kPDjvZntsSwAlELC5ZQSnilv9Ip8r+EnJFxI+DZvZnssCwClkHDpKuG3V5B7SXivMeHRdbSScAIuJDz4pjUz4+X9DHaRGfKWZhNcm7FwbhtLjwFghIRLdwlfk/Ps+OvIsq3ujjL3YWJuiEymDCRcSHj+DWvu8do09LVTdrfYDgDcQsKlqYQfPUcvNwkXEr78hhV5LiK+LSR8bltzV8kB4BYSLiRc+UROIeGfv2mtXIGek9/7H1fPvX7qx99Lr53azlI5AGCAhAsJP0i5CLiQ8Pwb2Nr/5/6WFevMa0k4gAgkXB5KwkXkvBKeGau9tGz26nZmTPhSGQDgFhIuJFxETnMlfO1uJuP/l5a9f03Lu6PcvgYAliDhQsIT8eFDSDju30QzfweAERIuJFxESHjiTXPp8drfAWCEhAsJFxESnn3jDAxVAYAlSLg0l/CliXSyk+gsrWfu+akJddbKFN12dEKetedESDgAPDYkXJpKeGYWyrXp5NeWXZpyPrrd7LYz+7O0TRESDgCPDQmXrhLeQtCzj1uuKyPhmXWKkHAAeGxIuJDwynXPDVu5j7YjJLzyzWomj/SG/UjbjbQH9XKcNnnUdrJn2wy9loQLCS9bd8nrREj48d9YjyAUmZk8r14XRyzPI0p4ZjbZo5X3iP0GCZeuEt5qDHV2TPgWEm5MuJDw68oPCT+uXJHwY+4zCSfhsrOE3wpyyd1Rso8j64qUqeaDhLujCAk/hgjMDU+I3FJwagbNojfUxHay67rdv+w21oR+aXjH2nZ71MncNpfqZaoNrK2ntMzFwlVYF63aVaQ91NZ9dNu152m0XW91npesj4RLcwnfIsRW5HgSvtU47ci09BnZqBGK2u1k1xkVoNJ6WJKLFuUv+VCQPW7Zx63qqUdd9GhXJXXY8pzpeZ5mjl+rc7L0GJBwIeEi0kTCt/zBZGaWysybZMuvrlusq5Wo9Fy25Dj1LG/tvmwlvS3aTk8Jb/Fcpi5K19tKwnuck9H1kXAh4SJyWQlfKtfccyXlj26HhB9bwqNtoqWEl7SdmnPuiBJeWgc1+9XznCThclkJFxESHn1zbyEitW/OLSSWhG8j4S2Occu6aNVGe9dvyyvh0eVr2k3vczK6PhIuJFxEqiT88zeUnceEl8pG7ZXwmnHHLd7we48Jb13+Rx+OUtoOty7PXhJuTDgJFxIuQsJPeHeUyTe65N0uau6aMPfmXHTnhIIfM0bqoeTuKKWy1/puLr2v6kfL3OPuKNnjWvPBt2TYTcu7o7RsK5HhKlvdBYmECwkXkctKOPpiJkhgu3ONhAsJFxES/sAisPQYQL9zj4QLCRcREv7oMrDBeH4Ad+cdCRcSLiIkHAC2g4QLCRcREg4AG0PChYSLCAl/duyx0C3vQnGG/QUeARIuJFxESPiz80gpCQeuAQkXEi4iJPwZCQew/blMwoWEi8gpJDw7ucj948hEG7UTo0QmDpl6HF02OplLZH9K9g9AG0i4kHAROYWEL0lmq9fVTnO91dTy0WW2mAIdQBkkXEi4iJxSwqeem/s3sr6MpJaWOVKute1H96lm/0g40B8SLiRcRE4h4Z+/aa0MvZj6d2r5kivT2eEoWQmfWzY6HKXFMB1DUoBtIOFCwkXkNBJ+/wZ2//8lCa8ZDrK07ZJ1RsdoZ/5fs7+kG9geEi4kXEROIeG1Er00Xjry+qXXRrdRumz0/4ajAOeBhAsJF5HTXAmP3N1k7vHt8nOvX1t/ZjjKUhmyy0aGo0y9LltfhqIA20HChYSLyGkkHACuwmEk/LXXXvvDp0+fPhnyrW9966++/vWv//X4eMhbb731VW+K++VP//RP/82TJ09+MuSFF174y6HhjI+HvPHGG7+rnkRIOAAgxmEk/KWXXnpn6tfZQwYh94a4+4ekbzs+IiQcANCGw0j4cCX1K1/5yt9NSd73v//9V70h7p/xCrjjI0LCAQB1HGpM+NTVcFdZj3013PERIeEAgDyHkvCpq+Gush77arjjI0LCAQB5Dnd3lNur4a6yHvtquOMjQsIBAGUcTsJvr4a7ynrsq+GOjwgJBwCUccj7hA9Xw11lPfbVcMdHhIQDAMo5pIQPV8OH+1J7EzxufvjDH35TPYiQcABAGbMSPgw1mLsvtIjIWn77t3/7k19+oH6ezJJwAMCXmZXwYRbEN998Uw0BKOL3f//3/9Y3JiQcADANCQfQBRJ+/vzRH/3Rf/CtjohIn/zmb/7m35JwAM0h4SIiIssh4QCaQ8JFRERIOICNIeEiIiIkHMDGkHARERESDmBjSLiIiAgJfwjGX9vuue3bvP32288+/fTTovLtuS9oAwkXEREh4Q/BESR85Oc///lnj999992i8pHw80PCRURESPhDcCQJry0PCT8/JFxERISEPwQRcf3ggw+evfLKK5+9bvj/yOuvv/7Z38bhIx9++OFnj3/2s599Yf3D60ol/PbxJ5988uzHP/7xF4auDH+beu1QhuH/77//voNMwkVEREg4ziXho1h/9NFHn2X4//C3Uc7H5wYGKb4dTjK+/lbcl7Y9vn5uOMoo/aOQD/8fpPz+teNzBJyEi4iIkHCcUsJvxXd8/Xhl+16Ex3UNV80HxqvWt1erp7Z9/8PMufKNV+OH9d5ebb9/7fC6WzkHCRcRESHhOJWELw0PuZX0cfjHeOV8/JHl3FCU+3V9/PHHX7qyff+aYRujiI+yfT/05TbDOkHCRURESDhOJ+FLV8IHxiEpt+u5fTw3FGVq26PA3y4zVb5B8IehJrdX3W9fO34gcDWchIuIiJBwnFLCl8aED4xDUm6Hkgxjum/HZ2e2PV7pHn/sefua2+Etw/P3HwhuXzt+OLgtK0i4iIgICcehJPw+t4x3RxkydWV7FOdReEdZv71KHZXwUfpHob99zSDet4I/SPnc3VEGBkEfynA7+Q9IuIiICAkHgBtIuIiICAkHsDEkXEREhIQD2BgSLiIiQsIBbAwJFxERIeEANoaEi4iIkHAAG0PCRURESDiAjSHhIiIiJBzAxpBwEREREg5gY0i4iIgICQewMSRcRESEhAPYGBIuIiJCwgFsDAkXEREh4QA2hoSLiIiQcAAbQ8JFREQuJuHPPffcLq878r4q43x5epSv9z6f4bivQcJFREQuJOGjnEQk5awis4c0XkH6avcls1zJNnqv/2iQcBERERL+EBJZs04STsJbQ8JFREQeSMKHv9+/Zm14wtTj2/VEn5srZ2Y993/Plm1qm2tlnno+up9T9Ty3rmx5M3W/Vmel+7v092h7ql1/th2QcBERkQeS8C2kICMqWSmrfW5JCrPrqVkuuuxS3WbHVEdlOlLekn1fE/hWx7f0uGxx3Em4iIjIA0r4rYD3FPGSq4VTopgR0FL5afXaGhnbQ8JbHa9e8lyz35HXZo5zpCxr7ZWEi4iIkPCuEj61jciV1lKpWRs6sLafmeEE2au8JUMYriDhJcc9U/eZ491KwpfWHxmWc+QhKSRcRETkIhJeI48ZCS8V2VIhLr0SXrPNM0p4zQeeFsclso0e5TzLlW8SLiIisrGE34v4VgJeK4G9JS0iVdkr4T0k9owS3upDTavhKNk6zpTFmHARERESvgtZgYwO11iSmq3ujrK0/ZKyRSUv8qGh9O4oPSQ8c1wyP2CNfCCKtqVIm8iUpbQuSLiIiAgJf1iudN9tOOYlkHARERESTsjgmG8MCRcRESHhhAxdj7Xj/WVIuIiICAkHsDEkXEREhIQD2BgSLiIiQsJ355GHKxiqEauXqw1rIeEiIiIk/NAiegXxOvP+7VW+0omgzgIJFxERIeEk1f4drnwk/DHy4osv/qepWYVFREROIeHRyW+WJlGJTkazNkHL0rCBkomC5mZLjJS3RZlq63Rt4piW9ZY9XtFJimonwylZz1QdkvDr5YUXXvjrn/70p5f7kAUAqOO99947j4TXTOvdYgr01tOctypvTZl61Wnp/pSUY+pxZmr32mnhS8vgSjgJBwA8LqeS8LnHtdOht9rO0rpqJDCz3q32tafktti/PSW8xX5eARJOwgEA81xGwpeGRZQMOZnbTma9LSU8ut6t9vUoEj63f2ttotW+1ZRhbgjSVYamkHASDgCY55JXwteWXXq+l5juKalb7+sR9i8jsS0kvKQMroSTcADA4/IwY8Kjj1uJacsr4a3GgGfWddbhKMaEHwcSTsIBAPOc7kp4zZ08Mq+vvVPH/fM1P1zMrLfl3V4ydRq5O0qL49H67ihzZd/y7ihr7eOskHASDgCY57TDUaBOcWxIeJ2EZz4I1v6OoOXvEI72m4Ye5bniLUUBbA8Jf2DUKXpCwssl/Oc///kXJHx4vHYuk/BYeT7++ONnb7/99qX2EcA5IeEPjDpFT0h4uYS///77n52fgywO/w6P185l53O831NXAI7AaSQcwLkg4eUS/sorr3wmip9++uln/w6P7xkE/fXXX3/2s5/9bPb2mMNzw7JDPvzww88yPh6eu3/9wCeffPLsxz/+8ed/G7Yz/G3tual1jXzwwQef79Pw/6nXD1eop8o2xe36bstwW66hnPflmft9ybvvvvv53+bKN7fOsV7GD0xDhuOy9u0FAJBwAF0g4WUSPg5FGcRwYBTEW6kbr5R/9NFHn/9/SsKH50eRHzJI+CCMoyjev35g+PutkA//H+Vz6bmpdQ0M2xzLMmQsx1RZx3VOfegYGST5/vXj8JKp4TtzdTNVl+MHmqnyLa1zqIPx+cg+AMAACQfQBRJeJuGjFI5Xg0cxvL1CO14FHlkTzczjcd2DWN5fkV56bm7dt+I+Pj/3AWDq8T33+7607cj6p+pyqXxzfxuu5A/H6PabAgBY4qHGhB+9Uzxq+XrdXaBlXXjDOx4kvEzCR2kdrmDftu+MuNY8HoewjH+7HR6y9FyvsmX6oxIJn5rZdq08938bPygN31qMV8L1SQDWeKgr4TWzKG5RhiN22j3KVPMme6a6e3RIeF7CbwVuKuPY555XwkeG4RXjVfn7oRVLz539SniLdZJwABFIeIPXtirDI0h4ZEp3En4NSHhewm/HO98yjqUeh6TcjmMex1y3kvBxOMUg/ON48lGal56bW3d0THj0/J8aEz73g8nI+m/rcm28/NzfRpEflh/3UZ8EYI3TDkdpNeNldJbDkokzsrMwrs1gGdm36BtaZH9qZoEsHW4SXf5+31rOfJqdLRPTkPC8hI9Xje/vODIlh8OPEcfhIC0lfJDr27uFDII7lmfpuaU+Z7ybyZC5u4+s9Vn365u6Q0tm6MjtD0pvf9x6f8eX6Dpv90//ASDCKSV8SaKiz2XELDLtesl6p5atKePa4y32J/NBZenvGYnPinarY41lSLhp6wEA81xCwude12u5mmEtrYW3x2tblSlTL5ljVbLdpW8OSo8tliHhJBwAMM/lhqNk5TOynqVfzs+VNVq+aNlL9q3F/pxZwiPHoXSoDtYh4SQcADDPJW5RuPVwlEw5z3AlvOX+lEr42m3CWperduw61iHhJBwAMI8x4c+eha6Ezz23Vk7DUWLrrX0+M15+aRuGp7SDhJNwAMA87o6yMDa49u4okfWula9m30rrr7QMc6+Prje7nrWr5pG7p6ytF+WQcBIOAJjHtPV4WEh2X0g4CQcAzEPC8bCQ8L6QcBIOAJiHhOPhMNRkG0g4CQcAzEPCAXSBhJNwAMA8JBxAF0g4CQcAzEPCAXSBhJNwAMA8p5TwVrfBy76uRxmvROZ2jFvX1aMdjyOMeyfhJBwAMM/pJDw602H0Nb3LuXe59qqDmlk5r1QPe5T3KPtKwsskvNcsrn6MfJxzOzpHQ82cDHPzSURnJc60odJ1ls5kfOZ2fhQ3wDEg4Rc/0Uj4/m1h6/KS8PNL+JrsHK1dXFmaetZTdOK2zLJLbaV2grXSmYezx157wqNwOQmfmiWx5WySNTM0Li2fncEyMpvn1N8j09nP/S1TtrXXR2azzJQ9UheZ16294czNqJptL0vrylwpyy67BSSchO9driNRM1Ny9rXR977oMcjOPEzCgRjNJHyLN/+MTK9NHb+0XO1zEQHNPJ6q59J1Ressur1oXWW3OfW4dt9K6iBSHyXbyS6baUOuhF9jOErmPCi9MBD5MLr2+poLC7UXJUrWUXsRZq7PaDWM6IgSvvS6lhKe6esjV+Zr6mvtuM6dW9n3s7X3gJqLfrXnQ6ljRfsWH5gaSXjtOLMoLSQse9K2aKy1+9GqDrL7UFO2XvuQuSJTKuG96rP2WLRaditIeH8Jr7kwUPKBvFVb790f9rjQMlUvNWUteV1Nv7e07pYSnnGA2jbecv9Lt1m67No5Fr1IU/IBsPZCV8u+5dFF/DQSPrWN2qEWa51I5kcte77pLNX9WSV8rZ7XPnmXXqHu8c1CiysQmTok4df5YWb0alnrtpz9zc1RJDy7zp4XNaJlzbzuiBJ+39fVrG9tKGnNMdnq4lZNeVqd263Oh0gf1Lp+Ho1TSfja31tJeHT9mUZYc4KXvrb25KgpW+/9b3kct7oSnqkHEk7C59p766u6kYsKc8uUrLtlf3C/rej2I8Ntsr8tye5nyetqh59E30dL78hS+7rI74pKL25sdXHrjBKebVst+xYSfoIx4aU/GintgHqfFIaj9LnatNWY8NL6dCWchGf7uy2vhK891+vqVq2ER94LSt8zavrDSJ22OC6Z/el1JbzV60qEr2SdtcfVlfDtLiRenVPcHSXTwDKfXpcaRc3dUTJ3Bomsd20foj/MWivnVhIeqavSqzFb3R0l87hkXaV3RzlSp0bC29wnvOf45sz52/LDas05FXlt6ZW/nsNRMq8vvS94yfZqP0j0+ADW8tvJFsel15jwtXMs8lzPMeEl+1/bLz0apq0HdAhdIOH9JXx8XHphoOSCRebHWZkPkyXLru3D2t0tMuubWyb7LXDJLUizY/QjbaXkm+uSOltbbupxy4sbkX695Liu3YEtOxRq6pyK1EFk/zLnerbdZ+uPhH8REg7oELpAwk1bDwzs3a/23v6j75/3zXJIOHCDzqQdJJyEAwMkvO/2tt4/V7PbQcIBdIGEk3BgT7aaEGYPCd1qgsTSIUiIQcIBdIGEk3AAwDwkHGF84kUGEk7CAQDzkPADcXTJJeHIQMLPI+FXOrf3Gv9bcgvc7O3lIsutzSx91vbRogxHbue953q4+rj8s0LCD3oSKh/ODgkn4VuUZ8uyR27Jtla+0tl+a2/HV1NPpcse7TieRcKvsK8tf7x5Zfc4lYT3mmAls42pbU5te60sS9Ms1+xzix9SlNbz3LLRNyE/8rgWJJyEb1GeI0l4pL8rmaCnxQyEJJyE77k/JHya00h4z6nGo9uYem5NgpdusB/dRnSft6iDFjODud3RY0DCyyW85MPs0ofkkgsVLT78RyZVqbkgEa2n0osKS2WOPncWCS85ViXHJnJsozNntpqEqqTtlZwTkXO0xb72Pi8yQ6Jq13v1C3SnHY5ScqU125lF1tFymuNer43sW4t6jpS39bTHOC4kvO2MmZkZ9KbOvxbT3Wc+/NeWt0VfWHNRIdtPle7L0t+3kvBex6rVRaaWx3yL867kPKyt363Oi5oLeq3O8Stx2uEoPST8fhuRdZxFwtf2rUU910h4yx8R4RiQ8DYSfqS+ZasLBdkfK/bYl5r6byHhNfJY8+PPlseqpXSVSllpPbaom9L22GNfe5zjLdtUq+N9Ni4zHGXt4EYlPLLNs0p4bYez1ZVwXAMSvs9wlBZ9S4sP4msiWCJh2TK1kvA5sY0OWWzd95a2g1bryA5tyLaHWgmPHqPa49LyPCyV8D3Oi8iHu9oLhST8wBJeciU82pgjjaRFZ1XS+HvJf6t67jEOHeeFhLf5YWaL31b0uLJZs56e5e0l4ZH+suS49T4mtceipq5afbvRqj6uJuF7nxd71duVOOVwlNJGE70isPbDgRaPl378ESnPFsNRpuq55AcZ0c7EUJRrQcKvOSY82u/0lJUtZaPkt0JrfXr0mPf8W+mxKa3jnsNRStt9q/Mus1+9xoTvcY5nzptW9XQ1Huo+4Ue42T/JxKNAwtsOR7n/+553R8k8Lrl17NpFipI7UrW8a8lc3UaWj4zXjk7Ekylv7e+hSu9GEr3TxdzxLW1bkQt2Jeddph3Pbb/H3VG2PC+iw1FKh7lE+oOrQMI3XgcJx6NAwre9T3jNnZ8A9Md5iHseQsJbfIpq9UnMSYhHgYSTcADOQ8xj2noAXSDhJByA8xDzkHAAXSDh55m2HgCwPSQcQBdIOAkHAMxDwgF0gYSTcADAPCQc2IFHGBtIwo8t4S3b4BHb81nvM2zcMPA4nGrGzMj9VdfW0atsR+bsnXrNMT9qfWbWcdbjR8JdCT/bebrHuUa6gcfllNPWR/5e+9oWZTsje+1L5vjuXd8kPAYJJ+FnO09JOIAtIeEdy3ZGjibhR6zvHhI+d7V/bYbEktkTt4KE101bH51p8P4410wpnpmpb229c2050k6zMzOW1EN0NsfMt3DR8t3vd81siXuf5wDKaSbhvYcLZK+Ulk7dnOlA58pQMzXuWvlKyp994yt9Qy3dt2zbyUwPvfa4pC3UrHdqmbVtRL8NONo0vyS8XMIz0z1np6qOtpdMv7ZWhuh2117boh6y04WX1EHmcW15zjr2HUAjCa8dqx3dRuTvPTrmyHrXyllbvpry166n1Ztbpr63aAslz9W2m5J2Uirhe0PC666Et+6bsv1WjYT3OH9a1kPr87nkOPbeZwDH51QSHtnOFuI1t2ztGMQt3my3qIcW643U19Lzc/+2LGvNePW1q+8RQVo6H0j4tSQ8MvSo5pyMtrHW/VjJRZRW9ZAdChIdlhMtX+/+GMDxOe2V8MiQkdKvZrOPS4ZTZMtXU/4tJbzVvkXawNJrIhIeHYedHW6SlZbsMYnUBQm/7pXwzOtbXgmPlmGrK+Gl9VBTnprjRsIB3HPqMeHZN44trgD3esOsWfZoX/lGHmeO69TrslfCS8tSWu4eY8JL6qsnJHz74Sg1Y8Kz5di6v+nRR7e8WFA6xp6EA4/Lqe+OcrThKHNlWlpurzHhveuhdr3R5yKvb9lOWu1X6XGO/o2EX0fCb9tE9q4g98tm+62au6P06m+i30JFz7GIPGfvjpI5ji3ujnLUPgDAMpe8RWHJLd2WlousN1LW+/Xcv3bru6NMPW4xRKa0DCVjnyNtokQwtrw7ytQy2VunHfGKGAnf5z7h5AsAzoFp6w/EGYYYAFFIOAkHAMxDwg8ECceVIOEkHAAwDwk/ECQcV4KEm7YeADAPCQfQBRJOwgEA85BwAF0g4SQcADAPCQfQBRJOwgEA85BwAF0g4SQcADAPCQfQBRJOwgEA85BwAF0g4SQcADAPCQfQBRJOwgEA85BwAF0g4SQcADAPCQfQBRJOwgEA8yxK+NOnT58Nbx4iItn8w3/4D/8bCf+VhL/zzjvahIiIfCE/+tGPpiX8tdde+/bw5iEiUpI//MM//N/eeuutrz66hH/ve9/799qDiIhM5aHfIEVERERE9ohKEBEREREh4SIiIiIiJFxEREREREi4iIiIiAgJFxEREREREi4iIiIiQsJFRERERISEi4iIiIiQcBEREREREi4iIiIiIhtI+BtvvPH8kydPfiIiIiIiIu0zKeH//clnb775poiIiIiINMyrr776bFbChxcAAAAAaMt7771HwgEAAIAtIeEAAADAxpBwAAAAYGNIOAAAALAxJBwAAADYmOYS/v777z975ZVXnj333HPPXn/99c8e3/PJJ588e/fddz97zZDh/8PfRoblhr/f/m1cblzvwLj8yPh4zPC6n//85+Gyj2W635/hb8M+ffDBB6c5sPd1s+f6f/azn33eJn784x+nl4+8tvf+Du1obHdj+/z0008/f37cv+HfkeH5pfY697e18+PIbSS6zuy5CQDA1Wgq4YNgDW+uo5x89NFHn70hv/3225+/ZnhuEJXhtcP/hwz/H/42LjfI7rDcsPwtH3744Wd/H2V4TsJHRpFZE5jh+aGM98uPAv7xxx9/vi9DGc7A/b4M+3B7HFqvf4lRUEuXj+xLbwm//UA5tqtRIscPh2PG9jY8P0r0XBnv/xY5P47cRqLHYajL8cMJAACPSDMJHwV57erWKLbD1dGRUVZGyRmlZrxqOjI8vpWcNQkfpOJ2vXOM21pb3/0HijPRWlJbX8nec1/WGNvR2GbvPwyOH9DGjB8exw+T4we3iIRHzo+ztJElhv0bP+ACAPCINJPwUWLXGL/Kv+f2a/vb141X/8av9m+/7l+T5qn1TjGKdUTC5/Zx+GBwK/LDOqeuwN8OMxgkbRS8e7kfr8zfSsr9svflGpaZGu5xP0xnqX6X6mpY//D8KFD3dTFVvqltz5Vv2Nfh+A65ldC1fZk6NsP2xyvwU8OI1rZ5y+03IgP3x2zc71HOxyvf98cwIuHR82OK232+b38lbSTb5u7Xef8N0+0QlOgHZAAArkozCY9eRZt73doVwfFq4+2bdlTCS6/Y3g47GKVhbl238jR3JX/cp2FfRpEdxC0ixHPL3pb79luIiKTeXrUd63du3Pvt9sf/Tx2vpfLN1fXtFeSx7ko+bI1/G2V4WN/cMKK1bd4y9QHzdnu3w21u17P2m4XIh4loO749nuP+3H6wK2kj2TZ3v46h3u6H7Nwf1/tzBACAR+GwEn4/nvZ+HO7UMq0lfGC8kjdeBZ5b1+0PD+euqN6PjR5FexSc8QPG1JCEuWWj+z03VGcUtXE/54YTTW3/9nFN+bLfQKyt7/44TV1FznzLMfXcKObjsRvrcfz72H7nrhJny7HWjqfG3a8tv7bt7DGda2fDB4TIcC8AAB6JZhK+JKiR102J0igB45XhEoFZusI5VYY1kZlb1+0dQMbX3cv40lXQcUjE+MO8++0sLVtaN/f1u1RPUTEuKV9rCS/5cJaV8PGD0tiex28QxivS44eapW9upv5WOhwl0nazdZA9pvd/Hz+gjHd3IeEAAPyaZhI+ykfJDzPvrwSPjFe/R6EZr4qPrL2pT/2gbWoIwNzyU8/fl+GeYZu3tzW8Zelq5TiEYtzX++ETS8uWSuZa/S5tf+2qaaZ8Z7wSfjsu/rbdj23u/kea0eOUOT+i7aO0jWSPae1xBQDgkWh6i8LhTTt6i8LxdUOG/0/dgu1edOauLM89jt6iMLL8uC9zd3O4vXPL3I8cb8fY3t/z/Hb79/egXlu2VMLX6ndu++MHhrnxw9nytZbwzJjwpXWOjB9Sbrm/LeHUuu/bXuYWhZHz45apMeG1Q2Gyx/T+76PE354/V7nbEAAAtXSZrOf2bghT99XOTEaSuXJ9/7X57Q/DItyvbyjTeFV1HLs9xyBIt/s0bHtqn27r5/4OFuNzc1c855aNCNYo3Pc/hFsS/3uGbY7DbJaGaGTLl5XuqX2ZuzvK3CRLGQkfBff+A9j9BEQjY5uJ/D6h5WQ9YzmX7o6SbSOZY3r/93GI1ngMbp8bf5NwpgmwAABoiWnrH5zxCr67VMwzXgVe+hCGHKPw95gJFACAM0DCH5hBgMaruQRzmeHqtqu27RjvmAIAwKNCwh+UtSFD+CLD8AnTrLdjqEuzZQIAHhkSDgAAAGwMCQcAAAA2hoQDAAAAG0PCAQAAgI0h4QAAAMDGkHAAAABgY0g4AAAAsDEkHAAAANgYEg4AAABsDAkHAAAANoaEAwAAABvTTMKfe+658PNz/8+uM/LazDqOQLRuti5LaX0Pj6ey9vzUerJlP/KxP1u7POs5pC6uXRdH278W71lXrf8W+7tlnZ2tvDgnTSV8ScxKJPnRJXzv9bWS8OjyvdvClY/zI1P7ge3Kx1E7U99X2l8SjqtBwg8GCe/XFq58nB8ZEq6dqe/H2F8SjqvRfDjK3BtidDjKrbBnhmZkpXDug8HccIil5+bWmXltpm5q/r60f0v1X1vfkeWj21t7XXSfI4/XjlP2w0GkbUePY6QdlbTzyPOR/aytz0gZsnWz1E+VnPfZOqrpX9bOnaW21eNYrq03smzt/rc4Jtk+PFvWaF9feq622KfS/Yi+f7c6VjXtLtPvtewjasqL63MoCY90fmvbX/v73Bv2Wqex9tza48hz0bqJ1Hd2H7L1f5Yr4TXHNNOOsmWqLUdkHSXtPHMMM8c/W5+ZMmT3vdc5U1o3Pc/btXqtKW/LviX6uKae1vY104fX9Nln3qfo/q4d49L9qm13Pdp3r/MEj0GXH2bWiHdNhxP5e+Zk6nVyl7w200m12Ha2PpbWsfajy5rtRdvi2uOeYtqyHC2OZXZftj4Pa9ti9hxvua3Seux13rZ8k+9Vph7nR+2xKd1OyTHeqr2V1nF0f3u8n7TuR45yzHucnzgnJPwCEh69q0j2DiQ9roSXdsS1V51rvhpvdbeWyOPoV521ErT2oSjyoSnSHmvKGy3DFgLYoh2cUcKX7mrU+hhE2mSk3mqGOdS2idK2ExnytMU+RY9Pq3aa3a/afqPm/S96zHv1c7gmJPzkEt5q/7L1XzMcZc8r4XOv7Xl1OHOcWpV3q3YQ3e89hsBE932v4Si9ytCrT93ySnhJO9qrDbW+MtzqNrU9hvy02t+a4Sil52Ov86jX1XY8Bt3uE146jqymgZYI4Fbjh2//32tMeO04vFoRLb16VdKZRcvVqox7tM21477H2MjS/TzrcJTsWObSNrBH/5I9j44+HKVHu81up6TtHOGDRfRvLfa35li1anc1vw1pNV689vjiGhxKwm8beOkPirLjjlv+Ajqz7z3ujrK0TKZ+Ml+NlY7z7nV3lOwxXStjzVfj2brNlCPTjkrrpOZbgtK7o2TKuNTGs20nct5Hzq9IOy65c0N0+FCkDyk5ltn1ZvrLmv615u4cpX14tl6isl1zR48W+xQ5Ni3rv+RY1bS7tW2unWcld06pLS+uj2nrN8aJ5ti2WH7PdqQNH7t+ztKOtNvj7ddR1qWPwaNAwjdG5+LYtliehDvH57ZHwh9rX48qziQcWIeEb4zOBVNtonaMObQhX2mjtv1oh8C2kHAAAABgY0g4AAAAsDEkHAAAANgYEg4AAABsDAkHAAAANoaEAwAAABtDwgEAAICNIeEAAADAxpBwAAAAYGNIOAAAALAxzSR8bZrammlszzYFbm15o8svvW6POotOV5wp2+1rS/apZPm92tt9/e09/XP2OE1lz/Poan3N3mW74lTkLdrs2vKtz4nIuuaeWyqj9h6v/yu0+7X/YxuaSnj2xN/7ZOyx3nGdpaJ5tDrqsf3SstZK+JG5L2ercm913i2d+2dq04/2JrR1P3WGfa+tkzWpKd1udF0R0SZe+gZt4RiQ8E7rJOHty0rCt20XJPz6kPDy/Sz9JnLtuUy5SLi+oeV+aQvb03w4ypxMTP09Ku7RZTOvX1rH0rpL62Fu/XNlW6rLqdfNrSNS39GvSrN1Fj2e0Xpf279oBxOt16k6zu5XZD8jbaLkGGbafen+ZOq/ZvuRY1bavjP7HO0fevVZLc/p2j5wbftTx3CtDqL9Zkn/FW2zmXO/ZN2ZfmJtuWh7ivaF2bprcUyy7S3bR2fK0+I9LtM/R45vbb+x1gbX/l/br7Y8Z6/ILhKelaDostk3x+wbabQOso+zf8/uS00dtKirVsdoLwmPlif7dXJNWyw5vjX7nW37rbffq31n9rn2fK49H1qf0zXtLCNMLY91zb7O7X/kA3ZtvZaWMfIhLNIGo/uUrbee7S/a19a0n9JzoUXfXtvnt3xPzp6Xvd6vHpEuP8xce9PYQjhKO7WaxtHj5M9e2ehRZz07qNIOYq1uouvqVa+l50yLc6LHNiL7svYjtz3O+5b73EvC17bTep9bHIPattNqXS3f0FvJXPQYZsoydZ5ljk/kGNR86O79YWWLi2k9jne07JlvOUpeH63bLerc1e8vckoJn3ujj3wtEv16t6RTWhORPSV8TY5aXQUsWTZ6jK4g4Zm2GG2b2W8hSiU5ev5Hj/FWEt5qnyP9Q3a/a364FzmfW57XNW2ptu3XHJMspVcqI/sf7R9KzrtSCW99UabkA1lmKGLJ9nq/x5Wej9EhmtF+o+S8L5XwzF2BSo7Ho3D6K+HZjq/X1yI1V6+2vhJeux/Zumt1vM8u4XtcWci0g5YSvmX91Fx1aXkFJypv2XprfZx7nIut1tv6mNT0dVtfoa/54Xn2FqG1P9Ls9b7a46ps6fnVYz+iba1lv1Faz62couc5fAW63Sd87/Gvc89v8TVW9ESr7ezPOCY8Up7MG0TLr71r6q7kxzBHHhOe7RxLJPwIv3k4w3CUs44J37vtl/bbcz9Iy3zzUVKm7DeprT587inhrcaEtzjHtx4TXlOesw1HMSZ8nl0k/L7DiXRIkWVL7rhQu+6SDq/2hyWlHVPtV0PZr+Gjx3PtGGU6nmhnk6nXSDuOdiaR/Vza1+wxnGtrtUO3oseh13nfsn1nhjPUjHcv6bO2OqdL97FkWM5Wbb+kX8rcHaKkzdZ+BZ85rpnnsvVX+/5e095at58ebanVelv0G2vHr/bH1yVlMRzl15i2HqfmSCexDgU4Fj2Gq6g/5QJaQcJxavbsjH2tBhwbEr5f/fUsh2ODq0DCcUqO8lWWr9WAa+KcPt7x0NfiapBwAAAAYGNIOAAAALAxJBwAAADYGBIOAAAAbAwJBwAAADaGhAMAAAAbQ8IBAACAjSHhAAAAwMaQcAAAAGBjSDgAAACwMU0l/HZa2bNOLzu1D6bJjdfdlcrY49jvUUdXbr/RY9TjOGa3e4W2pI0eq91PtcPMe9ee9V677ZLlj9jOWvhGZPlWTrO2nujz+oBf0UzClw78mfBmoN5blucI+3XVNp0RjJZ1kP0gd/XjoH1vW64lgcnKzZZ1N/Vh4YzHfYu+pLSPydR1Zhv/6B/9o9B6Ms/rG38FCT95ea8CCdemW+8XCX8Mrijh2WUfTcLPfAU/sq7oNmqObWQbg3yPAl7Svu6fJ+FfpruET73u/uuI6Ke2ua/e5tax9Pqa/dhqH1otn62j6LaW9jmzzcjXqmv7Ez3Oc2WsKc/c89F2kq3ntWMcOS7Z8pS2x2hdlZxv2WPRokylbTVzLqwdn0xbvt9W5lzRdzwLLZvdfrbdR6iV8LUhAjXn3lpbz7ajqXLNba+k/19qEy2Oa/TYlJQzs+6l5+/le2mZWglvNTQm2w9l+uWa82GNbmPCIwc9+qaw1mFnl4/uQ/bkbLkP0bqLLJ+to8y2lv7fapstj3nJvtQ87lHPkWNcsl81HXym7C23k+n8tyhTtO5b9COtzstMu3r0vqNHH1FyDG7/nhkOULJPrfY5s+6sFJeUt3T7LX1j7jiW1lOmHHPPT8l39BhG9in73lbSD/d4ruR8iNDt7iilHWl2fFPpeKhWDbfXPrRcvmV5SoQjsq6azjxS/7072uwHz9rttzoupZ3hFnXXst1vVaZo3Wf6kRYf6Fr2h/qO+naRPQ7RstUOR2m9D62PU8vzuqeolVL7AbT0uN8zdyX8toyZb/Cjx7KVq21x8bTVse9+i8K5y/ZLX00tHfToJ//SXwJnhoT03IdMoyqV8Ogv7EvKkf2F9hkkPPMNSe+OvnQ7rYajtBryEvkWp0W736pM0bo/u4Q/et+xVqbaNja1XOQ4bSHhpXfHaDUs4IgS3vpuai0unLT4nd6SjJf0w5F2WzpyIdtHlRzLHsd+0x9mbvFJPnsQezeompOltDNpXUclHULtFbSjXwkv7fCOLuGlz/W6UrTXlfDSMkXr/kpXwh+x72jxOFJ3W40Jb7UPvfqFHsMG9zifoseml4SXljUzRKV2H1sMTyn90Fr7bVcJu0p4j6uJtRXV+ivH2hOpxfIt39RKxx5n1tO642nRue0xJjy7X0caE97inGnZ7s80HCVanlLB3XI4ylX7jki9tmxj0WOy93CUXsepx/CBIwxHqf3tUuaYR8s1Xv2+T4t+KttP1pyPLerodMNRsl9VZTuL7DCA7K+Jo5W41T703qeaXxZnvyac6lAib2I9fxFe8uGu9K4AS9ts8ePi7C/9W/zKv6bsPbYTbWu1ZSr9JX7Jr/CjbxiZHxS1OJ8eve+I1mvN+RU9JzLnd2Y9tf3g2nEqGY6ylYQv1U3JcY16Qfa8yRzHVsNmMu+Dmfpo6VQ1x6T1+bCGaeuRPgGVz35DW7laG3UO4Yht69Hb5dX3n4TjUicECQeW2wYJdw7hPG2LhJNw4PAnRKtfpTsuuGr72Psc0XcA1zlv0AYSDgAAAGwMCQcAAAA2hoQDAAAAG3M6CT/j+KgWN6IHAADAdXioK+FnuisAWQcAALguJPyg2yXhAAAA16X5tPXZWeFazKw2NZtVZga1tTJMbXvq8dR6I+uYm5GrdF9L9xkAAADb0FTCW00ZuzRVbe00uJnylU4lXrIvkeda7OtRJu4AAAB4ZJpfCV/6W/QHitHl1gSyVsKX1tm7/C0/UET+DgAAgO3oLuH3mXt+aV0ZiV3bXsl2pl7TQsJL6yBSt2vrNhwFAABgPza9Eh5dvlTCWw9HWSpnKwkvqYNs3Ub2BwAAANtxmOEopWPCo+tYe/3autf2tWS9pfVT89iYcAAAgP3pKuHj33vfHWVqnVPP1wyJiT43td7S4SiZoTeZujccBQAAYF8OeZ/wo8sheQUAAEANJPyC5QMAAMCxIeHJchFwAAAA1PJQ09YDAAAAR4CEAwAAABtDwgEAAICNIeEAAADAxixK+De+8Y2/e+mll/5GRERERETa5R//43/8Xycl/I033nj+6dOnT0REREREpH0mJVxERERERPpFJYiIiIiIbJz/H/G5dwy1IuPtAAAAAElFTkSuQmCC\\\" style=\\\"width:6in;height:6.87153in\\\" /></p>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"085\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>COVID-19 Neonates born to mothers with confirmed or suspected infection MeG-CLS-085</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"neonates-born-to-confirmed-or-suspected-covid-19-mothers\\\">Neonates born to confirmed or suspected COVID-19 mothers</h1>\\r\\n<div data-custom-style=\\\"paragraph\\\">\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\"><em><strong>Executive summary</strong></em></span></p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"paragraph\\\">\\r\\n<p><strong><span data-custom-style=\\\"normaltextrun\\\">Introduction</span><span data-custom-style=\\\"eop\\\"> </span></strong></p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"paragraph\\\">\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\">Neonatal infection with SARS-CoV-2 is expected to be mild, with shortness of breath the main presenting symptom. Vertical transmission is unproven. However, this is based on limited data and all infection prevention control procedures should be followed to limit onward transmission of SARS-CoV-2 from exposed or infected neonates. There is currently no evidence supporting transmission of SARS-CoV2 in the breast milk but close proximity during breast feeding may be associated with transmission.</span></p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"paragraph\\\">\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\">Aim to keep the mother and baby together as much as possible unless there is a clinical need to separate them. This is to ensure breast milk feeding and bonding. Kangaroo mother care (KMC) can be provided, all of which are important to prevent neonatal illness and death from other conditions.</span></p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"paragraph\\\">\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\"><strong>Target User</strong></span></p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\">Nurses</span></p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\">Doctors</span></p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<div data-custom-style=\\\"paragraph\\\">\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\"><strong>Target area of use</strong></span></p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\">MRC Clinical Services Department</span></p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\">Other health facilities</span></p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"key-areas-of-focus-new-additions-changes\\\">Key areas of focus / New additions / Changes  </h2>\\r\\n<div data-custom-style=\\\"paragraph\\\">\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\">Clinical care of neonates with suspected or confirmed COVID19 disease</span></p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"paragraph\\\">\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\"><strong>Limitations</strong></span></p>\\r\\n</div>\\r\\n<p><span data-custom-style=\\\"normaltextrun\\\">The evidence base for managing COVID-19 infections is growing exponentially as we see more cases. For the most up to date information please see the links in the reference section below as our understanding and response to this disease will change over time.</span></p>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs\\\">Presenting symptoms and signs</h2>\\r\\n<h3 id=\\\"well-asymptomatic-neonate\\\">Well (asymptomatic) neonate:</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Well (asymptomatic) baby and well mother</strong>: Consider the best place for care to be provided and according to national guidelines. This may be in an inpatient setting or at home in self isolation. Encourage the mother to continue expressing milk with another relative feeding the baby, if possible. If this is not possible, encourage the mother to wear a face mask whilst breastfeeding.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Well (asymptomatic) baby and unwell mother:</strong> If mother is too unwell to care for the newborn, he/she should be in the care of a family member. This does not need to be in hospital if the family can ensure self-isolation for 14 days. If this is not possible the neonate may require admission to hospital or a self-isolation facility whilst awaiting testing.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Advise the mother to look out for signs of fast breathing, difficulty in breathing/feeding and fever or hypothermia and to contact health workers if any concerns.</p>\\r\\n<p>Testing for SARS-CoV-2 will be conducted according to national policy.</p>\\r\\n<h3 id=\\\"unwell-symptomatic-neonate\\\">Unwell / symptomatic neonate </h3>\\r\\n<p>The usual causes of neonatal illness and mortality (complications of prematurity, bacterial infection and intra-partum related birth asphyxia) may still be present in neonates born to mothers with suspected or confirmed COVID-19. These should be considered in any unwell baby and all other treatments provided as per standard neonatal protocols.</p>\\r\\n<p>Respiratory symptoms are the main clinical feature in neonates, particularly fast breathing. Other non-specific signs of illness (fever, hypothermia, lethargy, poor feeding, vomiting) may also be present and mimic sepsis.</p>\\r\\n<h2 id=\\\"investigations\\\">Investigations</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Testing for SARS-CoV-2 virus will be conducted according to national guidelines</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>FBC: WBC may be normal or low. If high suspect bacterial infection. Pay attention to neutrophil: lymphocyte ratio. If this is high it is a poor prognostic indicator in adults. Prognosis in neonates is not established.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Blood culture – should be done to identify bacterial sepsis, as the conditions may present in similar way</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Chest X-ray – radiologic signs are non-specific in neonates and CXR should be avoided unless for a specific indication which will change management (e.g. pneumothorax, pleural effusion etc).</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"management\\\">Management </h2>\\r\\n<h3 id=\\\"respiratory-support\\\">Respiratory support</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Prone (lying on abdomen) position is associated with better lung aeration and reduced oxygen requirement. Manage neonates in prone position as much as possible, with their heads turned to the side and arms/legs in flexed position.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Provide oxygen via nasal cannula to maintain SPO2 &gt;90% (&gt;88% for preterm neonates).</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Avoid potentially aerosolising techniques if possible (E.g. suctioning, CPAP).</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>If a neonate requires CPAP for clinical reasons (Silverman score ≥4 or persistently hypoxic despite oxygen – see appendix), ensure that the patient is managed in a separate area and all staff wear PPE whilst dealing with the baby.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"iv-fluids\\\">IV fluids</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Provide routine maintenance fluids according to age and weight, as per standard care.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>If signs of suspected infection treat as per usual protocols, with cautious use of fluid boluses.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"feeding\\\">Feeding</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Provide expressed breast milk as soon as possible as per standard neonatal care.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Follow standard feeding regimes, including use of gastric tubes and cup feeding.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"kangaroo-mother-care\\\">Kangaroo Mother Care</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Continue KMC for preterm / LBW neonates (&lt;2kg) as long as the baby and mother are well.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>With-holding KMC is likely to result in worse outcomes than from COVID19</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ensure adequate spacing (3 m) between beds if more than one mother / baby pair are receiving KMC.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"other-treatments\\\">Other treatments</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Provide all other treatments as needed, according to the likely diagnosis. Consider antibiotics early as the clinical signs of COVID19 may be very similar to bacterial sepsis.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Avoid using nebulised medications.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>There is currently no evidence for the benefits of steroids, diuretics or anti-virals in neonatal COVID19 disease.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Any use of other medications should be part of a clinical trial.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"key-issues-for-nursing-care\\\">Key Issues for Nursing care</h2>\\r\\n<h2 id=\\\"wear-ppe-during-all-clinical-encounters-especially-during-suctioning-bag-valve-mask-ventilation-management-on-cpap.-dispose-of-nappies-in-a-hygienic-manner-and-assume-to-be-contagious-until-more-evidence-is-available\\\">Wear PPE during all clinical encounters, especially during suctioning, bag-valve-mask ventilation, management on CPAP. Dispose of nappies in a hygienic manner and assume to be contagious until more evidence is available</h2>\\r\\n<p>Ensure hands are washed thoroughly with soap and running water for a t least 20 seconds before and after caring for (feeding, examining, changing) each neonate. Teach care giver to do the same.</p>\\r\\n<h2 id=\\\"figure-1.-overview-of-how-to-manage-neonates-born-to-mother-with-suspected-confirmed-covid-19\\\">Figure 1. Overview of how to manage neonates born to mother with suspected / confirmed COVID-19</h2>\\r\\n<p><img src=\\\"data:image/png;base64,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\\\" style=\\\"width:6in;height:8.58056in\\\" /></p>\\r\\n<h2 id=\\\"section\\\"><br />\\r\\n</h2>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<p>UNICEF guidance re. breastfeeding <a href=\\\"https://www.unicef.org.uk/babyfriendly/infant-feeding-during-the-covid-19-outbreak/\\\"><span data-custom-style=\\\"Hyperlink\\\">https://www.unicef.org.uk/babyfriendly/infant-feeding-during-the-covid-19-outbreak/</span></a></p>\\r\\n<p>COVID and KMC: <a href=\\\"https://kangaroo.care/blogs/covid-19/guidelines\\\"><span data-custom-style=\\\"Hyperlink\\\">https://kangaroo.care/blogs/covid-19/guidelines</span></a></p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Elizabeth Ledger</th>\\r\\n<th>Date: 09 April 2020</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Helen Brotherton</td>\\r\\n<td>Date: 09 April 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Baderinwa Abatan</td>\\r\\n<td>Date: 10 April 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td>10 April 2022</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<h2 id=\\\"appendix-i.-silverman-score-care-pathway-for-neonatal-cpap-in-resource-limited-settings\\\">Appendix I. Silverman score &amp; care pathway for neonatal CPAP in resource limited settings</h2>\\r\\n<p><img src=\\\"data:image/png;base64,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\\\" style=\\\"width:5.81177in;height:7.54072in\\\" /></p>\\r\\n<p><strong>Silverman-Anderson score</strong></p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Score</strong></th>\\r\\n<th><strong>Movement of abdomen &amp; chest</strong></th>\\r\\n<th><strong>Subcostal recession</strong></th>\\r\\n<th><strong>Xiphoid retraction</strong></th>\\r\\n<th><strong>Nasal Flare</strong></th>\\r\\n<th><strong>Grunt</strong></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>0</td>\\r\\n<td>Synchronised</td>\\r\\n<td>None</td>\\r\\n<td>None</td>\\r\\n<td>None</td>\\r\\n<td>None</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>1</td>\\r\\n<td>Abdomen lag on inspiration</td>\\r\\n<td>Just visible</td>\\r\\n<td>Just visible</td>\\r\\n<td>Minimal</td>\\r\\n<td>Stethoscope only</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>2</td>\\r\\n<td>See-Saw</td>\\r\\n<td>Marked</td>\\r\\n<td>Marked</td>\\r\\n<td>Marked</td>\\r\\n<td>Naked ear</td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"088\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>COVID-19 Palliative care MeG-CLS-088</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h2 id=\\\"covid-19-palliative-care\\\">COVID-19 Palliative Care </h2>\\r\\n<h2 id=\\\"executive-summary\\\"><em>Executive summary</em></h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<p>Palliative care is defined as the prevention and relief of suffering of patients facing a life-threatening illness (including those who may recover). It enhances quality of life, promotes dignity and comfort and may also positively influence the course of illness.</p>\\r\\n<p>Palliative care is not only started when all active care is stopped but rather it is applicable early in the course of illness in conjunction with other therapies intended to prolong life. It should be integrated with prevention, early diagnosis and treatment of serious or life-limiting health problems at all levels of any health system.</p>\\r\\n<p>There is currently no cure for COVID-19 and patients may well present very unwell with rapid deteriorations. As such, you will never be wrong to consider patients with a palliative approach of managing symptoms and making them as comfortable as possible whether it is for the last hours of life, the last days or, in fact, until they make a recovery.</p>\\r\\n<p>WHO state that “Humanitarian responses to emergencies and crises should include palliative care and symptom control. Responses that do not include palliative care are medically deficient and ethically indefensible.”</p>\\r\\n<h2 id=\\\"target-users\\\">Target users</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doctors</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nurses</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"target-area-of-use\\\">Target area of use </h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ward</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"key-areas-of-focus-new-additions-changes\\\">Key areas of focus / New additions / Changes </h2>\\r\\n<p>This guideline provides an assessment tool and guidance on symptom management. Also addresses fluids and nutrition at the end of life, patient-centred care and paediatric issues.</p>\\r\\n<h2 id=\\\"limitations\\\">Limitations</h2>\\r\\n<p>The Clinical Service Department may have to adapt depending on what stage of the pandemic we are in as well as staffing levels. Some interventions will depend on adequate staffing levels and some drugs may become unavailable at times.</p>\\r\\n<h2 id=\\\"assessment-tool\\\">Assessment Tool</h2>\\r\\n<p>The first stage of palliative care will always be a detailed and thorough assessment. Below are the key areas to address with each patient on a daily basis.</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Symptoms &amp; Side-effects</strong></th>\\r\\n<th><p>Is the patient experiencing:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Breathlessness</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Cough</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Delirium or agitation</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Fever</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nausea</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Pain</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Are any of the medications prescribed likely to cause side effects? If so, pre-empt these and write some PRN medications. For example, morphine will cause nausea and constipation, so prescribe metoclopramide and bisacodyl.</p></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Food &amp; Fluids</strong></td>\\r\\n<td>Is patient eating and drinking? Do they require nutrition or fluids? If they are very unstable then should feeds stop and be under review?</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Bowels &amp; bladder</strong></td>\\r\\n<td>Is the patient passing urine and opening bowels without difficulty? Do they require a catheter for comfort as they are unable to mobilise to the toilet or use a commode?</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Psychological &amp; Social</strong></td>\\r\\n<td>How is the patient’s mood? Is there anything you can do to support them?</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Tube review</strong></td>\\r\\n<td>What tubes (e.g. NG, catheter, cannula) are in situ, are they all functioning well and are they all still necessary?</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Mobility</strong></td>\\r\\n<td>Can the patient mobilise or change position independently. Are there are pressure sores?</td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<h2 id=\\\"section\\\"><br />\\r\\n</h2>\\r\\n<h2 id=\\\"symptom-control\\\">Symptom Control</h2>\\r\\n<h3 id=\\\"breathlessness\\\">Breathlessness</h3>\\r\\n<table>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><p><strong>Non-pharmacological Measures</strong></p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Positioning – sat up</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Relaxation techniques</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Cool cloth for the face</p>\\r\\n</div></li>\\r\\n</ul></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<h3 id=\\\"section-1\\\"></h3>\\r\\n<table>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><p><strong>Pharmacological Measures</strong></p>\\r\\n<p><em>Opioids for relieving breathlessness:</em></p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Morphine Sulphate Tablets 7.5 mg BD (titrate to maximum 30 mg BD noting that tablets are 15 mg each, can be cut into quarters and must always be BD as modified release).</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Oral morphine sulphate solution 2.5-5 mg PRN</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>SC morphine 1-2 mg PRN</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p><em>Distress caused by breathlessness</em></p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>SC Midazolam 2.5-5 mg PRN</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p><em>Severe breathlessness, not expected to survive</em></p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>SC morphine 5-10 mg PRN 2 hourly</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>SC midazolam 5-10 mg PRN 1-4 hourly</p>\\r\\n</div></li>\\r\\n</ul></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<h3 id=\\\"section-2\\\"></h3>\\r\\n<h3 id=\\\"cough\\\">Cough</h3>\\r\\n<table>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><p><strong>Non-pharmacological Measures</strong></p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Oral fluids</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Honey and lemon in warm water</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Suck hard sweets</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Elevate head when sleeping</p>\\r\\n</div></li>\\r\\n</ul></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<table>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><p><strong>Pharmacological Measures</strong></p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Oral morphine sulphate solution 2.5 mg 4 hourly</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>OR</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Codeine 15 mg 4 hourly</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>If severe or not expected to survive</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Continuous subcutaneous infusion injectable morphine sulphate 10 mg over 24 hours with 2.5-5 mg SC PRN 4 hourly for breakthrough coughing</p>\\r\\n</div></li>\\r\\n</ul></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<h3 id=\\\"delirium-agitation\\\">Delirium &amp; Agitation</h3>\\r\\n<table>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><p><strong>Non-pharmacological Measures</strong></p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Provide reassurance and reorientation (for example explaining to someone where they are and what your role is)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ensure adequate lighting</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Avoid moving people from one ward to another where possible</p>\\r\\n</div></li>\\r\\n</ul></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<table>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><p><strong>Pharmacological Measures</strong></p>\\r\\n<p>Delirium ONLY requires drugs if the patient is posing a risk to themselves or very agitated. If they are just mildly confused then medications may just cause them to be more drowsy and at greater risk of falls.</p>\\r\\n<p>First-line is haloperidol</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Haloperidol 1.25 mg oral PRN 2 hourly</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>If necessary increase in 1.25 mg increments up to 10 mg</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Second-line as an adjunct to haloperidol</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Diazepam 2 mg oral TDS (can increase incrementally up to 10 mg oral TDS)</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>OR</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Midazolam 2.5-5 mg SC PRN 1-2 hourly</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Not expected to survive</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>2.5-5 mg SC/IV stat then 1 hourly PRN</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Increase progressively to 10 mg SC/IV 1 hourly PRN</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Maintain with 10-60 mg/24 hours in subcutaneous continuous infusion</p>\\r\\n</div></li>\\r\\n</ul></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<h3 id=\\\"fever\\\">Fever</h3>\\r\\n<table>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><p><strong>Non-pharmacological Measures</strong></p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Encourage loose clothing</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Oral fluids</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Cool cloth for face</p>\\r\\n</div></li>\\r\\n</ul></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<table>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><p><strong>Pharmacological Measures</strong></p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Paracetamol 1 g IV/oral/PR up to QDS (but to maximum of 3 g per day if expected to survive)</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>NSAIDS not currently recommended in COVID-19, but at end of life could consider Ibuprofen 400 mg TDS</p></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<h3 id=\\\"pain\\\">Pain</h3>\\r\\n<table>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><p><strong>Commencing strong opioids</strong></p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Oral morphine sulphate solution (immediate release) and morphine sulphate tablets 15 mg (modified release) are available</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Always prescribe regular laxatives and anti-emetics when starting morphine</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Modified release tablets are BD and a PRN dose of immediate acting morphine should always be prescribed for breakthrough pain</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>PRN doses for breakthrough pain should be 1/10 to 1/6 of the total daily dose of morphine prescribed</p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>e.g. Morphine sulphate tablets 7.5 mg BD would require oral morphine sulphate solution 1.5 mg PRN as a breakthrough dose</p>\\r\\n</div></li>\\r\\n</ul></li>\\r\\n</ul>\\r\\n<p>Conversion table for opioids</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th></th>\\r\\n<th><em>Equivalence to oral morphine 30 mg:</em></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Codeine</td>\\r\\n<td>200 mg</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>SC morphine</td>\\r\\n<td>15 mg</td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<table>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><p><strong>Patient on no analgesia – mild pain</strong></p>\\r\\n<p><em>Step 1</em></p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Regular paracetamol 1g up to QDS (↓ dose in elderly/↓ eGFR &amp; weight &lt; 50 kg and max 3 g/day if expected to survive)</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p><em>Step 2</em></p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Regular paracetamol and add codeine 30-60 mg oral QDS</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p><em>Step 3</em></p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Stop codeine, continue paracetamol and commence strong opioid</p>\\r\\n</div></li>\\r\\n</ul></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<h3 id=\\\"section-3\\\"></h3>\\r\\n<table>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><p><strong>Suggested starting doses of strong opioids</strong></p>\\r\\n<p>Opioid naïve/frail/elderly</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Oral morphine sulphate solution or SC morphine 2.5-5 mg 4 hourly</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Previously using codeine regularly</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Morphine sulphate tablets 15-30 mg BD (7.5-15 mg BD if frail/elderly)</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Morphine is metabolized in the liver and excreted renally so patients with liver/renal impairment need lower doses which are cautiously titrated up</p></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<table>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><p><strong>Titrating opioid doses</strong></p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Calculate total daily dose of long acting and immediate release morphine prescribed</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>If adequate pain control, take the total daily dose and divide by 2 to get the BD dose of modified release morphine</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>e.g. A patient prescribed MST 15 mg BD also had 2 doses of 2.5 mg morphine SC during the day. Their total daily requirement was 30 mg oral plus 5 mg SC (which is equivalent to 10 mg oral) so total oral dose was 40 mg. MST tablet sizes are 15 mg and can be quartered so the most appropriate dose for this patient would be 22.5 mg BD</p>\\r\\n</div></li>\\r\\n</ul></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<h3 id=\\\"nausea\\\"><br />\\r\\nNausea</h3>\\r\\n<table>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><p><strong>Non-pharmacological Measures</strong></p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Sip clear fluids</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Smaller more frequent meals with bland food</p>\\r\\n</div></li>\\r\\n</ul></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<table>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><p><strong>Pharmacological Measures</strong></p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Metoclopramide 10 mg oral TDS</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Promethazine 25 mg oral/IV/deep IM TDS</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Haloperidol 1.25 mg oral BD (increased to maximum 10 mg/day in divided doses orally or 10 mg over 24 hours SC continuous infusion with syringe driver)</p>\\r\\n</div></li>\\r\\n</ul></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<p>Also see Appendix 1 for a one page overview of pharmacological management.</p>\\r\\n<h3 id=\\\"section-4\\\"></h3>\\r\\n<h3 id=\\\"fluids-and-nutrition-at-the-end-of-life\\\">Fluids and Nutrition at the End of Life</h3>\\r\\n<p>There is no clear evidence that fluids and nutrition improves someone’s quality of life or prolongs it when they are in their last days. Often appetite is much decreased. Comfort feeds or sips of oral fluids can be offered to those who are awake and able to swallow. Patients unable to swallow may benefit from regular mouthcare so their mouth does not dry out. Other patients may require SC fluids and NG tube feeds if that is decided to be the best course of action for the patient.</p>\\r\\n<h3 id=\\\"patient-centred-care\\\">Patient-Centred Care</h3>\\r\\n<p>As someone nears the end of life, there are many things you can do to promote their dignity. Care must be centred around the patient with their wishes respected. Physical needs must be cared for gently and with respect and there may be interventions which are no longer required. Observations can be stopped and any regular medications not providing symptomatic relief should also be stopped.</p>\\r\\n<h3 id=\\\"paediatric-considerations\\\">Paediatric Considerations</h3>\\r\\n<p>Paediatric palliative care is a specialist area but essentially, the key principles of assessing the patient and reacting to their symptoms and concerns remains at the core. There will be paediatric consultants available to review children who are very unwell. For paediatric drug doses, please consult the Association for Paediatric Palliative Medicine Master Formulary 2020 available online at <a href=\\\"https://www.appm.org.uk/guidelines-resources/appm-master-formulary/\\\"><span data-custom-style=\\\"Hyperlink\\\">https://www.appm.org.uk/guidelines-resources/appm-master-formulary/</span></a></p>\\r\\n<h2 id=\\\"key-issues-for-nursing-care\\\">Key issues for Nursing care</h2>\\r\\n<p>Patients nearing the end of life may be prescribed SC continuous infusions of medications or fluids. See below diagrams for a refresher on how this access can be secured.</p>\\r\\n<table>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><blockquote>\\r\\n<p><span data-custom-style=\\\"Body text (2)\\\">Securin</span>g <span data-custom-style=\\\"Body text (2)\\\">subcutaneous access;</span></p>\\r\\n</blockquote>\\r\\n<ol type=\\\"1\\\">\\r\\n<li><p>Obtain necessary supplies.</p></li>\\r\\n<li><p>Ensure appropriate hygiene and PPE.</p></li>\\r\\n<li><p>Explain the procedure to the patient.</p></li>\\r\\n<li><p>Appropriate sites of placement: infraclavicular. lower abdominal wall, anterior thighs or outer aspect of the upper arm.</p></li>\\r\\n<li><p>Site should be: easily accessible, free of lesions, away from large vessels, joints and bones, away from oedematous tissue that may alter medication/ fluid absorption.</p></li>\\r\\n<li><p>Clean skin with an alcohol swab for 15 seconds and allow skin to dry.</p></li>\\r\\n<li><p>Remove protective shield from needle.</p></li>\\r\\n<li><p>Using thumb and index finger to create a roll of tissue of approximately 2.5 cm. bunch the skin around selected insertion</p></li>\\r\\n</ol>\\r\\n<blockquote>\\r\\n<p>site.</p>\\r\\n</blockquote>\\r\\n<ol start=\\\"9\\\" type=\\\"1\\\">\\r\\n<li><p><img src=\\\"data:image/jpeg;base64,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\\\" style=\\\"width:1.86458in;height:1.44792in\\\" />Insert the entire butterfly needle (23G) or yellow Jelco (24G). bevel side up. under the skin at an angle of 45 degrees.</p></li>\\r\\n<li><p>Jelco: remove the needle and attach a short line; secure your cannula in place with Micropore.</p></li>\\r\\n<li><p>Butterfly needle: secure needle in place with Micropore.</p></li>\\r\\n<li><p>Attach a 3ml syringe and flush the tubing with normal saline.</p></li>\\r\\n<li><p>Cover the insertion site, hub and wings with a transparent moisture- responsive dressing.</p></li>\\r\\n</ol></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<p><img src=\\\"data:image/png;base64,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\\\" style=\\\"width:2.31221in;height:2.15598in\\\" /></p>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<p>Integrating palliative care and symptom relief into responses to humanitarian emergencies and crises: a WHO guide. https://apps.who.int/iris/handle/10665/274565</p>\\r\\n<p><a href=\\\"https://apmonline.org/news-events/apm-covid-19-resources-for-healthcare-professionals/\\\"><span data-custom-style=\\\"Hyperlink\\\">https://apmonline.org/news-events/apm-covid-19-resources-for-healthcare-professionals/</span></a></p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Daisy Taylor</th>\\r\\n<th>Date: 29 April 2020</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Karen Forrest</td>\\r\\n<td>Date: 08 May 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td>08 May 2022</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<p><strong>Appendix 1 – One page guide to symptom control in adult patients</strong></p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><p><strong>Breathlessness</strong></p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<blockquote>\\r\\n<p>Opioids may reduce the perception of breathlessness</p>\\r\\n</blockquote>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<blockquote>\\r\\n<p>MST 5 mg BD (titrate up to a maximum 15 mg BD)</p>\\r\\n</blockquote>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<blockquote>\\r\\n<p>Oral morphine solution 2.5-5 mg oral PRN (1-2 mg SC if unable to swallow)</p>\\r\\n</blockquote>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<blockquote>\\r\\n<p>Midazolam 2.5-5 mg SC PRN for associated agitation or distress</p>\\r\\n</blockquote>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<blockquote>\\r\\n<p>In the last days of life</p>\\r\\n</blockquote>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<blockquote>\\r\\n<p>Morphine 2.5-5 mg SC and/or midazolam 2.5 mg SC PRN</p>\\r\\n</blockquote>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<blockquote>\\r\\n<p>Morphine 10 mg and/or Midazolam 10 mg over 24 hours SC continuous infusion with syringe driver (titrate up to morphine 30 mg/midazolam 60 mg)</p>\\r\\n</blockquote>\\r\\n</div></li>\\r\\n</ul></li>\\r\\n</ul></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><p><strong>Severe Breathlessness</strong></p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<blockquote>\\r\\n<p>Morphine 5-10 mg SC PRN 2 hourly (reduce dose if low eGFR)</p>\\r\\n</blockquote>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<blockquote>\\r\\n<p>Midazolam 5-10 mg SC PRN 1-4 hourly</p>\\r\\n</blockquote>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<blockquote>\\r\\n<p>Morphine 10-20 mg and/or Midazolam 10-20 mg over 24 hours SC continuous infusion with syringe driver (titrate up every 8 hours to incorporate the PRN doses being required)</p>\\r\\n</blockquote>\\r\\n</div></li>\\r\\n</ul></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><p><strong>Cough</strong></p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<blockquote>\\r\\n<p>Oral morphine sulphate solution 2.5 mg oral 4 hourly</p>\\r\\n</blockquote>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<blockquote>\\r\\n<p>Severe or end of life</p>\\r\\n</blockquote>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<blockquote>\\r\\n<p>Morphine sulphate 10 mg over 24 hours SC continuous infusion with syringe driver AND 2.5-5 mg SC 1-2 hourly PRN</p>\\r\\n</blockquote>\\r\\n</div></li>\\r\\n</ul></li>\\r\\n</ul></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><p><strong>Delirium</strong></p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<blockquote>\\r\\n<p>First Line</p>\\r\\n</blockquote>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<blockquote>\\r\\n<p>Haloperidol 1.25 mg oral STAT then 2 hourly PRN (can use 2.5 mg in severe distress)</p>\\r\\n</blockquote>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<blockquote>\\r\\n<p>Midazolam 2.5-5 mg SC PRN 1-2 hourly</p>\\r\\n</blockquote>\\r\\n</div></li>\\r\\n</ul></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<blockquote>\\r\\n<p>End of Life</p>\\r\\n</blockquote>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<blockquote>\\r\\n<p>Midazolam 10-60 mg over 24 hours SC continuous infusion with syringe driver AND 2.5-10 mg SC PRN 1 hourly</p>\\r\\n</blockquote>\\r\\n</div></li>\\r\\n</ul></li>\\r\\n</ul></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><p><strong>Fever</strong></p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Paracetamol 1 g up to QDS oral/IV/PR (Max 3 g in 24 hours)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>NSAIDS not currently recommended in COVID-19, but at end of life could consider Ibuprofen 400 mg TDS</p>\\r\\n</div></li>\\r\\n</ul></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><p><strong>Nausea</strong></p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Metoclopramide 10 mg oral TDS</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Promethazine 25 mg oral/IV/deep IM TDS</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<blockquote>\\r\\n<p>Haloperidol 1.25 mg oral BD (increased to maximum 10 mg/day in divided doses orally or 10 mg over 24 hours SC continuous infusion with syringe driver)</p>\\r\\n</blockquote></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"059\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>Croup MeG-CLS-059</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"croup-acute-laryngotracheobronchitis\\\">Croup (Acute Laryngotracheobronchitis)</h1>\\r\\n<h2 id=\\\"executive-summary\\\"><em>Executive summary</em></h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<h2 id=\\\"croup-is-a-common-primarily-childhood-viral-respiratory-tract-illness-causing-symptoms-which-may-involve-a-harsh-barking-cough-and-inspiratory-stridor.-the-vast-majority-of-children-with-croup-recover-without-consequences-or-sequelae-however-it-can-be-life-threatening-in-young-infants.-croup-most-often-affects-children-aged-6-months-to-3-years-with-a-peak-incidence-during-the-second-year-of-life.-however-children-as-young-as-3-months-of-age-or-adolescents-and-very-rarely-adults-can-be-affected.-the-most-common-viral-causes-are-parainfluenza-viruses.\\\">Croup is a common, primarily childhood, viral respiratory tract illness causing symptoms which may involve a harsh barking cough and (inspiratory) stridor. The vast majority of children with croup recover without consequences or sequelae; however, it can be life-threatening in young infants. Croup most often affects children aged 6 months to 3 years, with a peak incidence during the second year of life. However, children as young as 3 months of age, or adolescents and, very rarely, adults can be affected. The most common viral causes are parainfluenza viruses.</h2>\\r\\n<h2 id=\\\"target-users\\\">Target users</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doctors</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nurses</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"target-area-of-use\\\">Target area of use </h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Outpatient department</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ward</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"key-areas-of-focus-new-additions-changes\\\">Key areas of focus / New additions / Changes </h2>\\r\\n<p>This guideline addresses the management of croup in children.</p>\\r\\n<h2 id=\\\"limitations\\\">Limitations</h2>\\r\\n<p>None</p>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs\\\">Presenting symptoms and signs</h2>\\r\\n<p>Croup usually begins with nonspecific respiratory symptoms (ie, rhinorrhoea, sore throat, cough). Fever is generally low grade and is present in 50% of cases.</p>\\r\\n<p>Within 1 to 2 days, the characteristic signs of hoarseness, barking cough, and inspiratory stridor develop; often suddenly.</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Stridor is often worse on exertion.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Variable degree of respiratory distress.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Symptoms generally worse at night.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Symptoms can last for 2 weeks but typically resolve within 3-7 days.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"westley-croup-score\\\">Westley croup score</h2>\\r\\n<p>Croup scores help clinicians in assessing the patient’s degree of respiratory compromise. The Westley score evaluates the severity of croup by assessing five factors: level of <strong>consciousness</strong>, <strong>cyanosis</strong>, <strong>stridor</strong>, <strong>air entry</strong>, and <strong>retractions</strong>. The point values given for each factor are listed below, and the final score sum has a range of 0 to 17.</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Westley croup score</strong></th>\\r\\n<th></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Stridor</td>\\r\\n<td>None: 0</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td></td>\\r\\n<td>With agitation: +1</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td></td>\\r\\n<td>At rest: +2</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Chest wall retractions</td>\\r\\n<td>None: 0</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td></td>\\r\\n<td>Mild: +1</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td></td>\\r\\n<td>Moderate: +2</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td></td>\\r\\n<td>Severe: +3</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Cyanosis</td>\\r\\n<td>None: 0</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td></td>\\r\\n<td>With agitation: +4</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td></td>\\r\\n<td>At rest: +5</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Level of consciousness</td>\\r\\n<td>Normal: 0</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td></td>\\r\\n<td>Disoriented: +5</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Air entry</td>\\r\\n<td>Normal: 0</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td></td>\\r\\n<td>Decrease: +1</td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<p><strong>Score &lt;2 – mild disease</strong> (occasional barking cough, hoarseness, no stridor at rest, mild or absent suprasternal or subcostal retractions)</p>\\r\\n<p><strong>Score 3-5: moderate disease</strong> (findings include frequent cough, audible stridor at rest, and visible retractions, but little distress or agitation)</p>\\r\\n<p><strong>Score 6-11: severe disease</strong> (patients present with prominent inspiratory, and occasionally expiratory stridor, frequent cough, marked chest wall retractions, decreased air entry on auscultation, significant distress and agitation.</p>\\r\\n<p><strong>A Westley score of ≥ 12 indicates impending respiratory failure</strong>; at this point, a barking cough and inspiratory stridor may no longer be prominent – it presents with lethargy, cyanosis and decreasing retractions.</p>\\r\\n<h2 id=\\\"management\\\">Management </h2>\\r\\n<p>Taking a child with stridor outdoor into the cool air for 10 minutes can give him/her some relieve. Parent can be advised to do this. In addition, advise caregivers to have the child breathe warm moist air. This can be done by:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>running hot water in your shower with the bathroom door closed. After the bathroom becomes steamy, the parent can sit with the child in the room for about 10 minutes.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Have the child breathe through a warm, wet washcloth lightly placed over the mouth and nose.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Treatment depends on the severity.</p>\\r\\n<p><strong>Mild disease:</strong></p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Give paracetamol (10-15 mg/kg TDS/QDS) or ibuprofen (5-10 mg/kg TDS) for fever</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Encourage adequate fluid intake</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Giving a single dose of oral dexamethasone 0.6mg/kg or prednisolone 1-2mg/kg may be of benefit.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Send patient home</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Advised to return if symptoms worsen</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p><strong>In moderate to severe croup</strong></p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Admit to the ward</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Start oxygen therapy</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Give dexamethasone 0.6 mg/kg or prednisolone 1-2 mg/kg by mouth. Repeat dose after 12 hours if necessary</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nebulised adrenaline (epinephrine) solution 1 in 1,000 (1 mg/mL) should be given with close clinical monitoring in a dose of 400 micrograms/kg (maximum 5 mg) repeated every 30 minutes if necessary.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Monitor closely and send home when respiratory distress and stridor resolves.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p><img src=\\\"data:image/jpeg;base64,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\\\" style=\\\"width:5.98958in;height:5.64583in\\\" /></p>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<p>Colledge, Nicki R., Brian R. Walker, Stuart Ralston, and Stanley Davidson. 2010. Davidson&#39;s principles and practice of medicine. Edinburgh: Churchill Livingstone/Elsevier.</p>\\r\\n<p>Kliegman, Robert., et al. Nelson Textbook of Pediatrics. Edition 20. Phialdelphia, PA: Elsevier, 2016.</p>\\r\\n<p>Management of acute respiratory diseases in the pediatric population. The role of oral corticosteroids. Italian Journal of Pediatrics 43(1). December 2017. Retrieved from https://www.researchgate.net/figure/Westley-croup-score_tbl7_315597265 on 25th February 2017.</p>\\r\\n<p>Waseem M (2018). Otitis Media. Medscape. Retrieved from https://emedicine.medscape.com/article/994656-overview on 26th February, 2019</p>\\r\\n<p>Standard Treatment Guidelines, 6th Edition, 2010. ISBN 978-9988-1-2538-7</p>\\r\\n<p>Zoorob R et al (2011). Croup: An Overview. Retrieved from https://www.aafp.org/afp/2011/0501/p1067.html on 25th February, 2019.</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Fatoumata Sawaneh</th>\\r\\n<th>Date: 27 February 2019</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Baderinwa Abatan</td>\\r\\n<td>Date: 3 May 2019</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td>31 May 2021</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"055\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>Deep venous thombosis and pulmonary embolism MeG-CLS-055</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"deep-vein-thrombosis-and-pulmonary-embolism\\\">Deep Vein Thrombosis and Pulmonary Embolism</h1>\\r\\n<h2 id=\\\"executive-summary\\\">Executive summary</h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<p>Deep venous thrombosis (DVT) and pulmonary embolism (PE) are both manifestations of venous thromboembolism. DVT can be defined as the formation of a blood clot (thrombus) within a deep vein, with the most common site of affectation being the lower limbs. PE, on the other hand, is a potentially life-threatening complication of DVT in which the thrombus formed becomes dislodged and migrates to occlude an artery within the lung.</p>\\r\\n<h2 id=\\\"target-users\\\">Target users</h2>\\r\\n<ul>\\r\\n<li><p>Nurses</p></li>\\r\\n<li><p>Doctors</p></li>\\r\\n</ul>\\r\\n<p><strong>Target area of use</strong></p>\\r\\n<ul>\\r\\n<li><p>Gate Clinic</p></li>\\r\\n<li><p>Outpatient Department</p></li>\\r\\n<li><p>Ward</p></li>\\r\\n</ul>\\r\\n<h2 id=\\\"key-areas-of-focus-new-additions-changes\\\">Key areas of focus / New additions / Changes </h2>\\r\\n<p>This guideline provides information on the diagnosis and treatment of deep vein thrombosis and pulmonary embolism. A large proportion of patients with pulmonary embolism are asymptomatic. History and examination should seek for risk factures and clinical features of these conditions. The Wells scoring systems should be used to assess clinical probability of DVT and PE respectively. Patients should be initially managed on the ward with heparin, warfarin (non-pregnant patients only) and supportive care. Anticoagulation status should be reviewed using coagulation studies. Warfarin if used should be given for at least 3 months.</p>\\r\\n<h2 id=\\\"limitations\\\">Limitations</h2>\\r\\n<p>Facilities for monitoring and treating venous thromboembolism are not available at Keneba and Basse. Patients presenting there with these conditions should be stabilized and referred.</p>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs\\\">Presenting symptoms and signs</h2>\\r\\n<p>Risk factors for venous thromboembolism should be ruled out.</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Malignancy</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Prolonged bed rest</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Smoking</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Stroke</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Obesity</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Pregnancy</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Recent long-distance travel</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Symptoms and signs of DVT usually occur distal to the site of venous occlusion and include:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Pain in affected limb: occurs in about 50% of cases</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Limb swelling: most specific symptom. DVT should be ruled out in all patients presenting with unilateral pedal swelling</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>In as many as 40% of patients, PE is silent without obvious symptoms. Those who are symptomatic may present with sudden onset of:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Shortness of breath</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Chest pain worse on inspiration</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Haemoptysis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Cough</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Syncope</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Death</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"examination-findings\\\">Examination findings</h2>\\r\\n<p>In suspected DVT, a general examination should be carried out, followed by examination of the affected limb. Presence of any of the following should raise suspicion of the presence of a DVT.</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Unilateral pitting oedema</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Homans sign: calf pain on foot dorsiflexion with the knee extended</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Pratt sign: Tenderness over calf muscle on palpation</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>PE may present with:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Deranged vitals:</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Low saturation of oxygen</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Tachypnoea</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Tachycardia</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hypotension</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Chest examination</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Maybe normal in the majority of patients.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Occasionally, a pleural friction rub may be heard over the affected area</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Cardiovascular examination (may be normal apart from tachycardia):</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Parasternal heave</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Loud pulmonary component of the second heart sound</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Raised jugular venous pressure</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"wells-scores\\\">Wells scores</h3>\\r\\n<p>If the diagnosis of DVT is suspected following history and physical examination, the two-level DVT Wells score should be used to estimate the clinical probability of DVT.</p>\\r\\n<p><em>Two-Level DVT Wells Score</em></p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Clinical Feature</strong></th>\\r\\n<th><strong>Points</strong></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Active cancer (treatment ongoing, within 6 months or palliative)</td>\\r\\n<td>1</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Paralysis, paresis or recent plaster immobilization of the lower extremities</td>\\r\\n<td>1</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Recently bedridden for 3 days or more or major surgery within 12 weeks requiring general or regional anaesthesia</td>\\r\\n<td>1</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Localized tenderness along the distribution of the deep venous system</td>\\r\\n<td>1</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Entire leg swollen</td>\\r\\n<td>1</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Calf swelling at least 3 cm larger than asymptomatic side</td>\\r\\n<td>1</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Pitting oedema confined to the symptomatic leg</td>\\r\\n<td>1</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Collateral superficial veins (non-varicose)</td>\\r\\n<td>1</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Previously documented DVT</td>\\r\\n<td>1</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Alternative diagnosis at least as likely as a DVT</td>\\r\\n<td>-2</td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<p><em>Interpretation:</em></p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th>DVT Likely</th>\\r\\n<th>2 Points Or More</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>DVT Unlikely</td>\\r\\n<td>1 Point Or Less</td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<p>If the diagnosis of PE is suspected following history and physical examination, the two-level PE Wells score should be used to estimate the clinical probability of PE.</p>\\r\\n<p><em>Two-Level PE Well’s Score</em></p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Clinical Feature</strong></th>\\r\\n<th><strong>Points</strong></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Clinical signs and symptoms of DVT (minimum of leg swelling and pain with palpation of the deep veins)</td>\\r\\n<td>3</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>An alternative diagnosis is less likely than PE</td>\\r\\n<td>3</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Heart rate &gt; 100 beats per minute</td>\\r\\n<td>1.5</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Immobilisation for more than 3 days or surgery in the previous 4 weeks</td>\\r\\n<td>1.5</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Previous DVT/PE</td>\\r\\n<td>1.5</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Haemoptysis</td>\\r\\n<td>1</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Malignancy (on treatment, treated in the last 6 months, or palliative)</td>\\r\\n<td>1</td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<p><em>Interpretation:</em></p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th>PE Likely</th>\\r\\n<th>More Than 4 Points</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>PE Unlikely</td>\\r\\n<td>4 Points Or Less</td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<h2 id=\\\"differential-diagnoses\\\">Differential diagnoses</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Cellulitis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Lymphoedema</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Soft tissue injury</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Dependent oedema</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Congestive cardiac failure</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Renal failure</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nephritic syndrome</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Swelling in a paralysed limb</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"investigations\\\">Investigations</h2>\\r\\n<p>All patients with suspected DVT should be offered:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doppler ultrasonography: to confirm the presence of a clot</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Coagulation studies: INR, PT, APTT to investigate for hypercoagulability if indicated.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>In suspected PE, the following should be done:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>CXR: findings might include: Enlarged pulmonary artery (Fleischner sign), peripheral wedge of airspace opacity which implies lung infarction (Hampton’s Hump), regional oligaemia (Westermark sign) or <a href=\\\"https://radiopaedia.org/articles/pleural-effusion\\\">pleural effusion</a> </p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>ECG: May show sinus tachycardia (most common), right heart strain pattern: seen as a right bundle branch block pattern or right axis deviation or S<sub>I</sub>Q<sub>III</sub>T<sub>III</sub> pattern: this refers to a deep S wave in lead I, Q wave and T wave inversion in lead III</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Echocardiography: Right ventricular wall hypokinesis, right ventricular dilatation, and pulmonary artery hypertension may be seen</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>INR: Done to get baseline value before the commencement of warfarin therapy</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"management\\\">Management </h2>\\r\\n<h3 id=\\\"management-in-gate-clinic\\\">Management in Gate Clinic</h3>\\r\\n<p>All patients with features of a DVT or PE should be referred immediately to the ward for urgent review by a doctor.</p>\\r\\n<h3 id=\\\"management-on-the-ward\\\">Management on the Ward</h3>\\r\\n<p>In suspected acute PE, commence intravenous fluid and oxygen (if oxygen saturation &lt; 88%).</p>\\r\\n<p>Heparin and warfarin should be started as soon as possible for prophylaxis in high-risk patients or treatment after confirmed DVT or PE. Heparin should be continued for at least 5 days or until 2 consecutive target INR results are obtained. In pregnancy, only heparin is used</p>\\r\\n<p>Unfractionated heparin can be given subcutaneously as 250 units/kg stat then every 12 hours. It is the preferred option in patients with kidney disease. Enoxaparin can be given subcutaneously as 1.5 mg/kg/dose OD.</p>\\r\\n<p>Monitor APTT (ideally, every 6 hours) and adjust unfractionated heparin dose accordingly.</p>\\r\\n<p>Warfarin can be initiated with a once-daily dose between 2 mg and 5 mg. The maintenance dose of warfarin is usually between 2 mg and 10 mg once daily.</p>\\r\\n<p>Daily INR monitoring should start from day 3 of initiation of therapy until INR is at target for more than 2 consecutive readings.</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Condition</strong></th>\\r\\n<th><strong>Target INR</strong></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>DVT prophylaxis</td>\\r\\n<td>2 – 2.5</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>DVT or PE treatment</td>\\r\\n<td>2 – 3</td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<p>Thereafter, the frequency of INR monitoring is twice weekly but can be reduced gradually to once-weekly, once every 2 weeks, and then once monthly as long as the patient’s INR remains within the therapeutic range. Warfarin doses should be adjusted according to the INR results. More frequent monitoring is needed after any dose adjustment until stable readings are obtained.</p>\\r\\n<p>Warfarin should be continued for at least 3 months. Warfarin therapy should be extended beyond 3 months for patients with unprovoked proximal DVT or PE if their risk of recurrence is high and there is no additional risk of major bleeding.</p>\\r\\n<p>Paracetamol can be prescribed for pain in DVT</p>\\r\\n<p><strong>Key Issues for Nursing care</strong></p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Monitor vital signs every hour initially in acute PE. This frequency may be reduced to every 4 hours as patient stabilizes.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Monitor vital signs once every shift in DVT.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nurse with affected leg elevated</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Avoid IM injections on the affected limb</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Strict fluid charts</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ensure enoxaparin is given at the same time every day.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Be wary of heparin concentrations when calculating doses</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Call the doctor if:</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Temperature &gt; 38.5ºC</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Pulse &lt; 50 or &gt; 120 bpm</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Systolic blood pressure &lt; 90 or &gt; 160 mmHg</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Diastolic blood pressure &lt; 60 or &gt; 90 mmHg</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Oxygen saturation &lt; 90%</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<p>NICE Guidance for Venous Thromboembolic Diseases <a href=\\\"https://www.nice.org.uk/guidance/cg144/chapter/recommendations#diagnosis-2\\\">https://www.nice.org.uk/guidance/cg144/chapter/recommendations#diagnosis-2</a></p>\\r\\n<p>Aggarwal V, Nicolais CD, Lee A; Bashir R. et al. Acute management of pulmonary embolism. <a href=\\\"https://www.acc.org/latest-in-cardiology/articles/2017/10/23/12/12/acute-management-of-pulmonary-embolism\\\">https://www.acc.org/latest-in-cardiology/articles/2017/10/23/12/12/acute-management-of-pulmonary-embolism</a></p>\\r\\n<p>Medscape. Pulmonary Embolism <a href=\\\"https://emedicine.medscape.com/article/300901-overview\\\">https://emedicine.medscape.com/article/300901-overview</a></p>\\r\\n<p>Diagnosis and Management of Acute Deep Vein Thrombosis: A Joint Consensus Document From the European Society of Cardiology Working Groups of Aorta and Peripheral Circulation and Pulmonary Circulation and Right Ventricular Function. Eur Heart J 2017; Feb 17:[Epub ahead of print].</p>\\r\\n<p>Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(suppl 2).</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Azeezat Sallahdeen</th>\\r\\n<th>Date: 24 November 2018</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Fatai Akemokwe</td>\\r\\n<td>Date: 30 January 2019</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td>31 January 2021</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>1.1</td>\\r\\n<td>Executive summary added</td>\\r\\n<td>31 January 2021</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"075\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>Depression MeG-CLS-075</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"depression\\\">Depression</h1>\\r\\n<h2 id=\\\"executive-summary\\\"><em>Executive summary</em></h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<h2 id=\\\"depression-is-a-common-mental-disorder-which-involves-low-mood-and-loss-of-pleasure-in-most-activities.-these-are-more-severe-and-long-lasting-than-normal-mood-fluctuations-or-emotional-responses-to-challenges-in-daily-life.-depression-varies-in-severity-and-duration-and-in-severe-forms-can-lead-to-suicide.-it-is-a-leading-cause-of-disability-worldwide.-effective-pharmacological-and-non-pharmacological-treatments-are-available-for-depression-so-identifying-and-managing-the-condition-is-important.\\\">Depression is a common mental disorder which involves low mood and loss of pleasure in most activities. These are more severe and long-lasting than normal mood fluctuations or emotional responses to challenges in daily life. Depression varies in severity and duration and in severe forms can lead to suicide. It is a leading cause of disability worldwide. Effective pharmacological and non-pharmacological treatments are available for depression so identifying and managing the condition is important. </h2>\\r\\n<h2 id=\\\"target-user\\\">Target User</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nurses</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doctors</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"target-area-of-use\\\">Target area of use </h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Gate clinic</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Outpatient department</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ward</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"key-areas-of-focus-new-additions-changes\\\">Key areas of focus / New additions / Changes </h2>\\r\\n<p>This guideline addresses the diagnosis, assessment and locally available management options for depression in adults.</p>\\r\\n<h2 id=\\\"limitations\\\">Limitations </h2>\\r\\n<p>We only have amitriptyline for use by the general public. Staff may be prescribed citalopram. Other patients wanting to use an SSRI (selective serotonin reuptake inhibitor) will need to purchase this at a local pharmacy.</p>\\r\\n<p>Access to psychological support is also limited especially for patients who do not speak English.</p>\\r\\n<h2 id=\\\"section\\\"><br />\\r\\n</h2>\\r\\n<h2 id=\\\"background\\\">Background</h2>\\r\\n<p>WHO estimates that around 120,000 people in the Gambia have a mental disorder requiring treatment. Of patients with severe mental disorders, 90% do not have access to treatment.</p>\\r\\n<p>Depression involves low mood and/or loss of pleasure in most activities. The severity of depression is determined by the number and severity of symptoms and the degree of functional impairment. Biological, psychological and social factors have a significant impact on the course of depression and the response to treatment. So ask about past history and family history of depression when undertaking a diagnostic assessment.</p>\\r\\n<p>Depression frequently takes a remitting and relapsing course, with symptoms persisting between more severe episodes. The key goal of interventions should be complete relief of symptoms (remission), which is associated with better functioning and a lower likelihood of relapse.</p>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs\\\">Presenting symptoms and signs</h2>\\r\\n<p>Be alert to possible depression in all patients, particularly those with a past history of depression or a chronic physical health problem with associated functional impairment.</p>\\r\\n<p>Ask anyone who may have depression two specific questions:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>During the last month, have you often been bothered by feeling down, depressed or hopeless?</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>During the last month, have you often been bothered by having little interest or pleasure in doing things?</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>(These symptoms should be present for at least 2 weeks and each symptom should be present for most of every day).</p>\\r\\n<p><strong>If any of the above are present, ask about associated symptoms:</strong></p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Depressed mood most of the day</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Reduced interest or pleasure in all or almost all activities</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Significant weight loss or gain (e.g. more than 5% of body weight) which is not due to dieting</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Insomnia or hypersomnia</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Psychomotor agitation or retardation which is observable by others</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Fatigue or loss of energy</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Feelings of worthlessness or guilt</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Reduced ability to concentrate or make decisions</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Recurrent thoughts of death, with or without a plan, or a suicide attempt or plan</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p><strong>Then ask about duration and associated disability, past and family history of mood disorders, and availability of social support.</strong></p>\\r\\n<h2 id=\\\"examination-findings\\\">Examination findings</h2>\\r\\n<p>Look for evidence of:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Self-neglect</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Self-harm</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Psychomotor retardation (slowed speech or movements or decreased speech output)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Agitation (restlessness, handwringing, inability to sit still, pulling on clothing or skin)</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>You should be able to classify the severity of depression (based on the criteria in DSM-IV):</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Diagnosis</strong></th>\\r\\n<th><strong>Criteria</strong></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Subthreshold depressive symptoms</strong></td>\\r\\n<td>Fewer than 5 symptoms of depression</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Mild depression</strong></td>\\r\\n<td>Few, if any, symptoms in excess of the 5 required to make the diagnosis, and symptoms result in only minor functional impairment</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Moderate depression</strong></td>\\r\\n<td>Symptoms or functional impairment are between &#39;mild&#39; and &#39;severe&#39;</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Severe depression</strong></td>\\r\\n<td>Most symptoms, and the symptoms markedly interfere with functioning. Can occur with or without psychotic symptoms</td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<h2 id=\\\"management\\\">Management</h2>\\r\\n<div data-custom-style=\\\"Normal (Web)\\\">\\r\\n<p>The first step involves risk stratification for each patient:</p>\\r\\n</div>\\r\\n<p>Factors that favour general advice and active monitoring:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Four or fewer of the above symptoms with little associated disability</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Symptoms intermittent, or less than 2 weeks&#39; duration</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Recent onset with identified stressor</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>No past or family history of depression</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Social support available</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Lack of suicidal thoughts</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Factors that favour more active treatment:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Five or more symptoms with associated disability</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Persistent, long-standing or recurrent symptoms</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Personal or family history of depression</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>History suggestive of bipolar disorder</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Low social support</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Suicidal thoughts</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Factors that favour urgent referral to EFSTH for psychiatry review and admission to Tanka Tanka hospital:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Actively suicidal ideas or plans</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Psychotic symptoms</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Severe agitation accompanying severe symptoms</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Severe self-neglect</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"management-of-less-severe-depression\\\">Management of less severe depression </h3>\\r\\n<p>(including subthreshold symptoms, mild depression, and the lower half of moderate depression).</p>\\r\\n<p>Encourage physical activity (45 minutes aerobic exercise of moderate intensity twice a week).</p>\\r\\n<p>Offer online cognitive behavioural therapy courses (where patients have sufficient English language and internet access to support this. See <strong>Resources</strong> section below).</p>\\r\\n<p>If patients can afford this and speak enough English: offer referral for clinical psychology (Silvia Lorenz is a clinical psychologist based near Turntable. She can be contacted by email on <a href=\\\"mailto:silvialorenzi.psy@gmail.com\\\"><span data-custom-style=\\\"Hyperlink\\\">silvialorenzi.psy@gmail.com</span></a>).</p>\\r\\n<p>Offer trial of antidepressant medication if there is no improvement with exercise and psychological interventions:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>1<sup>st</sup> line: Amitriptyline (25 mg at night) OR for staff and their immediate relatives Citalopram (20 mg OD)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>2<sup>nd</sup> line: SSRIs are available at local pharmacies – sertraline is the most affordable and can be used at a dose of 50 mg OD.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p><span data-custom-style=\\\"Heading 3 Char\\\">Management of more severe depression</span></p>\\r\\n<p>(including the upper half of moderate depression and severe depression).</p>\\r\\n<p>Offer antidepressant medication:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>1<sup>st</sup> line: Amitriptyline (25 mg at night) OR for staff and their immediate relatives Citalopram (20 mg OD)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>2<sup>nd</sup> line: SSRIs are available at local pharmacies – sertraline is the most affordable and can be used at a dose of 50 mg OD.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>3<sup>rd</sup> line: an SSRI and amitriptyline can be used in combination where necessary.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Offer referral to clinical psychology as above. Alternatively for patients who speak Wolof or French and have enough money to travel to Dakar, offer referral to the psychiatrist there.</p>\\r\\n<p>If there are psychotic features or active suicidal ideas or plans, refer urgently to Banjul polyclinic for psychiatry assessment.</p>\\r\\n<h3 id=\\\"ongoing-management\\\">Ongoing management</h3>\\r\\n<p>Review after 2 weeks to ensure new medication(s) are tolerated then every 4 weeks once their condition begins to improve. Advise that it usually takes 3-4 weeks before patients will start to feel better on treatment</p>\\r\\n<p>If an <span data-custom-style=\\\"Strong\\\">antidepressant</span> has been prescribed for 2 months with little or no response, double the dose.</p>\\r\\n<p>If there is no response to this increase in dose, switch to 2<sup>nd</sup> or 3<sup>rd</sup> line treatment.</p>\\r\\n<p>Once a patient has recovered, continue antidepressants for a further 6 months to reduce the risk of relapse.</p>\\r\\n<p>Once it is decided to stop antidepressants the dose should be tapered off gradually to avoid withdrawal symptoms.</p>\\r\\n<p>Withdrawal symptoms can occur if antidepressants are stopped suddenly. These may include:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Restlessness</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Problems sleeping</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Unsteadiness</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Sweating</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Abdominal symptoms</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Altered sensations</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Irritability, anxiety or confusion</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"resources\\\">Resources</h2>\\r\\n<p>Online resources may be offered to patients include:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>NHS patient information on depression: <a href=\\\"https://www.nhs.uk/conditions/clinical-depression/\\\"><span class=\\\"underline\\\">https://www.nhs.uk/conditions/clinical-depression/</span></a></p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Apps for do it yourself cognitive behavioural therapy:</p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><a href=\\\"https://www.nhs.uk/apps-library/catch-it/\\\"><span data-custom-style=\\\"Hyperlink\\\">https://www.nhs.uk/apps-library/catch-it/</span></a></p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><a href=\\\"https://moodgym.com.au/\\\"><span data-custom-style=\\\"Hyperlink\\\">https://moodgym.com.au/</span></a></p>\\r\\n</div></li>\\r\\n</ul></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Apps for managing anxiety: <a href=\\\"http://www.healthline.com/health/anxiety/top-iphone-android-apps\\\"><span class=\\\"underline\\\">www.healthline.com/health/anxiety/top-iphone-android-apps</span></a></p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"key-issues-for-nursing-care\\\">Key Issues for Nursing care</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Encourage adherence to medication</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Monitor inpatients for evidence of self-harm or suicidal behaviour among inpatients and contact medical staff for review</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<p>National Institute for Health and Clinical Excellence. <strong>Depression in adults: recognition and management</strong> <span data-custom-style=\\\"prod-title\\\">[CG90]</span> <span data-custom-style=\\\"published-date\\\">Published October 2009 Last updated: April 2018. Available from:</span> <a href=\\\"https://www.nice.org.uk/guidance/cg90\\\"><span class=\\\"underline\\\">https://www.nice.org.uk/guidance/cg90</span></a> Accessed: 10 May 2019</p>\\r\\n<p>World Health Organisation. Mental health situational analysis the Gambia. Published 7 May 2007. Available from <a href=\\\"https://www.who.int/mental_health/policy/country/thegambia/en/\\\"><span class=\\\"underline\\\">https://www.who.int/mental_health/policy/country/thegambia/en/</span></a> Accessed: 10 May 2019</p>\\r\\n<p>World Health Organisation. Depression Factsheet. Published 22 March 2018. Available from <a href=\\\"https://www.who.int/news-room/fact-sheets/detail/depression\\\"><span class=\\\"underline\\\">https://www.who.int/news-room/fact-sheets/detail/depression</span></a> Accessed: 13 May 2019</p>\\r\\n<p>UpToDate. <strong>Unipolar major depression in adults: Choosing initial treatment. Published 12 November 2017. Available from:</strong> <a href=\\\"https://www.uptodate.com/contents/unipolar-major-depression-in-adults-choosing-initial-treatment?search=depression&amp;source=search_result&amp;selectedTitle=2~150&amp;usage_type=default&amp;display_rank=2\\\"><span data-custom-style=\\\"Hyperlink\\\">https://www.uptodate.com/contents/unipolar-major-depression-in-adults-choosing-initial-treatment</span></a> Accessed: 14 May 2019</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Adam Boggon</th>\\r\\n<th>Date: 14 May 2019</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Karen Forrest</td>\\r\\n<td>Date: 22 May 2019</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td>31 May 2021</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"054\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>Developmental delay MeG-CLS-054</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"developmental-delay\\\">Developmental delay</h1>\\r\\n<h2 id=\\\"executive-summary\\\"><em>Executive summary</em></h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<p>Developmental delay (DD) is defined as significant delay (&gt;2 standard deviations below the mean) affecting children &lt; 5 years of age in one or more of the following developmental domains:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Gross motor</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Vision &amp; Fine motor</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hearing, Speech &amp; Language</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Social, Emotional &amp; Behavioural</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p><span class=\\\"underline\\\">Global</span> developmental delay is defined as significant delay in <span class=\\\"underline\\\">two or more</span> developmental domains. The degree of developmental delay is further subclassified as:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>mild (functional age &lt; 33% below chronological age)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>moderate (functional age 34%–66% of chronological age)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>severe (functional age &lt; 66% of chronological age).</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>While DD may not be permanent, it can provide a basis for identifying children who may experience a disability. Early recognition of DD is crucial to commencing timely interventions, prevention of complications, developing family understanding and support networks and creating a more stimulating and protective environment for the child.</p>\\r\\n<h2 id=\\\"target-users\\\">Target users</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nurses</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doctors</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"target-area-of-use\\\">Target area of use </h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Gate clinic</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Outpatient department</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ward</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"key-areas-of-focus-new-additions-changes\\\">Key areas of focus / New additions / Changes </h2>\\r\\n<p>This guideline provides an approach for doctors and nurses to follow in assessing children for developmental delay as well as some guidance in how to manage them.</p>\\r\\n<h2 id=\\\"limitations\\\">Limitations</h2>\\r\\n<p>We have limited access to tests and management options for these children.</p>\\r\\n<h2 id=\\\"causes-of-developmental-delay\\\">Causes of developmental delay</h2>\\r\\n<p>DD can result from antenatal or postnatal damage to brain development although in 50% of cases the cause is unknown:</p>\\r\\n<p><strong>Antenatal:</strong></p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Genetic/syndromes (20-50%)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Cerebral malformations (7%)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Early maternal infections e.g. rubella, toxoplasma, CMV</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Late maternal infections, such as varicella, malaria, HIV</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Toxins—for example, alcohol, pesticides, radiation, smoking</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Drugs—for example, cytotoxics, antiepileptics</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h5 id=\\\"postnatal\\\"><strong>Postnatal</strong></h5>\\r\\n<ul>\\r\\n<li><h5 id=\\\"cerebral-palsycomplications-of-prematurity-2-10\\\">Cerebral palsy/complications of prematurity (2-10%)</h5></li>\\r\\n<li><h5 id=\\\"postnatal-infections-e.g.-meningitis-encephalitis-cmv\\\">Postnatal infections e.g. meningitis, encephalitis, CMV</h5></li>\\r\\n<li><h5 id=\\\"metabolic-or-endocrine-disorders-such-as-hypoglycaemia-hyponatraemia-or-hypernatraemia-dehydration-1-5\\\">Metabolic or endocrine disorders, such as hypoglycaemia, hyponatraemia or hypernatraemia, dehydration (1-5%)</h5></li>\\r\\n<li><h5 id=\\\"toxins-e.g.-lead-mercury-arsenic-chlorinated-organic-compounds-solvents\\\">Toxins e.g. lead, mercury, arsenic, chlorinated organic compounds, solvents</h5></li>\\r\\n<li><h5 id=\\\"trauma-especially-head-injury\\\">Trauma, especially head injury</h5></li>\\r\\n<li><h5 id=\\\"severe-understimulation-maltreatment-or-domestic-violence\\\">Severe understimulation, maltreatment, or domestic violence</h5></li>\\r\\n<li><h5 id=\\\"malnutrition-especially-deficiency-of-iron-folate-and-vitamin-d\\\">Malnutrition, especially deficiency of iron, folate, and vitamin D</h5></li>\\r\\n<li><h5 id=\\\"maternal-mental-health-disorders-most-commonly-depression\\\">Maternal mental health disorders, most commonly depression</h5></li>\\r\\n</ul>\\r\\n<h2 id=\\\"red-flags-to-suggest-developmental-delay\\\">Red flags to suggest developmental delay</h2>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Age</strong></th>\\r\\n<th><strong>Signs</strong></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><em>6 weeks</em></td>\\r\\n<td>Unresponsive to sound or visual stimuli</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><em>6 months</em></td>\\r\\n<td>Poor head control, floppiness, not reaching</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><em>9 months</em></td>\\r\\n<td>Can’t sit unsupported; no babble</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><em>12 months</em></td>\\r\\n<td>Not communicating by gestures, such as pointing; not weight bearing through legs</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><em>18 months</em></td>\\r\\n<td>Not walking; no symbolic play; no speech</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><em>2 years</em></td>\\r\\n<td>Not joining two words; cannot run; not pointing at objects to share interest with others</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><em>3 years</em></td>\\r\\n<td>Not communicating with words; cannot climb stairs</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><em>All ages</em></td>\\r\\n<td><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Loss of developmental skills at any age (regression)</p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Parental or professional concerns about vision, fixing/following at any age</p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hearing loss at any age</p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Persistent low or high muscle tone, floppiness or asymmetry of movements</p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Complex disabilities</p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Persistently toe walking</p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Head circumference &gt; 99<sup>th</sup> centile or &lt; 0.4<sup>th</sup> centile</p>\\r\\n</div></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<h2 id=\\\"history\\\">History</h2>\\r\\n<p>A comprehensive clinical assessment, including history and examination, is crucial when planning investigations:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Studies have demonstrated that we can identify the cause of DD in 1/3<sup>rd</sup> of cases by history and examination alone.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>With clinical evaluation prompting investigations, we can identify another 1/3<sup>rd</sup>.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p><span class=\\\"underline\\\">Suggested screening questions:</span></p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Do you have any concerns about the way your child is behaving, learning, or developing?</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Do you have any concerns about the way he or she moves or uses his or her arms or legs?</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Do you have any concerns about how your child talks and understands what you say?</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Has your child ever stopped doing something he or she could previously do?</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Do you have any concerns about how your child is learning to do things for himself or herself?</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Clarify if this is a child who has <span class=\\\"underline\\\">never</span> met their developmental milestones vs. a child who has <span class=\\\"underline\\\"> regressed</span> developmentally, having previously been well. Regression suggests either a change in social/environmental factors, recent illness or neurological/neurodegenerative causes.</p>\\r\\n<p>A thorough and systematic pre-, peri- and postnatal history is crucial and will help guide investigations (aetiology) and management. Important factors to cover:</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><div data-custom-style=\\\"Normal (Web)\\\">\\r\\n<p><strong>Prenatal</strong></p>\\r\\n</div></th>\\r\\n<th><div data-custom-style=\\\"Normal (Web)\\\">\\r\\n<p><strong>Perinatal</strong></p>\\r\\n</div></th>\\r\\n<th><div data-custom-style=\\\"Normal (Web)\\\">\\r\\n<p><strong>Postnatal</strong></p>\\r\\n</div></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><p>Previous miscarriages or birth defects</p>\\r\\n<p>Unexplained sibling death</p>\\r\\n<p>Use of teratogens including drug and alcohol misuse</p>\\r\\n<p>Prenatal history of Intrauterine infections or severe maternal infection/life threatening event</p>\\r\\n<p>Maternal conditions e.g. HELLP syndrome, HTN, GDM, pre-eclampsia</p>\\r\\n<p>Fetal movements ↓</p>\\r\\n<p>Significant antepartum haemorrhage</p></td>\\r\\n<td><p>Birth weight and head circumference</p>\\r\\n<div data-custom-style=\\\"Normal (Web)\\\">\\r\\n<p>Birth asphyxia</p>\\r\\n</div>\\r\\n<p>Poor Apgars and requiring prolonged resuscitation</p>\\r\\n<p>Development of hypoxic ischaemic encephalopathy</p>\\r\\n<p>Birth trauma</p></td>\\r\\n<td><div data-custom-style=\\\"Normal (Web)\\\">\\r\\n<p>Trauma</p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"Normal (Web)\\\">\\r\\n<p>Current or previous Infection including meningitis/sepsis</p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"Normal (Web)\\\">\\r\\n<p>Seizures</p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"Normal (Web)\\\">\\r\\n<p>Episodes of hypoglycaemia</p>\\r\\n</div></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<div data-custom-style=\\\"Normal (Web)\\\">\\r\\n<p><span class=\\\"underline\\\">Other past medical history:</span> co-existing infections (acute or chronic), co-existing chronic conditions (particularly neurological), severe malnutrition</p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"Normal (Web)\\\">\\r\\n<p><span class=\\\"underline\\\">Social history:</span> parental consanguinity, familial relationships, environmental stress, neglect, health and development of siblings</p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"Normal (Web)\\\">\\r\\n<p><span class=\\\"underline\\\">Family history:</span> DD, neurological conditions, learning difficulties, genetic disease</p>\\r\\n</div>\\r\\n<h2 id=\\\"examination-findings\\\">Examination findings</h2>\\r\\n<h3 id=\\\"growth-parameters\\\">Growth parameters:</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Measure and plot head circumference on appropriate standardised WHO growth chart.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Measure weight and height/length. Calculate weight-for-height Z score (WHZ score &lt; -3 = severe acute malnutrition).</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"thorough-developmental-assessment\\\">Thorough developmental assessment:</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Examine all domains (gross motor, fine motor, language, socioemotional and cognitive skills).</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>If equivocal then follow up every 3-6 months with repeat clinical/dysmorphology and developmental assessments over time</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"detailed-top-to-toe-examination\\\">Detailed top-to-toe examination:</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Dysmorphism and congenital abnormalities</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Head shape (including fontanelle) and facial features</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Skin and cutaneous stigmata</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Spine</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Abdomen – check for organomegaly</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Limb abnormalities</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Genital abnormalities</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Abnormal neurological (especially tone) or cardiovascular examination</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"hearing-and-vision-assessment\\\">Hearing and vision assessment:</h3>\\r\\n<p>Identification and correction of sensory deficits are essential and may provide pointers to the underlying aetiology.</p>\\r\\n<p>The following features are suggestive of:</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Genetic cause/unifying syndrome</strong></th>\\r\\n<th><strong>Metabolic condition</strong></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<blockquote>\\r\\n<p>Any child with moderate/severe developmental delay of unknown cause.</p>\\r\\n</blockquote>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<blockquote>\\r\\n<p>Family history of DD or learning disability.</p>\\r\\n</blockquote>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<blockquote>\\r\\n<p>Parental consanguinity Congenital anomalies, unusual facial features or multisystem problems in addition to DD</p>\\r\\n</blockquote>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<blockquote>\\r\\n<p>Unusual growth parameters e.g. microcephaly or macrocephaly, short or tall stature, failure to thrive or severe obesity.</p>\\r\\n</blockquote>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<blockquote>\\r\\n<p>Sensory problems or odd behaviour</p>\\r\\n</blockquote>\\r\\n</div></li>\\r\\n</ul></td>\\r\\n<td><ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<blockquote>\\r\\n<p>Family history of DD or learning disability</p>\\r\\n</blockquote>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<blockquote>\\r\\n<p>Previous history of sudden infant death</p>\\r\\n</blockquote>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<blockquote>\\r\\n<p>Parental consanguinity</p>\\r\\n</blockquote>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<blockquote>\\r\\n<p>Regression</p>\\r\\n</blockquote>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<blockquote>\\r\\n<p>Abnormal head size</p>\\r\\n</blockquote>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<blockquote>\\r\\n<p>Organomegaly</p>\\r\\n</blockquote>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<blockquote>\\r\\n<p>Coarse features</p>\\r\\n</blockquote>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<blockquote>\\r\\n<p>Seizures</p>\\r\\n</blockquote>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<blockquote>\\r\\n<p>Abnormal neurology including hypotonia or movement disorder</p>\\r\\n</blockquote>\\r\\n</div></li>\\r\\n</ul></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<h2 id=\\\"section\\\"></h2>\\r\\n<h2 id=\\\"key-principles-of-management\\\">Key principles of management</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Exclude reversible causes:</p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Infection (acute or chronic e.g. TB)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Undernutrition/failure to thrive</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Social difficulties e.g. neglect, family isolation, maternal depression</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Iron deficiency anaemia,</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hypothyroidism</p>\\r\\n</div></li>\\r\\n</ul></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Prevention/amelioration of comorbidities, particularly nutritional.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Anticipate child needs and initiate multidisciplinary networks early.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Parental counselling and pychosocial support is very important.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Regular follow up and continue monitoring developmental progress/regression.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Where tests and treatments are not available at CSD or in Gambia, consider referral to Dakar if the parents are able to afford this (but remember to make it clear when making a diagnosis will not change outcome, as parents may spend their last money on this if they are not properly counselled).</p>\\r\\n<h2 id=\\\"investigations\\\">Investigations</h2>\\r\\n<p>Indications for further investigations are:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Severe delay: Development &lt;50% of expected milestones at that chronological age</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Global delay: Significant delay affecting 2 or more domains of development</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Any plateauing or regression of development</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"first-line-investigations\\\">First line investigations:</h3>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><em>Bloods</em></th>\\r\\n<th><p>FBC, Urea and creatinine, Electrolytes including HCO<sup>3</sup></p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Calculate anion gap (Na + K – Cl – HCO<sup>3</sup>) normal anion gap is 8-16 mEq/L</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>If the anion gap is high then consider <span class=\\\"underline\\\">metabolic acidosis</span> (+/- underlying metabolic disorders)</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Fasting blood glucose, AST, ALT, bone profile, uric acid, lipid profile, creatine kinase (CK)</p>\\r\\n<p>Thyroid function tests: TSH, free T4</p>\\r\\n<p>Other tests not available at CSD: Vitamin B12, lead level, lactate, iron studies</p></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><em>Serology for congenital infections</em></td>\\r\\n<td><p>Syphilis (RPR/TPHA) and HIV1+2</p>\\r\\n<p>Other tests not available at CSD: Toxoplasma, cytomegalovirus, rubella</p></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<h3 id=\\\"second-line-investigations\\\">Second line investigations:</h3>\\r\\n<p>These depend on clinical assessment and availability. Tests in bold are currently available in CSD.</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><p><em>Special blood tests (if</em></p>\\r\\n<p><em>available)</em></p></th>\\r\\n<th><p>Genetic tests: Karyotype and microarray</p>\\r\\n<p>Metabolic tests (in addition to 1<sup>st</sup> line above):</p>\\r\\n<ol type=\\\"a\\\">\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Blood: ammonia, serum amino acids, VLCFA, white cell enzymes</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Urine: organic acids, glycosaminoclycans (MPS screen)</p>\\r\\n</div></li>\\r\\n</ol>\\r\\n<p><strong>Infection screen:</strong> ESR, microbiology if suspect chronic infection, TB investigations (if +ve history)</p></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><em>Plain imaging (X Rays)</em></td>\\r\\n<td><p><strong>Chest XR:</strong> if chronic infection or malignancy suspected</p>\\r\\n<p><strong>Limb XR</strong>: useful if the child has limb abnormalities</p>\\r\\n<p><strong>Skull XR:</strong> Useful if abnormal sutures and cranial shape suspected (e.g. craniosynostosis)</p></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><em>Neuro-imaging</em></td>\\r\\n<td><p>Neuroimaging should be done if abnormal head circumference (microcephaly, non-familial macrocephaly, rapid change in head circumference), focal neurological signs, seizures</p>\\r\\n<ol type=\\\"a\\\">\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>MRI brain: gold standard</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Cranial ultrasound:</strong> may be useful to assess intracranial pathology in an infant (if anterior fontanelles not closed)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>CT head: only request if intracranial calcifications suspected (Toxoplasmosis, CMV)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>EEG: If seizures, speech regression, neurodegeneration/regression</p>\\r\\n</div></li>\\r\\n</ol></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><em>Ultrasound</em></td>\\r\\n<td><strong>Abdominal ultrasound</strong> is useful if multiple congenital abnormalities or hepatosplenomegaly on examination to exclude intraabdominal organ abnormality</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><em>ECHO</em></td>\\r\\n<td><strong>ECHO</strong> if multiple congenital abnormalities or dysmorphic features to exclude cardiac lesion</td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<h2 id=\\\"management-of-co-morbidities\\\">Management of co-morbidities</h2>\\r\\n<p><strong><span class=\\\"underline\\\">Congenital abnormalities:</span></strong> see details of cleft surgical and orthopaedic teams below.</p>\\r\\n<p><strong><span class=\\\"underline\\\">Sensory abnormalities</span> (hearing and vision):</strong> see contact details below</p>\\r\\n<p><strong><span class=\\\"underline\\\">Contractures/hypotonia:</span></strong> consider diazepam usually before bedtime (will help with discomfort), refer for physiotherapy support at Banjul, EFSTH.</p>\\r\\n<p><strong><span class=\\\"underline\\\">Seizures</span>:</strong> consider starting anti-epileptic medications e.g. carbamezapine or sodium valproate (avoid in women of child bearing age), refer to epilepsy guideline MeG-CLS-056.</p>\\r\\n<p><strong><span class=\\\"underline\\\"><br />\\r\\n</span></strong></p>\\r\\n<p><strong><span class=\\\"underline\\\">Malnutrition</span></strong> (including obesity) or failure to thrive:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Dietary advice should be given to parents</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>If severe acute malnutrition (WHZ score &lt; -3): refer to WHO malnutrition guidelines including supplementation and antibiotics; may need admission</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>If undernourished but not SAM, give dietary advice and refer to local clinics for nutritional support</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Ensure <strong><span class=\\\"underline\\\">vaccinations</span></strong> up to date and regular anti-worming treatment.</p>\\r\\n<p><strong><span class=\\\"underline\\\">Gastro-oesophageal reflux:</span></strong></p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>High index of suspicion if poor swallow evident (e.g. ++ mouth secretions), neurological abnormalities, recurrent vomiting especially post feeds, recurrent chest infections.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Consider Omeprazole +/- Ranitidine PO (refer to BNF for children for doses).</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Consider aspiration pneumonia as a differential for children with DD and poor swallow presenting with infective LRI symptoms.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p><strong><span class=\\\"underline\\\">Neurodevelopmental support:</span></strong></p>\\r\\n<p>There is little medical support available in the Gambia, but if parents can afford referral to Dakar, then the following criteria should be used to guide this:</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Features in the history</strong></th>\\r\\n<th><ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Regression or possible regression including significant change in behaviour</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Possible or definite seizures</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Movement disorder: continuous or paroxysmal</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Muscle pain/fatigue</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>New onset sensory impairment e.g. significant decline in visual acuity</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Cognitive decline/behavioural change in a child with epilepsy or ASD</p>\\r\\n</div></li>\\r\\n</ul></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Examination findings</strong></td>\\r\\n<td><ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Neurological signs: dystonia, ataxia, movement disorder, for example, chorea, focal signs, cranial nerve signs, muscle weakness/signs of a peripheral neuropathy, arthrogryposis/joint contractures, CP picture without a clear cause/history</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Other signs: sensorineural deafness</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Neurocutaneous features</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Organomegaly/cardiomegaly</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Course or dysmorphic facial features</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Cerebral palsy</p>\\r\\n</div></li>\\r\\n</ul></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<h2 id=\\\"multi-disciplinary-care-and-services\\\">Multi-disciplinary care and services</h2>\\r\\n<p>All referrals should be made on headed MRC paper (or from an MRC email):</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><span class=\\\"underline\\\">Epilepsy support</span>: Support for children with epilepsy: The Gambia Epilepsy Association, <a href=\\\"mailto:gambiaepilepsy@yahoo.co.uk\\\"><span data-custom-style=\\\"Hyperlink\\\">gambiaepilepsy@yahoo.co.uk</span></a>, +220 994 9034/ 995 5418</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><span class=\\\"underline\\\">Cleft team</span>: Smile Train charity offers free cleft surgery annually at the polyclinic EFSTH, Banjul, contact Dr Okafor +220 999 6487, Papis Sanneh +220 993 1506, Perannans +220 715 1055</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><span class=\\\"underline\\\">Dental team</span>: polyclinic EFSTH, Banjul</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><span class=\\\"underline\\\">Orthopaedic team</span>: Outpatient department EFSTH, Banjul. Clinic is usually held on Wednesday mornings.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><span class=\\\"underline\\\">Physiotherapy</span>: EFSTH paediatric daily outpatient clinics (they will liaise with Department of Social welfare who provide support from occupational therapy e.g. provision of mobility aids, wheelchairs)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><span class=\\\"underline\\\">Schools:</span> encourage parents to enroll children into educational system (either mainstream or special needs depending on level of disability)</p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Respite care home/school for children with learning difficulties (Eastern Gambia): Hart Foundation, Serrekunda, <a href=\\\"mailto:geoffharthouse@yahoo.com\\\"><span data-custom-style=\\\"Hyperlink\\\">geoffharthouse@yahoo.com</span></a>, +220 9926258</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Rural support organization for the disabled, Basse, +220 566 8101, <a href=\\\"mailto:rsodgambian@gmail.com\\\"><span data-custom-style=\\\"Hyperlink\\\">rsodgambian@gmail.com</span></a></p>\\r\\n</div></li>\\r\\n</ul></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><span class=\\\"underline\\\">Support for children with physical disabilities</span>: Gambia Association of the Physically disabled; also organizes sports activities and support groups – contact <a href=\\\"mailto:gambiadisabledsports@yahoo.co.uk\\\"><span data-custom-style=\\\"Hyperlink\\\">gambiadisabledsports@yahoo.co.uk</span></a>, +220 992 3377/ 7790158/ 9983480</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><span class=\\\"underline\\\">Hearing difficulties</span>:</p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Audiology at the polyclinic at EFSTH, Banjul</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>St John’s School For the Deaf, Kanifing <a href=\\\"mailto:stjohnsdeafgambia@hotmail.com\\\"><span data-custom-style=\\\"Hyperlink\\\">stjohnsdeafgambia@hotmail.com</span></a>, Daniel Mendy on +220 779 0286</p>\\r\\n</div></li>\\r\\n</ul></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><span class=\\\"underline\\\">Visual difficulties</span>:</p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Sheikh Zayed Eye care centre, Kanifing +220 996 7049/ 208 8707 (includes 2 visits per year by ophthalmology NGO Eye Care Gambia <a href=\\\"http://www.eyecaregambia.com\\\"><span data-custom-style=\\\"Hyperlink\\\">www.eyecaregambia.com</span></a>)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Fresh Start Foundation, Brikama, <a href=\\\"mailto:info@fsfgambia.org\\\"><span data-custom-style=\\\"Hyperlink\\\">info@fsfgambia.org</span></a></p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Sightsavers, Kairaba Avenue</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Gambia Organisation For The Visual Impaired (GOVI) and School For the Blind, Kanifing</p>\\r\\n</div></li>\\r\\n</ul></li>\\r\\n</ul>\\r\\n<h2 id=\\\"psychosocial-support\\\">Psychosocial support</h2>\\r\\n<p>Prepare, educate and support parents. It is important to tackle concerns around stigma and misunderstanding of aetiology of disease (e.g. supernatural causes).</p>\\r\\n<p><span class=\\\"underline\\\">Counselling:</span></p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Discuss parental concerns and expectations (refer to support organisations above).</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>If suspected genetic or metabolic disease – discuss likely recurrence risk for future pregnancy (+/- family planning options).</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Children with disabilities and DD often cannot communicate their pain or problems in the same ways as children without DD, therefore, advise parents to have a low threshold for seeking medical review (especially if unsettled/discomfort/pain/infective symptoms)</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p><span class=\\\"underline\\\">Support for literate parents:</span></p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><a href=\\\"https://www.parentcenterhub.org/dd/\\\"><span data-custom-style=\\\"Hyperlink\\\">https://www.parentcenterhub.org/dd/</span></a></p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><a href=\\\"https://parent2parent.org.nz/developmental-delay-dd-diagnosis-and-prognosis/\\\"><span data-custom-style=\\\"Hyperlink\\\">https://parent2parent.org.nz/developmental-delay-dd-diagnosis-and-prognosis/</span></a></p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><a href=\\\"https://specialneedsjungle.com/help-parents-worried-childs-development/\\\"><span data-custom-style=\\\"Hyperlink\\\">https://specialneedsjungle.com/help-parents-worried-childs-development/</span></a></p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"follow-up\\\">Follow up</h2>\\r\\n<p>Every 3-6 months depending on clinical need.</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Aim to repeat developmental assessment at every visit to monitor progress/regression</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Detailed history and examination including head circumference and other growth parameters (ensure plotted on WHO growth charts)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Assess for other comorbidities (may need medications e.g. for seizures or hypertonia)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Clarify baseline at each appointment to check progress/deterioration</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Explore parental ideas, concerns and expectations</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"key-issues-for-nursing-care\\\">Key Issues for Nursing care</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Be sensitive to looking after a child with disability or developmental delay and aware of potential limitations to movement and communication.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Clarify baseline at the start of admission so that any change or deterioration can be easily recognised (note that children with DD may not be verbal and may convey any pain or discomfort in an unusual way).</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<p>American Academy of Pediatrics, Council on Children with Disabilities, Section on Developmental and Behavioral Pediatrics. Identifying infants and young children with developmental disorder in the medical home: an algorithm for developmental surveillance and screening. Pediatrics2006;118:405-20.</p>\\r\\n<p>Bellman M, Byrne O, Sege R. Developmental assessment of children. BMJ 2013;346:e8687</p>\\r\\n<p>Bundey S, Aslam H. A five-year prospective study of the health of children in different ethnic groups, with particular reference to the effect of inbreeding. Eur J Hum Genet 1993;1:206-219</p>\\r\\n<p>Buch S. Investigation of Global Developmental Delay. Shropshire Community health NHS Trust guideline. <a href=\\\"http://www.shropscommunityhealth.nhs.uk/content/doclib/12052.pdf\\\"><span data-custom-style=\\\"Hyperlink\\\">http://www.shropscommunityhealth.nhs.uk/content/doclib/12052.pdf</span></a>. Accessed 22<sup>nd</sup> November 2018.</p>\\r\\n<p>Collins PY, Pringle B, Alexander C, Darmstadt GL, Heymann J, Huebner G, et al. (2017) Global services and support for children with developmental delays and disabilities: Bridging research and policy gaps. PLoS Med 14(9): e1002393. <a href=\\\"https://doi.org/10.1371/journal.pmed.1002393\\\"><span data-custom-style=\\\"Hyperlink\\\">https://doi.org/10.1371/journal.pmed.1002393</span></a></p>\\r\\n<p>Community Children’s Health Partnership. Developmental delay pathway. <a href=\\\"https://cchp.nhs.uk/sites/default/files/Care%20Pathway%20for%20Development%20Delay%20(2010).pdf\\\"><span data-custom-style=\\\"Hyperlink\\\">https://cchp.nhs.uk/sites/default/files/Care%20Pathway%20for%20Development%20Delay%20(2010).pdf</span></a> Accessed 22<sup>nd</sup> November 2018.</p>\\r\\n<p>Engle PL, Fernald LC, Alderman H, Behrman J, O’Gara C, Yousafzai A, et al. Strategies for reducing inequalities and improving developmental outcomes for young children in low-income and middle-income countries. Lancet 2011;378:1339-53.</p>\\r\\n<p>Horridge KA. Assessment and investigation of the child with disordered development. Arch Dis Child Educ Pract Ed2011;96:9-20</p>\\r\\n<p>Mithyantha R, Kneen R, McCann E, et al Current evidence-based recommendations on investigating children with global developmental delay Archives of Disease in Childhood 2017;102:1071-1076.</p>\\r\\n<p>Turner G, Partington M. Recurrence risks in undiagnosed mental retardation. J Med Genet 2000:37:E45</p>\\r\\n<p>WHO. Developmental difficulties in early childhood. Prevention, early identification, assessment and intervention in low- and middle-income countries: A Review. 2012.</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Anja Saso</th>\\r\\n<th>Date: 30 November 2018</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Baderinwa Abatan</td>\\r\\n<td>Date: 29 April 2019</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td>31 May 2021</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"004\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>Diabetes Mellitus MeG-CLS-004</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"diabetes-mellitus\\\">Diabetes Mellitus</h1>\\r\\n<h2 id=\\\"executive-summary\\\"><em>Executive summary</em></h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<h3 id=\\\"diabetes-mellitus-dm-is-a-metabolic-disorder-characterized-by-chronic-hyperglycemia.-it-predisposes-to-blindness-limb-amputation-and-is-a-major-risk-factor-for-cardiovascular-disease-and-death.-type-2-dm-is-the-most-common-type-with-many-patients-having-no-symptoms-and-diagnosed-incidentally.\\\">Diabetes mellitus (DM) is a metabolic disorder characterized by chronic hyperglycemia. It predisposes to blindness, limb amputation and is a major risk factor for cardiovascular disease and death. Type 2 DM is the most common type with many patients having no symptoms and diagnosed incidentally.</h3>\\r\\n<p>This guideline covers the diagnoses and treatment of diabetes mellitus.</p>\\r\\n<h3 id=\\\"target-user\\\">Target User</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nurses</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doctors</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"target-area-of-use\\\">Target area of use </h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Gate Clinic</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Outpatient Department</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ward</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"key-areas-of-focus-new-additions-changes\\\">Key areas of focus / New additions / Changes </h3>\\r\\n<p>DM is diagnosed if fasting blood glucose is ≥ 7.0 mmol/L or random blood glucose ≥ 11.1 mmol/L with typical symptoms. Patients with newly diagnosed DM or features suggestive of complications should be referred from the Gate Clinic to the OPD. Management of DM is aimed at blood glucose control and prevention of complications using pharmacologic and non-pharmacologic measures.</p>\\r\\n<p>Patients with type 1 DM will require lifelong insulin therapy and should be referred to EFSTH. Patients with type 2 DM will typically receive metformin alone or in combination with other drugs.</p>\\r\\n<p>Insulin therapy should be considered in the in-patient management of DM if blood glucose is persistently &gt; 10 mmol/l. This can be achieved by giving scheduled basal, premeal and correctional doses of insulin.</p>\\r\\n<h3 id=\\\"limitations\\\">Limitations </h3>\\r\\n<h2 id=\\\"this-guideline-does-not-address-the-management-of-hyperglycaemic-emergencies.-these-are-addressed-in-meg-cls-021-diabetic-ketoacidosis-and-meg-cls-046-hyperglycaemic-hyperosmolar-state.\\\">This guideline does not address the management of hyperglycaemic emergencies. These are addressed in MeG-CLS-021 Diabetic ketoacidosis and MeG-CLS-046 Hyperglycaemic hyperosmolar state.</h2>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs\\\">Presenting symptoms and signs</h2>\\r\\n<div data-custom-style=\\\"Default\\\">\\r\\n<p>Many patients have no symptoms and are diagnosed incidentally while being investigated or treated for some other medical condition.</p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"Default\\\">\\r\\n<p>Symptoms of diabetes mellitus at presentation may include:</p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"Default\\\">\\r\\n<p>Classic symptoms</p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"Default\\\">\\r\\n<p>increased thirst</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"Default\\\">\\r\\n<p>increased volume and frequency of urination</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"Default\\\">\\r\\n<p>polyphagia</p>\\r\\n</div></li>\\r\\n</ul></li>\\r\\n<li><div data-custom-style=\\\"Default\\\">\\r\\n<p>Recurrent Infections</p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"Default\\\">\\r\\n<p>recurrent boils and other skin infections</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"Default\\\">\\r\\n<p>recurrent genital infections (persistent whitish discharge with itch in women, inflammation of glans penis in men)</p>\\r\\n</div></li>\\r\\n</ul></li>\\r\\n<li><div data-custom-style=\\\"Default\\\">\\r\\n<p>unexplained abdominal pain (mimicking a surgical/acute abdomen),</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"Default\\\">\\r\\n<p>weight loss (more common in Type 1 DM)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"Default\\\">\\r\\n<p>marked weakness</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"Default\\\">\\r\\n<p>blurred vision</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"Default\\\">\\r\\n<p>abnormal sensation in the legs and feet: pain, burning, numbness (“feels like walking on mud when barefoot”)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"Default\\\">\\r\\n<p>foetal macrosomia</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"Default\\\">\\r\\n<p>foetal deaths</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<div data-custom-style=\\\"Default\\\">\\r\\n<p>Consider the possibility of diabetes in all adults of any age with a BMI &gt; 25 kg/m<sup>2</sup> plus one or more of the following:</p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hypertension &gt; 140/90 mmHg</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>First degree relative with Type 2 DM</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Polycystic ovarian syndrome</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Previous history of foetal macrosomia</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Cardiovascular disease</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Previous history of impaired glucose tolerance</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Physical inactivity</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Previous diagnosis of dyslipidaemia</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Consider a diagnosis of Type 1 DM if:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Younger than 35 years</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Slim physique</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Rapid onset of symptoms</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Severe symptoms at first presentation (including DKA)</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Apart from the symptoms listed earlier, complications include:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Autonomic neuropathy: Abnormal sweating, resting tachycardia, erectile dysfunction, postural hypotension, gastrointestinal symptoms such as early satiety, nocturnal diarrhea, constipation</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Motor: Painful proximal weakness (difficulty getting up from sitting position)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Sensory neuropathy: Bilateral distal lower limb pain,</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Vascular: leg fatigue, claudication, stroke, ischaemic heart disease.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"management-in-gate-clinic\\\">Management in Gate Clinic</h2>\\r\\n<h3 id=\\\"investigations\\\">Investigations</h3>\\r\\n<div data-custom-style=\\\"Default\\\">\\r\\n<p>Diagnose diabetes mellitus if you find:</p>\\r\\n</div>\\r\\n<ol type=\\\"1\\\">\\r\\n<li><div data-custom-style=\\\"Default\\\">\\r\\n<p><em><strong>Fasting Blood Glucose</strong></em> of 7.0 mmol/L or higher</p>\\r\\n</div></li>\\r\\n</ol>\\r\\n<div data-custom-style=\\\"Default\\\">\\r\\n<p><strong>OR</strong></p>\\r\\n</div>\\r\\n<ol start=\\\"2\\\" type=\\\"1\\\">\\r\\n<li><div data-custom-style=\\\"Default\\\">\\r\\n<p>A <em><strong>random blood glucose</strong></em> of 11.1 mmol/L or higher <strong>plus</strong> the classic symptoms of diabetes mellitus.</p>\\r\\n</div></li>\\r\\n</ol>\\r\\n<div data-custom-style=\\\"Default\\\">\\r\\n<p>If patient is asymptomatic with abnormal fasting glucose, repeat the test for confirmation.</p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"Default\\\">\\r\\n<p><em><strong>Dipstick urinalysis:</strong></em> This may show glycosuria. Proteinuria or ketonuria may also be present.</p>\\r\\n</div>\\r\\n<h3 id=\\\"alarm-features\\\">Alarm features</h3>\\r\\n<p>If a patient with high blood glucose has one or more of the following signs or symptoms, the doctor should be called to see them immediately.</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Drowsiness</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Fever &gt; 38ºC</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Severe Weakness</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Confusion</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Signs of dehydration</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Deep sighing breathing</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Abdominal pain</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"when-to-refer-to-the-doctor-in-opd\\\">When to refer to the doctor in OPD</h3>\\r\\n<p>Also refer patients to the doctor who have:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Newly diagnosed diabetes mellitus</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>You are unsure of the diagnosis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Proteinuria or ketonuria is discovered alongside high blood glucose</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Glycosuria of ++ or more</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Patient looks very ill and weak alongside a high blood glucose</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"management-of-patients-with-a-high-blood-glucose\\\">Management of patients with a high blood glucose </h3>\\r\\n<div data-custom-style=\\\"Default\\\">\\r\\n<p><em><strong>Patient Education:</strong></em></p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"Default\\\">\\r\\n<p>Structured education to all patients and carers about diabetes mellitus (cause, course and prognosis), diabetes self-management, nutrition and lifestyle modification. This includes diet, exercise and weight management (loss of 5-10% of body weight initially).</p>\\r\\n</div>\\r\\n<h2 id=\\\"management-in-opd\\\">Management in OPD</h2>\\r\\n<h3 id=\\\"routine-examination\\\">Routine examination</h3>\\r\\n<p>Review BMI at each visit.</p>\\r\\n<p>Check for postural hypotension at baseline, annually and if symptomatic.</p>\\r\\n<p>Foot exam:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Inspect both feet at each visit for calluses, dystrophic nails, joint deformities, tinea pedis, ulcers.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Check for reduced peripheral pulsation in feet at baseline, annually and if symptomatic.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Baseline and annual neurologic examination of feet (10 g monofilament and 128 Hz tuning fork vibration test).</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Fundoscopy for retinal changes.</p>\\r\\n<h3 id=\\\"routine-investigation\\\">Routine investigation</h3>\\r\\n<p><em>Fasting Blood Glucose</em> at each follow up visit</p>\\r\\n<p>Baseline and annual <em>serum electrolytes, urea and creatinine</em>: calculate estimated glomerular filtration rate (eGFR) at <span data-custom-style=\\\"Hyperlink\\\"><a href=\\\"https://www.kidney.org/professionals/kdoqi/gfr_calculator\\\">https://www.kidney.org/professionals/kdoqi/gfr_calculator</a></span></p>\\r\\n<p>Calculate cardiovascular risk at <span data-custom-style=\\\"Hyperlink\\\"><a href=\\\"https://qrisk.org/2017/\\\">https://qrisk.org/2017/</a></span> - check lipid profile if the risk is borderline (5-10% in the next 10 years).</p>\\r\\n<p><em>Urinalysis</em>: Glycosuria and ketonuria may be present. Proteinuria (++) or haematuria (with red cell casts) may indicate nephropathy.</p>\\r\\n<p>Baseline <em>ECG</em></p>\\r\\n<p>For staff and those who can afford private fees: baseline <em>HbA1c assay</em>, recheck 6-monthly (if at target) or 3-monthly (not at target)</p>\\r\\n<h3 id=\\\"treatment\\\">Treatment</h3>\\r\\n<p>The goals of treatment are:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Glucose control;</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Cardiovascular risk reduction;</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Prevention and management of complications.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p><em>Lifestyle measures</em>: Diet, smoking cessation, moderation in alcohol intake, adequate physical activity and weight management.</p>\\r\\n<p><em>Pharmacologic Therapy:</em></p>\\r\\n<p><em>Glucose control:</em> Target blood glucose levels are 4.4 – 7.2 mmol/l (fasting and pre-meal), less than 10.0 mmol/l post-prandial. Target HbA1c is less than 7%. Individualize higher targets for older patients or those prone to hypoglycaemia. (target up to 8.5% HbA1c and up to 10.0 mmol/l pre-meal blood glucose)</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Type 1 patients: usually insulin dependent from diagnosis. Usually maintained on combinations of regular insulin and intermediate acting insulin e.g. Mixtard (70/30). Refer to EFSTH</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Initial drug of choice in Type 2 is metformin unless contraindicated. Start at 500 mg orally once daily. Increase to 500 mg twice daily the next week and then 500 mg three times daily the week after. The usual maximum dose is 1000 mg twice daily.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>For patients with baseline FBS &gt; 16 mmol/l, baseline HbA1c ≥ 9% or FBS not at target after 3 months, commence gliclazide along with metformin.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Assess medication adherence at each visit.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>If still not at target despite maximal doses of gliclazide and metformin, consider adding another oral agent or insulin. Patients other than staff will need to be referred to EFSTH diabetic clinic at this point.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p><em>Hypoglycaemia:</em> Treat at blood glucose less than 4 mmol/l or presence of typical symptoms.</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Unlikely to occur if patient is on metformin monotherapy.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Educate patient on prevention, symptoms and immediate care needed. Patients on sulfonylureas or insulin should carry three candies (sweets) or sugar cubes always to treat hypoglycaemia.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>If hypoglycaemia occurs, assess diet, dose and physical activity with patient and agree on dose adjustment.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p><em>Blood pressure control:</em> Target BP is &lt; 140/90 mmHg</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>If BP is &lt; 160 mmHg systolic and &lt; 100 mmHg diastolic, start with a single drug preferably a Calcium Channel Blocker (use an ACE Inhibitor instead if proteinuria or chronic kidney disease is present)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>If BP is ≥ 160 mmHg systolic or 100 mmHg diastolic, start with two drugs preferably Calcium Channel Blocker + ACE Inhibitor</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Avoid beta blockers as they can mask hypoglycaemia symptoms</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p><em>Cholesterol:</em> Statin therapy with atorvastatin if patients is over 40 years or has a history of atherosclerotic cardiovascular disease. Higher doses are needed for patients with cardiovascular disease.</p>\\r\\n<p><em>Antiplatelet therapy:</em> consider if 10 year cardiovascular risk is &gt; 10% – Soluble aspirin 75 mg daily or clopidogrel 75 mg daily.</p>\\r\\n<p>Encourage patients to seek annual comprehensive eye examination at SZREC.</p>\\r\\n<p>For distal sensory polyneuropathy, carbamazepine or amitriptyline may provide improvement in discomfort over time. Metformin may cause Vitamin B12 deficiency which may contribute to neuropathy. This may be detected as a raised MCV and can be treated with 1 ml Vitamin B12 im monthly.</p>\\r\\n<p><em>Nephropathy:</em> Monitor serum electrolytes, urea and creatinine if proteinuria is present (or on ACE inhibitor). Discuss referral to EFSTH if eGFR is &lt; 60 mL/min/1.73 m<sup>2</sup>.</p>\\r\\n<h3 id=\\\"pregnancy-and-dm\\\">Pregnancy and DM</h3>\\r\\n<div data-custom-style=\\\"Default\\\">\\r\\n<p><em>Pre-existing Type 2 DM:</em> Tight glucose control is important. If this can be achieved on Metformin alone then this can continue. The patient will need specialist obstetric care and many will need insulin treatment.</p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"Default\\\">\\r\\n<p><em>Gestational Diabetes:</em></p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"Default\\\">\\r\\n<p>Lifestyle changes may be adequate for control</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"Default\\\">\\r\\n<p>Metformin is the first line therapy</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"Default\\\">\\r\\n<p>Insulin therapy may be needed.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"Default\\\">\\r\\n<p>Refer for specialist obstetric care</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"management-on-the-ward\\\">Management on the Ward</h2>\\r\\n<p>All adult patients (including those not previously diagnosed diabetic) admitted to the ward should have baseline blood glucose checked.</p>\\r\\n<p>Blood glucose &gt; 7.8 mmol/l in an in-patient is considered as hyperglycaemia. If blood glucose is persistently &gt; 10 mmol/l, consider starting insulin therapy with a target blood glucose of 7.8 – 10.0 mmol/l. Calculate total daily dose (TDD) in units of insulin required.</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>For patients recovering from DKA, TDD may safely be set at two-thirds (2/3) of their previous total daily requirement of IV soluble insulin.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>For patients previously on insulin at home, use previous total daily dose if they were at glucose targets.</p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Otherwise, calculate TDD by multiplying body weight in kg by the factor N from the Table 1 below</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Adjust TDD downward if nutritional intake is less than normal for patient.</p>\\r\\n</div></li>\\r\\n</ul></li>\\r\\n</ul>\\r\\n<p><em>Table 1. Factor for calculating Total Daily Dose of Insulin based on weight:</em></p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>If patient has these features...</strong></th>\\r\\n<th><strong>N =</strong></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Underweight, elderly, CKD or severe liver disease</td>\\r\\n<td>0.3</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Normal-weight patients, including Type 1 diabetes.</td>\\r\\n<td>0.4</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Overweight</td>\\r\\n<td>0.5</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Obese, high-dose steroids, or other markers of significant insulin resistance.</td>\\r\\n<td>0.6</td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<p>For patients who are able to eat or who are given tube feeding boluses, give half the calculated TDD as a <em>basal</em> subcutaneous insulin isophane (Insulatard) either as a single dose or as two divided doses 12 hourly. Give the other half as pre-<em>meal</em> subcutaneous soluble Insulin (Actrapid) 30 minutes before meals with the dose divided equally between the meals.</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>If pre-meal blood glucose is &lt; 3.9 mmol./l, treat for hypoglycaemia and reduce pre-meal doses of regular insulin by half.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>If pre-meal blood glucose is &gt;10 mmol/l, add <em>correctional</em> insulin dose to pre-meal dose of regular insulin using the Table 2 below.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<div data-custom-style=\\\"Default\\\">\\r\\n<p><em>Table 2. Correctional doses of insulin based on pre-meal or 6-hourly blood glucose</em></p>\\r\\n</div>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><em>Blood Glucose (mmol/l)</em></th>\\r\\n<th><em>If TDD &lt;40 units/day, add:</em></th>\\r\\n<th><em>If TDD is 40-80 units/day, add:</em></th>\\r\\n<th><em>If TDD &gt;80 units/day, add:</em></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>&lt; 3.9</strong></td>\\r\\n<td><strong>Reduce dose by half &amp; call doctor</strong></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>4 – 10</td>\\r\\n<td>0 unit</td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>10.1 - 11.0</td>\\r\\n<td>1 unit</td>\\r\\n<td>2 units</td>\\r\\n<td>4 units</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>11.1 - 12.5</td>\\r\\n<td>2 units</td>\\r\\n<td>4 units</td>\\r\\n<td>6 units</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>12.6 - 14.0</td>\\r\\n<td>3 units</td>\\r\\n<td>6 units</td>\\r\\n<td>8 units</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>14.1 - 16.5</td>\\r\\n<td>4 units</td>\\r\\n<td>8 units</td>\\r\\n<td>10 units</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>16.6 - 19.9</td>\\r\\n<td>5 units</td>\\r\\n<td>10 units</td>\\r\\n<td>12 units</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>20 and above</strong></td>\\r\\n<td><strong>6 units</strong></td>\\r\\n<td><strong>12 units</strong></td>\\r\\n<td><strong>14 units</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td></td>\\r\\n<td><strong>Call doctor after giving insulin</strong></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<p>For patients on nil per oral (NPO) or receiving only clear fluids, give only half (50%) of the calculated TDD as <em>basal</em> isophane insulin either as a single subcutaneous doses or as two divided doses every 12 hours. These patients should also receive 5% dextrose infusion at 500 mls 4 – 6 hourly.</p>\\r\\n<p>Check blood glucose 6 hourly. Give <em>correctional</em> dose of insulin if needed</p>\\r\\n<p>Reassess and modify insulin therapy daily based on trends of blood glucose.</p>\\r\\n<h2 id=\\\"key-issues-for-nursing-care\\\">Key Issues for Nursing care</h2>\\r\\n<h2 id=\\\"before-administering-insulin\\\">Before administering insulin:</h2>\\r\\n<ul>\\r\\n<li><h2 id=\\\"always-check-blood-glucose\\\">Always check blood glucose</h2></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Confirm type of insulin to be given and route</p>\\r\\n</div></li>\\r\\n<li><h2 id=\\\"confirm-insulin-concentration-should-be-100-uml\\\">Confirm insulin concentration (should be 100 U/ml)</h2></li>\\r\\n<li><h2 id=\\\"confirm-insulin-syringe-units-should-be-100-uml\\\">Confirm insulin syringe units (should be 100 U/ml)</h2></li>\\r\\n<li><h2 id=\\\"confirm-dosage-before-administration\\\">Confirm dosage before administration</h2></li>\\r\\n</ul>\\r\\n<h2 id=\\\"in-addition-for-pre-meal-insulin\\\">In addition, for pre-meal insulin:</h2>\\r\\n<ul>\\r\\n<li><h2 id=\\\"confirm-availability-of-food\\\">Confirm availability of food</h2></li>\\r\\n<li><h2 id=\\\"confirm-ability-and-willingness-of-patient-to-eat.\\\">Confirm ability and willingness of patient to eat.</h2></li>\\r\\n</ul>\\r\\n<p>Insulin protocols for each patient should be updated daily and available at the bedside.</p>\\r\\n<h2 id=\\\"references\\\">References:</h2>\\r\\n<h2 id=\\\"maynard-g-wesorick-dh-omalley-c-inzucchi-se-on-behalf-of-society-of-hospital-medicine-glycemic-control-task-force.-subcutaneous-insulin-order-sets-and-protocols-effective-design-and-implementation-strategies.-j-hosp-med.-2008-sep35-suppl29-41.-doi-10.1002jhm.354.\\\">Maynard G, Wesorick DH, O&#39;Malley C, Inzucchi SE on behalf of Society of Hospital Medicine Glycemic Control Task Force. Subcutaneous insulin order sets and protocols: effective design and implementation strategies. J Hosp Med. 2008 Sep;3(5 Suppl):29-41. doi: 10.1002/jhm.354.</h2>\\r\\n<h2 id=\\\"langan-rc-goodbred-aj.-vitamin-b12-deficiency-recognition-and-management.-am-fam-physician.-2017-sep-15966384-389\\\">Langan RC, Goodbred AJ. Vitamin B12 Deficiency: Recognition and Management. Am Fam Physician. 2017 Sep 15;96(6):384-389</h2>\\r\\n<h2 id=\\\"american-diabetes-association.-standards-of-medical-care-in-diabetes2018.-diabetes-care-201841suppl.-1\\\">American Diabetes Association. Standards of Medical Care in Diabetes—2018. Diabetes Care 2018;41(Suppl. 1)</h2>\\r\\n<p>Type 2 diabetes mellitus in adults. BMJ Best Practice. November 2017. Accessed 26th June 2018. Available at bestpractice.bmj.com</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Fatai Akemokwe</th>\\r\\n<th>Date: 30 June 2018</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Karen Forrest</td>\\r\\n<td>Date: 24 July 2018</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>2.0</td>\\r\\n<td>Expanded to include management in areas outside gate clinic</td>\\r\\n<td>31 July 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>2.1</td>\\r\\n<td>Executive summary added</td>\\r\\n<td>31 July 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"021\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>DKA MeG-CLS-021</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"diabetic-ketoacidosis-dka\\\">Diabetic Ketoacidosis (DKA)</h1>\\r\\n<h2 id=\\\"executive-summary\\\"><em>Executive summary</em></h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<p>Diabetic ketoacidosis is an acute, major, life-threatening complication of diabetes that mainly occurs in patients with type 1 diabetes, but it is not uncommon in some patients with type 2 diabetes. This condition is a complex disordered metabolic state characterized by hyperglycaemia, acidosis and ketonuria.</p>\\r\\n<p>This might be the <strong>FIRST</strong> presentation of diabetes mellitus.</p>\\r\\n<h2 id=\\\"target-user\\\">Target User</h2>\\r\\n<ul>\\r\\n<li><p>Doctors</p></li>\\r\\n<li><p>Nurses</p></li>\\r\\n</ul>\\r\\n<h2 id=\\\"target-area-of-use\\\">Target area of use </h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ward</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"key-areas-of-focusnew-additionschanges\\\">Key areas of focus/new additions/changes</h2>\\r\\n<p>This guideline addresses the management of DKA in our setting. It does not address ongoing management of diabetes after the initial admission.</p>\\r\\n<h2 id=\\\"limitations\\\">Limitations</h2>\\r\\n<p>Unavailability of blood gas analyzers means we are unable to get blood pH values and therefore have to wait at least 2 hours to get bicarbonate results in order to confirm the diagnosis.</p>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs\\\">Presenting symptoms and signs</h2>\\r\\n<p>Polydipsia, polyphagia, malaise, generalized weakness, nausea, vomiting, weight loss, decreased perspiration, altered consciousness, recurrent boils, persisting vaginal yeast infection, blurred vision, excessive tiredness</p>\\r\\n<p><strong>WITH</strong></p>\\r\\n<p>Fasting blood glucose of 7.0 mmol/L or higher</p>\\r\\n<p><strong>OR</strong></p>\\r\\n<p>A two hour post prandial glucose level of 11.1 mmol/l or higher</p>\\r\\n<p><strong>OR</strong></p>\\r\\n<p>A random blood glucose of 11.1 mmol/l or higher plus the classic symptoms of diabetes mellitus.</p>\\r\\n<p><strong>AND</strong></p>\\r\\n<p>Presence of ketones of ++ and above in urine</p>\\r\\n<p><strong>AND</strong></p>\\r\\n<p>Acidosis with serum bicarbonate of less than 18 mmol/L or blood pH less than 7.3</p>\\r\\n<h2 id=\\\"examination-findings\\\">Examination findings</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Looks sick</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Dry skin</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Laboured respiration</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Dry mucous membrane</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Decreased skin turgor</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Decreased reflexes</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Characteristic acetone breath</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Tachycardia</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hypotension</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Tachypnea</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hypotension</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Tachypnoea</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hypothermia</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Fever, if infection is present</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Confusion</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Coma</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Abdominal tenderness</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"differential-diagnosis\\\">Differential Diagnosis</h2>\\r\\n<p>Many of these may also precipitate DKA; beware of co-existing disease processes</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hypoglycaemia</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Subdural hematoma</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Stroke</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Cerebral malaria</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Meningitis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Sepsis</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"management\\\">Management </h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Call for help</strong> (other doctors, senior nurses).</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Check Airway, Breathing and Circulation.</strong> Ensure the patient is alive!</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Get two intravenous access</strong> with the widest cannula possible for the patient (try sizes 20 pink cannula, 22 blue cannula for children and 18 green cannula, 16 grey cannula for adults).</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>If in shock, give 10 mls/kg up to 1 litre of 0.9% normal saline after determining true weight. Give this over 30 minutes.</strong></p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Take samples: Blood: K, Na, HCO<sub>3</sub>, FBC, blood culture, Urine dipstick, urine: culture &amp; sensitivity.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Chest X-ray</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"immediate-treatment-in-children\\\">Immediate treatment in children</h3>\\r\\n<p>Treat DKA with oral fluids and subcutaneous insulin <strong>only</strong> if the child or young person is alert, not nauseated or vomiting, and not clinically dehydrated. If DKA is treated with oral fluids and subcutaneous insulin, ensure that the child or young person is recovering by monitoring for resolution of ketonaemia and acidosis.</p>\\r\\n<p>Treat DKA with intravenous fluids and intravenous insulin if the child or young person <strong>is not alert, is nauseated or vomiting or is clinically dehydrated.</strong></p>\\r\\n<p><strong>Fluid replacement:</strong> Use 0.9% normal saline.</p>\\r\\n<p>In children and young people with DKA, calculate their total fluid requirement for the first 48 hours by adding the estimated fluid deficit to the fluid maintenance requirement.</p>\\r\\n<p>When calculating the fluid requirement for children and young people with DKA, assume:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>a 5% fluid deficit in mild to moderate DKA (indicated by a HCO<sub>3</sub> above 8 mmol/l).</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>a 10% fluid deficit in severe DKA (indicated by a HCO<sub>3</sub> of 8 mmol/l or below).</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Calculate the maintenance fluid requirement for children and young people with DKA using the following &#39;reduced volume&#39; rules:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>if they weigh less than 10 kg, give 2 ml/kg/hour.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>if they weigh between 10 and 40 kg, give 1 ml/kg/hour.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>if they weigh more than 40 kg, give a fixed volume of 40 ml/hour.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>These are lower than standard fluid maintenance volumes because <strong>large fluid volumes are associated with an increased risk of cerebral oedema.</strong> Aim to replace the fluid deficit evenly over the first <span data-custom-style=\\\"no-break\\\">48 hours</span> in children and young people with DKA.</p>\\r\\n<p>Think about stopping intravenous fluid therapy for DKA in a child or young person if ketosis is resolving, they are alert, and they can take oral fluids without nausea or vomiting.</p>\\r\\n<p>Note:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Do not give an intravenous fluid bolus to children and young people with mild or moderate DKA (indicated by a HCO<sub>3</sub> above 8 mmol/l).</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Do not routinely give an intravenous fluid bolus to a child or young person with severe DKA (HCO<sub>3</sub> of 8 mmol/l or below).</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Do not give children and young people with DKA additional intravenous fluid to replace urinary losses.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p><strong>Insulin: Start an intravenous insulin infusion 1–2 hours</strong> after beginning intravenous fluid therapy in children and young people with DKA.</p>\\r\\n<p>Add 50 U actrapid to 50 ml 0.9% saline. Infuse insulin continuously at a dosage of between 0.05 and 0.1 U/kg/hour. Do not give bolus doses of intravenous insulin.</p>\\r\\n<p>Do not change from intravenous insulin to subcutaneous insulin in a child or young person with DKA until ketosis is resolving, they are alert, and they can take oral fluids without nausea or vomiting.</p>\\r\\n<p>Start subcutaneous insulin in a child or young person with DKA at least 30 minutes before stopping intravenous insulin.</p>\\r\\n<p><strong>Potassium replacement:</strong> Add K to fluid when patient is resuscitated and has started passing urine. Typical deficit is 3-5 mmol/kg. Plasma K falls with insulin administration. See table 1 below for guidance.</p>\\r\\n<p><strong>Table 1:</strong></p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Serum K Level (mmol/L)</strong></th>\\r\\n<th><strong>KCl amount to add per Litre of Fluid</strong></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>K &gt; 5.5</td>\\r\\n<td>No need to add KCL</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>K &lt; 5.5</td>\\r\\n<td>Add <strong>20 mmol</strong> of KCl</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>K &lt; 4.0</td>\\r\\n<td>Add <strong>30 mmol</strong> of KCl</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>K &lt; 3.0</td>\\r\\n<td>Add <strong>40 mmol</strong> of KCl</td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<h3 id=\\\"immediate-treatment-in-adults\\\">Immediate treatment in adults</h3>\\r\\n<p><strong>Fluid replacement:</strong> Use 0.9% normal saline.</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Typical fluid deficit is 100 ml/kg. Replace over 48 hours. Initially give 1 litre in 1<sup>st</sup> hour, 1L over 2 hours, 1 l over 2 hours, Il over 4 hours, 1L over 4 hours.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Most patient will require 4-6 litres of fluid in the first 24 hours.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Review fluid balance 4-6 hourly.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p><strong>Insulin:</strong> Start an infusion after rehydrating with 1-2 litres of 0.9% normal saline.</p>\\r\\n<p>Add 50 U actrapid to 50 ml 0.9% saline. Infuse insulin insulin continuously at 0.1 U/kg/hour. Aim for decreasing blood glucose by 3 mmol/L per hour and increasing bicarbonate by 3 mmol/l/hour. Run insulin in one iv line, while you run normal saline in the other line.</p>\\r\\n<p>Continue fixed rate insulin until bicarbonate is &gt; 18 mmol/l. After then, switch to sliding scale insulin for 24 hours to enable estimation of 24 hour insulin requirement. Use table 2 below to guide this.</p>\\r\\n<p><strong>Table 2:</strong></p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Blood glucose (mmol/l per hour)</strong></th>\\r\\n<th><strong>Insulin Infusion (units/hour)</strong></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>0.0-2.0</td>\\r\\n<td>Stop insulin-call doctor on duty</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>2.1-4.0</td>\\r\\n<td>Call doctor on duty</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>4.1-7.0</td>\\r\\n<td>0.5-1</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>7.1-11.0</td>\\r\\n<td>2</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>11.1-20.0</td>\\r\\n<td>4</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>&gt; 20.0</td>\\r\\n<td>7 &amp; call doctor on duty</td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<p>When glucose is &lt; 14 mmol/l, add 5% glucose to run with 0.9% saline and prevent hypoglycaemia. Aim to maintain blood sugar at 8-12 mmol/l.</p>\\r\\n<p><strong>Potassium replacement:</strong> Add K to fluid when patient is resuscitated and has started passing urine. Typical deficit is 3-5 mmol/kg. Plasma K falls with insulin administration. Use table 1 above.</p>\\r\\n<h3 id=\\\"transition-from-iv-insulin-and-fluids\\\">Transition from iv insulin and fluids</h3>\\r\\n<p>iv fluids can be stopped 1–2 hours after substantial consumption of oral fluids without vomiting, if there are no ketones and the serum HCO3 is above 15 mmol/l.</p>\\r\\n<p>Subcutaneous insulin injection can be started when iv fluids are no longer needed. Pre-supper or pre-breakfast time is most convenient for starting or restarting intermediate- or long-acting insulin. Before then, rapid-acting or regular insulin 0.25 U/kg subcutaneously can be given every ∼6 hours, and the insulin infusion stopped 60–120 minutes after the first subcutaneous dose of regular insulin or 60 minutes after a rapid-acting insulin analog.</p>\\r\\n<p>Patients should not be kept in the hospital simply to adjust insulin dosage because food, activity, and psychosocial environment are not normal in the hospital setting. Therefore, insulin requirements will not be particularly informative for home management.</p>\\r\\n<p>Established patients with DKA can resume their usual home dose of insulin.</p>\\r\\n<h3 id=\\\"ongoing-inpatient-management\\\">Ongoing inpatient management</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Check serum K, HCO<sub>3</sub> &amp; glucose every 6 hours.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Do hourly temperature, BP, neurological observations (GCS or BCS) , fluid balance and bedside blood sugar.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>If the patient has not passed urine by one hour into resuscitation, consider passing urinary catheter. Aim for a urinary output of &gt; 0.5 ml/kg/hour.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Change fluids to 0.9% normal saline with 5% glucose once the plasma glucose concentration falls below 14 mmol/l in children and young people with DKA.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Consider NG tube if vomiting or drowsy.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Do not give intravenous sodium bicarbonate to patients with DKA.</strong></p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Find and treat the cause of the DKA e.g. infection or other intercurrent illness, poor adherence to meds for previously known patients. Investigate as appropriate e.g. Chest X-ray, FBC, Blood culture, urine culture.</p>\\r\\n<p>Stop iv insulin infusion when BM is between 11.1-13.9 mmol/l and serum HCO<sub>3</sub> &gt; 15 mmol/l. Then switch to sc insulin at 0.5-0.8 U/kg in divided doses. Note that we usually have soluble insulin (actrapid) and isophane insulin (insulatard) available. Mixtard 30:70 is available for staff and their dependent relatives only.</p>\\r\\n<h3 id=\\\"long-term-care-of-diabetes\\\">Long term care of diabetes</h3>\\r\\n<p>At least in the short term, all children and many adults will need to remain on insulin. They should be referred to EFSTH or Pakala clinic in Banjul on discharge from the ward, as these clinics are able to provide insulin therapy to outpatients.</p>\\r\\n<p>Adults whose ketoacidosis has very rapidly resolved within 24 hours of admission may be switched to oral therapy prior to discharge from the ward. Guidance for their long term care can be found in the diabetes mellitus guideline.</p>\\r\\n<h2 id=\\\"key-issues-for-nursing-care\\\">Key Issues for Nursing care</h2>\\r\\n<p><strong>Assess skin turgor, mucous membranes, and thirst</strong>: This is to provide baseline data for further comparison. Skin turgor will decrease and tenting may occur. The oral mucous membranes will become dry, and the client may experience extreme thirst.</p>\\r\\n<p><strong>Monitor hourly intake and output:</strong> Oliguria or anuria results from reduced glomerular <a href=\\\"https://nurseslabs.com/fluid-and-electrolytes/\\\">filtration</a> and renal blood flow.</p>\\r\\n<p><strong>Monitor respirations, e.g., acetone breath, Kussmaul’s respirations</strong>: Acetone breath is due to the breakdown of acetoacetic acid. Kussmaul’s respiration (rapid and shallow breathing) represent a compensatory mechanism by the respiratory buffering system to raise arterial pH by exhaling more carbon dioxide.</p>\\r\\n<p><strong>Monitor heart rate</strong>: Compensatory mechanism results in peripheral vasoconstriction with a weak, thready pulse that is easily obliterated.</p>\\r\\n<p><strong>Monitor BP especially for orthostatic <a href=\\\"https://nurseslabs.com/hypovolemic-shock-nursing-care-plans/\\\">hypotension</a></strong>: Decreased blood volume may be manifested by a drop in systolic <a href=\\\"https://nurseslabs.com/cardiovascular-system-anatomy-physiology/\\\">blood pressure</a> and orthostatic hypotension</p>\\r\\n<p><strong>Assess for signs of infection and inflammation</strong>: Infection is a common cause of DKA. Signs of infection includes fever, chills, <a href=\\\"https://nurseslabs.com/impaired-urinary-elimination/\\\">dysuria</a>, and increased WBC count</p>\\r\\n<p><strong>Observe client’s feet for ulcers, infected toenails, or other medical problems and</strong> <strong>provide wound care where necessary</strong> : Due to impaired circulation in diabetes, foot injuries are predisposed to poor wound healing.</p>\\r\\n<p><strong>Observe aseptic technique during IV <a href=\\\"https://nurseslabs.com/muscular-system-anatomy-physiology/\\\">insertion</a> and medication administration</strong>: Elevated blood sugar weakens the immune system thus clients are more <a href=\\\"https://nurseslabs.com/patient-positioning/\\\">prone</a> to infection.</p>\\r\\n<p><strong>Administer <a href=\\\"https://nurseslabs.com/antibiotics/\\\">antibiotics</a></strong> as indicated: Early initiation of <a href=\\\"https://nurseslabs.com/antibiotics/\\\">antibiotic</a> may help to prevent <a href=\\\"https://nurseslabs.com/sepsis-nursing-care-plans/\\\">sepsis</a>.</p>\\r\\n<p><strong>Teach signs of hypoglycaemia:</strong> eg, dizziness, sweating, hunger, pallor, diaphoresis, nervousness, tremors. These are signs of excessive insulin dosage, resulting in hypoglycemia. Early recognition of these symptoms promotes immediate intervention.</p>\\r\\n<p><strong>Determine client’s dietary program and usual pattern</strong>: Recognizes deficits and deviations from therapeutic needs</p>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<p>von Oettingen J, Wolfsdorf J, Feldman HA, Rhodes ET. Use of Serum Bicarbonate to Substitute for Venous pH in New-Onset Diabetes. Pediatrics 2015; 136: e371–7.</p>\\r\\n<p>Internal Diabetes Foundation clinical guidelines for the management of diabetes.</p>\\r\\n<p>American Diabetes Foundation-Diabetes care Guidelines</p>\\r\\n<p>Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar Nonketotic Syndrome Nursing Care Plans <a href=\\\"https://nurseslabs.com/diabetic-ketoacidosis-nursing-care-plans/\\\"><span data-custom-style=\\\"Hyperlink\\\">https://nurseslabs.com/diabetic-ketoacidosis-nursing-care-plans/</span></a> (Accessed on 16/8/2018)</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Amie Secka</th>\\r\\n<th>Date: 03 June 2018</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Baderinwa Abatan</td>\\r\\n<td>Date: 01 August 2018</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>2.0</td>\\r\\n<td>Previous guidelines for adults and children were combined, transferred onto new template and updated.</td>\\r\\n<td>15 August 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>2.1</td>\\r\\n<td>Executive summary</td>\\r\\n<td>15 August 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"034\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>Dyspepsia MeG-CLS-034</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"dyspepsia\\\">Dyspepsia</h1>\\r\\n<h2 id=\\\"executive-summary\\\"><em>Executive summary</em></h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<p>Dyspepsia refers to symptoms arising from the upper GI tract. They may be caused by gastro-oesophageal reflux disease (GORD), peptic ulcer disease or functional disorders. 60-75% of patients with dyspepsia are estimated to have a functional rather than an organic cause.</p>\\r\\n<h2 id=\\\"target-users\\\">Target users</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doctors</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nurses</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"target-area-of-use\\\">Target area of use </h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Gate clinic</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Outpatients department</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"key-areas-of-focus-new-additions-changes\\\">Key areas of focus / New additions / Changes </h2>\\r\\n<p>This guideline outlines the management of dyspepsia due to reflux, peptic ulcer disease or functional disorders.</p>\\r\\n<h2 id=\\\"limitations\\\">Limitations</h2>\\r\\n<p>In view of our limited access to endoscopy, the guidelines aim to promote safe treatment of dyspepsia with relatively low usage of investigations.</p>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs\\\">Presenting symptoms and signs</h2>\\r\\n<p>Dyspeptic symptoms divide into two groups:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>heartburn and other symptoms typical of GORD</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>epigastric pain and other symptoms typical of peptic ulcer disease.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>In both cases, symptoms may be structural or organic in origin.</p>\\r\\n<h3 id=\\\"heartburn-gord\\\">Heartburn / GORD</h3>\\r\\n<p>A retrosternal burning sensation that may move upwards from the epigastrium to the neck or face.</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>May coexist with other upper GI symptoms.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>May be accompanied by regurgitation of sour tasting fluid or gastric contents into the mouth.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Symptoms usually intermittent. Often experienced soon after eating, during exercise, whilst lying down and at night.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Usually no abnormalities to identify on examination.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"peptic-ulcer-disease-functional-dyspepsia\\\">Peptic ulcer disease / Functional dyspepsia</h3>\\r\\n<p>A chronic or recurrent pain in the upper abdomen.</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>May be associated with a feeling of fullness when eating or inability to eat a full meal.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>May be accompanied by bloating, belching, nausea or heartburn.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>May be worsened or improved by eating.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"alarm-features-and-other-diagnoses\\\">Alarm features and other diagnoses</h3>\\r\\n<p>The presence of any of the following features suggests the possibility of malignancy or another serious illness. <strong>Refer to the Dr in OPD, in the presence of any of the following:</strong></p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Dysphagia or odynophagia</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Persistent vomiting</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Aspiration pneumonia or respiratory symptoms</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Altered voice</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>GI bleeding</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Persistent unintentional weight loss</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>New onset of symptoms over the age of 50 years</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Family history of oesophageal or gastric carcinoma</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Features which suggest other diagnoses include:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Symptoms related to physical activity, the menstrual cycle, urination or defecation</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Urinary urgency</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Abnormalities on examination</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>All such patients should be referred to the doctor.</p>\\r\\n<h2 id=\\\"examination-findings-doctors-should-look-for\\\">Examination findings doctors should look for;</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Most common finding is usually epigastric tenderness.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Melaena stool on PR, anaemia may suggest upper GI bleeding</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Succussion splash on abdominal examination may suggest partial or complete gastric outlet obstruction</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Severe abdominal pain, rebound tenderness, guarding &amp; rigidity may indicate a perforated PUD.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Epigastric mass, lymphadenopathy especially in the elderly strongly suggest malignancy.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"investigations\\\">Investigations</h2>\\r\\n<p>Dyspepsia may initially not require investigation (see management flowchart below).</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>The most important investigations in diagnosing PUD, gastric tumours, GORD are radiographic &amp; endoscopy.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Lab test (FBC, LFTs): laboratory abnormalities such as microcytic anaemia, low albumin, abnormal LFTs, raised ESR may suggest malignancy.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Barium meal: addition image may suggest ulcer while a filling defect malignancy.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Endoscopy is the mainstay of diagnosis and in some cases treatment.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Urinalysis and Abdominal US can be done to rule out other differentials.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"management\\\">Management</h2>\\r\\n<h3 id=\\\"heartburn-gord-1\\\">Heartburn / GORD</h3>\\r\\n<p>In the absence of alarm symptoms, patients should manage their symptoms themselves.</p>\\r\\n<p>Explain that this is likely to be a chronic problem which will recur from time to time.</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Identify trigger foods and behaviours and avoid these. Typical triggers include: ataya, coffee, alcohol, soft drinks, chocolate, oily foods, citrus fruits, tomatoes, garlic, onions and peppery foods.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Encourage weight loss if overweight.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Lifestyle changes may be effective and include: eating smaller meals more frequently, elevating the head of the bed by 20-25 cm by placing something under the legs and avoiding food or drink 3 hours prior to lying down at night.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Avoid drugs which cause heartburn including: NSAIDs, iron, doxycycline, phenobarbitone, beta-blockers, nifedipine or amlodipine, OCP, codeine, aminophylline and amitriptyline. ART can also cause heartburn, but this cannot be avoided and instead, patients may need ongoing treatment with omeprazole.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>For infrequent symptoms, patients may be offered antacids (such as magnesium trisilicate) to take when they are symptomatic. They may also take ranitidine 150 mg BD for short periods during symptomatic periods.</p>\\r\\n<p>For more frequent symptoms, omeprazole 20 mg BD should be prescribed for 2 weeks. In most cases, this should cause acid-related symptoms to resolve. Omeprazole can then be given on a PRN basis – with patients taking treatment for a few days if symptoms recur.</p>\\r\\n<p><strong>If symptoms persist after a 2 week course of omeprazole, <em>refer</em> the patient to the doctor</strong> who should consider other diagnoses</p>\\r\\n<p>Very severe cases of GORD may require ongoing treatment with omeprazole as well as the use of prokinetic agents. Metoclopramide is the only agent available in this context.</p>\\r\\n<p>Although severe GORD is associated with complications such as oesophageal stricture, Barrett’s oesophagus and oesophageal carcinoma, these are rare occurrences and we do not have the resources to prevent them in this context. <strong>Note that GORD is not associated with <em>H. pylori</em> infection and eradication does not usually help the patient.</strong></p>\\r\\n<h3 id=\\\"peptic-ulcer-disease-functional-dyspepsia-1\\\">Peptic ulcer disease / Functional dyspepsia</h3>\\r\\n<p>Any patient taking NSAIDs should stop these and be advised to avoid them in the future.</p>\\r\\n<p>In the absence of alarm features, begin by presuming the presence of <em>H. pylori</em>. <em>Refer</em> to the doctor for <em>H. pylori</em> eradication. Also refer any patient with symptoms of peptic ulcer disease or functional dyspepsia.</p>\\r\\n<p>See the flow chart on the next page for initial management of these patients.</p>\\r\\n<p>Patients with <strong>functional dyspepsia</strong> may benefit from longer term treatment with omeprazole 20-40 mg OD. Patients failing to respond to this may benefit from amitriptyline 10-25 mg nocte for a minimum of 8 weeks. Citalopram 20 mg nocte should be used in preference for staff and those who can afford it. If this effective it can be continued for 6 months in the first instance. If an attempt to withdraw treatment is unsuccessful, it can be continued long term. A small number of patients failing to respond to this may benefit from a 4 week trial of metoclopramide 10 mg 30 minutes prior to food and at night (QDS). This can be continued if it is effective.</p>\\r\\n<p><strong>Refer to ESFTH Surgical unit, if the following complications arise:</strong></p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Perforation (acute abdomen)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Malignancy</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Gastric outflow obstruction</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Complications like bleeding (hematemesis/melaena) should be managed by endoscopic therapy.</p>\\r\\n<h2 id=\\\"flow-chart-for-management-of-pud-functional-dyspepsia\\\">Flow chart for management of PUD / functional dyspepsia</h2>\\r\\n<p>If ≥ 55 years or alarm features, request for urgent endoscopy – see separate guidance on when to request endoscopy. If on NSAIDs, stop. In all other cases, consider the following management plan<strong>:</strong><img src=\\\"data:image/png;base64,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\\\" style=\\\"width:6in;height:5.33125in\\\" /></p>\\r\\n<h2 id=\\\"key-issues-for-nursing-care\\\">Key Issues for Nursing care</h2>\\r\\n<p>Refer to the doctor any patient with:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Dysphagia or odynophagia</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Persistent vomiting</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Aspiration pneumonia or respiratory symptoms</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Altered voice</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>GI bleeding</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Laboratory abnormalities such as microcytic anaemia, low albumin, abnormal LFTs, raised ESR</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Persistent unintentional weight loss</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Lymphadenopathy</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Epigastric mass</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>New onset of symptoms over the age of 50 years</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Family history of oesophageal or gastric carcinoma</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Symptoms related to physical activity, the menstrual cycle, urination or defecation</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Urinary urgency</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Abnormalities on examination.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Also refer patients with reflux symptoms that persist despite treatment with omeprazole and any patient with symptoms of peptic ulcer disease or functional dyspepsia.</p>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<p>Guideline Chey WD, Wong BC. American College of Gastroenterology guideline on the management of H pylori infection. Am J Gastroenterol.2007 Aug. 102(8):1808-25. [Medline]</p>\\r\\n<p>Wilkinson IB et al. Oxford Handbook of Clinical Medicine. Oxford University Press, 2017.</p>\\r\\n<p>Longstreth and Lacy 2017. Approach to the adult with dyspepsia. UpToDate Jan 2017.</p>\\r\\n<p>Kahrilas 2017. Clinical manifestations and diagnosis of gastroesophageal reflux in adults. UpToDate Jul 2017</p>\\r\\n<p>Kahrilas 2016. Medical management of gastroesophageal reflux disease in adults. UpToDate Mar 2016.</p>\\r\\n<p>Vakil 2017. Peptic ulcer disease: Clinical manifestations and diagnosis. UpToDate Sept 2017.</p>\\r\\n<p>Vakil 2017. Peptic ulcer disease: Management. UpToDate Sept 2017.</p>\\r\\n<p>Crowe 2017. Treatment regimens for Helicobacter pylori. UpToDate, Jul 2017.</p>\\r\\n<p>Longstreth and Lacy 2017. Functional dyspepsia in adults. UpToDate Apr 2017.</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Musa Jallow</th>\\r\\n<th>Date: 1 June 2018</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Karen Forrest</td>\\r\\n<td>Date: 21 June 2018</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>2.0</td>\\r\\n<td>Adapted from MEG-CLS-006 and version 1.0 of this document and updated</td>\\r\\n<td>31 July 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>2.1</td>\\r\\n<td>Executive summary added</td>\\r\\n<td>31 July 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"070\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>Ear pain MeG-CLS-070</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"ear-pain\\\">Ear pain</h1>\\r\\n<h2 id=\\\"executive-summary\\\"><em>Executive summary</em></h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<p>Ear pain (or otalgia) ranks as one of the common complaints among adults and especially children evaluated in the primary care or emergency setting. Most patients will have one of three common diagnoses (acute otitis media, otitis externa, or otitis media with effusion) which are generally not dangerous. The rare cases of more severe disease associated with ear pain usually result from extension of the ear infection to adjacent anatomic structures (e.g. mastoiditis, meningitis, malignant otitis externa, venous sinus thrombosis). A basilar skull fracture or epidural hematoma after head trauma may also present with ear pain.</p>\\r\\n<h2 id=\\\"target-users\\\">Target users</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doctors</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nurses</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"target-area-of-use\\\">Target area of use </h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Gate clinic</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Outpatient department</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ward</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"key-areas-of-focus-new-additions-changes\\\">Key areas of focus / New additions / Changes </h2>\\r\\n<p>This guideline outlines the differential diagnosis of ear pain and an approach to diagnosis. Management of common problems not addressed in other guidelines is briefly outlined.</p>\\r\\n<h2 id=\\\"limitations\\\">Limitations</h2>\\r\\n<p>Problems requiring surgical input will need referral elsewhere.</p>\\r\\n<h2 id=\\\"common-causes-of-ear-pain\\\">Common causes of ear pain</h2>\\r\\n<p>The causes of ear pain can be categorised by the anatomic site from which the pain originates:</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Auricle</strong></th>\\r\\n<th><strong>Diseases of the ear canal</strong></th>\\r\\n<th><strong>Diseases of the middle and inner ear</strong></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><p>Auricular haematoma or abrasions and lacerations – may suggest underlying basilar skull fracture</p>\\r\\n<p>Cellulitis</p>\\r\\n<p>Herpes zoster oticus</p></td>\\r\\n<td><p>Otitis externa</p>\\r\\n<p>Furuncle in ear canal</p>\\r\\n<p>Cerumen Impaction</p>\\r\\n<p>Foreign bodies</p></td>\\r\\n<td><p>Traumatic perforation of the TM (tympanic membrane)</p>\\r\\n<p>Acute otitis media</p>\\r\\n<p>Cholesteatoma</p></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<p>Pain may also originate outside the ear, known as secondary otalgia. The referred pain arises from nerves that partially innervate the auricle or external auditory canal and include spinal nerves C2 and C3 and cranial nerves V, VII, IX, and X.</p>\\r\\n<p>Two common examples include:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Parotitis — Parotid gland disorders cause pain just inferior to the ear. On examination, swelling and tenderness of this region will be evident, occasionally with overlying redness.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Temporomandibular joint (TMJ) dysfunction syndrome</strong> — Dysfunction of the temporal mandibular joint (TMJ) is common in children over 10 years of age.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs\\\">Presenting symptoms and signs</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Fever: common in minor illnesses, such as uncomplicated otitis media and upper respiratory infection with associated otitis media with effusion</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nasal congestion</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ear discharge</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Decreased hearing</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Dysphagia, odynophagia and jaw pain especially in children</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nausea, vomiting, focal neurologic complaints, or seizures, all of which may suggest intracranial injury</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"examination-findings\\\">Examination findings</h2>\\r\\n<p>An attempt should be made to examine the ear, including otoscopy when necessary.</p>\\r\\n<p>The findings will help you make a diagnosis as outlined below:</p>\\r\\n<p><img src=\\\"data:image/png;base64,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\\\" style=\\\"width:5.02153in;height:3.91721in\\\" /></p>\\r\\n<h2 id=\\\"investigations\\\">Investigations</h2>\\r\\n<h2 id=\\\"in-most-routine-cases-of-ear-pain-laboratory-investigations-are-not-necessary-however-investigations-may-be-appropriate-in-cases-where-more-serious-diagnoses-are-suspected.-some-of-which-may-include\\\">In most routine cases of ear pain, laboratory investigations are not necessary, however, investigations may be appropriate in cases where more serious diagnoses are suspected. Some of which may include:</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>FBC and ESR</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Bacterial or fungal culture of ear drainage: Reserved for patients with severe external otitis associated with periauricular cellulitis or fever.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Blood culture – if bacteraemia is suspected.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Lumbar puncture especially in children with signs of meningitis (A CT should be considered to exclude a brain abscess in such patients).</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"management\\\">Management </h2>\\r\\n<p>Management will depend on the diagnosis made:</p>\\r\\n<h3 id=\\\"otitis-externa\\\">Otitis externa</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Topical - Ciprofloxacin 0.2% otic solution (alone or in combination with dexamethasone 0.1% otic suspension) 3-4 drops BD in adult and children for up to 3 days after cessation of symptoms.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>The major components of managing external otitis include cleaning the ear canal, treating inflammation and infection, and pain control. To aid the absorption of antibiotics, a cotton wick may be placed in the affected ear after antibiotic application.</p>\\r\\n<h3 id=\\\"otitis-media\\\">Otitis media</h3>\\r\\n<p>See separate guideline MeG-CLS-023.</p>\\r\\n<h3 id=\\\"cerumen-accumulation\\\">Cerumen accumulation</h3>\\r\\n<p>Use cerumenolytic agents like Cerumol at two drops nocte for 5 days. Irrigation can be done if the above measure does not help.</p>\\r\\n<p>Other problems originating in the ear including perforated TM and difficult to remove wax or foreign body will require referral to an ENT specialist.</p>\\r\\n<h2 id=\\\"key-issues-for-nursing-care\\\">Key Issues for Nursing care</h2>\\r\\n<ul>\\r\\n<li><h2 id=\\\"refer-all-patients-who-do-not-respond-to-simple-treatment-as-expected-to-the-doctor.\\\">Refer all patients who do not respond to simple treatment as expected to the doctor.</h2></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Patients with otitis externa should be advised on keeping ears dry. Patients should be advised not to use any objects (including cotton buds) to clean inside their ears.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>All cases of traumatic ear injury and foreign body in the ear should be referred to the doctor.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<p>Ghanem T, Rasamny JK, Park SS. Rethinking auricular trauma. Laryngoscope 2005; 115:1251.</p>\\r\\n<p>Kansu L, Yilmaz I. Herpes zoster oticus (Ramsay Hunt syndrome) in children: case report and literature review. Int J Pediatr Otorhinolaryngol 2012; 76:772.</p>\\r\\n<p>Rosenfeld RM, Schwartz SR, Cannon CR, et al. Clinical practice guideline: acute otitis externa. Otolaryngol Head Neck Surg 2014; 150:S1.</p>\\r\\n<p>Rubin J, Yu VL, Stool SE. Malignant external otitis in children. J Pediatr 1988; 113:965.</p>\\r\\n<p>Lieberthal AS, Carroll AE, Chonmaitree T, et al. The diagnosis and management of acute otitis media. Pediatrics 2013; 131:e964.</p>\\r\\n<p>Hydén D, Akerlind B, Peebo M. Inner ear and facial nerve complications of acute otitis media with focus on bacteriology and virology. . Acta Otolaryngol 2006; 126:460.</p>\\r\\n<p>Wu JF, Jin Z, Yang JM, et al. Extracranial and intracranial complications of otitis media: 22-year clinical experience and analysis. Acta Otolaryngol 2012; 132:261.</p>\\r\\n<p>Hafidh MA, Keogh I, Walsh RM, et al. Otogenic intracranial complications. a 7-year retrospective review. Am J Otolaryngol 2006; 27:390.</p>\\r\\n<p>American Academy of Pediatrics Subcommittee on Management of Acute Otitis Media. Diagnosis and management of acute otitis media. Pediatrics. 2004 May;113(5):1451.</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Okpara Chibuike</th>\\r\\n<th>Date: 04 May 2019</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Karen Forrest</td>\\r\\n<td>Date: 22 May 2019</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td>31 May 2021</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"078\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>Endoscopy indications MeG-CLS-078</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"endoscopy-indications\\\">Endoscopy – indications</h1>\\r\\n<h2 id=\\\"executive-summary\\\"><em>Executive summary</em></h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<p>We are able to provide both upper and lower GI endoscopy. Referral for this service is to made through the EMRS system and according to this guidance. Note that you will have to give details about your patient’s fitness for the procedure when booking it using the ASA score.</p>\\r\\n<p>If you have any patient you believe may benefit from endoscopy who falls outside these guidelines please discuss with the endoscopist.</p>\\r\\n<h2 id=\\\"target-users\\\">Target users</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doctors</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nurses</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"target-area-of-use\\\">Target area of use </h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Outpatients</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ward</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"key-areas-of-focus-new-additions-changes\\\">Key areas of focus / New additions / Changes </h2>\\r\\n<p>This document outlines the indications for endoscopy in our service.</p>\\r\\n<h2 id=\\\"limitations\\\">Limitations</h2>\\r\\n<p>None</p>\\r\\n<h2 id=\\\"upper-gi-endoscopy\\\">Upper GI endoscopy</h2>\\r\\n<h3 id=\\\"urgent-referrals\\\">Urgent referrals</h3>\\r\\n<p>Refer the following patients for urgent endoscopy:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Anyone with dysphagia</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Anyone with an upper abdominal mass consistent with stomach cancer (after doing an US).</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Patients aged 55 years and older who have weight loss and one of upper abdominal pain, reflux or dyspepsia.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Anyone with findings suggestive of upper GI malignancy on barium study, CT or US.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Patients with haematemesis</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>When patients are admitted with active GI bleeding and haemodynamic instability, resuscitate the patient and urgently contact the endoscopist for review and possible emergency endoscopy.</p>\\r\\n<h3 id=\\\"routine-referrals\\\">Routine referrals</h3>\\r\\n<p>Refer the following patients for routine endoscopy:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Patients aged 55 years and older who have:</p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>treatment resistant dyspepsia</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>upper abdominal pain and low Hb</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>raised platelet count and nausea, vomiting, weight loss, reflux, dyspepsia or upper abdominal pain</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>nausea or vomiting and weight loss, reflux, dyspepsia or upper abdominal pain.</p>\\r\\n</div></li>\\r\\n</ul></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Patients with an established diagnosis of cirrhosis.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Patients with persistent microcytic anaemia which is unexplained and unresponsive to 3 months’ treatment with iron therapy and a course of anti-helminths.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Patients aged under 55 with the symptoms listed both under urgent and routine referrals are more likely to have another explanation for their symptoms. If no diagnosis can be found and you are concerned, make a request via EMRS and discuss with the endoscopist.</p>\\r\\n<h2 id=\\\"flexible-sigmoidoscopy\\\">Flexible sigmoidoscopy</h2>\\r\\n<p>Refer the following patients for flexible sigmoidoscopy:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Diarrhoea which doesn’t respond to treatment or persistent diarrhoea in an HIV negative patient.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Rectal bleeding in patients aged over 40 years with no change in bowel habit.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Rectal bleeding in patients aged under 40 years where it is not typical of haemorrhoids.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"colonoscopy\\\">Colonoscopy</h2>\\r\\n<p>Refer the following patients for colonoscopy:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Patients 40 years and older with rectal bleeding and an increase in stool frequency or looseness for more than 6 weeks.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Patients 60 years an older with either rectal bleeding for more than 6 weeks or an increase in stool frequency or looseness for more than 6 weeks.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Anyone with altered blood or blood mixed in the stool.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Patients with persistent microcytic anaemia which is unexplained and unresponsive to 3 months’ treatment with iron therapy and a course of anti-helminths.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"asa-score\\\">ASA score</h2>\\r\\n<p>The American Society of Anesthesiologists score is a subjective assessment of a patient’s overall health that has been shown to be related to outcome from surgical and other procedures and which can be used to estimate the risk of the procedure and the level of support the patient may require.</p>\\r\\n<p>The categories are outlined below. Please indicate which category your patient falls into when completing the request form on EMRS.</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>ASA score</strong></th>\\r\\n<th><strong>Definition</strong></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>I</td>\\r\\n<td>Patient is a completely healthy fit patient.</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>II</td>\\r\\n<td>Patient has mild systemic disease.</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>III</td>\\r\\n<td>Patient has severe systemic disease that is not incapacitating.</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>IV</td>\\r\\n<td>Patient has incapacitating disease that is a constant threat to life.</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>V</td>\\r\\n<td>A moribund patient who is not expected to live 24 hours with or without surgery or intervention.</td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<p>BSG, AUGIS, ACPGBI Position statement. Guidance on the indications for diagnostic upper GI endoscopy, flexible sigmoidoscopy and colonoscopy. 2011.</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Karen Forrest</th>\\r\\n<th>Date: 01 November 2019</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Will Taylor</td>\\r\\n<td>Date: 04 November 2019</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td>04 November 2021</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"063\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>Epiglottitis MeG-CLS-063</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<p><strong>Acute epiglottitis</strong></p>\\r\\n<h2 id=\\\"executive-summary\\\"><em>Executive summary</em></h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<p>Bacterial infection of the epiglottis in young children caused by <em>Haemophilus influenzae</em> type b (Hib). It is rare when Hib vaccine coverage is high. The most typical patient affected by epiglottitis is now an urban male in his mid-40s.It is a dramatic, potentially lethal condition characterized by an acute rapidly progressive respiratory obstruction. It is an important differential for croup.</p>\\r\\n<h2 id=\\\"target-users\\\">Target users</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doctors</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nurses</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"target-area-of-use\\\">Target area of use </h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Outpatient department</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ward</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"key-areas-of-focus-new-additions-changes\\\">Key areas of focus / New additions / Changes </h2>\\r\\n<p>This guidelines addresses the management of acute epiglottitis.</p>\\r\\n<h2 id=\\\"limitations\\\">Limitations</h2>\\r\\n<p>We have limited access to HDU / ITU level care and it may be difficult to get the necessary anaesthetic help to treat these patients in time.</p>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs\\\">Presenting symptoms and signs</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Rapid (less than 12-24 hours) onset of high fever</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Drooling</strong></p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Sore throat</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Dyspnoea</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Neck is hyperextending</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Typical “tripod or sniffing” position, preferring to sit, leaning forward with an open mouth, anxious appearing.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Difficulty swallowing</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Stridor may be present (as opposed to croup, hoarse voice and cough are usually absent). Stridor is a late sign and suggests near-complete airway obstruction.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Critically ill appearing.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Rapidly progressive respiratory obstruction with laboured breathing; a brief period of air hunger with restlessness may be followed by rapidly increasing complete airway obstruction. Complete obstruction of the airway and death can ensue.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Allow the patient to sit in a comfortable position. Do not force them to lie down (may precipitate airway obstruction). Death from asphyxia can occur. This might be precipitated by attempts to examine the throat<strong>; avoid using a tongue depressor or any instrument to examine the throat.</strong></p>\\r\\n<h2 id=\\\"management\\\">Management </h2>\\r\\n<p><strong>Emergency:</strong> ABC</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Give oxygen</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Secure IV access and give IV fluids.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Consider <strong>urgent referral</strong> in order to secure airway via emergency intubation and tracheostomy (intubate under anaesthesia).</p>\\r\\n<p>Start IV antibiotic therapy:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>IV ceftriaxone (3 minutes) or IV infusion (30 minutes) at 50 mg/kg OD children and 1 g OD for adults for 5 days.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>If clinical condition improves and oral treatment tolerated, switch to oral co-amoxiclav 50 mg/kg TDS or adults (375 mg TDS &amp; amoxicillin 250 mg TDS). Complete 10 days of antibiotics.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p><strong>Improvement criteria include:</strong> fever reduction, diminished respiratory distress, improved SpO2, improved appetite and/or activity</p>\\r\\n<p>PO Paracetamol at 15 mg/kg TDS</p>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<p>Colledge, Nicki R., Brian R. Walker, Stuart Ralston, and Stanley Davidson. 2010. Davidson&#39;s principles and practice of medicine. Edinburgh: Churchill Livingstone/Elsevier.</p>\\r\\n<p>Epiglotitis. Medical guidelines. Medecins Sans Frontieres. Retrieved from <a href=\\\"https://medicalguidelines.msf.org/viewport/CG/english/epiglottitis-16689226.html\\\"><span data-custom-style=\\\"Hyperlink\\\">https://medicalguidelines.msf.org/viewport/CG/english/epiglottitis-16689226.html</span></a> on 25th February, 2019.</p>\\r\\n<p>Kliegman, Robert., et al. Nelson Textbook of Pediatrics. Edition 20. Philadelphia, PA: Elsevier, 2016.</p>\\r\\n<p><a href=\\\"https://www.nice.org.uk/guidance/ng79/documents/consultation-document\\\"><span data-custom-style=\\\"Hyperlink\\\">https://www.nice.org.uk/guidance/ng79/documents/consultation-document</span></a> on 23/02/19.</p>\\r\\n<p>Standard Treatment Guidelines, 6th Edition, 2010. ISBN 978-9988-1-2538-7</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Fatoumata Sawaneh</th>\\r\\n<th>Date: 27 February 2019</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Baderinwa Abatan</td>\\r\\n<td>Date: 03 May 2019</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td>31 May 2021</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"056\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>Epilepsy MeG-CLS-056</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"epilepsy\\\">Epilepsy</h1>\\r\\n<h2 id=\\\"executive-summary\\\"><em>Executive summary</em></h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<p>Epilepsy is a chronic brain disorder characterized by a predilection to having afebrile epileptic seizures. Most epilepsy is of unknown cause (idiopathic epilepsy). Majority of people with epilepsy live in LMICs like The Gambia. Epilepsy can significantly impair quality of life and cause social stigma. Late presentation and poor adherence to treatment increases the risk of status epilepticus and sudden unexpected death in epilepsy.</p>\\r\\n<p>This guideline covers the diagnoses and treatment of epilepsy and status epilepticus.</p>\\r\\n<h3 id=\\\"target-users\\\">Target users</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nurses</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doctors</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"target-area-of-use\\\">Target area of use </h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Gate Clinic</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Outpatient Department</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ward</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"key-areas-of-focus-new-additions-changes\\\">Key areas of focus / New additions / Changes </h3>\\r\\n<p>The diagnosis of epilepsy requires two <em>unprovoked</em> epileptic seizures occurring at least 24 hours apart or a single <em>unprovoked</em> epileptic seizure with an underlying predisposition to recurrence. Epileptic seizures are classified based on onset, awareness and symptoms. The type of seizures and other findings on clinical examination assist in the choice of drug therapy in epilepsy.</p>\\r\\n<p>The diagnosis of epilepsy is clinical. EEG may assist in classifying seizure type. Other investigations may be requested to detect underlying causes or for monitoring patients on treatment.</p>\\r\\n<p>The goal of treatment is no seizures and no side effects. Anticonvulsant monotherapy is preferred. Patients and their caregivers should be involved in decision-making to improve adherence to drugs and lifestyle measures prescribed.</p>\\r\\n<p>Special situations discussed include status epilepticus, epilepsy in women of childbearing age including pregnancy, patients with first unprovoked seizure, and non-epileptic seizures.</p>\\r\\n<h3 id=\\\"limitations\\\">Limitations </h3>\\r\\n<p>EEG is not currently available in The Gambia.</p>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs\\\">Presenting symptoms and signs</h2>\\r\\n<h2 id=\\\"an-epileptic-seizure-is-a-transient-motor-sensory-or-psychic-manifestation-that-results-from-an-abnormal-paroxysmal-electrical-discharge-in-the-brain.-presence-of-epileptic-seizures-does-not-necessarily-imply-epilepsy-is-present-as-many-acute-conditions-can-present-with-epileptic-seizures-as-symptoms-acute-symptomatic-seizures.-however-significant-brain-injury-from-these-conditions-may-ultimately-result-in-epilepsy-secondary-or-symptomatic-epilepsy.\\\">An epileptic seizure is a transient motor, sensory or psychic manifestation that results from an abnormal paroxysmal electrical discharge in the brain. Presence of epileptic seizures does not necessarily imply epilepsy is present as many acute conditions can present with epileptic seizures as symptoms (acute symptomatic seizures). However, significant brain injury from these conditions may ultimately result in epilepsy (secondary or symptomatic epilepsy).</h2>\\r\\n<h2 id=\\\"onset\\\">Onset</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Seizures may be focal in onset (one side of the brain) or generalized (both sides of the brain).</p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Focal seizures may become secondarily generalized. This initial focal component may be missed if eye-witnesses or the patient are not specifically questioned. An “aura” preceding a generalized seizure is considered a focal seizure.</p>\\r\\n</div></li>\\r\\n</ul></li>\\r\\n</ul>\\r\\n<h2 id=\\\"awareness\\\">Awareness</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>In generalized seizures, the patient is unconscious or has complete loss of awareness.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Focal seizures may present with intact awareness (‘focal aware seizure”, formerly called “simple partial seizure”) or with impaired awareness.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"symptoms\\\">Symptoms</h2>\\r\\n<p>Seizures may present as motor or non-motor symptoms</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Focal motor seizures may present as abnormal involuntary movements of the eyes, face, head or limbs;</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Focal non-motor seizures may present as abnormal sensations (strange odours, paraesthesia, abdominal pain) or as changes in cognition, emotions or behaviour.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Generalized motor seizures are most commonly tonic-clonic but other forms including tonic, atonic, clonic and myoclonic seizures may occur alone or in combination.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Generalized non-motor seizures usually present as absence seizures with brief episodes of loss of awareness. Automatisms may be present but are not considered motor seizures.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"others\\\">Others</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Seizures may occur alone, as part of a recognizable epilepsy syndrome or as a component of a broader neurological disorder.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Not all seizure-like activities are epileptic in nature; tics, tremors, spasms, non-epileptic myoclonus, syncope and psychogenic non-epileptic seizures among many other conditions may mimic epileptic seizures.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>History should include questions about</p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Symptoms</p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Warning signs (“aura’) before episode</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nature of activity during episode</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Awareness during episode and ability to recall after episode</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Patient’s state and time to full recovery after episode</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Duration and frequency of episodes</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Triggers</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Response to any previous therapy</p>\\r\\n</div></li>\\r\\n</ul></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Prenatal, perinatal and developmental assessment.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>History of severe illness or severe head trauma</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ongoing drug use (illicit drugs, anticonvulsants)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Consanguinity and family history of seizures.</p>\\r\\n</div></li>\\r\\n</ul></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>There is room for uncertainty when describing epilepsy in the absence of adequate information e.g generalized tonic-clonic epilepsy with <em>unknown onset</em>, focal epilepsy, <em>awareness unknown</em>.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Eye-witness accounts and video recordings are very helpful in diagnosis.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"examination-findings\\\">Examination findings</h2>\\r\\n<p>Examination of patients with epilepsy should asses cardiac and neurological function, including mental status. Examination of the skin may reveal abnormalities associated with some neurological syndromes. Patients with generalized epilepsy may show signs of past or recent trauma such as scars, bruises and lacerations.</p>\\r\\n<h2 id=\\\"management\\\">Management </h2>\\r\\n<p><strong><span class=\\\"underline\\\">Diagnosis</span></strong></p>\\r\\n<p>Diagnosis of epilepsy is based on clinical findings. Investigations may be carried out to detect underlying causes and to support the diagnosis where features are not typical.</p>\\r\\n<p>Video EEG is the gold standard for classifying seizure types and detecting psychogenic non-epileptic seizures. It is expensive and unavailable in our setting.</p>\\r\\n<p>Inter-ictal EEG can be done at Dakar, if necessary. Inter-ictal EEG alone should not be used to differentiate epileptic seizures from other diagnoses as false-positive findings can occur in persons without epilepsy.</p>\\r\\n<p>CT scan or MRI can be requested if the patient has abnormal neurologic findings. MRI is available in Dakar and may be informative in patients with difficult-to-control focal-onset epilepsy. These tests should not be routinely requested for patients with a clinical diagnosis of idiopathic generalized epilepsy.</p>\\r\\n<p>Lumbar puncture for CSF analysis is useful in patients with suspected meningitis, encephalitis, subarachnoid haemorrhage or prolonged alteration in consciousness.</p>\\r\\n<div data-custom-style=\\\"numbered-paragraph\\\">\\r\\n<p>Adults with suspected epilepsy should have a standard electrocardiogram done. Young adults and children may also have an ECG done if the diagnosis of epilepsy is uncertain.</p>\\r\\n</div>\\r\\n<div data-custom-style=\\\"Normal (Web)\\\">\\r\\n<p>Adults with epilepsy should do the following tests every 2 years:</p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"Normal (Web)\\\">\\r\\n<blockquote>\\r\\n<p>Full blood count</p>\\r\\n</blockquote>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"Normal (Web)\\\">\\r\\n<blockquote>\\r\\n<p>Electrolytes, urea and creatinine,</p>\\r\\n</blockquote>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"Normal (Web)\\\">\\r\\n<blockquote>\\r\\n<p>Liver function tests</p>\\r\\n</blockquote>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"Normal (Web)\\\">\\r\\n<blockquote>\\r\\n<p>Serum calcium</p>\\r\\n</blockquote>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p><strong><span class=\\\"underline\\\">Treatment</span></strong></p>\\r\\n<p>Patients with suspected epilepsy should be sent to the outpatient department for review by a doctor.</p>\\r\\n<p>The goal of epilepsy treatment is to stop seizures completely without causing adverse effects from treatment (“no seizures, no side-effects”). Studies have shown that this can be achieved in up to 60% of patients. Up to 70% of patients remain seizure-free when medications are discontinued after 2 - 5 years of treatment.</p>\\r\\n<p>To limit adverse events and drug interactions, treatment with a single appropriate anticonvulsant drug is preferred. Choosing this drug will require accurate classification of the type of epilepsy and assessing its suitability for the particular patient. Patients who remain uncontrolled on a single drug at maximum tolerated dose can have another appropriate drug added to the regimen. The new drug should be titrated to its maximum effective dose after which the old drug is tapered off gradually.</p>\\r\\n<p>If the second drug is not helpful, any of the two drugs can be tapered off first and then a third drug started. If attempts at combination therapy are unhelpful, it is best to stay with the most effective regimen tolerated by the patient.</p>\\r\\n<p>Lamotrigine and valproate are broad-spectrum anticonvulsants but are best reserved for generalized onset epilepsy. Valproate is notoriously teratogenic. It should be used by girls and women of childbearing age only if there is no alternative on the condition that they are counselled fully on the risk-benefit and the need for effective contraception. Valproate is significantly more expensive than carbamazepine. Lamotrigine is even more expensive.</p>\\r\\n<p>Epilepsy in adults is most commonly focal in onset; this type of epilepsy generally responds to carbamazepine. Myoclonic seizures and absence seizures may be worsened by carbamazepine and should be treated with valproate.</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Epilepsy Syndrome</strong></th>\\r\\n<th><strong>First Line</strong></th>\\r\\n<th><strong>Alternative / Adjunctive</strong></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Focal</td>\\r\\n<td>Carbamazepine</td>\\r\\n<td><p>Lamotrigine</p>\\r\\n<p>Sodium valproate</p></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Generalized tonic-clonic</td>\\r\\n<td>Sodium valproate</td>\\r\\n<td><p>Lamotrigine</p>\\r\\n<p>Carbamazepine</p></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Unclassified</td>\\r\\n<td>Sodium valproate</td>\\r\\n<td>Lamotrigine</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Absence</td>\\r\\n<td><p>Ethosuximide (not readily available),</p>\\r\\n<p>Sodium valproate</p></td>\\r\\n<td>Lamotrigine</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Myoclonic</td>\\r\\n<td>Sodium valproate</td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Atonic or Tonic</td>\\r\\n<td>Sodium valproate</td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Infantile spasms</td>\\r\\n<td><p>Vigabatrin (not readily available),</p>\\r\\n<p>ACTH (not readily available),</p>\\r\\n<p>Prednisolone</p></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<p>Discuss the nature of the diagnosis and treatment with patient and caregivers. Lifestyle modifications and restrictions should be discussed including hazards such as using dangerous equipment, driving, working at heights, cooking over open flames and swimming. Drug adherence and the risks associated with sudden drug discontinuation should be emphasized.</p>\\r\\n<p>If the patient is seizure-free for 2 to 5 years, drug therapy can be tapered off over a 3-month period at least. For patients on multiple drugs, discontinue one drug at a time. The risks of drug discontinuation including the possibility of relapse should be discussed and a clear plan agreed on with the patient.</p>\\r\\n<p><strong><span class=\\\"underline\\\">Special Situations</span></strong></p>\\r\\n<p><strong>Status Epilepticus:</strong></p>\\r\\n<p>Generalized convulsive status epilepticus is a life-threatening emergency. The typical patient with status epilepticus is one who suddenly discontinued anti-epileptic medications. Structural and metabolic disturbances can also lead to status epilepticus.</p>\\r\\n<p>Generalized convulsive status epilepticus is diagnosed when:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>A generalized tonic-clonic seizure lasts for more than 5 minutes (Note that this period is for active fitting only and does not include the post-ictal phase of sleep or confusion), <strong>or</strong></p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>A patient has a second generalized tonic-clonic seizure without recovering fully from the first seizure.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p><em><strong>Treatment:</strong></em></p>\\r\\n<p><em>1st stage (0−10 minutes)</em></p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Secure airway and resuscitate</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Administer oxygen</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Assess cardiorespiratory function</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Establish intravenous access</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Administer glucose (50 ml of 50% solution) in adults (with intravenous thiamine 100 mg if there is any feature suggestive of alcoholism or malnutrition).</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Call the doctor on call</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p><em>2nd stage (0−30 minutes)</em></p>\\r\\n<p>Commence regular monitoring of vital signs</p>\\r\\n<p>Send samples for emergency investigations</p>\\r\\n<p>Consider the possibility of non-epileptic seizures</p>\\r\\n<p>Emergency anticonvulsant therapy with IV diazepam</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Give 0.15 mg/kg of IV diazepam over 5 minutes or 0.5 mg/kg PR (draw up the iv solution and use the syringe without an attached needle to deliver the drug PR).</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Give usual anti-epileptic medication via NG tube if already on treatment for epilepsy.</p>\\r\\n<p>Continue emergency anticonvulsant therapy with :</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Phenytoin infusion at a dose of 20 mg/kg at a rate of 50 mg/minute (do NOT mix with dextrose-containing infusion; use normal saline).</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>OR</p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>IV phenobarbital bolus of 15 mg/kg at a rate of 100 mg/minute if phenytoin is unavailable.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Urethral catheterization</p>\\r\\n<p><em><br />\\r\\n</em></p>\\r\\n<p><em>3rd stage (0−60 minutes)</em></p>\\r\\n<p>Identify aetiology of status epilepticus and treat medical complications.</p>\\r\\n<p>If seizures persist 20 minutes after initial phenytoin infusion, give additional 10 mg/kg of phenytoin infusion.</p>\\r\\n<p><em>4th stage (30−90 minutes)</em></p>\\r\\n<p>If still in status epilepticus 20 minutes after second phenytoin infusion, give IV phenobarbital at 15 mg/kg.</p>\\r\\n<p><em>Emergency investigations</em></p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Blood glucose</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Urinalysis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Serum electrolytes, urea and creatinine</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Liver function tests</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Serum calcium and magnesium</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Full blood count</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Clotting profile</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Chest radiograph may be needed to check for possible aspiration.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Blood culture (if clinically indicated)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Cranial CT Scan (if clinically indicated)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Lumbar puncture for CSF analysis (if clinically indicated)</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Ideally, patients should have continuous EEG monitoring, toxicologic screening, arterial blood gases and assay of anticonvulsant levels performed but these are not presently feasible.</p>\\r\\n<p><strong>Girls and women of child bearing age:</strong></p>\\r\\n<p>Many anticonvulsant drugs reduce the effectiveness of oral contraceptive pills. Other forms of contraception should be recommended.</p>\\r\\n<p>Girls and women of childbearing age on treatment for epilepsy should be prescribed 5 mg of folic acid daily.</p>\\r\\n<p>Anticonvulsant medications should not be switched during pregnancy even when the mother is on sodium valproate. Switching drugs increases the risks to both the mother and her fetus. Pregnant patients with epilepsy should be referred to the obstetrician early in the antenatal period.</p>\\r\\n<p><strong>Patient with first unprovoked first seizure:</strong></p>\\r\\n<p>Although the risk of development of epilepsy is higher in persons who have had a first unprovoked seizure, it is recommended that anti-epileptic drugs be withheld until a second unprovoked seizure occurs.</p>\\r\\n<p><strong>Non-epileptic seizures:</strong></p>\\r\\n<p>Some patients with psychological or psychiatric problems may present with non-epileptic seizures (pseudoseizures, psychogenic seizures). Other patients may produce seizure-like movements either subconsciously (factitious disorder) or intentionally (malingering).</p>\\r\\n<p>Some of these patients actually have an underlying epilepsy syndrome while others may have been misdiagnosed and wrongly placed on epilepsy treatment.</p>\\r\\n<p>It is difficult to differentiate non-epileptic seizures from true seizures without video-EEG monitoring. However, presence of severe tongue biting, an ictal cry and incontinence makes non-epileptic seizures unlikely.</p>\\r\\n<p>The following features are not definitive but suggest a non-epileptic seizure especially when they occur together:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Eyes closed during seizure and resistance to passive eye-opening by examiner</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Patient’s hand fails to fall on face when dropped over the head</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Side-to-side head movements during seizure</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Pelvic thrusts during seizure</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Seizures occurring with audiences (consulting room, waiting room, ward rounds)</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Patients with suspected non-epileptic seizures should do an EEG and undergo psychological evaluation. Maintain their current therapy status until reviewed.</p>\\r\\n<h2 id=\\\"key-issues-for-nursing-care\\\">Key Issues for Nursing care</h2>\\r\\n<ul>\\r\\n<li><h2 id=\\\"monitor-closely-and-document-seizures-which-may-be-subtle-e.g-lip-twitching\\\">Monitor closely and document seizures which may be subtle (e.g lip twitching)</h2></li>\\r\\n<li><h2 id=\\\"monitor-and-document-vital-signs-fluids-and-level-of-consciousness\\\">Monitor and document vital signs, fluids and level of consciousness</h2></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<blockquote>\\r\\n<p>Nurse patients having generalized seizures in left lateral position with bed rails raised up.</p>\\r\\n</blockquote>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<blockquote>\\r\\n<p>Do not force any object between the teeth during a seizure</p>\\r\\n</blockquote>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<p>National Institute for Health and Care Excellence. Epilepsies: diagnosis and management. Clinical guideline [CG137] Published: January 2012 Last updated: April 2018. Available from: <a href=\\\"https://www.nice.org.uk/guidance/cg137\\\"><span data-custom-style=\\\"Hyperlink\\\">https://www.nice.org.uk/guidance/cg137</span></a> Accessed: 11th November 2018</p>\\r\\n<h1 id=\\\"devinsky-o-gazzola-d-lafrance-wc-jr.-differentiating-between-nonepileptic-and-epileptic-seizures.-nat-rev-neurol.-2011-apr74210-20.\\\"><a href=\\\"https://www.ncbi.nlm.nih.gov/pubmed/?term=Devinsky%20O%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21386814\\\">Devinsky O</a>, <a href=\\\"https://www.ncbi.nlm.nih.gov/pubmed/?term=Gazzola%20D%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21386814\\\">Gazzola D</a>, <a href=\\\"https://www.ncbi.nlm.nih.gov/pubmed/?term=LaFrance%20WC%20Jr%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21386814\\\">LaFrance WC Jr</a>. Differentiating between nonepileptic and epileptic seizures. <a href=\\\"https://www.ncbi.nlm.nih.gov/pubmed/21386814\\\">Nat Rev Neurol.</a> 2011 Apr;7(4):210-20. </h1>\\r\\n<p><a href=\\\"https://www.ncbi.nlm.nih.gov/pubmed/?term=Krumholz%20A%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25901057\\\">Krumholz A</a>, <a href=\\\"https://www.ncbi.nlm.nih.gov/pubmed/?term=Wiebe%20S%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25901057\\\">Wiebe S</a>, <a href=\\\"https://www.ncbi.nlm.nih.gov/pubmed/?term=Gronseth%20GS%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25901057\\\">Gronseth GS</a>. Evidence-based guideline: Management of an unprovoked first seizure in adults: Report of the Guideline Development Subcommittee of the American Academy of Neurology and the American Epilepsy Society. <a href=\\\"https://www.ncbi.nlm.nih.gov/pubmed/25901057\\\">Neurology.</a> 2015 Apr 21;84(16):1705-13.</p>\\r\\n<p>Medscape. Psychogenic Nonepileptic Seizures. Available from: <a href=\\\"http://reference.medscape.com/article/1184694\\\"><span data-custom-style=\\\"Hyperlink\\\">http://reference.medscape.com/article/1184694</span></a> Accessed: 30 November 2018</p>\\r\\n<p>Medscape. Epilepsy and Seizures. Available from: <a href=\\\"http://reference.medscape.com/article/1184846\\\"><span data-custom-style=\\\"Hyperlink\\\">http://reference.medscape.com/article/1184846</span></a> Accessed: 25 November 2018</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Fatai Akemokwe</th>\\r\\n<th>Date: 30 November 2018</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Karen Forrest</td>\\r\\n<td>Date: 12 December 2018</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td>31 January 2021</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>1.1</td>\\r\\n<td>Executive summary added</td>\\r\\n<td>31 January 2021</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"057\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>Fungal Skin Infections MeG-CLS-057</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h2 id=\\\"fungal-skin-infections\\\">Fungal skin infections</h2>\\r\\n<h2 id=\\\"executive-summary\\\"><em>Executive summary</em></h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<p>Common fungal skin infections in our environment include:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Tinea pedis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Tinea cruris</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Tinea corporis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Tinea capitis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Cutaneous candidiasis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Pityriasis versicolor</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Seborrhoeic dermatitis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nail infections</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"target-users\\\">Target users</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doctors</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nurses</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"target-area-of-use\\\">Target area of use</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Gate clinic</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Outpatient department</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ward</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"key-areas-of-focus-new-additions-changes\\\">Key areas of focus / New additions / Changes</h2>\\r\\n<p>This guideline outlines the management of fungal skin infections in our setting. In most cases topicals can be used in order to reduce the side effects of systemic treatment. Patients must be encouraged to continue treatment until the lesions have disappeared and then for a further week to reduce the incidence of treatment failure.</p>\\r\\n<h2 id=\\\"limitations\\\">Limitations</h2>\\r\\n<p>Terbinafine is not provided at the clinic and may be unaffordable for most patients.</p>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs\\\">Presenting symptoms and signs</h2>\\r\\n<p>Most fungal skin infections present with an itchy rash.</p>\\r\\n<p><strong><span class=\\\"underline\\\">Tinea pedis</span>:</strong> Itching and/or burning sensation in the feet. It may present as:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Interdigital: toe-web infection, usually occurs between two smallest toes with redness, blisters or softening and breaking down of the skin</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Moccasin: involves the entire sole of the foot and extend to the sides of the foot with peeling, cracking and scaling of the feet</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Vesicular: fluid-filled blisters on the underside of the foot, the toes, the heel or on top of the foot</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p><strong><span class=\\\"underline\\\">Tinea cruris</span>:</strong> Affects genitals, inner thighs and buttocks. It appears as a red, scaly, itchy rash that is often ring-shaped. It is mildly contagious</p>\\r\\n<p><strong><span class=\\\"underline\\\">Tinea corporis</span>:</strong> Occures anywhere on the body. Each lesion is circular, red, scaly flat lesion. The outer part of the rash is raised while the skin in the middle appears normal. Lesions may coalesce. It is contagious.</p>\\r\\n<p><strong><span class=\\\"underline\\\">Tinea capitis</span>:</strong> Affects the scalp and is most common in children. It is contagious and facilitated by overcrowding and poor hygiene. Features include:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Itchy patches on the scalp, scaly, red areas with bald spots</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Broken off hair</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Brittle hair</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Painful scalp</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Crusty swellings which may become bacterially infected (kerion)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Swollen cervical lymph nodes</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Low grade fever</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p><strong><span class=\\\"underline\\\">Cutaneous candidiasis</span>:</strong> Affects nearly any skin surface of the body but most common in warm, moist areas in contact such as the armpits, breast folds and groin. They are common among obese people, diabetics and people on antibiotics. In children, it causes a diaper rash. It presents as itchy or burning red patches that may ooze clear fluid with some surrounding pimple-like bumps. Other presentations include oral/vaginal thrush and nail infection. It is not contagious</p>\\r\\n<p><strong><span class=\\\"underline\\\">Pityriasis (tinea) versicolor</span></strong>: Common among teenagers and young adults. It presents as multiple hypopigmented (light) or hyperpigmented (dark) scaly, dry patches usually over the face, neck, upper arms and trunk. The lesions may be itchy. It is not contagious.</p>\\r\\n<p><strong><span class=\\\"underline\\\">Seborrhoeic dermatitis</span></strong>: Presents on the scalp as dandruff. It also involves the face, neck, trunk and any other hair-bearing area presenting as scaly hypopigmented or red patches. It is not contagious.</p>\\r\\n<p><strong><span class=\\\"underline\\\"><br />\\r\\n</span></strong></p>\\r\\n<p><strong><span class=\\\"underline\\\">Nail Infections (onychomycosis):</span></strong> May present as thickened and discolored nails. Nails may become, black, yellow or green. The nail may be brittle and may separate from the nail bed. The underlying skin may become inflamed and infected.</p>\\r\\n<p>If a cutaneous dermatophyte infection is misdiagnosed and initially treated with a topical corticosteroid, the appearance of the infection may be altered, making diagnosis more difficult (i.e., tinea incognito). Patients can develop diminished erythema and scale, loss of a well-defined border, exacerbation of disease, or a deep-seated folliculitis (Majocchi&#39;s granuloma).</p>\\r\\n<p>The simultaneous presence of more than one type of dermatophyte infection is common (e.g. tinea pedis and tinea cruris or tinea pedis and tinea unguium). Performance of a full skin examination including the skin, hair, and nails aids in the detection of additional sites of infection. Occasionally, patients develop a dermatophytid reaction, a secondary dermatitic reaction at a distant site that may reflect an immunologic reaction to the infection.</p>\\r\\n<h2 id=\\\"management-in-gate-clinic\\\">Management in Gate clinic</h2>\\r\\n<p>Most fungal skin infections can be treated with topical antifungals. Clotrimazole or miconazole cream can be applied thinly twice daily over localized lesions.</p>\\r\\n<p>Seborrhoeic dermatitis and pityriasis versicolor can be treated with either ketoconazole shampoo or selenium sulfide shampoo applied to lesions twice weekly. Skin lesions in seborrhoeic dermatitis can also be treated with 1% hydrocortisone cream twice each day until healing occurs.</p>\\r\\n<p>Tinea capitis can be treated with Whitfield’s ointment applied twice daily. Add cloxacillin 20-25 mg/kg (max 500 mg) QDS for 5 days if kerion is present.</p>\\r\\n<p><strong>DO NOT</strong> prescribe griseofulvin – as it is teratogenic even up to six months after conception. This is true for both men and women.</p>\\r\\n<p>Review patients after 4 weeks of treatment to asses improvement. If rash shows some improvement, ask patient to continue treat treatment until one week after lesions have cleared.</p>\\r\\n<p>Refer patients to the doctor if:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Immunosuppressed (HIV, Diabetes mellitus)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Widespread rash</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Unfamiliar rash / Rash does not appear typical</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>No improvement after 4 weeks of treatment (except nail infections and pityriasis versicolor)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nail infections</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"management-in-opd\\\">Management in OPD</h2>\\r\\n<p>For patients with widespread rash, atypical rash or minimal improvement on topical therapy, consider alternative diagnosis or background immunosuppression.</p>\\r\\n<p>HIV testing, VDRL, Fasting blood glucose may assist in diagnosis of unusual rash.</p>\\r\\n<p>Patients with fungal skin infections and immunosuppression may require systemic(oral) therapy. Options include fluconazole (continuous or pulse therapy), itraconazole or terbinafine. Drug interactions, contra-indications and adverse effects must be considered in drug choice.</p>\\r\\n<p>Nail Infections: account for less than half of all nail lesions. Treatment of onychomycosis is not mandatory in all patients. Weigh the risk of treatment against potential benefit for each individual patient.</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Oral – terbinafine (76% effective), itraconazole (60% effective), or fluconazole (48 % effective). Oral ketoconazole is not usually recommended due to side effects and the need for a long course of treatment. However, it is often the only effective and affordable option in our setting. DO NOT prescribe griseofulvin (see note above).</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Others – chemical keratolytic agents (e.g. urea cream), surgical debridement of the affected nails.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p><strong>References</strong></p>\\r\\n<p>Gupta AK1, Drummond-Main C, Paquet M. Evidence-based optimal fluconazole dosing regimen for onychomycosis treatment. <a href=\\\"https://www.ncbi.nlm.nih.gov/pubmed/22694221\\\">J Dermatolog Treat.</a> 2013 Feb;24(1):75-80. doi: 10.3109/09546634.2012.703308</p>\\r\\n<p>Rajagopalan M, Inamadar A, Mittal A, Miskeen AK, Srinivas CR, Sardana K, Godse K, Patel K, Rengasamy M, Rudramurthy S, Dogra S. Expert consensus on the management of dermatophytosis in India (ECTODERM India). BMC dermatology. 2018 Dec;18(1):6.</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Danlami Garba</th>\\r\\n<th>Date: 28 August 2018</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Fatai Akemokwe</td>\\r\\n<td>Date: 12 September 2018</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td>31 January 2021</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>1.1</td>\\r\\n<td>Executive summary added</td>\\r\\n<td>31 January 2021</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"033\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>Gastroenteritis MeG-CLS-033</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"gastroenteritis\\\">Gastroenteritis</h1>\\r\\n<h2 id=\\\"executive-summary\\\"><em>Executive summary</em></h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<p>Bacterial and viral gastroenteritis causes acute inflammation of the GI mucosa of the middle or lower intestine. It has many causes, can range from mild to severe, and typically manifests with symptoms of vomiting, diarrhoea, and abdominal discomfort. It is primarily an acute, self­limited illness. Immunocompromised patients can develop unremitting or fatal symptoms from gastroenteritis.</p>\\r\\n<p>Gastroenteritis is commonly due to infectious agents—viruses, bacteria, and parasites. There are four viral agents: rotavirus, norovirus, enteric adenovirus, and astrovirus. Rotavirus is the most common cause of severe diarrhoea in children. Exotoxins produced by some organisms induce hypersecretion or increased peristalsis resulting in diarrhoea or vomiting. Viruses destroy enterocytes of the upper jejuna.</p>\\r\\n<p>Bacteria such as E. coli and Salmonella penetrate and invade the gastric mucosa and lead to diarrhoea accompanied by fever and faecal leukocytes.</p>\\r\\n<h2 id=\\\"target-user\\\">Target User</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doctors</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nurses</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"target-area-of-use\\\">Target area of use </h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ward</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Outpatient department</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Gate clinic</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"key-areas-of-focusnew-additionschanges\\\">Key areas of focus/new additions/changes</h2>\\r\\n<p>This guideline addresses the management of gastroenteritis as well as persistent diarrhoea in children, adults and those infected with HIV.</p>\\r\\n<h2 id=\\\"limitations\\\">Limitations</h2>\\r\\n<p>We have limited access to diagnostic tests for persistent diarrhoea.</p>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs\\\">Presenting symptoms and signs</h2>\\r\\n<p>In all age groups, gastroenteritis may present with fever, abrupt onset of nausea and vomiting, abrupt onset of diarrhoea, explosive flatulence, cramping abdominal pain, mucoid stools with or without blood, tenesmus, myalgia, headache, malaise, potential for seizures in children with high fever or electrolyte abnormalities</p>\\r\\n<p>Any patient complaining of diarrhoea and vomiting should be asked for more details in order to establish:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>how frequent the stools and vomiting are</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>how long the illness has gone on for</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>the nature of the stools and vomitus</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>if there are any risk factors for more serious illness</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>recent study abroad</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>if there is a potential outbreak in the compound or surrounding area</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"examination-findings\\\">Examination findings</h2>\\r\\n<p>Examine the patient looking for evidence of:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Dehydration – see below for classification of severity.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Malnutrition (<strong>in which case they must be managed according to the malnutrition protocol</strong>).</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Chronic illness and sepsis.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Rule out a surgical cause (such as intussusception in a child).</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Auscultate the abdomen in all quadrants for bowel sounds; note hyperactive bowel sounds, absent or hypoactive bowel sounds (common with botulism), and borborygmi.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Palpate the abdomen for diffuse tenderness, slight distension, masses, rebound tenderness, and spasm.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Rectal exam: Check for masses, fissures, inflammation, perianal erythema, or stool in ampulla.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Neurologic exam: Check for dizziness, difficulty swallowing, and other neurologic signs. (Neurologic signs and symptoms indicate botulism and require emergency intervention.)</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"severity-of-dehydration\\\">Severity of dehydration</h3>\\r\\n<p>Children:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Some dehydration: Two or more of the following signs</p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>restlessness or irritability</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>sunken eyes</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>drinks eagerly, thirsty</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>skin pinch goes back slowly</p>\\r\\n</div></li>\\r\\n</ul></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Severe dehydration: Two or more of the following signs:</p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>lethargy or unconsciousness</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>sunken eyes</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>unable to drink or drinks poorly</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>skin pinch goes back very slowly (≥ 2 s)</p>\\r\\n</div></li>\\r\\n</ul></li>\\r\\n</ul>\\r\\n<p>Adults:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Severe dehydration is present in adults with reduced level of consciousness, reduced urine output, clammy extremities, tachycardia, low blood pressure or peripheral cyanosis.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"when-to-refer-to-doctor-in-opd\\\">When to refer to doctor in OPD</h3>\\r\\n<p>Refer patients with:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>diarrhoea for more than 2 weeks (persistent or intermittent)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>malnutrition</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>known HIV infection</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>severe dehydration</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>chronic illness</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>sepsis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>a surgical abdomen.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Other patients can be managed in gate clinic without further investigation.</p>\\r\\n<h2 id=\\\"investigations\\\">Investigations</h2>\\r\\n<p>May not be necessary but for more severe cases consider:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>FBC.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Stool for M,C&amp;S.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>If there is fever, test for malaria.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>If there is evidence of systemic compromise, send blood for U&amp;Es – children frequently present with severe electrolyte disturbance.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>If there is evidence of chronic illness, counsel and test the patient for HIV.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Urinalysis: Excludes UTI as cause of nonspecific vomiting.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Abdominal US to rule out intussusception.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"differential-diagnoses\\\">Differential Diagnoses</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Acute viral hepatitis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Acute appendicitis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Cholecystitis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Inflammatory bowel disease</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Pelvic inflammatory disease</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Intussusception</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Bowel obstruction from other causes</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"management-in-gate-clinic\\\">Management in Gate clinic</h2>\\r\\n<p>Treat patients with some dehydration with ORS. Give 50-100 ml/kg over 4 hours to replace the existing deficit.</p>\\r\\n<p>If patient cannot drink the prescribed ORS, the diarrhoea losses are large or they fail to improve with the ORS, then refer to the doctor.</p>\\r\\n<p>If the patient improves, prescribe further ORS for the rest of the day. Advise them to make up sugar-salt-solution the next day. If the diarrhoea persists after this, tell them to return to the clinic.</p>\\r\\n<h3 id=\\\"acute-watery-diarrhoea-with-or-without-vomiting\\\">Acute watery diarrhoea with or without vomiting</h3>\\r\\n<p>Give zinc supplements to all children for 10-14 days in a dose of 20 mg/day for those aged 6 months and above and 10mg/day for those aged under 6 months.</p>\\r\\n<p>Antibiotics are not indicated unless the diarrhoea is profuse and cholera is suspected.</p>\\r\\n<h3 id=\\\"dysentery-with-or-without-vomiting\\\">Dysentery with or without vomiting </h3>\\r\\n<p>This is most commonly caused by shigella. It should be treated with ciprofloxacin 20 mg/kg up to 500 mg BD for 5 days.</p>\\r\\n<p>If there is no response after 48 hours, then the possibility of amoebic dysentery should be considered. Give metronidazole 15 mg/kg up to 500 mg TDS for 7-10 days.</p>\\r\\n<h2 id=\\\"management-in-opd-or-on-the-ward\\\">Management in OPD or on the ward</h2>\\r\\n<p>See flow chart for quick reference.</p>\\r\\n<h3 id=\\\"rehydration\\\">Rehydration</h3>\\r\\n<p>All patients with dehydration must be rehydrated.</p>\\r\\n<p><em><strong>Treat all patients with severe dehydration with iv fluids.</strong></em> ORS should be started at the same time unless the patient is vomiting. Give a 30 ml/kg bolus of Ringer’s lactate over 30 minutes. Follow this in children with a further 70 ml/kg infusion of Ringer’s lactate over 2.5 hours. Give adults a further 100 ml/kg over the next 4 hours.</p>\\r\\n<p>Treat patients with some dehydration with ORS. Give 50-100 ml/kg over 4 hours to replace the existing deficit. Add extra fluid by measuring ongoing losses and replacing ml for ml.</p>\\r\\n<h3 id=\\\"acute-watery-diarrhoea-or-dysentery-with-or-without-vomiting\\\">Acute watery diarrhoea or dysentery with or without vomiting</h3>\\r\\n<p>Treat as described for Gate clinic above</p>\\r\\n<h3 id=\\\"persistent-diarrhoea-and-vomiting-in-patients-with-hiv\\\">Persistent diarrhoea and vomiting in patients with HIV</h3>\\r\\n<p>This is most commonly caused by an infection, although other possibilities should be considered. Infectious causes include all the usual enteric bacteria, viruses and protozoa such as cryptosporidium. Abdominal TB and HIV itself can cause diarrhoea, as can infiltrative conditions such as lymphoma and Kaposi’s sarcoma.</p>\\r\\n<p>Begin by assuming a bacterial or parasitic cause. After sending a stool culture, treat with Metronidazole 10 mg/kg up to 500 mg TDS for 7 days and Chloramphenicol 12.5 mg/kg up to 500 mg QDS for 7 days. High dose septrin can be used as an alternative to Chloramphenicol for patients not on septrin prophylaxis. The dose is 48 mg/kg (max 1920 mg) BD for 2 weeks, followed by 24 mg/kg (max 960 mg) BD for another 3 weeks.</p>\\r\\n<p>If the diarrhoea has been present for more than 2 weeks, then also add albendazole 7.5 mg/kg up to 400 mg BD for 3 days. Then repeat this treatment after 2 weeks.</p>\\r\\n<p>Refer the patient to an ART centre to ensure they are assessed and started on treatment. Encourage the patient to eat nutritious meals on a frequent basis.</p>\\r\\n<p>If diarrhoea persists after this, consider an alternative cause. Is there evidence of abdominal TB, lymphoma or KS?</p>\\r\\n<p>Refer to a gastroenterologist for further management.</p>\\r\\n<h3 id=\\\"persistent-diarrhoea-and-vomiting-in-children\\\">Persistent diarrhoea and vomiting in children </h3>\\r\\n<p>This is most commonly infectious in origin. There are a number of different mechanisms for the persistence:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>the infection is difficult to clear</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>there is secondary damage to the intestine such as lactulose intolerance or antibiotic-associated diarrhoea</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>intestinal healing is delayed by specific deficiencies or malnutrition</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>there are multiple acute infections with different agents mimicking persistent diarrhoea.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Malnutrition may also itself cause chronic diarrhoea which may be associated with allergic enteropathy and small bowel bacterial overgrowth.</p>\\r\\n<p>Treat as for acute watery diarrhoea, but with extra concern for nutritional status. Give multivitamins for 2 weeks. Advise the carer to avoid giving milk-based products until the diarrhoea has resolved and to feed the child little and often.</p>\\r\\n<p>If the diarrhoea fails to respond to these measures, do not use loperamide or other anti-diarrhoeal agents. Refer to a paediatrician for further assessment.</p>\\r\\n<h3 id=\\\"persistent-diarrhoea-and-vomiting-in-adults\\\">Persistent diarrhoea and vomiting in adults </h3>\\r\\n<p>This may also be caused by a persistent pathogen, however, other causes may need to be considered – most patients are likely to have been treated with antibiotics prior to presenting to us.</p>\\r\\n<p>Consider the possibility of difficult to treat infections and send stools for MC&amp;S prior to further treatment. If the patient has been given many courses of antibiotics, antibiotic-associated diarrhoea may be the cause. This is best treated with a 2 week course of metronidazole (500 mg TDS).</p>\\r\\n<p>In other cases, refer to a gastroenterologist for further assessment.</p>\\r\\n<p><img src=\\\"data:image/png;base64,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\\\" style=\\\"width:6.00475in;height:0.70472in\\\" /><img src=\\\"data:image/png;base64,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\\\" style=\\\"width:6in;height:3.89167in\\\" /><img src=\\\"data:image/png;base64,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\\\" style=\\\"width:6in;height:3.85556in\\\" /></p>\\r\\n<h2 id=\\\"key-issues-for-nursing-care\\\">Key Issues for Nursing care</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ensure the patient is receiving the right fluid replacement and is taking everything as prescribed.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ensure that the patient or their carer informs you of all episodes of diarrhoea and vomiting and record losses – either by weighing nappies or estimating quantities.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Send stool samples prior to starting antibiotics wherever possible.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ensure meticulous hand washing to decrease transmission.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>If the patient is diapered and/or incontinent, tell the patient or caregiver to adhere strictly to contact precautions.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Diaper changing areas should be separate from food preparation areas.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Chlorine­based disinfectants inactivate rotavirus and may prevent disease transmission from contact with environmental surfaces.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<p>LaRocque and Pietroni 2017. Approach to the adult with acute diarrhea in resource-limited countries. UpToDate May 2017.</p>\\r\\n<p>Harris and Pietroni 2017. Approach to the child with acute diarrhea in resource-limited countries. UpToDate Mar 2017.</p>\\r\\n<p>Moore 2016. Persistent diarrhoea in children in resource-limited countries. UpToDate Dec 2016.</p>\\r\\n<p>Bonis and Lamont 2017. Approach to the adult with chronic diarrhea in resource-rich settings. UpToDate Jun 2017.</p>\\r\\n<p>The Gambia HIV treatment manual 2011. Banjul, The Gambia: National Aids Secretariat; 2011.</p>\\r\\n<p>Centers for Disease Control and Prevention: www.cdc.gov</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Amie Secka</th>\\r\\n<th>Date: 16 July 2018</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Baderinwa Abatan</td>\\r\\n<td>Date: 01 August 2018</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>2.0</td>\\r\\n<td>Adapted from previous guideline on diarrhoea</td>\\r\\n<td>15 August 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>2.1</td>\\r\\n<td>Executive summary added</td>\\r\\n<td>15 August 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"007\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>General Body Pain MeG-CLS-007</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"general-body-pain\\\">General Body Pain</h1>\\r\\n<h2 id=\\\"executive-summary\\\"><em>Executive summary</em></h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<p>This is a very common presentation. Everyone at some point in their life suffers from general body aches and pain. It is your body’s way of letting you know it is time to make some changes and slow down.</p>\\r\\n<p>The human body is under constant gravity and movement pressure as demanded by our lifestyle: work activities, posture, home duties, shopping, carrying, lifting, bending over, farming, gardening, exercise etc. All these activities require body movement and can cause General Body Aches &amp; Pains.</p>\\r\\n<p>Usually, when general body aches and pain are felt, it is caused by life stress, fatigue, restless/ poor sleep, muscle strain, poor eating habits, lack of exercise, poor posture, an injury or over-use. Today’s lifestyle, family and work are all demanding on our body.</p>\\r\\n<p>It may also reflect the presence of a very severe illness, such as sepsis or rheumatoid arthritis, joint inflammation, ligament trauma, or it may indicate something milder, like a fresh cold. It is not unusual for mental illness, especially depression, to present this way.</p>\\r\\n<p>Thankfully, many general body aches and pains are treatable.</p>\\r\\n<h2 id=\\\"target-users\\\">Target users</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nurses</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"target-area-of-use\\\">Target area of use </h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Gate clinic</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"key-areas-of-focus-new-additions-changes\\\">Key areas of focus / New additions / Changes </h2>\\r\\n<p>This guideline is intended to help nurses think about the possible causes of general body pain.</p>\\r\\n<h2 id=\\\"limitations\\\">Limitations</h2>\\r\\n<p>None.</p>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs\\\">Presenting symptoms and signs</h2>\\r\\n<p>Ask the patient how long the general body pain has been present. Is it present at all times? Are there parts of the body that are more painful than others?</p>\\r\\n<p>Are there any associated symptoms, such as fever, joint pain or swelling, cough, diarrhoea, nausea and vomiting, weight loss, reduced appetite, difficulty sleeping?</p>\\r\\n<p>How does the patient present themselves? Do they make eye contact with you? Are they able to talk comfortably?</p>\\r\\n<h2 id=\\\"management\\\">Management</h2>\\r\\n<p>If the patient is able to describe other symptoms, then treat them according to the diagnosis that these suggest. Consider the possibility of malaria, fresh cold or another infection.</p>\\r\\n<p>If you are unable to make a diagnosis and the symptoms seem severe, refer the patient to the doctor.</p>\\r\\n<p>If the patient does not seem to be severely unwell, consider treating with 3 days of paracetamol 15-20 mg/kg (max 1g) TDS for 3 days. Ask the patient to return if they are not better.</p>\\r\\n<p>For patients with persisting general body pains, conditions to consider include:</p>\\r\\n<ol type=\\\"1\\\">\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Stress</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Dehydration</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Lack of refreshing sleep</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Anaemia</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Vitamin D Deficiency</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Arthritis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Depression</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Anxiety disorder</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Lupus</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Neurological pathologies like Multiple Sclerosis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Fibromyalgia</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Chronic Fatigue Syndrome</p>\\r\\n</div></li>\\r\\n</ol>\\r\\n<h2 id=\\\"suggested-treatment-modalities\\\">Suggested Treatment Modalities</h2>\\r\\n<ol type=\\\"1\\\">\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Physiotherapy Treatments methods- To promote relaxation include</p>\\r\\n</div>\\r\\n<ol type=\\\"a\\\">\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Manipulation: Spine, joints etc</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Mobilisation- Joints basically</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Massage (deep tissue massage)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Exercises to strengthen the muscles that support the spine and vital organs.</p>\\r\\n</div></li>\\r\\n</ol></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Rheumatologist- Need to refer to Dakar, Senegal</p>\\r\\n</div></li>\\r\\n</ol>\\r\\n<h2 id=\\\"when-to-refer-to-dr-in-opd\\\">When to refer to Dr in OPD</h2>\\r\\n<p><em>Refer</em> to the doctor</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>if you are unable to make a diagnosis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>if the patient is severely unwell</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>if you make a diagnosis needing a doctors review</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p><strong>References</strong></p>\\r\\n<p>‘General Body Aches &amp; Pains-101 Physio’ Australian Physiotherapy Association. Accessed at <a href=\\\"http://101physio.com.au/101-physio-general-body-pain-therapy\\\"><span data-custom-style=\\\"Hyperlink\\\">http://101physio.com.au/101-physio-general-body-pain-therapy</span></a></p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Babatunde Awokola</th>\\r\\n<th>Date: 12 May 2018</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Karen Forrest</td>\\r\\n<td>Date: 31 July 2018</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>2.0</td>\\r\\n<td>Transferred to new template and revised</td>\\r\\n<td>31 July 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>2.1</td>\\r\\n<td>Executive summary added</td>\\r\\n<td>31 July 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"045\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>Headache MeG-CLS-045</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"headache\\\">Headache</h1>\\r\\n<h2 id=\\\"executive-summary\\\"><em>Executive summary</em></h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<p>Headache is the most common neurologic complaint occurring alone or as part of other syndromes. Most headaches are benign especially where the neurologic examination is normal. However secondary headaches may occasionally have a serious underlying cause which needs to be investigated.</p>\\r\\n<p>Migraine and tension-type headache are the more common types of primary headache.</p>\\r\\n<h3 id=\\\"target-users\\\">Target users</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nurses</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doctors</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"target-area-of-use\\\">Target area of use </h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Gate clinic</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Outpatient department</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ward</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"key-areas-of-focus-new-additions-changes\\\">Key areas of focus / New additions / Changes </h3>\\r\\n<p>This guideline covers the diagnoses and treatment of the common types of headache.</p>\\r\\n<p>Patients without features of a potentially dangerous headache should be managed at the Gate Clinic.</p>\\r\\n<p>Patients referred to the OPD should be assessed for cause of headache and presence of red flag features. Primary headaches typically do not need any further investigations in the absence of red flags.</p>\\r\\n<p>Patients with acute migraine attacks need immediate treatment with analgesics and antiemetics. Those with more frequent attacks may benefit from long-term prophylaxis.</p>\\r\\n<p>Acute tension-type headache can be treated with analgesics. Chronic tension-type headaches may improve with lifestyle changes and amitriptyline.</p>\\r\\n<p>Consider medication overuse headache in patients with chronic headache and longstanding analgesic use.</p>\\r\\n<h2 id=\\\"limitations\\\">Limitations</h2>\\r\\n<p>Some patients with secondary headaches will require referral to Sheikh Zayed Eye Care Centre or EFSTH depending on their suspected diagnoses.</p>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs\\\">Presenting symptoms and signs</h2>\\r\\n<p>Suspect a <em>migraine</em> headache if a patient has episodes of moderate to severe unilateral throbbing headache lasting between 4 hours and 3 days with associated nausea, vomiting, photophobia and/or phonophobia. There may be preceding warning signs (aura) which are typically visual. The patient may be able to identify and avoid triggers such as certain foods, menstruation or lifestyle changes.</p>\\r\\n<p><em>Tension-type</em> headaches are usually less severe, described as tightness or heaviness on head and mostly generalized. There may associated neck and upper back pain. Features of background anxiety disorder or depression may be present. It may be either episodic or chronic (occurring on more than 15 days in a month).</p>\\r\\n<p><em>Cluster</em> headaches are unilateral with associated eye pain, excessive tearing, nasal congestion or discharge. They occur mostly in male smokers, occurring frequently over a time period (“cluster”) and are far less common causes of headache.</p>\\r\\n<h3 id=\\\"important-things-to-look-for\\\">Important things to look for</h3>\\r\\n<p>Symptoms and signs of a potentially dangerous headache include the following:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Worst headache patient has ever had: <em>Call the doctor!</em></p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Severe headache with nausea and /or vomiting: <em>Call the doctor!</em></p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Limb weakness, slurred speech or facial asymmetry: <em>Call the doctor</em> <em>!</em></p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Visual disturbances (blurred vision, aversion to light): <em>Call the doctor!</em></p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Recent neck stiffness: <em>Call the doctor!</em></p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>New type of headache in a patient (“never had this type before”)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Headache that varies with position</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Persistent morning headache with nausea</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>History of head trauma in the last 3 months</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>New onset of headache in:</p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Patient younger than 12 years or older than 50 years</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>HIV or Cancer patient</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Female patient on combined oral contraceptive pills</p>\\r\\n</div></li>\\r\\n</ul></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Raised blood pressure</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Headache present every day for more than 2 weeks</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Patients with any of these features should be referred from the Gate clinic to the outpatient clinic.</p>\\r\\n<h2 id=\\\"management-in-gate-clinic\\\">Management in Gate clinic</h2>\\r\\n<p>Treat all patients not referred to the outpatient clinic with</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>oral paracetamol 1 g 3 – 4 times daily for 3 days or</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>ibuprofen 400 mg 3 times daily after meals for 3 days (if patient has used paracetamol already without relief and there are no peptic ulcer symptoms)</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Tell the patient to return if they deteriorate or if they are not better after 2 days.</p>\\r\\n<p>If the headache is present along with symptoms of another underlying illness, manage according to the guidelines for that condition.</p>\\r\\n<h2 id=\\\"management-in-opd\\\">Management in OPD</h2>\\r\\n<p>The first step of management is to determine if the headache is a primary or secondary headache. The history is particularly useful in making this distinction.</p>\\r\\n<p>If it is a secondary headache, look out for sinister features that may suggest a serious underlying cause.</p>\\r\\n<p>New onset of headache in a patient under 10 or over 50 suggests a secondary cause. Changes in character of a patient’s usual headache is suspicious.</p>\\r\\n<p>Neurological examination and fundoscopy are very useful in excluding secondary causes of hypertension and should be done at first visit as well as any time there is a change in character of the headache. Visual acuity tests are usually unhelpful.</p>\\r\\n<p>Primary headaches typically do not need any further investigations in the absence of red flags.</p>\\r\\n<p>Patients with a history of opioid use for more than 10 days in a month or other analgesics for more than 15 days in a month are at risk for medication overuse headache. Treatment requires withdrawal of the analgesics, psychological support and review after 2 months to determine and treat the underlying primary headache.</p>\\r\\n<p><strong>Migraine Headache</strong></p>\\r\\n<p>Start treatment as early as possible during an attack with</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>ibuprofen 400 – 600 mg up to 4 doses in 24 hours or</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>aspirin 600 – 900 mg (not for children or those with contraindications)</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Add oral metoclopramide 10 mg (in adults) or oral promethazine 1.1 mg/kg (maximum 25 mg) if significant nausea or vomiting is present</p>\\r\\n<p>Add omeprazole for gastroprotection in those with history of peptic ulcer disease.</p>\\r\\n<p>A short acting sedative for a few days</p>\\r\\n<p>Avoid opioids in acute migraine treatment as they worsen nausea and vomiting.</p>\\r\\n<p>Patients who use analgesics for migraine two or more times every week will need prophylaxis with:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>First line: beta blocker (propranolol, atenolol or bisoprolol)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Second line: amitriptyline</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Third line: sodium valproate.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>For emergency treatment of patients with severe headaches or unable to tolerate oral medications:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>IM Diclofenac 75 mg stat</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>IM Chlorpromazine 25 mg or IM Metoclopramide 10 mg stat (adults only. Beware acute dystonic reactions)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Continue with oral therapy</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p><strong>Tension-type Headache</strong></p>\\r\\n<p>If episodes are two or less per week:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>ibuprofen 400 – 600 mg up to 4 doses in 24 hours or</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>aspirin 600 – 900 mg (not for children or those with contraindications)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Add omeprazole for gastroprotection in those with history of peptic ulcer disease.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Advise to stop drugs once pain is relieved.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>For more frequent episodes or chronic type:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Do not give NSAIDs (risk of medication overuse headache)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Start amitriptyline 12.5 mg nocte. Titrate dose every 2 weeks until improvement or limiting side-effects occur (up to a maximum of 75 mg nocte).</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>After sustained improvement for 4 months, gradually taper off dose.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Reassure the patient on the nature of the headache.</p>\\r\\n<p>Counsel on the need for regular exercise and stress management. Non-depressed patients on amitriptyline may require reassurance that they are not been managed for depression.</p>\\r\\n<p>Avoid opioids.</p>\\r\\n<p><strong>Diagnoses Not To Miss (Investigate and manage urgently)</strong></p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Intracranial tumours: morning headache with nausea or vomiting, focal neurologic deficits, seizures (do CT scan)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Meningitis: fever, neck stiffness (do lumbar puncture)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Subarachnoid haemorrhage (SAH): neck stiffness, worst ever headache (do CT scan ± lumbar puncture)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Giant cell (temporal) arteritis: older patient with scalp tenderness, jaw pain when chewing, firm palpable temporal arteries (Do ESR if suspected; treated with steroids)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Primary angle-closure glaucoma: unilateral painful red eye of sudden onset with blurred vision (refer to the eye hospital urgently)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Idiopathic intracranial hypertension: Usually adolescent or young adult female with bilateral blurred vision, vomiting (Fundoscopy – bilateral papilloedema, refer to the eye hospital)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Chronic carbon monoxide poisoning: Blurred vision, fatigue, nausea, vomiting. Ask for history of indoor exposure to wood fires and kerosene stoves. Gas cookers producing yellow/orange flames (instead of blue) also increase this risk. (Counsel on risk and advise to discontinue exposure)</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<p><strong>British Association for the Study of Headache. Guidelines for All Healthcare Professionals in the Diagnosis and Management of Migraine, Tension-Type, Cluster and Medication-Overuse Headache. 3<sup>rd</sup> ed. 2010</strong></p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Fatai Akemokwe</th>\\r\\n<th>Date: 23 June 2018</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Karen Forrest</td>\\r\\n<td>Date: 24 July 2018</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td>31 July 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>1.1</td>\\r\\n<td>Executive summary added</td>\\r\\n<td>31 July 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"040\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>Heart failure adults MeG-CLS-040</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"heart-failure-in-adults\\\">Heart failure in adults</h1>\\r\\n<h2 id=\\\"executive-summary\\\"><em>Executive summary</em></h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<p>Heart failure is a syndrome resulting from poor cardiac function. In the Gambia, the most common cause of this in adults is dilated cardiomyopathy secondary to long-standing untreated hypertension. Other causes include rheumatic heart disease, post-partum cardiomyopathy and, less commonly, ischaemic heart disease. Cardiac dysfunction might also be a consequence of chronic respiratory disease.</p>\\r\\n<p>Heart failure may present acutely or more chronically. There may be signs of both poor perfusion of end organs and fluid overload. Left heart failure presents primarily with breathlessness. Right heart failure presents primarily with peripheral oedema. Congestive cardiac failure is the combination of both types. Acute left heart failure is a medical emergency and the patient should be sent to the ward (or to see the doctor in Keneba) as soon as possible.</p>\\r\\n<p>It is important to consider and treat both the underlying cause and possible exacerbating factors.</p>\\r\\n<h2 id=\\\"target-users\\\">Target users</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nurses</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doctors</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"target-area-of-use\\\">Target area of use </h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Outpatient department</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ward</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"key-areas-of-focus-new-additions-changes\\\">Key areas of focus / New additions / Changes </h2>\\r\\n<p>This guideline outlines pragmatic management of acute and chronic heart failure in our setting.</p>\\r\\n<h2 id=\\\"limitations\\\">Limitations</h2>\\r\\n<p>We lack access to HDU level care and cannot give inotropes.</p>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs\\\">Presenting symptoms and signs</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Shortness of breath on exertion, at rest, or during the night.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Swelling of ankles / body.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Grade the severity of symptoms using the New York Heart Association (NYHA) classification:</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>NYHA class</strong></th>\\r\\n<th><strong>Symptoms</strong></th>\\r\\n<th><strong>One-year mortality</strong></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>I</td>\\r\\n<td>No limitations</td>\\r\\n<td>5-10%</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>II</td>\\r\\n<td>Slight limitation of activity – comfortable at rest and on mild exertion</td>\\r\\n<td>15%</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>III</td>\\r\\n<td>Marked limitation of activity – only comfortable at rest</td>\\r\\n<td>30%</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>IV</td>\\r\\n<td>Any activity brings on discomfort – symptoms present at rest</td>\\r\\n<td>50-60%</td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<h2 id=\\\"examination-findings\\\">Examination findings</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Fast HR, Fast RR, Displaced apex beat, gallop rhythm, basal lung crackles, pleural effusions – all consistent with left heart failure.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Oedema, raised JVP, hepatomegaly – all consistent with right heart failure.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hypotension, confusion, cold peripheries are all suggestive of severe hypoperfusion.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hypertension – if this is the underlying cause.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Murmurs suggest underlying rheumatic or congenital heart disease.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Arrhythmia – might be cause of an acute exacerbation.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"important-things-to-look-for\\\">Important things to look for</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Recent acute viral illness, TB, known HIV, known COPD, recent pregnancy, alcohol ingestion, smoking history – can all help to identify a possible cause.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Check adherence to medications.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Rule out intercurrent illness as cause of exacerbation.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Review medication history – for instance NSAIDs, aspirin and calcium channel blockers may worsen heart failure.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"investigations\\\">Investigations</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>FBC – as anaemia may exacerbate heart failure.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>U&amp;Es – renal failure can be a complication of heart failure or of its treatment.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>HIV – if there is no obvious cause or if there is any other suggestive features.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>CXR – if there is evidence of left heart failure.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>ECG – if there is arrhythmia or any reason to consider ischaemic heart disease.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>ECHO – to confirm diagnosis and identify cause. It is usually not necessary to do this at initial diagnosis, unless there is a reason to suspect valvular heart disease. It is usually only necessary to confirm the cause of the heart failure and then does not need to be repeated unless there is a specific reason (passage of time from previous ECHO is not a good reason).</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>It is not usually necessary to do LFTs – they are likely to be abnormal if there is right heart failure, but do not need specific treatment or monitoring.</p>\\r\\n<h2 id=\\\"management\\\">Management</h2>\\r\\n<p>The underlying problem should be treated once identified – however, in many cases, initial treatment will be determined by the presentation.</p>\\r\\n<h3 id=\\\"acute-left-heart-failure\\\">Acute left heart failure</h3>\\r\\n<p><em>This is an emergency – transfer the patient to the ward as soon as possible!</em></p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Sit the patient up. Give high flow O<sub>2</sub>.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Give iv furosemide 40-80 mg.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Give morphine 5-10 mg iv only if the patient is in severe respiratory distress.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Reassess the patient – furosemide can be repeated to a maximum of 160 mg. Sublingual nitrates may be helpful if available.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>If a patient fails to respond to iv furosemide, consider the use of a continuous furosemide infusion. There are theoretical reasons why this might be more effective and some study evidence to support its use. Give the same total dose of furosemide over 24 hours via syringe driver up to a maximum dose of 720 mg per day.</p>\\r\\n<p>If there are is still no improvement and you have no other options, you can consider the use of a loading dose of iv aminophylline (5 mg/kg over 20 minutes via syringe driver) – it has diuretic, positive chronotropic and inotropic actions.</p>\\r\\n<p>Add other treatments as tolerated during admission and whilst keeping a close eye on the renal function.</p>\\r\\n<h3 id=\\\"left-heart-failure\\\">Left heart failure</h3>\\r\\n<p>Use this guidance for a newly diagnosed patient who is not acutely ill or once a patient with acute left heart failure is stabilized. Treatment should be stepped up gradually in the order listed below as the patient’s blood pressure and renal function allow. Check BP at every appointment. Check renal function at least once after any major change in treatment or if there is a change in the patient’s condition.</p>\\r\\n<p>Begin treatment with oral <strong>furosemide</strong> 40-160 mg per day to reduce oedema and congestion of the lungs.</p>\\r\\n<p>Add an <strong>ACE inhibitor</strong> next. This improves prognosis. Do not use if there is hypotension, hyperkalaemia, renal artery stenosis or stenotic cardiac valvular disease. Ramipril is our first line option. Use 1.25 mg OD and increase to maximum dose of 10 mg OD as tolerated. Captopril is available if the patient will be transferred back to government care in the near future.</p>\\r\\n<p><strong>Beta-blockers</strong> should be used only in stable patients. Again they improve prognosis. First line choice for control of HR in atrial fibrillation. Avoid in asthma or COPD. Do not give if HR is below 50 bpm or there is 2<sup>nd</sup> or 3<sup>rd</sup> degree heart block. If the patient presented with acute heart failure, do not start until they return for follow-up or until they have been managed or oral diuretics for 1-2 days. Give bisoprolol 1.25 mg OD and increase as tolerated to a maximum dose of 10 mg OD.</p>\\r\\n<p><strong>Spironolactone</strong> improves prognosis in patients with moderate or severe heart failure who are already on an ACE inhibitor. It can cause severe hyperkalaemia. Give 25-50 mg OD.</p>\\r\\n<p><strong>Digoxin</strong> may improve symptoms and reduce hospital admission. No evidence of improved prognosis. High risk of toxicity, especially in elderly patients or those with renal failure. Toxicity presents with bradycardia, nausea and vomiting, altered vision. Give 2 doses of 0.5 mg 12 hours apart then continue maintenance treatment with 0.12-0.25 mg OD.</p>\\r\\n<p><strong>Isosorbide dinitrate</strong> and <strong>hydralazine</strong> in combination have been shown to help black patients who have NYHA class III-IV heart failure unresponsive to standard treatment. Contraindicated in mitral or aortic stenosis, pericardial effusion and constrictive pericarditis. Give 20-80 mg isosorbide dinitrate TDS (to maximum dose of 240 mg daily) and hydralazine 25-100 mg QDS.</p>\\r\\n<p>If the patient is hypertensive and standard heart failure treatment has not brought the blood pressure down, amlodipine can be added to achieve this.</p>\\r\\n<p>Where there is evidence of ischaemic heart disease, aspirin, clopidogrel and statins should be considered.</p>\\r\\n<h3 id=\\\"right-heart-failure\\\">Right heart failure</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Exclude pericardial effusion by echocardiography.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Treat primary pulmonary condition (for instance giving salbutamol inhaler or nebulisers to patients with COPD).</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Add furosemide and spironolactone to treat oedema. ACE inhibitors and other treatment for left heart failure are not indicated.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"key-issues-for-nursing-care\\\">Key Issues for Nursing care</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Heart failure should not be managed in Gate clinic, but must be referred to the doctors in OPD.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Patients admitted with severe heart failure should be nursed in an upright position, with their legs slightly raised above their hips.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Any dose of furosemide above 60 mg iv should be given over at least 20 minutes using a syringe driver.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Patients on iv diuretics should have close monitoring of weight (daily) and urine output (in/out chart).</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<p>National Institute for Health and Care Excellence (2014). Acute heart failure: diagnosis and management. NICE guideline (CG187).</p>\\r\\n<p>National Institute for Health and Care Excellence (2010). Chronic heart failure: diagnosis and management. NICE guideline (CG108).</p>\\r\\n<p>Sloan, Phiri and Zijlstra (2012). The clinical book of the Department of Medicine, College of Medicine, Blantyre, Malawi.</p>\\r\\n<p>Ellison and Felker (2017). Diuretic treatment in heart failure. N Engl J Med 2017; 377:1964-75.</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Karen Forrest</th>\\r\\n<th>Date: 22 May 2018</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Fatai Akemokwe</td>\\r\\n<td>Date: 17 June 2018</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td>15 August 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>1.1</td>\\r\\n<td>Executive summary added</td>\\r\\n<td>15 August 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"091\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>Hepatitis B and Fibroscan MeG-CLS-091</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"hepatitis-b\\\">Hepatitis B</h1>\\r\\n<h2 id=\\\"executive-summary\\\">Executive summary</h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<p>Hepatitis B virus (HBV) infection is a worldwide healthcare problem, especially in developing areas. In The Gambia, approximately 1 in every 10 adults is chronically infected with HBV. This virus can be passed in blood, from mother to child at birth, in early life from child to child with close contact, or through unprotected sex with an infected partner. For the last 25 years, all children born in The Gambia are offered vaccination against HBV. However, adults over 30 years of age were born before the vaccine was introduced and may carry the virus.</p>\\r\\n<p>People with HBV may have no symptoms. However, in some people, the virus may silently damage the liver and eventually cause liver cancer and liver failure. Hence, the need for follow up of all hepatitis B patients with or without symptoms.</p>\\r\\n<p>Because not everyone who is infected with HBV will develop symptoms and disease, current international guidelines recommend treatment for those HBV infected patients with or at risk of advanced liver disease or liver cancer.</p>\\r\\n<h2 id=\\\"target-users\\\">Target users</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doctors</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nurses</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"target-area-of-use\\\">Target area of use </h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>CSD clinic</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Liver clinic</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"key-areas-of-focus-new-additions-changes\\\">Key areas of focus / New additions / Changes </h2>\\r\\n<p>This document outlines the initial assessment and annual review of HBV infected patients who are not on treatment, as well as the referral protocol for HBV patients between CSD and MATCH B/ Liver clinic. Also outlined is Fibroscan interpretation in chronic liver disease.</p>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs\\\">Presenting symptoms and signs</h2>\\r\\n<h3 id=\\\"the-pathogenesis-and-clinical-manifestations-of-hepatitis-b-are-due-to-the-interaction-of-the-virus-and-the-host-immune-system-which-leads-to-liver-injury-and-potentially-cirrhosis-and-hepatocellular-carcinoma.-patients-can-have-either-an-acute-symptomatic-disease-or-an-asymptomatic-disease.\\\">The pathogenesis and clinical manifestations of hepatitis B are due to the interaction of the virus and the host immune system, which leads to liver injury and, potentially, cirrhosis and hepatocellular carcinoma. Patients can have either an acute symptomatic disease or an asymptomatic disease.</h3>\\r\\n<p>Majority of the HBV patients who present to the MATCH B/Liver clinic and the MRCG CSD will be in the immune tolerant phase of the infection and/or will have an inactive chronic infection without any evidence of active disease. These are asymptomatic carriers. A few patients will present with chronic active hepatitis and may have symptoms ranging from those of acute hepatitis to end-stage liver disease.</p>\\r\\n<p>Icteric hepatitis is associated with a prodromal period during which a serum sickness-like syndrome can occur. The symptomatology is more constitutional and includes the following:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Anorexia</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nausea</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Vomiting</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Low-grade fever</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Myalgia</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Fatigability</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Right upper quadrant and epigastric pain (intermittent, mild to moderate)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ascites</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Gastrointestinal bleeding</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Coagulopathy</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Mental confusion</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Coma</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hepatic encephalopathy</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Disturbances in sleep pattern</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Somnolence</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"examination-findings\\\">Examination findings</h2>\\r\\n<p>The physical examination findings in hepatitis B disease vary from minimal to impressive (in patients with hepatic decompensation), according to the stage of disease.</p>\\r\\n<p>Patients with acute hepatitis usually do not have any clinical findings, but the physical examination can reveal the following;</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Low-grade fever</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Jaundice</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hepatomegaly</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Splenomegaly</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Palmar erythema</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>The physical examination of patients with chronic hepatitis B virus infection can reveal stigmata of chronic liver disease such as the following:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hepatomegaly</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Splenomegaly</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Muscle wasting</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Palmar erythema</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Vasculitis</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Patients with (decompensated) cirrhosis may have the following findings:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ascites</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Jaundice</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>History of variceal bleeding</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Peripheral oedema</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Gynaecomastia</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Abdominal collateral veins</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"management\\\">Management </h2>\\r\\n<h3 id=\\\"acute-hepatitis-b-virus-infection\\\">Acute Hepatitis B virus infection</h3>\\r\\n<p>The incidence of acute HBV infection has been decreasing for a number of years due to widespread vaccination and routine blood testing. Acute HBV infection is characterised by the onset of symptoms 1–4 months after exposure. A serum sickness-like syndrome may occur, followed by an illness characterised by anorexia, nausea, jaundice and right upper quadrant pain. Symptoms usually disappear after 1–3 months, but some patients have prolonged fatigue even after liver function tests have normalised.</p>\\r\\n<p>Elevated ALT/AST with values up to 1000–2000 IU/L are characteristic of acute HBV. Prothrombin time is the best guide to prognosis. In the early phase of infection, HBsAg, anti-HBc IgM and HBeAg are all positive.</p>\\r\\n<p>The management of acute HBV is symptomatic care:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Bed rest and nutritional support are central.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Anti-nausea medications may be of benefit, and</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>limited doses of paracetamol (&lt; 2 g a day) or codeine may be cautiously administered for abdominal pain or fevers.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Since most patients recover, antiviral therapy is not generally recommended. Patients should be monitored regularly with laboratory tests during the acute phase of their illness, and referred for specialist review if they have a prolonged prothrombin time, elevated serum bilirubin concentration, signs of encephalopathy, or if the illness is uncharacteristically lengthy.</p>\\r\\n<p>Repeat HBV serological assessment (HBsAg, HBeAg, and anti-HBc) following recovery from the icteric illness to identify the small proportion of patients who develop CHB.</p>\\r\\n<h3 id=\\\"chronic-hepatitis-b-virus-infection\\\">Chronic Hepatitis B virus infection</h3>\\r\\n<p>The physical examination in chronic HBV patients should include an assessment for spider angioma, gynecomastia, and splenomegaly, which are indicative of more advanced liver disease.</p>\\r\\n<p>An assessment of family history of cirrhosis and HCC, alcohol and smoking habits, and current medication and herbal product use should be undertaken. Although prothrombin time and bilirubin are normal in most outpatients with chronic HBV, serial assessment of serum aminotransferase (i.e., aspartate aminotransferase [AST] and alanine aminotransferase [ALT]) levels can help determine the current status of infection.</p>\\r\\n<p>In addition, a complete blood count can help detect thrombocytopenia, which is an early marker of portal hypertension. Chronic HBV patients should be screened for concomitant human immunodeficiency virus coinfection.</p>\\r\\n<p>Finally, a baseline serum alpha‐fetoprotein level, transient elastography (TE) or FibroScan and liver ultrasound is recommended to screen for early stage HCC, cirrhosis, and other causes of liver disease.</p>\\r\\n<h3 id=\\\"initial-assessment-of-chronic-hbv-patients-not-on-treatment\\\">Initial assessment of chronic HBV patients not on treatment</h3>\\r\\n<p>History and physical examination</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Education to reduce transmission</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Test/vaccinate household and sexual contacts</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Minimize alcohol and smoking</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Family history of HCC/cirrhosis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Assess body mass index</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Examine for signs of liver disease (spider nevi, gynecomastia, ascites, collateral veins (abdomen), etc.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Laboratory tests</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Serum AST/ALT, albumin, bilirubin, INR, complete blood count, platelet count</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Renal function (serum creatinine)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Quantitative HBV DNA viral load level</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Exclude HIV coinfection</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Serum AFP and liver ultrasound</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Transient Elastography (TE) or FibroScan</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"annual-followup-evaluation-for-chronic-hbv-patients-not-on-treatment\\\">Annual follow‐up evaluation for chronic HBV patients not on treatment</h3>\\r\\n<p>This should be done every 6-12 months in patients who are stable and do not require antiviral therapy. Reassessment includes:</p>\\r\\n<p>History and physical examination for any liver disease or progression.</p>\\r\\n<p>Laboratory tests/ Imaging</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>LFT (ALT, AST and GGT)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Serum creatinine</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Complete blood count</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Abdominal Ultrasound scan</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Transient Elastography (TE) or FibroScan</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"transient-elastography-te-or-fibroscan\\\">Transient Elastography (TE) or FibroScan</h2>\\r\\n<p>Transient elastography (TE) or FibroScan is a painless, non-invasive technique that estimates the degree of liver scarring. Results are measured in kilopascals (kPa) which correlate with fibrosis score as determined by biopsy. Cut-off values are given that can accurately place the patient in different stages of fibrosis. A meta-analysis of the use of TE in chronic HBV found that it performed well in detecting cirrhosis (sensitivity 85% and specificity 82%).</p>\\r\\n<h3 id=\\\"indications\\\">Indications</h3>\\r\\n<div data-custom-style=\\\"Normal (Web)\\\">\\r\\n<p>FibroScan® is very useful in the assessment of patients with chronic liver disease, including chronic hepatitis C, chronic hepatitis B, chronic alcohol abuse, and non-alcoholic fatty liver disease. The concept is that as more fibrosis and scarring occur, the higher the liver stiffness reading will be. This reading may be used to:</p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>estimate the existing degree of liver damage</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>monitor disease progression or regression via serial measurements</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>guide prognosis and further management, including treatment.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>FIBROSCAN VALUE(KPa)</strong></th>\\r\\n<th><strong>2-7.4</strong></th>\\r\\n<th><strong>7.5-8.2</strong></th>\\r\\n<th><strong>8.3-9.4</strong></th>\\r\\n<th><strong>≥9.5</strong></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>METAVIR</strong></td>\\r\\n<td>F0/F1</td>\\r\\n<td>F2</td>\\r\\n<td>F3</td>\\r\\n<td>F4</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>INTERPRETATION</strong></td>\\r\\n<td>No or mild fibrosis</td>\\r\\n<td>Fibrosis</td>\\r\\n<td>Significant fibrosis</td>\\r\\n<td>Cirrhosis</td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<p>Possible reasons for an over-estimation of FibroScan:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Liver inflammation (eg. active hepatitis)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Cholestasis (eg. biliary obstruction)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Mass lesions within the liver (eg. tumour)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Liver congestion (eg. heart failure)</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Failure or unreliable readings are seen more frequently in patients with the following characteristics:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Obesity (BMI &gt;30–35 kg/m<sup>2</sup>)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Older age</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Presence of ascites</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Features of the metabolic syndrome (type 2 diabetes, hypertension, increased waist circumference)</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p><strong><br />\\r\\n</strong></p>\\r\\n<p><strong>Algorithm for referral of hepatitis b patients to match b/ liver clinic</strong></p>\\r\\n<p><strong><br />\\r\\n</strong></p>\\r\\n<h2 id=\\\"general-recommendations-for-hbv-patients\\\">General recommendations for HBV patients</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Minimize alcohol consumption</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Stop smoking</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Stop eating mouldy groundnuts</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Avoid toxins and herbal medications</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Balanced diet and exercise to reduce insulin resistance/hepatic steatosis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Acetaminophen analgesics &lt; 4 g/day preferred over NSAIDs/aspirin</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Use of steroids/immunosuppressants/chemotherapy requires prophylactic oral antiviral</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<p>Terrault N, Bzowej N, Chang K, Hwang JP, Jonas MM, Murad MH; American Association for the Study of Liver Diseases. AASLD guidelines for treatment of chronic hepatitis B. Hepatology 2016;63:261-83.</p>\\r\\n<p>European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017;67:370-98.</p>\\r\\n<p>Lemoine M, Shimakawa Y, Nayagam S, et al. The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa. Gut 2015.</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th>Written by:</th>\\r\\n<th>Name: Sulayman Bah</th>\\r\\n<th>Date: 24 March 2020</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Reviewed by:</td>\\r\\n<td>Name: Gibril Ndow</td>\\r\\n<td>Date: 16 April 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Version:</td>\\r\\n<td>Change history:</td>\\r\\n<td>Review due date:</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td>16 April 2022</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Review Comments (if applicable)</td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"046\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>HHS MeG-CLS-046</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"hyperglycaemic-hyperosmolar-state\\\">Hyperglycaemic Hyperosmolar State</h1>\\r\\n<h2 id=\\\"executive-summary\\\"><em>Executive summary</em></h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<p>Hyperglycaemic hyperosmolar state (HHS) is a medical emergency that should be referred to a doctor immediately. It is a hyperglycaemic complication of type II diabetes mellitus patients, typically seen in middle-age to elderly type II diabetics.</p>\\r\\n<h2 id=\\\"target-users\\\">Target users</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nurses</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doctors</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"target-area-of-use\\\">Target area of use </h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Gate clinic</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Outpatient department</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ward</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"key-areas-of-focus-new-additions-changes\\\">Key areas of focus / New additions / Changes </h2>\\r\\n<p>This guideline outlines the recognition and acute management of HHS.</p>\\r\\n<h2 id=\\\"limitations\\\">Limitations</h2>\\r\\n<p>Management of diabetes mellitus after the emergency is over is covered by a separate guideline (MeG-CLS-004).</p>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs\\\">Presenting symptoms and signs</h2>\\r\\n<p>Patient is usually a known diabetic. He / She may present with</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hypovolemia</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Marked hyperglycemia of 30 mmol/L or more</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Absence of ketones in urine (or 1+)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>No acidosis (bicarbonate greater than 15 mEq/L)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Osmolality usually 320 mOsmol/kg or more</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>N.B. A mixed picture of HHS and DKA may occur.</p>\\r\\n<p>Other symptoms may include;</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Weakness</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Weight loss</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Polyuria &amp; polydipsia</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Signs of dehydration</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Lethargy and confusion</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Convulsions and coma</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"immediate-action\\\">Immediate action</h2>\\r\\n<p><strong>This is a medical emergency – a doctor should be called and the patient should be transferred to the ward as soon as possible.</strong></p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Call for help (senior nurses, other physicians)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Check Airway, Breathing and Circulation status. Ensure the patient is alive!</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Get two Intravenous access with the widest cannula possible for the adult (try sizes 18 [green cannula] &amp; 16 [grey cannula])</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>If shocked, give 1 Litre of 0.9% Saline. Give this over 30 minutes. Reassess thereafter. Repeat if necessary.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Check the following before the doctor arrives;</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Vital Signs (PR, BP, RR, Temp, SpO<sub>2</sub> , weight &amp; height if possible)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Blood sugar</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Urine dipstick</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"medical-assessment\\\">Medical Assessment</h2>\\r\\n<h3 id=\\\"examination-findings\\\">Examination findings</h3>\\r\\n<p>May include: tachycardia, tachypnea, hypotension, fever (if infection is present), orthostatic hypotension, altered mental status, confusion, lethargy, coma, signs of dehydration.</p>\\r\\n<h3 id=\\\"differential-diagnosis\\\">Differential Diagnosis</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>CNS infection</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hypoglycemia</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Sepsis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Uremia</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Severe dehydration</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hyponatremia</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"investigations\\\">Investigations</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>FBC, U&amp;Es, Cr, LFTs, serum blood sugar, Urinalysis and Urine microscopy, culture &amp; sensitivity.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>ECG &amp; Renal US (underlying chronic kidney disease or heart failure is common in HHS)</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>The diagnosis is confirmed if:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hyperglycemia 30 mmol/L or more</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Serum bicarbonate &gt; 15 mEq/L</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Serum osmolality &gt; 310 mOsm/kg – ideally measured – to calculate it = 2Na + 2K + glucose + urea</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Normal anion gap &lt; 14 mEq/L – to calculate it = Na - (Cl + HCO<sub>3</sub>)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>No acidosis - blood pH &gt; 7.3 (not available to us)</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"management\\\">Management</h3>\\r\\n<p>If the patient is not already there, send to the ward immediately for admission.</p>\\r\\n<p><strong>Fluids</strong>: IV fluid rehydration with 0.9% Normal Saline; Give 4-6 Litres of fluid in the first 8-10 hrs (1 Litre stat, then 1 Litre in 1 hour, 1 Litre in 2 hours, 1 Litre in 2 hours, 1 Litre in 4 hours), then continue with 1 Litre 4 hourly.</p>\\r\\n<p>Only switch to 0.45% sodium chloride solution if the osmolality is not declining despite adequate positive fluid balance. An initial rise in sodium is expected and is not itself an indication for hypotonic fluids. The rate of fall of plasma sodium should not exceed 10mmol/L in 24 hours.</p>\\r\\n<p>Change to 5% dextrose saline once the blood sugar is &lt; 14 mmol/L.</p>\\r\\n<p><strong>Insulin therapy</strong> should be delayed as fluid replacement alone can reduce hyperglycemia considerably by correcting the hypovolemia.</p>\\r\\n<p>Low dose IV insulin (0.05 units/kg/hr) should only be commenced once the blood glucose is no longer falling with IV fluids alone OR immediately if there is significant ketonaemia (urine ketones greater than 2+).</p>\\r\\n<p>The fall in blood glucose should be no more than 5 mmol/L/hr</p>\\r\\n<p>Once the patient is stabilized and the blood glucose falls to around 13.9 mmol/L, insulin can be given subcutaneously.</p>\\r\\n<p><strong>Potassium replacement</strong>: Add K to fluids if the patient is on insulin infusion and has started passing urine. Typical deficit is 3-5 mmol/kg. Plasma K falls with insulin administration.</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Serum K Level (mmol/L)</strong></th>\\r\\n<th><strong>KCl amount to add per Litre of Fluid</strong></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>K &gt; 5.5</td>\\r\\n<td>No need to add KCL</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>K &lt; 5.5</td>\\r\\n<td>Add <strong>20mmol</strong> of KCl</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>K &lt; 4.0</td>\\r\\n<td>Add <strong>30mmol</strong> of KCl</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>K &lt; 3.0</td>\\r\\n<td>Add <strong>40mmol</strong> of KCl</td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<p><strong><br />\\r\\n</strong></p>\\r\\n<p><strong>Other issues and ongoing monitoring:</strong></p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Check serum K, HCO<sub>3</sub> &amp; glucose every 6 hours.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Do hourly temperature, BP, neurological observation (Glasgow Coma score), fluid balance and bedside BM.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>If the patient has not passed urine by one hour into resuscitation, consider passing a urinary catheter. Aim for a urinary output of &gt; 0.5 ml/kg/hour.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Consider NG tube if vomiting or drowsy.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Find and treat the cause of the HHS e.g. infection or other inter-current illness, poor adherence to medications for previously known patients. Investigate as appropriate e.g. Chest X-ray, FBC, blood culture for suspected Pneumonia.</p>\\r\\n<p>See guideline on Diabetes Mellitus for ongoing care of these patients once the emergency is over.</p>\\r\\n<h2 id=\\\"key-issues-for-nursing-care\\\">Key Issues for Nursing care</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Always check the blood sugar in unconscious or very sick patients and do urinalysis if the blood sugar is high.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Refer patients with high blood glucose, significant urine dipstick findings and/or very sick patients to the doctor.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nurse unconscious patients and monitor them closely as instructed by the doctor.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<p>Nyenwe EA et al. Evidence-based management of hyperglycemic emergencies in diabetes mellitus. Diabetes Res Clin Pract. 2011 Dec;94(3):340-51.[PMID:21978840]</p>\\r\\n<p>Wilkinson IB et al. Oxford Handbook of Clinical Medicine. Oxford University Press, 2017.</p>\\r\\n<p><strong>Scott AR;</strong> Joint British Diabetes Societies (JBDS) for Inpatient Care; JBDS <strong>hyperosmolar hyperglycaemic guidelines group. Management of hyperosmolar hyperglycaemic state (HHS) in adults with diabetes. Diabet Med. 2015 Jun;32(6):714-24. [PMID:25980647]</strong></p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Musa Jallow</th>\\r\\n<th>Date: 5 June 2018</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Babatunde Awokola</td>\\r\\n<td>Date: 12 July 2018</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td>31 July 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>1.1</td>\\r\\n<td>Executive summary added</td>\\r\\n<td>31 July 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"035\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>HIV MeG-CLS-035</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"hiv\\\">HIV</h1>\\r\\n<h2 id=\\\"executive-summary\\\"><em>Executive summary</em></h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<p>Although we do not provide ongoing care of HIV-related disease, many patients present to us with symptoms and signs of undiagnosed HIV. It is important that this diagnosis is recognized and that patients are appropriately referred on to HIV-care services.</p>\\r\\n<h2 id=\\\"target-users\\\">Target users</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nurses</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doctors</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"target-area-of-use\\\">Target area of use </h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Gate Clinic</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>OPD</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ward</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"key-areas-of-focus-new-additions-changes\\\">Key areas of focus / New additions / Changes </h2>\\r\\n<p>This guideline provides information on the counseling, diagnostic and treatment processes involved in HIV care. HIV infection may be asymptomatic at presentation.</p>\\r\\n<p>HIV counseling and testing (HCT) has replaced voluntary counseling and testing (VCT). Provider-initiated HCT should be offered to all inpatients, all outpatients with features of chronic disease and all children with malnutrition.</p>\\r\\n<p>Commence seropositive patients on co-trimoxazole if sulfa allergy is absent, manage their acute/opportunistic conditions and refer for antiretroviral therapy (ART).</p>\\r\\n<p>The current policy in The Gambia is to provide ART to all patients with HIV after diagnosis irrespective of their CD4 count. However, this may delayed to allow for treatment of opportunistic infections.</p>\\r\\n<h2 id=\\\"limitations\\\">Limitations</h2>\\r\\n<p>Antiretroviral therapy and CD4 testing are not routinely available in our facility.</p>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs\\\">Presenting symptoms and signs</h2>\\r\\n<p>There may be no signs or symptoms, however, common presentations which should raise the possibility of HIV-related disease are listed here:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>unexplained weight loss</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>fevers</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>persistent diarrhoea</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>oral candida</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>oral hairy leukoplakia</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>herpes zoster</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Kaposi’s sarcoma</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>persistent generalized rashes</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>generalized lymphadenopathy</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>peripheral neuropathy</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>aseptic meningitis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>unexplained cytopenia</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>dementia in a young or middle-aged person</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>any opportunistic infection.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"examination-findings\\\">Examination findings</h2>\\r\\n<p>No physical findings are specific to HIV infection. The physical findings are those of the presenting infection or illness. Generalized lymphadenopathy is common. Weight loss may be apparent. Herpetic lesions on the groin or widespread oral candidiasis may also be clues to HIV infection.</p>\\r\\n<h2 id=\\\"screening-and-hiv-counselling-and-testing-hct\\\">Screening and HIV counselling and testing (HCT)</h2>\\r\\n<p>HIV counselling and testing (HCT) is the current recommended nomenclature for this (replacing VCT). It includes both provider-initiated testing (when there are clinical indications) and patient-initiated testing (when the patient requests a test).</p>\\r\\n<p>International guidelines suggest that in areas where the HIV prevalence is above 1%, the best practice is to offer HIV counselling and testing to all adults who are sick enough to be admitted to hospital. Therefore, unless there is a clear non-HIV related reason for admission, <strong>an HIV test should be considered as part of the initial management of all admitted adult patients in our setting.</strong></p>\\r\\n<p>HCT should also be offered to all outpatients with signs of chronic disease and to all children with malnutrition or failure to thrive. Where the child is still breastfed, if they are extremely ill and an immediate diagnosis will change management, then the molecular diagnostics laboratory may be able to help with a viral PCR.</p>\\r\\n<p>All patients tested for HIV should be counselled before and after testing.</p>\\r\\n<p>Other test that may be performed at treatment centres to assist with diagnosis or staging includes the following:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Viral culture</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Lymph node biopsy</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Genotyping of viral DNA/RNA.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"management\\\">Management </h2>\\r\\n<h3 id=\\\"post-test-counselling\\\">Post-test counselling</h3>\\r\\n<p>It is important to emphasise to patients who are HIV-positive that this diagnosis is no longer a death sentence – it is treatable and even in Africa many patients will have a near-normal life expectancy, so long as they take their medications as prescribed. They should be encouraged to seek further help at an ART centre.</p>\\r\\n<p>The modes of transmission must be explained and patients should be encouraged to consider how they can avoid passing the virus on to others.</p>\\r\\n<p>Studies in Gambia have demonstrated that patients who share their diagnosis with someone they trust live longer than those who keep it a secret from everyone. Ideally, this trusted person should live in the same compound. They can act as a treatment supporter, encouraging the patient to take their medicine, and can ensure the patient is taken to a centre who knows how to treat HIV if they deteriorate or are unwell. Counsellors should do all they can to help patients identify a treatment supporter and to facilitate disclosure.</p>\\r\\n<h3 id=\\\"initial-treatment\\\">Initial treatment</h3>\\r\\n<p>All patients diagnosed with HIV should initially be put on septrin (cotrimoxazole) at a dose of 36-48 mg/kg (max 960 mg OD) unless contraindicated (e.g sulfa allergy).</p>\\r\\n<p>Patients who are malnourished or wasted will also benefit from regular multivitamins.</p>\\r\\n<p>Any opportunistic infections should be appropriately treated.</p>\\r\\n<h3 id=\\\"anti-retroviral-therapy-art\\\">Anti-retroviral therapy (ART)</h3>\\r\\n<p>In most cases, ART does not need to be started in a hurry – it is more important to stabilise the patient, counsel them and give them time to understand their diagnosis and future treatment. These patients should be referred to their local ART centre for further assessment and treatment once they have recovered from their initial illness. <strong>The current policy in The Gambia is “Test and Treat” which means that once a client is diagnosed with HIV infection, treatment can be commenced irrespective of CD4 count.</strong></p>\\r\\n<p>CD4 count is not routinely available in MRCG. There are a few exceptions to this general rule which include patients with TB, patients with cryptococcal meningitis and children with malnutrition or failure to thrive. In these cases, it is possible to get a CD4 count done in discussion with the TB team.</p>\\r\\n<p>Patients with both HIV and TB are usually started on TB medication prior to ART. If their CD4 count is less than 100, it has been shown that once TB treatment is started, ART should be started about 2 weeks later – any further delay is associated with an increase in mortality. Patients may experience an increase in symptoms when TB treatment is started. This is a form of IRIS (immune reconstitution inflammatory syndrome). It is important to continue their medication.</p>\\r\\n<p>Patients with cryptococcal meningitis should not start ART until they have received at least 6 weeks’ treatment for their meningitis. Prior to this, ART often causes IRIS and this is usually fatal.</p>\\r\\n<p>Children with malnutrition or failure to thrive who are HIV positive and do not have TB are difficult to treat and typically do not improve until ART is started.</p>\\r\\n<p>Therefore, patients with TB or children with malnutrition may need to be referred to an ART centre before they are ready for discharge – the nearest centre to Fajara is Serekunda General Hospital while the nearest centres to Keneba are Bwiam General Hospital and Soma District Hospital. Other centres are found in Banjul, Bundung and Brikama.</p>\\r\\n<h2 id=\\\"key-issues-for-nursing-care\\\">Key Issues for Nursing care</h2>\\r\\n<p><strong>It is important to</strong> recognize suspected cases of HIV and perform <strong>s</strong>creening and HIV counselling and testing (HCT).</p>\\r\\n<p>Refer stable patients to an ART centre, while sick patients should first be referred to a doctor.</p>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<p>Guidelines for Antiretroviral Therapy for the Prevention and Treatment of HIV in The Gambia 2015. WHO/Ministry of Health &amp; Social Welfare.</p>\\r\\n<p>Qaseem A, Snow V, Shekelle P, Hopkins R Jr, Owens DK. Screening for HIV in Health care settings: a guidance statement from the American college of Physicians and HIV Medicine Association. Ann Intern Med.2009 Jan 20.150(2):125-31.</p>\\r\\n<p>Panel on ARV guidelines for Adults and Adolescents. Guidelines for the use of ARV agents in HIV-1 infected adults and adolescents. Department of health and human services. October 17, 2017.</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Musa Jallow</th>\\r\\n<th>Date: 29 June 2018</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Fatai Akemokwe</td>\\r\\n<td>Date: 02 August 2018</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>2.0</td>\\r\\n<td>Updated and transferred to new template</td>\\r\\n<td>15 August 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>2.1</td>\\r\\n<td>Executive summary added</td>\\r\\n<td>15 August 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"010\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>Hypertension MeG-CLS-010</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"hypertension\\\">Hypertension</h1>\\r\\n<h2 id=\\\"executive-summary\\\"><em>Executive summary</em></h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<p>Hypertension means elevated (arterial) blood pressure. It is the leading modifiable risk factor for death and disability worldwide. Starting from 115/75 mmHg, every 20 mmHg increase in systolic blood pressure or 10 mmHg rise in diastolic blood pressure doubles the risk of death from cardiovascular disease.</p>\\r\\n<p>Between 18 to 32% of adults in The Gambia are hypertensive. Over 90% of hypertension is of unknown cause (essential/primary/ idiopathic) with risk factors including increasing age, male sex, Black race and family history of hypertension. Most cases of secondary hypertension result from renal disease.</p>\\r\\n<h3 id=\\\"target-users\\\">Target users</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nurses</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doctors</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"target-area-of-use\\\">Target area of use </h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Gate clinic</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Outpatient department</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"key-areas-of-focus-new-additions-changes\\\">Key areas of focus / New additions / Changes </h3>\\r\\n<p>This guideline addresses the diagnosis and treatment of hypertension in the CSD.</p>\\r\\n<p>The evaluation of patients with hypertension is aimed at identifying possible underlying causes, assessing overall cardiovascular risk and detecting complications.</p>\\r\\n<p>Patients seen at the Gate Clinic with blood pressure above 140/90 mmHg should be referred to the outpatient department if there is markedly or persistently raised blood pressure, hyperglycaemia, proteinuria or alarming symptoms.</p>\\r\\n<p>Drug therapy combined with lifestyle measures is recommended to achieve a target blood pressure of less than 140/90 mmHg. Choice of drugs depends on stage of hypertension at presentation, compelling indications and presence of comorbid conditions. Once-daily medications are preferred to improve adherence to drug therapy. Drug therapy should be adjusted until target blood pressure is reached provided adherence is satisfactory. Once blood pressure control is achieved, do not reduce medication doses unless side-effects occur.</p>\\r\\n<p>Patients seen in Fajara should be discharged to local care when they are stable. Patients in Keneba should continue care at their Gate Clinic.</p>\\r\\n<p>This guideline has been updated to address differences between Fajara and Keneba.</p>\\r\\n<h3 id=\\\"limitations\\\">Limitations </h3>\\r\\n<h2 id=\\\"this-guideline-does-not-address-the-emergency-management-of-acute-hypertensive-emergencies.\\\">This guideline does not address the emergency management of acute hypertensive emergencies.<br />\\r\\n</h2>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs\\\">Presenting symptoms and signs</h2>\\r\\n<p>Hypertension is generally accepted as a systolic blood pressure ≥ 140 mmHg, diastolic blood pressure ≥ 90 mmHg or use of antihypertensive medication prescribed by a qualified clinician.</p>\\r\\n<h3 id=\\\"symptoms\\\">Symptoms:</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Uncomplicated essential hypertension is usually asymptomatic.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Secondary hypertension may present with symptoms of underlying disease condition.</p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Facial puffiness, nocturia, or passage of dark or frothy urine is suggestive of renal disease</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Excessive sweating, palpitations and heat intolerance suggests hyperthyroidism</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Episodes of palpitations, dizziness, headache and sweating may occur in phaeochromocytoma</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Suspect secondary hypertension in patients newly diagnosed with hypertension who are younger than 30 years.</p>\\r\\n</div></li>\\r\\n</ul></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Features of some common complications:</p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Dyspnea on exertion, difficulty lying flat (orthopnea), bilateral leg swelling in heart failure</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Slurred speech, limb weakness in stroke</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Headache, abnormal behavior, altered consciousness, seizures in hypertensive encephalopathy</p>\\r\\n</div></li>\\r\\n</ul></li>\\r\\n</ul>\\r\\n<h3 id=\\\"signs\\\">Signs:</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>In earlier stages, no other presenting signs apart from raised blood pressure in essential hypertension</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Secondary hypertension may present with signs of the underlying condition</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hypertension may also present with signs of complications such as stroke, encephalopathy, renal failure or heart failure.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"examination-findings\\\">Examination findings</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Elevated blood pressure</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"important-things-to-look-for-in-opd\\\">Important things to look for in OPD: </h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Features of long-standing hypertension: thickened arterial walls, heaving apex beat, loud aortic component of second heart sound, retinal changes on fundoscopy.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Radiofemoral delay: Coarctation of the aorta</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Renal bruit: Renal artery stenosis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ballotable kidneys: Polycystic kidney disease</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Pallor, peripheral oedema, facial oedema: Chronic kidney disease</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"differential-diagnoses\\\">Differential diagnoses</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Renal disease</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Vascular disorders</p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Renal artery stenosis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Coarctation of the aorta</p>\\r\\n</div></li>\\r\\n</ul></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Endocrine disorders</p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hypothyroidism</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hyperthyroidism</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Phaeochromocytoma</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Adrenal hypersecretion (Cushing syndrome, Conn syndrome)</p>\\r\\n</div></li>\\r\\n</ul></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Drugs:</p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Steroids (including oral contraceptive pills)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Non-steroidal anti-inflammatory drugs (NSAIDs)</p>\\r\\n</div></li>\\r\\n</ul></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hypertensive disorders of pregnancy</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"investigations\\\">Investigations</h2>\\r\\n<h3 id=\\\"to-exclude-a-secondary-cause\\\">To exclude a secondary cause </h3>\\r\\n<p>For all patients under 30 years and others where there are signs to suggest another problem:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Urinalysis</p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Proteinuria of 2+ or more suggests renal cause</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Haematuria may indicate nephritic syndrome</p>\\r\\n</div></li>\\r\\n</ul></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Serum Electrolytes, Urea &amp; Creatinine</p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Elevated creatinine suggests renal involvement</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Derangements in potassium and bicarbonate may point to an adrenal problem</p>\\r\\n</div></li>\\r\\n</ul></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Full blood count</p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Chronic kidney disease causes anaemia (microcytic or normocytic)</p>\\r\\n</div></li>\\r\\n</ul></li>\\r\\n</ul>\\r\\n<h3 id=\\\"to-assess-other-important-cardiovascular-risk-factors\\\">To assess other important cardiovascular risk factors</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Fasting plasma glucose</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Fasting Serum Cholesterol (total and HDL only) – these should only be done if the patient does not already have a history of ischaemic heart disease or stroke. For such patients – estimate their cardiovascular risk using QRISK2 <a href=\\\"https://qrisk.org/2017/\\\"><span data-custom-style=\\\"Hyperlink\\\">https://qrisk.org/2017/</span></a></p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>If the risk is &gt; 10%, do not check the cholesterol, but advise the patient to start taking a statin anyway.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>If the risk is &lt; 5%, they will not need to take a statin whatever their cholesterol level.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Only check the cholesterol for those patients with risk of 5-10%, then recalculate the risk once the result is available and recommend statins for those with a risk of 10% or more.</p>\\r\\n</div></li>\\r\\n</ul></li>\\r\\n</ul>\\r\\n<h3 id=\\\"to-detect-subclinical-complications\\\">To detect subclinical complications</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>ECG</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"management-in-gate-clinic\\\">Management in Gate Clinic</h2>\\r\\n<h2 id=\\\"at-the-first-visit-if-the-bp-is-14090-request-urine-dipstick-and-test-blood-glucose.\\\">At the first visit if the BP is &gt; 140/90, request urine dipstick and test blood glucose.</h2>\\r\\n<p>Refer to a doctor if:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>BP is greater than 180 mmHg (systolic) or 110 mmHg (diastolic)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>protein in the urine</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>blood glucose is raised (fasting &gt; 6.9 mmol/l, random &gt; 11.1 mmol/l)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>any complaints of shortness of breath, chest pain, severe headaches or visual disturbance.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Otherwise, advise the patient to:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>reduce the salt in their diet</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>lose weight if they are overweight</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>increase their regular exercise.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Increase intake of fruits, vegetables and nuts</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Stop smoking and limit alcohol (if applicable)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ask them to return in 1-2 days.</p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Repeat BP at the return visit. If it is greater than 140/90 mmHg on a second occasion, refer to the doctor.</p>\\r\\n</div></li>\\r\\n</ul></li>\\r\\n</ul>\\r\\n<h2 id=\\\"management-in-opd\\\">Management in OPD</h2>\\r\\n<p>The target blood pressure for treating hypertension is a systolic blood pressure of 140mmHg <strong>and</strong> a diastolic blood pressure of 90 mmHg. Drugs given once daily are preferred to improve adherence to treatment. Counsel patients adequately on the benefits of their treatment, side-effects and the risks of non-adherence. Remind them of the importance of avoiding salt intake and emphasise the need for life-long therapy.</p>\\r\\n<p>Generally, for patients with systolic blood pressure less than 160 mmHg <strong>and</strong> diastolic blood pressure less than 100 mmHg, it is preferable to start with a <strong>single drug</strong>.</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<blockquote>\\r\\n<p>If the patients is not diabetic and has no signs of kidney disease, start with a thiazide at low dose (Bendroflumethiazide 2.5 mg OD)</p>\\r\\n</blockquote>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<blockquote>\\r\\n<p>If the patient is diabetic without signs of kidney disease, start with a calcium channel blocker at low dose (Amlodipine 5 mg OD)</p>\\r\\n</blockquote>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<blockquote>\\r\\n<p>If the patient has features of chronic kidney disease, place them on an ACE inhibitor (usually Ramipril 2.5 mg OD) at the lowest effective dose after excluding contraindications.</p>\\r\\n</blockquote>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>If blood pressure is still &gt;140/90 mmHg at subsequent clinic visits:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Enquire about adherence to drug therapy and lifestyle changes. Patients should be encouraged to bring their leftover/empty medication containers on clinic visits</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>If adherence appears satisfactory, increase the dose of the medication gradually with each clinic visit until target blood pressure is reached or maximum dose of the drug is achieved.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>If blood pressure is not at target despite maximum dose of the drug, add a second antihypertensive from a different class to the patient’s treatment (see flow chart below).</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Gradually increase this second drug until target blood pressure is reached or maximum dose of the drug is achieved.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Do not reduce drug doses after target blood pressure is attained unless patient has symptoms and signs of hypotension.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>For patients who present initially with systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg, or patients whose blood pressure is not at target despite maximum dose of the drug, <strong>combination therapy</strong> is recommended.</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>For patients without diabetes mellitus or kidney disease, start with a combination of a calcium channel blocker and a thiazide diuretic (Amlodipine 5 mg OD and Bendroflumethiazide 2.5 mg OD).</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>For patients with diabetes mellitus, start with a calcium channel blocker and an ACE inhibitor.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>For patients with kidney disease, place the patient on a combination of an ACE inhibitor with either a calcium channel blocker or a thiazide diuretic.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Gradually increase the doses of individual drugs at subsequent clinic visits until either target blood pressure is achieved or the maximum doses of <strong>both</strong> drugs are reached.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Compelling indications are special conditions in which particular classes of hypertension drugs must be prescribed.</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Pregnancy: alpha-methyldopa, nifedipine, labetalol or hydralazine</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Chronic kidney disease: ACE inhibitors</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Heart failure: ACE inhibitors + spironolactone + diuretics (+ beta blocker when stable)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Previous stroke: ACE inhibitors or thiazide diuretic.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p><img src=\\\"data:image/png;base64,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\\\" style=\\\"width:6in;height:5.92083in\\\" /></p>\\r\\n<p>Patients who do not have adequate control after following this flow chart:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Those who are not at target despite a combination of two drugs at maximum doses should have a third drug from an unused class added (ACEI +CCB +Thiazide).</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Those who remain uncontrolled at maximal doses of three drugs should be re-evaluated for secondary hypertension. A fourth drug (spironolactone or a beta blocker) can be added.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"considerations-for-individual-drugs\\\">Considerations for individual drugs</h3>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Drug group</strong></th>\\r\\n<th><strong>Indications</strong></th>\\r\\n<th><strong>Contraindications and monitoring</strong></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><p><strong>Thiazides</strong></p>\\r\\n<p><em>Bendroflumethiazide 2.5 mg OD</em></p></td>\\r\\n<td><p>First line if no DM or heart failure.</p>\\r\\n<p>Add to ACEi / CCB to improve control.</p>\\r\\n<p>Do not increase dose – it increases the side effects without improving effectiveness.</p></td>\\r\\n<td>Ensure that patients are counseled regarding risks of diuretic use and necessity to omit medications when having an intercurrent diarrhoeal illness.</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><p><strong>Calcium channel blockers (CCB)</strong></p>\\r\\n<p><em>Amlodipine 5-10 mg OD</em></p></td>\\r\\n<td><p>First line for co-existing DM.</p>\\r\\n<p>Second line in pregnancy (but use nifedipine not amlodipine).</p></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><p><strong>ACE inhibitors (ACEi)</strong></p>\\r\\n<p><em>Ramipril 2.5-10 mg OD</em></p></td>\\r\\n<td>First line for co-existing heart failure.</td>\\r\\n<td><p>Check K and Creatinine one month after start of treatment and stop if creatinine rises by &gt; 30%.</p>\\r\\n<p>ACE inhibitors can cause a chronic dry cough. All patients should watch out for angioedema.</p>\\r\\n<p>Female patients on ACE inhibitors should be counseled on the danger of using them in pregnancy.</p></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><p><strong>Spironolactone</strong></p>\\r\\n<p><em>25-100 mg OD</em></p></td>\\r\\n<td>Fourth line for patients with uncontrolled BP despite being on 3 other medications.</td>\\r\\n<td>Avoid if serum potassium is &gt; 4.5 mmol/l.</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><p><strong>Beta blockers</strong></p>\\r\\n<p><em>Bisoprolol 1.25-10 mg OD</em></p></td>\\r\\n<td>Fourth line for stable heart failure or for patients with uncontrolled BP despite being on 3 other medications.</td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><p><strong>Methyldopa</strong></p>\\r\\n<p>250 mg BD – 500 mg TDS</p></td>\\r\\n<td>First line for pregnancy.</td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<p><strong>For patients seen at Fajara, discharge to local care once stable on medication</strong>.<br />\\r\\n<strong>For patients seen at Keneba, continue care at the Gate Clinic once stable on medication.</strong></p>\\r\\n<p>Recommend patient remains on medication and has annual blood tests.</p>\\r\\n<h2 id=\\\"key-issues-for-nursing-care\\\">Key Issues for Nursing care</h2>\\r\\n<p>How to measure blood pressure correctly:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>The patient should be relaxed, comfortably seated with back supported, legs uncrossed and measured arm supported at heart level.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Radial or brachial pulse should be assessed for rhythm<strong>.</strong></p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>If irregular, do not use the automatic blood pressure machine. Use a manual sphygmomanometer instead.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>An appropriate cuff size should be selected and applied mid-arm (about 2 cm above the elbow)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>The patient should not speak during blood pressure measurement.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Measure the blood pressure in both arms. If the difference is more than 20 mmHg between both arms, document the arm with higher reading and use this arm for all future measurements in the patient.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>If the blood pressure reading is higher than 140/90 mmHg, repeat the measurement. If second measurement is significantly different, take a third reading and keep the lower of the last two values.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<p>Flack JM, Sica DA, Bakris G, Brown AL, Ferdinand KC, Grimm RH Jr et al. Management of High Blood Pressure in Blacks: An Update of the International Society on Hypertension in Blacks Consensus Statement. Hypertension. 2010;56:780-800.</p>\\r\\n<p>National Institute for Health and Care Excellence (NICE). Hypertension in adults: diagnosis and management. NICE; 2011. Available from: <a href=\\\"http://www.nice.org.uk/guidance/cg127/chapter/1-Guidance\\\"><span data-custom-style=\\\"Hyperlink\\\">www.nice.org.uk/guidance/cg127/chapter/1-Guidance</span></a></p>\\r\\n<p>James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J.2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8).JAMA. 2014 Feb 5;311(5):507-20. doi: 10.1001/jama.2013.284427.</p>\\r\\n<p>Armstrong C; Joint National Committee.JNC8 guidelines for the management of hypertension in adults.Am Fam Physician. 2014 Oct 1;90(7):503-4.</p>\\r\\n<p>Williams SK, Ravenell J, Seyedali S, Nayef S, Ogedegbe G. Hypertension Treatment in Blacks: Discussion of the U.S. Clinical Practice Guidelines. Prog Cardiovasc Dis. 2016 Nov-Dec; 59(3): 282–288.</p>\\r\\n<p>World Health Organization (WHO). Raised blood pressure. Geneva: WHO; 2018. Available from: <a href=\\\"http://www.who.int/gho/ncd/risk_factors/blood_pressure_prevalence_text/en/\\\"><span data-custom-style=\\\"Hyperlink\\\">http://www.who.int/gho/ncd/risk_factors/blood_pressure_prevalence_text/en/</span></a></p>\\r\\n<p>Alexander MR. Hypertension. Medscape; 2018. Available from: <a href=\\\"https://emedicine.medscape.com/article/241381\\\"><span data-custom-style=\\\"Hyperlink\\\">https://emedicine.medscape.com/article/241381</span></a></p>\\r\\n<p><span data-custom-style=\\\"Hyperlink\\\"><br />\\r\\n</span></p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Fatai Momodu Akemokwe</th>\\r\\n<th>Date: 22 May 2018</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Karen Forrest</td>\\r\\n<td>Date: 25 June 2018</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>2.0</td>\\r\\n<td>Rewritten on new template and to address differences between Fajara and Keneba</td>\\r\\n<td>31 July 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>2.1</td>\\r\\n<td>Executive summary added</td>\\r\\n<td>31 July 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"027\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>Hyperthyroidism and goitre MeG-CLS-027</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"hyperthyroidism-and-goitre\\\">Hyperthyroidism and goitre</h1>\\r\\n<h2 id=\\\"executive-review\\\"><em>Executive review</em></h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<p>Hyperthyroidism and goitre in The Gambia are most often caused either by Grave’s disease or by nodular disease. As everywhere, thyroid disease is more common in women than in men.</p>\\r\\n<p>Nodular disease is probably linked to chronic iodine deficiency and is more common in older patients. It may or may not be associated with hyperthyroidism.</p>\\r\\n<h3 id=\\\"target-user\\\">Target User</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nurses</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doctors</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"target-area-of-use\\\">Target area of use </h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Outpatient department</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ward</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"key-areas-of-focus-new-additions-changes.\\\">Key areas of focus / New additions / Changes.</h3>\\r\\n<p>This guideline addresses the diagnosis and management of hyperthyroidism and goitre.</p>\\r\\n<h3 id=\\\"limitations\\\">Limitations </h3>\\r\\n<p>There is limited availability of an alternative to carbimazole in the country.</p>\\r\\n<p>Thyroidectomy is only available when skilled surgeons visit The Gambia. There is no access to radioiodine treatment.</p>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs\\\">Presenting symptoms and signs</h2>\\r\\n<p>Goitre is a common presenting symptom of thyroid disease.</p>\\r\\n<p>Other symptoms related to hyperthyroidism include:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Unintentional weight loss (despite increased appetite) (although a few patients may gain weight, if excessive intake outstrips weight loss)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Shakiness</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nervousness</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Anxiety</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Increased perspiration</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Heat intolerance</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Palpitations</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Chest pain – often occurs in the absence of cardiovascular disease</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Frequent bowel movements</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Reduction in menstrual flow or oligomenorrhea</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Elderly patients may have only cardiovascular symptoms, commonly new onset atrial fibrillation.</p>\\r\\n<p>Patients with Grave’s disease may also present with eye disease (proptosis, periorbital oedema, diplopia) and may have a past medical history of autoimmune disease (such as rheumatoid arthritis, vitiligo etc).</p>\\r\\n<h2 id=\\\"examination-findings\\\">Examination findings</h2>\\r\\n<h3 id=\\\"general-examination\\\">General examination</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Raised HR or AF</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hypertension – with wide pulse pressure</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Warm moist, smooth skin,</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Lid lag, staring appearance</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Tremor</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Muscle weakness</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"thyroid\\\">Thyroid</h3>\\r\\n<p>In Grave’s disease, the thyroid is typically diffusely enlarged and firm. Multinodular goitres are softer, but may be much larger. Pain is very unusual.</p>\\r\\n<h2 id=\\\"differential-diagnoses\\\">Differential diagnoses</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Anxiety Disorders</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Panic Disorder</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Withdrawal Syndromes</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Delirium Tremens (DTs)</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"investigations\\\">Investigations</h2>\\r\\n<p>US of neck is essential to identify nodules.</p>\\r\\n<p>ECG may show sinus tachycardia or atrial fibrillation (especially in elderly patients).</p>\\r\\n<p>The most reliable screening measure of thyroid function is the thyroid-stimulating hormone (TSH) level. Hyperthyroidism is confirmed by the presence of a TSH level which is low or suppressed to unmeasurable levels (except in the case of secondary hyperthyroidism due to pituitary disease, which is not considered in this guideline).</p>\\r\\n<p>If the TSH is low, then order free T<sub>3</sub> and free T<sub>4</sub> at the next appointment. The diagnosis is confirmed if these are raised. Sub-clinical hyperthyroidism is defined as a decreased but not undetectable TSH level (&lt; 0.5 μIU/mL) in combination with serum concentrations of T<sub>3</sub> and T<sub>4</sub> that are within the reference range.</p>\\r\\n<h2 id=\\\"management\\\">Management </h2>\\r\\n<h2 id=\\\"non-toxic-goitre\\\"><span class=\\\"underline\\\">Non-toxic goitre</span></h2>\\r\\n<p>This does not usually need any immediate treatment. Encourage the patient to use iodised salt. If the goitre is large or the patient is distressed, then consider referral to the surgeons at KGH as they sometimes have a team of visiting thyroid surgeons.</p>\\r\\n<p><strong><span class=\\\"underline\\\">Hyperthyroidism.</span></strong></p>\\r\\n<p>Once hyperthyroidism is confirmed by a low TSH, it becomes necessary to check free T<sub>4</sub> and T<sub>3</sub> (fT<sub>3</sub>, fT<sub>4</sub>). Also check FBC and LFTs.</p>\\r\\n<p><span class=\\\"underline\\\">Initial treatment</span></p>\\r\\n<p>Start</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>adults with HR &gt; 90 on Propranolol 40 mg TDS.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>children with HR &gt; 100 and cardiovascular symptoms on Propranolol 0.5-1.0 mg/kg TDS.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Once the fT<sub>4</sub> is available, start Carbimazole as outlined in the table below.</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>fT<sub>4</sub></strong></th>\\r\\n<th><strong>Adult dose</strong></th>\\r\\n<th><strong>Children’s dose</strong></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.85 – 2.78 ng/dl</td>\\r\\n<td>5-10 mg OD</td>\\r\\n<td>0.25 mg/kg OD</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>2.78 – 3.7 ng/dl</td>\\r\\n<td>10-20 mg OD</td>\\r\\n<td>0.5 mg/kg OD</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>3.7 – 5.55 ng/dl</td>\\r\\n<td>30-40 mg OD</td>\\r\\n<td>0.75 mg/kg OD</td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<p>Recheck fT<sub>3</sub> and fT<sub>4</sub> (but not TSH which is slow to normalize) 1 month after starting treatment. Once the levels of both are normal, reduce Carbimazole dose by 50% and then recheck again in 6/52.</p>\\r\\n<p><span class=\\\"underline\\\">Maintenance</span></p>\\r\\n<p>Once the patient is euthyroid and stable on a maintenance dose of Carbimazole (typically 10 mg OD in adults), check the fT<sub>3</sub>, fT<sub>4</sub> every 3/12. Stop the propranolol.</p>\\r\\n<p>Carbimazole is associated with a 1 in 1000 risk of agranulocytosis and a 3 in 10000 risk of liver failure.</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Warn the patient to return urgently if they develop a febrile illness, pharyngitis, itchy rash, jaundice, change of colour of stool or urine, abdominal pain or bloating, anorexia, nausea or vomiting.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Check the FBC or LFTs as appropriate in any patient presenting with these symptoms.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>If either have changed from baseline, then you may need to stop the carbimazole – remembering that there is no alternative treatment easily available in the Gambia.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p><span class=\\\"underline\\\">Further treatment</span></p>\\r\\n<p>Patients with a toxic nodular goitre are very likely to need surgery once they are euthyroid and should be referred for this.</p>\\r\\n<p>Patients with Grave’s disease who have been on treatment for 18 months or more may be able to stop treatment and remain in remission.</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Review the patient clinically 1/12 after stopping treatment. If they are well, review 3 monthly and check TSH, fT<sub>3</sub>, fT<sub>4</sub> at each appointment until they have been euthyroid off treatment for 1 year. Then discharge the patient.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>If they develop hyperthyroidism once again, then reestablish on treatment and, once they are euthyroid, refer for surgery.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"key-issues-for-nursing-care\\\">Key Issues for Nursing care</h2>\\r\\n<h2 id=\\\"refer-all-patients-with-possible-thyroid-disease-to-the-doctor.\\\">Refer all patients with possible thyroid disease to the doctor. </h2>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<p>Erik D Schraga (30 May 2014). &quot;Hyperthyroidism, Thyroid Storm, and Graves Disease&quot;. Archived from the original on 5 April 2015. Retrieved 20 April 2015.</p>\\r\\n<p>Hyperthyroidism&quot;. www.niddk.nih.gov. July 2012. Archived from the original on 4 April 2015. Retrieved 2 April 2015.</p>\\r\\n<p>Ross et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid (2016) 26:1343-1421.</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Chibuike Okpara</th>\\r\\n<th>Date: 9 June 2018</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Babatunde Awokola</td>\\r\\n<td>Date: 2 July 2018</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>2.0</td>\\r\\n<td>Updated and transferred to new template</td>\\r\\n<td>31 July 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>2.1</td>\\r\\n<td>Executive summary added</td>\\r\\n<td>31 July 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"074\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>Hypocalcaemia and hypercalcaemia MeG-CLS-074</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"hypocalcaemia-and-hypercalcaemia\\\">Hypocalcaemia and hypercalcaemia</h1>\\r\\n<h2 id=\\\"executive-summary\\\"><em>Executive summary</em></h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<h2 id=\\\"abnormalities-in-calcium-levels-are-less-common-than-other-electrolyte-disturbances.-they-are-important-to-note-as-they-often-indicate-a-serious-underlying-condition.-calcium-levels-should-always-be-corrected-for-the-albumin-level-before-being-interpreted.\\\">Abnormalities in calcium levels are less common than other electrolyte disturbances. They are important to note as they often indicate a serious underlying condition. Calcium levels should always be corrected for the albumin level before being interpreted. </h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Corrected Ca mmol/l = (0.02 x (40 – serum albumin)) + Ca</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"target-users\\\">Target users</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doctors</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nurses</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"target-area-of-use\\\">Target area of use </h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Outpatient department</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ward</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"key-areas-of-focus-new-additions-changes\\\">Key areas of focus / New additions / Changes </h3>\\r\\n<h2 id=\\\"this-guideline-outlines-the-correction-of-abnormal-calcium-levels.\\\">This guideline outlines the correction of abnormal calcium levels. </h2>\\r\\n<h2 id=\\\"limitations\\\">Limitations</h2>\\r\\n<h2 id=\\\"we-do-not-keep-bisphosphonates-but-they-are-often-available-locally-for-purchase.\\\">We do not keep bisphosphonates, but they are often available locally for purchase.</h2>\\r\\n<h1 id=\\\"hypocalcaemia\\\">Hypocalcaemia</h1>\\r\\n<p>This is defined as corrected serum calcium &lt; 2.15 mmol/l. Mild hypocalcaemia is between 1.9 mmol/l and 2.14 mmol/l while moderate hypocalcaemia is between 1.5 mmol/l and 1.8 mmol/l. Severe hypocalcaemia is &lt;1 .5 mmol/l.</p>\\r\\n<h2 id=\\\"causes\\\">Causes</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hypoparathyroidism</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Pancreatitis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Sarcoidosis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hypomagnesaemia</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hypophosphataemia</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hypoalbuminemia</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Vitamin D deficiency</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Chronic Kidney disease</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs\\\">Presenting symptoms and signs </h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Perioral or finger paraesthesiae</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Tetany evidenced by the presence of:</p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Chvostek sign :Twitching of facial muscles in response to tapping over the area of the facial nerve</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Trousseau’s sign: carpopedal spasm that results from ischemia, such as that induced by pressure applied to the upper arm from an inflated sphygmomanometer cuff</p>\\r\\n</div></li>\\r\\n</ul></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Seizures</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"management\\\">Management </h2>\\r\\n<p>For mild to moderate hypocalcaemia and in chronic hypocalcaemia , oral therapy with effervescent or non-effervescent calcium carbonate tablets at 1000-1500 mg OD or BD should be prescribed with food.</p>\\r\\n<p>Severe and symptomatic hypocalcaemia is treated with intravenous calcium gluconate infusion. IV 10% Calcium gluconate 20 mls in 100ml of 0.9% saline infusion over 20 minutes. Then 100 ml of 10% calcium gluconate in 900 ml of 0.9% saline infusion at 50 ml/hr over the next 24 hours. Check serum calcium every 4 hours.</p>\\r\\n<p>Treat underlying condition.</p>\\r\\n<h1 id=\\\"hypercalcaemia\\\">Hypercalcaemia </h1>\\r\\n<p>This is defined as corrected serum calcium &gt; 2.55 mmol/l. Mild hypercalcemia is from 2.56-2.59 mmol/l, moderate is 3.0-3.2 mmol/l, while severe is &gt; 3.2 mmol/l. Hypercalcaemia can result in nephrolithiasis as well as renal failure.</p>\\r\\n<h2 id=\\\"causes-1\\\">Causes</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hyperparathyroidism</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Sarcoidosis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Malignancies e.g multiple myeloma</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hypervitaminosis D</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hyperthyroidism</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs-1\\\">Presenting symptoms and signs</h2>\\r\\n<p>These occur as hypercalcemia becomes more severe.</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Lethargy</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Weakness</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Confusion</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Coma</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Polyuria</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nocturia</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Dehydration</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Constipation</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nausea</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Anorexia</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Abdominal pains</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"management-1\\\">Management </h2>\\r\\n<p>Severe hypercalcaemia is a medical emergency and is corrected by rehydration with 0.9% saline at 60 ml/hr to as high as 200-300 ml/hr.</p>\\r\\n<p>Bisphophonate therapy is required for severe hypercalcaemia. If the patient cannot afford this, then furosemide can be added to the treatment, but this may not be very effective.</p>\\r\\n<p>Dialysis may be necessary.</p>\\r\\n<p>For mild to moderate hypercalcaemia, dietary restriction and increased oral fluid intake is appropriate treatment.</p>\\r\\n<h2 id=\\\"key-issues-for-nursing-care\\\">Key Issues for Nursing care</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Follow the fluid instructions very carefully.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Make sure repeat tests are done on time and are reviewed by a doctor promptly.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>All patients with abnormal Ca levels should have strict monitoring of fluid input and output.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<p>Bartel B, Gau E. Fluid and Electrolyte Management. Critical Care Pharmacotherapeutics. Burlington, MA: Jones &amp; Bartlett Learning. 2012 Feb 8:125-50.</p>\\r\\n<p>Hoorn EJ, Tuut MK, Hoorntje SJ, van Saase JL, Zietse R, Geers AB. Dutch guideline for the management of electrolyte disorders-2012 revision. Neth J Med. 2013 Apr 1;71(3):153-65.</p>\\r\\n<p>Kraft MD, Btaiche IF, Sacks GS, Kudsk KA. Treatment of electrolyte disorders in adult patients in the intensive care unit. American Journal of Health-System Pharmacy. 2005 Aug 15;62(16):1663-82.</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Orighomisan Agboghoroma</th>\\r\\n<th>Date: 07 January 2019</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Karen Forrest</td>\\r\\n<td>Date: 09 May 2019</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td>31 May 2021</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"073\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>Hypokalaemia, hyperkalaemia, hypermagnesaemia MeG-CLS-073</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"hypokalaemia-hyperkalaemia-and-hypomagnesaemia\\\">Hypokalaemia, hyperkalaemia and hypomagnesaemia</h1>\\r\\n<h2 id=\\\"executive-summary\\\"><em>Executive summary</em></h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<p>Abnormalities in serum potassium are relatively common in our admitted population, but can also be seen in outpatients. Abnormal K is a risk factor for sudden cardiac death and must be addressed whenever it is noted. Abnormal magnesium levels are less common and do not need to be actively sought out except in the presence of hypokalaemia, which will be difficult to correct in the presence of hypomagnesaemia.</p>\\r\\n<p>Falsely high potassium levels are very common, usually resulting from errors in taking blood samples and handling the sample prior to analysis. Abnormal potassium levels must always be rechecked prior to treatment – although where the initial result is severe and consistent with the clinical state of the patient, treatment may be initiated prior to receiving the repeated result.</p>\\r\\n<h2 id=\\\"target-users\\\">Target users</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doctors</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nurses</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"target-area-of-use\\\">Target area of use </h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Outpatient department</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ward</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"key-areas-of-focus-new-additions-changes\\\">Key areas of focus / New additions / Changes </h2>\\r\\n<p>This guidelines addresses the correction of abnormal potassium and magnesium results.</p>\\r\\n<p>Note that great care should be taken in correcting low potassium and magnesium levels in malnourished children as the supplements they are given already contain extra doses of these minerals. Senior support should be sought where the measured level is very low.</p>\\r\\n<h2 id=\\\"limitations\\\">Limitations</h2>\\r\\n<p>Patients requiring dialysis must be referred to the teaching hospital.</p>\\r\\n<h1 id=\\\"hypokalaemia\\\">Hypokalaemia</h1>\\r\\n<p>This defined as K &lt; 3.5 mmol/l. Mild to moderate level is between 2.5 mmol/L and 3.4 mmol/L and severe hypokalaemia is defined as &lt; 2.5 mmol/L</p>\\r\\n<h2 id=\\\"causes\\\">Causes</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Enteral losses e.g. diarrhoea , vomiting</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Drugs e.g. insulin, theophylline, caffeine, salbutamol, loop and thiazide diuretics</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Metabolic alkalosis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Malnutrition with refeeding</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hypomagnesemia (it will be impossible to correct the hypokalaemia until the Mg level is treated)</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs\\\">Presenting symptoms and signs </h2>\\r\\n<p>Patients are usually asymptomatic.</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Weakness</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Respiratory compromise</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Paralysis.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>ECG changes: T wave depression and inversion, ST Segment depression, U waves, cardiac depression</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"management\\\">Management </h2>\\r\\n<p>Always repeat the electrolytes to ensure the initial result is accurate. For severe hypokalaemia, start treatment before this result is available, but it must be reviewed immediately the repeat result is available.</p>\\r\\n<p>Check serum magnesium and bicarbonate.</p>\\r\\n<p>Withdraw medications that cause hypokalaemia.</p>\\r\\n<p>Dietary supplementation with potassium – food for patients with mild hypokalaemia e.g bananas, oranges, green leafy vegetables, potatoes, cucumbers etc.</p>\\r\\n<p>Note that F75 and F100 have extra potassium in them, so malnourished children with mild to moderate hypokalaemia do not need extra oral potassium supplements.</p>\\r\\n<h3 id=\\\"correction\\\">Correction</h3>\\r\\n<p>Mild to moderate hypokalaemia may be treated with oral potassium supplements i.e Slow K at 1200 mg (16 mmol) BD or 10% of Potassium chloride solution given at 15 mls (20 mmol) 2-3 times daily. This dosage can be increased as needed. Monitor potassium every 48 hours.</p>\\r\\n<p>Severe hypokalaemia is corrected with IV potassium chloride in normal saline infusion .</p>\\r\\n<p>For patients with potassium level &lt; 3.0 mmol/l give a total 60 – 80 mmol of Potassium chloride in 24 hours at 10 mmol/hr. Patients with potassium levels between 3.0 and 3.4 mmol/l and cannot take potassium enterally give 20 – 40 mmol/l intravenously and in infusion.</p>\\r\\n<p>Avoid using dextrose containing fluid for infusion.</p>\\r\\n<p>Monitor potassium levels every 2-6 hours.</p>\\r\\n<h1 id=\\\"hyperkalaemia\\\">Hyperkalaemia </h1>\\r\\n<p>In children and adults, this is defined as potassium levels &gt; 5.5 mmol/l. Mild hyperkalaemia is 5.5-5.9 mmol/L, moderate is 6.0-6.4 mmol/L and severe is ≥ 6.5 mmol/l. Severe hyperkalaemia is also present when serum potassium &gt; 5.5mmol/L with ECG changes. Unless samples are haemolysed, all cases of hyperkalaemia should be treated immediately.</p>\\r\\n<p>For infants aged 2 weeks to 3 months, hyperkalaemia is defined as K &gt; 5.7 mmol/l.</p>\\r\\n<p>For neonates aged less than 2 weeks, hyperkalaemia is defined as K &gt; 6.0 mmol/l.</p>\\r\\n<h2 id=\\\"causes-of-hyperkalaemia\\\">Causes of hyperkalaemia</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Extracellular shift: metabolic acidosis, rhabdomyolysis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Medications: succinylcholine, beta blockers and digoxin</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Reduced excretion- potassium sparing diuretics,renal failure</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"causes-of-pseudohyperkalaemia\\\">Causes of pseudohyperkalaemia: </h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Prolonged tourniquet time or repeated fist clenching</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Test tube haemolysis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Sample contamination with potassium EDTA (anticoagulant)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Delayed analysis (prolonged storage of blood)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Marked leucocytosis and thrombocytosis (measure plasma not serum concentration in these disease states)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Sample taken from a vein infused with IV fluids containing potassium (hospital setting)</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>These should be avoided when taking and analyzing samples. It should be kept in mind when reviewing laboratory results where there is high potassium level.</p>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs-1\\\">Presenting symptoms and signs</h2>\\r\\n<p>Patients are usually asymptomatic.</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Muscle twitching</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Cramps</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Weakness and paralysis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>ECG changes: Peaked T waves, widened QRS complexes, Prolonged PR interval and prolonged QT interval</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Arrhythmias</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Note that the absence of ECG changes does not exclude severe hyperkalaemia and does not mean that the patient cannot die suddenly of an arrhythmia.</p>\\r\\n<h2 id=\\\"management-1\\\">Management </h2>\\r\\n<p>All patients with hyperkalaemia should have an ECG done. Ideally they should be monitored during correction with an ECG<strong>.</strong></p>\\r\\n<p>Stop all supplements containing potassium and all potassium-containing IV fluids. Review drugs and consider stopping drugs which cause K retention.</p>\\r\\n<p>For severe hyperkalaemia:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>IV 10 ml of 10% calcium gluconate in a central vein or slowly over 2-3 minutes</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>IV 50 ml of 50% dextrose +10 units of soluble insulin over 10 minutes. In diabetes mellitus, if the blood sugar is raised, insulin should be given without glucose.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Give nebulised salbutamol 10mg stat.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Repeat potassium levels every one hour. If insulin is used, monitor blood sugar hourly too.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>These measures all temporarily shift the serum potassium into the cells. To remove potassium from the patient’s system, consider if furosemide is an appropriate treatment.</p>\\r\\n<p>If hyperkalaemia remains intractable, patient should be referred to the teaching hospital for dialysis.</p>\\r\\n<p>For mild to moderate hyperkalaemia, restrict potassium in diet and review medications.</p>\\r\\n<h1 id=\\\"hypomagnaesemia\\\">Hypomagnaesemia</h1>\\r\\n<p>This is defined as serum magnesium levels less than 0.7 mmol/L. It is said to be severe if &lt; 0.4 mmol/L.</p>\\r\\n<h2 id=\\\"causes-1\\\">Causes</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Malnutrition</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Pancreatitis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Diarrhoea</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Diuretics</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Sepsis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Trauma</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Burn</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Alcoholism</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs-2\\\">Presenting symptoms and signs</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Seizures</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Coma</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Weakness</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Cardiac arrythmias.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"management-2\\\">Management </h2>\\r\\n<p>Mild to moderate hypomagnesaemia: IV Magnesium sulphate solution 2 g in 100 ml 0.9% saline over 2 hours.</p>\\r\\n<p>Severe hypomagnesaemia: IV Magnesium sulphate solution 4 – 6 g in 250 mls of 0.9% saline over 4 hours (not exceeding 12 g per day).</p>\\r\\n<h2 id=\\\"key-issues-for-nursing-care\\\">Key Issues for Nursing care</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hypokalaemia and hyperkalaemia can both be associated with sudden cardiac death and must be treated.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Follow the fluid instructions very carefully.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Make sure repeat tests are done on time and are reviewed by a doctor promptly.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>All patients given insulin must have hourly bedside blood sugar monitoring.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Seek senior support if you are at all concerned about the patient.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<p>Bartel B, Gau E. Fluid and Electrolyte Management. Critical Care Pharmacotherapeutics. Burlington, MA: Jones &amp; Bartlett Learning. 2012 Feb 8:125-50.</p>\\r\\n<p>Hoorn EJ, Tuut MK, Hoorntje SJ, van Saase JL, Zietse R, Geers AB. Dutch guideline for the management of electrolyte disorders-2012 revision. Neth J Med. 2013 Apr 1;71(3):153-65.</p>\\r\\n<p>Kraft MD, Btaiche IF, Sacks GS, Kudsk KA. Treatment of electrolyte disorders in adult patients in the intensive care unit. American Journal of Health-System Pharmacy. 2005 Aug 15;62(16):1663-82.</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th><p>Name: Orighomisan Agboghoroma</p>\\r\\n<p>Mariama Sonko</p></th>\\r\\n<th>Date: 07 January 2019</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Karen Forrest</td>\\r\\n<td>Date: 09 May 2019</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td>31 May 2021</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"072\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>Hyponatraemia and hypernatraemia MeG-CLS-072</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"hyponatraemia-and-hypernatraemia\\\">Hyponatraemia and hypernatraemia</h1>\\r\\n<h2 id=\\\"executive-summary\\\"><em>Executive summary</em></h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<p>Abnormalities in serum sodium are relatively common in our admitted population – especially in those with hypertension, heart failure or liver disease. An abnormal sodium level has been shown to be associated with poor outcome following hospital admission. It is very important that these abnormalities are noticed and responded to as soon as possible.</p>\\r\\n<p>Remember that abnormalities can result from laboratory errors or other factors around specimen collection and storage. It is very important to relate any abnormal results to the clinical state of the patient and to repeat the laboratory test whenever there is any uncertainty.</p>\\r\\n<p>Note:</p>\\r\\n<p>TBW (men) = 0.6 L/kg × weight in kg</p>\\r\\n<p>TBW (women) = 0.5 L/kg × weight in kg</p>\\r\\n<h2 id=\\\"target-users\\\">Target users</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doctors</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nurses</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"target-area-of-use\\\">Target area of use </h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Outpatient department</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ward</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"key-areas-of-focus-new-additions-changes\\\">Key areas of focus / New additions / Changes </h2>\\r\\n<p>This guideline describes the correction of abnormal sodium results.</p>\\r\\n<p>Note that great care should be taken in correcting the sodium level in malnourished children. Commonly, these children have raised total body sodium even if the serum sodium level is reduced. Usually the blood results will improve as the nutrition status improves.</p>\\r\\n<p>Rapid shifts in serum sodium are associated with irreversible brain injury so correction must be undertaken cautiously.</p>\\r\\n<h2 id=\\\"limitations\\\">Limitations</h2>\\r\\n<p>We do not keep hypertonic or hypotonic sodium solutions.</p>\\r\\n<h1 id=\\\"hyponatraemia\\\">Hyponatraemia</h1>\\r\\n<p>This is defined as Na &lt; 135 mmol/L. It is severe if ≤ 120 mmol/L.</p>\\r\\n<h2 id=\\\"causes\\\">Causes</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Isotonic hyponatraemia: hyperlipidemia or proteinaemia</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hypertonic hyponatraemia: glucose or mannitol infusion.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Euvolemic hyponatraemia: syndrome of inappropriate ADH (SIADH) secretion, hypothyroidism, adrenal insufficiency and medications such as thiazide diuretics, NSAIDs and SSRIs</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hypovolemic: haemorrhage, vomiting, diarrhoea, burns</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hypervolemic: congestive heart failure, liver cirrhosis.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs\\\">Presenting symptoms and signs</h2>\\r\\n<p>Symptoms and signs are usually obvious in patients who have sudden onset of hyponatraemia or have severe hyponatraemia and they include :</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Headache</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Lethargy</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nausea</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Depressed reflexes</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Disorientation</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Seizures</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Coma</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Other symptoms and signs are dependent on the volume status of the patient:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Dizziness, postural hypotension and syncope – hypovolaemia</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Peripheral oedema, pleural effusion or ascites – hypervolaemia</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"management\\\">Management</h2>\\r\\n<p>Medications such as diuretics should be reviewed or stopped if they are thought to be responsible for hyponatraemia.</p>\\r\\n<p>The causes of hyperlipidaemia and hyperproteinaemia should be found and treated.</p>\\r\\n<p>Endocrinologic disorders should be managed accordingly. SIADH is managed with fluid restriction at first and then diuresis if there is no improvement.</p>\\r\\n<p>The treatment of hypervolemic hyponatraemia is with diuresis - preferably loop diuretics.</p>\\r\\n<h3 id=\\\"correction\\\">Correction</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Na deficit (mmol/L) = Total Body Water (TBW) × (140 – measured serum Na concentration)</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Normal saline is used for correction of hyponatremia in our setting and this can be calculated using the following formula:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Change in serum Na = Infusate Na – Serum Na / (total body water +1)</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>This gives the change in serum sodium per litre of infusate. Note: Infusate Na is 154 mmol/L for 0.9% saline intravenous infusion.</p>\\r\\n<div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Use the calculator on this website to determine the infusion rate: <a href=\\\"https://www.mdcalc.com/sodium-correction-rate-hyponatremia-hypernatremia\\\"><span data-custom-style=\\\"Hyperlink\\\">https://www.mdcalc.com/sodium-correction-rate-hyponatremia-hypernatremia</span></a></p>\\r\\n</div>\\r\\n<p>Correction should be done at a rate of 1-2 mmol/L/hour (in acute conditions) or 0.5 mmol/L/hour (in chronic conditions) over 40 hours. Fifty percent of the fluid should be given in the 1st 24 hrs and not exceeding 12 mmol/24hrs. This is to prevent cerebral pontine myelinolysis</p>\\r\\n<p>Monitoring of serum Na should be done after every 4-6 hours.</p>\\r\\n<h1 id=\\\"hypernatraemia\\\">Hypernatraemia</h1>\\r\\n<p>This is defined as Na &gt; 145 mmol/L. It is severe if ≥ 160 mmol/L.</p>\\r\\n<h2 id=\\\"causes-1\\\">Causes </h2>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Type of fluid loss or gain</strong></th>\\r\\n<th><strong>Causes</strong></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Net water loss</td>\\r\\n<td><ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Unreplaced insensible loss (dermal and respiratory)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Inadequate fluid intake/impaired thirst – typically in elderly people</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Diabetes insipidus</p>\\r\\n</div></li>\\r\\n</ul></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Hypotonic fluid loss</td>\\r\\n<td><ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Renal causes, e.g. osmotic diuresis in uncontrolled diabetes</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Medicines, e.g. loop diuretics, mannitol, urea, corticosteroids (increase production of urea), high protein supplements</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Gastrointestinal losses, e.g. diarrhoea, vomiting, fistulae, use of osmotic laxatives (lactulose, sorbitol)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Cutaneous loss, e.g. burns, excessive sweating</p>\\r\\n</div></li>\\r\\n</ul></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Hypertonic fluid gain</td>\\r\\n<td><ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ingestion of salt, salt water, sodium rich enemas</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>IV hypertonic infusions, e.g. sodium bicarbonate, sodium chloride</p>\\r\\n</div></li>\\r\\n</ul></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs-1\\\">Presenting symptoms and signs </h2>\\r\\n<p>These become obvious as the hypernatraemia becomes more severe:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Thirst</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Fever</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Sensorium change</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Seizure</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Focal neurological deficits</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hyperventilation</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"management-1\\\">Management</h2>\\r\\n<p>Stop or decrease dosage of medications and infusions which are likely causes of hypernatremia.</p>\\r\\n<h3 id=\\\"adults\\\">Adults</h3>\\r\\n<p><strong>Mild to moderate hypernatraemia</strong> (Na 146-159 mmol/l): oral water therapy may be sufficient.</p>\\r\\n<p><strong>Severe hypernatraemia</strong> (Na &gt; 160 mmol/l): use IV 5% Dextrose with the aim to reduce Na at a rate of 0.5 mmol/hr and not more than 10 mmol/24hrs. Monitor Na every 4 hours. Note that too rapid a correction of the Na can cause cerebral oedema, convulsions and brain injury.</p>\\r\\n<h3 id=\\\"children\\\">Children</h3>\\r\\n<p><strong>Mild hypernatraemia</strong> (Na 146-149 mmol/l): enourage drinking. Stop any feed fortifications (eg extra scoops of formula – not F75 or F100).</p>\\r\\n<p><strong>Moderate hypernatraemia</strong> (Na 150-169 mmol/l):</p>\\r\\n<p>If &quot;shocked&quot;, resuscitate with boluses 20ml/kg of 0.9% saline as required.</p>\\r\\n<p>After initial resuscitation, replace the deficit plus maintenance slowly at a uniform rate <strong><a href=\\\"https://www.rch.org.au/clinicalguide/guideline_index/Hypernatraemia/#1\\\"><span class=\\\"underline\\\">over 48 hours</span></a>.</strong></p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nasogastric rehydration is preferred</p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Carefully regulate fluid intake - do not allow excessive intake in a thirsty child.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>If the serum sodium falls too rapidly (&gt; 0.5 mmol/l/hr) slow the rate of rehydration (for example, by 20%) or change to intravenous fluids.</p>\\r\\n</div></li>\\r\\n</ul></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>If needing intravenous rehydration use <strong>0.9% sodium chloride (normal saline) and 5% Glucose</strong>. Add maintenance KCl once urine output established.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Check U&amp;Es and glucose frequently intially.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>If after 6 hours of rehydration therapy, the sodium is decreasing at a steady rate then check the U&amp;Es and glucose 4 hourly.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>If serum sodium is falling faster than 1 mmol/l/hr, stop infusate and seek senior support.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p><strong>Severe hypernatraemia</strong> (Na &gt; 170 mmol/l):</p>\\r\\n<p>This is a medical emergency. After initial resuscitation, aim to replace deficit and maintenance with <strong>0.9% sodium chloride (normal saline) and 5% glucose</strong> over 72 - 96 hours. Seek senior support early and monitor U&amp;Es up to hourly. Involve lab staff as soon as possible.</p>\\r\\n<h3 id=\\\"calculation\\\">Calculation</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Water deficit (in litres) = TBW × ([Na/140] – 1</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>This determines the amount of fluid to be infused over 48 hours.</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Change in Na = Infusate Na – Na / (total body water +1)</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>This gives the change in Na per litre of infusate. If using 5% dextrose the infusate Na is 0.</p>\\r\\n<p>You may use the calculator on this website to determine the rate of fluid infusion : <a href=\\\"https://www.mdcalc.com/sodium-correction-rate-hyponatremia-hypernatremia\\\"><span data-custom-style=\\\"Hyperlink\\\">https://www.mdcalc.com/sodium-correction-rate-hyponatremia-hypernatremia</span></a></p>\\r\\n<h2 id=\\\"key-issues-for-nursing-care\\\">Key Issues for Nursing care</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Severe hyponatraemia and hypernatraemia can both have serious long term consequences. These can be worsened if the correction is too rapid.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Follow the fluid instructions very carefully.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Make sure repeat tests are done on time and are reviewed by a doctor promptly.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>All patients with abnormal Na levels should have strict monitoring of fluid input and output.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<p>Bartel B, Gau E. Fluid and Electrolyte Management. Critical Care Pharmacotherapeutics. Burlington, MA: Jones &amp; Bartlett Learning. 2012 Feb 8:125-50.</p>\\r\\n<p>Hoorn EJ, Tuut MK, Hoorntje SJ, van Saase JL, Zietse R, Geers AB. Dutch guideline for the management of electrolyte disorders-2012 revision. Neth J Med. 2013 Apr 1;71(3):153-65.</p>\\r\\n<p>Kraft MD, Btaiche IF, Sacks GS, Kudsk KA. Treatment of electrolyte disorders in adult patients in the intensive care unit. American Journal of Health-System Pharmacy. 2005 Aug 15;62(16):1663-82.</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th><p>Orighomisan Agboghoroma</p>\\r\\n<p>Mariama Sonko</p></th>\\r\\n<th>Date: 07 January 2019</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Karen Forrest</td>\\r\\n<td>Date: 08 May 2019</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td>31 May 2021</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"036\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>Hypothyroidism MeG-CLS-036</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"hypothyroidism\\\">Hypothyroidism</h1>\\r\\n<h2 id=\\\"executive-summary\\\"><em>Executive summary</em></h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<p>Hypothyroidism presents with non-specific symptoms and is rarely diagnosed in the Gambia. It is more common in women than in men.</p>\\r\\n<p>It has major consequences on intellectual development and growth in infants and children (cause of cretinism). In adults, it may be the cause of heart disease and dementia. Once hypothyroidism has been diagnosed, in most cases, the patient will need to stay on thyroxine for the rest of their life.</p>\\r\\n<p>Hypothyroidism should be considered as a possible cause of hypercholesteraemia, macrocytic anaemia, elevated CK and hyponatraemia.</p>\\r\\n<h2 id=\\\"target-users\\\">Target users</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nurses</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doctors</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"target-area-of-use\\\">Target area of use</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Outpatient department</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ward</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"key-areas-of-focus-new-additions-changes\\\">Key areas of focus / New additions / Changes </h2>\\r\\n<p>This guideline addresses the diagnosis and management of hypothyroidism.</p>\\r\\n<h2 id=\\\"limitations\\\">Limitations</h2>\\r\\n<p>Investigation of central hypothyroidism is difficult as we have limited access to other hormone assays.</p>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs\\\">Presenting symptoms and signs</h2>\\r\\n<p>The symptoms of hypothyroidism are non-specific including:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>General body pain</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Tiredness</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Weakness</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Dry coarse skin</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Feeling cold</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Difficulty in concentration and poor memory</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Constipation</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Weight gain with poor appetite,</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Dyspnoea</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hoarseness of voice,</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Menorrhagia (late oligo-menorrhea or amenorrhea)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Paraesthesias</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Impaired hearing</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Myxoedema – cool peripheral extremities, puffy face, hands and feet</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Congenital hypothyroidism presents in infants with lethargy, feeding problems, drowsiness, constipation, puffy facies, big tongue, large fontanelles, hypotonia, dry skin, hypothermia, prolonged jaundice. They may be big babies and there may be associated congenital malformations.</p>\\r\\n<h2 id=\\\"examination-findings\\\">Examination findings</h2>\\r\\n<p>Signs of hypothyroidism include:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Bradycardia (&lt;60 per minute)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Dry coarse skin</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Puffy face</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Pallor</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hoarse voice</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Slow reflexes</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Goitre may be present</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Non-pitting edema (myxoedema)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Pitting edema of lower extremities</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hyporeflexia with delayed relaxation, ataxia, or both</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Cool peripheral extremities, puffy face, hands and feet</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"investigations\\\">Investigations:</h2>\\r\\n<p>Thyroid function tests show either:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>High TSH in association with a low free T<sub>4</sub> (primary hypothyroidism which is most common)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Low (or sometimes normal) TSH in association with a low free T<sub>4</sub> (central hypothyroidism suggesting a pituitary or hypothalamic problem).</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Therefore request TSH only – if this is abnormal, the measurement should be repeated along with T<sub>3</sub> and T<sub>4</sub>.</p>\\r\\n<p>If the TSH is normal and the patient has very convincing symptoms of hypothyroidism such that central hypothyroidism is possible, then you may want to go ahead with a full set of thyroid function tests anyway.</p>\\r\\n<p>CT scan of the head is indicated only if a pituitary cause is expected after doing establishing that there is a low or normal TSH and a low free T<sub>4</sub>.</p>\\r\\n<p>See flow chart below.</p>\\r\\n<h2 id=\\\"section\\\"><img src=\\\"data:image/png;base64,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\\\" style=\\\"width:6in;height:6.77986in\\\" /></h2>\\r\\n<h2 id=\\\"management\\\">Management</h2>\\r\\n<p>Treatment of primary and central hypothyroidism is with thyroxine (or levothyroxine). This is given once a day.</p>\\r\\n<p>Usual adult requirements are 1.5 mcg/kg/day. This dose can be given immediately to most patients. A lower dose may be used and titrated up for those who have heart disease. The medication should be taken on an empty stomach and food should not be eaten for one hour after this.</p>\\r\\n<p>Children clear T4 more rapidly than adults and need a higher dose:</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Age</strong></th>\\r\\n<th><strong>Dose</strong></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>&lt;1 year</td>\\r\\n<td>10-15 mcg/kg</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>1-3 years</td>\\r\\n<td>4-6 mcg/kg</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>3-10 years</td>\\r\\n<td>2-5 mcg/kg</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>10-16 years</td>\\r\\n<td>2-4 mcg/kg</td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<p>Recheck TSH 6 weeks after starting treatment. If the TSH remains high, increase the dose by 12-25 mcg/day. Repeat this until the TSH is normal. If the patient is very symptomatic the interval may be reduced to 3 weeks. Most adult patients end up taking 100-150 mcg OD.</p>\\r\\n<p>Symptom relief usually occurs about 3 to 6 months after normal TSH.</p>\\r\\n<p>Once a patient is on a stable dose, the TSH can be measured once a year or when there is a change in symptoms. Patients who become pregnant, who gain weight or who start taking rifampicin, carbamazepine, phenytoin or phenobarbital may need their dose of thyroxine increasing.</p>\\r\\n<p>Women of reproductive age should be euthyroid before conceiving, as the hypothyroidism is associated with abnormal neural development. The dose may be doubled during pregnancy and returned to the normal dose after delivery.</p>\\r\\n<p>See flow chart on next page.</p>\\r\\n<p>Children with congenital hypothyroidism need closer monitoring, to account for the changes that occur as they grow. The TSH should be checked every 2 weeks until it is normal, then every 3 months until age 3 years. After this it can be done 6-12 monthly until they stop growing.</p>\\r\\n<p><img src=\\\"data:image/png;base64,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\\\" style=\\\"width:6in;height:3.78611in\\\" /></p>\\r\\n<p><strong>References</strong></p>\\r\\n<p>Hypothyroidism. National Institute of Diabetes and Digestive and Kidney Diseases. March 2013. Archived from the original on 5 March 2016. Retrieved 10 June 2018.</p>\\r\\n<p>Ferri, Fred F. Ferri&#39;s differential diagnosis : a practical guide to the differential diagnosis of symptoms, signs, and clinical disorders (2nd ed.). Philadelphia, PA: Elsevier/Mosby. 2010.</p>\\r\\n<p>Ross 2017. Diagnosis of and screening for hypothyroidism in nonpregnant adults. UpToDate June 2017.</p>\\r\\n<p>Ross 2017. Treatment of primary hypothyroidism in adults. UpToDate June 2017</p>\\r\\n<p>LaFranchi 2017. Acquired hypothyroidism in childhood and adolescence. UpToDate June 2017.</p>\\r\\n<p>LaFranchi 2017. Clinical features and detection of congenital hypothyroidism. UpToDate Jun 2017.</p>\\r\\n<p>LaFranchi 2017. Treatment and prognosis of congenital hypothyroidism. UpToDate June 2017.</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Chibuike Okpara</th>\\r\\n<th>Date: 9 June 2018</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Babatunde Awokola</td>\\r\\n<td>Date: 3 July 2018</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>2.0</td>\\r\\n<td>Revised and transferred to new template</td>\\r\\n<td>31 July 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>2.1</td>\\r\\n<td>Executive summary added</td>\\r\\n<td>31 July 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"058\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>Infective Endocarditis MeG-CLS- 058</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"infective-endocarditis\\\">Infective Endocarditis</h1>\\r\\n<h2 id=\\\"executive-summary\\\"><em>Executive summary</em></h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<h2 id=\\\"infective-endocarditis-ie-refers-to-infection-of-the-endocardial-surface-of-the-heart-it-usually-refers-to-infection-of-one-or-more-heart-valves-or-infection-of-an-intracardiac-device.\\\">Infective endocarditis (IE) refers to infection of the endocardial surface of the heart; it usually refers to infection of one or more heart valves or infection of an intracardiac device.</h2>\\r\\n<h3 id=\\\"target-users\\\">Target users</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doctors</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"target-area-of-use\\\">Target area of use </h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ward</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>OPD</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"key-areas-of-focus-new-additions-changes\\\">Key areas of focus / New additions / Changes </h3>\\r\\n<p>This guideline focuses on the diagnostic criteria and the anti- infective therapy for infective endocarditis. It covers treatment of bacterial and fungal infective endocarditis.</p>\\r\\n<p>Users should take particular note of the indications for surgical intervention.</p>\\r\\n<h2 id=\\\"limitations\\\">Limitations</h2>\\r\\n<p>Patients requiring surgical intervention may need to be referred to surgeons outside of the Gambia.</p>\\r\\n<h2 id=\\\"risk-factors\\\">Risk factors</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Age &gt;60 years</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Male sex</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Poor dentition or dental infection</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Heart problem: Structural heart disease, Valvular disease, Congenital heart disease</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Prosthetic valve</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>History of prior IE</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>HIV infection</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Injection drug use</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Chronic hemodialysis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Intravascular device</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"pathogen\\\">Pathogen</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><em>S.aureus</em> (31%)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Viridans group streptococci (17%)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Enterococci (11%)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Coagulade-negative staphylococci (11%)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><em>Streptococcus bovis</em> (7%)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Other streptococci (5%)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Non-HACEK gram-negative bacteria (2%)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Fungi (2%)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>HACEK (2%): organisms in this category include a number of fastidious gram-negative bacilli: <em><strong>H</strong>aemophilus aphrophilus,</em> <em><strong>A</strong>ctinobacillus actinomycetemcomitans,</em> <em><strong>C</strong>ardiobacterium hominis</em>; <em><strong>E</strong>ikenella corrodens</em>; and <em><strong>K</strong>ingella kingae</em></p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs\\\">Presenting symptoms and signs</h2>\\r\\n<p>Fever is the most common symptom (&gt; 90%). It is often associated with chills, anorexia, and weight loss.</p>\\r\\n<p>Other common symptoms include malaise, headache, myalgia, arthralgia, night sweats, abdominal pain, dyspnoea, cough, and pleuritic pain. Note that these symptoms are non-specific and there may be not much more than a sense that something is wrong.</p>\\r\\n<p>Patients with IE associated with dental infection may report tooth pain or related symptoms.</p>\\r\\n<h2 id=\\\"examination-findings\\\">Examination findings</h2>\\r\\n<p>Cardiac murmurs are the most common sign. Supportive signs include splenomegaly and cutaneous manifestations such as petechiae or splinter hemorrhages.</p>\\r\\n<p>Relatively uncommon clinical manifestations that are highly suggestive of IE include:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Janeway lesions</strong> – Nontender erythematous macules on the palms and soles.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Osler nodes</strong> – Tender subcutaneous violaceous nodules mostly on the pads of the fingers and toes, which may also occur on the thenar and hypothenar eminences.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Roth spots</strong> – Exudative, edematous hemorrhagic lesions of the retina with pale centers.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Complications as presenting symptoms:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Cardiac complications (&gt;50%) – Valvular insufficiency, heart failure, and others</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Neurologic complications (&gt;40%) – Embolic stroke, intracerebral hemorrhage, brain abscess, and others</p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Septic emboli (&gt;25%) – Infarction of kidneys, spleen, and other organs. In right-sided endocarditis, septic pulmonary emboli may be seen.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Spleen embolic: radiating abdominal pain that goes to the left shoulder</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Renal: flank pain in the groin with possible pus or blood in the urine</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Brain (stroke): changes in neuro status, confusion, speech difficulty</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Pulmonary: chest pain, shortness of breath, dyspnea, decreased oxygen saturation</p>\\r\\n</div></li>\\r\\n</ul></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Metastatic infection – vertebral osteomyelitis, septic arthritis, psoas abscess</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Systemic immune reaction – glomerulonephritis</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p><strong>Diagnosis</strong></p>\\r\\n<p>This is based on a combination of clinical suspicion, the presence of risk factors, examination findings and the following investigations:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Urine dipstick (looking especially for blood)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>ECG</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>ECHO</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Blood cultures – 3 samples each from 2 or more different sites at least 1 hour apart and ideally taking 10 ml of blood each time. These must be completed before antibiotics are started.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>These results can be combined to formally make a diagnosis of IE using modified Duke criteria. Note that some patients will not meet these criteria in our setting, but will still have a high suspicion of IE and no alternative treatable diagnosis, so will need to be treated for IE anyway.</p>\\r\\n<h3 id=\\\"modified-duke-criteria\\\">Modified Duke criteria</h3>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Major criteria</strong></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><em><strong>Positive blood culture</strong></em> with common endocarditis pathogen (grown in 2 separate cultures)</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><p><em><strong>Evidence of endocardial involvement</strong></em> either</p>\\r\\n<div data-custom-style=\\\"List Paragraph\\\">\\r\\n<blockquote>\\r\\n<p>Echocardiogram vegetation <strong>OR</strong></p>\\r\\n</blockquote>\\r\\n</div>\\r\\n<div data-custom-style=\\\"List Paragraph\\\">\\r\\n<blockquote>\\r\\n<p><span class=\\\"underline\\\">New</span> valvular regurgitation</p>\\r\\n</blockquote>\\r\\n</div></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Minor criteria</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>One of the risk factors</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Fever (Documented temp =&gt; 38.0°C)</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><em><strong>Vascular phenomena:</strong></em> major arterial emboli, septic pulmonary infarcts, mycotic aneurysm, intracranial hemorrhage, conjunctival hemorrhages, or Janeway lesions</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><em><strong>Immunologic phenomena:</strong></em> Glomerulonephritis, Osler nodes, Roth spots, or rheumatoid factor</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><em><strong>Microbiologic evidence:</strong></em> Positive blood cultures that do not meet major criteria <strong>OR</strong> serologic evidence of active infection with organism consistent with IE</td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<p><strong>Definite IE:</strong> 2 major criteria <em>or</em> 1 major + 3 minor criteria <em>or</em> 5 minor criteria</p>\\r\\n<p><strong>Possible IE:</strong> 1 major + 1 minor criteria <em>or</em> 3 minor criteria</p>\\r\\n<h2 id=\\\"management\\\">Management </h2>\\r\\n<h3 id=\\\"antibiotic-therapy\\\">Antibiotic therapy</h3>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th></th>\\r\\n<th><strong>Native heart valve</strong></th>\\r\\n<th><strong>Prosthetic heart valve(s)</strong></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><p>Empiric</p>\\r\\n<p><em>(paediatric dosing)</em></p></td>\\r\\n<td><p>Ampicillin 2 g (<em>50 mg/kg</em>) q4h IV <strong>AND</strong></p>\\r\\n<p>Gentamicin 3 mg/kg OD IV</p></td>\\r\\n<td><p>Ampicillin 2 g (<em>50 mg/kg</em>) q4h IV <strong>AND</strong></p>\\r\\n<p>Gentamicin 5 mg/kg OD IV <strong>AND</strong></p>\\r\\n<p>Rifampicin 600 mg (<em>10 mg/kg</em>) BD PO</p></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<p><span class=\\\"underline\\\">Note on usage of gentamicin for IE</span></p>\\r\\n<p>The gentamicin dose is adjusted from UK guidelines (but is consistent with US / European guidelines) because we do not have access to the therapeutic drug monitoring necessary to safely dose gentamicin in a more than OD regimen.</p>\\r\\n<p>eGFR must be calculated as soon as possible when gentamicin is started. If this is reduced below &lt; 50 ml/min, then the dose of gentamicin should be reduced to by 50%. All patients expected to receive gentamicin for more than 1 week must have their U&amp;Es checked 3 times per week and the gentamicin stopped as soon as there is any change in the results.</p>\\r\\n<h3 id=\\\"blood-culture-positive\\\">Blood culture positive</h3>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th></th>\\r\\n<th><strong>Native heart valve</strong></th>\\r\\n<th><strong>Prosthetic heart valve(s)</strong></th>\\r\\n<th></th>\\r\\n<th></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Pathogen</strong></td>\\r\\n<td><strong>Dose</strong> (<em>paediatric dosing)<strong>)</strong></em></td>\\r\\n<td><strong>Duration (weeks)</strong></td>\\r\\n<td><strong>Dose</strong> <em>paediatric dosing<strong>)</strong></em></td>\\r\\n<td><strong>Duration (weeks)</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><em>S.aureus</em> (Methicillin sensitive)</td>\\r\\n<td>Cloxacillin 2 g (<em>50 mg/kg</em>) QDS IV</td>\\r\\n<td>4</td>\\r\\n<td><p>Cloxacillin 2 g (<em>50 mg/kg</em>) QDS IV <strong>AND</strong></p>\\r\\n<p>Rifampicin 600 mg (<em>10 mg/kg</em>) BD PO</p></td>\\r\\n<td><p>6</p>\\r\\n<p>6</p></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>MRSA</td>\\r\\n<td>Requires vancomycin or teicoplanin and rifamipicin. Would be very difficult to treat in our setting.</td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><em>Streptococcus</em> spp</td>\\r\\n<td><p>Benzylpenicillin 2.4 g (<em>35 mg/kg</em>) q4h IV <strong>AND</strong></p>\\r\\n<p>Gentamicin 3 mg/kg OD IV</p></td>\\r\\n<td><p>4-6</p>\\r\\n<p>2</p></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><em>Enterococcus</em></td>\\r\\n<td><p>Ampicillin 2 g (<em>30 mg/kg</em>) q4h IV <strong>AND</strong></p>\\r\\n<p>Gentamicin 3 mg/kg OD IV</p></td>\\r\\n<td><p>4-6</p>\\r\\n<p>4-6</p></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>HACEK</td>\\r\\n<td><p>Ceftriaxone 2 g (<em>80 mg/kg</em>) OD IV <strong>AND</strong></p>\\r\\n<p>Gentamicin 3 mg/kg OD IV</p></td>\\r\\n<td><p>4-6</p>\\r\\n<p>2</p></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<h3 id=\\\"blood-culture-negative\\\">Blood culture negative</h3>\\r\\n<p>It is not possible to distinguish between different causes of blood culture negative IE in our setting. Therefore, empiric treatment is used as below where good quality blood cultures taken before antibiotic therapy are negative and there is suspicion of possible infection with <em>Brucella</em>, <em>Coxiella burnetii</em> or <em>Bartonella</em>. Specialist advice should be sought about this as soon as possible.</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Agent</strong></th>\\r\\n<th><strong>Dose</strong> (<em>paediatric dosing)</em></th>\\r\\n<th><strong>Duration (weeks)</strong></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Empiric</td>\\r\\n<td><p>Doxycycline 200 mg (<em>4.4 mg/kg</em>) OD PO <strong>AND</strong></p>\\r\\n<p>Ceftriaxone 2 g (<em>80 mg/kg</em>) OD IV <strong>AND</strong></p>\\r\\n<p>Gentamicin 3 mg/kg OD IV</p></td>\\r\\n<td><p>6 (may need to be longer)</p>\\r\\n<p>4</p></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<p>Note doxycycline cannot be used below the age of 12 years.</p>\\r\\n<h3 id=\\\"fungal-endocarditis\\\">Fungal endocarditis</h3>\\r\\n<p>Fungal endocarditis is most common in patients with prosthetic valves, but also occurs in intravenous drug abusers, neonates and immunocompromised patients. Mortality is very high (50%), and treatment necessitates combined antifungal administration and surgical valve replacement.</p>\\r\\n<p>Unfortunately, we do not have access to the necessary drugs, so the best we can do is use high dose fluconazole.</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Agent</strong></th>\\r\\n<th><strong>Primary</strong></th>\\r\\n<th><strong>After patient is stable</strong></th>\\r\\n<th><strong>Duration</strong></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Dose</strong> <em>(paediatric dosing)</em></td>\\r\\n<td>Fluconazole 1200 mg <em>(18 mg/kg) OD PO</em></td>\\r\\n<td>Fluconazole 800 mg (12 mg/kg) OD PO</td>\\r\\n<td><p>For at least 6 weeks after surgery</p>\\r\\n<p>*For patients who cannot undergo valve replacement; lifelong</p></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<p>In case a patient has the means to purchase more effective drugs, they would need to be given amphotericin and flucytosine.</p>\\r\\n<p><strong>Indications for Surgery</strong></p>\\r\\n<p>Ideally, a surgical opinion should be sought for every patient with endocarditis. Unfortunately, this is not possible here for most patients. However, it may be possible to discuss children with endocarditis with the Chain of Hope team. The indications for surgery are listed below.</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Heart Failure</strong></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><p>Aortic or mitral IE with:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Severe acute regurgitation or valve obstruction</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Persistent heart failure</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Refractory pulmonary oedema / cardiogenic shock</p>\\r\\n</div></li>\\r\\n</ul></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Uncontrolled infection</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Abscess, false aneurysm, enlarging vegetation</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Persisting fever and positive blood culture for &gt; 10 days after commencing appropriate antimicrobial therapy</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Caused by fungi or multiresistant micro organisms</p>\\r\\n</div></li>\\r\\n</ul></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Prevention of embolism</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Large vegetations (&gt; 10 mm) + embolic episodes</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Large vegetations (&gt; 10 mm) + other predictors of complicated cause</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Very large vegetation (&gt; 15 mm)</p>\\r\\n</div></li>\\r\\n</ul></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<p><strong><br />\\r\\n</strong></p>\\r\\n<p><strong>Endocarditis Prophylaxis</strong></p>\\r\\n<p><strong><span class=\\\"underline\\\">Indication</span></strong>: A cardiac condition AND a procedure</p>\\r\\n<p><strong>Cardiac conditions</strong>: Prosthetic valve, unrepaired cyanotic congenital heart disease, some patients with repaired congenital heart disease (check online for current guidance), previous infective endocarditis.</p>\\r\\n<p><strong>Procedures</strong>:</p>\\r\\n<ol type=\\\"1\\\">\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Dental procedure: manipulation of gingival tissue or periapical region of teeth or perforation of the oral mucosa.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Respiratory procedure: incision or biopsy of respiratory mucosa.</p>\\r\\n</div></li>\\r\\n</ol>\\r\\n<p><strong>Regimens</strong>: Amoxicillin 2 g IV (Penicillin allergic: clindamycin 600 mg PO)</p>\\r\\n<p><strong>Timing</strong>: 30-60 min before the procedures</p>\\r\\n<h2 id=\\\"key-issues-for-nursing-care\\\">Key Issues for Nursing care</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Monitor vital signs especially temperature, heart rate, blood pressure, oxygen saturation.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Educate the patient about:</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<ol type=\\\"1\\\">\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>The need to inform other healthcare practitioners about history of endocarditis because they are at risk for it again and will need prophylactic antibiotics prior to invasive procedures</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>How to take or administer antibiotics (complete all doses)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>The importance of good oral care.</p>\\r\\n</div></li>\\r\\n</ol>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<p>Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: Journal of Antimicrobial Chemotherapy, Volume 67, Issue 2, 1 February 2012, Pages 269–289</p>\\r\\n<p>2015 ESC Guidelines for the management of infective endocarditis: European Heart Journal (2015) 36, 3075–3123 doi:10.1093/eurheartj/ehv319</p>\\r\\n<p>Up to date: Antimicrobial therapy of prosthetic valve endocarditis: last updated: Sep 06, 2018</p>\\r\\n<p>Up to date: Clinical manifestations and evaluation of adults with suspected native valve endocarditis last updated: Apr 27, 2018</p>\\r\\n<p>Up to date: Epidemiology, risk factors, and microbiology of infective endocarditis: last updated: Oct 26, 2018.</p>\\r\\n<p>Up to date: Infective endocarditis in children: last updated: Nov 29, 2017.</p>\\r\\n<p>Endocarditis NCLEX Review| Registered Nurse RN. com| NCLEX Review. Web. 19 Aug. 2016</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Eriko Ikeda</th>\\r\\n<th>Date: 16 November 2018</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Karen Forrest</td>\\r\\n<td>Date: 21 November 2018</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td></td>\\r\\n<td>Name: Thushan de Silva</td>\\r\\n<td>Date: 21 November 2018</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td>31 January 2021</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.1</td>\\r\\n<td>Executive summary added</td>\\r\\n<td>31 January 2021</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"041\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>Inflammatory arthritis and connective tissue disease MeG-CLS-041</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"inflammatory-arthritis-and-connective-tissue-disease\\\">Inflammatory arthritis and connective tissue disease</h1>\\r\\n<h2 id=\\\"executive-summary\\\"><em>Executive summary</em></h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<p>Rheumatological disorders are difficult to diagnose accurately in our setting and can be difficult to treat, as we are limited by the poor availability of tests and treatments. They are also not common. Despite this, we are able to improve the quality of life and prognosis of most of the patients with the medications we have available.</p>\\r\\n<p>Rheumatoid arthritis is the most common condition seen. It is a symmetric, inflammatory, peripheral polyarthritis. Untreated, it leads to joint destruction and disability.</p>\\r\\n<p>Other connective tissue disorders are much less common. However, similar principles can be used to care for these patients.</p>\\r\\n<h2 id=\\\"target-users\\\">Target users</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doctors</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"target-area-of-use\\\">Target area of use </h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Outpatient department</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"key-areas-of-focus-new-additions-changes\\\">Key areas of focus / New additions / Changes </h2>\\r\\n<p>This guideline outlines an approach to connective tissue and inflammatory conditions in our setting. It describes the use of methotrexate (the only available DMARD in our setting) and the clinical disease activity index for monitoring progress.</p>\\r\\n<h2 id=\\\"limitations\\\">Limitations</h2>\\r\\n<p>We have no access to autoantibodies and other diagnostic tests. We cannot do CRP routinely.</p>\\r\\n<p>We have limited access to drugs and no access to biologicals.</p>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs\\\">Presenting symptoms and signs</h2>\\r\\n<p>Rheumatoid arthritis presents with joint pain and swelling of the peripheral joints (affecting at least 3 joints), and morning stiffness, all lasting at least 6 weeks. Other conditions such as psoriasis, inflammatory bowel disease, SLE should be absent. It is often gradual in onset, but may be intermittent at the beginning. Very occasionally, rheumatoid arthritis may present with a persistent monoarthritis. In these cases, septic arthritis, gout and other explanations must be excluded until a polyarthritis develops.</p>\\r\\n<p>Extra-articular features of rheumatoid arthritis include anaemia, fatigue, pericarditis, rashes, eye complications, neuropathy, splenomegaly, Sjogren’s syndrome, vasculitis and others. Alternatively, these and other systemic features may reflect another connective tissue disorder.</p>\\r\\n<h2 id=\\\"examination-findings\\\">Examination findings</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Painful, tender, swollen joints – especially the proximal interphalangeal and metocarpophalangeal joints, the wrists, elbows, shoulders and knees.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Typical rheumatoid deformities may be seen in long-standing untreated cases.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>C-spine pain and stiffness, which may eventually lead to instability.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Where an alternative diagnosis is suspected, examine carefully in all systems – paying particular attention to dermatological and musculoskeletal features.</p>\\r\\n<h2 id=\\\"investigations\\\">Investigations</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Plain films of affected joints – may show osteopenia, joint space narrowing and bone erosions. However, they are not helpful if the diagnosis is clinically clear.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Rheumatoid factor – found in 70-80% of patients (and in 5-10 % of healthy people and 20-30 % of patients with other inflammatory conditions). Helpful, but not essential to the diagnosis.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>ESR – used for monitoring disease activity.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>U&amp;Es, LFTs and FBC – useful to establish baseline values for patients who will start methotrexate.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Other tests such as CK, U&amp;Es, HIV may be important in excluding alternative diagnoses.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"further-investigation-where-diagnosis-unclear\\\">Further investigation where diagnosis unclear</h3>\\r\\n<p>Further investigations are not available in the Gambia. If patients are interested and able, there are most investigations available in Dakar and a referral should be made to Professor Pouye at Hôpital Le Dantec.</p>\\r\\n<h2 id=\\\"management\\\">Management</h2>\\r\\n<p>Patients with probable rheumatoid arthritis and raised ESR should be started on disease modifying treatment (DMARD) as soon as possible.</p>\\r\\n<p>All patients without contraindications should start on methotrexate.</p>\\r\\n<p>Contraindications include:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Women who are pregnant or who want to be pregnant.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Patients with liver disease</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Patients with severe renal impairment (eGFR &lt; 30 ml/min)</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>The presence of respiratory disease is a relative contraindication, so if there are respiratory symptoms, a chest X-ray is helpful to exclude TB or other relevant concerns.</p>\\r\\n<h3 id=\\\"disease-modifying-treatment-dmard\\\">Disease modifying treatment (DMARD)</h3>\\r\\n<p>Start with <strong>methotrexate</strong> 7.5-15 mg once per week and titrate up as tolerated. Patients who are older, less heavy and with reduced renal function (eGFR &lt; 60 ml/min) should have the lower doses. Increase approximately every 4 weeks to a target dose of 15-25 mg once per week. If these doses are ineffective, the bioavailability can be increased without increasing gastrointestinal side effects by dividing the dose into 2 (taken on the same day once per week).</p>\\r\\n<p>Patients on methotrexate should have FBC and LFTs checked once every 3 months. A chest X-ray should be done if there is any suggestion of respiratory symptoms.</p>\\r\\n<p>Patients on methotrexate should take folic acid daily at a dose of 1 mg OD. As we have only 5 mg tablets, dosing once per week is adequate.</p>\\r\\n<p>Methotrexate should be continued at an effective rate for 3-6 months after the disease enters remission. After this, the dose can be titrated down to the lowest effective level.</p>\\r\\n<p>Combination DMARD treatment can be used for patients who continue to have high disease activity after 3-6 months of treatment with methotrexate. The methotrexate is continued and <strong>sulfasalazine</strong> and <strong>hydroxychloroquine</strong> are added. Sulfasalazine and hydroxychloroquine can also be used in combination for patients that cannot take methotrexate.</p>\\r\\n<p>Sulfasalazine is started at 500 mg BD and increased by 500 mg each week to a dose of 1500 mg BD.</p>\\r\\n<p>Hydroxychloroquine is given at a dose of 400 mg OD (maximum of 5 mg/kg/day).</p>\\r\\n<h3 id=\\\"symptomatic-treatment\\\">Symptomatic treatment</h3>\\r\\n<p>NSAIDS rapidly reduce inflammation and provide pain relief. They should be used for all patients with active disease at maximal anti-inflammatory doses for at least 2 weeks before being withdrawn gradually. Use <strong>ibuprofen</strong> 800 mg QDS (ibuprofen is more effective and has fewer gastric side effects than diclofenac). Consider also given omeprazole 20 mg OD for patients who also receive steroid treatment.</p>\\r\\n<p>Steroids can be used to rapidly control disease in patients with more severe disease or in patients for whom NSAID treatment is ineffective. Give <strong>prednisolone</strong> 20 mg OD for 1 month. Reduce the dose gradually to a maintenance level of 5-10 mg OD once symptoms settle and wean off completely within 4 months.</p>\\r\\n<p>These treatments can be repeated as necessary for patients experiencing flares of their disease.</p>\\r\\n<h3 id=\\\"monitoring-disease-activity\\\">Monitoring disease activity</h3>\\r\\n<p>Various scores are available for monitoring disease activity in rheumatoid arthritis. The Clinical Disease Activity Indicator (CDAI) is simple to calculate and is suitable for our setting.</p>\\r\\n<p>28 joints are reviewed – 10 proximal interphalangeal joints, 10 metocarpophalangeal joints, 2 wrists, 2 elbows, 2 shoulders and 2 knees. Each should be examined for swelling and tenderness. Estimate out of 10 (where 0 is completely well and 10 is as ill as possible) how ill you think the patient is. Ask the patient the same question.</p>\\r\\n<p>Now add the number of swollen joints, the number of tender joints, your assessment and the patient’s assessment. This gives a score out of 76.</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Activity level</strong></th>\\r\\n<th><strong>CDAI score</strong></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Remission</td>\\r\\n<td>&lt; 2.8</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Low disease activity</td>\\r\\n<td>3-10</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Moderate disease activity</td>\\r\\n<td>11-22</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>High disease activity</td>\\r\\n<td>&gt; 22</td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<h2 id=\\\"key-issues-for-nursing-care\\\">Key Issues for Nursing care</h2>\\r\\n<p>Patients with inflammatory arthritis should be seen by a doctor whenever possible, given how uncommon it is in the Gambia.</p>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<p>National Institute for Health and Care Excellence (2009). Rheumatoid arthritis in adulte:management. NICE guideline (CG79).</p>\\r\\n<p>Ally, Meyer and Anderson (2016). Early rheumatoid arthritis: focus on RA in the developing world. South African Family Practice 2016; 58(4):164-166.</p>\\r\\n<p>Singh et al (2016). 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Care and Research 2016; 68(1):1-25.</p>\\r\\n<p>Smolen and Aletaha (2018). Assessment of rheumatoid arthritis activity in clinical trials and clinical practice. Up To Date.</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Karen Forrest</th>\\r\\n<th>Date: 22 May 2018</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Fatai Akemokwe</td>\\r\\n<td>Date: 17 June 2018</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td>15 August 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>1.1</td>\\r\\n<td>Executive summary added</td>\\r\\n<td>15 August 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"009\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>Intestinal helminths MeG-CLS-009</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"intestinal-helminth-infection\\\">Intestinal helminth infection</h1>\\r\\n<h2 id=\\\"executive-summary\\\"><em>Executive summary</em></h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<p>Helminths are small worms and parasites that often cause illness when they infect human beings. The commonest helminth infections are those affecting the intestines including ascariasis, trichuriasis and hookworms.</p>\\r\\n<h2 id=\\\"target-user\\\">Target User</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doctors</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nurses</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"target-area-of-use\\\">Target area of use </h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Gate clinic</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Outpatient Department</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ward</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"key-areas-of-focusnew-additionschanges\\\">Key areas of focus/new additions/changes</h2>\\r\\n<p>A vast majority of intestinal helminths infections are asymptomatic,c however infected persons may present with pulmonary or potentially severe gastrointestinal complaints.</p>\\r\\n<p>The guidelines do not address the management of complications of intestinal helminth infections such as biliary colic, cholangitis, liver abscess, pancreatitis, intestinal obstruction or appendicitis.</p>\\r\\n<h2 id=\\\"limitations\\\">Limitations </h2>\\r\\n<p>Increase in IgE and later IgG markers may well be suggestive of an Intestinal helminth infection and PCR is another diagnostic tool for helminths, however, these tests are not readily available in our setting.</p>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs\\\">Presenting symptoms and signs</h2>\\r\\n<p>Patients often complain that they have worms or blame their symptoms on a worm – even symptoms that are not usually associated with worms. In fact, most worm infections (of all kinds) are asymptomatic.</p>\\r\\n<p>Intestinal worms may present with</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>itching around the anus,</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>abdominal pain or bloating,</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>nausea and vomiting,</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>passage of worms in the stools,</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>melaena,</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>cough and wheezing (a consequence of larval migration through the lungs),</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>flatulence,</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>failure to thrive</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>microscopic blood loss in the stools and</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>iron deficiency anaemia.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>More rarely, ascariasis can cause biliary colic, cholangitis, liver abscess, pancreatitis, intestinal obstruction or appendicitis. The adult worms may be coughed up from the lungs. Trichuriasis can cause rectal prolapse in young children.</p>\\r\\n<p>Hookworms can invade the skin and cause “creeping eruption” – a snake-like itchy red rash which moves through the skin.</p>\\r\\n<h3 id=\\\"classificationcauses\\\">Classification/Causes</h3>\\r\\n<p>Below is a list of common intestinal helminths that cause diseases:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><em>Ascaris lumbricoides</em> (Roundworm)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><em>Trichuris trichuria</em> (whip worm)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><em>Enterobius vermicularis</em> (pin worm or thread worm)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><em>Necator americanus</em> (hookworm)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><em>Strongyloides stercoralis.</em></p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"examination-findings\\\">Examination findings</h2>\\r\\n<p>Skin and pulmonary findings are minimal. Physical findings in the early stage of the disease may present as erythematous, pruritic, papulovesicular rash at the site of initial infection as in the case of hookworm infestation.</p>\\r\\n<p>When the worm breaks through from the venous circulation into the pulmonary air spaces, cough, fever and reactive bronchoconstriction may be observed (eg hookworm, strongyloidiasis)</p>\\r\\n<p>Vague gastrointestinal signs such as mild abdominal tenderness may be present.</p>\\r\\n<p>Neurologic manifestations such as altered mental state, focal seizures and nuchal rigidity may be seen in severe strongyloidiasis.</p>\\r\\n<p>Later signs of helminth infection include signs of anaemia (pallor, spooning nails, tachycardia, signs of high output cardiac failure). Hypoproteinemia may lead to anasarca and peripheral oedema.</p>\\r\\n<p>Very rarely jaundice may be seen in ascaris infection where there is biliary obstruction.</p>\\r\\n<p>Stunted growth may be observed in children with severe infestations.</p>\\r\\n<h2 id=\\\"investigations.\\\">Investigations.</h2>\\r\\n<p>It is not necessary to request investigations routinely. If they are considered they might include:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>FBC (iron deficiency anaemia, eosinophilia)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Stool microscopy: The diagnosis is often confirmed with direct microscopic analysis of fecal samples to verify the presence of the worms or its ova.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Chest radiography: In cases of severe infection, chest x-ray may show diffuse alveolar infiltrates during the migration of the larvae through the lung. Once infection is established in the gut, imaging studies are not helpful.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"management\\\">Management</h2>\\r\\n<p>Most common intestinal helminth infestations can be treated with either of the following:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Oral albendazole</p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>400 mg stat if 2 years or older (month)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>200 mg stat if between 1 and 2 years of age</p>\\r\\n</div></li>\\r\\n</ul></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Oral mebendazole 100 mg 12 hourly for 3 days.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Avoid these medications if pregnant or planning to conceive in the next 1 month – Levamisole may sometimes be available and is safe for these patients. The dose is 2.5 mg/kg up to 150 mg stat.</p>\\r\\n<p>Treatment course may be repeated after 3 weeks if infestation persists.</p>\\r\\n<p>Preventive measures against helminthic infections include adequate sanitation, appropriate personal and food hygiene, and use of protective footwear.</p>\\r\\n<p>Treatment peculiar to some intestinal helminthic infestations are shown below:</p>\\r\\n<h3 id=\\\"enterobius-vermicularis\\\">Enterobius vermicularis</h3>\\r\\n<p>Treat patient and whole family with:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Oral Mebendazole 100 mg od as single dose (repeat after 3 weeks if symptoms persist)</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>or</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Oral Albendazole 400 mg stat (repeat after 2 weeks)</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"strongyloides-stercoralis\\\">Strongyloides stercoralis</h3>\\r\\n<p>The drug of choice is ivermectin 200 micrograms/kg as a single dose, or two doses on successive days. It is rarely available. It is not routinely recommended for children aged under 5 years and less than 15 kg, but has been used in younger children for mass drug administration with few adverse events.</p>\\r\\n<p>The alternative is albendazole 15 mg/kg 12 hourly for 3 days. This can be used in children over the age of 2 years: albendazole 400 mg 12 hourly for 3 days (Repeated after 3 weeks if necessary).</p>\\r\\n<p>In hyperinfestation, ivermectin 200 micrograms/kg daily until stool microscopy is negative for 2 weeks.</p>\\r\\n<p><strong><span class=\\\"underline\\\"><br />\\r\\n</span></strong></p>\\r\\n<p><strong><span class=\\\"underline\\\">Tapeworms:</span></strong></p>\\r\\n<p>Praziquantel 5-10 mg/kg as single dose (4 years and older).</p>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<p>Centers for Disease Control and Prevention. Strongyloides – Resources for Health Professionals. 2016. Available from: <a href=\\\"https://www.cdc.gov/parasites/strongyloides/health_professionals/index.html\\\"><span data-custom-style=\\\"Hyperlink\\\">www.cdc.gov/parasites/strongyloides/health_professionals/index.html</span></a> Accessed 15<sup>th</sup> August 2018</p>\\r\\n<p>Hökelek M. Nematode Infections. Medscape. 2017. Available at <a href=\\\"https://emedicine.medscape.com/article/224011-overview\\\"><span data-custom-style=\\\"Hyperlink\\\">https://emedicine.medscape.com/article/224011-overview</span></a>. Accessed 15<sup>th</sup> August 2018</p>\\r\\n<p>British National Formulary 70<sup>th</sup> edition. September 2015-March 2016.</p>\\r\\n<p>Wilkins AL, Steer AC, Cranswick N, Gwee A. Question 1: Is it safe to use ivermectin in children less than five years of age and weighing less than 15 kg? <em>Archives of Disease in Childhood</em> 2018; <strong>103</strong>: 514–9.</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Amie Secka</th>\\r\\n<th>Date: 16 July 2018</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Fatai Akemokwe</td>\\r\\n<td>Date: 15 August 2018</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>2.0</td>\\r\\n<td>Updated from previous version and made specific to intestinal helminths</td>\\r\\n<td>20 August 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>2.1</td>\\r\\n<td>Executive summary added</td>\\r\\n<td>20 August 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"047\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>Introduction and abbreviations MeG-CLS-047</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"introduction-to-clinical-services-department-csd-guidelines\\\">Introduction to Clinical Services Department (CSD) guidelines</h1>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<h2 id=\\\"csd-has-produced-a-set-of-guidelines-to-be-used-in-the-department-with-the-aim-of-standardizing-care-to-ensure-we-are-making-the-best-use-of-the-resources-and-facilities-available-to-us-and-to-help-new-doctors-and-nurses-settle-in.\\\">CSD has produced a set of guidelines to be used in the department with the aim of standardizing care to ensure we are making the best use of the resources and facilities available to us and to help new doctors and nurses settle in.</h2>\\r\\n<p>This introductory document outlines some of the approaches that have been taken and lists abbreviations used in the guidelines</p>\\r\\n<h2 id=\\\"general-approach\\\">General approach</h2>\\r\\n<p>As far as possible, CSD guidelines recommend the use of investigations and drugs available within the department. Where something is temporarily unavailable, it will have been included as if it were available.</p>\\r\\n<p>Exceptions to this include:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>investigations which are available in country</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>drugs which have a good evidence base and are easily accessible in country</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>emergency interventions which are last ditch attempts to save a life and which might be available depending on the skill of the doctor on duty.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>In general, it is assumed that most doctors will be able to do all the procedures referred to. If an individual is not experienced, then they can ask the consultants in the department for help.</p>\\r\\n<p>Some specific procedures are not included as guidelines, but as formal SOPs. These are usually those that are necessary for research patients or that need standardized approaches. The latest version of each of these has been placed in a folder alongside the guidelines.</p>\\r\\n<p>The guidelines provide support to nurses who see patients and prescribe as well as to doctors – including guidance on when patients should be referred from the care of a nurse to a doctor.</p>\\r\\n<h2 id=\\\"controlling-guidelines\\\">Controlling guidelines</h2>\\r\\n<p>Please note that the guidelines are only controlled when they are viewed online. Any printed version is by definition uncontrolled and may not be the latest version.</p>\\r\\n<p>All SOPs are only controlled when viewed on sharepoint (although in practice, as soon as they are updated the version in the guidelines’ folder is also updated).</p>\\r\\n<h2 id=\\\"app\\\">App</h2>\\r\\n<p>These guidelines are also available in app form for mobile phones.</p>\\r\\n<h2 id=\\\"abbreviations\\\">Abbreviations</h2>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th>ºC</th>\\r\\n<th>Degrees Celsius</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>µIU</td>\\r\\n<td>Micro-international unit</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>µmol</td>\\r\\n<td>Micromole</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>ABM</td>\\r\\n<td>Acute bacterial meningitis</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>ACEi</td>\\r\\n<td>Angiotensin converting enzyme inhibitor</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>ACS</td>\\r\\n<td>Acute coronary syndrome</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>ACTH</td>\\r\\n<td>Adreno-corticotropic hormone</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>AF</td>\\r\\n<td>Atrial fibrillation</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>AFB</td>\\r\\n<td>Acid fast bacilli</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>AFP</td>\\r\\n<td>Alpha-fetoprotein</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>AKI</td>\\r\\n<td>Acute kidney injury</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>ALT</td>\\r\\n<td>Alanine aminotransferase</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>AM</td>\\r\\n<td>Acute mastoiditis</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>AMI</td>\\r\\n<td>Acute myocardial infarction</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>AMPLE</td>\\r\\n<td>Allergies, medications, past medical history / pregnancy, last eaten, events</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>AOM</td>\\r\\n<td>Acute otitis media</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>APTT</td>\\r\\n<td>Activated partial thromboplastin time</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>ARBs</td>\\r\\n<td>Angiotensin receptor blockers</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>ARF</td>\\r\\n<td>Acute rheumatic fever</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>ART</td>\\r\\n<td>Anti-retroviral therapy</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>ASD</td>\\r\\n<td>Atrial septal defect</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>AST</td>\\r\\n<td>Aspartate aminotransferase</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>AVSD</td>\\r\\n<td>Atrioventricular septal defect</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>BD</td>\\r\\n<td>Twice per day</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>BMI</td>\\r\\n<td>Body mass index</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>BNF</td>\\r\\n<td>British National Formulary</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>BP</td>\\r\\n<td>Blood pressure</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>CCB</td>\\r\\n<td>Calcium channel blocker</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>CCHD</td>\\r\\n<td>Cyanotic congenital heart disease</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>CD4</td>\\r\\n<td>Cluster differentiation 4</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>CHD</td>\\r\\n<td>Congenital heart disease</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>CHF</td>\\r\\n<td>Congestive heart failure</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>CKD</td>\\r\\n<td>Chronic kidney disease</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>CKD-EPI</td>\\r\\n<td>Chronic kidney disease – epidemiology collaboration</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Cl</td>\\r\\n<td>Chloride</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>CK</td>\\r\\n<td>Creatinine kinase</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>CKMB</td>\\r\\n<td>Creatine kinase Muscle Brain</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>CLD</td>\\r\\n<td>Chronic liver disease</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>CM</td>\\r\\n<td>Cryptococcal meningitis</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>CMV</td>\\r\\n<td>Cytomegalovirus</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>COPD</td>\\r\\n<td>Chronic obstructive pulmonary disease</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>CP</td>\\r\\n<td>Cerebral palsy</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Cr</td>\\r\\n<td>Creatinine</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>CRP</td>\\r\\n<td>C-reactive protein</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>CSD</td>\\r\\n<td>Clinical services department</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>CSF</td>\\r\\n<td>Cerebrospinal fluid</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>CT</td>\\r\\n<td>Computed tomography</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>CXR</td>\\r\\n<td>Chest X-ray</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>DCT</td>\\r\\n<td>Direct Coombs test</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>DD</td>\\r\\n<td>Developmental delay</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>DIP</td>\\r\\n<td>Distal interphalangeal joints</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>DKA</td>\\r\\n<td>Diabetic ketoacidosis</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>dl</td>\\r\\n<td>decilitre</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>DM</td>\\r\\n<td>Diabetes mellitus</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Dr</td>\\r\\n<td>Doctor</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>DSM-IV</td>\\r\\n<td>Diagnostic and statistical manual of mental disorders – 4<sup>th</sup> edition</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>DTs</td>\\r\\n<td>Delirium tremens</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>DVT</td>\\r\\n<td>Deep vein thrombosis</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>ECG</td>\\r\\n<td>Electrocardiogram</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>ECHO</td>\\r\\n<td>Echocardiogram</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>EDTA</td>\\r\\n<td>Ethylenediamine tetraacetic acid (anticoagulant)</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>EEG</td>\\r\\n<td>Electroencephalogram</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>EFSTH</td>\\r\\n<td>Edward Francis Small teaching hospital</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>eGFR</td>\\r\\n<td>Estimated glomerular filtration rate</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>EMRS</td>\\r\\n<td>Electronic medical record system</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>ENT</td>\\r\\n<td>Ear, nose and throat</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>ESR</td>\\r\\n<td>Erythrocyte sedimentation rate</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>F75</td>\\r\\n<td>Formula 75 – WHO formula for malnutrition with 75 kCal/100ml</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>F100</td>\\r\\n<td>Formula 100 – WHO formula for malnutrition with 100 kCal/100ml</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>FBC</td>\\r\\n<td>Full blood count</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>FBS</td>\\r\\n<td>Fasting blood sugar</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>FSGS</td>\\r\\n<td>Focal segmental glomerulosclerosis</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>(f)T<sub>4</sub></td>\\r\\n<td>(Free) thyroxine</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>(f)T<sub>3</sub></td>\\r\\n<td>(Free) triiodothyronine</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>g</td>\\r\\n<td>Gram(s)</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>GAS</td>\\r\\n<td>Group A streptococcus</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>GCS</td>\\r\\n<td>Glasgow coma scale</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>GDM</td>\\r\\n<td>Gestational diabetes mellitus</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>GFR</td>\\r\\n<td>Glomerular filtration rate</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>GI</td>\\r\\n<td>Gastrointestinal</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>GORD</td>\\r\\n<td>Gastro-oesophageal reflux disease</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>HAV</td>\\r\\n<td>Hepatitis A virus</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Hb</td>\\r\\n<td>Haemoglobin</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>HbA1c</td>\\r\\n<td>Haemoglobin A1c</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>HACEK</td>\\r\\n<td><em>Haemophilus aphrophilus, Actinobacillus actinomycetemcomitans , Cardiobacterium hominis, Eikenella corrodens, Kingella kingae</em></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>HBsAg</td>\\r\\n<td>Hepatitis B surface antigen</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>HBV</td>\\r\\n<td>Hepatitis B virus</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>HCC</td>\\r\\n<td>Hepatocellular carcinoma</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>HCG</td>\\r\\n<td>Human chorionic gonadotropin</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>HCO<sub>3</sub></td>\\r\\n<td>Bicarbonate</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>HCV</td>\\r\\n<td>Hepatitis C virus</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>HDL</td>\\r\\n<td>High density lipoprotein</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>HDU</td>\\r\\n<td>High dependency unit</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>HELLP</td>\\r\\n<td>Haemolysis, elevated liver enzymes, low platelet count</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>HHS</td>\\r\\n<td>Hyperglycaemic hyperosmolar state</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Hib</td>\\r\\n<td><em>Haemophillus influenzae b</em></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>HIV</td>\\r\\n<td>Human immunodeficiency virus</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>HP / H pylori</td>\\r\\n<td>Helicobacter pylori</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>HR</td>\\r\\n<td>Heart rate</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>hr</td>\\r\\n<td>Hour</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>HSV</td>\\r\\n<td>Herpes simplex virus</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>HTN</td>\\r\\n<td>Hypertension</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Hz</td>\\r\\n<td>Hertz</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>ICP</td>\\r\\n<td>Intracranial pressure</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>IE</td>\\r\\n<td>Infective endocarditis</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>im</td>\\r\\n<td>Intramuscular</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>INR</td>\\r\\n<td>International normalised ratio</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>ITU</td>\\r\\n<td>Intensive therapy unit</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>IV</td>\\r\\n<td>Intravenous</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>K</td>\\r\\n<td>Potassium</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>kg</td>\\r\\n<td>Kilogram</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>l</td>\\r\\n<td>Litre</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>LA</td>\\r\\n<td>Left atrium</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>LBP</td>\\r\\n<td>Lower back pain</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>LFTs</td>\\r\\n<td>Liver function tests</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>LGV</td>\\r\\n<td>Lymphogranuloma venereum</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>LP</td>\\r\\n<td>Lumbar puncture</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>L-R</td>\\r\\n<td>Left to right</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>LRI</td>\\r\\n<td>Lower respiratory infection</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>LV</td>\\r\\n<td>Left ventricle</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>MC&amp;S</td>\\r\\n<td>Microscopy, culture and sensitivities</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>MCD</td>\\r\\n<td>Minimal change disease</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>mcg</td>\\r\\n<td>Microgram</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>MCV</td>\\r\\n<td>Mean cell volume</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>MEWS</td>\\r\\n<td>MRC early warning score</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>mEq</td>\\r\\n<td>Milliequivalent</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>mg</td>\\r\\n<td>Milligrams</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>ml</td>\\r\\n<td>Millilitres</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>mm<sup>3</sup></td>\\r\\n<td>Millimetre cubed</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>mmHg</td>\\r\\n<td>Milimetres of mercury</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>mmol</td>\\r\\n<td>Millimole</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>mOsm</td>\\r\\n<td>Milliosmole</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>MPS</td>\\r\\n<td>Mucopolysaccharidoses</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>MR</td>\\r\\n<td>Mitral regurgitation</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>MRC</td>\\r\\n<td>Medical research council</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>MRI</td>\\r\\n<td>Magnetic resonance imaging</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>MRSA</td>\\r\\n<td>Methicillin-resistant <em>staphylococcus aureus</em></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>MST</td>\\r\\n<td>Morphine slow release tablets</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>MUAC</td>\\r\\n<td>Mid upper arm circumference</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Na</td>\\r\\n<td>Sodium</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>NPO</td>\\r\\n<td>Nil per oral</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>NS</td>\\r\\n<td>Nephrotic syndrome</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>NSAIDs</td>\\r\\n<td>Non-steroidal anti-inflammatory drugs</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>NSTEMI</td>\\r\\n<td>Non-ST elevation myocardial infarction</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>O<sub>2</sub></td>\\r\\n<td>Oxygen</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>OA</td>\\r\\n<td>Osteoarthritis</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>OCP</td>\\r\\n<td>Oral contraceptive pill</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>OD</td>\\r\\n<td>Once per day</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>OM</td>\\r\\n<td>Osteomyelitis</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>OM</td>\\r\\n<td>Otitis media</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>OME</td>\\r\\n<td>Otitis media with effusion</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>OPD</td>\\r\\n<td>Outpatient department</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>P</td>\\r\\n<td>Plasmodium</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>PA</td>\\r\\n<td>Pulmonary artery</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>PCR</td>\\r\\n<td>Polymerase chain reaction</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>PCV</td>\\r\\n<td>Packed cell volume</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>PDA</td>\\r\\n<td>Patent ductus arteriosus</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>PE</td>\\r\\n<td>Pulmonary embolism</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>PEFR</td>\\r\\n<td>Peak expiratory flow rate</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>PID</td>\\r\\n<td>Pelvic inflammatory disease</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>PIP</td>\\r\\n<td>Proximal interphalangeal joints</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>PO</td>\\r\\n<td>Per oral</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>PR</td>\\r\\n<td>Per rectum</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>PR</td>\\r\\n<td>Pulse rate</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>PRN</td>\\r\\n<td>As required</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>PS</td>\\r\\n<td>Pulmonary stenosis</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>PSA</td>\\r\\n<td>Prostate specific antigen</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>PUD</td>\\r\\n<td>Peptic ulcer disease</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>QDS</td>\\r\\n<td>Four times per day</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>QRISK</td>\\r\\n<td>Q research cardiovascular risk score</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>qSOFA</td>\\r\\n<td>Quick sequential organ failure assessment score</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>RDT</td>\\r\\n<td>Rapid diagnostic test (for malaria)</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>RF</td>\\r\\n<td>Rheumatoid factor</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>RHD</td>\\r\\n<td>Rheumatic heart disease</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>RNA</td>\\r\\n<td>Ribonucleic acid</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>ROSIER</td>\\r\\n<td>Recognition of stroke in the emergency room</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>RPR</td>\\r\\n<td>Rapid plasmin reagent</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>RR</td>\\r\\n<td>Respiratory rate</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>RTA</td>\\r\\n<td>Road traffic accident</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>RTUF</td>\\r\\n<td>Ready to use food</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>RVOTO</td>\\r\\n<td>Right ventricular outflow tract obstruction</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>SA</td>\\r\\n<td>Septic arthritis</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>SAAG</td>\\r\\n<td>Serum ascites albumin gradient</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>SAH</td>\\r\\n<td>Subarachnoid haemorrhage</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>SBP</td>\\r\\n<td>Spontaneous bacterial peritonitis</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>sc</td>\\r\\n<td>Subcutaneous</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>SCORTEN</td>\\r\\n<td>Severity of illness score for toxic epidermal necrolysis</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>SIADH</td>\\r\\n<td>Syndrome of inappropriate anti-diuretic hormone</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>SJS</td>\\r\\n<td>Stevens-Johnson syndrome</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>SLE</td>\\r\\n<td>Systemic lupus erythematosus</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>SOP</td>\\r\\n<td>Standard operating procedure</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>SpO<sub>2</sub></td>\\r\\n<td>Oxygen saturations</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>SSRI</td>\\r\\n<td>Selective serotonin reuptake inhibitor</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Stat</td>\\r\\n<td>Statim (Instantly/Immediately)</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>STEMI</td>\\r\\n<td>ST elevation myocardial infarction</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>STI</td>\\r\\n<td>Sexually transmitted infection</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>SZREC</td>\\r\\n<td>Sheikh Zayed regional eyecare centre</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>T or Temp</td>\\r\\n<td>Temperature</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>TB</td>\\r\\n<td>Tuberculosis</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>TB4</td>\\r\\n<td>Tuberculosis combination tablets with 4 drugs</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>TBW</td>\\r\\n<td>Total body water</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>TDD</td>\\r\\n<td>Total daily dose</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>TDS</td>\\r\\n<td>Three times per day</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>TEN</td>\\r\\n<td>Toxic epidermal necrolysis</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>TM</td>\\r\\n<td>Tympanic membrane</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>TOF</td>\\r\\n<td>Tetralogy of Fallot</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>TPHA</td>\\r\\n<td>Treponema pallidum hemagglutination assay</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>TSH</td>\\r\\n<td>Thyroid-stimulating hormone</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>U</td>\\r\\n<td>Units</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>UA</td>\\r\\n<td>Unstable angina</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>U&amp;Es</td>\\r\\n<td>Urea and electrolytes</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>UK</td>\\r\\n<td>United Kingdom</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>URTIs</td>\\r\\n<td>Upper respiratory tract infections</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>US</td>\\r\\n<td>Ultrasound</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>UTI</td>\\r\\n<td>Urinary tract infection</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>VDRL</td>\\r\\n<td>Venereal disease research laboratory test</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>VLCFA</td>\\r\\n<td>Very long chain fatty acids</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>VSD</td>\\r\\n<td>Ventricular septal defect</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>WHO</td>\\r\\n<td>World health organisation</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>WHZ</td>\\r\\n<td>Weight for height Z score</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>XR</td>\\r\\n<td>X-ray</td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Karen Forrest</th>\\r\\n<th>Date: 31 May 2019</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name:</td>\\r\\n<td>Date:</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td>31 July 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>2.0</td>\\r\\n<td>Updated with extra abbreviations and existence of mobile app</td>\\r\\n<td>31 May 2021</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"031\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>Liver disease MeG-CLS-031</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"liver-disease\\\">Liver disease</h1>\\r\\n<h2 id=\\\"executive-summary\\\"><em>Executive summary</em></h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<p>The liver is responsible for many critical functions within the body and should it become diseased or injured, the loss of those functions can cause significant damage to the body. Liver disease is a broad term that covers all the potential problems that cause the liver to fail to perform its designated functions. Usually, more than 75% or three quarters of liver tissue needs to be affected before a decrease in function occurs.</p>\\r\\n<p>Management of these patients is divided into the assessment and treatment of patients with a new diagnosis of liver disease and that of those with established chronic liver disease (CLD) who have decompensated.</p>\\r\\n<h2 id=\\\"target-user\\\">Target User</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doctors</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nurses</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"target-area-of-use\\\">Target area of use </h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ward</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"key-areas-of-focusnew-additionschanges\\\">Key areas of focus/new additions/changes</h2>\\r\\n<p>This guideline outlines the initial diagnosis of liver disease in our setting as well as the management of patients with established disease who decompensate.</p>\\r\\n<h2 id=\\\"limitations\\\">Limitations</h2>\\r\\n<p>We have limited access to most of the diagnostic tests for causes of liver disease.</p>\\r\\n<p>Access to higher level care is largely not available – except for dialysis, which might be possible at the teaching hospital.</p>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs\\\">Presenting symptoms and signs</h2>\\r\\n<p>If the patient is in extremis, they should be resuscitated prior to any other intervention – the most likely causes are an acute GI bleed or bacterial septicaemia.</p>\\r\\n<p>Patients with liver disease can present with many different symptoms including:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Weakness and fatigue</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Jaundice</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nausea</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Vomiting</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Weight loss</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Right upper quadrant pain</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Confusion</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Reduced GCS</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Clubbing</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hematemesis.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>They may present with signs of anaemia, sepsis, acute liver disease or chronic liver disease.</p>\\r\\n<p>The patient’s background history must be taken in order to establish the cause of the underlying liver disease. This may affect the treatment given.</p>\\r\\n<p>The history of the current event must also be taken with particular note of any gastrointestinal bleeding, change in girth size, pain, confusion, difficulty breathing, increase in jaundice, recent medications and traditional treatments taken.</p>\\r\\n<h2 id=\\\"examination-findings\\\">Examination findings</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>General findings: anaemia, fever, tachycardia, altered level of consciousness or confusion, peripheral oedema.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Signs of chronic liver disease: liver flap, clubbing, palmar erythema, bruising, spider naevi, gynaecomastia, testicular atrophy, ascites, venous collaterals.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Liver: small in cirrhosis, large in acute hepatitis or neoplasm.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Splenomegaly: suggests portal hypertension.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>PR: this is essential if there is any suggestion of a GI bleed.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Signs of excess alcohol – Dupuytren’s contracture – parotid enlargement.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Stigmata of HIV: Oral thrush, Herpes Zoster scar.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"investigations\\\">Investigations</h2>\\r\\n<p>Tests which may be appropriate to assess patient’s current condition include:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>FBC, LFTs, albumin, INR, U&amp;Es, blood glucose</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Urinary dipstick</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Blood cultures and chest X-ray</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ascitic tap (if ascites is present this is essential) – send for MC&amp;S, albumin, AFBs.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Note that FBC, INR, U&amp;Es, LFTs and ascitic tap microscopy and albumin are all urgent tests and <em><strong>the results should be reviewed within 4 hours of admission</strong></em> to the ward in any acutely unwell patient.</p>\\r\\n<p>Tests to identify possible causes include:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Viral serology: HIV, HBsAg (HCV, HAV when available)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hb genotype</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ultrasound – for jaundiced patients ask directly about duct dilatation.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Consider autoantibodies, ferritin and AFP when available.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"causes-of-decompensation-in-cld\\\">Causes of decompensation in CLD</h2>\\r\\n<p>For patients with chronic liver disease, management will depend on the cause of the decompensation. Patients with CLD may decompensate because of a complication of their underlying liver disease or because of a second insult to the liver or their overall system.</p>\\r\\n<p>Complications of CLD are:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Variceal haemorrhage</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Portal vein thrombosis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ascites</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Spontaneous bacterial peritonitis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hepatic encephalopathy</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hepatorenal syndrome</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hepatopulmonary syndrome</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hepatocellular carcinoma</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Common causes of a second insult are:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Acute viral hepatitis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Drug-induced liver injury (which may be caused by traditional treatment as well as prescribed medications)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Bacterial infection (UTI, LRI etc)</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"management\\\">Management</h2>\\r\\n<h3 id=\\\"newly-diagnosed-liver-disease\\\">Newly diagnosed liver disease</h3>\\r\\n<p>Treat precipitants and possible causes.</p>\\r\\n<p>Ensure adequate hydration and nutrition (give e-pap if there is any doubt).</p>\\r\\n<p>Avoid hepatotoxic drugs.</p>\\r\\n<p>Manage according to particular complications (hepatic encephalopathy is common).</p>\\r\\n<p>Seek specialist support if acute liver disease is suspected.</p>\\r\\n<h3 id=\\\"all-patients-with-cld\\\">All patients with CLD</h3>\\r\\n<p>All patients admitted with CLD should have their Child-Pugh score calculated in order to provide prognostic information.</p>\\r\\n<p>Use the table below to assign a score for each item:</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Points</strong></th>\\r\\n<th><strong>1</strong></th>\\r\\n<th><strong>2</strong></th>\\r\\n<th><strong>3</strong></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Ascites</td>\\r\\n<td>None</td>\\r\\n<td>Slight</td>\\r\\n<td>Moderate or above</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Bilirubin</td>\\r\\n<td>&lt;34.2</td>\\r\\n<td>34.2-51.3</td>\\r\\n<td>&gt;51.3</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Serum albumin</td>\\r\\n<td>&gt;35</td>\\r\\n<td>28-35</td>\\r\\n<td>&lt;28</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>INR</td>\\r\\n<td>&lt;1.7</td>\\r\\n<td>1.7-2.3</td>\\r\\n<td>&gt;2.3</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Encephalopathy</td>\\r\\n<td>None</td>\\r\\n<td>Grade 1-2</td>\\r\\n<td>Grade 3-4</td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<p>Add the score and interpret the findings according to this table:</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Class</strong></th>\\r\\n<th><strong>Score</strong></th>\\r\\n<th><strong>1 year survival rate</strong></th>\\r\\n<th><strong>2 year survival rate</strong></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>A</td>\\r\\n<td>5-6</td>\\r\\n<td>100%</td>\\r\\n<td>85%</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>B</td>\\r\\n<td>7-9</td>\\r\\n<td>80%</td>\\r\\n<td>60%</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>C</td>\\r\\n<td>10-15</td>\\r\\n<td>45%</td>\\r\\n<td>35%</td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<p>In the rare cases where the patient can control a cause of deterioration (especially alcoholic liver disease), if they remove this risk factor (i.e. stop drinking) they can improve their prognosis significantly.</p>\\r\\n<p>If the INR is greater than 3.5, then vitamin K should be prescribed. In most cases, 10 mg OD orally for 3 days is adequate.</p>\\r\\n<h3 id=\\\"variceal-haemorrhage\\\">Variceal haemorrhage</h3>\\r\\n<p>This should be suspected whenever there is GI bleeding. It may present with either haematemesis or melaena.</p>\\r\\n<p>Other causes of GI haemorrhage are possible, but are less serious. Only 50% of bleeding varices will stop bleeding spontaneously. The outlook is even worse for patients with Child-Pugh Class C disease.</p>\\r\\n<p>Re-bleeding is also very common and is more likely for older patients, those with encephalopathy, ascites, renal failure, alcoholic liver disease or low platelets.</p>\\r\\n<p>Management begins with urgent fluid resuscitation including the siting of 2 large bore cannulas, iv normal saline to restore BP and urgent cross-matching of blood. Whole blood should be transfused as soon as possible aiming for an Hb of 9 g/dl.</p>\\r\\n<p>Endoscopy should be arranged if available.</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Unstable patients with severe acute upper GI bleeding should be scoped as soon as possible after resuscitation.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Stable patients with upper GI bleeding should be scoped within the next working day after admission.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Any varices should be banded. If another cause of bleeding is identified, management should be altered to reflect this.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>None of the vasoactive medications shown to be effective in controlling acute bleeding are available here.</p>\\r\\n<p>Patients are at high risk of concomitant infection and the presence of infection increases the risk of re-bleeding so all patients should be given prophylactic antibiotics – usually ciprofloxacin 500 mg BD for 7 days.</p>\\r\\n<p>Patients are at high risk of encephalopathy and should be treated with lactulose if they are not passing stool at least twice each day – 20 ml TDS to start.</p>\\r\\n<p><em>Secondary prophylaxis</em></p>\\r\\n<p>This should be offered to all patients who have had a variceal bleed.</p>\\r\\n<p>Both non-cardioselective beta blockers and variceal band ligation should be given.</p>\\r\\n<p>Give propranolol 40 mg BD and titrate up the dose until the HR is 50-55 bpm. The maximum dose is 320 mg per day. This should also be given to patients identified as having varices who have not yet had a bleed (primary prophylaxis).</p>\\r\\n<h3 id=\\\"spontaneous-bacterial-peritonitis-sbp\\\">Spontaneous bacterial peritonitis (SBP)</h3>\\r\\n<p>The signs of SBP can be very subtle and therefore it should be considered a possibility in all patients with ascites due to portal hypertension.</p>\\r\\n<p>Ascitic fluid should be aspirated and sent for immediate fluid albumin and microscopy including cell count. If plenty of fluid is obtained – some can be used to inoculate blood culture bottles.</p>\\r\\n<p>SBP is considered to be present if the granulocyte count is greater than 250 cells/mm3. It should be suspected if there are typical clinical signs such as Temp &gt; 37.8ºC, abdominal pain or tenderness or change in mental status.</p>\\r\\n<p>As soon as the samples are obtained, if there are clinical signs of SBP, then treatment should be started. iv ceftriaxone 1 g OD or oral ciprofloxacin 500 mg BD are both appropriate empirical options. Most patients will recover with a 5 day course of treatment.</p>\\r\\n<p>If the patient is on propranolol, this should be stopped permanently.</p>\\r\\n<p>When the patient has recovered, they should be placed on antibiotic prophylaxis. The best choice is Septrin 960 mg OD. Ciprofloxacin 500 mg OD is an alternative.</p>\\r\\n<p><span data-custom-style=\\\"Heading 3 Char\\\"><br />\\r\\n</span></p>\\r\\n<p><span data-custom-style=\\\"Heading 3 Char\\\">Hepatic encephalopathy</span></p>\\r\\n<p>This is a common complication which can be difficult to diagnose in its subtler forms. It is graded according to the following table:</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th>Grade 1</th>\\r\\n<th>Changes in behaviour, mild confusion, slurred speech, disordered sleep</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Grade 2</td>\\r\\n<td>Lethargy, moderate confusion</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Grade 3</td>\\r\\n<td>Marked confusion, incoherent speech, sleeping but rousable</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Grade 4</td>\\r\\n<td>Coma</td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<p>It may be precipitated by GI bleeding, infection (including SBP), low K<sup>+</sup>, renal failure, hypovolaemia, hypoxia, sedatives, hypoglycaemia, constipation.</p>\\r\\n<p>Patients should be treated with lactulose, beginning with a dose of 20 ml TDS. The dose should be increased until they pass stools at least twice each day.</p>\\r\\n<p>Any potential triggers of encephalopathy should be corrected.</p>\\r\\n<h3 id=\\\"hepatorenal-syndrome\\\">Hepatorenal syndrome</h3>\\r\\n<p>This is the cause of about 15% of cases of renal failure in chronic liver disease. It refers to renal failure arising from falling renal perfusion as a direct effect of liver dysfunction. It has a very poor prognosis and there is no treatment available for it in this setting. Other causes of renal failure must therefore be excluded or treated before this diagnosis is made.</p>\\r\\n<p>Consider alternative diagnoses of renal failure such as hypovolaemia, sepsis, glomerulonephritis, or obstruction.</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Dip the urine – if there are white cells or red cells, consider glomerulonephritis or a urinary infection with septic shock.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Stop any diuretics.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Give 1 litre of normal saline over 1-2 hours and monitor urinary output and observations. If the renal failure is caused by hypovolaemia, you should see an increase in urine output and improving observations.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Treat any infection.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Arrange for a renal and bladder ultrasound to exclude obstruction.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Any patient who has no other diagnosis identified and who has not had an improvement in their renal function with these interventions may have hepatorenal syndrome. The diagnosis can be confirmed if the creatinine rises by 25 or more within 48 hours or if there is a 50% rise from baseline within 7 days. The treatment is supportive. A small number will recover if they can be supported until their liver function improves.</p>\\r\\n<h3 id=\\\"hepatopulmonary-syndrome\\\">Hepatopulmonary syndrome</h3>\\r\\n<p>Diagnosed when a patient with CLD becomes hypoxic and is found to have a hyperdynamic circulation. They may become hypoxic only on sitting upright.</p>\\r\\n<p>Treat with oxygen and exclude other causes of hypoxia. There is no specific treatment and the prognosis is very poor.</p>\\r\\n<h3 id=\\\"ascites\\\">Ascites</h3>\\r\\n<p>Ascites is a very common complication of chronic liver disease. It is usually diagnosed clinically and confirmed by abdominal ultrasound.</p>\\r\\n<p>All CLD patients presenting with ascites should have an immediate ascitic tap with samples sent for albumin, cell count and culture.</p>\\r\\n<p>Calculate the serum ascites albumin gradient (SAAG):</p>\\r\\n<p>SAAG = serum albumin – ascites albumin</p>\\r\\n<p>If SAAG is greater than 11, the ascites is caused by portal hypertension – usually because of liver disease, but could be due to heart failure or Budd-Chiari syndrome. If SAAG is less than 11, an alternative diagnosis must be sought.</p>\\r\\n<p>If the cell count shows &gt; 250 granulocytes/mm<sup>3</sup>, then the patient has SBP and should be treated accordingly.</p>\\r\\n<p>Ascites that is due to portal hypertension in the context of CLD should be treated with salt restriction and diuretics. Start with 40 mg furosemide OD and 100 mg spironolactone OD. If there is no response after 3-5 days, the doses can be increased in the same ratio up to a maximum of 160 mg furosemide and 400 mg spironolactone. A patient with ascites and oedema may lose up to 2 kg/day whilst a patient with only ascites typically loses no more than 0.75 kg/day.</p>\\r\\n<p>If the ascites is tense or the ascites needs to be removed more quickly, large volume paracentesis can be undertaken. Up to 5 litres can be removed each day without replacement with albumin or other fluids.</p>\\r\\n<p><em><strong>Patients who develop ascites should not continue treatment with propranolol or an ACE inhibitor.</strong></em></p>\\r\\n<h3 id=\\\"hepatocellular-carcinoma\\\">Hepatocellular carcinoma</h3>\\r\\n<p>In our setting, many patients do not present with CLD until they already have a large hepatocellular carcinoma. There is little that can be done to treat them apart from symptom control.</p>\\r\\n<p>Patients with CLD who present with a sudden deterioration in liver function may have developed a HCC and should be sent for ultrasound. If a new HCC is present, they should be referred to the liver clinic for assessment once they have recovered from their acute decompensation.</p>\\r\\n<p>Patients should be treated with analgesia according to the WHO analgesic ladder if they are in pain. Paracetamol is safe in this setting. NSAIDs should be used with caution, but are the most effective option for pain due to stretching of the liver capsule. Codeine and morphine may trigger hepatic encephalopathy, but should be used if the patient’s pain is severe and unresponsive to other options.</p>\\r\\n<h2 id=\\\"key-issues-for-nursing-care\\\">Key Issues for Nursing care</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Refer all patients with suspected liver disease or complications to a doctor.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Assess need for pain control.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Check on frequency of bowel movements and if less than or greater than two stools / day advise doctor to adjust lactulose dose accordingly.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ask patient if they have melaena stools.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Document presence of confusion and or changes in behaviour which may be signs of evolving hepatic encephalopathy.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Order a low salt diet in patients with ascites.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ensure adequate nutrition (with epap supplements if necessary) for all patients with liver disease.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<p>Goldberg and Chopra 2017. Cirrhosis in adults: Overview of complications, general management, and prognosis. UpToDate Mar 2017.</p>\\r\\n<p>Sanyal 2017. General principles of the management of variceal haemorrhage. UpToDate Feb 2017</p>\\r\\n<p>Runyon 2015. Spontaneous bacterial peritonitis in adults: Diagnosis. UpToDate Aug 2015.</p>\\r\\n<p>Runyon 2016. Spontaneous bacterial peritonitis in adults: Treatment and prophylaxis. UpToDate Jan 2016.</p>\\r\\n<p>Ferenci 2015. Hepatic encephalopathy in adults: Clinical manifestations and diagnosis. Sept 2015.</p>\\r\\n<p>Fenerci 2017. Hepatic encephalopathy in adults: Treatment. Aug 2017.</p>\\r\\n<p>Runyon 2016. Hepatorenal syndrome. UpToDate June 2016.</p>\\r\\n<p>Goldberg and Chopra 2016. Hepatopulmonary syndrome in adults: Prevalence, causes, clinical manifestations, and diagnosis. Dec 2016.</p>\\r\\n<p>Such and Runyon 2017. Ascites in adults with cirrhosis: Initial therapy. June 2017.</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Amie Secka</th>\\r\\n<th>Date: 6 June 2018</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Karen Forrest</td>\\r\\n<td>Date: 14 June 2018</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>2.0</td>\\r\\n<td>Adapted from previous guideline on CLD and format updated.</td>\\r\\n<td>31 July 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>2.1</td>\\r\\n<td>Executive summary added</td>\\r\\n<td>31 July 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"022\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>Lower back pain MeG-CLS-022</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"lower-back-pain\\\">Lower Back Pain</h1>\\r\\n<h2 id=\\\"executive-summary\\\"><em>Executive summary</em></h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction </h2>\\r\\n<p>Lower back pain is a very common presentation in General Medical Practice. Up to 80-90% of people will suffer lower back pain (LBP) in their lifetime. Lower back pain is classified as acute lower back pain (duration &lt; 6 weeks), sub-acute lower back pain (6-12 weeks) and chronic lower back pain (&gt; 3 months). Most lower pain results from benign acute musculoskeletal conditions, relating to the strain put on the back during work, leisure and daily life</p>\\r\\n<h2 id=\\\"target-users\\\">Target users</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nurses</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doctors</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"target-area-of-use\\\">Target area of use </h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Gate Clinic</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>OPD</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p><strong>Key areas of focus / New additions / Changes</strong></p>\\r\\n<p>Features suggestive of serious or unusual causes of lower back pain should be sought for during history and physical examination. Investigations are most useful for patients with unremitting acute lower back pain and in other patients with severe or suspicious features. General measures for treatment include lifestyle changes, analgesia and physical therapy.</p>\\r\\n<h2 id=\\\"limitations\\\">Limitations</h2>\\r\\n<p>Patients may need referral for physiotherapy and specialist services which are not available in our facility.</p>\\r\\n<h2 id=\\\"common-causes-of-lbp\\\">Common causes of LBP</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Minor tissue injuries – by far the commonest. Settles easily usually</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Mechanical back pain – dysfunction of elements of facet joint, intervertebral joint (with its disc) and the ligamentous and muscular attachments (also known as ‘non-specific back pain’).</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Lumbar spondylosis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Spondylolisthesis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Musculoligamentous strain/tears</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Spondyloarthropathies: Ankylosing spondylitis, reactive arthritis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Malignant disease: Metastasis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Depression</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"history\\\">History</h2>\\r\\n<p>A focused history taking should be conducted to place patient with low back pain into one of three categories:</p>\\r\\n<ol type=\\\"1\\\">\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Non-specific low back pain: <strong>SOCRATES</strong>- <strong>S</strong>ite <strong>O</strong>nset <strong>C</strong>haracter <strong>R</strong>adiation <strong>A</strong>ctivity in<strong>T</strong>ensity <strong>E</strong>xacerbating/Relieving factors &amp; <strong>S</strong>ymptoms associated</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Back pain potentially associated with radiculopathy or spinal stenosis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Back pain associated with another specific spinal cause (tumour, infection, fracture).</p>\\r\\n</div></li>\\r\\n</ol>\\r\\n<h3 id=\\\"diagnostic-pointers\\\">Diagnostic pointers</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Continuous pain (day and night), fever +/- Constitutional symptoms = Neoplasia or infection.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Pain with standing/walking (relief with sitting) = Spondylolisthesis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Pain (and stiffness) at rest, relief with activity = Inflammation</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Stiffness at rest, pain with or after activity, relief with rest = osteoarthritis.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Pain provoked by activity, relieved with rest = mechanical dysfunction</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Pain in bed at early morning = depression then inflammation, or malignancy/infection.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"red-flags-for-serious-causes-of-lbp\\\">Red flags for serious causes of LBP</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Unremitting/constant pain- worse at night pain</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Unexplained weight loss</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Symptoms in other systems e.g. cough, breast mass</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Progressive neurological deficit: e.g. weakness in limbs, loss of sphincteric control</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Bilateral sciatica</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Age at onset&gt; 50 years and &lt; 20 years</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Associated temperature &gt; 37.8ºC</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Significant/violent trauma</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>No improvement after one month</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Recent onset bladder dysfunction</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>History of cancer</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"yellow-flag-signs-in-lbp-psychosocial-issues-that-impede-recovery\\\">Yellow flag signs in LBP (Psychosocial issues that impede recovery)</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Compensation issues</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Failure to return to work</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Refusal of treatment</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Unsatisfactory response to treatment</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Atypical physical signs</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Unsupportive home environment</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Inappropriate expectations</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Belief that activity &amp; physiotherapy are harmful</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"examination--gait-look-move-special-tests\\\">Examination- Gait, Look, Move &amp; Special Tests</h2>\\r\\n<p>The main components of the physical examination are:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Inspection: abnormalities of gait (stance &amp; sway), spine curvatures, scars revealing previous spine procedure or trauma, spine abnormalities (e.g. gibbus) etc.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Active movements: These includes forward flexion (to reproduce patient symptoms), extension (to reproduce patient’s symptoms), lateral flexion (R&amp;L) to reproduce patient’s symptoms.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Provocative tests (to reproduce the patient’s symptoms) e.g. Slump test, Lasegue or straight leg raising test, Cross straight leg raising test</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Palpation (to detect level of tenderness).</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Neurological examination of lower limbs (if appropriate).</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Testing of related joints (hip, sacroiliac).</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Assessment of pelvis and lower limbs for any deformity (e.g. leg shortening).</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>General medical examination, including rectal examination as indicated in patients presentation</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"section\\\"><img src=\\\"data:image/jpeg;base64,/9j/4AAQSkZJRgABAQEAYABgAAD/2wBDAAoHBwkHBgoJCAkLCwoMDxkQDw4ODx4WFxIZJCAmJSMgIyIoLTkwKCo2KyIjMkQyNjs9QEBAJjBGS0U+Sjk/QD3/2wBDAQsLCw8NDx0QEB09KSMpPT09PT09PT09PT09PT09PT09PT09PT09PT09PT09PT09PT09PT09PT09PT09PT09PT3/wAARCAEMAkADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDxmiiigAooooAKKKKACiiigAooooAKKKKACiiigAo60U+CZ7e4jmjOHjYOpIzyDkUAJ5T5xsbP0ppBBwRg16DYazqM3wt1u9e8uDcjUIgsvmHcoIyQD2HtVO10Wz1HR7bxF4hvHK3t4beVlbZ5YUDLcK25sduOnvVWFc4qjFdxpPg/SdUQpZXy3ly9zLHFC8wtnkiH3GjDKQ5PORkYxipbjS9Jfwf4XjuI5raW6uJkluI41LcSAMWAGWAGcCjlC5wVSQ201wzCCGSUqpZgilsAdScdq6TxT4bt9J0+C9sGjntJZ3iS4hulmR8AEAjAKtjqK0Y5rfTvhdaXFobq3uri8liklhcIZCEHDHqUwen1pWC5w1Fd+fA+mJ4in0FpbkXMWnm7F3uGwuE3424+52znNZWq6Lo2m+GdMvv9Oe61K2eSNdybI3VwvPGSOvFFgucsEdhlVYjpwKGRl+8pH1Fdz8OpmTSPFW6aWONNOL7k5KHP3gMjn8qq2qafrurafZ6jqGq3NnLG0cVwVG6KU8tkHOVHyk4PAOadgucfRXXXXhAWWuyaY1tc3Bs7c3FzMsqxxuvUOpI+WPB68k+laK+CNIl8Z6dpiT3Ytb6wF2CHUuh2M2M7eR8voOtHKwujgKURsyllUlV6kDpXbW/h3w/LpWi6gyalsvr1rJ4xMmQQR84O336frT00hdM07xrZQXt2qWDIhVSoSdfN2rvGM5HXg0coXOFor0HTvB2hXN94etJm1DfrVqZg6yJiJvm7beR8vtVLwt4OtdVubWLUo7lIb2eSCC4SZUyUHVUwS2O/QCjlC6OLxmnNG6HDqVOM4IxXZzWWmW3wySaa3dpzqkkXnRhQzbU4BJBO329a0dS8Nx6v4nKXl9eXEVroiXx3lTK6hMiMEDAHI5we9HKFzzmiu3sfCWl6lb+HLtHuYYtVu3tJYfMVmQqQAynHI55BFQal4b0hPDerX1ibxJ9NvxanznVllBJGcADB496VgucfRRRSGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAF+LXtSh0xtOju5Fsn+9AMbWPqR3PvS6fr+qaXBLBY3ssMMpy8YOVY+uDxn3rPro/Amm2OreJFt9RCunkyPFEz7RLKFyik+57d6auIzYde1SNBFDeTD5mK4+8C33iD1BPtV67n8RaFp9na3NzNb2+8zwReYCY2B5OAcqc9jiuq0Wwtl/wCEavbjS4rfV21Xy2hVWTdCMfvCmeNp79PXNcn4zYnxbqQNqtvi4k4XcPM+Y/Ock9fbinshXuyALrPiC5trMCaeSQloIcBFYnqVHAycdfao7vVNUhtG0e5uJBb27lTbnBVGBwfx4616TcJJN4t8DSR2aiE29sVuULMFxksmc4wOp4z71kanp1lqOha3cz6dFa3Nlqyx+fHu3mN2JYtknPHOcU7Bc4x/EOqyWn2Z76YxeX5WC3Oz+5nrt9s4q3AviDxNZC3hFxe29muQgwRCv07D9K6bxdo+l6NbalbQ6RO0OI20++jT5AOMlpNx37s9MDBqr8M45JD4i8tGYtpMqAAdWOMD6n0pW1sx9DlrHWNS0bz47G7ltxL8sojP3wOx9RTp/EOq3KlZb2VgYzERwPlPUceuOfWt/wAI+FfM1mJdetGiSWKY20E5MfnyooKr2OMkfXpVmeHTbHQdF1LVNLt4b1r547i1Ksnm24xlimcgg5AIxRZhc5uHxTrcDQmLU7lTBCYI/n+7Gf4fpSr4p1pLmK4GpXHnxR+UkpbLKvoD1xXc3PhPRJNZ1bRIHtk1GTF5Yy5/dRRLyIz7lCWP0FZ2k6fpet22u39jYo9zayxi2tI4vM/c5IZ/LLDcemeeM9Kdn3FdHJnxFqpt4oPtsoihk86NBgBHzncPQ5qzaaz4g1S6ntbW6nnmvj+9QYzOff8AvGurg07SJoPE17D4ddUs1hkt7e53hlYkb14bp3x1APWuV8OP9p8c6bJFCsYe+jcRx5wg3g4HsP6Uuoy5dnxhYrFd3P26IaadiSgf8e2RjGR93r0rNg8V65bRhINTuYlWUzAI+AHPUj0zXoOtlVtPG4dW0xHnyJ92ftzBjiPDdu/y/jxVKXwnFaeFdVjvNPt2uoLGG6t57dWzliM/OW+fjrgYFNp9BX7nER67qr28tkl7L5FzKJHiJG1n45x09KuavqPiTS9ZibU7m5h1CCMbCzDeqEcDI7Y7Vs+KNETRbf7Ppukx3enXFtE8OpBWdy527juBx1yNuO9dF4u0AX97fXVlFHeatFawZtJ1I2xCMAvGM4dgeCO3oTSswujzb/hIdVF5BdC9lWa3BELLgeVnrtA4H4Uj6/qckN1E95KYrtg86cYkYdyPX3qgwIYgjB9KSlcoKKKKQBRRRQAUUUUAFFFavh3QZvEOpizgkSL5GkaR84UAZ7d6NhpX0Mqiuz134a6hpdv9os5BexDqFXD+5C+nX8q4wgg4IwRSTT2HKLjuFFFFMkKKKKACiiigAooooAKB1p8cRf2Hqalx5XKrnHGT1BqlFsCLySOpAPoTTCCpIPUVOxBJDYAPKnFRyHIHc0NKwDKKKKkAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoxVjT47eXULdLxzHbtKolcdVTIyfyzXpGs+FbmNr6XRtH0bUdFELeSbV1aZF2/K5bO4sDyeuaznVjBpPqOx5fRXZX3hGxTwhoN7Bd20N3fGQytNMcNhgoCgKemeao6x4Ll0O7+yXuq6YtyJRG8YlJMY2bt7ccDt657c0Rqxlon3/AACxzdHIrqJ/CM2lXei3AurG7tNRfMEjB1RirDKuCAwBOB071Pq3ha5vPEeus62Fhb6bh7kwBvKizgAIMZOT7etNVYvr/WwrHJmWR33M7lsYySc01mZjliSfUmu98PeE10nxloUd/Lp9/baltdItpYtEykhirLxyPrWbrXhFxaajrFre2MsEF4YpoImIMG5iFB4Ax06Gp9tG9rjscr5jgAB2wOnPSjzHOfmbnrzXVeOfDNl4fmshYTxFZLWJ3jMpaRmYElsYxt9KuaJb2cnwv1q/lsLSS8tJo4opniBYBiM/U8nmn7VcqkuoWOIMjlAhZto6DPAoDMvQkfQ1paLoN1rs062oVY7aIzTytnEaDvgck+gHJrXPw+1Fr6zhhmgkt7u2e6S4IZVWNPvllI3AjjjHcVTqRi7NiscsXZiCzE49TSvI8jbnZmb1Y5rc1PwsbDQ7fV49RtJ7O5LLDt3q7lThhtK9vrW34Fs7S88O+I5LnT7S5nsrdZbdpkyVc5HXuOB1qZVVGPNv/VgscPuOc5OfrQjsjbkYq3qDiuz8a2Nlp+laTa3Gnw2PiAhnu44AVQIT8mecZ78dOazbrwhJD4ek1i31GzuoIJVhnEW/MbHpglQGHuM041E0n3HY5/e/95uuetNBIOQSD6iu41Twpe6lqWh6fbW2mQyT6eJle034kQZPmPkZLEDoBVPQvDxh8X6bbQyafevNkiC8SSNCRkbXUrkHuO1L2sWr3EcoXY4yxOOmT0pfMfj5m4GOvaujh8Jz6nHq98l1p9tBYTlZ1ZmUR5cgYGD8vXHfipZvh9qK65YadbXFrci+t/tMNwjERmPBJY5GRjHpT9rHa4WOX81woUO20HIGeAaPMckHc2R0Oelbt74UNtoCazDqdnPZyO0ScOjs46qFK+nNSeF7y2fUNM02XS7Ofz7tVmlmQszKzKNo54xz+dDmuVyXQDnOSaK7TxTHC3irUfDumaNaBzcrDatEm2RTkcZzznpzVO78BX8FlcXEM0M7WtwltcRqGUo7HaMFgAwzxkGkqsWk3pcdjl6K6e98GtpepRWl7exCb7SkEsZR48Z6lWZcMBjGR6io/HWg2vh/xJc2ljLG1ujbVjEhaRMAffyOpJzTVSLaSFY5yiiirAKKKKACu8+FWrm21e405lQx3UZkBIGQ6c9fpu4rg62/Bc5t/GWkuO9yin6E4P6GpkrplQdpJn0QkMb5Z1DMyN19c5rwHxt4dudE1iSV0/0e4ctG4HGe4+tfQoi4BUcDFYvjPw9Br3hueEqAwG5GAyUYd65qcuVnZVipKx830VteIfCmo+G3Q3cYe3l5juI+UfvjPY+xrFrrvc4mraMKKKKBBRQAScAZNP8AJI6kZ9M0ANVGc4UU8xADkk+4HFPUhYkxyCctTlwoZi+7cMc/zNWl1YhMZQYPKjI9xTGfaxIH3hytMdvmG3gDgU3OetJy0sFhWbPHakooqRhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBPY3C2l9BPJEsyRSK5jbo4Bzg+x6V0Fh4msNCu7m90SyuYrqeN4kE84ZIQ3UgBQWI7Z/WuYoqZRUtwOnl8U2V34b0fTbqwm83S5GKTRTBQys24gqVPPA5q2/jizk8enxI+lM4kUiS3eUNg7NoZTt4Ixnkda42ip9lDt3/AB3A6/UPGdlqNro8EljdhdMneUM115jyhm3YZivXgc/Xit3R9ah1TU/Euvx2N3IlxEkcljBMGlJY8sF24ZQF6kHGa8zpySNGwZGZWHQg4NJ0Y2sv61uO56PqGp6ZompaL4jeLUzqCu+6wu7hS6oowh+78q8nAwK50+KbM6NrmnLZzhNTuFuFfzRmIqSQD8vIyfbiuZZ2dizEknqSc5pKFSit/wCuoXOh8V+JLbxK1lOtnJb3UFulvI3m7kcKMDAxkd+5qbR/E9jYeEr7Q7uxuJkvZllkljnCFduMAAqfSuYoqvZx5eXoFzrtH8Y2Og3TrY6ZL9huLZre5jkuP3smWzuDqowR0HFX/CN9b3Pis3lmuoOlnaSyeTLeb55zjG1MKAeuduOQD16VwVKrFSCpII5BFTKlF38wud54pTT73wqL2WPVLC8gmWG1tbyVSroclyiBV2gdzjrWP4b8T2eh6Nq1jPZzznU4vJd0mChF5wQCp55rnHkeVt0jMzerHJptNU1y8r2Fc6y48aQajoenWmq6ebu802QGC6aQDfECD5bjHzDjHX+ubmtePrPVtN1WxTTbmGK/kjlBN1u8or/Cq7cBfYVw9FL2MO39bjudheeMrG6utKlSyvYDp9l9jR47oK4AB2uCF4YE/Q1MfiH5uuaNf3lvcXQ0lW8tpJR5szE5y7bcYHQAD8a4min7KHYVzqofFVhDpmv2YsrkjV3VyxmXMW1iwH3eeSfwrb8Pa/Frmv6C0VtNFLotiybEuMNchFPyoMD5iT93OCK86oBIOQcEUpUYu/8AXSw7noPiMWGpeFbm8uIdW064tpFW0t7uRdkpY5fagVcYHJOPSuP0HUINJ1u0v7iKSZbaRZQiOFLMpyBkg8VQkleVt0jsxxjLHNNqo0+WLiK50Oo+KRN40/4SLT4Ggm88XHlysHAYHpkAcVZ1zxVp+rXpu0sr5JJZlllgkvS8PXLBV25GfrxXK0UKnFW020C52N/4+luNNWxQXdxCLqO5U304laIIchFOAcepNZXi3XLXxHrs2p21pLavcYaVHlD5bGOOBgcVh0URpxi7pBcKKKKsAoooHWgAxWp4Y48U6Wf+nqP/ANCFdj4Y8E+GtY0u1luNYY3MkZaZElVPJbPC4I5rdsvhpo+nahb3lrqk8zwyCRAGQjI55wOazlNK6NY0pNpnpNu29AasOFMLbgApGDWLHGqW4LX0pyMkZAI/Kqs0EM5wbmVl7hnY5rmTOtx5mU5fs17pcun30K3FoSU2t6A8EH1HrXkPjLwp/wAI9drJaM8thN9x2+8h/ut/Q969n+yxldqlio6YGAKztU0mDULaW0nj3RsMHcMc9se9EKkk/IdSlGa8zwXacZwcetJXot18NSkm6O7k8s8YZBx7Usfwp3gP/aDbDzxGP8a6nUjZO5yfV5nAR/JECOrHBPcD0pduSxYgjso716TB8KoGTLXlyMnoVXmp4/hVZqf3k0zj0yB/Kh4iCVhrDTZ5UzYb5Tj1xTCxbqc17TB8NtIjA325b6k1fi8CaJEBiwjP1FZvER7D+rPueD4pfLc9Fb8q+gk8KaVFjZZQD/gAqyuiWiDC28I/4AKn6x5D+r+Z85kEdRiivcfEPg611C0cpDGrgcYXFeN6rpsumXjwyKRg8GtYVFMynTcSlRRRWhmFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUAE9qK1dG1qPSPNL6Zp98ZAAPtkRcJj0wR/kU0AmieH7zXpriOzVSbeB7iTccfIvXHqfQVpXXgu5TQdP1GyE9212ZQ8Mdu26HyyAc4z3NTeC/ENppOoag17LNbxXlnLAJLdcmNmxg7QRwK39K8badp0PhsG9vCdPuZprsKhHmBzn1+Y+ufWt4xjYzbdzgLfSr27SR7a1mmWMZcxxlgv1x0qxovh68126lgslUvFC87bjgbVGT+PoK7O08Z6da6XBHbXRtL6xu554Z/sfmiUSHrjcNrAcc5GKxPBviK10fWrua+mnhiurWaAyQrkozjhsAjoaThFMabMBNHvpYZZY7S4aOL/WOI2IT6nHFPj0K/kjikFrMIpWVEkMZCEk4HPSu1j8aWSaHYpb3T2+o2UU0BZ7XzftCuT82S3yk5wc5ptz4x0yTS4EkUTXcItlhmihMMqLGQSrkHa4ABC4HvxVezhcnmZx2raFd6Lq0unXifv4n2Hbkhj7HvVjUfDcsGqNaab59+FjV9yWzoeQCflIyME4z3q74w1i11rxXc31neXElvPJvRpkKmLJ+6Bk8D2rp7rxvpU2t39ykyzWt5FbpJFd2hdX8tcHo2QcjIIOOealQjYbbPOFsrh7k26wyGcEqYwhLZHUY61NPo9/axJJcWlxFG52q0kTKGPoCRzXS6DeQX3xQsrnTo5YoJdSR40ZizBS/QnvW7qXi2HQdXvbSR59RB1dbuRZ1KiIRufkUMTyfXpgChU4hzM8+uNE1C1VDcWVxEJDhC8TLuPoMjk1e03wxPPqcdpqQuLBZFZg7WzueBx8oGTk8Z7V1x8a6bayXX2W7uZftmqpfiR4cm2CknoT8zZOOOMDrT7TxpokHiLTr4r9n8iOcXL2kLqkrOCBtjZuOuSe9VyQFzSOQHhS8GnWWoSLi0u5miRkUuw2kBiQB0549ah1Pw7cWl5dLapPc2sEhT7R9ndFP1BHynnoa6VPE9h/wjWj2Av7qKawvHdwqEpJGzAg9e2OnvVh/GmkyeIfEH2r7RPo2rAyFAu11kBDJxnjkYJ9DTlCAKUjiV0PUnuTbpY3JnC7jEIWLAeuMZxUEOn3VzcGCC3llmGf3aIWbjrwOa7fSPGlq+nahDqMpt7ye8S8iuRB5yhlGAhXIIA7elc8niSeHxeutiUyTrdC4L7Am/5sn5RwM+nvUOEV1KTZnLo980gQWk5YuYwojOSwGSuPUDtWzJ4MuW8PWuoWqz3E888kL2qW7FoigyScZ9R2ro5/HukbtTgtrSRbVJftelEgBo7g53Mx9DuJ/4CBUOjeMNP03StChN5dLLZ6kbu5WNDh0OOM55PHf1pqEbC5mcRb6Te3ZkFtazzGMZfy42bb9cdKfBoepXQU29jdShgSpjhZgQOuMCu9i8a6XHbyLb3LWlzBqUt9b3BtPMEgfsV3DDDpzkVHpvjexs7TQRJeXW+y1CS6ukSMgMjnOBzg4weOnNDpx6BzM4fSNFuta1a3060VftE77EDHAB9z2rXj8F3E2hXV7EZZLq3u1tTaJAxZiwJ3A9cYHpU2i+IbLSviDFq7PK1ot20rFFwxRie2ffpWmviiwttE1G1h1O8e5n1CO4jl8tlLRp2J3cHnp7UKEQbZxkWj38909tDZzyTpndEsbFlx6jGRVSSNonKSKVZTggjBBr0+88b6LeXuubJXhF7dRXdvcPbb9rIMbGXIPuCD1rz3XNRfVdZur2WXzZJpC7SbAm4+u0dPpUTiktCotsoUUUVkUFFFFABQKKUKWIAGSegHegD1Lw3rmgXmlQQt4Qmm8iNY5JIbdZVZwOSSecnrXX2Z0Cch4NBngVRja2nlCPyrkvh3aeJNLsD5wittMeTzRFPCWkZumVAwRnjr+Vegi6vbiLbHZkjOeY9v8AM1y1Gr6HbTvZNjVm0+P5YdMuIf8AaaDaPzqxbkzJmOBVUf36i+1ap0uJraKPoVK5anNLb/ZwJb1NoGTggcVDg3YvmsSm7jiIAVSe5UcClu7c3cIZVBK8gjuKpm9tLiMr9qhDD7sYb7o9TTobpIIjGlw9weyxLwPx6VppDVE6vQmht1vYCjgBhwT2PvT4dFaBNqyZycnNcbrXxGi8OXywT6bM24ZVllFVE+Ndh/Fp12Poymp5XJaLQHPldmz0RdPlH8Q/KpBZMB8zc1wMPxo0hj+8tr1Pfap/rWjb/Frw7NjfcyxH/bial7NroL2l+p1pszjrTfsZ/vGsm28feHbkgJq1tk9mfb/OtKHX9NnGYtQtnHtKv+NFkugczJfsY9SaYbcr0FWEvYJR8k0TfRgakEinoQaVkF2ZrxHkEGvPPiD4ZFxbtcwp8y88CvVd4PXFZ2sRWz2MvnvGo2nlmAqouzuTLVHzA6lGKsOQcGkrT8RLbprM4tXV0DdV5FZlda1OQKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoooFAChSelL5Z9K7zwECfDXiUxvbRSxQQvFLOFxG3mYzkg4z0rTXWtJu9UkvxqNva3trZwRu4QRreShv3jA7TgYx0ALfSt1TTVyHPU89tNIku7G7uVmt0W1VWZJJQrvk4+Rf4j61TKEV6bqWoaPJL4w+y3WniO78trEDA3HcC23jjgH0q5Lr+lNI1q99pptJtC8mQBVAN2F4yQuc5PB6U3SVhc7PJNpJ6UvltjOOK63wfe2Fqmrx3E0VvfS2hSyuJPupJnn5v4SRwDXSyatod00givbODWk0yGNb91xG06tl8NjG4rgbsetJU13HzM8t8tvSjY1ejR6vD/ZUlzaanpsGtC7d7wyKAtzGVAUIduCoweBjk5rQ0DV9Gx4currUtPi+y288F3FLH85c52Ejbgj7vze1P2SXUXMzy6F57eUPA7xyDoyMVI/EU2eSa4kMk7vJIeSzsST+Jr0H+2ba18K6RaRXWmtP9okS9VkVz5RddoJxkrwc4OcVT8danpmo2ttJayBbrz5DJbxzieJFIGCjYBUEjhO3tSdO3UFJnDiMnoOlXdK0mTVb1baOa3gZgTvuJRGgwM8k/Su50nxXpNvoGi3N+sdzf2E727WzLxJC2P3jepCllHufaptO1fR7TxrbW0V/byaJYwyRpNcKMSblYg8jJIYqB/u01TiDkzhrfw9e3AtHEYjhvJTDDNIdqM4IBGfxFQ6vpM2japc2FyUM1tIY32HIyOuK7uDV7V/Cug2f9o2SPaX7m5jYgMELqQwOOmAeQal8Va9YarpXiSE31lO51BJ7DAUMYzncVIHXpkHmnOnFbCUmcNa+Hrm60G71aN4vs9q6RyKWO/LnC4GP69qzDG2eldnoN7Yw+BtWtbm5hEs91byLAXw8iITux+B4roNV1zSBfRLZPo82lyXcM8CysxMCqOUKbfkXs3XPXml7NMfM0eV+W2OlOjheWRY41LOxCgDufSvUJNc0X+1Le6QwyS/Zp1lt570MsRZhjy5wvDYyRnOBxxmuY1m+05PG0V3Y3LzWyPCzSSYcggLuGcANjHXHPWl7NIFJmfH4R1FotUaQRwyaWm+5ikbDqMgcDvyaxTGw7cV6ve6/af2v4ruotX09zdQbbFl2/N84YD7vLADqe+Oaiu9S0i71ganFq9pBcrpcJymE82cffBO07T9Bz0qvZxYczPLdjelNII616te6zpKan4quLC805VuYI2svlXmUbSxUEcHg/jXKfEC9s9S1S0u7Ka3lMllCJ2iwP3oXD7hjrmolTSVxqTZydFFFYlhRRSqpZgqgkngADrQAlABJwOtdVofgDUtUZZLlfskB5y4+Yj2H+NekaH4I0rR1VktxLMP+WkvzH/61ZTqxibww8pavQ8y0PwLqusMjtGba3bnzJByR7CvVPDfgTS9CVJREJbgDmWUZb8PSt6MJEPlUDFNkvMJuQFucZwcCsHOdTRHVGlCBblEXlYc7QDkMDgg1RuHeCEMk0zIOm6TqP8Kbd3cU1rvJCkep6H0rMN6xhUXKuoP+riHDSL7n+Fffqe1L4Fcbs9COQpfQOsaLhf8AXSyNhUJ7lj/IVUtLKGPcoj+0KTwT8in3/vEflWRq3ivTNJJWV1nnQ/Lbw/dj9vQfXrXG6l461e/JWGUWkXQLD1/7661XJOd+xLqxj8X3I9ZjNpYRlrhrW3j6lABGp+vc/iTWZq3xF0axiaO3nEzDjbCM/r0rza28I+Itb0S51uO2nntIBuMjsS0g7lQeWx3xXOng1UcMlq2ZPFdIxsafiDWpNd1FrmRQigbUTOcD/GsyiiuhKysjllJyd2FFFFMQUUUUASJczR/6uWRf91iKsJrGoxj5L66X6St/jVOiiw7svf25qhH/ACEbv/v83+NQTX11cf6+5mk/35CagopWQXYUUUUxBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFAoA09O1nUbK0uLOylKw3YCyxhFbzAOgOQTVP7NcOzhY5CU5cBSdv19K7nwXBYweEdS1CRbk3Ru4bUva486KJs5Kk/dyeCevGO9dTHpx0K80a0024knA1+SK6lU8y8LgSY64UtweOtdChdbmblY8Y+YHGale2uI4VlkikWJ+FdlIDfQ966vTPD9p4h8c31nCxFsHuJY0hxmRUyVRfrwK6r+xYte0PwhpdxDcadDNdXSlZGLMuADhdw4zjAFL2XdhzHkmTRk+9ei2vhbQr3VbS1VLuKfyrgz2+2QKZEGUAdlBAP8Rxxj3qWz8J6Dea1aWJtr5Geye4uNkuVjkVSdiEr8w4HOe+KPZMOdHmuT6mjcfU16Jp3hrw/daVHrMsN2LGW7+zPCrs7wKEBLZRTlic4BAHaiHwjoVtpFne3sl1LBeifEscb7oWQkINqgjPALBiOvHSj2THzo87yfU0cmu61LwrpieFZL2wkWS5t4IZLlZZGSWNnIz8hG0qcjGDnvUWh+HdOfwxBqt1BLeyTaktkYY5CvlKRndwMlj27VPs29A5kchb2lzdOUtoZJWClisaliAOpwO1IltPJG7xxyMiDLMqkhR7ntXpupWNp4Y8Ka9Fp/2kvBqwthdRS7GK+WSASByoJ5Hc+lY/gZ1Gg+KhMkklsLBS8aPt3fvB35x9cVXs0HMcTHDLISI1diASdoJwB1NMOc8mvVLfw9Z6f4kmj05763iuNDa8ASX5lym4oTj5lOB6VR0zwtoc1l4clubO9kOrPJHM6ThVh2sF3D5ew5we2abou10LnR5yMk4FWptLvrdXM1rcRhAGbfGwwD0JyOM11ngKxs/wDhZNrb7ftkCTyCJsDDbQ21yOfQH64rTtLmTUPBnitmkuTGZLRf9IlMhUeYep4ojSv1BzPNssKVFeRwqAsxOAAMk16Hr3hbQtCkuLSRLye5heExNGGxdI2N2Tt2rnPylc+lWpfCVjo3iHRZdPF81ve3ieXcLIA9qcgGI4BHmKckk+mPWkqTfUOdHmTK6MVYEMDgg8EU3J9TXpF14bsPLvtSvIrm/lfW2sWj80hkXJ+diBkse3aluvCGhaZHrEssd1eLYalHaJsnCB0Ycg/KeR04/Sm6T7hzo823HuTSE5rqPGPhZtG13VYrCC4fT7KZYzMykhNwBAZvXmuXrGSa3LTuFGK0dH0G/wBcn8qxgLAfekPCr9TXpvh3wHY6QVmuMXd0OdzD5UPsP6msp1Iw3N6dGU/Q4fQvA+oauqzTD7LbHkM4+Zh7L/WvSNB8H2GkqDBAGl7yyDLH/D8K6GG1GQTVgRksI4+DjJb+6K5ZVJT0OyNOFPbcgWNIsKAWf0UZNOzKoLNCdo64YHFWIYgyHy2KJnGQMlvcmoIpltTLE53NnIA7mmoIHO4lz+8tQ0WSp5NRSX4dBFDEzysNqoBkUhudkAUSLDCoJeZuQD6KP4j9K5vW9cgghkcySQ2+MMXb55PqR0H+yKd18KJvfYnuL6LT5pnaWOZo+rtgxQn+TMPyHvXnniLxncXsssVjM6xuf3kx+/Kfr2FZeueIZtWfy0/dWqn5Yxxn3NZPluULhW2AgFscA+mfwraNNX5pbnPOr9mP3ixRSXM6xQo0krnCqoyzE9gO5r2DwX8IoLKD+1/GTJHHGvmC0dwFQesrf+y/n6VnfDPxJ4Q8NaJdahfxsNahOMsN7SKegi7L6H+eK5nxr8Q9U8Y3BSVvs+nq2Y7VDx7Fj/Ef09K1Oc6/xz8YS8b6V4T/AHFso2G7C7SR0xGP4R79fTFeSEljk8k0UUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAWbTUbuwcvaXM0DEYLRSFSR6cU6HVb23SVILueJZf9YEkZQ/1weaqUVSk1oKyJobqa3mWWCV45EOVdGKlT7EdKsS61qEwxNeXEg3+Z88rH5v73J6+9UaKFNoLI6LSfF93Z38lzey3N1I8DQrKbhhLDu/iRjnB/xNS6t441C/srS0hurxY7Yuyyy3DPK5bGctxwMDArmKKr2khcqLtvrOoWjSNa3txCZf8AWGOVl3/XB5oh1m/t4JIIby4jhl5kjSVlV/qAcGqVFTzy7jsi5Nqt7cW6QTXU8kKY2xtISq46YGaS11S9sd/2S6ng38N5UhXd9cVUoo5mFkW/7VvfsrWwu5xA2cxCRtpz1yM4pLbUru0jeO2uZokk++schUN9QOtVaKOZ7hZGjHr2pxspW/uhtXYMTMML6dentWtqHi97vwvYaRAlxALUOHcXB2z7zuO5QB0PSuYop+0lawuVFi2vrmzl8y1uJYZMY3RuVOPqKl/tm/2SJ9suNkpJkXzWw59SM8/jVKikptbDsi//AG5qXlRRfb7ry4SDGnnNhCOmBnimw6xf26BYby4jUP5gVJWADdN3B6+9UqKOeXcLIvx65qUU0ksd9cpJL/rHWZgX+pzzTE1a+jgaBLqdYWO5oxIQpPqRnGabY6Xe6lJssraWdv8AYXOPxrqLD4Z6tOA168Vop7E7m/If40nVtuy40nLZHNS6nqF4GilurmbziNytIzbyOmRnnHaus8N/Dya72XOr5hhPIhH32+voP1rq9E8K6XoIDxp5tyP+W0nJ/Adq6OB0fowOOtc1Su3sddPDKOsxllYwWdukFrEkMSjAVBgVeSEKMnoKRJYw4Rfmc8AU6bzYdrSMHQkHA6fSso03J6m0qltEPjuIw4QhgD/ERxUsjrbXJaThJF27vSmXUkc0S7Wyx+4MZJ9sU0CTYIpScgfcABY/Xsv4803KEPXsZNtkXntC3lxTRsGOVVeW/KqzMOSiCRu5P3B9T1Y+3Sr/ANlRUYbEjU8lE/i/3m6n+VZGsapBpts8s7rHEg5JpOTk+w1Fv4tjJ1y8FrA89zLnYMlm7fQdvwryfWtXl1a7LkkRLwi/1+tW/EviWbXbohdyWqn5E9fc133w48BaGdFXxR4hvbae2TLCEt+7hI/56Z6t/s/zropw5VdmFatze7HYwPAnwt1DxW8d5fb7PSuvmkfPN7ID2/2jx9a6/wAdeI/Cnhjw1P4T0mwt7uRl2uin5YW/vs/UuPr9cdKxvHfxfn1JZNM8NF7Sxxsa4A2ySD0X+4v6/SvLScnJ61qc4UUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUV03h3wFq3iLbJHH9ntT/y3mGAfoOpr0/Qfhxo+ihZZI/tdyP8AlpKOAfZegqJTSNI03I8h0zwtq+rANaWUhQ/xsNq/ma7HRPhylqVl1cedIOkSn5R9fWvUv3cSgKgAHoKhkuOoVRWE6rex1U6MYu71Me3eDTYAlvbhFHRVXAqF7i5uX4BArY+zPO3zClkgjgKLkLu6tjoKyUZSeh0Oooox0s5mPzU7yns5l+TER6kdT71o3MdvABK26NR0ycsx9hSXihoFN/L9kRuVTG6Zvovb6mrfJDd7mbqXK04wyPGSZCeAvJb6VqBJJIwlz8jEAmJMM/49l/Gq1o6qgSzjNtHjBctulf6t2+gq7HsiTCgDuayc5S02/MnlbfYfFCI1IRREp6hDlj9W6/lipVVUXCKFUdqy9S8RafpURku7iOMD1br+Fec+IvipLch4NHjMaHjznHP4CrhTb2QnKMNzuPE3i3T9Agbz5d0xHyxJyxrzS2tfEPxN1nyrSLFuh+ZjkRQj1Y9z+ta3gn4Yaj4wmTVtcmlg0+Q7gSf3twP9n0Hv+VdX4o+JGjeCLD+wvCMFvJcRAqWTmKE9yT/G3+Se1dUKaictSq5aGd4r8EeD/B3gp7bULl21eUb4Z15ldx2CZwE7HP55ryAXMwtmtxLIIGYOY9x2lh3x0zUuo6ld6tfSXl/cSXFxIctJIck/4D2qtWhkFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUVJBby3MqxQRtJIxwFUZJrv8Aw18NHnC3GsFlXqIFPP4mplJR3LhCU9jjdI0HUNbnEdjAzjOGc8Kv1Neq+Fvhrp2lhLjUQLy6HOGH7tPoO/1NdRY6bb2ECxW8KRxqOFUYq3uwOKwlUbOqFBR82WFKRqFUAAcACmvLxxUIyetMd9uBglmOAo71mrvQ05UtxT87Y7VDH5iTskiDJOF9jT98sEo3hCOpUc/5NWb0RvbiVSOOmOp9vrWsYJfERKXYiuLZ4Y/NEhJXk9sVXkkXULdZMiKNeDM3TPoo/iqxK5jRVuwJJgP9QD8q+7nufasPU9XEOXkcM6jAPQKPQDsKylVctIaeYoRcnoSXF7Dpy7rcMJO00pDSfgOi/wA6wzfx+Y1xdShV6l5G6/UmuP17xlvmdLTDuON5+6Pp61yVze3F5IXuJWkb3PT8KuNG+rG60KWkVdnqV58RNKsAVt2e5cdoxx+ZrltV+JWq3wKWgW0jPdfmb8zXH5rofCXgjVfGN55dhFst0IEtzIMRx/4n2FbRpRRzyrzkZcMWoa7qKQxLPeXczYVRlmY13mq/B+40XwVNq19qMEV/F87W7MBGF/u7u7/p2967hm8K/B3SSFH2nVJV6cGab6/3E/zya8d8WeM9V8YX3nahLiFCfKtk4jiHsO59zzWhiNtvGuu2Xh19Dtr+SOydiSq/eAPVQ3UKfQVhUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFafhzRZPEGu2unx7wsrjzHUZ8tP4m/AVqeO/CsHhXVooLSeSa3lj3q0mNwPccUrq9h8rtc5iiiimIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoooxQAUUYooAKKKKACiirmnaVd6rciGzhaRu57D6mjYaTbsimK6DQPB1/rjK4Qw256yMOv0Fdj4e+H1tZlZtQxcTjnb/Av4d67y2gSBAqqAB0ArnlX6ROuGGtrMyfD3hOx0KAC3jBlI+aVuWaugRQoAFCjPSlfdHEzKMkVkryZvpFaDwpNKFAqKG4adAqACTHzE9BTHM9vMhd96McdKvkexHNcaZjPMYY8pn+LvVtomSHMa7pAMA96ZNZmSZXjIRgeT/WrJkESksRx1NDaVrBq9yHbttx56BEHVQcs5qvNOLQkKFFwB06iEf1alu7026CXj7RIP3KEf6tf759/SuY1LVFgiYKxJ6lieSfU1zubqu3T8wp0+Z36FnUtWS2gfD47lievua8p8R+JZNSneG3ciDOC3d/8A61J4j8RS38rQQufJzhiP4v8A61c8Tmu2nTtqzKtW+xDYKMGremaVeazfx2enW73FzIcLGgyfqfQe5r2vw18PNE8A6f8A254subeS6jAYb+Y4W9FH8b/5A71qch5Jf+Ddc0zQYNYvLCWKzmbarMPmX0LDqAe2a6rSfi9faL4Lj0ezs4UvYvkjuQAFVPUr3f3/ABOaj8ffFW88UiXT9OVrTSicEH/WTj/a9B7D8c159QBNeXtzqF3JdXk8k9xKdzySNlmP1qGiigAooooAKKKKACiiigAooooAKKKKACiiigAooqxYWU+o30FpaoZJpnCIo7k0AelfBfSJHub7VHXEKqIUPctkMf5CsL4pakL3xQYU6W67T9TzXsGiaTB4b8P29jBjES4Zh/Gx6n8TXi3xJUDxbKwH341J/WsU7zOlx5aRydFFFbHMFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBreH7ZLm8CyIrj0IzXpll4O0i6hBl06InHUAj+Vee+EF3amo969z0qFVtlOOcVz1G76HXQtbVHJP8ADbQ5Ofsjr/uyMKpz/C/SGH7trmM/7+f516RgelRSxqRyOajmkuptyQe6PKbj4VR4PkX7g9t6A/yrLn+GWpRn93c27/XIr12VcGqkmc9qXtpIf1aEjznTfh0kbBtRnMp/55x8L+J612umaVBYwrFbQpEg7KKt+Xls1ZjAVSW4A71nKcpvU2jThSXukkUW0DFWUjyKjhXzY8qSpI4JHIp1nIY3MEnXPGauNO6uZSmTlhGdiKXfGcD+tNimdpCjxYx1IOQPrUZjlS5c7WZXPO3jIqwUC7XmAjRfuxjnJrXlSRlzPqRfZZYrgNAOG/IfWrBjzIGkfeR0GMAVX+3sZxGFyx/hHOKnY468VnObKpx5thzybQeaqSTxxwm7uhmFTiOP/ns/+Ap5KSK8kzbLWP757sf7o965nXNXa5mLkBVUbUQdEX0rklJyfKjpVHm0XzGajqjM8ksr7pZDlj/Qe1efeKdZmmJt7cNsP33A/TNddp2lza07SyMUtVOM93PoK3hoFvsCiFCBwBitoSUHsVUgnHki7HgxHrTzbzLAkzROInJCSFTtYjqAe+M19Gad8PrCcrNqVrEIhyIyoy319BU/iS20rU9JTR0sLd7SIjZhMLGR/cx0+tdntPd5pKx5Tpe9yxdzj/D/AI48HeC/BUU+kW7SapOu2WBv9azjrvfsnpj8utcpf2Piz4l2Muvhlu44ZWiW0jbb5QAB+RTwevrk10s/w30aX7sLxn/Yc11/gvTrTwxpf9nQtIVknaTc3OMgD+lc+IxThT5qauynh5Lc+dLi2mtJmhuYpIZUOGSRSrD8DUVe/eO/A0fiLUYr67vbnylXYsSbcIfbjPPvXMD4WaR3ub3/AL6X/Cro4qFWCkSqMmro8oor0+4+Etsyk2upyqfSSIH9Risyb4UXyH93qFsw9SrCtvax7i9jPscHRXbP8L7+MZe/swPU7v8ACmD4a3rjKahZuPYt/hVc8d7h7GfY4yiuxb4aamPu3NqfxI/pUZ+G+rdpLU/8DP8AhS9pDuHsanY5Kiuqb4d6yvT7OfpIf8KrSeBtaj/5Yxt/uuKfPHuL2M+xz1FbZ8H6yP8AlzJ+jCoW8Maun3rGT9KOaPcXs59jKoq8+i6ghwbOb/vmmHSb8f8ALnP/AN8GnzIXJLsVKKuro2oscCyuD/wA1btvCes3UgVLCVc93+UfrRzIOSXYyURpHVUUszHAAGST6V7j8NPAq6BbjUtSQHUJVwEP/LBT2/3j3/Ks/wAB+BLfRZ1vtRZZ70D5AB8kXuPU+9ekAfIAOKhyT2NY02tWRXx3KWbAReRXz547uxeeKbhwchQFFe4a9P8AZbOWSRjt2nivnnVp/tOq3Mp/ic1nT1mzWrpSSKVFFFdBxhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAdD4P/wCQov1r3nSkDWy/SvBvB/8AyFF+te8aS3+jp9K56m500djR8nioZYsCrCnI60j8ipaRom7mTOmM8VSZTmtW4Xgk8AVkyXEDBlcPs6FgvArHluzpVRRWo5VUrvyNvr2qWKWEsFDde5HFVrcrHKFdt0XUEcjPrVxliunRIiC2fmYdhWqppPUmU21oIyva3PmHJRuufSrktok5RlbafX1FLPcQwACTkjkLWbPqVy7hoVCITy7dAPb1P6VXM3qjGTsa8kqwIN2SegHdqzXknvbgpDgtj5mz8qCo4VuNRmAiLbTwzt6VqxQRwwiOIYjH/j3uam9gUXJkMEEdqhEXLH70p6n6egpgBnLkv5cMYzJIe3sPepm/e7vnEcUf35D29h71kalfqYwiAxwJyidyfU+9cdSo2+WJ20oX92JW1jUhIqqi+XBGMRp/U+9c/aWUmuXpjUlbdOZZB/Ie5qK8nn1G9W2tuXc9eyj1Nd14f0BvsaQQDZCv35SOWPc+5qoQtpE2qzjSjboRRRRwRJFCoSNBtVR2FdFYWtpZWy3csiyMRkH09gPWodRtLK2hSKLPnL3HJP1qgFwAOcCtV+7lrqcMn7aOmiL17qLXY2LlIv7vr9ap+Wp7UdDSM3pSc3J3ZUYKKshDEvYUhjA64ppLZpuGJ70rjsa8JF9YNG3LAbSffsa52QlWI6EcGtvR8iSUHpgGsvWU8uWRYiqtJJt3scKmT1PsK5MPG1aVNGUWoOXYpRtdXS3MlsitDbKWld32jgZOPX/69VXvh9je73RxWqEI00pON55CgAEk459qtaTYXJPiAi4sTCbH7PbKl2rhF+b5nx93JOST6+1UoVVfA1gJTGfL1GVJSrBlLYYDB7jpzX0McJTVr6nG8VN7EkyPFdSx3IiEkli72cud0TOw+VgTx69ehqTSrWSeHTvNUG5S2K3bgDDPu+XJHBYDqRV+1XzovDikZIsmLf7uVx/KtwQKowoA+lZV5qnH2aRVNOUudsyv7PA6gU02e09BWqYjTHjB7VwWOxTMz7Lx2qNrIelXpEK9KgMjp70h3K/2If3aY2nIx5UVaFzmnrJu6mmh3ZSXTYf7i1MmmRdlXFWhsPcCnfIB98VSE5MiTS4P4go/Cp0srdeMD8qgkcDpJ+tV3mlX7jU+ZLoTZy6mlJDFbrvUg+2KX7SGIKmsWS4uX6nIHapY7kqRnij2iH7J21DxJGLiyOTxt6V8+anH5WpXCekhr6CvpPOtJc9NuK8I8Sw+TrU2OjYatKLvJmeIj+6T7MyaKKK6TgCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA3PCsjR6mpVC3PQda9v0i/geFULbHx0cYNeI+FP+Qkv1r3DTFEtmqyKrrjowzWFXc6aOxsJIMdacZMjFZCwbpillI8B6/Nyv5VWkuZdPuVM4K5OAxOVb2zSUOjNbov3zko3mZEfRUU8uaw0uJLS5BC7geqjnAPaugeCO7KOxYDHSpTp9jEn+oHPJJc80uay0M5xuznLmGC4G5UKnqdpwD+VQ5lUgFyQtbkwss7UiYH2eqFzYsAX5VfVuKwdZo66OHT3GxbDAs0pLM/OOo6kVYtoXu3ywwvvUdlpF6oDxLFNGWLBPNCsM+ntWdrM1+92ti9s0APIiRt7P+XapnVaV2dlPCwlPki0dDa3kURkhgmXYDgsOc/SpzOjw72Yx2443d39lH9a5yCFdMI+2YkuOotkbhf8AfP8ASrX2qSdvNnbc3QAcBR6AVzKvKppHbuVLCpv3Nu/+RZu7syAAjZEn3Ix29z6muX1bUCzeWnLMcADvWv5N1qdwLayiMkh69go9Sewo1fwsPDot7uW6Sd3+VlPGG/2R3FbwpWjdLQU6kKVqaepr+FPBi2Nv9r1TAkcbmQnoPc+ntW1d62mDDY4VBxvAx+VcZJ4inktY7eSdjCnRf8fWo49YUnrW3tElaJwOjKUuao7nTqwJyTknvTs1gpqyAcsKbJriKPvCszSxvnHrQCg6muUl8SxJnMgH41n3Hi+Fc4kAHqTQlfYLeZ3fmxf3hTWuoV7ivL7vx/BGCEcsfbmr3h6fXfFkaT6ZBH9l+0eRLLI+DFwCW29xg/nVSXLHmlojOU4LqepaUyyRPKPuk4B+nWsuWdLqaQkDazHr3rN8feLIvBXh2K1strXs42Qo3OFH3nP8vqfavLR8T9WIw8FsSO4BH9a5sJRnUcq3fYwjVipNs9Yi0s2/2lbX7LHHdJ5c+6AMZV54Jz7mgaHGlhJZxtE1rKQz28ibk3DoRzkH6GvMrb4rXycT2iOPZsVsWXxXszgXNvLGfUc16XtcREShQlsej2Vr9nk82RxJLtEYIAUIo6Ko7AVpKwNcBB8TdDcDNwy/7ykVcHxI0ALk36fTmsW5yd5F2jFWR2jMAKgLZNcVcfFTQoxxOz+yqTWRd/F+xTP2a1nk+uFp8kn0EpRXU9JdRjmsy8mjhzlgPxryy++LeozKVtbWOLPdm3GuWv8AxVq+osTcXsmD/Ch2j9KpUpPcXt4I9kl1e2R8+ao+pqtL4t063GHvYR/wMV4g88shy8jsf9piaZmrVBLqJ4rsj2G4+Imjw5/0kufSNSay7n4qWo/497SeT3Zgv+NeZUVfsombxE+h29x8T792Pk2kCD/aJb/CoU+J2sIwPlWpHptP+NcdRT9nHsT7afc9IsPixkhdQsOP70LZ/Q/411el+L9F1bAt7lBJ/wA85Dsb8j1/CvDKAcVEqEXsaRxM1vqfQN3qFuYGDSoi455FeMeKruG71lzbsGRBt3DoayDNIV2mRyPTcaZRTo8jvcdbE88eVKwUUUVscoUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAG/4S/wCQkv1r3fSEH2RPXFeFeD8f2omfWve9IjBtUKkEYrnqrU6KL0JJLVmmWSIgHPJPapbqziuoSjqCCKnEZHSmuCvU8VDk2rM0Wjujngl5p0pRN08PYZ+Zakkv1df3qyxn/aQ1oyAF6Uwqw6UuW6L57bmAZIWlyky5/wB7FRahPPcGBfMMkUTbsE8GtubTIZgd8Y/Ks+fQUyTESPoawqULpo7qGKpq3MUWubQ9dLj3dyZCP5UHU59myDZbL0/dL82P9480sml3MQ+Ukj3FVGSWI/PEfqK5Pqqj/TPQhKhJdyVXZ/vdPpitnSdCuNUIc5itu7kct/u/41jQXEMc0TzYEYcFwR2zzXTTfE/wjErRPqJCgbSFgkxj04FduHpKWsjlx2JnTSjSW/XsRa34s0vwfbmx01EmvP4lByFPq57n2/lXmOp+JJ9Qumubycyyt3Pb2A7Cuyk8U/CxyfMSBj1ObSU/0qI+IfhMx5gtj/25y/4V1ypuWlzx4V4Q1SbfdnAtreOC1Qv4hK9DisW1urT/AISWGS4OdOF2C6kHHlb+Rjrjb2r1v+2vhF/z62v/AIBy/wCFJUEEsXJ7HnEnillHDkn2qhN4luZPuk16t/bXwi/59bX/AMA5f8KP7b+EX/Pra/8AgHL/AIVapRRm8RN9TxqbU7mU5aU/hVZ5Xc/OxP1NbGgTaTF4wtpdVVG0oXBMqshYbOccDn0r1b+2vhF/z62v/gHL/hVpJbGLk3ueH5r1HwB4+0bwh4OeG686a9kuXk8mFO2FAyx4HT3rf/tr4Rf8+tr/AOAcv+FQ3ms/CdrGcW9tbecY2Ef+iSj5scdvWs61GNaPJPYE7HnHjXxVH4u1j7etgtowUIT5pcuB0zngfgK5yuj8C3Gh23iaOTxMiPpwjcMHjZxuxxwOetem/wBtfCL/AJ9bX/wDl/wq4xUIqMdkI8PozXuH9tfCL/n1tf8AwDl/wrM8Sat8MpvDl/Ho9vbrqDQkW5W1kUh+3JGBVAeRUZrpfAlzoNt4kWTxOiPp/lOCHjZxu4xwOa9L/tr4Rf8APra/+Acv+FAHh9Fe4f218Iv+fW1/8A5f8KyvE+q/DObw3fx6Lb266g0REBW1kUhvqRgUAeSUV13w7u/DNpq1y3i2ON7UwYiDxM+H3DsvtmvQv7a+EX/Pra/+Acv+FAHh9Fe4f218Iv8An1tf/AOX/CsHxrqfw7uPC1zH4bggTUiyeWVt5EONw3ckY6ZoA8torvPhxfeDbO2vx4viikkZ08jfC8mBg7vujjtXaf238Iv+fW1/8A5f8KAPD6K9w/tr4Rf8+tr/AOAcv+Fcp8QtQ8DXeiQJ4ThhS8E4MhSB0Ozac8sPXFAHnVFd78Ob/wAGWdnfDxdFDJK0imDfA8mFwc/dHHauz/tv4Rf8+tr/AOAcv+FAHh9Fe4f218Iv+fW1/wDAOX/CuT+IeoeB7vR7ZPCUMMd2J8ylIHQ7Np7sPXFAHndFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAaGjXX2S9V84wa9g8O+JklhRBKA3oTXh9SxXc8JBjldSPQ1lUpuWzNadRR0aPpeDUWkAyD9asszOMrzXz1p/jXV7ArtuC6js1dtonxiiiKpqlnIB0LxEH9DWHs6i6GvPB6pnozS7XwwqRLlelVtL1/R/Edv5um3cMxA5jzh1+qnmiZMMcYBHY8Uaopcsi6JgeDSHY1ZnmMD6U9JmHUmhTG6ZeMQPQVBNaiQcKKEuPc/lUwuBjkU7p7iSlHYyp9EEqn5RXM6t4Hhu92YQSe6jBrvhcIRyKVXjJ5wanl6pm3t52szw7U/h7dQEtasSP7r/wCNcxd6Re2LEXFtInvjIr6aZLd+GUH8Kry6ZYTAh4Yz9RWiqSW+phKFOXSx8wkYPNGK+jLjwpo0wPmWcRH+6KrDwdoiMDFbQA/7gqnWt0IVC/U+fMUYr6MPhrTSm1raAj3QVmX3gfQJ0YyWkAbH8A2n9KX1hdUP6v2Z4NRXqs/wu0ydybee4hB6YIYD86yNT+E2pW8Zk06ZbxQMlSu1quNaEiZYecTgaMV3Phnwna3yoLuMysx/1anDE9/oKyPGPhtPDmoiEXMLPISxt0JLQL/CCT14NVGak7IVSjKmk2c7RRRVmIUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFACpI8bho2ZWHQqcEVtWnjPX7JQseqXDIP4ZW3j9c1iUUNXGnbY6+D4k6tHjzkglx3wVP6Vp2/xXmU/vrIH/df/GvPaKj2cexftp9z1CP4t238djMPoRViP4r6cfv29wv4A/1ryeip9lEpV5I9fX4qaP3W4H/bOrCfFHQj96SZf+2Rrxiil7GI/byPa/8AhaOgg/62Q/8AbM1IvxS8P95JP++DXiFFHsYi9u+x7zH8SPDUvW82/wC8pFWo/Gfhq4IA1O2BP958fzr59ozR7Bdx+2fY+lIbvTLwA293BLnpslB/rT5NNRuVAP1r5oUlSCpII7itOz8RaxY4+y6neRgdhKcflUvD9mNYho9zk0LfcGZAI3xjKkqR+VMufs+n20i32utbqylWxIA2Pqa8ZuPGfiG7j2y6tdY6fK23+VYksskzl5ZHkY9WYkk0KhbqXLFX6HrGp+P9F8OWIt/DsMVxcbcKwHyJ7serH2ryu+vbjUr6a7u5WlnmYu7t1JNQGitoxUdjnnNzeoUUUVRAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB/9k=\\\" style=\\\"width:6in;height:2.79167in\\\" /></h2>\\r\\n<h2 id=\\\"section-1\\\"><img src=\\\"data:image/jpeg;base64,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\\\" style=\\\"width:3.82292in;height:3.46875in\\\" /></h2>\\r\\n<h2 id=\\\"management\\\">Management</h2>\\r\\n<h3 id=\\\"for-acute-lower-back-pain\\\">For acute lower back pain</h3>\\r\\n<p>Explanation and reassurance.</p>\\r\\n<p>Back education:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Lie down on side with pillow in between thigh, avoid lying down on the back.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Do not slouch when sitting on chairs.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Sit up straight with back abutting on the chair back.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Place on foot on a small stool/platform if prolonged sitting for 2 hours or more warranted.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Walk around for 15 minutes after every two hours of sitting down.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Encouragement of normal daily activities according to degree of comfort.</p>\\r\\n<p>Prescribe simple exercises (provided no aggravation of pain).</p>\\r\\n<p>Regular non-opioid analgesics (e.g. paracetamol).</p>\\r\\n<p>Consider physiotherapy based on your assessment of the severity.</p>\\r\\n<p>If very severe, review in about 5 days – one week (probably best time for physiotherapy).</p>\\r\\n<p><strong>No investigation is needed initially!!</strong></p>\\r\\n<h3 id=\\\"for-sub-acute-lower-back-pain\\\">For sub-acute lower back pain</h3>\\r\\n<p>If severe or any diagnostic pointer (as listed above) present:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Plain x- rays of the affected part. Review this with the most experienced clinician around after going through it yourself.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>ESR, PSA (for staff or where they can afford it) in males older than 50 years.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Blood culture if pyogenic infection suspected.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>For longstanding disorders especially mechanical disorders e.g. CT scan, MRI.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"for-chronic-lower-back-pain\\\">For chronic lower back pain</h3>\\r\\n<p>Investigate as under sub-acute lower back pain.</p>\\r\\n<p>Back education (as highlighted above) and ongoing support</p>\\r\\n<p>Encouragement of normal activity</p>\\r\\n<p>Prescription of simple exercise as the client’s body permits.</p>\\r\\n<p>Analgesics (e.g. P.O. Paracetamol 500 mg - 1 g up to QDS for 4 days).</p>\\r\\n<p>NSAIDs for 14–21 days (especially if inflammation is suspected).</p>\\r\\n<p>Graded physiotherapy with trial of mobilisation (at least three treatments) – if no contraindications.</p>\\r\\n<p>Consider amitriptyline 10-25 mg (nocte) increasing to maximum 75–100 mg</p>\\r\\n<p>Refer appropriately based on what you find while investigating.</p>\\r\\n<p>A multidisciplinary team approach is recommended – Primary care physician, physiotherapist and the orthopaedic surgeon.</p>\\r\\n<h3 id=\\\"follow-up\\\">Follow up</h3>\\r\\n<p>Patients should be informed that an ongoing back care program should give them an excellent outlook.</p>\\r\\n<h3 id=\\\"prevention\\\">Prevention</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Education about back care.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Golden rules to live by: how to lift, sit, and bend.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>An exercise program: a tailor-made program for the patient.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"when-to-refer-to-a-specialist-orthopaedic-neurosurgeon-or-spine-specialist\\\">When to refer to a specialist – orthopaedic, neurosurgeon or spine specialist </h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Myelopathy, especially acute cauda equina compression syndrome.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Severe radiculopathy with progressive neurologic deficit.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Spinal fractures.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<p>Murtagh JM <em>General Practice</em> . 2015. McGraw Hill, Australia Pgs. 401-421</p>\\r\\n<p>Royal College of General Practitioners et al. <em>Clinical Guidelines for the Management of Acute Low Back Pain.</em> London: RCGP, 1996.</p>\\r\\n<p>Sloane P, Slatt M, Baker R. <em>Essentials of Family Medicine.</em> Baltimore: Williams &amp; Wilkins, 1988: 228–35.</p>\\r\\n<p>Kenna C, Murtagh J. <em>Back Pain and Spinal Manipulation</em> (2<sup>nd</sup> edn). Oxford: Butterworth Heinemann, 1997: 70–164</p>\\r\\n<p>American Chronic Pain association-Guidelines on management of Low back pain.</p>\\r\\n<p>American Physical Therapy Low back pain clinical guidelines on the International classification of functioning disability and health</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Babatunde Awokola</th>\\r\\n<th>Date: 13 May 2018</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Fatai Akemokwe</td>\\r\\n<td>Date: 4 July 2018</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>2.0</td>\\r\\n<td>Rewritten and updated</td>\\r\\n<td>31 July 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>2.1</td>\\r\\n<td>Executive summary added</td>\\r\\n<td>31 July 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"011\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>LRI MeG-CLS-011</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"lower-respiratory-tract-infection\\\">Lower respiratory tract infection</h1>\\r\\n<h2 id=\\\"executive-summary\\\"><em>Executive summary</em></h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<p>Pneumonia or lower respiratory tract infection (LRI) is a common condition in both adults and children. It may be viral in origin, but the risks of not treating bacterial infection are high in this setting, so it is more usual to treat it as bacterial infection.</p>\\r\\n<h2 id=\\\"target-users\\\">Target users</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doctors</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nurses</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"target-area-of-use\\\">Target area of use </h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Gate clinic</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Outpatient department</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ward</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"key-areas-of-focus-new-additions-changes\\\">Key areas of focus / New additions / Changes </h2>\\r\\n<p>Introduces the use of CRB65 / CURB65 scores for adults.</p>\\r\\n<p>Consolidates best practice for treatment of children and adults.</p>\\r\\n<p>Provides advice on supportive care and when it is safe to discharge a patient.</p>\\r\\n<h2 id=\\\"limitations\\\">Limitations</h2>\\r\\n<p>None</p>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs\\\">Presenting symptoms and signs</h2>\\r\\n<p>In all age groups, LRI may present with fever, cough, fast breathing and crackles in the lung. Young children especially may lack specifically respiratory symptoms, but may not be able to feed or drink.</p>\\r\\n<h3 id=\\\"important-things-to-look-for\\\">Important things to look for</h3>\\r\\n<p>Assess the severity of the infection. Patients with signs of severe lower respiratory tract infection should be referred from the Gate clinic to the outpatient clinic.</p>\\r\\n<p>In children, these signs are:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Age less than 6 months old</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Feeding difficulty</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Looks unwell</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Chest indrawing, flaring nostrils, head nodding, grunting</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Central cyanosis or O<sub>2</sub> sats &lt; 90%</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Raised respiratory rate</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>&gt; 50 bpm</p>\\r\\n</div></th>\\r\\n<th><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Under 1 year</p>\\r\\n</div></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>&gt; 40 bpm</p>\\r\\n</div></td>\\r\\n<td><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>1-5 years</p>\\r\\n</div></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>&gt; 30 bpm</p>\\r\\n</div></td>\\r\\n<td><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Above 5 years</p>\\r\\n</div></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>If they return no better after 1-2 days.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>In adults, the signs are:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Confusion</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Respiratory rate above 30 bpm</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>BP &lt; 90/60 mmHg</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Age &gt; 65 years old</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>O<sub>2</sub> saturations are &lt; 90%.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"management-in-gate-clinic\\\">Management in Gate clinic</h2>\\r\\n<p>Treat all patients not referred to the outpatient clinic with <strong>Amoxicillin</strong> 30 mg/kg (max 500 mg) TDS for 5 days. If the patient is allergic to penicillin then use <strong>Azithromycin</strong> 10 mg/kg (max 500 mg) OD for 3 days.</p>\\r\\n<p>Tell the patient to return if they deteriorate or if they are no better after 2 days.</p>\\r\\n<p>Advise patients that full recovery from LRI is a long slow process. Their fever should have resolved within a week of treatment, but it can take 4 weeks for the sputum to clear and the chest pain to resolve and 6 weeks for cough and shortness of breath to resolve. So long as they are feeling better, they will not need to seek further medical help for these symptoms.</p>\\r\\n<h2 id=\\\"management-in-opd\\\">Management in OPD</h2>\\r\\n<h3 id=\\\"classification-of-adults\\\">Classification of adults</h3>\\r\\n<p>Adults referred to OPD should be assessed using the CRB65 score. One point is given for each of the following signs:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Confusion</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Respiratory rate above 30</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>BP &lt; 90/60</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Age &gt; 65 years old</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Management of patients based on CRB65 score:</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Score</strong></th>\\r\\n<th><strong>Management</strong></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>0</td>\\r\\n<td>Gate clinic</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>1</td>\\r\\n<td>Send to OPD for assessment</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>&gt; 1</td>\\r\\n<td>Admit</td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<h3 id=\\\"classification-of-children\\\">Classification of children</h3>\\r\\n<p>Classify the infection as pneumonia or severe pneumonia.</p>\\r\\n<p>Severe pneumonia is present when there is any one of:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Sats &lt; 90% or central cyanosis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Severe respiratory distress with grunting or severe chest indrawing</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Danger signs: inability to breastfeed or to drink, lethargy, reduced level of consciousness, fits</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Other cases are pneumonia.</p>\\r\\n<p>Admit all children with severe pneumonia. Children with pneumonia can usually be managed as outpatients, but can be admitted if there is any additional reason for concern.</p>\\r\\n<h3 id=\\\"other-considerations-for-all-patients\\\">Other considerations for all patients</h3>\\r\\n<p>Consider a diagnosis of TB in any patient who has had a cough for more than 2 weeks, who also describes weight loss, night sweats or has a TB contact. Request 2 sputums for AFBs and review the patient to check they have improved after 5-7 days. Check the SOP on Investigation of TB for guidance on whether GeneXpert is indicated.</p>\\r\\n<p>Consider alternative diagnoses such as PCP or TB in patients known to be HIV positive or who appear to be chronically unwell.</p>\\r\\n<p>Treat patients managed for LRI in OPD the same way as those managed in Gate clinic.</p>\\r\\n<h2 id=\\\"management-on-the-ward\\\">Management on the ward</h2>\\r\\n<p><strong>Investigations</strong></p>\\r\\n<p>All patients admitted to the ward with presumed LRI should be investigated with FBC, U&amp;Es, Blood cultures and CXR. Request sputum AFBs in any patient with risk factors for TB.</p>\\r\\n<p>Adults who are admitted to the ward should be assessed using the CURB65 score. This is the same as CRB65, but with one extra point available for a raised urea (above 7 mmol/l).</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Score</strong></th>\\r\\n<th><strong>Management</strong></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>0 or 1</td>\\r\\n<td>Manage as outpatient</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>2</td>\\r\\n<td>7 day course of oral antibiotics – admit if looks unwell</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>&gt; 2</td>\\r\\n<td>Admit and give iv antibiotics</td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<p>Note that a patient with a score of 3 or above is high risk with a mortality risk of above 15%.</p>\\r\\n<p><strong>Treatment</strong></p>\\r\\n<p>Once a diagnosis of LRI is made empirical antibiotics should be started:</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Patient group</strong></th>\\r\\n<th><strong>No Penicillin allergy</strong></th>\\r\\n<th><strong>Penicillin allergy</strong></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Outpatient treatment for all ages</td>\\r\\n<td>po <strong>Amoxicillin</strong> 30 mg/kg (max 500 mg) TDS for 5/7</td>\\r\\n<td>po <strong>Azithromycin</strong> 10 mg/kg (max 500 mg) OD for 3/7</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Moderate risk inpatient treatment (adults with CURB65 score = 2 or children admitted with pneumonia)</td>\\r\\n<td>po <strong>Amoxicillin</strong> 30 mg/kg (max 500 mg) TDS for 7/7</td>\\r\\n<td>po <strong>Azithromycin</strong> 10 mg/kg (max 500 mg) OD for 3/7</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>High risk inpatient treatment for adults (with higher CURB65 score)</td>\\r\\n<td>iv <strong>Benzylpenicillin</strong> 50,000 units/kg (max 2 MU) QDS</td>\\r\\n<td>iv <strong>Chloramphenicol</strong> 25 mg/kg (max 500mg) QDS</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Patient is particularly ill or failing to respond to treatment</td>\\r\\n<td>Add iv <strong>Chloramphenicol</strong> 25 mg/kg (max 500mg) QDS or po <strong>Azithromycin</strong> 10 mg/kg (max 500 mg) OD for 3/7</td>\\r\\n<td>Add po <strong>Azithromycin</strong> 10 mg/kg (max 500 mg) OD for 3/7</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Severe pneumonia in children under 5 years old</td>\\r\\n<td>iv <strong>Ampicillin</strong> 50 mg/kg (max 1 g) QDS <em>and</em> <strong>Gentamicin</strong> 7.5 mg/kg OD</td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Patient not improving after 48 hours of iv antibiotics</td>\\r\\n<td>Replace with iv <strong>Ceftriaxone</strong> 80 mg/kg (max 2 g) OD</td>\\r\\n<td>Replace with iv <strong>Ceftriaxone</strong> 80 mg/kg (max 2 g) OD</td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<p>Once a patient is clinically improving, cardiovascularly stable, afebrile and able to take oral medications, they can be switched to oral medications. Aim to complete at least a 7 day course of treatment including the period on iv antibiotics. If they have been treated with Ceftriaxone or Ampicillin and Gentamicin, use <strong>Co-amoxiclav</strong>. Prescribe by amoxicillin dose – 30 mg/kg up to 500 mg TDS. However if the amoxicillin per dose is greater than 250 mg, then use one co-amoxiclav tablet (250 mg Amoxicillin + 125 mg clavulanate) and make up the dose with plain amoxicillin.</p>\\r\\n<p>If a patient is not responding to treatment, reconsider a diagnosis of TB. Other diagnoses to consider include COPD, bronchiectasis, pleural effusion or empyema, underlying malignancy, or pertussis.</p>\\r\\n<p>Supportive treatment includes:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Paracetamol</strong> and/or <strong>ibuprofen</strong> to control pain and allow good coughing, as well as to reduce fevers.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Oxygen</strong> therapy to maintain saturations above 92%.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>iv fluids</strong> if the patient cannot drink because of shortness of breath or tiredness or if the airway is at risk. Try to avoid an NG tube if breathing is compromised.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Encourage oral feeding</strong> (or breast feeding).</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p><strong>Discharge criteria</strong></p>\\r\\n<p>Patients should not be discharged from the ward if they have had 2 or more of the following in the last 24 hours:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Temperature &gt; 37.5ºC</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Raised RR</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>&gt; 50 bpm</p>\\r\\n</div></th>\\r\\n<th><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Under 1 year</p>\\r\\n</div></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>&gt; 40 bpm</p>\\r\\n</div></td>\\r\\n<td><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>1-5 years</p>\\r\\n</div></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>&gt; 30 bpm</p>\\r\\n</div></td>\\r\\n<td><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>5-15 years</p>\\r\\n</div></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>&gt; 24 bpm</p>\\r\\n</div></td>\\r\\n<td><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Adults</p>\\r\\n</div></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>HR &gt; 100 bpm</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Systolic BP &lt; 90 mmHg</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>O<sub>2</sub> saturations &lt; 90%</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Confusion</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Difficulty in eating</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p><strong><br />\\r\\n</strong></p>\\r\\n<p><strong>References</strong></p>\\r\\n<p>Barson 2017. Pneumonia in children: Inpatient treatment. UpToDate May 2017.</p>\\r\\n<p>Barson 2016. Community-acquired pneumonia in children: Outpatient treatment. UpToDate June 2016.</p>\\r\\n<p>File 2017. Treatment of community-acquired pneumonia in adults who require hospitalization. UpToDate Sept 2017.</p>\\r\\n<p>File 2017. Treatment of community-acquired pneumonia in adults in the outpatient setting. UpToDate June 2017.</p>\\r\\n<p>Harris et al. British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011. Thorax 2011; 66:ii1-ii23.</p>\\r\\n<p>NICE 2014. Pneumonia in adults: diagnosis and management. Clinical Guideline CG191. December 2014.</p>\\r\\n<p>World Health Organization 2013. Pocket book of hospital care for children: Guidelines for the management of common illnesses with limited resources. 2<sup>nd</sup> ed. Geneva: World Health Organization; 2013.</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Karen Forrest</th>\\r\\n<th>Date: 22 May 2018</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Fatai Akemokwe</td>\\r\\n<td>Date: 17 June 2018</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>2.0</td>\\r\\n<td>Adapted from previous version to include OPD and ward care</td>\\r\\n<td>15 August 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>2.1</td>\\r\\n<td>Executive summary added</td>\\r\\n<td>15 August 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"012\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>Malaria MeG-CLS-012</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"malaria\\\">Malaria</h1>\\r\\n<h2 id=\\\"executive-summary\\\"><em>Executive summary</em></h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction </h2>\\r\\n<p>Malaria is a preventable and curable disease which is caused by parasites of the genus Plasmodium. Species that can cause malaria include <em>P. falciparum, P. vivax, P. ovale and P. malariae</em>. Of these, <em>P. falciparum</em> is the deadliest as well as the most common specie in sub-Saharan Africa. They are usually transmitted through the bite of an infected female Anopheles mosquito. As the endemicity of malaria reduces in The Gambia, non-development of immunity in childhood may cause increased number of severe malaria cases among older patients in the near future.</p>\\r\\n<p>This guideline covers the diagnosis and treatment of both uncomplicated and severe malaria.</p>\\r\\n<h2 id=\\\"target-users\\\">Target users</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nurses</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doctors</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"target-area-of-use\\\">Target area of use </h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Gate Clinic</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Outpatient Department</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ward</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"key-areas-of-focus-new-additions-changes\\\">Key areas of focus / New additions / Changes </h2>\\r\\n<p>This guidelines describes the features of uncomplicated malaria and those of severe malaria. The differential diagnoses of malaria is extensive. The diagnosis of malaria requires the use of rapid diagnostic tests or blood films.</p>\\r\\n<p>Most patients with uncomplicated malaria should be treated with co-artem at the Gate Clinic. Babies under 5 kg, pregnant women in first trimester and patients with positive blood smears despite treatment within the preceding fortnight should be referred to the outpatient department.</p>\\r\\n<p>Severe malaria is a medical emergency requiring inpatient parenteral therapy for at least 24 hours. The drug of choice is artesunate. Quinine and artemether are alternatives.</p>\\r\\n<p>Febrile patients should not be tepid sponged.</p>\\r\\n<h2 id=\\\"limitations\\\">Limitations </h2>\\r\\n<p>Patients with coma, severe anaemia, spontaneous bleeding or shock cannot be managed adequately at Keneba. Such patients should be given parenteral antimalarials and referred immediately.</p>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs\\\">Presenting symptoms and signs</h2>\\r\\n<p>Initial symptoms are non-specific and may include</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Myalgia</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Arthralgia</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Headache</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Abdominal discomfort</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Fatigue</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Following the initial stage, other symptoms such as fever ( &gt; 37.5ºC), chills, anorexia, vomiting and increasing malaise may arise.</p>\\r\\n<p>Younger children may present with lethargy and refusal of feeds.</p>\\r\\n<p>The following symptoms/signs, if present, allow for the diagnosis of <strong>severe malaria</strong>.</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Impaired consciousness: Glasgow coma score &lt; 11 in adults, Blantyre coma score &lt; 3 in children</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Weakness such that the patient cannot walk or sit without help</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>In a young child, failure to feed</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Convulsions: more than 2 episodes in 24 hours</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Respiratory distress</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Shock</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Jaundice</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hematuria</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Spontaneous bleeding</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Pulmonary oedema: oxygen saturation of &lt; 92% with a respiratory rate of &gt; 30 /minute or confirmed radiologically</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hypoglycemia: blood glucose &lt; 2.2 mmol/l</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Severe anaemia: Hb &lt; 5 g/dl or PCV &lt; 15%</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Persistent vomiting</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hyperparasitaemia: Malaria smear &gt; 100/l</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Renal impairment: serum creatinine &gt; 265 µmol/l or blood urea &gt;20 mmol/l</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"examination-findings\\\">Examination findings</h2>\\r\\n<p>General examination: Fever, Pallor</p>\\r\\n<p>Central Nervous system: coma score and orientation (especially important in cases of severe malaria).</p>\\r\\n<h3 id=\\\"important-things-to-look-for\\\">Important things to look for </h3>\\r\\n<h2 id=\\\"any-symptom-or-sign-indicative-of-severe-malaria-should-be-looked-for-to-ensure-early-treatment.\\\">Any symptom or sign indicative of severe malaria should be looked for to ensure early treatment.</h2>\\r\\n<h2 id=\\\"differential-diagnoses\\\">Differential diagnoses</h2>\\r\\n<p>Not all fever is malaria. The list of differential diagnoses is long and includes:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Bacteraemia from any cause</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>African trypanosomiasis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Amoebiasis and amoebic liver abscess</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Enteric fever</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Viral haemorrhagic fevers</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Dengue fever</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Encephalitis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hepatitis</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"investigations\\\">Investigations</h2>\\r\\n<p>Rapid diagnostic test (RDT).</p>\\r\\n<p>Malaria microscopy smear (Blood film):</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>if no RDT available or</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>if the patient was treated for malaria within the last 2 weeks (the RDT will still be positive from the last infection).</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Blood glucose.</p>\\r\\n<p>Hb or PCV (if patient is pale).</p>\\r\\n<p>Liver function tests (should not be routinely requested unless clinically indicated).</p>\\r\\n<p>Renal function tests (should not be routinely requested unless clinically indicated).</p>\\r\\n<h2 id=\\\"management-of-malaria-in-gate-clinic\\\">Management of malaria in gate clinic</h2>\\r\\n<p>Refer the following patients to the doctor:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Patients with any sign or symptom of severe malaria (call the doctor).</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Babies under 5 kg.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Pregnant women in first trimester.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Patients who were treated in the last 2 weeks and have a positive malaria smear.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>All other patients can be treated in Gate clinic.</p>\\r\\n<p>Co-artem is given in 6 doses based on body weight. Give first dose under supervision. Repeat after an anti-emetic if it is vomited. Advise patient to take second dose 8 hours later after food and to continue taking subsequent doses morning and evening.</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Weight in Kg</strong></th>\\r\\n<th><strong>Dose</strong></th>\\r\\n<th><strong>Number of tablets</strong></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>5 to &lt; 15</td>\\r\\n<td>20/120</td>\\r\\n<td>1</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>15 to &lt; 25</td>\\r\\n<td>40/240</td>\\r\\n<td>2</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>25 to &lt; 35</td>\\r\\n<td>60/360</td>\\r\\n<td>3</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>≥ 35</td>\\r\\n<td>80/480</td>\\r\\n<td>4</td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<p>Give paracetamol for symptom relief.</p>\\r\\n<h2 id=\\\"management-of-malaria-in-opd\\\">Management of malaria in OPD</h2>\\r\\n<h3 id=\\\"uncomplicated-malaria-in-special-groups\\\">Uncomplicated malaria in special groups:</h3>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Group</strong></th>\\r\\n<th><strong>Treatment</strong></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Pregnant women (1<sup>st</sup> trimester)</td>\\r\\n<td>Oral quinine and clindamycin for 7 days</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Infants &lt; 5 kg</td>\\r\\n<td>Artemether / lumefantrine at 4 mg artemether / 24 mg lumefantrine /kg body weight</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Non-immune travellers</td>\\r\\n<td>Artemether / lumefantrine</td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<h3 id=\\\"uncomplicated-p.-ovale-p.-malariae-p.-vivax-malaria\\\">Uncomplicated <em>P. ovale, P. malariae, P. vivax</em> malaria</h3>\\r\\n<p>Treat as for <em>P. falciparum</em> malaria with co-artem. Add primaquine to eliminate hypnozoites if confirmed to have <em>P. ovale</em> or <em>P. vivax</em>.</p>\\r\\n<h2 id=\\\"management-of-severe-malaria-on-the-ward\\\">Management of severe malaria on the ward</h2>\\r\\n<p>The drug of choice for severe malaria is parenteral artesunate. If not available, consider parenteral artemether or quinine.</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Drug</strong></th>\\r\\n<th><strong>Dosage</strong></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Artesunate</td>\\r\\n<td><p>2.4 mg/kg iv or im on admission, then at 12 hours, then at 24 hours, then daily until oral medications can be tolerated. It should be given for a <strong>minimum</strong> of 24 hours.</p>\\r\\n<p><strong>Note</strong>: Children &lt; 20 kg should receive a higher dosage of 3 mg/kg.</p></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Quinine</td>\\r\\n<td>Loading dose by infusion at 20 mg/kg in 10 ml/kg of iv fluid over 2-4 hours, then after 8 hours, 10 mg/kg in iv fluid over 2 hours, 8 hourly until patient can tolerate oral medications.</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Artemether</td>\\r\\n<td>3.2 mg/kg im on admission, then 1.6 mg/kg daily until patient can tolerate oral medication.</td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<p>Parenteral drugs should be given to ALL patients with severe malaria for <em>at least</em> 24 hours and then followed by a full-course of an artemisinin-based combination therapy (ACT).</p>\\r\\n<h3 id=\\\"complications-of-severe-malaria\\\">Complications of severe malaria</h3>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Complication</strong></th>\\r\\n<th><strong>Treatment</strong></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Coma</td>\\r\\n<td><p>Treat as an unconscious patient; regular turning, maintain airway, rule out other treatable causes.</p>\\r\\n<p><em>Keneba: Commence antimalarial therapy and refer patient.</em></p></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Hyperpyrexia</td>\\r\\n<td>Expose and give paracetamol – <strong>do not tepid sponge.</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Convulsions</td>\\r\\n<td>Prompt treatment with iv or rectal diazepam or im paraldehyde</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Hypoglycaemia</td>\\r\\n<td>Threshold for intervention is 3.0 mmol/l in children younger than 5 years and 2.2 mmol/l in patients aged 5 years or older. Correct hypoglycemia and give maintenance fluid which contains glucose (50% dextrose 1 ml/kg diluted in an equal strength of water for injection).</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Severe Anaemia</td>\\r\\n<td><p>Transfusion with fresh whole blood.</p>\\r\\n<p><em>Keneba: Commence antimalarial therapy and refer patient</em></p></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Acute Pulmonary Oedema</td>\\r\\n<td><p>Nurse in 45° propped-up position.</p>\\r\\n<p>Start oxygen therapy.</p>\\r\\n<p>Give diuretic (intravenous furosemide).</p></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Spontaneous Bleeding</td>\\r\\n<td><p>Transfuse with fresh whole blood.</p>\\r\\n<p><em>Keneba: Commence antimalarial therapy and refer patient</em></p></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Shock</td>\\r\\n<td><p>Suspect bacterial sepsis.</p>\\r\\n<p>Take samples for cultures.</p>\\r\\n<p>Give broad spectrum parenteral antibiotics.</p>\\r\\n<p><em>Keneba; Commence antimalarial therapy, parenteral antibiotics and refer patient</em></p></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<h2 id=\\\"key-issues-for-nursing-care\\\">Key issues for nursing care</h2>\\r\\n<p>Do not tepid sponge febrile patients. Check charts and consider giving paracetamol if not already given.</p>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<p>World Health Organization (WHO). Factsheet on malaria [internet].Geneva: WHO; 2018. Available from: <span data-custom-style=\\\"Hyperlink\\\"><a href=\\\"http://www.who.int/en/news-room/fact-sheets/detail/malaria\\\">http://www.who.int/en/news-room/fact-sheets/detail/malaria</a></span> Accessed: June 11th 2018</p>\\r\\n<p>World Health Organization (WHO). Guidelines for the treatment of malaria. 3<sup>rd</sup> ed. Geneva: WHO; 2015. Available from: <span data-custom-style=\\\"Hyperlink\\\"><a href=\\\"http://apps.who.int/iris/bitstream/handle/10665/162441/9789241549127_eng.pdf;jsessionid=3B5C932E177AC0E91DFA84112DEBD6C7?sequence=1\\\">http://apps.who.int/iris/bitstream/handle/10665/162441/9789241549127_eng.pdf;jsessionid=3B5C932E177AC0E91DFA84112DEBD6C7?sequence=1</a> Accessed: June 9<sup>th</sup> 2018</span></p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Azeezat Sallahdeen</th>\\r\\n<th>Date: 31 July 2018</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Fatai Akemokwe</td>\\r\\n<td>Date: 31 July 2018</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document a</td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>2.0</td>\\r\\n<td>Adjusted to broaden relevance beyond gate clinic</td>\\r\\n<td>31 July 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>2.1</td>\\r\\n<td>Executive summary added</td>\\r\\n<td>31 July 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"037\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>Malnutrition MeG-CLS-037</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"severe-acute-malnutrition\\\">Severe acute malnutrition</h1>\\r\\n<h2 id=\\\"executive-summary\\\"><em>Executive summary</em></h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<p>Malnutrition is a significant public health problem. Severe acute malnutrition is defined as the presence of oedema of both feet or severe wasting (weight for height/length less than -3 SD or mid-upper arm circumference &lt; 115 mm). It is a medical emergency requiring prompt assessment and specialized treatment. Children with severe acute malnutrition should first be assessed with a full clinical examination to confirm if they have any general danger sign, medical complication and an appetite.</p>\\r\\n<h2 id=\\\"children-who-have-a-good-appetite-and-no-medical-complication-can-be-managed-as-outpatients-with-plumpynut-a-ready-to-use-food-rtuf.\\\">Children who have a good appetite and no medical complication can be managed as outpatients with PlumpyNut (a ready to use food – RTUF). </h2>\\r\\n<p>Children with severe acute malnutrition with loss of appetite or any medical condition have complicated severe acute malnutrition and should be admitted for inpatient care. The treatment of malnutrition is divided into 3 main stages: urgent treatment, stabilisation and rehabilitation.</p>\\r\\n<h2 id=\\\"target-users\\\">Target users</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doctors</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nurses</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"target-area-of-use\\\">Target area of use </h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Gate clinic</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Outpatients</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ward</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Supplement Centre</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"key-areas-of-focus-new-additions-changes\\\">Key areas of focus / New additions / Changes </h3>\\r\\n<p>This guideline takes into consideration the differences between Fajara and Keneba in care of children with severe acute malnutrition.</p>\\r\\n<h2 id=\\\"limitations\\\">Limitations</h2>\\r\\n<p>This guideline is limited in scope to children under 12 years of age. Outpatient management and post-discharge care are only available in Keneba.</p>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs\\\">Presenting symptoms and signs</h2>\\r\\n<p>Any child who is severely wasted or who has bilateral oedema of the feet should be assumed to be severely malnourished.</p>\\r\\n<p>All patients with severe malnutrition should be referred to the doctor as a priority. These patients should not be kept waiting in the OPD queue, but should see the next available doctor, with the exception that patients with the emergency features described below must be sent straight to the ward and have the doctor called to see them immediately.</p>\\r\\n<h3 id=\\\"important-things-to-look-for\\\">Important things to look for</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Assess for general danger signs or emergency signs. Children with the following features should be sent directly to the ward and <strong><em>should be immediately reviewed by a doctor</em></strong></p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><blockquote>\\r\\n<p>Hypothermia (axillary temperature &lt; 35°C)</p>\\r\\n</blockquote></th>\\r\\n<th></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><blockquote>\\r\\n<p>Signs of respiratory distress, such as nasal flaring or chest indrawing, or increased RR</p>\\r\\n</blockquote></td>\\r\\n<td><blockquote>\\r\\n<p>Age under 2 months: &gt; 60 bpm</p>\\r\\n</blockquote></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td></td>\\r\\n<td><blockquote>\\r\\n<p>2-12 months: &gt; 50 bpm</p>\\r\\n</blockquote></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td></td>\\r\\n<td><blockquote>\\r\\n<p>1-5 years: &gt; 40 bpm</p>\\r\\n</blockquote></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td></td>\\r\\n<td><blockquote>\\r\\n<p>over 5 years: &gt; 30 bpm</p>\\r\\n</blockquote></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><blockquote>\\r\\n<p>Fever (&gt; 38.5°C)</p>\\r\\n</blockquote></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><blockquote>\\r\\n<p>Unconscious or fitting</p>\\r\\n</blockquote></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><blockquote>\\r\\n<p>Weakness, lethargy</p>\\r\\n</blockquote></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><blockquote>\\r\\n<p>Severe or intractable vomiting</p>\\r\\n</blockquote></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><blockquote>\\r\\n<p>Profuse diarrhoea</p>\\r\\n</blockquote></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><blockquote>\\r\\n<p>Severe dehydration based on clinical signs</p>\\r\\n</blockquote></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><blockquote>\\r\\n<p>Extensive skin lesions</p>\\r\\n</blockquote></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><blockquote>\\r\\n<p>Severe anaemia (either PCV &lt; 12% or very pale)</p>\\r\\n</blockquote></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><blockquote>\\r\\n<p>Spontaneous bleeding.</p>\\r\\n</blockquote></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<p><strong><span class=\\\"underline\\\"><br />\\r\\n</span></strong></p>\\r\\n<p><strong><span class=\\\"underline\\\">Initial assessment</span></strong></p>\\r\\n<p>Whilst the patient is waiting for the doctor to arrive, the nurses should measure the weight, length or height, MUAC, temperature, HR, RR, blood glucose. They should start to complete the Malnutrition Care Pathway.</p>\\r\\n<p>The doctor should take history concerning:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Weight loss or failure to gain appropriate weight</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Recent intake of food and fluids</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Usual diet before current illness</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Fever</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Diarrhoea: type, duration and frequency of diarrhoea</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Vomiting</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Loss of appetite/poor appetite</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Cough &gt; 2 weeks, history of contact with TB</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Known or suspected HIV infection / exposure</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"examination-findings\\\">Examination findings</h2>\\r\\n<p>Severe acute malnutrition is characterized by wasting and/or edema:</p>\\r\\n<p>Wasting (loss of muscle bulk with no subcutaneous fat, loose skin folds)</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Weight-for-length/height &lt; -3 SD or</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Mid upper arm circumference &lt; 115 mm</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Oedema of both feet (with or without severe wasting)</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>below ankle (grade 1 +)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>oedema in both feet and legs (grade 2 ++)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>oedema in both feet, legs, arms and face (grade 3 +++)</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Other findings in severe acute malnutrition may include:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Restless, miserable, irritable</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Severe palmar pallor, mouth ulcers, oral candidiasis,</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Eye signs of vitamin A deficiency: dry conjunctivitis or cornea, Bitots spots, corneal ulceration, keratomalacia</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Localizing signs of infection including ear and throat infection, skin infections, skin changes, hypo or hyperpigmentation, desquamation, skin ulcerations, exudative lesions resembling severe burns with secondary infections including Candida.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Conduct an appetite test to check if child has appetite by providing ready to use therapeutic foods.</p>\\r\\n<h2 id=\\\"differential-diagnosis\\\">Differential diagnosis</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Tuberculosis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>HIV</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Congenital heart disease</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Other underlying medical or social conditions</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"investigations\\\">Investigations</h2>\\r\\n<p>Essential investigations:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Blood glucose</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Full Blood Count</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>HIV test</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Other tests that may be requested for patients who are very ill, have other specific conditions or fail to respond to standard care include:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Urine dipstick,</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Urine MC&amp;S</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Stool MC&amp;S</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Blood culture</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Chest X-ray</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>GeneXpert</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Serum Electrolytes, Urea and Creatinine</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Liver Function tests</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"management\\\">Management</h2>\\r\\n<p>Children who pass the appetite test and are clinically well and alert should be treated as outpatients for uncomplicated severe acute malnutrition with PlumpyNuts. Such patients should be sent to the Nutritional Rehabilitation Centre (if residing near Keneba) or to their local Nutrition Officer.</p>\\r\\n<p>Children who have severe oedema (+++), fail the appetite test, present with one or more general danger signs or have medical conditions requiring admission should be treated as inpatients. This care is divided into 3 main stages: urgent treatment, stabilisation and rehabilitation. In Keneba, stabilisation and rehabilitation typically take place in the Nutritional Rehabilitation Centre (Supplement Centre) except where medical complications are present.</p>\\r\\n<h2 id=\\\"urgent-treatment\\\">Urgent Treatment</h2>\\r\\n<p>The Malnutrition Care Pathway will guide the urgent treatment of these patients (See Attachment 01).</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Condition</strong></th>\\r\\n<th><strong>Immediate action</strong></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><p><strong>Hypoglycaemia</strong></p>\\r\\n<p>Diagnose if blood glucose &lt; 3 mmol/l</p>\\r\\n<p>Assume hypoglycaemia is present if no dextrosticks available.</p></td>\\r\\n<td><p><strong>If conscious:</strong> Give 50 ml 10% glucose orally or via NG tube. Start F75 as soon as possible.</p>\\r\\n<p><strong>If unconscious:</strong> Give 1 ml/kg 50% glucose diluted with 4 ml/kg water for injection iv.</p></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><p><strong>Hypothermia</strong></p>\\r\\n<p>Diagnose if axillary temperature &lt; 35°C</p></td>\\r\\n<td><p>Give 50 ml 10% glucose orally or via NG tube. Start F75 as soon as possible.</p>\\r\\n<p>Keep warm – nurse child skin-to-skin on mother’s chest and cover them.</p></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><p><strong>Severe anaemia</strong></p>\\r\\n<p>Diagnose if Hb &lt; 4g/dl</p>\\r\\n<p>OR</p>\\r\\n<p>Hb 4-6 and respiratory distress</p></td>\\r\\n<td><p>If no signs of heart failure: Give 10 ml/kg whole blood over 3 hours.</p>\\r\\n<p>If signs of heart failure: Give 5-7 ml/kg packed cells over 3 hours.</p>\\r\\n<p>In both cases: give furosemide 1 ml/kg at the start of the transfusion</p>\\r\\n<p><em>(Refer if seen at Keneba)</em></p></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><p><strong>Shock</strong></p>\\r\\n<p>Diagnose if child is lethargic</p>\\r\\n<p><strong>OR</strong></p>\\r\\n<p>Unconscious with cold hands</p>\\r\\n<p><strong>AND either</strong></p>\\r\\n<p>Capillary refill more than 3s</p>\\r\\n<p><strong>OR</strong></p>\\r\\n<p>Weak fast pulse</p></td>\\r\\n<td><p>Give O<sub>2</sub>.</p>\\r\\n<p>Give bolus of 5 ml/kg 10% dextrose iv.</p>\\r\\n<p>Follow this with 15 ml/kg fluid over 1 hour. Suitable fluids are:</p>\\r\\n<ul>\\r\\n<li><p>Ringer’s lactate with 5% dextrose (remove 50 ml from a 500ml bag of Ringer’s and add 50 ml 50% dextrose).</p></li>\\r\\n<li><p>Half-normal saline with 5% dextrose</p></li>\\r\\n<li><p>Ringer’s (only if you cannot add dextrose rapidly)</p></li>\\r\\n</ul>\\r\\n<p>Monitor HR ad RR every 10 minutes.</p>\\r\\n<p>If HR and RR fall, continue this for a second hour.</p>\\r\\n<p>Otherwise treat for septic shock.</p></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><p><strong>Septic shock</strong></p>\\r\\n<p>Diagnose if child has not responded to initial treatment for shock.</p></td>\\r\\n<td><p>Continue current iv fluids at rate of 4 ml/kg/hr.</p>\\r\\n<p>Arrange urgent transfusion of 10 ml/kg fresh whole blood over 3 hours.</p>\\r\\n<p>Start iv antibiotic treatment. <em>(and refer if seen at Keneba)</em></p></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><p><strong>Severe dehydration</strong></p>\\r\\n<p>Diagnose if there is no shock, but 2 or more of the following signs:</p>\\r\\n<ul>\\r\\n<li><p>Profuse watery diarrhoea</p></li>\\r\\n<li><p>Sunken eyes (if new)</p></li>\\r\\n<li><p>Absent tears</p></li>\\r\\n<li><p>Dry mouth</p></li>\\r\\n<li><p>Thirst</p></li>\\r\\n<li><p>Rapid HR and RR</p></li>\\r\\n<li><p>Reduced urine output</p></li>\\r\\n</ul></td>\\r\\n<td><p><strong>DO NOT GIVE iv FLUIDS</strong></p>\\r\\n<p>Give ReSoMal 5 ml/kg every 30 mins for 2 hours.</p>\\r\\n<p>Monitor HR and RR every 30 mins.</p>\\r\\n<p>Follow with ReSoMal 5-10 ml/kg every 2 hours (alternating with F75) for 4-10 hours.</p>\\r\\n<p><strong>STOP</strong> ReSoMal if signs of dehydration resolve or if HR or RR increase or if oedema develops. Do not continue it for more than 10 hours.</p>\\r\\n<p>Do not delay F75 because you are giving ReSoMal.</p></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Corneal ulceration</strong></td>\\r\\n<td><p>If present, give vitamin A immediately (Age &lt; 6/12 50,000 IU, 6-12/12 100,000 IU, &gt; 12/12 200,000 IU)</p>\\r\\n<p>Also instill 1 drop of 1% atropine to the affected eye. Apply chloramphenicol eye ointment, then cover the eye with saline soaked eye pad.</p></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><p><strong>Congestive heart failure</strong></p>\\r\\n<p>Usually occurs as a complication of over-hydration, very severe anaemia, transfusion or ingestion of too much sodium.</p></td>\\r\\n<td><p>Presents with:</p>\\r\\n<ul>\\r\\n<li><p>fast breathing and respiratory distress</p></li>\\r\\n<li><p>fast pulse</p></li>\\r\\n<li><p>engorged jugular vein</p></li>\\r\\n<li><p>cold hand and feet</p></li>\\r\\n<li><p>central cyanosis.</p></li>\\r\\n</ul>\\r\\n<p>If fluid overload is thought to be the cause:</p>\\r\\n<ul>\\r\\n<li><p>Stop all oral and iv intake</p></li>\\r\\n<li><p>Give furosemide 1 mg/kg iv stat.</p></li>\\r\\n<li><p>Reintroduce feeds and fluids only once there is clinical improvement.</p></li>\\r\\n</ul>\\r\\n<p>May also present during later phases of feeding. If HR and RR rise and persist at this stage, reduce feed volumes to 100 ml/kg/day for at least 24 hours and gradually increase feeds after this.</p></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<h2 id=\\\"stabilisation\\\">Stabilisation</h2>\\r\\n<p>This phase seeks to treat and prevent the main features and complications of malnutrition.</p>\\r\\n<p><strong><span class=\\\"underline\\\">Hypoglycaemia</span></strong></p>\\r\\n<p>Defined as blood glucose below 3 mmol/l.</p>\\r\\n<p><span class=\\\"underline\\\">Signs</span> are lethargy, reduced conscious level and drowsiness, hypothermia.</p>\\r\\n<p>Assume there is hypoglycaemia present if any of these signs are present and you are unable to test the blood glucose level.</p>\\r\\n<p><span class=\\\"underline\\\">Treat</span> as described under urgent treatment.</p>\\r\\n<p>After the initial treatment, give F75 and antibiotics as described below as soon as possible.</p>\\r\\n<p>Check blood glucose 2 hours after treatment and retreat if necessary.</p>\\r\\n<p><span class=\\\"underline\\\">Prevent</span> recurrence by feeding with F75 every 3 hours during day and night.</p>\\r\\n<p><strong><span class=\\\"underline\\\">Hypothermia</span></strong></p>\\r\\n<p>Defined as axillary T &lt; 35°C.</p>\\r\\n<p><span class=\\\"underline\\\">Treat</span> as described under urgent treatment. Treat all hypothermic children for hypoglycaemia and infection.</p>\\r\\n<p>Check temperature every 2 hours until it rises above 36°C.</p>\\r\\n<p><span class=\\\"underline\\\">Prevent</span> recurrence by</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>feeding with F75 every 2 hours during day and night</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>keeping child covered and away from draughts</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>keeping child dry (including nappies)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>encouraging mother and child to sleep together at night.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p><strong><span class=\\\"underline\\\">Dehydration and electrolyte imbalance</span></strong></p>\\r\\n<p>Dehydration can be overdiagnosed and its severity overestimated. Malnourished children usually have raised total body Na and are deficient in K and Mg. ReSoMal is specially formulated to provide less Na than ORS and to replace the electrolyte deficiencies. Extra electrolytes are also added to F75 and F100 and extra supplements are not usually needed.</p>\\r\\n<p><span class=\\\"underline\\\">Treat</span> as described under urgent treatment.</p>\\r\\n<p>Check HR, RR, urine frequency and stool frequency every 30 mins for the first 2 hours, then every 2 hours for the next 10 hours.</p>\\r\\n<p><span class=\\\"underline\\\">Prevent</span> recurrence by</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>feeding with F75 every 2 hours during day and night</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>encouraging mother to continue breastfeeding</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>replace ongoing losses due to diarrhoea, by weighing nappies and giving equivalent volume of ReSoMal.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p><span class=\\\"underline\\\">Note</span> that malnourished children often pass many small unformed stools – this is not diarrhoea and does not need replacing.</p>\\r\\n<p><strong><span class=\\\"underline\\\">Infection</span></strong></p>\\r\\n<p><span class=\\\"underline\\\">Test</span> all febrile children for malaria and treat if positive. Also test all mothers of breastfeeding children and all other children for HIV.</p>\\r\\n<p><span class=\\\"underline\\\">Treat</span> all malnourished children for infection. Children who appear well should be given oral amoxicillin 25 mg/kg TDS for 5 days.</p>\\r\\n<p>If there are signs of shock, treat as described under urgent treatment.</p>\\r\\n<p>If the child is ill or has any complications (hypoglycaemia, hypothermia, broken skin, obvious RTI or UTI), then give:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ampicillin 50 mg/kg iv QDS for at least 48 hours (then follow with oral amoxicillin if improving).</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>AND</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Gentamicin 7.5 mg/kg iv OD for 7 days.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>If there is no improvement in fever after 48 hours, add Chloramphenicol 25 mg/kg iv QDS for 5 days.</p>\\r\\n<p>Children who continue to be febrile after 48 hours of chloramphenicol should have their antibiotics changed to Ceftriaxone 80 mg/kg iv OD for 7 days.</p>\\r\\n<p>Children who remain febrile after this are very likely to have TB and should have a CXR, plus sputum induction or gastric washings sent for GeneXpert.</p>\\r\\n<p>If there are any specific signs of infection, then add the appropriate antibiotics to the above regimen.</p>\\r\\n<p>If the child is over 9 months old and has not had measles vaccination, they should be immunized as soon as possible (<em>Keneba</em>) or sent to Bakau Health Centre for this as soon as they are stable (<em>Fajara</em>).</p>\\r\\n<p><strong><span class=\\\"underline\\\">Worms</span></strong></p>\\r\\n<p>Delay worm treatment until the patient is on F100. Then give mebendazole 100 mg BD for 3 days to all children over the age of 1 year.</p>\\r\\n<p><strong><span class=\\\"underline\\\">Micronutrient deficiency</span></strong></p>\\r\\n<p>All malnourished children have vitamin and mineral deficiencies. Sachets of F75, F100 and PlumpyNut contain supplements of these. It is not necessary to give separate supplementation of any micronutrients to children receiving these (the only exception being a child with measles or eye complications).</p>\\r\\n<p><strong><span class=\\\"underline\\\">Initial Feeding</span></strong></p>\\r\\n<p>All children with malnutrition need feeding as soon as possible. However, the initial feeds must be small and frequent.</p>\\r\\n<p>Start feeding with F75. This contains 75 kcal/100ml of feed. There is 0.9 g protein in each 100 ml.</p>\\r\\n<p>Start feeding at a rate of 130 ml/kg/day unless the child has oedema in which case the initial rate is reduced to 100 ml/kg/day. Give the feeds every 3 hours, unless the child is shocked or severely ill, in which case 2 hourly feeds must be given at first.</p>\\r\\n<p>Give the feeds from a cup (using a syringe or dropper if the child is very weak).</p>\\r\\n<p>An NG tube may be used if</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>the child is unconscious</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>the child cannot take more than 75% of the prescribed feed</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>there are painful mouth lesions</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>the respiratory rate is raised.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Children who are breast fed can continue this, but should take their prescribed feeds first. Children should not eat other food, but can drink extra liquid if they are thirsty.</p>\\r\\n<p>The volume of F75 is not increased.</p>\\r\\n<h2 id=\\\"treatment-of-complications-during-stabilisation\\\">Treatment of complications during stabilisation</h2>\\r\\n<p><strong><span class=\\\"underline\\\">Eye conditions</span></strong></p>\\r\\n<p>Vitamin A deficiency may present with dry eyes, Bitot spots, corneal ulceration, keratomalacia and photophobia.</p>\\r\\n<p><span class=\\\"underline\\\">Treat</span> children with corneal ulceration as described under urgent treatment. Give all children with eye signs vitamin A (age &lt; 6/12 50,000 IU, 6-12/12 100,000 IU, &gt; 12/12 200,000 IU) on days 1, 2 and 14 of admission.</p>\\r\\n<p><strong><span class=\\\"underline\\\">Skin conditions</span></strong></p>\\r\\n<p>Dermatosis presents with hypo- or hyper-pigmentation, desquamation, ulceration, exudative lesions looking like burns (which is often infected with candida).</p>\\r\\n<p>Soak the affected areas in 1% potassium permanganate solution for 10 minutes per day. Apply zinc and castor ointment to the lesions. Also apply anti-fungal cream if there is evidence of candida infection. Avoid using nappies to allow the perineum to dry.</p>\\r\\n<p>Zinc supplementation is an important part of the treatment, but is provided in the feeds given to the child.</p>\\r\\n<p><strong><span class=\\\"underline\\\">Continuing diarrhoea</span></strong></p>\\r\\n<p>Diarrhoea is common and often resolves without specific treatment. If the diarrhoea is not associated with weight loss or dehydration, then it does not require intervention. However, if it continues and there is evidence of dehydration or weight loss, then consider the following options.</p>\\r\\n<p><span class=\\\"underline\\\">Giardia</span> is common. Send the stools for microscopy. If suspicion of giardiasis remains or the diagnosis is confirmed, treat with 7.5 mg/kg metronidazole po TDS for 7 days.</p>\\r\\n<p>Diarrhoea that worsens with the introduction of feeding may be caused by small bowel bacterial overgrowth or lactose intolerance.</p>\\r\\n<p><span class=\\\"underline\\\">Small bowel bacterial overgrowth</span> is also common. It usually resolves within a few days without specific intervention. If there is no resolution, then consider using a flour-based F75 formula. If you do this, then you will need to provide vitamin and mineral supplementation (follow the instructions in the WHO blue book).</p>\\r\\n<p><span class=\\\"underline\\\">Lactose intolerance</span> is very rare. F75 is a low lactose feed. Diarrhoea which worsens with the introduction of F100 could be due to this. If necessary, either use a flour-based F100 formula (and supplement with vitamins and minerals) or substitute feeds with plumpy nut as soon as possible.</p>\\r\\n<p><span class=\\\"underline\\\">Ileus</span> may occur and is a poor prognostic sign. It presents with absent bowel sounds and distended abdomen. Treat as follows:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Withhold all drug treatment as it is most commonly a sign of drug toxicity.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Give the child 2 ml 50% magnesium sulphate IM BD until they pass stool.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Insert an NG tube and aspirate the stomach contents. Flush the stomach with 50ml 5% dextrose until the aspirated fluid is clear. Then leave 5 ml/kg 10% dextrose in the stomach. Aspirate again after 1 hour. Measure the fluid and make up the volume to 5 ml/kg with more 10% dextrose. Continue this until there are signs of improvement, whilst monitoring for hypoglycaemia.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>If there is no sign of improvement after 6 hours, then give iv fluids as described under treatment for shock.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>As soon as there is improvement, start feeding with F75. Use half the usual volume in the first instance. Aspirate the stomach prior to feeding. Reduce the feeds until there is nothing left in the stomach prior to the next feed. Once the stomach is empty when the next feed is due, the volume of feeds can be increased.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"rehabilitation\\\">Rehabilitation</h2>\\r\\n<h2 id=\\\"as-soon-as-the-childs-appetite-returns-and-any-oedema-has-gone-replace-the-f75-with-the-same-volume-and-frequency-of-f100.-if-this-is-tolerated-then-increase-the-volume-of-feeds-by-as-much-as-10-ml-per-feed-until-the-child-can-no-longer-drink-the-volume-offered.\\\">As soon as the child’s appetite returns and any oedema has gone, replace the F75 with the same volume and frequency of F100. If this is tolerated, then increase the volume of feeds (by as much as 10 ml per feed) until the child can no longer drink the volume offered. </h2>\\r\\n<p>Children who are breastfed should be offered this prior to their therapeutic feeds. Therapeutic feeds must, however, be given prior to any other food.</p>\\r\\n<p>Once the child is tolerating F100 with no problems, replace it with PlumpyNut (1 PlumpyNut sachet is equivalent to 500ml of F100).</p>\\r\\n<p>Monitor</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>weight gain</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>heart rate and respiratory rate</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>presence of oedema</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>abdominal girth – for hepatomegaly or ileus.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>If there is rapid weight gain (&gt; 10 g/kg/day), worsening oedema, diarrhoea causing weight loss or dehydration, or the child needs NG feeding, move back to F75 and the stabilisation phase of treatment.</p>\\r\\n<h2 id=\\\"infants-under-6-months-of-age\\\">Infants under 6 months of age</h2>\\r\\n<p>Malnutrition under the age of 6 months is very rare and is usually a sign of an underlying medical problem. The principles of treatment are the same as in older children.</p>\\r\\n<p>Wherever possible, the mother should be encouraged to breast feed their child and breast milk should be given <em>before</em> other feeds. Re-lactation treatment or a supply line can be used to promote breastfeeding.</p>\\r\\n<p>If the mother cannot express enough breast milk, then infant formula should be used to make up the volume of feed.</p>\\r\\n<h2 id=\\\"discharge-from-ward\\\">Discharge from ward</h2>\\r\\n<h2 id=\\\"children-can-be-discharged-from-the-ward-to-complete-their-rehabilitation-phase-in-the-community-once\\\">Children can be discharged from the ward to complete their rehabilitation phase in the community, once:</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>They are clinically well and no longer on parenteral treatment.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>All complications have resolved.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Their appetite has returned and they are eating their PlumpyNut well.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>They are steadily gaining weight.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Refer the child to the Supplement Centre (if resident in Keneba) or to their local nutrition officer for ongoing monitoring and provision of PlumpyNut.</p>\\r\\n<h2 id=\\\"key-issues-for-nursing-care\\\">Key Issues for Nursing care</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Prevent hypothermia actively by making sure child is clothed especially the head, cover with warm blankets and by using Kangaroo care. Place the bed in a warm part of the ward. Change wet nappies and wet clothes to keep the child dry.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Be familiar with appetite testing and nasogastric tube feeding.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ensure patient’s hands and face are washed before feeding.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Offer the child plenty of water when child is eating RTUF.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Sensory stimulation helps: Provide a cheerful stimulating environment, structured play therapy for 15-30 mins/day, provide suitable toys and play activities for the child.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<p><span data-custom-style=\\\"cit-article-title\\\"><em>Protocol on the integrated management of acute malnutrition. Banjul., The Gambia: Ministry of State for Health and Social Welfare and National Nutrition Agency; 2013.</em></span></p>\\r\\n<p><span data-custom-style=\\\"cit-article-title\\\"><em>Pocket book of hospital care for children: Guidelines for the management of common illnesses with limited resources. 2nd ed. Geneva: World Health Organization; 2013.</em></span></p>\\r\\n<h2 id=\\\"attachments\\\">Attachments</h2>\\r\\n<p>Attachment 01: Severe acute malnutrition urgent care pathway</p>\\r\\n<p><img src=\\\"data:image/png;base64,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\\\" style=\\\"width:6in;height:3.47361in\\\" /></p>\\r\\n<p>Attachment 02: Discharge letter</p>\\r\\n<p><img src=\\\"data:image/png;base64,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\\\" style=\\\"width:6in;height:3.85764in\\\" /></p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Dr Yorro Bah</th>\\r\\n<th>Date: 12 April 2019</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Dr Baderinwa Abatan</td>\\r\\n<td>Date: 12 April 2019</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>2.0</td>\\r\\n<td>Updated and transferred to new template</td>\\r\\n<td>31 May 2021</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"028\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>Meningitis MeG-CLS-028</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"meningitis\\\">Meningitis</h1>\\r\\n<h2 id=\\\"executive-summary\\\"><em>Executive summary</em></h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<h2 id=\\\"meningitis-is-defined-as-inflammation-of-the-pia-and-arachnoid-meninges-and-the-cerebrospinal-fluid-csf-that-surrounds-the-brain-and-spinal-cord.-the-main-infectious-causes-are-viral-bacterial-and-fungal.\\\">Meningitis is defined as inflammation of the pia and arachnoid meninges and the cerebrospinal fluid (CSF) that surrounds the brain and spinal cord. The main infectious causes are viral, bacterial and fungal. </h2>\\r\\n<h2 id=\\\"meningitis-is-classified-clinically-as-either-acute-or-chronic.-acute-meningitis-occurs-within-hours-or-days-whereas-chronic-meningitis-evolves-over-weeks.-acute-meningitis-is-classified-as\\\">Meningitis is classified clinically as either acute or chronic. Acute meningitis occurs within hours or days, whereas chronic meningitis evolves over weeks. Acute meningitis is classified as </h2>\\r\\n<ul>\\r\\n<li><h2 id=\\\"aseptic-which-is-mostly-viral-in-origin-or\\\">aseptic (which is mostly viral in origin) or </h2></li>\\r\\n<li><h2 id=\\\"septic-or-pyogenic-which-is-caused-by-bacteria.\\\">septic or pyogenic which is caused by bacteria. </h2></li>\\r\\n</ul>\\r\\n<h2 id=\\\"chronic-meningitis-is-a-complex-entity-with-both-infectious-and-noninfectious-causes.\\\">Chronic meningitis is a complex entity with both infectious and noninfectious causes.</h2>\\r\\n<h3 id=\\\"target-users\\\">Target users</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doctors</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"target-area-of-use\\\">Target area of use </h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ward</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"key-areas-of-focus-new-additions-changes\\\">Key areas of focus / New additions / Changes </h3>\\r\\n<p>This guideline addresses the management of the infective causes of meningitis in children and in adults. It provides advice on empirical antibiotic therapy.</p>\\r\\n<p>The treatment of infective chronic meningitis has been added to this guideline and the management of meningitis in the immunocompromised has been adopted in this new version.</p>\\r\\n<p>Antibiotic therapy is for two weeks at least.</p>\\r\\n<h2 id=\\\"limitations\\\">Limitations</h2>\\r\\n<h2 id=\\\"none.\\\">None.</h2>\\r\\n<h2 id=\\\"pathogens\\\">Pathogens</h2>\\r\\n<p><strong>1) Bacterial:</strong></p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Age range</strong></th>\\r\\n<th><strong>Organism</strong></th>\\r\\n<th><strong>Site of entry</strong></th>\\r\\n<th><strong>Predisposing conditions</strong></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>All ages</td>\\r\\n<td><em>Neisseria meningitidis</em></td>\\r\\n<td>Nasopharynx</td>\\r\\n<td>Usually none, rarely complement deficiency</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>All ages</td>\\r\\n<td><em>Streptococcus pneumoniae</em></td>\\r\\n<td><p>Nasopharynx,</p>\\r\\n<p>direct extension across skull fracture, or from contiguous or distant foci of infection</p></td>\\r\\n<td>All conditions that predispose to pneumococcal bacteremia, fracture of cribriform plate, cochlear implants, cerebrospinal fluid otorrhea from basilar skull fracture, defects of the ear ossicle</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>All ages</td>\\r\\n<td><em>Coagulase-negative staphylococci</em></td>\\r\\n<td>Foreign body</td>\\r\\n<td>Surgery and foreign body, especially ventricular drains</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>All ages</td>\\r\\n<td><em>Staphylococcus aureus</em></td>\\r\\n<td>Bacteremia, foreign body, skin</td>\\r\\n<td>Endocarditis, surgery and foreign body, especially ventricular drains; cellulitis, decubitus ulcer</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Older adult (&gt;50yrs) and neonates</td>\\r\\n<td><em>Listeria monocytogenes</em></td>\\r\\n<td>Gastrointestinal tract, placenta</td>\\r\\n<td>Glucocorticoids, Transplantation (especially renal transplantation), Pregnancy, Liver disease, Alcoholism, Malignancy</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Older adults and neonates</td>\\r\\n<td><em>Gram-negative bacilli</em></td>\\r\\n<td>Various</td>\\r\\n<td>Advanced medical illness, neurosurgery, ventricular drains, disseminated strongyloidiasis</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Adults; infants and children if not vaccinated</td>\\r\\n<td><em>Haemophilus influenzae</em></td>\\r\\n<td>Nasopharynx, contiguous spread from local infection</td>\\r\\n<td>Diminished humoral immunity</td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<p><strong>2) Viral:</strong></p>\\r\\n<p>A number of viruses produce aseptic meningitis including enteroviruses, herpes simplex virus (HSV), human immunodeficiency virus (HIV), West Nile virus, varicella-zoster virus, mumps, and lymphocytic choriomeningitis virus.</p>\\r\\n<p><strong>3) Chronic meningitis:</strong></p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Age range</strong></th>\\r\\n<th><strong>Organism</strong></th>\\r\\n<th><strong>Site of entry</strong></th>\\r\\n<th><strong>Predisposing conditions</strong></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>All ages</td>\\r\\n<td><span data-custom-style=\\\"Emphasis\\\">Mycobacterium tuberculosis</span></td>\\r\\n<td>Pulmonary TB</td>\\r\\n<td><p>Acute complication of pulmonary TB or as a reactivation of extra pulmonary TB.</p>\\r\\n<p>HIV significantly increases the risk.</p></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>All ages</td>\\r\\n<td><span data-custom-style=\\\"Emphasis\\\">Cryptococcus neoformans</span></td>\\r\\n<td></td>\\r\\n<td>CD4 counts &lt; 100 cells/mm<sup>3</sup>.</td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs\\\">Presenting symptoms and signs</h2>\\r\\n<p>The main clinical features of acute bacterial meningitis (ABM) are headache, fever and meningism. When this triad is accompanied by alteration in consciousness or seizures, the diagnosis is usually not in doubt. Other symptoms include photophobia, nausea, vomiting, backache and lethargy. Progression occurs rapidly over 1-3 days but a smaller number may have an acute fulminant course lasting hours. However patients with HIV infection may present with only one or two of these main features.</p>\\r\\n<p>TB Meningitis is a difficult condition to diagnose and confirm clinically. The clinical features are those of slowly progressive. Constitutional TB symptoms including fever, night sweats, weight loss and malaise may be present for a week or more early on but these may also be absent or are not specific for TB. The main neurological symptoms suggestive of TB meningitis are headache, nausea, vomiting, irritability, behaviour change and meningism of gradual onset usually for a period of one week or usually longer in adults. However, headaches may be less prominent in children, fever may be absent in 10-20% of adults and the signs of meningitis are generally less prominent as compared to acute bacterial meningitis.</p>\\r\\n<h2 id=\\\"examination-findings\\\">Examination findings</h2>\\r\\n<h2 id=\\\"management\\\">Management </h2>\\r\\n<p><strong>Investigations</strong>:</p>\\r\\n<p><strong>1) Blood culture</strong> are often positive and can be useful in the event that cerebrospinal fluid (CSF) cannot be obtained before the administration of antimicrobials. Approximately 50 to 90 percent of patients with bacterial meningitis have positive blood cultures.</p>\\r\\n<p><strong>2) Lumbar puncture (LP)</strong> is the key investigation and is an overall simple and very safe test.</p>\\r\\n<p>*CONTRAINDICATIONS- Increased intracranial pressure; Thrombocytopenia or other bleeding diathesis; Cardiopulmonary instability; Soft tissue infection at the puncture site.</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th></th>\\r\\n<th><strong>Acute bacterial meningitis</strong></th>\\r\\n<th><strong>Tuberculous</strong></th>\\r\\n<th><strong>Cryptococcal</strong></th>\\r\\n<th><strong>Viral</strong></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Appearance</strong></td>\\r\\n<td>cloudy, purulent</td>\\r\\n<td>yellow/cloudy</td>\\r\\n<td>clear/cloudy</td>\\r\\n<td>Clear (cloudy)</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Cell/mm<sup>3</sup></strong></td>\\r\\n<td><p>high</p>\\r\\n<p>&gt; 2000/mm<sup>3</sup></p>\\r\\n<p>neutrophils</p></td>\\r\\n<td><p>increased</p>\\r\\n<p>50-500/mm<sup>3</sup></p>\\r\\n<p>lymphocytes</p></td>\\r\\n<td><p>normal/increased</p>\\r\\n<p>0-100/mm<sup>3</sup></p>\\r\\n<p>lymphocytes</p></td>\\r\\n<td><p>normal/increased</p>\\r\\n<p>0-500/mm<sup>3</sup></p>\\r\\n<p>lymphocytes</p></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><p><strong>Glucose</strong></p>\\r\\n<p><strong>(n=&gt; 50% of plasma level)</strong></p></td>\\r\\n<td><p>very low/absent</p>\\r\\n<p>&lt;1mmol/L</p></td>\\r\\n<td>low</td>\\r\\n<td>normal/low</td>\\r\\n<td>normal</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><p><strong>Protein</strong></p>\\r\\n<p><strong>(n=&lt; 0.5 mg/l)</strong></p></td>\\r\\n<td><p>elevated</p>\\r\\n<p>1-2 mg/L</p></td>\\r\\n<td><p>high/very high</p>\\r\\n<p>1-5 mg/L</p></td>\\r\\n<td><p>normal/elevated</p>\\r\\n<p>0.5-2 mg/L</p></td>\\r\\n<td><p>normal/elevated</p>\\r\\n<p>0.5-1 mg/L</p></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Diagnosis confirmed</strong></td>\\r\\n<td>Gram stain &amp; culture</td>\\r\\n<td>ZN stain &amp; culture</td>\\r\\n<td>India ink stain/ Cryptococcal Antigen/Culture</td>\\r\\n<td>PCR</td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<p><strong>Treatment:</strong></p>\\r\\n<p><strong>Bacterial</strong> — The mainstay of management of ABM is prompt diagnosis and early treatment with antimicrobials. It is important that antimicrobials should be given straight away (within 20-30 mins of first seeing the patient) and not to delay treatment because of ongoing investigations including a LP. In adults ceftriaxone is now the drug of first choice. In adult, the dose is 4g/day while in children, 100 <span data-custom-style=\\\"nowrap\\\">mg/kg</span>/day IV (maximum dose 4 <span data-custom-style=\\\"nowrap\\\">g/day)</span> in 1 or 2 divided doses. The use of steroids in the treatment of ABM in adults is currently not recommended in Africa.</p>\\r\\n<p><strong>Viral</strong> — Most patients with viral meningitis require only supportive care. Patients who are elderly, immunocompromised, or have received antibiotics prior to presentation may be considered for empiric antibacterial therapy for 48 hours, even if viral meningitis is the suspected diagnosis.</p>\\r\\n<p>If HIV is a diagnostic consideration, then blood testing for HIV RNA and HIV antibody should be performed.</p>\\r\\n<p>If aseptic meningitis due to HSV is suspected, empiric therapy with intravenous acyclovir (for adult and children: 10-15 mg/kg every 8 hours, for neonates: 60 mg/kg per day divided every 8 hours) can be considered for hospitalized patients.</p>\\r\\n<p><strong>TB</strong> — All four TB drugs are given for the first 2 months after which isoniazid and rifampicin are continued usually for another 10 months. In practice the standard total period of treatment is 12 months for tuberculous meningitis and longer for tuberculoma.</p>\\r\\n<p>In general, glucocorticoid therapy is warranted for all patients (including those with HIV) with convincing epidemiologic or clinical evidence for tuberculous meningitis. The regimen consists of oral prednisolone: children: 2 to 4 <span data-custom-style=\\\"nowrap\\\">mg/kg</span> per day; adolescents and adults: 60 <span data-custom-style=\\\"nowrap\\\">mg/day</span>. Administer initial dose for two weeks, then taper gradually over the next six weeks (ie, reduce daily dose by 10 mg each week); total duration is approximately eight weeks.</p>\\r\\n<p>Starting ART is recommended after the first 2 weeks of TB meningitis treatment in HIV.</p>\\r\\n<p><strong>Cryptococcal</strong> — The treatment of Cryptococcal meningitis (CM) in Africa is mostly based on fluconazole alone. There are three phases: induction phase, consolidation phase and maintenance phase. In the induction phase, fluconazole (1200 mg orally per day) may be administered for at least 10 weeks or until CSF culture results are negative, followed by consolidation therapy with fluconazole (400 mg orally daily). The maintenance or prophylaxis phase uses fluconazole 200 mg daily until the CD4 count is &gt; 200/mm<sup>3</sup> for &gt;6 months. Multiple lumbar punctures may be needed to relieve raised ICP.</p>\\r\\n<p>A delay in initiation of ART until at least 4 weeks after the start of the treatment phase appears to have a better outcome in fluconazole treated patients. Long-term mortality in CM is high (&gt; 50%) even with ART.</p>\\r\\n<p><strong>Unclear etiology</strong> — When it is not clear whether the patient has a viral or bacterial process, we recommend empirical antibiotics after obtaining blood and CSF cultures or observation with repeat lumbar puncture in 6 to 24 hours. If the patient is symptomatically improved and culture results are negative, then antibiotics can generally be stopped without a repeat LP. However, repeat LPs may be indicated in patients with persistent symptoms who do not have a clear diagnosis.</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th></th>\\r\\n<th><strong>Acute bacterial meningitis</strong></th>\\r\\n<th><strong>Tuberculous</strong></th>\\r\\n<th><strong>Cryptococcal</strong></th>\\r\\n<th><strong>HSV</strong></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><p><strong>Medication dose</strong></p>\\r\\n<p><strong>(<em>in children</em>)</strong></p></td>\\r\\n<td><p>Ceftriaxone</p>\\r\\n<p>4 g <em>(100 mg/kg</em>) OD</p></td>\\r\\n<td><p><sup>1)</sup>TB4</p>\\r\\n<p><sup>2)</sup>Prednisolone<br />\\r\\n60 mg <em>(2-4 mg/kg)</em> OD</p></td>\\r\\n<td><p>Fluconazole</p>\\r\\n<p><sup>1)</sup>1200 mg <em>(18 mg/kg)</em> OD</p>\\r\\n<p><sup>2)</sup>400 mg <em>(6 mg/k</em>g) OD</p>\\r\\n<p><sup>3)</sup>200 mg <em>(3 mg/kg)</em> OD</p></td>\\r\\n<td><p>Acyclovir</p>\\r\\n<p>10-15 mg/kg TDS</p>\\r\\n<p><em>(neonate: 60 mg/kg divided every 8 hours</em>)</p></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><p><strong>Duration</strong></p>\\r\\n<p><strong>(<em>in children</em>)</strong></p></td>\\r\\n<td><p>2 weeks</p>\\r\\n<p><em>(3 weeks)</em></p></td>\\r\\n<td><p><sup>1)</sup> 12 months</p>\\r\\n<p><sup>2)</sup> 2 weeks, then taper gradually over the next six weeks</p></td>\\r\\n<td><p><sup>1)</sup>10 weeks</p>\\r\\n<p><sup>2)</sup>8 weeks</p>\\r\\n<p><sup>3)</sup>until the CD4 count is &gt;200/mm3 for &gt; 6 months</p></td>\\r\\n<td>2 weeks</td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<h2 id=\\\"key-issues-for-nursing-care\\\">Key Issues for Nursing care</h2>\\r\\n<ul>\\r\\n<li><h2 id=\\\"deterioration-in-clinical-status-can-occur-rapidly-so-frequently-assess-the-patients-neurologic-status-especially-level-of-consciousness-and-vital-signs.-report-new-focal-signs-immediately.\\\">Deterioration in clinical status can occur rapidly, so frequently assess the patient&#39;s neurologic status, especially level of consciousness and vital signs. Report new focal signs immediately.</h2></li>\\r\\n<li><h2 id=\\\"try-to-minimize-increases-in-the-patients-icp.-appropriate-measures-may-include-keeping-the-patients-head-of-bed-elevated-to-30-degrees-keeping-the-head-midline-minimizing-suctioning-using-sedation-keeping-the-room-quiet-and-dark-and-avoiding-hypercapnia.\\\">Try to minimize increases in the patient&#39;s ICP. Appropriate measures may include keeping the patient&#39;s head of bed elevated to 30 degrees, keeping the head midline, minimizing suctioning, using sedation, keeping the room quiet and dark, and avoiding hypercapnia.</h2></li>\\r\\n<li><h2 id=\\\"patients-with-bacterial-meningitis-may-develop-dehydration-shock-syndrome-of-inappropriate-secretion-of-antidiuretic-hormone-andor-intracranial-hypertension.-closely-monitor-for-fluid-and-electrolyte-imbalances.\\\">Patients with bacterial meningitis may develop dehydration, shock, syndrome of inappropriate secretion of antidiuretic hormone, and/or intracranial hypertension. Closely monitor for fluid and electrolyte imbalances.</h2></li>\\r\\n<li><h2 id=\\\"analgesics-may-be-required-to-treat-headache.-darkening-the-room-may-help-if-the-patient-complains-of-photophobia.\\\">Analgesics may be required to treat headache. Darkening the room may help if the patient complains of photophobia. </h2></li>\\r\\n<li><h2 id=\\\"the-patients-hearing-should-be-assessed-before-discharge-because-hearing-loss-is-a-common-late-complication-of-bacterial-meningitis.\\\">The patient&#39;s hearing should be assessed before discharge because hearing loss is a common late complication of bacterial meningitis.</h2></li>\\r\\n<li><h2 id=\\\"keep-in-mind-that-because-n.-meningitidis-is-easily-spread-from-person-to-person-secondary-cases-need-to-be-prevented.-suspected-meningococcal-disease-should-be-reported-to-the-local-public-health-department.-people-in-close-contact-with-an-infected-person-should-receive-chemoprophylaxis-with-single-dose-of-oral-ciprofloxacin-500-mg-daily-adults-only-or-oral-rifampicin-10-mgkg-twice-daily-up-to-1200-mgday-for-4-days\\\">Keep in mind that because <em>N. meningitidis</em> is easily spread from person to person, secondary cases need to be prevented. Suspected meningococcal disease should be reported to the local public health department. People in close contact with an infected person should receive chemoprophylaxis with single dose of oral ciprofloxacin 500 mg daily (adults only) or oral rifampicin 10 mg/kg twice daily (up to 1200 mg/day) for 4 days </h2></li>\\r\\n</ul>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<p>NEUROLOGY IN AFRICA; William Howlett: Updated Oct 17,.2018 (First published: Aug 16, 2012)</p>\\r\\n<p>Up To Date: Central nervous system tuberculosis: last updated: Oct 26, 2018.</p>\\r\\n<p>Up To Date: Epidemiology of bacterial meningitis in adults: last updated: Sep 26, 2018.</p>\\r\\n<p>Up To Date: Lumbar puncture: Indications, contraindications, technique, and complications: last updated: Sep 26, 2018.</p>\\r\\n<p>Up To Date: Fluconazole: Drug information</p>\\r\\n<p>Up To Date: Aseptic meningitis in adults: last updated: Sep 26, 2018.</p>\\r\\n<p>Up To Date: Clinical features and diagnosis of acute bacterial meningitis: This topic last updated: Aug 30, 2018</p>\\r\\n<p>Fire up to beat the threat of bacterial meningitis; Miller A, Nursing2013: December 2013 - Volume 43 - Issue 12 - p 52,58–58</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Eriko Ikeda</th>\\r\\n<th>Date: 29 October 2018</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Fatai Akemokwe</td>\\r\\n<td>Date: 07 November 2018</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>2.0</td>\\r\\n<td>Rewritten to include the management of chronic meningitis and adapted to the new template</td>\\r\\n<td>31 January 2021</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>2.1</td>\\r\\n<td>Executive summary added</td>\\r\\n<td>31 January 2021</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Review Comments (if applicable)</td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"060\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>Neonatal jaundice MeG-CLS-060</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"neonatal-jaundice\\\">Neonatal jaundice</h1>\\r\\n<h2 id=\\\"executive-summary\\\"><em>Executive summary</em></h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<p>Jaundice is a common problem affecting up to 60% of term neonates and 80% of preterm neonates.</p>\\r\\n<p>It is thought to develop due to the occurrence of:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Elevated bilirubin production due to the shortened life span of fetal erythrocytes and a relatively high haematocrit at birth</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Reduced hepatic excretory capacity</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>In the vast majority of neonates, this physiological jaundice will resolve spontaneously (by about 10 days of age) and causes no harm. In exclusively breast-fed babies it may persist for longer.</p>\\r\\n<p>It is important to identify those neonates with jaundice who require further investigation and treatment.</p>\\r\\n<p>Even in those neonates where physiological jaundice is presumed, bilirubin can sometimes rise to potentially dangerous levels and require intervention.</p>\\r\\n<h3 id=\\\"target-users\\\">Target users</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doctors</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nurses</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"target-area-of-use\\\">Target area of use </h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ward</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"key-areas-of-focus-new-additions-changes\\\">Key areas of focus / New additions / Changes </h3>\\r\\n<p>This guidelines outlines in clinical form the management of neonatal jaundice. For research participants, there is a more formal Standard Operating Procedure SOP-CLS-012 on sharepoint, which should be followed.</p>\\r\\n<h2 id=\\\"limitations\\\">Limitations</h2>\\r\\n<p>We do not routinely offer exchange transfusion. Patients seen in Keneba will require referral as serum bilirubin assay and phototherapy are not routinely available there.</p>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs\\\">Presenting symptoms and signs</h2>\\r\\n<p>Jaundice appears as a yellow discolouration of the sclerae and skin which typically starts centrally (face and chest) and spreads out to the peripheries.</p>\\r\\n<p>Visual inspection for the level of jaundice alone is unreliable and therefore a bilirubin level should always be measured urgently if a baby appears visibly jaundiced</p>\\r\\n<p>The baby should be examined for associated features including:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Signs of dehydration</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Signs of infection</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Lethargy</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Poor feeding</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Every baby with jaundice should be weighed and the percentage of its birth weight lost needs to be calculated:</p>\\r\\n<blockquote>\\r\\n<p>(birth weight – current weight x100)<br />\\r\\nbirth weight</p>\\r\\n</blockquote>\\r\\n<p>Babies who have lost &gt; 10% of their birth weight are more likely to have some degree of dehydration which will make their jaundice worse. These babies need particular attention to be paid to their hydration status.</p>\\r\\n<h2 id=\\\"differential-diagnoses\\\">Differential diagnoses</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Rhesus haemolytic disease</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>ABO incompatibility</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Congenital spherocytosis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Intrauterine infection</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Glucose-6-phosphate dehydrogenase deficiency</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Bacterial sepsis</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"investigation\\\">Investigation</h2>\\r\\n<p>All babies with suspected jaundice should have an urgent bilirubin level checked.</p>\\r\\n<p>Further investigations may be necessary depending on your clinical assessment. The following can be considered:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Group and save</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Full blood count and blood film</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Direct Coomb’s Test and maternal blood group</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Renal function</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Liver function</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Culture of blood, urine and CSF if considering sepsis as the cause</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Jaundice appearing within the first 24 hours of life is more likely to be pathological and often indicates haemolysis. These babies require urgent medical review and investigation as they are most at risk of developing encephalopathy due to a rapidly rising bilirubin.</p>\\r\\n<p>All babies with jaundice appearing within the first 24 hours should have the following investigations:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Total serum bilirubin</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>FBC and blood film</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Blood group and DCT</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Maternal blood group</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Culture of blood, urine and CSF (if concerned about sepsis)</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Once the bilirubin level is obtained, it should be plotted on the correct gestation specific chart (<a href=\\\"https://www.nice.org.uk/guidance/cg98/resources/treatment-threshold-graphs-excel-544300525\\\"><span data-custom-style=\\\"Hyperlink\\\">https://www.nice.org.uk/guidance/cg98/resources/treatment-threshold-graphs-excel-544300525</span></a>)</p>\\r\\n<p>In babies with jaundice within the first 24 hours or those who appear to be significantly jaundiced, consider starting phototherapy before the result is back if there is a delay in getting the results.</p>\\r\\n<h2 id=\\\"phototherapy\\\">Phototherapy</h2>\\r\\n<p>Babies whose bilirubin level plots between the phototherapy and exchange transfusion lines on the treatment threshold graph should be placed in a basinet and started on phototherapy.</p>\\r\\n<p>Consider intense phototherapy (2 lamps) in babies who:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Have a bilirubin level which plots within 50 micromol/L of the exchange transfusion line or higher</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Have a rapidly rising bilirubin (&gt; 8.5 micromol/L per hour)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Have a bilirubin level that fails to respond to initial phototherapy</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Once phototherapy is initiated, a repeat bilirubin level should be checked in 4-6 hours</p>\\r\\n<p>During phototherapy the bilirubin level should be measured every 6-12 hours once the bilirubin is stable or falling</p>\\r\\n<p>When the bilirubin level is more than 50 micromol/L below the phototherapy threshold line, phototherapy can be stopped</p>\\r\\n<p>Check for rebound hyperbilirubinaemia by repeating a bilirubin level 12-18 hours after stopping phototherapy</p>\\r\\n<p><strong>Exchange transfusion:</strong> if the bilirubin level exceeds the exchange transfusion line on the treatment graph, this baby needs to be discussed with the on-call consultant and consider transfer to EFSTH for exchange transfusion.</p>\\r\\n<h2 id=\\\"prolonged-jaundice\\\">Prolonged jaundice</h2>\\r\\n<p>Prolonged jaundice refers to jaundice persisting beyond 14 days in a term neonate and 21 days in a preterm neonate.</p>\\r\\n<p>This must be investigated as some causes may require further treatment.</p>\\r\\n<p>The following steps must be taken where prolonged jaundice occurs:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>a full history and clinical examination should be performed</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>a weight should be measured</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>stools should be examined: pale, chalky stools and dark urine suggests cholestasis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>check FBC, LFTs and thyroid function tests</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>serum bilirubin should be taken to establish whether the bilirubin is conjugated or unconjugated. Conjugated bilirubinaemia is defined as a conjugated bilirubin &gt; 17 mmol/L if the total bilirubin is &lt; 85 mmol/L or more than 20% of the total bilirubin if the total is &gt; 85 mmol/L</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>If the bilirubin is <strong>conjugated</strong>, consultation with a specialist should take place to determine further investigation and management.</p>\\r\\n<p>Most commonly the diagnosis is unconjugated hyperbilirubinaemia due to breast milk jaundice, but this is a diagnosis of exclusion.</p>\\r\\n<p>In babies who are well with normal bloods and an unconjugated hyperbilirubinaemia no further investigations are required.</p>\\r\\n<h2 id=\\\"key-issues-for-nursing-care\\\">Key Issues for Nursing care</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ensure the lights are placed at the correct distance from the baby, as per manufacturers advice (generally this is at 30 cm).</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Place the baby in a supine position.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ensure the maximum area of skin is exposed (baby should only be in a nappy).</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ensure the eyes are covered.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Babies should remain under the phototherapy lights as much as possible, having short breaks for feeds and cares.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Monitor the baby’s temperature and other vital signs every 4 hours as babies receiving phototherapy are at increased risk of dehydration and so their hydration status should be assessed daily and feeding support given to their carers.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Daily weights should be recorded.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<p>NICE guidelines: Jaundice in newborn babies under 28 days (2010 updated 2016).</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Lucy Affleck</th>\\r\\n<th>Date: 17 May 2019</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Karen Forrest</td>\\r\\n<td>Date: 22 May 2019</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td>31 May 2021</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"061\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>Nephrotic Syndrome MeG-CLS-061</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"nephrotic-syndrome\\\">Nephrotic syndrome </h1>\\r\\n<h2 id=\\\"executive-summary\\\"><em>Executive summary</em></h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<h2 id=\\\"nephrotic-syndrome-ns-is-a-clinical-disorder-characterized-by-the-presence-of-massive-proteinuria-hypoalbuminaemia-and-oedema.-it-may-be-idiopathic-or-secondary.-a-secondary-cause-must-be-sought-for-before-commencement-of-treatment-.\\\">Nephrotic syndrome (NS) is a clinical disorder characterized by the presence of massive proteinuria, hypoalbuminaemia and oedema. It may be idiopathic or secondary. A secondary cause must be sought for before commencement of treatment .</h2>\\r\\n<h2 id=\\\"idiopathic-ns-the-cause-is-usually-unknown-but-histologic-findings-include-minimal-change-disease-mcd-membranous-nephropathy-mn-and-focal-segmental-glomerulosclerosis-fsgs.-these-are-very-common-in-children-and-responsive-to-steroid-therapy-.-they-may-also-be-seen-in-adults.\\\">Idiopathic NS: The cause is usually unknown but histologic findings include minimal change disease (MCD), membranous nephropathy (MN) and focal segmental glomerulosclerosis (FSGS). These are very common in children and responsive to steroid therapy . They may also be seen in adults.</h2>\\r\\n<h2 id=\\\"secondary-ns-these-may-have-similar-histologic-features-as-idiopathic-ns-but-are-due-to-known-causes-such-as-viral-infections-e.g.-hiv-hbv-and-hcv-non-communicable-diseases-such-as-diabetes-mellitus-multiple-myeloma-and-amyloidosis-and-auto-immune-disorders-such-as-systemic-lupus-erythematosus.-secondary-ns-makes-up-a-small-fraction-of-ns-and-requires-treatment-of-the-underlying-cause.\\\">Secondary NS: These may have similar histologic features as idiopathic NS but are due to known causes such as viral infections e.g. HIV, HBV and HCV , non-communicable diseases such as diabetes mellitus, multiple myeloma and amyloidosis; and auto-immune disorders such as systemic lupus erythematosus. Secondary NS makes up a small fraction of NS and requires treatment of the underlying cause.</h2>\\r\\n<h3 id=\\\"target-users\\\">Target users</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doctors</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"target-area-of-use\\\">Target area of use </h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ward</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Outpatient department</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"key-areas-of-focus-new-additions-changes\\\">Key areas of focus / New additions / Changes </h3>\\r\\n<p>This guideline focuses on the diagnosis and treatment of idiopathic nephrotic syndrome in adults and children. Treatment of secondary nephrotic syndrome requires treatment of the underlying cause. These can be found in the related specific guideline .</p>\\r\\n<p>Treatment of nephrotic syndrome may take up to 3 months in children and 7 months in adults.</p>\\r\\n<h3 id=\\\"limitations\\\">Limitations </h3>\\r\\n<p>Cases of relapse and steroid resistance require referral to nephrologist</p>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs\\\">Presenting symptoms and signs</h2>\\r\\n<p>These include:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Passage of frothy urine</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Leg swelling</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Facial swelling</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Abdominal swelling</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Breathlessness</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Dizziness</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Reduction in urine output</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"important-warning-features\\\">Important warning features :</h3>\\r\\n<p>These findings may indicate a diagnosis other than NS :</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Macroscopic haematuria – coke-colored urine or blood in urine</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Elevated blood pressure</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Jaundice</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Paroxysmal nocturnal dyspnea</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Raised jugular venous pressure</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p><strong>Diagnosis</strong></p>\\r\\n<p>Diagnosis of NS is made when the following are present:</p>\\r\\n<ol type=\\\"1\\\">\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Oedema</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Urine dipstick showing 3-4+ protein OR urine protein/creatinine ratio ≥ 2 g/g OR protein in 24-hour urine of ≥ 3.0 g</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hypoalbuminaemia (&lt; 25 g/L).</p>\\r\\n</div></li>\\r\\n</ol>\\r\\n<p>Hyperlipidaemia (high LDL cholesterol levels) may be present but is not necessary for diagnosis. In view of this, there is no indication to check the lipid profile.</p>\\r\\n<h2 id=\\\"examination-findings\\\">Examination findings</h2>\\r\\n<p>The most common examination findings include</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Peripheral oedema</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Periorbital oedema</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ascites</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p><strong>Investigations</strong></p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Urine dipstick</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Early morning urine protein/creatinine ratio</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Serum creatinine</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Serum albumin</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Serum lipid profile</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Plain chest X-ray</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>FBC</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Renal biopsy</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<blockquote>\\r\\n<p>Other tests to rule out secondary causes of NS:</p>\\r\\n</blockquote>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>HIV Serology</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hepatitis serology</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Serum or urine protein electrophoresis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Blood glucose</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"management\\\">Management </h2>\\r\\n<h3 id=\\\"for-children-with-ns\\\">For children with NS </h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Admit child with first presentation of NS.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Oedema: Reduce salt intake and maintain strict fluid balance. If oedema is symptomatic there may be need to give IV frusemide 1 mg/kg OD (not more than 40 mg per dose).</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Prophylaxis against complications:</p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Infections: Oral penicillin V at 125 mg BD if under 5 years, or 250 mg BD if over 5 years. This should continue until oedema subsides. If the child is profoundly ill or appears to have sepsis use IV Ceftriaxone 50 mg/kg OD (max 2g)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Prednisolone - induced gastritis: Oral omeprazole 0.5 - 1.5 mg OD (max 40 mg OD )</p>\\r\\n</div></li>\\r\\n</ul></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Immunosuppressive therapy: To induce remission, followed by a slow wean to reduce risk of relapse: Oral prednisolone 60 mg/m<sup>2</sup>/day or 2mg /kg (max 80 mg) OD for 4 weeks, then 40 mg/m<sup>2</sup>/alternate days (max 60 mg) for 4 weeks, then 20 mg/m<sup>2</sup>/alternate days for 10 days, then 10 mg/m<sup>2</sup>/on alternate days for 10 days, then 5 mg/m<sup>2</sup>/alternate days for 10 days, then cease.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"for-adults-with-ns\\\">For adults with NS </h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Oedema: Restrict dietary sodium to less than 3 g per day and fluid to less than 1,500 mL per day. Strict fluid balance.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Treat oedema with loop diuretics – oral or IV – depending on degree of oedema. The aim is to reduce patient’s weight by 0.5-1 kg /day.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Proteinuria: Give ACE inhibitors regardless of blood pressure. Start at low dose.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>There is no evidence to support the use of corticosteroids in adult NS. However, it is recommended based on histological reports. Patients with Idiopathic NS from MCD and FSGS may be placed on prednisolone 1 mg/kg/day (max 80 mg/day) for 4 weeks (or continued over 16 weeks) with treatment tapered off over 6 months.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Treat secondary cause of NS if present.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Anticoagulation, statin therapy and infection prophylaxis are not recommended for adults. However, treat infections, if they occur and provide prophylaxis for patients at high risk of thromboembolic events.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Refer patients who still have proteinuria after treatment to nephrologist for expert management.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"special-issues-and-complications\\\">Special issues and complications </h3>\\r\\n<p><strong>Remission</strong> is present when the urine dipstick protein ≤ 1+ on 3 consecutive days after completion of treatment course.</p>\\r\\n<p><strong>Relapse</strong> is defined as the presence of oedema plus urine dipstick protein of ≥ 3+ for 3 consecutive days after remission. This requirements the re-commencement of steroid therapy.</p>\\r\\n<p><strong>Steroid resistance</strong> exists when urine dipstick protein ≥ 3+ for 3 consecutive days with oedema, after a 4-week course of treatment with steroids in adults and 3 month course in children.</p>\\r\\n<p>In the case of relapse or steroid resistance, consider referring patient to nephrologist for specialist care.</p>\\r\\n<p>Complications include hypovolaemia, infection and thrombosis and acute kidney injury.</p>\\r\\n<h2 id=\\\"key-issues-for-nursing-care\\\">Key Issues for Nursing care</h2>\\r\\n<h2 id=\\\"while-a-patient-is-on-admission-the-following-should-be-done\\\">While a patient is on admission the following should be done:</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Daily urine dipstick measurement</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Daily weighing</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Blood pressure monitoring</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Strict fluid balance chart.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<p>National Kidney Foundation. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl. 2012(2)</p>\\r\\n<p>Kodner C. Nephrotic syndrome in adults: diagnosis and management. American family physician. 2009 Nov 15;80(10).</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Orighomisan Agboghoroma</th>\\r\\n<th>Date: 15 November 2018</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Karen Forrest</td>\\r\\n<td>Date: 16 November 2018</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td>31 January 2021</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>1.1</td>\\r\\n<td>Executive summary added</td>\\r\\n<td>31 January 2021</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"042\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>Osteoarthritis MeG-CLS-042</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"osteoarthritis\\\">Osteoarthritis</h1>\\r\\n<h2 id=\\\"executive-summary\\\"><em>Executive summary</em></h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<p>Osteoarthritis (OA) is a common condition resulting in mechanical and biological dysfunction of joints leading to loss of cartilage, sclerosis and eburnation of the subchondral bone, osteophytes, and subchondral cysts. It is characterized by joint pain, stiffness, and functional limitation. Key risk factors include age over 50 years, female sex, obesity and occupation.</p>\\r\\n<h2 id=\\\"target-users\\\">Target users</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nurses</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doctors</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"target-area-of-use\\\">Target area of use </h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Gate Clinic</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>OPD</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"key-areas-of-focus-new-additions-changes\\\">Key areas of focus / New additions / Changes </h2>\\r\\n<p>This guideline provides information on the diagnosis and treatment of osteoarthritis. Patients with typical presentation do not require further workup. Treatment involves both non-pharmacologic and pharmacological measures.</p>\\r\\n<h2 id=\\\"limitations\\\">Limitations</h2>\\r\\n<p>Physical and occupational therapy services are not available in our facility. Surgical therapy is currently not available within The Gambia<strong>.</strong></p>\\r\\n<h2 id=\\\"introduction-1\\\">Introduction</h2>\\r\\n<p>Osteoarthritis (OA) is a condition resulting in mechanical and biological dysfunction of joints leading to loss of cartilage, sclerosis and eburnation of the subchondral bone, osteophytes, and subchondral cysts. It is characterized by joint pain, stiffness, and functional limitation.</p>\\r\\n<p>Key risk factors include:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Age over 50 years</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Female sex</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Obesity</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Physical or manual occupation including agricultural work.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs\\\">Presenting symptoms and signs</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Pain relating to physical activity and weight bearing activity.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Functional difficulties such as knee giving way.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Commonly affects knees, hips, hands, lumbar and cervical spine.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Unlikely to involve the ankles (which helps in differential diagnosis)</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Morning stiffness is rare and would require further investigation (if present for more than 30 minutes.)</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"examination-findings\\\">Examination findings</h2>\\r\\n<ul>\\r\\n<li><h2 id=\\\"oa-can-cause-pain-along-the-joint-line.\\\">OA can cause pain along the joint line.</h2></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Crepitus (palpable &amp; sometimes audible creaking of joint in active and passive movement.)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Bony deformity (especially in the hands there is enlargement of the proximal interphalangeal (PIP) and distal interphalangeal (DIP) joints. In advanced knee osteoarthritis there may be new bone formation causing bony swelling.)</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"differential-diagnoses\\\">Differential diagnoses</h3>\\r\\n<p><strong>Rheumatoid arthritis</strong> - small joint symmetrical polyarthritis, with prolonged morning stiffness. Exacerbations can be associated with malaise and feeling generally unwell. May have raised ESR, raised CRP and erosive changes on X-ray.</p>\\r\\n<p><strong>Psoriatic arthritis</strong> – Associated with psoriasis but can occur without skin lesions. It usually affects DIP joints (asymmetrical) and shows erosive changes on X-ray.</p>\\r\\n<p><strong>Gout &amp; Pseudogout</strong> – Normally more acute onset with hot, swollen, tender joints. Gout affects first metatarsophalangeal joint (big toe pain), while pseudogout most commonly affects wrist and knee. Aspiration of the joint can diagnose this.</p>\\r\\n<p><strong>Avascular necrosis</strong> –Consider if patients with history of corticosteroid use or young adults with sickle cell disease. Half of these cases will have associated effusion.</p>\\r\\n<p><strong>Bursitis</strong> (Greater trochanteric gives pain over lateral aspect of the hip, pes anserine bursitis gives pain over medial aspect of the knee.)</p>\\r\\n<h2 id=\\\"investigations\\\">Investigations</h2>\\r\\n<p>Generally, no investigations are required if ALL the following are true</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Over 50</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>No morning stiffness (or less than 30 minutes.)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Crepitus</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Joint line tenderness</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Bony enlargement (in knee) or classical Heberden or Bouchard nodes (in hands)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>No palpable warmth</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Where there is doubt:</p>\\r\\n<ol type=\\\"1\\\">\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>X-ray of affected joint – Will show new bone formation (osteophytes), joint space narrowing, and subchondral sclerosis and cysts.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>ESR: ordered if inflammatory arthritis is suspected. In OA, ESR should be less than 40 mm/hour</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Rheumatoid Factor (RF) – If inflammatory arthritis is suspected.</p>\\r\\n</div></li>\\r\\n</ol>\\r\\n<p>Uric acid is not generally indicated but may be worthwhile in conjunction with joint aspiration when calculating risk of gout over septic arthritis in hot, red swollen joint.</p>\\r\\n<h2 id=\\\"management\\\">Management</h2>\\r\\n<h3 id=\\\"non-pharmacological-management\\\">Non pharmacological management</h3>\\r\\n<p>Weight loss and exercise are key aspects of management.</p>\\r\\n<p>Physiotherapy including quadriceps exercises is helpful.</p>\\r\\n<p>Occupational therapy – supportive footwear and stick/ cane on contralateral side of arthritic joint.</p>\\r\\n<h3 id=\\\"pharmacological\\\">Pharmacological </h3>\\r\\n<p>1<sup>st</sup> line: Topical/ local treatment – diclofenac gel + non pharmacological management</p>\\r\\n<p>2<sup>nd</sup> line: Oral treatment – Regular Paracetamol + 1<sup>st</sup> line measures.</p>\\r\\n<p>3<sup>rd</sup> line: NSAIDS for shortest possible duration (Ibuprofen 200-400mg TDS) + paracetamol + 1<sup>st</sup> line measures. (Consider gastroprotection with omeprazole when prescribing NSAIDS) .</p>\\r\\n<p>4<sup>th</sup> line: Codeine (15-60mg QDS) + NSAIDS + paracetamol + 1<sup>st</sup> line measures.</p>\\r\\n<p>5<sup>th</sup> line: May include the addition of stronger opioids – such as Morphine Slow-Release Tablets (MST).</p>\\r\\n<p><strong>Adjuvant therapy</strong> such as intraarticular methylprednisolone injections during any line of management to help improve pain and daily functioning. These may be available in some private clinics locally.</p>\\r\\n<p>Patients unable to gain adequate/ acceptable pain control with functional impairment may wish to seek referral outside of The Gambia for surgical management.</p>\\r\\n<h2 id=\\\"key-issues-for-nursing-care\\\">Key Issues for Nursing care</h2>\\r\\n<p>Patients should be advised about weight loss and exercise.</p>\\r\\n<p>Anyone with red, hot , or swollen joint should be seen/discussed with a doctor in OPD</p>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<p>Badlissi F. Osteoarthritis. BMJ Best Practice. May 2018. Available from: <a href=\\\"https://bestpractice.bmj.com/topics/en-us/192\\\"><span data-custom-style=\\\"Hyperlink\\\">https://bestpractice.bmj.com/topics/en-us/192</span></a> Accessed: June 2018</p>\\r\\n<p>National Institute of Clinical excellence (NICE) clinical guideline [CG177] Osteoarthritis Care and Management February 2014</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: David Burgess</th>\\r\\n<th>Date: 01 June 2018</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Fatai Akemokwe</td>\\r\\n<td>Date: 11 June 2018</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td>31 July 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>1.1</td>\\r\\n<td>Executive summary added</td>\\r\\n<td>31 July 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"023\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>Otitis media MeG-CLS-023</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"otitis-media\\\">Otitis media</h1>\\r\\n<h2 id=\\\"executive-summary\\\"><em>Executive summary</em></h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<h2 id=\\\"acute-otitis-media-aom-is-a-self-limiting-infection-of-the-middle-ear-mainly-affecting-children.-it-can-be-caused-by-viruses-and-bacteria-and-both-are-often-present-at-the-same-time.-symptoms-last-for-about-3-days-but-can-last-for-up-to-7-or-8most-children-get-better-within-3-days-without-antibiotics.-antibiotics-make-little-difference-to-the-rates-of-common-complications-such-as-hearing-loss-which-is-usually-temporary-perforated-eardrum-and-recurring-infection.-acute-otitis-media-is-uncommon-in-adults.\\\">Acute otitis media (AOM) is a self-limiting infection of the middle ear mainly affecting children. It can be caused by viruses and bacteria, and both are often present at the same time. Symptoms last for about 3 days, but can last for up to 7 or 8–most children get better within 3 days without antibiotics. Antibiotics make little difference to the rates of common complications, such as hearing loss (which is usually temporary), perforated eardrum and recurring Infection. Acute otitis media is uncommon in adults.</h2>\\r\\n<p>A particular subtype of AOM is acute suppurative otitis media (OM), which is characterized by the presence of pus in the middle ear. If the ear drum perforates then ear discharge will be present. The perforation usually heals spontaneously.</p>\\r\\n<h2 id=\\\"target-users\\\">Target users</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doctors</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nurses</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"target-area-of-use\\\">Target area of use </h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Gate clinic</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Outpatient department</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ward</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"key-areas-of-focus-new-additions-changes\\\">Key areas of focus / New additions / Changes </h2>\\r\\n<p>This guideline addresses recognition and treatment of otitis media.</p>\\r\\n<h2 id=\\\"limitations\\\">Limitations</h2>\\r\\n<p>None</p>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs\\\">Presenting symptoms and signs</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>earache (in older children)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>pulling, tugging, or rubbing of the ear</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>non-specific symptoms such as fever, irritability, crying, poor feeding</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>restlessness at night</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>cough</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>rhinorrhoea (in younger children)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>fever</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"examination-findings\\\">Examination findings</h2>\\r\\n<p>Examination with an otoscope may show signs of:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>a distinctly red, yellow or opaque ear drum</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>moderate to severe bulging of the ear drum with loss of normal landmarks</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>an air-fluid level behind the ear drum</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>perforation of the ear drum or discharge in the external auditory canal</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>In babies under 6 months, diagnosis can be difficult because of non-specific symptoms or coexisting systemic illness and examination with an otoscope can be more challenging.</p>\\r\\n<h2 id=\\\"management\\\">Management </h2>\\r\\n<p>Acute otitis media could have a viral or bacterial cause, and distinguishing between these is difficult. Both are usually self-limiting and do not routinely need antibiotics. Antibiotics should be used if:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>symptoms significantly worsen or do not improve within 3 days</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>child is under 2 years with acute otitis media in both ears</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>children of any age with otorrhoea (discharge following perforation of the ear drum)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>children that are systemically very unwell</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>children at high risk of complications because of pre-existing comorbidity e.g AOM in the only hearing ear, AOM post cochlear implant and immunocompromised states.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Oral analgesia: Paracetamol 10-15 mg/kg/dose TDS/QDS or Ibuprofen 5-10 mg/kg/dose TDS</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Antibiotics to use in AOM</strong></th>\\r\\n<th></th>\\r\\n<th></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><em><strong>First choice</strong></em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td></td>\\r\\n<td>Amoxicillin</td>\\r\\n<td><p>&lt;12 years: 80 mg/kg TDS for 7 days</p>\\r\\n<p>&gt;12 years: 500 mg TDS for 7 days</p></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><em>In penicillin allergy use</em></td>\\r\\n<td>Erythromycin (in pregnancy)</td>\\r\\n<td>&gt;8 years: 250 mg to 500 mg QDS for 7 days or 500 to 1000 mg BD for 7 days</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td></td>\\r\\n<td>Azithromycin</td>\\r\\n<td>10 mg/kg OD for 3 days</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><em><strong>Second choice</strong></em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td></td>\\r\\n<td>Co-amoxiclav</td>\\r\\n<td>80-90 mg/kg/day BD for 7 days</td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<p>The symptoms of AOM should resolve within 72 hours of initiating antibiotic treatment.</p>\\r\\n<h2 id=\\\"complications-of-aom-include\\\">Complications of AOM include:</h2>\\r\\n<h2 id=\\\"tympanic-membrane-perforation-aom-with-tm-perforation-is-common-and-results-in-otorrhoea-and-frequently-relief-of-pain.\\\">Tympanic membrane perforation: AOM with TM perforation is common and results in otorrhoea and frequently, relief of pain. </h2>\\r\\n<h2 id=\\\"acute-mastoiditis-am-acute-mastoiditis-although-rare-is-the-most-common-suppurative-complication-of-aom-and-may-be-associated-with-intracranial-complications.-the-diagnosis-of-am-is-based-on-post-auricular-inflammatory-signs-erythema-oedema-tenderness-or-fluctuance-a-protruding-auricleexternal-auditory-canal-oedema-and-signs-of-aom.-ent-involvement-is-required-and-some-cases-may-require-surgical-treatment.\\\">Acute mastoiditis (AM): Acute mastoiditis, although rare, is the most common suppurative complication of AOM and may be associated with intracranial complications. The diagnosis of AM is based on post-auricular inflammatory signs (erythema, oedema, tenderness or fluctuance), a protruding auricle/external auditory canal oedema and signs of AOM. ENT involvement is required and some cases may require surgical treatment.</h2>\\r\\n<h2 id=\\\"otitis-media-with-effusion-ome\\\">Otitis Media with Effusion (OME)</h2>\\r\\n<h2 id=\\\"otitis-media-with-effusion-previously-termed-serous-otitis-or-glue-ear-is-fluid-in-the-middle-ear-and-is-often-asymptomatic-other-than-transient-hearing-impairment\\\">Otitis media with effusion, previously termed serous otitis or glue ear, is fluid in the middle ear and is often asymptomatic, other than transient hearing impairment</h2>\\r\\n<p>Antibiotics and ENT referral are not routinely required for OME, as the majority of cases occur after an episode of AOM and resolve spontaneously with no long term effects on language, literacy or cognitive development. The effusion may persist for up to 1 month in 50% of patients and up to 3 months in 10% of patients despite bacteriological cure.</p>\\r\\n<h2 id=\\\"if-effusion-persists-for-more-than-3-months-refer-for-hearing-assessment-and-ent-review.\\\">If effusion persists for more than 3 months, refer for hearing assessment and ENT review.</h2>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<p>Acute otitis media. Retrieved <a href=\\\"https://www.rch.org.au/clinicalguide/guideline_index/acute_otitis_media/#otitis-media-with-effusion-ome\\\"><span data-custom-style=\\\"Hyperlink\\\">https://www.rch.org.au/clinicalguide/guideline_index/acute_otitis_media/#otitis-media-with-effusion-ome</span></a> on 25th February, 2019</p>\\r\\n<p>Colledge, Nicki R., Brian R. Walker, Stuart Ralston, and Stanley Davidson. 2010. Davidson&#39;s principles and practice of medicine. Edinburgh: Churchill Livingstone/Elsevier.</p>\\r\\n<p>Guideline Otitis media (acute): antimicrobial prescribing. National Institute for Health and Care Excellence. Retrieved from <a href=\\\"https://www.nice.org.uk/guidance/ng91/documents/draft-guideline\\\"><span data-custom-style=\\\"Hyperlink\\\">https://www.nice.org.uk/guidance/ng91/documents/draft-guideline</span></a> on 27th February, 2019.</p>\\r\\n<p>Kliegman, Robert., et al. Nelson Textbook of Pediatrics. Edition 20. Phialdelphia, PA: Elsevier, 2016.</p>\\r\\n<p>Waseem M (2018). Otitis Media. Medscape. Retrieved from <a href=\\\"https://emedicine.medscape.com/article/994656-overview\\\"><span data-custom-style=\\\"Hyperlink\\\">https://emedicine.medscape.com/article/994656-overview</span></a> on 26th February, 2019</p>\\r\\n<p>Standard Treatment Guidelines, 6th Edition, 2010. ISBN 978-9988-1-2538-7</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Fatoumatta Sawaneh</th>\\r\\n<th>Date: 27 February 2019</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Baderinwa Abatan</td>\\r\\n<td>Date: 03 May 2019</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td>31 May 2021</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>2.0</td>\\r\\n<td>Updated and transferred to new template</td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"064\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>Palliative Care  MeG-CLS-064</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"palliative-care\\\">Palliative care</h1>\\r\\n<h2 id=\\\"executive-summary\\\"><em>Executive summary</em></h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<h2 id=\\\"palliative-care-is-given-when-a-patient-is-known-to-be-dying-or-when-they-have-a-condition-which-cannot-be-cured-and-which-will-cause-them-to-gradually-deteriorate-until-they-die.-the-priority-under-these-circumstances-is-to-maintain-the-patients-comfort-and-to-avoid-distressing-interventions-or-indeed-any-intervention-that-is-uncomfortable-unless-there-is-a-clear-benefit.\\\">Palliative care is given when a patient is known to be dying or when they have a condition which cannot be cured and which will cause them to gradually deteriorate until they die. The priority under these circumstances is to maintain the patient’s comfort and to avoid distressing interventions or, indeed, any intervention that is uncomfortable unless there is a clear benefit. </h2>\\r\\n<h2 id=\\\"target-users\\\">Target users</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nurses</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doctors</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"target-area-of-use\\\">Target area of use </h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Outpatient department</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ward</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"key-areas-of-focus-new-additions-changes\\\">Key areas of focus / New additions / Changes </h2>\\r\\n<p>This guideline briefly discusses the principles of palliative care and the important decisions that need to be made. It outlines the treatment options available to patients receiving palliative care.</p>\\r\\n<h2 id=\\\"limitations\\\">Limitations</h2>\\r\\n<p>None</p>\\r\\n<h2 id=\\\"decisions-about-resuscitation-and-escalation-of-treatment\\\">Decisions about resuscitation and escalation of treatment</h2>\\r\\n<p>The doctors should make a decision to approach a patient palliatively when they have a diagnosis that is causing significant symptoms and which cannot be reversed. This can be a very difficult call to make and where there is uncertainty, it is appropriate to involve a consultant in the decision-making process.</p>\\r\\n<p>Once the decision has been made that a patient should be approached palliatively, two other factors should be considered.</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Is this patient likely to die during this admission? Should they be resuscitated if they die?</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Should the nurses continue to check their observations? Even if they continue, should they calculate MEWS and alert the doctors about any changes?</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Both of these topics must be discussed with a consultant and any decision not to attempt resuscitation or not to calculate MEWS should be clearly documented in the notes and communicated to all staff looking after the patient.</p>\\r\\n<p>There must be careful consideration of how this is communicated with the patient and their relatives. International best practice suggests that this communication occurs, but this must be modified in accordance with our cultural context. The senior staff of the department should be consulted about this.</p>\\r\\n<h2 id=\\\"approach-to-the-patient-receiving-palliative-care\\\">Approach to the patient receiving palliative care</h2>\\r\\n<h3 id=\\\"important-issues-to-consider\\\">Important issues to consider</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Does the patient need to be kept in hospital or can their needs be met at home? If they can go home, do the carers know how to look after the patient? Do they know what to do if they need help or they have any questions or concerns?</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Does the patient need all the medications they are currently taking? Are the medicines likely to improve the outcome or the symptoms that the patient has? Are they causing any side effects?</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Is the patient in pain? If they are taking strong pain killers, are they nauseated and have they been to toilet? Do they have any other side effects?</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Are there any other distressing symptoms – cough, shortness of breath, difficulty sleeping etc?</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Can the patient swallow? What are they eating or drinking?</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"specific-treatments\\\">Specific treatments</h2>\\r\\n<p>In a palliative care setting, it is sometimes appropriate to use medications in unusual ways. This is because the risk of addiction is not important and because the patient’s comfort is more important than theoretical long term risks. Many of the recommendations below are, therefore, unlicensed and should only be prescribed by a doctor.</p>\\r\\n<h3 id=\\\"pain\\\">Pain</h3>\\r\\n<p>Pain relief in palliative care is aimed at controlling the pain completely. It is better to give medications regularly and in adequate doses to prevent pain than to give pain relief once the pain has developed. Different medications can be used in combination to effectively treat the patient.</p>\\r\\n<p>It is best to begin with simple analgesia and gradually increase the strength of medications given until the pain is controlled. However, in our setting, patients often present in severe established pain and, in these circumstances, we must be more aggressive in our treatment.</p>\\r\\n<p>Note that all patients prescribed codeine or morphine in a palliative care setting must also be prescribed medication for nausea and constipation.</p>\\r\\n<p><span class=\\\"underline\\\">Simple pain relief</span></p>\\r\\n<p>Paracetamol should be used in the first instance at a dose of 15 mg/kg up to 1 g PO QDS. This should be spread throughout the 24 hour period.</p>\\r\\n<p>If this is not adequate, consider introducing ibuprofen 10 mg/kg up to 400 mg PO TDS. This is contraindicated in patients with a history of dyspepsia and must be taken after food. Ibuprofen is an anti-inflammatory agent, so is particularly effective where inflammation is causing the pain and is the first line option in these circumstances.</p>\\r\\n<p><span class=\\\"underline\\\">Mild opiates</span></p>\\r\\n<p>If simple analgesia is not effective, then add codeine.</p>\\r\\n<p>Codeine phosphate is useful for moderate pain. Give 1 mg/kg up to 60 mg PO TDS.</p>\\r\\n<p>Some doctors like to use tramadol at this point. However, this is a partial agonist with complex pharmacokinetics. This means it cannot be used in combination with strong opiates and that it is impossible to predict what dose will be needed in any particular patient.</p>\\r\\n<p><span class=\\\"underline\\\">Strong opiates</span></p>\\r\\n<p>These should be introduced in the place of mild opiates if they have not been effective in controlling the pain or if the patient is in severe pain, they may be used in the first instance.</p>\\r\\n<p>All patients should be prescribed both a regular dose of morphine (usually as MST) as well as a PRN dose of oral morphine solution to be given if they experience breakthrough pain. The dose of the PRN dose is usually one third of that of the regular BD MST dose.</p>\\r\\n<p>The initial dose of morphine is 0.1 mg/kg up to 5 mg PO every 4 hours for oral morphine solution or 0.3 mg/kg up to 15 mg PO BD for MST. If the patient is already taking codeine, then divide the total daily dose by 8-10 to get the equivalent total daily dose of morphine. (A patient taking 60 mg TDS of codeine needs at least 18-22 mg a day of morphine for the equivalent effect).</p>\\r\\n<p>Note that MST must be given strictly every 12 hours and should never be given more frequently than this. The dose must be increased instead of the frequency. The dose should be increased under the supervision of the doctors until the patient’s pain is controlled.</p>\\r\\n<p><span class=\\\"underline\\\">Specific kinds of pain:</span></p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Neuropathic pain – shooting or burning pains which do not respond to simple pain relief or to opiates. Amitriptyline 0.2 mg/kg up to 50 mg PO should be given at night.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Muscle spasm – give diazepam 0.25 mg/kg up to 5 mg PO TDS (note that this should only ever be given to palliative care patients for this indication).</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Colicky pain – pain due to gastric or intestinal spasm may be improved by Buscopan (hyoscine butylbromide) 0.3 mg/kg up to 10 mg TDS – this is not on our formulary, but is easily obtained from local pharmacies. Loperamide 0.1 mg/kg up to 4 mg PO QDS is an alternative, but will cause constipation.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"poor-appetite\\\">Poor appetite</h3>\\r\\n<p>Consider using prednisolone 0.5-1 mg/kg up to 15-30 mg PO OD.</p>\\r\\n<h3 id=\\\"dry-or-sore-mouth\\\">Dry or sore mouth</h3>\\r\\n<p>Examine the mouth for candida and treat with nystatin oral solution 1,000,000 units QDS if found.</p>\\r\\n<p>If there is no obvious cause, sucking papaya or pineapple slices can be very effective.</p>\\r\\n<p>If the mouth is very sore, a loperamide capsule can be opened and the contents suspended in water. The suspension should be swilled around the mouth and spat out. This can be done up to 4 times a day and provides very effective local pain relief.</p>\\r\\n<h3 id=\\\"difficulty-swallowing\\\">Difficulty swallowing</h3>\\r\\n<p>If there is an obstructing tumour, try dexamethasone 0.15 mg/kg up to 8 mg OD to temporarily reduce the obstruction. If this is not available, the equivalent dose of prednisolone is 1-2 mg/kg up to 50 mg OD.</p>\\r\\n<p>Check that there is no evidence of oesophageal candidiasis. If there is, then treat with fluconazole 3 mg/kg up to 200 mg OD.</p>\\r\\n<h3 id=\\\"hiccups\\\">Hiccups</h3>\\r\\n<p>This is often a consequence of gastric distension and can be treated with magnesium trisilicate. If this doesn’t help, try omeprazole 0.5 mg/kg up to 20 mg OD and metoclopramide 0.1 mg/kg up to 10 mg TDS. Other alternatives include chlorpromazine 0.5 mg/kg up to 25 mg up to TDS and nifedipine 0.5 mg/kg up to 20 mg OD.</p>\\r\\n<h3 id=\\\"nausea-and-vomiting\\\">Nausea and vomiting</h3>\\r\\n<p>The cause of this must be identified and treated. The commonest cause is related to opiate prescription and all patients receiving opiates should be prescribed anti-emetics prophylactically. Often the nausea settles after 4-5 days of treatment and the anti-emetic can then be stopped. Haloperidol, metoclopramide and promethazine are all effective.</p>\\r\\n<p>Metoclopramide 0.1 mg/kg up to 10 mg PO TDS is useful for gastric and functional intestinal causes of nausea and vomiting.</p>\\r\\n<p>Promethazine 0.5 mg/kg up to 25 mg PO TDS can be used when the cause is mechanical obstruction or raised intracranial pressure.</p>\\r\\n<p>Haloperidol 0.125 mg/kg up to 1.5 mg PO up to BD is particularly useful when the cause is renal failure or suspected electrolyte disturbance.</p>\\r\\n<h3 id=\\\"constipation\\\">Constipation</h3>\\r\\n<p>This is often distressing for patients and is an inevitable consequence of treatment with opiates. Lactulose 2.5-20ml PO BD should be given to prevent this. Once constipation develops, patients often need bisacodyl 5-20 mg PO at night.</p>\\r\\n<h3 id=\\\"fitting\\\">Fitting</h3>\\r\\n<p>This is common in patients with cerebral tumours, but is also seen in patients with uraemia. Phenytoin (starting dose 1.5-2.5 mg/kg up to 150 mg BD) or carbamazepine (starting dose 5 mg/kg up to 200 mg at night) should be prescribed early – even before a fit has occurred if the patient is at risk of this.</p>\\r\\n<h3 id=\\\"restlessness-and-confusion\\\">Restlessness and confusion</h3>\\r\\n<p>This may require treatment with an antipsychotic. The dose and frequency needs to be adjusted according to the patient’s response. Begin with promethazine 0.25 mg/kg up to 12.5 mg PO TDS. This can be increased to a maximum dose of 0.5 mg/kg up to 25 mg TDS.</p>\\r\\n<p>Alternatively, haloperidol may be used at a dose of 0.1-0.25 mg/kg up to 1-3 mg PO up to TDS.</p>\\r\\n<h3 id=\\\"raised-intracranial-pressure\\\">Raised intracranial pressure</h3>\\r\\n<p>Headache due to raised intracranial pressure should be treated with high dose steroids. Use dexamethasone 0.3 mg/kg up to 16 mg PO in the morning for 4-5 days, then reduce to 0.1 mg/kg up to 5 mg OD.</p>\\r\\n<h3 id=\\\"difficulty-sleeping\\\">Difficulty sleeping</h3>\\r\\n<p>Look for the cause of this – possibilities include discomfort, cramps, night sweats, joint stiffness and fear. The cause should be treated in the first instance. If this is not effective, diazepam 0.25 mg/kg up to 5 mg PO at night can be used.</p>\\r\\n<h3 id=\\\"shortness-of-breath\\\">Shortness of breath</h3>\\r\\n<p>This can be very distressing for patients. If there is any wheeze or obstruction, try dexamethasone 0.075-0.15 mg/kg up to 4-8 mg PO OD. If the patient is anxious, diazepam up to 5 mg PO TDS may help. Otherwise, this symptom often responds to a regular low dose of oral morphine – prescribe as for pain.</p>\\r\\n<h3 id=\\\"intractable-cough\\\">Intractable cough</h3>\\r\\n<p>Oral morphine is effective if given regularly – usually lower doses are needed compared to those required for pain relief.</p>\\r\\n<h3 id=\\\"fungating-tumours-and-painful-wounds\\\">Fungating tumours and painful wounds</h3>\\r\\n<p>Fungating smelly tumours should be dressed and treated with topical metronidazole, which is made up by crushing metronidazole tablets into paraffin ointment. Some patients will require oral metronidazole.</p>\\r\\n<p>Where wounds are painful, this can be reduced by opening a loperamide capsule and suspending the contents in water. The suspension can be painted over the wound as often as necessary.</p>\\r\\n<h3 id=\\\"itch\\\">Itch</h3>\\r\\n<p>This is often helped by the use of emulsifying ointment – which can be rubbed on as often is necessary. Anti-histamines are usually ineffective and may cause significant side effects.</p>\\r\\n<h2 id=\\\"key-issues-for-nursing-care\\\">Key Issues for Nursing care</h2>\\r\\n<h2 id=\\\"it-is-very-important-that-patients-know-that-they-can-ask-for-help-at-any-time.-tell-them-and-their-relatives-to-inform-the-nursing-staff-if-they-are-in-pain-vomiting-or-having-any-other-symptoms.-if-a-patient-informs-you-about-these-problems-check-the-drug-chart-and-dispense-any-prn-medications-prescribed.-if-the-problems-are-new-or-nothing-is-prescribed-call-the-doctor-to-review-the-patient.\\\">It is very important that patients know that they can ask for help at any time. Tell them and their relatives to inform the nursing staff if they are in pain, vomiting or having any other symptoms. If a patient informs you about these problems, check the drug chart and dispense any PRN medications prescribed. If the problems are new or nothing is prescribed, call the doctor to review the patient. </h2>\\r\\n<p>Patients and their relatives may be very afraid during this phase of care. Take time to listen to them, to identify their fears and to honestly reassure them. This does not mean telling them not to worry, but reassuring them that we are there to help and will do all we can to ensure they are not in any discomfort or distress.</p>\\r\\n<p>Ensure you are aware of which patients are for palliative care. Check if MEWS should be calculated and if resuscitation is to be initiated if they deteriorate.</p>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<p>Joint Formulary Committee (2016) British National Formulary. 72nd Ed., London: British Medical Association and  Royal Pharmaceutical Society of Great Britain.</p>\\r\\n<p>Joint Formulary Committee (2016) British National Formulary for Children. London: British Medical Association and  Royal Pharmaceutical Society of Great Britain.</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Karen Forrest</th>\\r\\n<th>Date: 06 November 2018</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Fatai Akemokwe</td>\\r\\n<td>Date: 14 November 2018</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td>31 January 2021</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>1.1</td>\\r\\n<td>Executive summary added</td>\\r\\n<td>31 January 2021</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"015\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>Rectal prolapse MeG-CLS-015</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"rectal-prolapse\\\">Rectal prolapse</h1>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<p>Rectal prolapse occurs when a mucosal or full-thickness layer of rectal tissue protrudes through the anal orifice. There can be complications if it is not treated promptly and properly.</p>\\r\\n<p>Rectal prolapse is a relatively rare condition but more common in adults than children. Most cases are due to underlying conditions causing chronic straining with defecation &amp; constipation. In children, it is usually seen as a complication of acute diarrhoea or worm infestation.</p>\\r\\n<h2 id=\\\"target-users\\\">Target users</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doctors</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nurses</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"target-area-of-use\\\">Target area of use</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Outpatient</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ward</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"key-areas-of-focus-new-additionschanges\\\">Key areas of focus/ new additions/changes</h2>\\r\\n<p>This guideline primarily describes the diagnosis of rectal prolapse as well as the immediate medical management.</p>\\r\\n<h2 id=\\\"limitations\\\">Limitations</h2>\\r\\n<p>Adults with rectal prolapse should be referred to the surgeons as soon as possible. Children with worms or recent diarrhoea may be managed medically if the prolapse is reducible and doesn’t recur.</p>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs\\\">Presenting symptoms and signs</h2>\\r\\n<p>The patient or their caregiver will complain of a mass protruding through the anus. Pain may be variable and sometimes may present with rectal bleeding. History may also include constipation or fecal incontinence.</p>\\r\\n<h2 id=\\\"examination-findings\\\">Examination findings</h2>\\r\\n<p>On inspection of the anus, the rectal mucosa will be protruding through the anus. Rectal bleeding may be seen or a solitary rectal ulcer. There is usually a decreased anal sphincteric tone.</p>\\r\\n<p>The patient may give a history of a recent diarrhoeal illness or itching anus.</p>\\r\\n<h2 id=\\\"investigations\\\">Investigations</h2>\\r\\n<p>Evaluation depends on the underlying disorder.</p>\\r\\n<p>Laboratory test such as FBC may be necessary to exclude anaemia.</p>\\r\\n<p>Barium enema or colonoscopy should be done for all adults to rule out malignancies.</p>\\r\\n<h2 id=\\\"management\\\">Management</h2>\\r\\n<p>If the condition is a new problem and has been present for no more than a few days, then you should be able to gently return the anus to its normal place with a gloved finger. If there is a history of diarrhea or constipation then treat accordingly. The presence of itchy anus should be treated as per helminth infestation.</p>\\r\\n<p><strong>If the condition has been recurrent, longstanding or the anus cannot be reduced, then consider referring to the EFSTH surgical unit.</strong></p>\\r\\n<p>Note: In adults medical treatment of rectal prolapse is essentially surgical; no specific medical treatment is available. Children, however, can usually be treated nonsurgically, by managing the underlying condition.</p>\\r\\n<p><strong>Refer urgently to a general surgeon if any of the following is seen (Danger signs);</strong></p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Irreducible prolapse</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Presence of gangrene or rupture of the rectal mucosa</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Anal incontinence</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"key-issues-for-nursing-care\\\">Key Issues for Nursing care</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Recognize quickly the danger signs and refer to the doctor.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Counsel the patient on the risk factors, sitz baths and how to keep a good anal hygiene.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<p>Gourgiotis S, Baratsis S. Rectal prolapse. Int J Colorectal Dis. 2007 Mar. 22(3):231-43. [Medline]</p>\\r\\n<p>Wilkinson IB et al. Oxford Handbook of Clinical Medicine. Oxford University Press, 2017.</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Musa Jallow</th>\\r\\n<th>Date: 26 June 2018</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Baderinwa Abatan</td>\\r\\n<td>Date: 01 August 2018</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>2.0</td>\\r\\n<td>Expanded and updated</td>\\r\\n<td>15 August 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>2.1</td>\\r\\n<td>Executive summary added</td>\\r\\n<td>15 August 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"029\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>Red eye MeG-CLS-029</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"red-eye\\\">Red eye</h1>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<h2 id=\\\"red-eye-is-a-condition-where-the-white-of-the-eyes-sclera-have-become-reddened-or-bloodshot.-it-most-commonly-results-from-dilatation-of-blood-vessels-in-the-anterior-portion-of-the-eye.-diagnosis-may-be-aided-by-differentiation-between-ciliary-and-conjunctival-injection.-ciliary-injection-involves-branches-of-the-anterior-ciliary-arteries-and-indicates-inflammation-of-the-cornea-iris-or-ciliary-body.-conjunctival-injection-mainly-affects-the-posterior-conjunctival-blood-vessels.-because-these-vessels-are-more-superficial-than-the-ciliary-arteries-they-produce-more-redness.-haemorrhage-into-the-subconjunctival-space-may-also-present-as-red-eye.\\\">Red eye is a condition where the white of the eyes (sclera) have become reddened or bloodshot. It most commonly results from dilatation of blood vessels in the anterior portion of the eye. Diagnosis may be aided by differentiation between ciliary and conjunctival injection. Ciliary injection involves branches of the anterior ciliary arteries and indicates inflammation of the cornea, iris or ciliary body. Conjunctival injection mainly affects the posterior conjunctival blood vessels. Because these vessels are more superficial than the ciliary arteries, they produce more redness. Haemorrhage into the subconjunctival space may also present as red eye.</h2>\\r\\n<h2 id=\\\"causes-of-red-eye\\\">Causes of red eye</h2>\\r\\n<h3 id=\\\"conjunctivitis\\\">Conjunctivitis </h3>\\r\\n<p>The most common cause of red eye, characterized by vascular dilatation of the superficial conjunctival blood vessels, cellular infiltration and exudate. It must be differentiated on the basis of aetiology (viral, bacterial or allergy):</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Allergic conjunctivitis</strong> - often presents with pruritus in individuals with atopy.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Viral conjunctivitis</strong> - tends to be associated with enlarged, tender preauricular nodes, watery discharge and upper respiratory tract infection.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Bacterial conjunctivitis</strong> - tends to be associated with more mucopurulent or purulent discharge.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"subconjunctival-haemorrhage\\\">Subconjunctival haemorrhage</h3>\\r\\n<p>Results from bleeding of the conjunctival or episcleral blood vessels into the subconjunctival space. The classical presentation involves a patient without eye pain or visual disturbance who discovers the red eye in the mirror or from a friend or family member. Usually self-limiting condition when not associated with systemic illness or significant trauma.</p>\\r\\n<p>Causes include:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Idiopathic</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Valsalva (eg coughing, straining, weightlifting, working under a sink<strong>)</strong></p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Traumatic (eg mild isolated lesion due to eye rubbing or sports injuries)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hypertension or arteriosclerosis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Bleeding disorders ( if recurrent or in young patients without a history of trauma or infection), including hematologic or hepatic disease, diabetes, systemic lupus erythematosus, parasites and vitamin C deficiency</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Various antibiotics, anticoagulants (eg warfarin), analgesics (eg NSAIDS), steroids, contraceptives and vitamins A and D</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Normal sequel of ocular surgery, even if there is no conjunctival incision</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Febrile systemic infections such as meningococcal septicaemia, scarlet fever, typhoid fever, measles, yellow fever, malaria, rickettsia and sandfly fever</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"other-causes\\\">Other causes</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Glaucoma</strong> (acute angle closure) – patients are usually older than 50 years of age and complain of a severely painful eye. Nausea and vomiting are common due to elevated intraocular pressure. <strong>This is a true emergency!</strong></p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Iritis</strong> – inflammation of the anterior uveal tract. In most cases, the cause cannot be determined, however, it can be caused by any systemic inflammatory disease. Trauma is a common cause.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Scleritis</strong> – universally accompanied by pain, especially with tenderness exacerbated by digital pressure. Gradual onset of red eye and insidious decrease in vision are typically noted. Bilateral in 50% of patients.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Blepharitis</strong> – inflammation of the eyelids, usually involving the lid margins. It may be seborrhoeic or may be caused by staphylococcal infection.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Keratitis</strong> – inflammation of the cornea and can be bacterial, viral, fungal or parasitic.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Pterygium</strong> – a benign conjunctival growth made of triangular band of fibrovascular tissue caused by long-term exposure to ultraviolet light, dust and low humidity. Usually arises from the nasal side of sclera and encroach onto cornea.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Corneal injury</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Dry eye syndrome (keratoconjunctivitis sicca)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Canaliculitis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Trauma</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Dacryocystitis</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs\\\">Presenting symptoms and signs</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Burning sensation</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Watery eyes</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Itchy eyelids</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Itchy eyes</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Swollen eyelids</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Discharge; could be thick or watery</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Foreign body sensation</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Photophobia (light sensitivity)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Dermatitis (crusting or scaling of the eyelid skin)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Eyelashes falling out. This is typically associated with blepharitis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Redness</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Pain</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Bilateral or unilateral</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"examination-findings\\\">Examination findings</h2>\\r\\n<p>It is important to look closely and check if the eye itself is red or if the problem primarily affects the tissues around the eye. Also look at the whole patient to identify systemic problems that might affect the eyes. In children, this could be measles. In adults, connective tissue diseases are more likely.</p>\\r\\n<p>Perform a complete ophthalmologic examination on all patients, to include the following:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Visual acuity (each eye should be tested separately)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Extraocular movements</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Pen light examination (should test for pupil reactivity, pupil shape, discharge, pattern of injection and corneal injection)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Test for direct and consensual photophobia</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Further examinations that are not available at MRCG, but are useful include:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Slit lamp examination</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Anterior chamber evaluation</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Intraocular pressure (IOP) measure</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"management\\\">Management </h2>\\r\\n<p>The key to management is making the correct diagnosis in a timely fashion. Uncomplicated cases of conjunctivitis and subconjunctival haemorrhage may be managed by a primary care physician. Subconjunctival haemorrhage with no history of trauma does not require treatment. See below for treatment of conjunctivitis.</p>\\r\\n<p>Other possible causes of red eye require ophthalmologic consultation within an appropriate time period.</p>\\r\\n<p><span data-custom-style=\\\"Heading 3 Char\\\">Emergency referral to eye hospital</span></p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Acute angle closure glaucoma – affects a single eye, which has reduced vision and is exquisitely painful.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Penetrating trauma – affects a single eye which has been penetrated.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p><span data-custom-style=\\\"Heading 3 Char\\\">Urgent referral to eye hospital</span></p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Iritis, scleritis – usually bilateral, painful and in context of systemic disease.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Non-penetrating trauma – usually unilateral. May be painful, but less so than in glaucoma. Given topical antibiotics prior to referral.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p><span data-custom-style=\\\"Heading 3 Char\\\">Routine referral to eye hospital</span> – blepharitis, keratitis, pterygium, unclear diagnosis in absence of concern for more urgent diagnoses, conjunctivitis or haemorrhage which have not improved as expected.</p>\\r\\n<p><span data-custom-style=\\\"Heading 3 Char\\\">Treat in OPD</span> – conjunctivitis – treat with topical antibiotics. Tetracycline eye ointment should be inserted twice each day except in more complex cases. The ointment is placed along the bottom lid and then the patients encouraged to blink to spread it over the conjunctiva. Allergic conjunctivitis is treated with topical antihistamines.</p>\\r\\n<h2 id=\\\"key-issues-for-nursing-care\\\">Key Issues for Nursing care</h2>\\r\\n<p>Refer the following patients to a doctor immediately</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Patients with sudden changes in vision</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Severe pain accompanying redness</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Red eye with accompanying fever of over 38.3 °C (101 °F)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Red eye caused by blunt or penetrating trauma</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Red eye associated with facial swelling ( neck, lips, tongue etc)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>When red eyes are persistent or recurrent</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<p>Shields SR. Managing eye disease in primary care</p>\\r\\n<p>Kunimoto DY ,Kanitkar KD, Makar M. Diagnosis and treatment of eye disease</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Mariama Sonko</th>\\r\\n<th>Date: 01 July 2019</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Karen Forrest</td>\\r\\n<td>Date: 24 July 2019</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td>30 August 2021</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"065\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>Rheumatic heart disease MeG-CLS-065</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"rheumatic-heart-disease\\\">Rheumatic heart disease</h1>\\r\\n<h2 id=\\\"executive-summary\\\"><em>Executive summary</em></h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<p>Rheumatic heart disease (RHD) is a serious complication of rheumatic fever. It refers to the chronic heart valve damage that can develop years after single or repeated episodes of acute rheumatic fever (ARF). Acute rheumatic fever is an inflammatory autoimmune disease which occurs following inadequately treated infection with Group A Streptococcus (GAS). Repeated episodes of ARF can lead to inflammation of the heart either on the surface of the heart (pericarditis), within the heart (endocarditis) leading to accumulative damage to one or more of the four heart valves (endocarditis) or involving the heart muscle itself (myocarditis). Untreated RHD can lead to heart failure, stroke, arrhythmia and complications in pregnancy.</p>\\r\\n<p>RHD is a disease of poverty, associated with overcrowding and poor living conditions, as well as lack of access to health care and services.</p>\\r\\n<p>Group A streptococcal infection, acute rheumatic fever and rheumatic heart disease are preventable with improved housing and living conditions, and early antibiotic treatment.</p>\\r\\n<h2 id=\\\"target-users\\\">Target users</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doctors</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nurses</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"target-area-of-use\\\">Target area of use </h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Outpatient department</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ward</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"key-areas-of-focus-new-additions-changes\\\">Key areas of focus / New additions / Changes </h2>\\r\\n<p>This guidelines describes the initial diagnosis and management of rheumatic heart disease. Advanced rheumatic heart disease requires surgical treatment which is delivered through a partnership with the UK charity Chain of Hope. Management of these children is shared with overseas paediatric cardiologists who will advise on more complex problems.</p>\\r\\n<h2 id=\\\"limitations\\\">Limitations</h2>\\r\\n<p>Access to surgery is limited and many children must be managed medically.</p>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs\\\">Presenting symptoms and signs</h2>\\r\\n<p>The most common forms of RHD include mitral valve disease (mitral stenosis, mitral regurgitation), aortic valve disease (aortic stenosis, aortic regurgitation) and tricuspid regurgitation. Atrial fibrillation is often associated with mitral stenosis.</p>\\r\\n<p>Clinical features of RHD vary depending on which heart valves are affected and how severely. Early in the onset of disease, cases may be asymptomatic for many years. As valvular disease progresses, cases will have symptoms of some degree of heart failure, ranging from mild to severe exertional dyspnoea, fatigue, peripheral oedema and palpitations. The severity of RHD increases with repeated episodes of ARF.</p>\\r\\n<p>Complications of RHD include heart failure, stroke, arrhythmias, infective endocarditis and complications during pregnancy. Heart failure is the major cause of disability and death from RHD. Infective endocarditis is more likely to occur when there is damage to the heart valves and is a serious illness requiring hospitalisation and intravenous antibiotics, which is also associated with a significant mortality and morbidity burden.</p>\\r\\n<p>Other symptoms due to rheumatic heart disease are:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Chest pain.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Heart palpitations.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Shortness of breath especially with physical exertion.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Swollen ankles, legs, wrists, and stomach.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Excessive fatigue.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Thumping sensation in chest.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"examination-findings\\\">Examination findings</h2>\\r\\n<p>These vary with the severity of valve calcification, the severity of stenosis, and left ventricular (LV) function.</p>\\r\\n<p>With mild disease, the apex beat is brisk and hyper dynamic. The S<sub>1</sub> is usually soft, and a widely split S<sub>2</sub> is common. A diastolic rumble and S<sub>3</sub> may be present even if there is no LV dysfunction.</p>\\r\\n<p>With severe mitral regurgitation (MR), the apex may be enlarged and displaced laterally. The systolic murmur of MR varies according to its cause. It is usually heard best at the apex in the left lateral decubitus position. With severe degenerative MR, the murmur is holosystolic, radiating into the axilla. Early systolic murmurs are typical of acute MR. Late systolic murmurs are typical of mitral valve prolapse or papillary muscle dysfunction.</p>\\r\\n<p>Signs of pulmonary hypertension, such as a loud P<sub>2</sub>, represent advanced disease.</p>\\r\\n<h2 id=\\\"differential-diagnosis\\\">Differential diagnosis</h2>\\r\\n<p>The main alternative diagnosis in children is infectious endocarditis or congenital heart disease. In adults, valvular heart disease might be due to degenerative changes.</p>\\r\\n<h2 id=\\\"investigations\\\">Investigations</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>CXR</strong></p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Heart failure: enlarged heart, congested pulmonary vasculature. If more severe: enlarged right atrium and right ventricle.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Chronic MR: cardiomegaly (LV and LA enlargement).</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Acute MR or progressive LV failure: Kerley B lines and interstitial oedema.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Pulmonary hypertension: right-sided chamber enlargement.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Severe mitral stenosis: left atrial enlargement.</p>\\r\\n</div></li>\\r\\n</ul></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>ECG</strong> – Looking for LV hypertrophy, LA enlargement, conduction abnormality (left and right bundle branch block), altered axis, atrial fibrillation.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>ECHO</strong> – Essential to confirm the diagnosis and grade the severity of disease.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Other investigations are not available in the Gambia.</p>\\r\\n<h2 id=\\\"management\\\">Management </h2>\\r\\n<p>There are 2 goals in treating RHD:</p>\\r\\n<ol type=\\\"1\\\">\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Prevention of further damage to the heart valves.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Treatment of heart failure.</p>\\r\\n</div></li>\\r\\n</ol>\\r\\n<h3 id=\\\"prevention-of-further-damage-to-the-valves\\\">Prevention of further damage to the valves</h3>\\r\\n<p>Primary prevention involves the use of antibiotics to treat GAS throat infections.</p>\\r\\n<p>Secondary prevention of ARF: once a person has had ARF, it is important to prevent future episodes, this is best provided by monthly IM injections of Benzathine penicillin at a dose of 1.2 MU. This is increased to 3 weekly if the patient is at especially high risk. It should be continued until 10 years after the last episode of ARF or the age of 21 years. This treatment reduces the number of ARF episodes and should be offered to all patients with rheumatic carditis. For persons with established rheumatic heart disease, secondary prevention with continuous antibiotics should be continued for longer periods – even for life. It is also continued even after valve surgery.</p>\\r\\n<p>Penicillin V has been used in place of Benzathine penicillin. Patients prefer it, but there is concern that it is less effective because it depends on them taking medication every day. There is no evidence to support its use.</p>\\r\\n<h3 id=\\\"treatment-of-heart-failure\\\">Treatment of heart failure</h3>\\r\\n<p><span class=\\\"underline\\\">Medical treatment</span></p>\\r\\n<p><strong>ACE inhibitors</strong> block the formation of angiotensin II, this medication lowers blood pressure and reduces sodium retention in people who have heart failure. They are relatively contraindicated in patients with mitral or aortic stenosis.</p>\\r\\n<p>Use enalapril 100 micrograms/kg OD initially. The dose can be increased up to 1 mg/kg OD. The maximum dose is 10 mg OD. Ramipril or captopril can be substituted according to availability.</p>\\r\\n<p><strong>Beta blockers</strong> block the effect of adrenaline on the heart to reduce excess stress on the failing heart. These medications are most commonly used for dilated cardiomyopathy.</p>\\r\\n<p>Use bisoprolol 1.25 mg OD in older children. Use in younger children only on the advice of a cardiologist.</p>\\r\\n<p><strong>Diuretics</strong> stimulate the body to lose water by acting on the kidneys. This effect decreases fluid retention and edema and provides symptomatic relief to the patient.</p>\\r\\n<p>Start with furosemide 0.5 mg/kg OD. The dose can be increased as high as 12 mg/kg, but it is unusual to need doses higher that 2 mg/kg OD.</p>\\r\\n<p>Add spironolactone 1 mg/kg OD. The dose can be increased up to 9 mg/kg OD, but usually lower doses are needed in heart failure.</p>\\r\\n<p><span class=\\\"underline\\\">Surgical treatment</span></p>\\r\\n<p>Patients with significant heart failure should be considered for valve repair or replacement surgery. In an ideal world, even asymptomatic patients should be considered for this in order to prevent significant heart damage.</p>\\r\\n<p>Patients are often very young when operated and, therefore, are given mechanical valves if they need replacement surgery, as they last longer. However, they then require warfarin treatment. Girls offered mechanical valves should be counselled about the risks of being pregnant on warfarin treatment and about the option of using low-molecular weight heparin through the pregnancy. The target INR is usually 2.5-3.5.</p>\\r\\n<h2 id=\\\"key-issues-for-nursing-care\\\">Key Issues for Nursing care</h2>\\r\\n<h2 id=\\\"make-sure-patients-and-their-caregivers-understand-why-they-have-been-given-penicillin-prophylaxis-and-how-important-it-is-to-prevent-further-episodes-of-arf.\\\">Make sure patients and their caregivers understand why they have been given penicillin prophylaxis and how important it is to prevent further episodes of ARF.</h2>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<p>Queensland Health Guidelines</p>\\r\\n<p>Maganti, K., Rigolin,V.H., Sarano, M.E.,MD, and Bonow, R.O. Valvular Heart Disease: Diagnosis and Management. Mayo Clin Proc. 2010. 85(5): 483–500.</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Baderinwa Abatan</th>\\r\\n<th>Date: 13 March 2019</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Karen Forrest</td>\\r\\n<td>Date: 07 May 2019</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td>31 May 2021</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"066\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>Scabies  MeG-CLS-066</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"scabies\\\">Scabies</h1>\\r\\n<h2 id=\\\"executive-summary\\\"><em>Executive summary</em></h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<h2 id=\\\"scabies-is-a-cutaneous-infestation-caused-by-the-mite-sarcoptei-scabei-and-usually-affecting-the-extremities.-it-is-transmitted-by-close-cutaneous-contact-sexually-and-by-contact-with-infested-fomites-e.g.-towels-clothing.\\\">Scabies is a cutaneous infestation caused by the mite <em>Sarcoptei scabei</em> and usually affecting the extremities. It is transmitted by close cutaneous contact, sexually, and by contact with infested fomites (e.g. towels, clothing).</h2>\\r\\n<h3 id=\\\"target-user\\\">Target User</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doctors</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nurses</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"target-area-of-use\\\">Target area of use </h3>\\r\\n<p>OPD</p>\\r\\n<h3 id=\\\"key-areas-of-focus-new-additions-changes\\\">Key areas of focus / New additions / Changes </h3>\\r\\n<p>This guideline focuses on the common types of scabies and their management and recommends use of topical treatment. It also advises on the elimination of the causative mites.</p>\\r\\n<p>Management of scabies is dependent on the type of scabies the patient presents with and there may be need to add oral medication to the treatment.</p>\\r\\n<p>It is important that close human contacts and fomites are treated as well as the presenting patient.</p>\\r\\n<h3 id=\\\"limitations\\\">Limitations </h3>\\r\\n<h2 id=\\\"none.\\\">None.</h2>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs\\\">Presenting symptoms and signs</h2>\\r\\n<p>Presentation is dependent on the immune status of the patient.</p>\\r\\n<h3 id=\\\"classical-scabies\\\">Classical scabies</h3>\\r\\n<p>Occurs in immunocompetent patients.</p>\\r\\n<p>Symptoms include:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Erythematous papules located in the interdigital spaces of fingers, periumbilical region, axillary folds, breasts, genitalia, extensor surfaces of limbs. The face, soles and palms are usually spared.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Pruritus which is worse at night</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>There may be signs of secondary bacterial infection</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"crusted-scabies\\\">Crusted scabies</h3>\\r\\n<p>Occurs in patients who are severely immune-compromised e.g. in HIV, malignancy.</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Pruritus is often absent or mild</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Lesions are generalized, consisting of poorly defined fissured plaques covered by crusts and scales</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Secondary bacterial infection may result in malodorous lesions</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"examination-findings\\\">Examination findings</h2>\\r\\n<p>Examination of affected areas may reveal</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Scratch marks</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Papular lesions, which are erythematous, located in areas of predilection</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Fissured plaques covered by crusts and scales</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>The burrow (a pathognomonic sign) appearing as a thin, brown-grey elevations in the superficial epidermis usually of 0.5–1 cm in size.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"differential-diagnoses\\\">Differential diagnoses</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Drug reactions</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Viral exanthem</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Bullous pemphigoid</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Necrotizing vasculitis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>B-cell lymphoma with monoclonal infiltrate</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Dermatologic manifestations of renal disease</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Erythroderma (generalized exfoliative dermatitis)</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Folliculitis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Insect bites</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Lice</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Lichen planus</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Neurotic excoriations</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Papular urticaria</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Psoriasis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Sea bather’s eruption</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Syphilis</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"investigations\\\">Investigations</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Microscopy of skin scrapings to identify mites, eggs or faecal matter.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>STI screen should be done in all sexually active patients</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"management\\\">Management</h2>\\r\\n<p>All patients diagnosed with scabies should be advised to machine wash all clothing, towels and beddings at 50 degrees Celsius or higher OR to seal all clothing, towels and beddings in a plastic bag for at least 1 week. In our context, leaving all items outside in the hot sun for a full day is also effective.</p>\\r\\n<h3 id=\\\"classical-scabies-1\\\">Classical scabies</h3>\\r\\n<p>Benzyl benzoate lotion 10–25% applied once daily at night on 2 consecutive days with re-application at 7 days</p>\\r\\n<p>Topical treatment should be applied to all skin regions including scalp, groin, navel, external genitalia, finger and toe web spaces and the skin beneath the ends of the nails at night, and left for 8–12 h. The skin should be cool and dry. Re-application is recommended after 7–14 days. After applying treatment, patients should change into clean clothing. All the patient’s close personal contacts should be treated simultaneously to avoid re-infestation.</p>\\r\\n<h3 id=\\\"crusted-scabies-1\\\">Crusted scabies</h3>\\r\\n<p>Benzyl benzoate lotion 10-25% applied once daily on 7 consecutive days, then twice weekly until cured AND oral Ivermectin 200 µg/kg OD on days 1, 2, 8, 9, and 15. Ivermectin should not be used in children &lt; 15 kg and pregnant women.</p>\\r\\n<p>Follow up visit for microscopy examination should be made 2 weeks after completion of therapy .</p>\\r\\n<p><strong>References</strong></p>\\r\\n<p>UpToDate: Management of scabies https://www.uptodate.com/contents/scabies-management?csi=aafa7509-fad8-4d21-89d6-c7bf3b5272d4&amp;source=contentShare</p>\\r\\n<p>European guideline for the management of scabies C.M. Salavastru et al https://iusti.org/regions/Europe/pdf/2017/Scabies.pdf</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Azeezat Sallahdeen</th>\\r\\n<th>Date: 24 November 2018</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Orighomisan Agboghoroma</td>\\r\\n<td>Date: 06 December 2018</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td>31 January 2021</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>1.1</td>\\r\\n<td>Executive summary added</td>\\r\\n<td>31 January 2021</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"043\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>Sepsis in adults MeG-CLS-043</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"sepsis-in-adults\\\">Sepsis in adults</h1>\\r\\n<h2 id=\\\"executive-summary\\\"><em>Executive summary</em></h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<p>Sepsis is a serious diagnosis which must be rapidly recognized and treated. Evidence shows that the patient’s chances of survival are directly related to the speed at which treatment is started.</p>\\r\\n<h2 id=\\\"target-users\\\">Target users</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nurses</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doctors</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"target-area-of-use\\\">Target area of use </h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Outpatient department</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ward</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"key-areas-of-focus-new-additions-changes\\\">Key areas of focus / New additions / Changes </h2>\\r\\n<p>This guideline outlines the rapid recognition and response required to treat sepsis. It summarises the empirical antibiotics appropriate in our setting.</p>\\r\\n<h2 id=\\\"limitations\\\">Limitations</h2>\\r\\n<p>We do not have access to HDU level care.</p>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs\\\">Presenting symptoms and signs</h2>\\r\\n<p>Sepsis can present in many different ways depending on where the infection is. Immunocompromised patients may not mount the same response as other patients.</p>\\r\\n<p>Common symptoms are:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Fever (&gt; 38ºC)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Cough</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Pain (abdominal, joint, headache)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Shortness of breath</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Confusion</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"examination-findings\\\">Examination findings</h2>\\r\\n<h2 id=\\\"depend-on-the-type-of-sepsis.\\\">Depend on the type of sepsis.</h2>\\r\\n<p>Patients should undergo a full examination including:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Cardiovascular</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Respiratory</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Abdominal</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ear, nose and throat</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>General; look for any joint swellings, skin rashes , abscess</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Neurological; any signs of meningism</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>It is very important to look for signs of immunosuppression.</p>\\r\\n<h3 id=\\\"differential-diagnosis\\\">Differential diagnosis</h3>\\r\\n<p>The list is endless! Heart failure, asthma, severe COPD, hypoglycaemia, tuberculosis can all present like sepsis.</p>\\r\\n<h2 id=\\\"management\\\">Management</h2>\\r\\n<p>If you think of sepsis, admit to the ward and use the sepsis cards to prioritise care.</p>\\r\\n<p>In OPD, you can calculate a qSOFA score. Score 1 for each of:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Systolic blood pressure (&lt;100mmHg)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Tachypnoea (RR &gt;22 per minute)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Altered mental state</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>A score of 2 or more indicates that a doctor should consider sepsis and intervene rapidly.</p>\\r\\n<h3 id=\\\"investigations\\\">Investigations</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>FBC, U+E, LFTs, glucose</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Take 2 x 10mls for blood culture</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Chest x-ray</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Urine dip</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>HIV test if status unknown</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Lumbar puncture if meningitis suspected and no focal neurological deficit</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"management-1\\\">Management</h3>\\r\\n<p><em>The Golden Hour</em>: all patients who are septic should have IV fluids, oxygen (if required) and IV antibiotics within the first hour of admission.</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>IV access</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Bloods (as above)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Assess fluid status – if hypotensive, fluid challenge of 250-500mls assess response</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>IV antibiotics – see below</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>At least 1 hourly observations in first few hours of admission</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Urinary catheter to monitor fluid status</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>The antibiotic given depends on the presumed source of sepsis.</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th></th>\\r\\n<th><strong>IV therapy</strong></th>\\r\\n<th><strong>Oral therapy for step down</strong></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Source unknown</strong></td>\\r\\n<td>Ampicillin 1 g 8 hourly + Gentamicin 5-7.5 mg/kg once daily</td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Respiratory</strong></td>\\r\\n<td><p>Benzylpenicillin 1.2 g 6 hourly + Chloramphenicol 500 mg 6 hourly</p>\\r\\n<p>If atypical suspected, add azithromycin 500mg OD</p></td>\\r\\n<td><p>Amoxicillin 500 mg 8 hourly</p>\\r\\n<p>OR</p>\\r\\n<p>Doxycycline 200 mg OD</p></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Urinary</strong></td>\\r\\n<td>Ampicillin 1 g 8 hourly + Gentamicin 5-7.5 mg/kg once daily</td>\\r\\n<td>Nitrofurantoin 50 mg QDS</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Soft tissue</strong></td>\\r\\n<td><p>Cloxacillin 1 g QDS (2 g in severe infection )</p>\\r\\n<p>+ Benzypenicillin or Ampicillin if severe</p></td>\\r\\n<td>Cloxacillin 500 mg QDS</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Meningitis</strong></td>\\r\\n<td>Ceftriaxone 2 g 12 hourly for 14 days depending on organism</td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Abdominal sepsis</strong></td>\\r\\n<td>Triple therapy; Ampicillin 1 g 8 hourly + Gentamicin 5-7.5 mg/kg OD + Metronidazole 500 mg TDS</td>\\r\\n<td><p>Depends on source; e.g.cholecystitis; amoxicillin and metronidazole</p>\\r\\n<p>Spontaneous bacterial peritonitis; ciprofloxacin and metronidazole</p></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<p><strong>Notes:</strong></p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Gentamicin – one dose can be given before the renal function is known, but further doses should only be continued if renal function is normal. There are very few circumstances where a course should continue beyond 5 days.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ceftriaxone – is often used as a second line option where there seems to be a failure to respond to first line medications. If there is no clear diagnosis, it should usually be stopped after 5 or at most 7 days.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>If not responding – look for a reason and consider changing the antibiotics.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Blood cultures should be followed up after 48 hours with a phone call to the microbiology lab.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>If after 48 hours, there is no clear diagnosis and the patient is clinically improved and stable consider switching to oral antibiotics.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"key-issues-for-nursing-care\\\">Key Issues for Nursing care</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>The Golden Hour – Make sure antibiotics and fluids are given within the first hour.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Monitor patients using the Early Warning Score.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<h2 id=\\\"sepsis-recognition-diagnosis-and-early-management.-nice-guidelines-published-july-2016.-available-at-httpswww.nice.org.ukguidanceng51chapterrecommendationsstratifying-risk-of-severe-illness-or-death-from-sepsis\\\">Sepsis; recognition , diagnosis and early Management. NICE guidelines, published July 2016. Available at <a href=\\\"https://www.nice.org.uk/guidance/NG51/chapter/Recommendations#stratifying-risk-of-severe-illness-or-death-from-sepsis\\\"><span data-custom-style=\\\"Hyperlink\\\">https://www.nice.org.uk/guidance/NG51/chapter/Recommendations#stratifying-risk-of-severe-illness-or-death-from-sepsis</span></a> </h2>\\r\\n<p>SIRS, qSOFA and new Sepsis definition. Marik P, Taeb A. Journal of Throacic disease, 2017 Apr; 9(4): 943-945. Available at <a href=\\\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5418298/\\\"><span data-custom-style=\\\"Hyperlink\\\">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5418298/</span></a></p>\\r\\n<p>qSOFA Score for Patients with Sepsis in Low and Middle Income countries. Adhikari N, Rubenfeld D. JAMA, published online May 2018 DOI 10.1001/jama.2018.6413. Available at <a href=\\\"https://jamanetwork.com/journals/jama/fullarticle/2681800\\\"><span data-custom-style=\\\"Hyperlink\\\">https://jamanetwork.com/journals/jama/fullarticle/2681800</span></a></p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Caitlin Jones</th>\\r\\n<th>Date: 31/05/2018</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Karen Forrest</td>\\r\\n<td>Date: 14/06/2018</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td>31 July 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>1.1</td>\\r\\n<td>Executive summary added</td>\\r\\n<td>31 July 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"076\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>Sickle cell disease MeG-CLS-076</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"sickle-cell-disorders\\\">Sickle cell disorders</h1>\\r\\n<h2 id=\\\"executive-summary\\\"><em>Executive summary</em></h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<p>Haemoglobin (Hb) is a tetrameric protein composed of four subunits. In the foetus, the predominant Hb is HbF (which has 2 alpha and 2 gamma subunits). This is replaced in the postnatal period by HbA (which has 2 alpha and 2 beta subunits) and HbA2 (2 alpha and 2 delta subunits).</p>\\r\\n<p>In sickle cell disease, an individual inherits 2 abnormal beta subunits, at least one of which is HbS. This produces red blood cells which are prone to sickling and cause a range of symptoms and pathology.</p>\\r\\n<p>The common sickle cell syndromes are: HbSS disease, HbSC disease, HbS-beta thalassaemia and other rare variants. The inheritance of SS disease follows simple Mendelian principles.</p>\\r\\n<h2 id=\\\"target-users\\\">Target users</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doctors</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nurses</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"target-area-of-use\\\">Target area of use </h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ward</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Outpatient department</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"key-areas-of-focus-new-additions-changes\\\">Key areas of focus / New additions / Changes </h2>\\r\\n<p>This guideline outlines the initial diagnosis and management of sickle cell disease and its complications.</p>\\r\\n<h2 id=\\\"limitations\\\">Limitations</h2>\\r\\n<p>Exchange transfusion and modern preventative treatments such as hydroxyurea are not available in the Gambia.</p>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs\\\">Presenting symptoms and signs</h2>\\r\\n<p>The most common signs and symptoms are linked to anaemia. As a result, they may feel tired or weak. Fatigue is one of the most common symptoms of sickle cell anaemia.</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Non-specific symptoms:</p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<blockquote>\\r\\n<p>Fatigue</p>\\r\\n</blockquote>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<blockquote>\\r\\n<p>Headaches</p>\\r\\n</blockquote>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<blockquote>\\r\\n<p>Dizziness</p>\\r\\n</blockquote>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<blockquote>\\r\\n<p>Fever</p>\\r\\n</blockquote>\\r\\n</div></li>\\r\\n</ul></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Pain in any part of the body</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Symptoms of specific syndromes:</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Shortness of breath</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Cough</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Abdominal distension</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Swelling of the hands or feet</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Leg ulcers</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"examination-findings\\\">Examination findings</h2>\\r\\n<p>The early signs include: pallor, jaundice, hepato-splenomegaly (signs of visceral sequestration) and hand-foot syndrome (dactylitis).</p>\\r\\n<p>Signs consistent with important complications include:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<blockquote>\\r\\n<p>Tachycardia, tachypnoea and hypotension (signs of sepsis)</p>\\r\\n</blockquote>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<blockquote>\\r\\n<p>Signs of heart failure and murmur due to anaemia</p>\\r\\n</blockquote>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<blockquote>\\r\\n<p>Respiratory distress (acute chest syndrome)</p>\\r\\n</blockquote>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<blockquote>\\r\\n<p>Bone pain consistent with vaso-occlusive crisis or osteomyelitis</p>\\r\\n</blockquote>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<blockquote>\\r\\n<p>Priapism</p>\\r\\n</blockquote>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<blockquote>\\r\\n<p>Haematuria</p>\\r\\n</blockquote>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<blockquote>\\r\\n<p>Evidence of stroke</p>\\r\\n</blockquote>\\r\\n</div></li>\\r\\n</ul>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Leg ulcers</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Frontal bossing and protrusion of upper teeth (gnathopathy)</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"differential-diagnoses\\\">Differential diagnoses</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Rheumatic fever</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Rheumatoid arthritis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Osteomyelitis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Leukaemia</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Splenic abscess</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hepatitis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ischaemic colitis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Peptic ulcer.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"investigations\\\">Investigations</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Blood Tests:</p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hb genotype (sickle test has very low specificity and sensitivity and is not useful)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>FBC &amp; reticulocytes( Reduced Hb, elevated WCC, elevated Platelets, increased retics)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Group and save</p>\\r\\n</div></li>\\r\\n</ul></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Blood film or RDT for malaria parasites (sickled cells, poikilocytes and target cells)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Microbiological screen: Urine dipstick &amp; culture, blood culture</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Radiology:</p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Chest x-ray if indicated (i.e. symptoms/signs)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>X-ray of the hands: initially not informative but later shows evidence of destruction and repair of bones</p>\\r\\n</div></li>\\r\\n</ul></li>\\r\\n</ul>\\r\\n<h2 id=\\\"management-in-opd\\\">Management in OPD</h2>\\r\\n<h3 id=\\\"antibiotics\\\">Antibiotics: </h3>\\r\\n<p>Patients who have previously been admitted to hospital with a serious infection should be treated with prophylactic penicillin V 7.5 mg/kg up to 500 mg BD.</p>\\r\\n<h3 id=\\\"folic-acid\\\">Folic acid:</h3>\\r\\n<p>From 1 month to 3 years of age, give 2.5 mg OD. Above 3 years of age give, 5 mg OD.</p>\\r\\n<h3 id=\\\"anti-malarials\\\">Anti-malarials:</h3>\\r\\n<p>Patients should receive anti-malarial prophylaxis during the transmission season. This should usually be started as soon as the first rain has occurred (and not before) and should continue until the end of the calendar year. Give mefloquine (5-10 mg/kg up to 250 mg once per week).</p>\\r\\n<h3 id=\\\"appointments\\\">Appointments</h3>\\r\\n<p>Children with sickle cell disease are seen 3 monthly until 2 years of age and six-monthly thereafter, unless there are medical, educational or psychosocial concerns in which case they should be seen more frequently. If patients are stable, in Fajara, they should be referred on to another health facility for ongoing care.</p>\\r\\n<p>Children who have frequent crises have been shown to have better outcomes if their parents bring them for medical care sooner when they deteriorate. Teach carers about the importance of taking pain and fevers seriously. Studies have shown that parents can be taught to recognize splenomegaly, which is an indication to present to the clinic.</p>\\r\\n<h2 id=\\\"management-on-the-ward\\\">Management on the ward</h2>\\r\\n<p>Management is supportive unless there are complications or indications for exchange transfusion. (This is not routinely offered and must be discussed with a consultant.)</p>\\r\\n<p>General management includes:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Reassurance that the patient’s pain will be relieved as soon as possible</strong></p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Massage and distraction techniques may help some children</strong></p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Warmth</strong></p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Establishing a position of maximum comfort</strong></p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Hyperhydration (see below)</strong></p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Oxygen supplementation when necessary</strong></p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Establish IV access as soon as possible</strong></p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Identification and treatment of infection</strong></p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Regular observations and reassessment</strong></p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"fluids-sodium-chloride-0.9\\\">Fluids (Sodium chloride 0.9%)</h3>\\r\\n<p>Aim to give 1.5 times as much fluid as usual:</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Body weight (kg)</strong></th>\\r\\n<th><strong>Fluids (mL/kg/day)</strong></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Up to 10 kg</td>\\r\\n<td>150 mL/kg/day</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>11 - 20 kg</td>\\r\\n<td>1500 mL + 75 mL/kg/day for each kilo over 10 kg</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>&gt;20 kg</td>\\r\\n<td>2250 mL + 30 mL/kg/day for each 1 kg body weight over 20kg</td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<h3 id=\\\"analgesia\\\">Analgesia </h3>\\r\\n<p>An analgesic ladder is used according to the severity of pain and a pain tool must always be used to monitor effectiveness of pain relief.</p>\\r\\n<p>Give paracetamol (15 mg/kg up to 1 g QDS) or ibuprofen (5 mg/kg up to 400 mg TDS) as a single agent of pain relief if not already given.</p>\\r\\n<p>If pain persists, give paracetamol and ibuprofen together.</p>\\r\\n<p>If pain persists, continue paracetamol and ibuprofen and add:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Codeine phosphate (0.5-1.0 mg/kg up to 30 mg TDS) for rapid oral opiate pain relief.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>If injectable pain relief required: SC Morphine (begin with 0.1-0.2 mg/kg up to 2.5 mg and titrate until pain is controlled).</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>If the patient requires regular on-going opiate pain relief, Morphine Slow-release Tablets (MST) may be used in place of codeine phosphate. To find the equivalent dose, divide total daily dose of codeine by 8-10 and give half this amount as MST BD).</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"management-of-complications\\\">Management of complications</h2>\\r\\n<p><strong><span class=\\\"underline\\\">Veno-occlusive crisis:</span></strong> Presents with bone or body pain. Occurs when hypoxia, infection, dehydration or pregnancy trigger sickling which causes capillary blockage. This results in local ischaemia of tissues. In infants and toddlers, it often affects the hand and feet and presents as dactylitis (which is a poor prognostic factor). If the spleen is involved, it may suddenly enlarge and is very painful. This is also a poor prognostic factor. Treatment is with pain relief and hyperhydration. If there is evidence of infection, this should be treated.</p>\\r\\n<p><strong><span class=\\\"underline\\\">Infection</span></strong>: Occurs as a complication of a veno-occlusive crisis or secondary to asplenism. Patients are at increased risk of sepsis from capsulated bacteria including <em>pneumococcus</em>, <em>haemophilus influenzae</em> and <em>salmonella</em> spp. Patients presenting with infections severe enough to require hospital admission should be treated with the usual antibiotics indicated for the suspected site of infection. The exception to this is osteomyelitis, which should be treated with chloramphenicol 25 mg/kg up to 500 mg QDS for 2 weeks. Also, ensure child is fully vaccinated as this helps with infection from some of the encapsulated bacteria listed above.</p>\\r\\n<p><strong><span class=\\\"underline\\\">Stroke:</span></strong> This is a complication of veno-occlusive crisis affecting the brain. Ten percent (10%) of sickle cell patients will have a stroke before the age of 20 years and those who have had one stroke have a 60% chance of having a second stroke. Patients with an acute stroke have a better outcome if they receive blood transfusion to keep their Hb above 10 g/dl and oxygen to keep their saturations above 95%. They should then continue to receive regular transfusions to keep their Hb at 10 g/dl. This should ideally be done by exchange transfusion, but this is not available in our setting.</p>\\r\\n<p><strong><span class=\\\"underline\\\">Acute chest syndrome:</span></strong> This is a complication of veno-occlusive crisis affecting the lungs. This is commonly associated with secondary respiratory infection. The mortality rate is 10% even in the best centres. The patient should be treated with oxygen, salbutamol nebulisers and benzyl penicillin 500,000 units/kg up to 2 megaunits QDS and chloramphenicol 25 mg/kg up to 500 mg QDS. Transfuse if the Hb is below 10 g/dl.</p>\\r\\n<p><strong><span class=\\\"underline\\\">Renal failure:</span></strong> will occur in one third of patients over their lifetime. This is due to recurrent renal ischaemia. Patients with sickle cell disease who are admitted must be adequately hydrated as above.</p>\\r\\n<p><strong><span class=\\\"underline\\\">Complications of pregnancy:</span></strong> occur when the placenta becomes ischaemic during a crisis. This presents with spontaneous abortion, placental abruption and premature labour. Pregnant sickle cell patients require specialised obstetric care. Early referral to the O&amp;G unit of EFSTH is thus necessary.</p>\\r\\n<p><strong><span class=\\\"underline\\\">Priapism:</span></strong> occurs when sickling affects the penis and is very painful. It should be treated with adequate pain relief and hyperhydration. If there is no rapid relief, blood must be aspirated from the penis with a needle. Referral to the urologist is necessary at this point.</p>\\r\\n<h2 id=\\\"key-issues-for-nursing-care\\\">Key Issues for Nursing care</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Timely assessment of patients.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Advocate for rapid and effective treatment of pain.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Develop trusting relationship with patient and family.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Educate patients to use a pro-active approach in pain management.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<p>Sickle Cell Information Center (2016) What is sickle cell disease. Retrieved from http://scinfo.org/index.php/what-is-sickle-cell-disease</p>\\r\\n<p><a href=\\\"http://www.sicklecelldisease.org/\\\"><span class=\\\"underline\\\">http://www.sicklecelldisease.org/</span></a>:</p>\\r\\n<p><a href=\\\"http://www.sicklecellsociety.org/\\\"><span class=\\\"underline\\\">http://www.sicklecellsociety.org/</span></a> : information, Counselling and Caring for those with Sickle Cell Disorders and their families: UK based</p>\\r\\n<p>Expert Panel Report, US Department of Health and Human Services. Evidence-Based Management of Sickle Cell Disease. <em>National Institutes of Health</em>. 2014.</p>\\r\\n<p>Imperial Paediatric Sickle Cell Pain Management Protocol</p>\\r\\n<p>http://www.who.int/en/</p>\\r\\n<p>Nelson text book of paediatrics</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Yorro Bah</th>\\r\\n<th>Date: 22 June 2019</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Karen Forrest</td>\\r\\n<td>Date: 24 July 2019</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td>30 August 2021</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"062\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>Sinusitis MeG-CLS-062</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"sinusitis\\\">Sinusitis</h1>\\r\\n<h2 id=\\\"executive-summary\\\"><em>Executive summary</em></h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<p>Sinusitis is an acute inflammatory condition of one or more of the paranasal sinuses. Infection plays an important role in this affliction. Sinusitis often results from infections of other sites of the respiratory tract since the paranasal sinuses are contiguous to, and communicate with, the upper respiratory tract. Acute sinusitis is commonly viral but a bacterial cause is likely if it persists for 7-10 days or worsens within 10 days after initial relief.</p>\\r\\n<p><em>Streptococcus pneumoniae</em>, <em>Haemophilus influenzae</em>, and <em>Moraxella catarrhalis</em> are the commonest bacterial aetiology for acute sinusitis. Chronic sinusitis is commonly a mixed infection of aerobic and anaerobic organisms.</p>\\r\\n<p>Sinusitis is classified as:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Acute: an infection lasting 7-30 days.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Subacute: the inflammation lasts 4-12 weeks.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Recurring: there are &gt;3 significant acute episodes in a year lasting ≥10 days with no intervening symptoms.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Chronic: symptoms persist for &gt;90 days (these may be caused by irreversible changes in the mucosal lining of the sinuses), with or without acute exacerbations.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"target-users\\\">Target users</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doctors</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nurses</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"target-area-of-use\\\">Target area of use </h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Gate clinic</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Outpatient department</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ward</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"key-areas-of-focus-new-additions-changes\\\">Key areas of focus / New additions / Changes </h2>\\r\\n<p>This guidelines addresses the diagnosis and management of sinusitis.</p>\\r\\n<h2 id=\\\"limitations\\\">Limitations</h2>\\r\\n<p>None</p>\\r\\n<p><strong>Presenting symptoms and signs</strong></p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>The maxillary and ethmoid sinuses are most commonly involved in sinusitis. The frontal sinuses are less often involved and the sphenoid sinuses are rarely affected.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Facial pain, sensation of pressure and tenderness over the affected sinus are present.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Purulent nasal discharge</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Fever, fatigue and headache</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Postnasal discharge</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Persistent coughing</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hyposmia or anosmia</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ear pressure or fullness</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Halitosis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Maxillary dental pain</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"sinusitis-in-children\\\">Sinusitis in children</h3>\\r\\n<p>There is some controversy as to whether this diagnosis can be made in young children who have very poorly developed sinuses - radiographic evidence of sinuses is only visible from about 9 years of age. Current consensus is that it can occur in children over the age of 1 year. Symptoms may vary a little from those of adults and can include <strong>irritability, lethargy, snoring, mouth breathing, feeding difficulty and hyponasal speech.</strong></p>\\r\\n<p><strong>Examination findings</strong></p>\\r\\n<p>The most helpful examination technique is simple palpation, as this is quick and easy to perform. Percussion and transillumination are also described although these are not reliable.</p>\\r\\n<p>All but the sphenoidal sinuses can be palpated for tenderness:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Frontal sinus</strong> - press upward beneath the medial side of the supraorbital ridge.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Maxillary sinus</strong> - press against the anterior wall, below the inferior orbital margin.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Ethmoidal sinus</strong> - press medially against the medial wall of the orbit.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Other examination findings include</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Oedematous and hyperaemic nasal mucosa</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Purulent nasal secretions</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Purulent posterior pharyngeal secretions</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Periorbital oedema</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Air-fluid levels on transillumination of the sinuses</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"investigations\\\">Investigations</h2>\\r\\n<p>Diagnosis is clinical. Investigations are not necessary but may be done in the case of diagnostic uncertainty.</p>\\r\\n<p><strong>X-ray findings</strong>: Thickening of the sinus mucosa and a fluid level are usually seen in x-ray films or magnetic resonance imaging. X-rays are not needed to make a diagnosis.</p>\\r\\n<p>Diagnosis of acute bacterial sinusitis should be suspected if</p>\\r\\n<ol type=\\\"1\\\">\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Presence of symptoms or signs for 10 days or more</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Worsening of symptoms or signs after an initial improvement.</p>\\r\\n</div></li>\\r\\n</ol>\\r\\n<h2 id=\\\"management\\\">Management </h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Paracetamol (1 g TDS/QDS) or ibuprofen (200-600 mg TDS) for pain/fever.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Intranasal decongestant (oral is not recommended for sinusitis) for a maximum of a week.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nasal irrigation with warm saline solution.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Warm face packs may provide localised pain relief.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Adequate fluids and rest.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Antibiotics: for suspected bacterial sinusitis</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>1<sup>st</sup> line antibiotics</strong></th>\\r\\n<th></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Amoxicillin</td>\\r\\n<td>1 g orally TDS or 80-90 mg/kg/day for 5 days</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Penicillin V</td>\\r\\n<td><p>1 to 11 months, 62.5 mg QDS for 5 days</p>\\r\\n<p>1 to 5 years, 125 mg QDS for 5 days</p>\\r\\n<p>6 to 11 years, 250 mg QDS for 5 days</p>\\r\\n<p>≥12 years, 500 mg QDS for 5 days</p></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Doxycycline</td>\\r\\n<td><p>PO 200 mg BD for 5-7 days</p>\\r\\n<p>NB: contraindicated in pregnancy and children less than 8 years</p></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Erythromycin (recommended in pregnancy)</td>\\r\\n<td><p>PO 400 mg QDS for 10-14 days (may increase to 4 g/day depending on severity) or</p>\\r\\n<p>30-50 mg/kg/day; can give 60-100 mg/kg/day in severe infection</p></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Azithromycin</td>\\r\\n<td><p>PO 500 mg/day for 3 days or 2 g once</p>\\r\\n<p>Paeds: 10 mg/kg/day for 3 days</p></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>2<sup>nd</sup> line antibiotics</strong></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Co-amoxiclav</td>\\r\\n<td>500 mg of amoxicillin TDS for 5 - 10 days or 40 mg/kg/day</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Ciprofloxacin</td>\\r\\n<td>PO 500 mg BD or IV 400 mg BD for 10 days</td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<p>Admit patient if there is severe systemic infection, complications of sinusitis and immunocompromised patients.</p>\\r\\n<p><strong><br />\\r\\n</strong></p>\\r\\n<p><strong>Complications are rare</strong>. They occur more commonly in children. They include orbital cellulitis, meningitis, brain abscess, osteomyelitis (known as Pott&#39;s puffy tumour when the frontal bone is affected) and cavernous sinus thrombosis. Acute sinusitis can become chronic.</p>\\r\\n<p><strong>Refer for urgent ENT review if</strong>:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>there are unilateral symptoms (eg, mass, bloodstained discharge, crusting, non-tender facial pain, facial swelling or unilateral nasal polyps or unilateral nasal polyps).</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>persistent infections (three or more attacks per year) or</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>persistent symptoms despite an adequate course of second-line antibiotics.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p><strong>Prognosis</strong></p>\\r\\n<p>Symptoms are likely to be relatively slow to resolve (2-3 weeks, regardless of whether antibiotics are taken or not) but over two-thirds of patients experience improvement or resolution of symptoms without antibiotic treatment.</p>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<p>Colledge, Nicki R., Brian R. Walker, Stuart Ralston, and Stanley Davidson. 2010. Davidson&#39;s principles and practice of medicine. Edinburgh: Churchill Livingstone/Elsevier.</p>\\r\\n<p>Henderson R (2014). Sinusitis. Certified by The Information Standard. Retrieved from <a href=\\\"https://patient.info/doctor/sinusitis-pro\\\"><span data-custom-style=\\\"Hyperlink\\\">https://patient.info/doctor/sinusitis-pro</span></a> on 23/02/19.</p>\\r\\n<p>Kliegman, Robert., et al. Nelson Textbook of Pediatrics. 20<sup>th</sup> Edition. Philadelphia, PA: Elsevier, 2016.</p>\\r\\n<p>Sinusitis (acute): antimicrobial prescribing. NICE. Retrieved from <a href=\\\"https://www.nice.org.uk/guidance/ng79/documents/consultation-document\\\"><span data-custom-style=\\\"Hyperlink\\\">https://www.nice.org.uk/guidance/ng79/documents/consultation-document</span></a> on 23/02/19.</p>\\r\\n<p>Standard Treatment Guidelines, 6th Edition, 2010. ISBN 978-9988-1-2538-7</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Fatoumata Sawaneh</th>\\r\\n<th>Date: 27 February 2019</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Baderinwa Abatan</td>\\r\\n<td>Date: 03 May 2019</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td>31 May 2021</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"067\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>Stevens-Johnson syndrome MeG-CLS-067</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"stevens-johnson-syndrome\\\">Stevens-Johnson Syndrome</h1>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<p>Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe mucocutaneous adverse reactions, most commonly triggered by medications, characterized by fever and extensive necrosis and detachment of the epidermis. SJS and TEN are considered a disease continuum and are distinguished chiefly by severity, based upon the percentage of body surface involved with skin detachment.</p>\\r\\n<p>SJS is the less severe condition, in which skin detachment is &lt;10% of the body surface. Mucous membranes are affected in over 90 percent of patients, usually at two or more distinct sites (ocular, oral, and genital).</p>\\r\\n<p>TEN involves detachment of &gt;30% of the body surface area. Mucous membranes are also involved in over 90% of cases.</p>\\r\\n<p>SJS/TEN overlap describes patients with skin detachment of 10 to 30% of body surface area. Mucous membranes are also involved in over 90% of cases.</p>\\r\\n<p>Here, &quot;SJS/TEN&quot; is used to refer collectively to SJS, TEN, and SJS/TEN overlap.</p>\\r\\n<h2 id=\\\"target-user\\\">Target User</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doctors</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nurses</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"target-area-of-use\\\">Target area of use </h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ward</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Outpatient department</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"key-areas-of-focusnew-additionschanges\\\">Key areas of focus/new additions/changes</h2>\\r\\n<p>These guidelines addresses the management of Stevens Johnson.</p>\\r\\n<h2 id=\\\"limitations\\\">Limitations</h2>\\r\\n<p>Lack of an intensive care unit to nurse patient with extensive lesions.</p>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs\\\">Presenting symptoms and signs</h2>\\r\\n<p>Typical prodromal symptoms of SJS are as follows:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Cough productive of a thick, purulent sputum</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Headache</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Malaise</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Arthralgia</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Patients may complain of a burning rash that begins symmetrically on the face and the upper part of the torso. This may be accompanied by ocular symptoms.</p>\\r\\n<p>In addition to the skin, lesions in SJS may involve the following parts of the body:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Oral mucosa</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Oesophagus</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Pharynx</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Larynx</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Anus</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Trachea</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Vagina</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Urethra</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Ocular symptoms include the following: red eye, tearing, dry eye, pain, blepharospasm, itching, grittiness, heavy eyelid, foreign body sensation, decreased vision, burning sensation, photophobia, diplopia</p>\\r\\n<h2 id=\\\"examination-findings\\\">Examination findings</h2>\\r\\n<p>The rash can begin as macules that develop into papules, vesicles, bullae, urticarial plaques, or confluent erythema. The centre of these lesions may be vesicular, purpuric, or necrotic.</p>\\r\\n<p>Lesions may become bullous and later rupture, leaving denuded skin. The skin becomes susceptible to secondary infection.</p>\\r\\n<p>Urticarial lesions typically are not pruritic. Infection may be responsible for the scarring associated with morbidity.</p>\\r\\n<p>Although lesions may occur anywhere, the palms, soles dorsum of the hands, and extensor surfaces are most commonly affected.</p>\\r\\n<p>The rash may be confined to any one area of the body, most often the trunk. Mucosal involvement may include erythema, oedema, sloughing, blistering, ulceration, and necrosis.</p>\\r\\n<p>The following signs may also be noted on examination:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Fever</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Tachycardia</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hypotension</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Altered level of consciousness, epistaxis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Conjunctivitis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Corneal ulceration</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Erosive vulvovaginitis or balanitis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Seizures</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Coma</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"differential-diagnoses\\\">Differential Diagnoses</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Trauma</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Irradiation</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Porphyria cutanea tarda</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Staphylococcal scalded skin syndrome</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Sebaceous cell carcinoma</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Adenoviral conjunctivitis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Intraepithelial epithelioma</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Acute generalized exanthematic pustulosis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Chemical burns</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"investigations\\\">Investigations</h2>\\r\\n<p>There are no specific laboratory studies (other than biopsy) that can definitively establish the diagnosis of SJS but the following investigations can be done:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>FBC, severely elevated WBC count indicates the possibility of a superimposed bacterial infection.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>U&amp;E, LFT may be needed to help manage related problems</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Skin and blood cultures have been advocated because the incidence of serious bacterial bloodstream infections and sepsis contribute to morbidity and mortality.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>CXR may indicate the existence of a pneumonitis when clinically suspected. Otherwise, routine plain films are not indicated.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Skin biopsy specimens demonstrate that the bullae are subepidermal. Epidermal cell necrosis may be noted. Perivascular areas are infiltrated with lymphocytes.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"management\\\">Management</h2>\\r\\n<p>The main principles of supportive care are the same as for major burns and include wound care, fluid and electrolyte management, nutritional support, temperature management, pain control, and monitoring or treatment of superinfections</p>\\r\\n<h3 id=\\\"initiate-a-primary-management-plan\\\">Initiate a primary management plan:</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Establish peripheral venous access: Site venous lines through non-lesional skin, whenever possible, and change peripheral venous cannulas every 48 hours.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Establish adequate intravenous fluid replacement initially. Fluid replacement can be guided by urine output and other endpoint measurements. Individualized fluid management should be adjusted on a daily basis, but replacement volumes are approximately one-third lower than those needed for burn victims.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>With improvement of SJS/TEN mouth involvement, oral administration of fluids should be progressively increased.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>If patient cannot maintain adequate nutrition orally, insert a nasogastric tube and institute nasogastric feeding.</p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Insert a urinary catheter if urogenital involvement is causing significant dysuria/retention.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"prognostic-scoring\\\">Prognostic scoring </h3>\\r\\n<p>The prognosis of individual patients can be rapidly evaluated on admission by applying a prognostic scoring system called <strong>SCORTEN</strong>. SCORTEN is based upon seven independent and easily measured clinical and laboratory variables <span class=\\\"underline\\\"> </span> and has been validated for use on days one and three of hospitalization for SJS/TEN.</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Prognostic factors</strong></th>\\r\\n<th><strong>Score</strong></th>\\r\\n<th></th>\\r\\n<th><strong>SCORTEN</strong></th>\\r\\n<th><strong>Mortality(%)</strong></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Age &gt; 40 years</td>\\r\\n<td>1</td>\\r\\n<td></td>\\r\\n<td>0-1</td>\\r\\n<td>3</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Tachycardia &gt;120 bpm</td>\\r\\n<td>1</td>\\r\\n<td></td>\\r\\n<td>2</td>\\r\\n<td>12</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Neoplasia</td>\\r\\n<td>1</td>\\r\\n<td></td>\\r\\n<td>3</td>\\r\\n<td>35</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Initial detachment &gt; 10%</td>\\r\\n<td>1</td>\\r\\n<td></td>\\r\\n<td>4</td>\\r\\n<td>58</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Serum urea &gt; 10 mmol/L</td>\\r\\n<td>1</td>\\r\\n<td></td>\\r\\n<td>≥5</td>\\r\\n<td>90</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Serum bicarbonate &lt; 20 mmol/L</td>\\r\\n<td>1</td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Blood glucose &gt; 14 mmol/L</td>\\r\\n<td>1</td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<p>The decision to refer the patient to an intensive care or burn unit should be made on a case-by-case basis, based upon the extent of skin involvement and the presence of comorbidities. Patients with a limited skin involvement, a SCORTEN score <span class=\\\"underline\\\"> </span> of 0 or 1, and disease that is not rapidly progressing may be treated in nonspecialized wards. Patients with more severe disease (skin detachment &gt;30% of the body surface area) <span data-custom-style=\\\"Strong\\\">or</span> a SCORTEN score ≥2 should be transferred to intensive care units, burn units, or specialized dermatology units, if available.</p>\\r\\n<h3 id=\\\"skin-care\\\">Skin Care </h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Employ strict barrier nursing to reduce nosocomial infections</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Take swabs for bacterial and candidal culture from three areas of lesional skin, particularly sloughy or crusted areas, on alternate days throughout the acute phase.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Administer systemic antibiotics only if there are clinical signs of infection</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Regularly cleanse wounds and intact skin by irrigating gently using warmed sterile water, saline or an antimicrobial such as chlorhexidine (1/5000)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Apply a greasy emollient, such as emulsifying ointment, 50% white soft paraffin with 50% liquid paraffin, over the whole epidermis, including denuded areas</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Apply a topical antimicrobial agent to sloughy areas only (choice should be guided by local microbiological advice·</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>The detached, lesional epidermis may be left <em>in situ</em> to act as a biological dressing. Blisters should be decompressed by piercing and expression or aspiration of tissue fluid.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Apply non-adherent dressings to denuded dermis</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"analgesia\\\">Analgesia</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Use a patient appropriate validated pain tool to assess pain in all conscious patients at least once a day.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Patients should receive adequate analgesia to ensure comfort at rest, with the addition of supplementary opiates, as required.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Additional analgesia may be needed to address increased pain associated with patient handling, re-positioning and dressing changes</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"supportive-therapeutic-measures\\\">Supportive therapeutic measures</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Immobile patients should receive low molecular weight heparin</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Patients in whom enteral nutrition cannot be established should receive a proton pump inhibitor to reduce the risk of stress-related gastro-intestinal ulceration</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"ocular-care\\\">Ocular Care</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Apply an ocular lubricant (e.g. non-preserved hyaluronate or carmellose eye drops) every two hours through the acute illness</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ocular hygiene must be carried out each day</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Application of topical corticosteroid drops (e.g. non-preserved dexamethasone 0.1% twice a day) may reduce ocular surface damage</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Administer topical antibiotic as prophylaxis (e.g. ciprofloxacin drops four times a day) in the presence of corneal ulceration</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>In the unconscious patient, prevention of corneal exposure is essential.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"mouth-care\\\">Mouth care</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Daily oral review is necessary during the acute illness</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Apply white soft paraffin ointment to the lips every two hours through the acute illness</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Clean the mouth daily with warm saline mouthwashes or an oral sponge</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"urogenital-caret\\\">Urogenital Caret</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Daily urogenital review is necessary during the acute illness</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Apply white soft paraffin ointment to the urogenital skin and mucosae every four hours throughout the acute illness</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Use a potent topical corticosteroid ointment once a day to the involved, but non-eroded surfaces.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"nutritional-care-of-airway\\\">Nutritional care of airway</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Provide continuous enteral nutrition throughout the acute phase</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Deliver up to 20 to 25 kcal/kg/day during the early, catabolic phase and 25 to 30 kcal/kg/day during the anabolic, recovery phase.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"discharge-and-follow-up\\\">Discharge and follow up</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Give the patient written information about drug(s) to avoid</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Drug allergy should be documented in the patient’s notes; all doctors involved in the patient’s care should be informed</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Organize an out-patient clinic appointment, and if required an ophthalmology out-patient appointment, within a few weeks of discharge</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Refer for review to unit with appropriate sub-speciality interest</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"key-issues-for-nursing-care\\\">Key Issues for Nursing care</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Sterile handling and/or reverse-isolation nursing techniques are essential to decrease the risk of nosocomial infection</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Daily ocular and mouth hygiene</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Effective and timely skin care</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<ol type=\\\"1\\\">\\r\\n<li><blockquote>\\r\\n<p><a href=\\\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-management-prognosis-and-long-term-sequelae/abstract/1\\\">Bastuji-Garin S, Rzany B, Stern RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993; 129:92.</a></p>\\r\\n</blockquote></li>\\r\\n<li><blockquote>\\r\\n<p><a href=\\\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-management-prognosis-and-long-term-sequelae/abstract/2\\\">Creamer D, Walsh SA, Dziewulski P, et al. U.K. guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016. Br J Dermatol 2016; 174:1194.</a></p>\\r\\n</blockquote></li>\\r\\n<li><blockquote>\\r\\n<p><a href=\\\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-management-prognosis-and-long-term-sequelae/abstract/3\\\">Harr T, French LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet J Rare Dis 2010; 5:39.</a></p>\\r\\n</blockquote></li>\\r\\n<li><blockquote>\\r\\n<p><a href=\\\"https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-management-prognosis-and-long-term-sequelae/abstract/4\\\">Bastuji-Garin S, Fouchard N, Bertocchi M, et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000; 115:149.</a></p>\\r\\n</blockquote></li>\\r\\n<li><blockquote>\\r\\n<p><strong>UK guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis 2016</strong> Creamer D, Walsh SA , Dziewulski P, Exton LS, Lee HY, Dart JKG, Setterfield J, Bunker CB, Ardern-Jones MR, Watson KMT,Wong GAE, Philippidou M, Vercueil A, Martin RV, Williams G, Shah M, Brown D, Williams P, Mohd Mustapa MF, Smith CH.</p>\\r\\n</blockquote></li>\\r\\n<li><blockquote>\\r\\n<p><em>Br J Dermatol</em> <strong>2016</strong>; 174: 1194-1227 &amp; <em>J Plast Reconstr Aesthet Surg</em> <strong>2016</strong>; 69: e119e153</p>\\r\\n</blockquote></li>\\r\\n</ol>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Amie Secka</th>\\r\\n<th>Date: 30 November 2018</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Orighomisan Agboghoroma</td>\\r\\n<td>Date: 06 December 2018</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td>31 January 2021</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>1.1</td>\\r\\n<td>Executive summary added</td>\\r\\n<td>31 January 2021</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"038\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>STI MeG-CLS-038</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"sexually-transmitted-infections-sti\\\">Sexually transmitted infections (STI)</h1>\\r\\n<h2 id=\\\"executive-summary\\\"><em>Executive summary</em></h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<p>Sexually transmitted infections are infections that can be transferred through sexual contact, from one individual to another. They include: syphillis, gonorrhoea, chlamydia, chancroid, genital herpes, genital warts, <em>Trichomonas vaginalis</em> and HIV (discussed in a separate guideline).</p>\\r\\n<p>Majority of people with STIs are asymptomatic or may present with non-specific signs and symptoms. Early detection and treatment are however of great significance as some STIs may result in serious long-term reproductive health problems.</p>\\r\\n<h2 id=\\\"target-users\\\">Target users</h2>\\r\\n<ul>\\r\\n<li><p>Nurses</p></li>\\r\\n<li><p>Doctors</p></li>\\r\\n</ul>\\r\\n<h2 id=\\\"target-area-of-use\\\">Target area of use </h2>\\r\\n<ul>\\r\\n<li><p>Gate Clinic</p></li>\\r\\n<li><p>OPD</p></li>\\r\\n<li><p>Ward</p></li>\\r\\n</ul>\\r\\n<h2 id=\\\"key-areas-of-focus-new-additions-changes\\\">Key areas of focus / New additions / Changes </h2>\\r\\n<p>This guideline provides information on the diagnosis and treatment of common STIs using a syndromic approach. Patients with typical presentation do not require further workup beyond HIV screening unless specific indications are present. Treatment involves use of oral and/or parenteral antibiotics. Inpatient therapy may be indicated in some patients with acute pelvic inflammatory disease.</p>\\r\\n<h2 id=\\\"limitations\\\">Limitations</h2>\\r\\n<p>Culture and sensitivity studies are currently not available at Keneba and Basse<strong>.</strong></p>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs\\\">Presenting symptoms and signs</h2>\\r\\n<h3 id=\\\"men\\\">Men:</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Urethral discharge: It is usually accompanied by dysuria. Frequency and itchy sensation may also be present</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Genital ulcers</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Inguinal mass</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Scrotal swelling</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Painful micturition</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>May be asymptomatic</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"women\\\">Women:</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Vaginal discharge</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Genital ulcers</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Inguinal mass</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Lower abdominal pain</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Fever</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>May be asymptomatic</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"examination-findings\\\">Examination findings</h2>\\r\\n<h2 id=\\\"following-a-general-and-abdominal-examination-in-depth-examination-of-the-genitalia-should-be-undertaken.\\\">Following a general and abdominal examination, in-depth examination of the genitalia should be undertaken.</h2>\\r\\n<h3 id=\\\"men-1\\\">Men:</h3>\\r\\n<p>Inspection: the penis should be inspected. The opening of the urethra should be examined for discharge. Discharge should be milked-out if none is seen at initial inspection. The phallus skin should be examined for ulcers. If ulcers are present, note their number and the presence of any tenderness.</p>\\r\\n<p>Palpation: palpate for inguinal lymph nodes</p>\\r\\n<h3 id=\\\"women-1\\\">Women:</h3>\\r\\n<p>Inspection: the vulva region should be inspected first for any discharge, ulcers or warts. Following this, a speculum examination should be carried out. Inspect the cervix, and vagina as the speculum is eased out. The origin of vaginal discharge is of importance. If it is seen to come from the cervix, gonorrhoeal and chlamydial infections are more likely.</p>\\r\\n<h3 id=\\\"important-things-to-look-for\\\">Important things to look for </h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Colour and consistency of discharge if present</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Number of ulcers if present and associated tenderness</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Presence of inguinal lymph nodes</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"differential-diagnoses\\\">Differential diagnoses</h2>\\r\\n<p>Urethral discharge: gonorrhea, chlamydia</p>\\r\\n<p>Genital ulcer: syphilis, chancroid, granuloma inguinale, lymphogranuloma venereum (LGV), herpes simplex virus</p>\\r\\n<p>Scrotal swelling: testicular torsion, epididymitis (gonorrhea, chlamydia)</p>\\r\\n<p>Vaginal discharge: candidiasis, bacterial vaginosis, chlamydia, gonorrhea, <em>Trichomonas vaginalis</em></p>\\r\\n<p>Neonatal conjunctivitis: gonorrhea, chlamydia, other organisms: <em>Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus spp</em></p>\\r\\n<h2 id=\\\"investigations\\\">Investigations</h2>\\r\\n<p>HIV Screen should be offered to all patients.</p>\\r\\n<p>Syndromic management does not require other investigations to be done. If there are specific indications appropriate investigations might include:</p>\\r\\n<p>FBC, Urethral swab M,C&amp;S, High vaginal swab M,C&amp;S, Endocervical swab M,C&amp;S</p>\\r\\n<p>Test for syphilis (VDRL, TPHA) – especially for patients with genital ulcer.</p>\\r\\n<h2 id=\\\"management\\\">Management</h2>\\r\\n<p>Ask all patients about their sexual partners.</p>\\r\\n<p>Describe sexual transmission of infections and advise on reducing the risk of this by being faithful to one partner who is also faithful (or group of partners in a polygamous marriage) and by condom use if this is not possible.</p>\\r\\n<p>Ask patients to bring partners to the clinic for treatment Advise them to abstain from sexual contact until all partners have been treated.</p>\\r\\n<p>Provide pre-test counselling for HIV testing and offer a test if accepted.</p>\\r\\n<p>Advise patients to seek further medical attention if their symptoms have not resolved by a week after treatment. Give them an appointment 7 days later to check on their progress and to facilitate partner management.</p>\\r\\n<p>A syndromic approach to management is currently advocated for by WHO in low-resource settings due to the lack of appropriate investigations. This involves the use of certain signs and symptoms to guide treatment.</p>\\r\\n<p>There are 6 syndromes:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Urethral discharge</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Vaginal discharge</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Scrotal swelling</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Genital ulcer</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Lower abdominal pain</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Neonatal conjunctivitis</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Note that urethral discharge, scrotal swelling and vaginal discharge coming from the cervix are all treated in the same way.</p>\\r\\n<h3 id=\\\"urethral-discharge-scrotal-swelling-vaginal-discharge\\\">Urethral discharge, scrotal swelling, vaginal discharge</h3>\\r\\n<p>Examine men complaining of discharge to identify it. If none is seen, gently milk the penis to see if discharge is produced. Swab the discharge and send for urgent microscopy</p>\\r\\n<p>Examine men with scrotal swelling to exclude other causes of scrotal swelling, such as trauma, testicular torsion or tumour. Consider requesting an ultrasound.</p>\\r\\n<p>All women with vaginal discharge should be examined with a speculum and a high vaginal swab taken and sent for microscopy.</p>\\r\\n<p>Treat patients thought to have STI as the cause of these symptoms with Ciprofloxacin 500 mg orally as a single dose PLUS Doxycycline 100 mg orally BD for 7 days.</p>\\r\\n<p>If a woman is pregnant and cannot take these medications, use azithromycin 2 g orally as a single dose.</p>\\r\\n<p>Recommend bed rest and scrotal support for men with scrotal swelling until the inflammation has reduced.</p>\\r\\n<h3 id=\\\"vaginal-discharge-not-from-the-cervix\\\">Vaginal discharge (not from the cervix)</h3>\\r\\n<p>Treat this with Metronidazole 500 mg BD for 7 days (OR Metronidazole 2 g as a single dose) PLUS Clotrimazole 200 mg intravaginally OD for 3 days (OR Fluconazole 150 mg orally as a single dose).</p>\\r\\n<h3 id=\\\"genital-ulcer\\\">Genital ulcer</h3>\\r\\n<p><strong>Vesicular, multiple or recurrent</strong>: Aciclovir 400 mg TDS for 7 days</p>\\r\\n<p><strong>Non-vesicular:</strong> Doxycycline 100 mg twice daily for 15 days PLUS Ciprofloxacin 500 mg twice daily for 3 days. This covers chancroid, LGV and syphilis.</p>\\r\\n<p>If the patient is pregnant, then use im Ceftriaxone 250 mg as a single dose PLUS erythromycin 500 mg QDS for 14 days.</p>\\r\\n<h3 id=\\\"lower-abdominal-pain\\\">Lower abdominal pain</h3>\\r\\n<p>Lower abdominal pain may be caused by pelvic inflammatory disease (PID). There may also be pain during intercourse, vaginal discharge, dysuria, increased length and frequency of menses, increased pain during menses, fever, nausea and vomiting.</p>\\r\\n<p>Women complaining of lower abdominal pain should be fully examined. On pelvic examination there may be adnexal tenderness, cervical motion tenderness and visible discharge. They may also have a tender pelvic mass, and rebound tenderness.</p>\\r\\n<p>Inpatient care of patients with acute pelvic inflammatory disease should be considered when one or more of the following are present:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Uncertain diagnosis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Failure to exclude surgical emergencies for example appendicitis and ectopic pregnancy</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Suspected pelvic abscess</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>A severe illness which will prevent outpatient management</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>A pregnant patient</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Inability to tolerate outpatient regimen</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Failure to respond to therapy on an out-patient basis.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p><strong>Outpatient management:</strong> Ceftriaxone 250 mg IM as a single dose PLUS Doxycycline 100 mg orally BD for 14 days <em><strong>PLUS</strong></em> Metronidazole 500 mg orally BD for 14 days</p>\\r\\n<p>Inpatient management: Ceftriaxone 250 mg by intramuscular injection OD PLUS Doxycycline, 100mg orally or by intravenous injection BD PLUS Metronidazole 500mg orally or iv TDS.</p>\\r\\n<p>Inpatient therapy should be continued until at least 2 days after the patient has improved, after which doxycycline should be given at 100mg orally, twice daily for 14 days.</p>\\r\\n<h3 id=\\\"ophthalmia-neonatorum\\\">Ophthalmia neonatorum</h3>\\r\\n<p>Ceftriaxone 50 mg/kg by intramuscular injection as a single dose, to a maximum of 125 mg PLUS Erythromycin syrup 50 mg/kg per day orally, in 4 divided doses for 14 days.</p>\\r\\n<h2 id=\\\"key-issues-for-nursing-care\\\">Key Issues for Nursing care</h2>\\r\\n<p>Refer the following patients to see a doctor:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>A man with persistent or recurrent urethritis.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Patients with genital ulcers that do not improve with treatment.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Patients with genital ulcers where the diagnosis is unclear.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Men with inguinal mass which is fluctuant or of uncertain cause.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Men with scrotal swelling of uncertain cause.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Women with vaginal discharge unless you can do a speculum and pelvic examination yourself.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Women with lower abdominal pain unless you can do a pelvic examination yourself.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<p><a href=\\\"http://www.who.int/news-room/fact-sheets/detail/sexually-transmitted-infections-(stis)\\\"><span data-custom-style=\\\"Hyperlink\\\">http://www.who.int/news-room/fact-sheets/detail/sexually-transmitted-infections-(stis)</span></a></p>\\r\\n<p>WHO guidelines for management of sexually transmitted infections <a href=\\\"http://apps.who.int/medicinedocs/en/d/Jh2942e/3.1.html\\\"><span data-custom-style=\\\"Hyperlink\\\">http://apps.who.int/medicinedocs/en/d/Jh2942e/3.1.html</span></a></p>\\r\\n<p><a href=\\\"http://apps.who.int/medicinedocs/documents/s22268en/s22268en.pdf\\\"><span data-custom-style=\\\"Hyperlink\\\">http://apps.who.int/medicinedocs/documents/s22268en/s22268en.pdf</span></a></p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Azeezat Sallahdeen</th>\\r\\n<th>Date: 22 May 2018</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Fatai Akemokwe</td>\\r\\n<td>Date: 11 June 2018</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>2.0</td>\\r\\n<td>Adapted from previous version and MeG-CLS-016 to combine into one document relevant to all areas</td>\\r\\n<td>31 July 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>2.1</td>\\r\\n<td>Executive summary added</td>\\r\\n<td>31 July 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"020\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>Stroke MeG-CLS-020</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"stroke\\\">Stroke</h1>\\r\\n<h2 id=\\\"executive-summary\\\"><em>Executive summary</em></h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<p>A stroke is the sudden loss of neurological function resulting from death of brain tissue from vascular occlusion or rupture.</p>\\r\\n<p>Stroke is the second leading cause of death globally and the number one cause of functional disability. It is a feared complication of hypertension, diabetes mellitus and heart disease.</p>\\r\\n<p>The gold standard for stroke treatment includes an early CT scan to rule out bleeding followed by thrombolysis. These are not readily available in The Gambia but should not prevent our patients from receiving the best possible care that is available.</p>\\r\\n<h3 id=\\\"target-users\\\">Target users</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doctors</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nurses</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"target-area-of-use\\\">Target area of use </h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Gate clinic</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Outpatient department</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ward</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"key-areas-of-focus-new-additions-changes\\\">Key areas of focus / New additions / Changes </h3>\\r\\n<p>This guideline covers the diagnoses and management of stroke. It updates the previous guideline on acute stroke care.</p>\\r\\n<p>Patients suspected to have suffered a stroke should be sent from the Gate Clinic to the ward for urgent review by a doctor.</p>\\r\\n<p>The ROSIER score can assist the doctor in diagnosis if the presentation is unclear.</p>\\r\\n<p>For patients presenting in Keneba, refer after emergency care.</p>\\r\\n<p>Ideally, patients should have a non-contrast cranial CT scan to rule out haemorrhage. Treatment on the ward involves maintenance of hydration, management of intracranial pressure, antithrombotics (if ischaemic), DVT and pressure ulcer prophylaxis, physical therapy and other supportive care. In addition, patients with suspected SAH require sedation, analgesia, laxatives and possible early neurosurgical referral.</p>\\r\\n<p>Post-discharge care should be planned in consultation with the patient and/or caregivers. This may include palliative care in patients with severe functional disability.</p>\\r\\n<h2 id=\\\"limitations\\\">Limitations</h2>\\r\\n<p>CT scan and rehabilitation services may not be readily accessible to most patients. Thrombolysis for stroke is currently unavailable in The Gambia.</p>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs\\\">Presenting symptoms and signs</h2>\\r\\n<p>Stroke typically presents as sudden, rapidly peaking loss of neurological function. A history of sudden limb weakness, slurring of speech or visual deficits suggests a stroke or, if resolved within 24 hours, a transient ischaemic attack. Rarely, a stroke may present with only paraesthesia, balance problems or language problems.</p>\\r\\n<p>Ask for head trauma within the past 3 months.</p>\\r\\n<p>If any of coma, neck stiffness, seizures, diastolic blood pressure &gt; 110 mmHg, vomiting, or headache is also present, the patient is more likely to have had a haemorrhagic type of stroke. A history of sudden severe headache and neck stiffness is in keeping with subarachnoid haemorrhage.</p>\\r\\n<p>A history of only loss of consciousness or seizures suggests an alternative diagnosis.</p>\\r\\n<h2 id=\\\"examination-findings\\\">Examination findings</h2>\\r\\n<p>Assess airway, breathing and circulation. Check the observations (HR, BP, RR, O<sub>2</sub> saturations, Temperature).</p>\\r\\n<p>Assess consciousness, then orientation in time, place and person. Observe for confusion and difficulty producing or understanding speech.</p>\\r\\n<p>Check for neck stiffness which suggests subarachnoid haemorrhage.</p>\\r\\n<p>Assess the pupils, eye movements and facial symmetry. If patient is conscious, ask them to protrude their tongue.</p>\\r\\n<p>Assess tone, power and reflexes across the limbs.</p>\\r\\n<p>Observe the gait if the patient is able to walk.</p>\\r\\n<p>Listen over the heart for rhythm, murmurs and over the neck for carotid bruit.</p>\\r\\n<h2 id=\\\"investigations\\\">Investigations</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Blood glucose as soon as possible (Both hypo- and hyperglycaemia are stroke mimics. They also worsen stroke outcome)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>CT Scan of the brain without contrast to rule out haemorrhage. This should be done same day if stable or next day (if available and affordable).</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Full Blood Count</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>ESR (helps exclude vasculitis in younger patients)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Electrolytes, Urea and Creatinine</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Urinalysis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>ECG (rule out atrial fibrillation)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>CXR</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Sepsis screen (if fever develops)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Clotting profile (if previously on warfarin)</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"aim-to-have-acted-on-the-results-for-the-above-tests-excluding-cultures-in-less-than-four-hours.\\\">Aim to have acted on the results for the above tests (excluding cultures) in less than four hours.</h2>\\r\\n<h2 id=\\\"management\\\">Management </h2>\\r\\n<h3 id=\\\"management-in-gate-clinic\\\">Management in Gate Clinic</h3>\\r\\n<p>All patients with features of a possible stroke (recent onset of facial weakness, limb weakness or speech problems) should be referred immediately to the ward for urgent review by a doctor.</p>\\r\\n<h3 id=\\\"management-on-the-ward\\\">Management on the Ward</h3>\\r\\n<p><span class=\\\"underline\\\">Assessment:</span></p>\\r\\n<p>Use the ROSIER (Recognition of Stroke in the Emergency Room) score if uncertain of the diagnosis of stroke</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Feature</strong></th>\\r\\n<th><strong>Score</strong></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Loss of consciousness or syncope</td>\\r\\n<td>-1</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Seizure activity</td>\\r\\n<td>-1</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Asymmetric facial weakness*</td>\\r\\n<td>+1</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Asymmetric arm weakness*</td>\\r\\n<td>+1</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Asymmetric leg weakness*</td>\\r\\n<td>+1</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Speech disturbance*</td>\\r\\n<td>+1</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Visual field defect*</td>\\r\\n<td>+1</td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>*of recent sudden onset or noticed on waking from sleep</p>\\r\\n</div>\\r\\n<p>If the total ROSIER score is less than 1, a diagnosis of stroke is unlikely.</p>\\r\\n<p>Consider other diagnosis if the patient is young, has gradual progression over days, is febrile or has papilloedema.</p>\\r\\n<p><span class=\\\"underline\\\">Treatment:</span></p>\\r\\n<p><span class=\\\"underline\\\">Starting at admission:</span></p>\\r\\n<ol type=\\\"1\\\">\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hydrate initially with <strong>IV normal saline</strong>.</p>\\r\\n</div>\\r\\n<ol type=\\\"a\\\">\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nothing by mouth if dysarthric. Start on NG tube. Repeat <strong>swallow test</strong> daily for conscious patients.</p>\\r\\n</div></li>\\r\\n</ol></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>If there are signs of <strong>raised ICP,</strong> give IV furosemide 40 mg bolus and IV mannitol 0.5 g/kg given over 20 minutes 4 - 6 hourly.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Antithrombotics: If CT scan rules out haemorrhage, commence <strong>oral aspirin</strong> at 300 mg daily for 4 weeks. For patients without a CT scan but unlikely to have haemorrhagic stroke, start aspirin on day 2 at 150 mg daily for 2 weeks. Reduce to 75 mg daily subsequently.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>For suspected vasculitis (e.g raised ESR), consider starting 1 mg per kg prednisolone.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>For stroke patients presenting in Keneba, commence emergency care and refer immediately.</p>\\r\\n</div></li>\\r\\n</ol>\\r\\n<p><span class=\\\"underline\\\">Starting after 24 hours:</span></p>\\r\\n<ol start=\\\"6\\\" type=\\\"1\\\">\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>DVT prophylaxis</strong> with <strong>heparin</strong> after 2 days for immobile patients if hemorrhage is ruled out or unlikely.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Early mobilization</strong> of the patient is encouraged but minimize within first 24 hours.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Statins</strong> should be commenced after 48 hours if patient is able to obtain the drug.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Treat <strong>recurrent seizures</strong> with oral carbamazepine or valproate.</p>\\r\\n</div></li>\\r\\n</ol>\\r\\n<p><span class=\\\"underline\\\">Ongoing supportive care</span></p>\\r\\n<ol start=\\\"10\\\" type=\\\"1\\\">\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p><strong>Supplemental Oxygen</strong> should be given for patients with oxygen saturations below 94%.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Keep <strong>systolic BP</strong> below 180 mmHg with oral antihypertensives. Consider IV labetalol if systolic blood pressure is &gt;220 mmHg</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Maintain <strong>blood glucose</strong> between 7.7 – 10 mmol/l. Hypoglycaemia should be identified and treated promptly. Hyperglycaemia may require insulin therapy as discussed in the Diabetes Mellitus guideline.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Maintain normal <strong>body temperature</strong>. Fever &gt;37.5°C should be treated with paracetamol. Search for possible infections and do sepsis screening. Avoid indwelling catheters if feasible, otherwise monitor daily.</p>\\r\\n</div></li>\\r\\n</ol>\\r\\n<p><span class=\\\"underline\\\">SAH:</span></p>\\r\\n<ol start=\\\"14\\\" type=\\\"1\\\">\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>For suspected or confirmed subarachnoid haemorrhage,</p>\\r\\n</div>\\r\\n<ol type=\\\"a\\\">\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Keep systolic BP below 130 mmHg with a calcium channel blocker but avoid hypotension</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Lactulose suspension to keep stools soft (prevents straining and raised ICP)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Oral diazepam for light sedation</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Analgesics</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Consider early referral for neurosurgical management especially for unconscious patients or sudden deterioration</p>\\r\\n</div></li>\\r\\n</ol></li>\\r\\n</ol>\\r\\n<h3 id=\\\"discharge-planning-and-post-discharge-care\\\">Discharge planning and Post-Discharge Care</h3>\\r\\n<p>Discharge planning should involve the patient, their caregivers at home and the clinical team. Stroke patients should be discharged home when agreed-upon achievable goals of inpatient care have been reached and the home environment made safe. Patients with severe residual brain injury from stroke may require palliative care.</p>\\r\\n<p>Assess functional independence at discharge</p>\\r\\n<p>Plan safe care at home e.g sturdy arm-chairs resting against walls, wheelchairs, relocate patient to a ground-floor bedroom, install hand-holds on walls.</p>\\r\\n<p>Explain stroke risk factors and prescriptions to the patient and caregivers.</p>\\r\\n<p>Patients with persistent swallowing difficulties may be fed with thickened fluids if tolerated. For patients requiring nasogastric feeding, discuss feasibility of a PEG tube insertion.</p>\\r\\n<p>Patient should be referred for physical and psychological rehabilitation services. Regardless of clinical recovery, patients with stroke should be advised not to drive for at least one month post-discharge.</p>\\r\\n<p>Schedule first follow-up visit for 4 weeks after discharge but advise caregivers to present early if they notice any deterioration in the patient’s state.</p>\\r\\n<h2 id=\\\"key-issues-for-nursing-care\\\">Key Issues for Nursing care</h2>\\r\\n<p>Monitor vital signs every 4 hours. Call the doctor if:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Temperature &gt; 37.5</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Blood glucose &lt; 6 mmol/l or &gt; 10 mmol/l</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Systolic blood pressure &lt; 140 or &gt; 180 mmHg</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>GCS drops by 1 point compared to last observation</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Oxygen saturation &lt; 95%</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Nurse in 30 degrees head up position with head in midline</p>\\r\\n<p>Two-hourly turning and surveillance for pressure ulcers if unconscious/immobile</p>\\r\\n<p>Suction oral cavity and airway as needed if unconscious</p>\\r\\n<p>Strict fluid charts</p>\\r\\n<p>Strict bed rest if SAH is suspected</p>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<p>Prasad K, Kaul S, Padma MV, Gorthi SP, Khurana D, Bakshi A. Stroke management. Ann Indian Acad Neurol. 2011;14(Suppl 1):S82-96.</p>\\r\\n<p>Berkowitz AL. Managing acute stroke in low-resource settings. Bull World Health Organ. 2016;94(7):554-6.</p>\\r\\n<p>Stroke and transient ischaemic attack in over 16s: diagnosis and initial management. NICE Guideline. March 2017</p>\\r\\n<p>Nor AM, Davis J, Sen B, Shipsey D, Louw SJ, Dyker AG, Davis M, Ford GA. The Recognition of Stroke in the Emergency Room (ROSIER) scale: development and validation of a stroke recognition instrument.Lancet Neurol. 2005 Nov;4(11):727-34.</p>\\r\\n<p>Medscape. Subarachnoid haemorrhage. Available at: <a href=\\\"https://emedicine.medscape.com/article/1164341-overview\\\"><span data-custom-style=\\\"Hyperlink\\\">https://emedicine.medscape.com/article/1164341-overview</span></a> Accessed: 9<sup>th</sup> January 2019</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Fatai Akemokwe</th>\\r\\n<th>Date: 09 January 2019</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Karen Forrest</td>\\r\\n<td>Date: 14 January 2019</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>2.0</td>\\r\\n<td>Previous guideline was updated and transferred onto the new template</td>\\r\\n<td>31 January 2021</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>2.1</td>\\r\\n<td>Executive summary added</td>\\r\\n<td>31 January 2021</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"044\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>TB MeG-CLS-044</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"tuberculosis\\\">Tuberculosis</h1>\\r\\n<h2 id=\\\"executive-summary\\\"><em>Executive summary</em></h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<p>Tuberculosis still remains highly prevalent in The Gambia with rates at 128 cases per 100,000 population<strong>.</strong> It is often difficult to diagnose (especially in children) and requires a combination of clinical history, examination and diagnostics.</p>\\r\\n<h2 id=\\\"target-users\\\">Target users</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nurses</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doctors</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"target-area-of-use\\\">Target area of use </h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Gate clinic</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Outpatient clinic</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ward</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"key-areas-of-focus-new-additions-changes\\\">Key areas of focus / New additions / Changes </h2>\\r\\n<p>This guideline outlines the investigation and treatment of TB.</p>\\r\\n<h2 id=\\\"limitations\\\">Limitations</h2>\\r\\n<p>Please also refer to the SOP on investigation of TB (SOP-CLS-003) to ensure proper use of our diagnostic resources.</p>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs\\\">Presenting symptoms and signs</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Fever</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Night sweats</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Weight loss</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Cough</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p><em>For two weeks or more</em></p>\\r\\n<h3 id=\\\"important-things-to-ask\\\">Important things to ask</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Previous TB diagnosis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Any contacts who have chronic cough, has had TB or currently on treatment</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>HIV status – being HIV positive increases risk of having TB and complicates treatment</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Smoking status</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"examination-findings\\\">Examination findings</h2>\\r\\n<p>Typical findings include:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Wasting</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Lymphadenopathy</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Respiratory examination; any signs of respiratory distress, chest may be clear, other signs of consolidation or collapse</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"important-things-to-look-for\\\">Important things to look for:</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Signs of immunosuppression,</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Signs of extra-pulmonary TB (gibbus, organomegaly, skin lesions, bony lesions)</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"differential-diagnoses\\\">Differential diagnoses</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Pneumonia</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Underlying chronic lung disease</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Lung cancer</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"investigations\\\">Investigations</h2>\\r\\n<p>General investigations that might be useful for more complex patients, but do not need to be done routinely:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>FBC – to look for signs of acute infection.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Urea &amp; electrolytes – for baseline.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Liver function tests – baseline before starting anti-TB treatment.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Important investigations to diagnose TB:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Chest x-ray (findings typical of TB include upper zone collapse or consolidation).</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Sputum x 2 for Acid fast bacilli (ask patient to cough and produce sputum into 2 labelled sputum pots, request sputum for AFB on EMRS – the patient or nurse should deliver them to the TB clinic and ask the attendant to sign them into the fridge).</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>NB: Send to TB clinic for sputum induction if producing quality sputum is a challenge.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>For children in whom TB is suspected and the sputum is either difficult to collect or shows AFB negative, ask TB clinic to review. They may suggest gastric washings or sputum induction.</p>\\r\\n<p>Gene Xpert (TB PCR test): This is indicated for patients with possible extra-pulmonary TB, for patients known to have HIV and for those patients who have had negative AFBs but who are thought to have TB. Please see the separate SOP on Investigation of TB (SOP-CLS-003).</p>\\r\\n<p>HIV test (if status unknown) should be done for all patients diagnosed with TB.</p>\\r\\n<h2 id=\\\"management\\\">Management </h2>\\r\\n<p>Assess whether the patient requires admission based on your clinical examination and early warning score.</p>\\r\\n<p>Note all children with either confirmed or suspected TB should be referred to the childhood TB team. All adults with sputum positive TB should be referred to the TB clinic. These patients are eligible for recruitment into TB studies.</p>\\r\\n<h3 id=\\\"if-clinically-unwell-needs-admission\\\">If clinically unwell, needs admission</h3>\\r\\n<p>Admit to a side room for adults and adolescents with pulmonary TB. If a side room is not available, the patient must be transferred elsewhere.</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Start IV antibiotics (see sepsis guideline).</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>IV fluids if indicated.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ensure necessary bloods and sputum samples are collected.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"clinically-well\\\">Clinically well</h3>\\r\\n<p>Review in 1 week with results. In meantime, treat for a lower respiratory tract infection if indicated.</p>\\r\\n<p>Treat according to results:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Sputum positive – refer to TB clinic.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Sputum negative but high suspicion of TB – if you are convinced this is TB, refer for treatment of sputum negative TB via TB clinic. If you are unsure, discuss with TB team to agree on further assessment.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Sputum negative and improved symptoms – consider discharge or follow up in 1 month to ensure improvement persists.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"anti-tb-medication\\\">Anti-TB medication </h3>\\r\\n<p>Combination therapy of Rifampicin, Isoniazid, Pyrazinamide and Ethambutol. Add pyridoxine 25 mg OD orally to prevent peripheral neuropathy.</p>\\r\\n<p>Medication comes as a combination therapy (TB4) – the number of tablets depends on the weight of the patient.</p>\\r\\n<p>Patients will need referral to national treatment centre for follow up and treatment at diagnosis for outpatients or at discharge for inpatients. This can be arranged by sending them to the TB clinic.</p>\\r\\n<h2 id=\\\"key-issues-for-nursing-care\\\">Key Issues for Nursing care</h2>\\r\\n<p>Nurses’ role in OPD:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Make sure the sputum samples are adequate.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Properly label samples.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Deposit in fridge in TB clinic; <em>samples need to be signed in to the book on top of TB fridge.</em></p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<p>A Tuberculosis Nationwide Prevalence Survey in Gambia 2012. Adetifa I et al. Bulletin World Health Organisation 2016; 94:433-441 doi: <a href=\\\"http://dx.doi.org/10.2471/BLT.14.151670\\\"><span data-custom-style=\\\"Hyperlink\\\">http://dx.doi.org/10.2471/BLT.14.151670</span></a></p>\\r\\n<p>Tuberculosis. Pai M et al. Nature, Article number : 16076, volume 2 DOI 10.1038/nrdp.2016.76. Published online 27 Oct 2016.</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Caitlin Jones</th>\\r\\n<th>Date: 6 June 2018</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Babatunde Awokola</td>\\r\\n<td>Date: 17 July 2018</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td>31 July 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>1.1</td>\\r\\n<td>Executive summary added</td>\\r\\n<td>31 July 2020</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"024\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>Tonsillitis and pharyngitis MeG-CLS-024</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"tonsillitis-and-pharyngitis\\\">Tonsillitis and pharyngitis</h1>\\r\\n<h2 id=\\\"executive-summary\\\"><em>Executive summary</em></h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<p>Pharyngitis is an inflammation of the pharynx involving lymphoid tissues of the posterior pharynx and lateral pharyngeal bands. The etiology can be bacterial, viral and fungal infections. Most cases are due to viral infections and accompany a common cold or influenza. Respiratory disease caused by group A strep infection in children younger than 3 years old rarely manifests as acute pharyngitis. These children usually have mucopurulent rhinitis followed by fever, irritability, and anorexia (called “streptococcal fever” or “streptococcosis”). In contrast to typical acute group A strep pharyngitis, this presentation in young children is subacute and high fever is rare.</p>\\r\\n<h2 id=\\\"target-users\\\">Target users</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doctors</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nurses</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"target-area-of-use\\\">Target area of use </h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Gate clinic</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Outpatient department</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ward</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"key-areas-of-focus-new-additions-changes\\\">Key areas of focus / New additions / Changes </h2>\\r\\n<p>This guideline outlines the diagnosis and treatment of pharyngitis – particularly emphasizing how to decide when antibiotics are appropriate.</p>\\r\\n<h2 id=\\\"limitations\\\">Limitations</h2>\\r\\n<p>Facilities for throat culture are not available at Keneba and Basse.</p>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs\\\">Presenting symptoms and signs</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Sore throat</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Hoarse voice or loss of voice with pain on speaking</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Dysphagia or odynophagia maybe present</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Painful, non-productive cough</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Stridor in children</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Fever, myalgia and headaches may be present</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"examination-findings\\\">Examination findings</h2>\\r\\n<ul>\\r\\n<li><h2 id=\\\"pharyngeal-and-tonsillar-erythema\\\">Pharyngeal and tonsillar erythema</h2></li>\\r\\n<li><h2 id=\\\"tonsillar-hypertrophy\\\">Tonsillar hypertrophy</h2></li>\\r\\n<li><h2 id=\\\"an-inflammatory-exudate-or-membranes-may-cover-the-tonsils-and-tonsillar-pillars.\\\">An inflammatory exudate or membranes may cover the tonsils and tonsillar pillars.</h2></li>\\r\\n<li><h2 id=\\\"palatal-petechiae\\\">Palatal petechiae</h2></li>\\r\\n<li><h2 id=\\\"vesicles-or-ulcers-may-also-be-seen-on-the-pharyngeal-walls\\\">Vesicles or ulcers may also be seen on the pharyngeal walls </h2></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Anterior cervical lymphadenopathy is common</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Patients with group A strep pharyngitis may also present with a scarlatiniform rash. The resulting syndrome is called scarlet fever or scarlatina.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>People with a sore throat caused by streptococcal bacteria are more likely to benefit from antibiotics. Centor criteria is a clinical scoring tool that can help to identify the people in whom this is more likely.</p>\\r\\n<h3 id=\\\"centor-criteria\\\">Centor criteria</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Tonsillar exudate</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Tender anterior cervical lymphadenopathy or lymphadenitis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>History of fever (over 38°C)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Absence of cough</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Each of the Centor criteria score 1 point (maximum score of 4).</p>\\r\\n<p>A score of 0, 1 or 2 is thought to be associated with a 3 to 17% likelihood of isolating streptococcus.</p>\\r\\n<p>A score of 3 or 4 is thought to be associated with a 32 to 56% likelihood of isolating streptococcus.</p>\\r\\n<h3 id=\\\"red-flag-signs-for-sore-throat\\\">Red flag signs for sore throat</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Persistent fever</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Failed antibiotic treatment</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Medication-induced agranulocytosis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Mouth drooling-consider epiglottis (don’t examine the throat)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Sharp pain on swallowing (? Foreign object)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Marked swelling of quinsy</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Candidiasis-consider diabetics or immunosuppression.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"investigations\\\">Investigations</h2>\\r\\n<p>No investigations are required, except for children aged 3 years or older who have a Centor score of 3 or 4. These children should have a throat swab for culture to confirm the presence of group A strep pharyngitis.</p>\\r\\n<p>Testing for group A strep pharyngitis is not routinely indicated for children younger than 3 years of age and adults because acute rheumatic fever is very rare in those age groups.</p>\\r\\n<p>Children who have a throat swab taken should be given a follow up appointment to get the results one week later. They should be given antibiotics in the meantime as described below.</p>\\r\\n<h2 id=\\\"management\\\">Management </h2>\\r\\n<p>Pharyngitis is usually self-limiting. Symptoms can last up to a week and most people will get better in a week regardless of the aetiology.</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Rest</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Analgesics: paracetamol; adults 1 g 6-8 hourly; 10-15 mg/kg for children</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Steam inhalations may help</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>If likely to be strep pneumonia (Centor score 3 or 4) or symptoms lasting more than 2 weeks, antibiotics can be used:</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Antibiotics</strong></th>\\r\\n<th></th>\\r\\n<th></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1<sup>st</sup> choice</td>\\r\\n<td>Phenoxymethypenicillin (Penicillin V)</td>\\r\\n<td><p>500 mg qds or 1 g QDS for 10 days</p>\\r\\n<p>Children: 50-75 mg/kg/day QDS for 10 days</p></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><em>Alternative first choices for penicillin allergy or intolerance</em></td>\\r\\n<td>Erythromycin</td>\\r\\n<td><p>250 mg to 500 mg QDS or</p>\\r\\n<p>500 mg to 1 g BD</p>\\r\\n<p>for 5 days</p></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td></td>\\r\\n<td>Azithromycin</td>\\r\\n<td>10 mg/kg OD for 3 days</td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<h3 id=\\\"complications\\\">Complications</h3>\\r\\n<p>Suppurative complications result from the spread of group A strep from the pharynx to adjacent structures. They can include:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Peritonsillar abscess</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Retropharyngeal abscess</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Cervical lymphadenitis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Mastoiditis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Other focal infections or sepsis are even less common.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Group A streptococcal pharyngitis is of special concern because its complications include streptococcal toxic shock syndrome, acute rheumatic fever (ARF), acute glomerulonephritis, and scarlet fever, as well as cutaneous infections. In addition, this pathogen is readily transmissible, especially in households, families, and other intimate groups.</p>\\r\\n<h3 id=\\\"differential-diagnoses\\\">Differential diagnoses</h3>\\r\\n<p><strong>Candida pharyngitis</strong>: Determine the underlying cause (HIV, DM, corticosteroids including inhalers, overuse of broad spectrum antibiotics) and treat accordingly. Use Nystatin suspension to rinse and swallow QDS 6hrly for 7 to 14 days.</p>\\r\\n<p><strong>Diphtheria</strong>: Due to <em>Corynebacterium diphtheria</em> always fatal in non-immunized people.</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Give antitoxins, penicillin or erythromycin 500 mg QDS x 10/7.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Isolate patient.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p><strong>Acute epiglottitis:</strong> In children, it is a medical emergency. Child usually holds head still, leaning forward and drooling saliva. Admit in the ward and treat with parenteral antibiotics. DO NOT ATTEMPT TO EXAMINE THE THROAT AS THE CHILD MAY GO INTO LARYNGOSPASM.</p>\\r\\n<h2 id=\\\"key-issues-for-nursing-care\\\">Key Issues for Nursing care</h2>\\r\\n<p>Good hand hygiene and respiratory etiquette can reduce the spread of all types of group A streptococcal infection and should be advocated to patients. Treating an infected person with an antibiotic for 24 hours or longer generally eliminates their ability to transmit the bacteria.</p>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<p>Acute otitis media. Retrieved from <a href=\\\"https://www.rch.org.au/clinicalguide/guideline_index/acute_otitis_media/#otitis-media-with-effusion-ome\\\"><span data-custom-style=\\\"Hyperlink\\\">https://www.rch.org.au/clinicalguide/guideline_index/acute_otitis_media/#otitis-media-with-effusion-ome</span></a> on 25th February, 2019</p>\\r\\n<p>Carillo-Marquez MA (2017). Bacterial Pharyngitis. Medscape. Retrieved from <a href=\\\"https://emedicine.medscape.com/article/225243-overview\\\"><span data-custom-style=\\\"Hyperlink\\\">https://emedicine.medscape.com/article/225243-overview</span></a></p>\\r\\n<p>Colledge, Nicki R., Brian R. Walker, Stuart Ralston, and Stanley Davidson. 2010. Davidson&#39;s principles and practice of medicine. Edinburgh: Churchill Livingstone/Elsevier.</p>\\r\\n<p>Kliegman, Robert., et al. Nelson Textbook of Pediatrics. Edition 20. Philadelphia, PA: Elsevier, 2016.</p>\\r\\n<p>Management of acute respiratory diseases in the pediatric population. The role of oral corticosteroids. Italian Journal of Pediatrics 43(1). December 2017. Retrieved from <a href=\\\"https://www.researchgate.net/figure/Westley-croup-score_tbl7_315597265\\\"><span data-custom-style=\\\"Hyperlink\\\">https://www.researchgate.net/figure/Westley-croup-score_tbl7_315597265</span></a> on 25th February 2017.</p>\\r\\n<p>Pharyngitis (Strep Throat). Group A Streptococcal Disease. Centers for Disease Control and Prevention (2018). Retrieved from <a href=\\\"https://www.cdc.gov/groupastrep/diseases-hcp/strep-throat.html\\\"><span data-custom-style=\\\"Hyperlink\\\">https://www.cdc.gov/groupastrep/diseases-hcp/strep-throat.html</span></a> on 23rd February 2019.</p>\\r\\n<p>Sore throat (acute): antimicrobial prescribing. NICE guideline Published: 26 January 2018 Retrieved from <a href=\\\"https://www.nice.org.uk/guidance/ng84/resources/sore-throat-acute-antimicrobial-prescribing-pdf-1837694694085\\\"><span data-custom-style=\\\"Hyperlink\\\">https://www.nice.org.uk/guidance/ng84/resources/sore-throat-acute-antimicrobial-prescribing-pdf-1837694694085</span></a></p>\\r\\n<p>Standard Treatment Guidelines, 6th Edition, 2010. ISBN 978-9988-1-2538-7</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Fatoumata Sawaneh</th>\\r\\n<th>Date: 27 February 2019</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Karen Forrest</td>\\r\\n<td>Date: 03 May 2019</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>2.0</td>\\r\\n<td>Updated and transferred to new template</td>\\r\\n<td>31 May 2021</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"068\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>Trauma MeG-CLS-068</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h2 id=\\\"trauma\\\">Trauma</h2>\\r\\n<h2 id=\\\"executive-summary\\\"><em>Executive summary</em></h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<p>Traumatic injuries can range from minor isolated wounds to complex injuries involving multiple organ systems. All trauma patients require a systematic approach to management to maximize outcomes and reduce the risk of undiscovered injuries and death.</p>\\r\\n<p>Relatively few patients die after the first 24 hours following injury. Rather, the majority of deaths occur either at the scene or within the first four hours after the patient reaches a trauma centre.</p>\\r\\n<p>The &quot;golden hour&quot; concept, which emphasises the increased risk of death and the need for rapid intervention during the first hour of care following major trauma should guide our practice locally.</p>\\r\\n<p>Most trauma cases should be referred on to the EFSTH, where a multi-disciplinary team is on call 24 hrs. However in some cases a minor trauma case like RTA without fracture or bleeding may be managed conservatively and discharged.</p>\\r\\n<h2 id=\\\"target-users\\\">Target users</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nurses</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doctors</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"target-area-of-use\\\">Target area of use</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Outpatient department</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ward</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"key-areas-of-focus-new-additions-changes\\\">Key areas of focus / New additions / Changes </h3>\\r\\n<p>This guideline outlines the initial stabilization of trauma cases within CSD. Most patients will then need to be transferred elsewhere for definitive care.</p>\\r\\n<p>When more than 1 major trauma case is received out-of-hours or 2 or more are received at any time, then a major incident must be declared and SOP-CLS-015 should be followed to guide management of the department.</p>\\r\\n<h3 id=\\\"limitations\\\">Limitations </h3>\\r\\n<p>There are no surgeons or anaesthetists at the unit, so our involvement is limited to the initial resuscitation and stabilization of patients.</p>\\r\\n<p><strong><br />\\r\\n</strong></p>\\r\\n<p><strong>Presenting symptoms and signs</strong></p>\\r\\n<p>Mechanism — Particular mechanisms predispose patients to specific injuries. Common blunt trauma mechanisms and their most frequently associated injuries are described in the accompanying table (Table 1 below). In addition, certain high-risk blunt mechanisms, including pedestrians struck by automobiles, motorcycle accidents, severe motor vehicle accidents (e.g., extensive damage leading to prolonged extrication time), and falls greater than 20 feet, have been associated with greater morbidity and mortality.</p>\\r\\n<p>Table 1: Blunt trauma mechanisms and associated injuries</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Mechanism of injury</strong></th>\\r\\n<th><strong>Potential associated injuries</strong></th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Motor vehicle collision: Head-on collision, Windshield damage, Steering wheel damage</td>\\r\\n<td>Facial injuries, Lower extremity injuries, Aortic injuries, Thoracic injuries, Abdominal injuries: spleen, liver etc.</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>Pedestrian versus automobile: Low or high speed (braking automobile,</td>\\r\\n<td>Tibia and fibula fractures, knee injuries</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Falls:</td>\\r\\n<td><p>Calcaneal and lower extremity fractures, Pelvic fractures</p>\\r\\n<p>Closed head injuries, Cervical spine fractures, Hand and wrist fractures</p></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n<p><strong>Preparation</strong></p>\\r\\n<p>Whenever possible, the ward should be notified that a trauma patient is <em>en route</em>. This provides the receiving nurses and doctors with information and time that can be crucial to the management of the severely injured patient.</p>\\r\\n<p>When trauma cases, do however present to the ward. Efforts should be made to assess, stabilise and refer to the appropriate centre where necessary.</p>\\r\\n<h3 id=\\\"primary-evaluation-and-management\\\">Primary evaluation and management</h3>\\r\\n<p>A clear, simple, and organized approach is needed when managing a severely injured patient prior to referral for a definitive treatment.</p>\\r\\n<p>The primary survey consists of the following steps:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Airway assessment and protection (maintain cervical spine stabilization when appropriate)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Breathing and ventilation assessment (maintain adequate oxygenation, usually oxygen saturation above 96%)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Circulation assessment (control haemorrhage and maintain adequate end-organ perfusion)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Disability assessment (perform basic neurologic evaluation)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Exposure, with environmental control (undress patient and search everywhere for possible injury, while preventing hypothermia)</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>While performing the primary survey, keep the following points in mind <strong>:</strong></p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Airway obstruction is a major cause of death immediately following trauma. The airway may be obstructed by the tongue, a foreign body, aspirated material, tissue oedema, or expanding haematoma.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Haemorrhage is the most common preventable cause of mortality in trauma. Be alert for subtle signs of haemorrhagic shock, particularly in the elderly, who may be on cardiovascular medications that blunt such signs, and young, healthy adults who may not present with obvious manifestations. Hypotension generally does not manifest until at least 30 percent of the patient&#39;s blood volume has been lost. Such patients are at high risk of death. Elderly patients may be hypotensive relative to their baseline blood pressure but still have blood pressure measurements in the &quot;normal&quot; range.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Brain injuries are common in patients who have sustained severe blunt trauma and even a single episode of hypotension increases their risk of death</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"management\\\">Management </h2>\\r\\n<p>Patients should be managed on the ward – the endoscopy room or the emergency bed are best as there is plenty of room to access the patient. The aim is to stabilise and refer, especially in a major case.</p>\\r\\n<h3 id=\\\"airway-assessment\\\">Airway Assessment </h3>\\r\\n<p>In a conscious patient, initial airway assessment can be performed as follows</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Begin by asking the patient a simple question (e.g., &quot;What is your name?&quot; especially in adults). A clear accurate response verifies the patient&#39;s ability to mentate, phonate, and to protect their airway, at least temporarily.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Observe the face, neck, chest, and abdomen for signs of respiratory difficulty, including tachypnea, accessory or asymmetric muscle use, abnormal patterns of respiration, and stridor.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Inspect the oropharyngeal cavity for disruption; injuries to the teeth or tongue; blood, vomitus, or pooling secretions.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Inspect and palpate the anterior neck for lacerations, hemorrhage, crepitus, swelling, or other signs of injury.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h3 id=\\\"breathing-and-ventilation\\\">Breathing and ventilation</h3>\\r\\n<p>Once airway patency is ensured, assess the adequacy of oxygenation and ventilation. Inspect the chest wall looking for signs of injury, including asymmetric or paradoxical movement (e.g., flail chest), auscultate breath sounds at the apices and axillae, and palpate for crepitus and deformity. Where necessary provide supplemental oxygen to keep saturation &gt;96%.</p>\\r\\n<p>Presumptively treat patients with signs of tension pneumothorax, including hypotension, dyspnoea, and ipsilateral decreased breath sounds, with needle decompression before obtaining imaging or referring to the EFSTH. Needle decompression is performed with a large bore (14 gauge or larger), either in the second intercostal space in the midclavicular line or in the fifth intercostal space in the midaxillary line.</p>\\r\\n<h3 id=\\\"circulation-recognition-and-management-of-haemorrhage\\\">Circulation: Recognition and management of haemorrhage</h3>\\r\\n<p>Once the airway and breathing are stabilized, perform an initial evaluation of the patient&#39;s circulatory status by palpating central pulses. If a carotid or femoral pulse is verified and no obvious exsanguinating external injury is noted, circulation may be assumed to be intact. While circulation is assessed, one or two large-bore (16 gauge or larger) intravenous (IV) catheters are placed, most often in the antecubital fossa of each arm.</p>\\r\\n<p><em>Life-threatening haemorrhage must be controlled</em>. A combination of manual pressure, proximal compression with either a tourniquet or a manual blood pressure cuff, and elevation is typically sufficient to control external arterial haemorrhage. Venous bleeding is controlled with direct pressure. Bleeding from severe pelvic injuries may require the application of a pelvic binder. Most trauma patients with hypotension or signs of shock (eg, pale, cool, moist skin) could be bleeding internally, initial fluid resuscitation for these patients may consist of a bolus of intravenous crystalloid (eg, 20 mL/kg isotonic saline) while arrangement is being made to transfer to the EFSTH for definitive treatment</p>\\r\\n<h3 id=\\\"disability-and-neurologic-evaluation\\\">Disability and neurologic evaluation </h3>\\r\\n<p>Once problems related to the airway, breathing, and circulation are addressed, perform a focused neurologic examination. This should include a description of the patient&#39;s level of consciousness using the Glasgow Coma Scale (GCS) score or the paediatric GCS, a validated scale for children ≤2 year old and assessments of pupillary size and reactivity, gross motor function, and sensation. Trauma patients with a GCS ≤8 or who are unresponsive or only respond to pain have severe altered mental status and require rapid resuscitative efforts.</p>\\r\\n<h3 id=\\\"exposure-and-environmental-control\\\">Exposure and environmental control </h3>\\r\\n<p>Be certain that the trauma patient is completely undressed and that his or her entire body is examined for signs of injury during the primary survey. Missed injuries pose a grave threat. Regions often neglected include the scalp, axillary folds, perineum, and in obese patients, abdominal folds.</p>\\r\\n<p>Patients should be stabilized as well as possible without delaying transfer; delays are associated with increased mortality. Criteria for transfer are based upon the patient&#39;s demographics, mechanism of injury, and clinical findings.</p>\\r\\n<h3 id=\\\"secondary-survey\\\">Secondary Survey</h3>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>AMPLE History: <strong>A</strong>llergies, <strong>m</strong>edications, <strong>p</strong>ast medical history/<strong>p</strong>regnancy, <strong>l</strong>ast meal, <strong>e</strong>vents and <strong>e</strong>nvironment surrounding injury.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Physical examination from head to toe including a rectal examination (major trauma)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Decide on definitive management (is emergency referral needed?)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Use MIST template when writing a referral to have a patient transferred to EFSTH for further care. This includes: <strong>m</strong>echanism of injury plus sex and age of patient, <strong>i</strong>njuries, <strong>s</strong>igns and and symptoms and <strong>t</strong>reatment so far</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p><strong><span class=\\\"underline\\\"><br />\\r\\n</span></strong></p>\\r\\n<p><strong><span class=\\\"underline\\\">Laboratory investigations.</span></strong></p>\\r\\n<p>It cannot be overemphasized that a complete workup is not a requirement for transfer or referral to the EFSTH, Banjul; postponing transfer to obtain laboratory results or imaging studies only delays definitive treatment. Often such studies must be repeated at the receiving facility.</p>\\r\\n<p>However some laboratory and radiological studies that may be done are</p>\\r\\n<ol type=\\\"1\\\">\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Portable radiographs</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ultrasound scan</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Blood sugar</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>HCG - especially in women of child-bearing age .</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Haemoglobin.</p>\\r\\n</div></li>\\r\\n</ol>\\r\\n<h2 id=\\\"key-issues-for-nursing-care\\\">Key Issues for Nursing care</h2>\\r\\n<p>Always call the attention of the Doctor when you are presented with a case of a major trauma.</p>\\r\\n<p>Check vital sign on arrival and attempt to start resuscitation management as outlined above if required until the doctor arrives.</p>\\r\\n<p>The decision to refer should be made by the doctor or the senior nurse on duty upon initial assessment.</p>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<p>1. Feliciano, DV, Mattox, et al. Trauma, 6th, McGraw-Hill, New York 2008.</p>\\r\\n<p>2. CDC. National estimates of the ten leading causes of nonfatal injuries, Centers for Disease Control and Prevention 2004. www.cdc.gov/injury/wisqars.html.</p>\\r\\n<p>3. Mackenzie EJ, Rivara FP, Jurkovich GJ, et al. The National Study on Costs and Outcomes of Trauma. J Trauma 2007; 63:S54.</p>\\r\\n<p>4. Global Status on Road Safety 2015, World Health Organization, http://www.who.int/violence_injury_prevention/road_safety_status/2015/.</p>\\r\\n<p>5. Søreide K. Epidemiology of major trauma. Br J Surg 2009; 96:697.</p>\\r\\n<p>6. Demetriades D, Murray J, Sinz B, et al. Epidemiology of major trauma and trauma deaths in Los Angeles County. J Am Coll Surg 1998; 187:373.</p>\\r\\n<p>7. Evans JA, van Wessem KJ, McDougall D, et al. Epidemiology of traumatic deaths: comprehensive population-based assessment. World J Surg 2010; 34:158.</p>\\r\\n<p>8. MacKenzie EJ, Rivara FP, Jurkovich GJ, et al. A national evaluation of the effect of trauma-center care on mortality. N Engl J Med 2006; 354:366.</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Okpara Chibuike</th>\\r\\n<th>Date: 26 November 2018</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Orighomisan Agboghoroma</td>\\r\\n<td>Date: 31 December 2018</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td>31 January 2021</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>1.1</td>\\r\\n<td>Executive summary added</td>\\r\\n<td>31 January 2021</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"018\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>Upper respiratory tract infections MeG-CLS-018</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"upper-respiratory-tract-infections\\\">Upper respiratory tract infections</h1>\\r\\n<h2 id=\\\"executive-summary\\\"><em>Executive summary</em></h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<p>Upper respiratory tract infections (URTIs) are very common in both adults and children. Most URTIs are caused by viruses and are self-limiting. Antibiotic treatment is avoided or delayed. The common cold is the most common of these and affects the nasopharyngeal mucosa. It is contagious and is spread by airborne droplets.</p>\\r\\n<p>In some cases, antibiotic treatment is required to avoid complications. The following subgroups can be considered for an immediate antibiotic prescribing strategy:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>bilateral acute otitis media in children younger than 2 years</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>acute otitis media in children with otorrhoea</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>acute sore throat/acute pharyngitis/acute tonsillitis under certain circumstances</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>epiglottitis</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>The routine practice of prescribing antihistamines and steroids (except in croup) in URTIs is not found to change the disease cause and thus should be avoided.</p>\\r\\n<h2 id=\\\"target-users\\\">Target users</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nurses</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doctors</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"target-area-of-use\\\">Target area of use </h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Gate clinic</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Outpatient department</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ward</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"key-areas-of-focus-new-additions-changes\\\">Key areas of focus / New additions / Changes </h2>\\r\\n<p>This guideline primarily addresses the diagnosis of the common cold and other viral URTIs. The following topics are addressed in the following guidelines:</p>\\r\\n<ol type=\\\"1\\\">\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Sinusitis MeG-CLS-062</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Tonsillitis and pharyngitis MeG-CLS-024</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Acute otitis media MeG-CLS-023</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Laryngotracheobronchitis (croup) MeG-CLS-059</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Epiglottis MeG-CLS-063</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Bronchiolitis</p>\\r\\n</div></li>\\r\\n</ol>\\r\\n<h2 id=\\\"limitations\\\">Limitations</h2>\\r\\n<p>None</p>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs\\\">Presenting symptoms and signs</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nasal discharge</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nasal obstruction</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Sneezing</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Sore throat</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Cough</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Slight fever</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Myalgia and headache may be present</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"examination-findings\\\">Examination findings</h2>\\r\\n<ul>\\r\\n<li><h2 id=\\\"low-grade-fever\\\">Low grade fever</h2></li>\\r\\n<li><h2 id=\\\"runny-nose\\\">Runny nose</h2></li>\\r\\n<li><h2 id=\\\"cervical-lymph-nodes-may-be-mildly-inflamed\\\">Cervical lymph nodes may be mildly inflamed </h2></li>\\r\\n</ul>\\r\\n<h2 id=\\\"management\\\">Management </h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Encourage lots of oral fluids and bed rest usually suffice.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Paracetamol oral</p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Adults: 1 g QDS</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Children: 10-15 mg/kg/dose TDS/QDS</p>\\r\\n</div></li>\\r\\n</ul></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ibuprofen, oral,</p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Adults: 200-400 mg TDS</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Children: 50-100 mg TDS</p>\\r\\n</div></li>\\r\\n</ul></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Saline nasal drops: 2 drops into each nostril, to relieve congestion as required</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Note: symptoms resolve without antibiotic treatment within 2 weeks. If the “cold” lasts longer and there is persistent fever and cough associated with offensive nasal discharge, there is a possibility of secondary bacterial infection of the respiratory tract or influenza. In children, the common cold may be complicated by suppurative otitis media or acute bacterial rhinosinusitis.</p>\\r\\n<h2 id=\\\"key-issues-for-nursing-care\\\">Key Issues for Nursing care</h2>\\r\\n<p>Restriction of activities to avoid infecting others, along with good hand washing, are the best measures to prevent spread of the disease.</p>\\r\\n<h3 id=\\\"when-to-refer-to-a-doctor\\\">When to refer to a Doctor</h3>\\r\\n<p>Refer patients with:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Symptoms persisting beyond 2 weeks</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Symptoms not resolving with treatment</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Bilateral ear discharge</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Drooling of saliva and unable to swallow food or drinks</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Fast breathing</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Chest indrawing</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Persistent cough beyond 2 weeks</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Coughing up blood (hemoptysis)</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Stridor at rest</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Immunocompromised state</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Neonates</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<p>Colledge, Nicki R., Brian R. Walker, Stuart Ralston, and Stanley Davidson. 2010. Davidson&#39;s principles and practice of medicine. Edinburgh: Churchill Livingstone/Elsevier.</p>\\r\\n<p>Kliegman, Robert., et al. Nelson Textbook of Pediatrics. Edition 20. Philadelphia, PA: Elsevier, 2016.</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Fatoumata Sawaneh</th>\\r\\n<th>Date: 27 February 2019</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Baderinwa Abatan</td>\\r\\n<td>Date: 29 April 2019</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>2.0</td>\\r\\n<td>Updated and transferred to new template</td>\\r\\n<td>31 May 2021</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",\n\"019\": \"<!DOCTYPE html>\\r\\n<!--\\r\\n==============================================================================\\r\\n           \\\"GitHub HTML5 Pandoc Template\\\" v2.1 — by Tristano Ajmone           \\r\\n==============================================================================\\r\\nCopyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:\\r\\n\\r\\n- https://github.com/tajmone/pandoc-goodies\\r\\n\\r\\nThe CSS in this template reuses source code taken from the following projects:\\r\\n\\r\\n- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):\\r\\n  https://github.com/sindresorhus/github-markdown-css\\r\\n\\r\\n- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):\\r\\n  http://primercss.io/\\r\\n\\r\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\r\\nThe MIT License \\r\\n\\r\\nCopyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)\\r\\nCopyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)\\r\\nCopyright (c) 2017 GitHub Inc.\\r\\n\\r\\n\\\"GitHub Pandoc HTML5 Template\\\" is Copyright (c) Tristano Ajmone, 2017, released\\r\\nunder the MIT License (MIT); it contains readaptations of substantial portions\\r\\nof the following third party softwares:\\r\\n\\r\\n(1) \\\"GitHub Markdown CSS\\\", Copyright (c) Sindre Sorhus, MIT License (MIT).\\r\\n(2) \\\"Primer CSS\\\", Copyright (c) 2016 GitHub Inc., MIT License (MIT).\\r\\n\\r\\nPermission is hereby granted, free of charge, to any person obtaining a copy\\r\\nof this software and associated documentation files (the \\\"Software\\\"), to deal\\r\\nin the Software without restriction, including without limitation the rights\\r\\nto use, copy, modify, merge, publish, distribute, sublicense, and/or sell\\r\\ncopies of the Software, and to permit persons to whom the Software is\\r\\nfurnished to do so, subject to the following conditions:\\r\\n\\r\\nThe above copyright notice and this permission notice shall be included in all\\r\\ncopies or substantial portions of the Software.\\r\\n\\r\\nTHE SOFTWARE IS PROVIDED \\\"AS IS\\\", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\\r\\nIMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\\r\\nFITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\\r\\nAUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\\r\\nLIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\\r\\nOUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE\\r\\nSOFTWARE.\\r\\n==============================================================================-->\\r\\n<html>\\r\\n<head>\\r\\n  <meta charset=\\\"utf-8\\\" />\\r\\n  <meta name=\\\"generator\\\" content=\\\"pandoc\\\" />\\r\\n  <meta name=\\\"viewport\\\" content=\\\"width=device-width, initial-scale=1.0, user-scalable=yes\\\" />\\r\\n  <title>UTI MeG-CLS-019</title>\\r\\n  <style type=\\\"text/css\\\">\\r\\n@charset \\\"UTF-8\\\";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,\\\"Segoe UI\\\",Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\",\\\"Segoe UI Symbol\\\";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:\\\"\\\"}.markdown-body hr::after{display:table;clear:both;content:\\\"\\\"}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:\\\" \\\"}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,\\\"Liberation Mono\\\",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:\\\"\\\"}.markdown-body::after{display:table;clear:both;content:\\\"\\\"}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}\\r\\n  </style>\\r\\n  <style type=\\\"text/css\\\">code{white-space: pre;}</style>\\r\\n  <!--[if lt IE 9]>\\r\\n    <script src=\\\"//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js\\\"></script>\\r\\n  <![endif]-->\\r\\n</head>\\r\\n<body>\\r\\n<article class=\\\"markdown-body\\\">\\r\\n<h1 id=\\\"urinary-tract-infection\\\">Urinary Tract Infection</h1>\\r\\n<h2 id=\\\"executive-summary\\\"><em>Executive Summary</em></h2>\\r\\n<h2 id=\\\"introduction\\\">Introduction</h2>\\r\\n<p>Urinary tract infection (UTI) is the most common bacterial disease in childhood. Incidence is high among febrile children and recurrence is also common (up to 50%). It is also one of the most commonly diagnosed infections in both hospitalized and community-dwelling older adults. The definition of symptomatic UTI in adults generally requires the presence of localized genitourinary symptoms caused by bacteria present in the urine. In children, UTIs are associated with primary vesico-ureteral reflux; the resulting reflux nephropathy (renal scars) is a possible cause of childhood hypertension and chronic kidney disease.</p>\\r\\n<p>This guideline covers management of uncomplicated and complicated UTI in all age groups and pregnant women.</p>\\r\\n<h2 id=\\\"target-users\\\">Target users</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nurses</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Doctors</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"target-area-of-use\\\">Target area of use </h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Gate Clinic</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Outpatient Department</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Ward</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"key-areas-of-focus-new-additions-changes\\\">Key areas of focus / New additions / Changes </h2>\\r\\n<p>This guideline describes the features of UTI in different clinical populations and stratifies the treatment accordingly.</p>\\r\\n<p>Diagnosis of UTI is particularly challenging in children. Dipstick urine testing is useful in children and non-pregnant women. Non-pregnant women with multiple UTI features can receive empirical therapy without dipstick testing. Urine microscopy, culture and sensitivity can provide definitive diagnosis and guide antibiotic therapy.</p>\\r\\n<p>Most UTI can be treated on outpatient basis with oral antibiotics. However, complicated or severe infections require inpatient therapy with parenteral antibiotics.</p>\\r\\n<h2 id=\\\"limitations\\\">Limitations </h2>\\r\\n<p>Urine culture and sensitivity are currently available only at Fajara. In addition, patients requiring prolonged in-patient care for pyelonephritis or complicated UTI cannot be managed at Keneba or Basse.</p>\\r\\n<h2 id=\\\"presenting-symptoms-and-signs\\\">Presenting symptoms and signs</h2>\\r\\n<p>Symptoms of lower UTI</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Dysuria</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Frequency of micturition</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Urgency</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Cloudy urine</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Coca-cola coloured urine</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Malodorous urine</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Lower abdominal discomfort</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Rectal pain in men</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>New onset of incontinence and/or enuresis</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Symptoms of an upper tract UTI include:</p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Pain and in the upper back and sides</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Chills</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Fever</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nausea</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Vomiting</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p>Patients with fever, back pain or flank pain may have pyelonephritis and should be referred to the doctor.</p>\\r\\n<p>The presence of vaginal itch or discharge make another diagnosis more likely. Patients with these symptoms need a speculum and pelvic examination. Refer to the doctor if you cannot do this.</p>\\r\\n<p>Elderly patients are more difficult to diagnose – so if you are unsure refer them to the doctor.</p>\\r\\n<p>Infants and young children: Findings are typically non-specific in infants and young children. Unexplained high fever is the most common presenting symptom for UTI in infants. Others may include fever, malaise, vomiting, lethargy, irritability, poor feeding and abdominal pain. Symptoms become more specific as the child grows older.</p>\\r\\n<p>Generally, female sex is a major risk factor for UTI but uncircumcised male infants have even higher risk due to physiologic phimosis.</p>\\r\\n<p>Constipation is a risk factor for UTI in young children and should be specifically asked about.</p>\\r\\n<h2 id=\\\"examination-findings\\\">Examination findings</h2>\\r\\n<p>Patients with uncomplicated UTI may appear uncomfortable but typically are not toxic. Suprapubic tenderness may be present. The presence of toxic signs such as fever, chills, nausea, and vomiting suggests pyelonephritis. Costovertebral tenderness also suggests pyelonephritis.</p>\\r\\n<p><strong>Important things to look for</strong></p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Costovertebral tenderness</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Suprapubic tenderness</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Features of Chronic Kidney Disease</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>High blood pressure</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<p><strong>Differential diagnoses</strong></p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Nephrolithiasis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Appendicitis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Glomerulonephritis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Urethritis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Gastroenteritis</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Schistosomiasis</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"investigations\\\">Investigations</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Dipstick Urinalysis: Nitrite and leucocyte esterase are the most useful markers. Haematuria and proteinuria may be present.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Urine microscopy, culture and sensitivity:</p>\\r\\n</div>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Asymptomatic bacteriuria is defined as the presence of bacteria in the urine in quantities of 10<sup>5</sup> colony forming units per milliliter or more in 2 consecutive urine specimens in women or 1 urine specimen in men in the absence of clinical signs and symptoms suggestive of a UTI. It is more common in older women and in diabetic patients. This does not necessarily lead to illness and does not need to be treated except in pregnant women.</p>\\r\\n</div></li>\\r\\n</ul></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Full Blood Count: useful in complicated UTI, pyelonephritis.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"management-in-gate-clinic\\\">Management in Gate Clinic</h2>\\r\\n<p>Advise all patients to drink plenty of water.</p>\\r\\n<h3 id=\\\"non-pregnant-women-16-years-and-older\\\">Non-pregnant women (16 years and older)</h3>\\r\\n<p>Women with dysuria and frequency or who have 3 or more symptoms of UTI (and no symptoms of pyelonephritis) can be diagnosed clinically without any further investigation. Treat with nitrofurantoin 100 mg BD for 3 days.</p>\\r\\n<p>Women with 1 or 2 symptoms of UTI should provide a urine sample for dipstick. Any symptomatic woman whose dipstick is positive for leukocytes or nitrites should be treated for UTI as above.</p>\\r\\n<h3 id=\\\"pregnant-women\\\">Pregnant women</h3>\\r\\n<p>Urine dipstick is not sufficiently sensitive for UTI in pregnant women. Women with symptoms of UTI should be treated with nitrofurantoin 100 mg BD for 7 days. Oral amoxicillin 500 mg TDS for 7 days is preferable for pregnant women already at term.</p>\\r\\n<p>A urine sample should be sent to the lab for MC&amp;S. Ask the patient to return to the clinic after the course of antibiotics. A further urine MC&amp;S should be sent to ensure the infection has been cured.</p>\\r\\n<h3 id=\\\"men-16-years-and-older\\\">Men (16 years and older)</h3>\\r\\n<p>Urine dipstick is not useful in men. Send a sample of urine for MC&amp;S. Treat empirically with Ciprofloxacin 500 mg BD for 10 days. Ask the patient to return after this if they are not better. <em>Refer</em> the patient to the doctor if they return.</p>\\r\\n<h3 id=\\\"children-16-years\\\">Children (&lt;16 years)</h3>\\r\\n<p>Children under 3 months should be <em>referred</em> to the doctor.</p>\\r\\n<p>Children over 3 months, but under 3 years who have specific urinary symptoms should be assumed to have a UTI. Urine should be sent for MC&amp;S. Treat as described below. <em>Refer</em> other children in this age group to the doctor.</p>\\r\\n<p>Children over 3 years old in whom UTI is suspected should provide a urine sample for dipstick. If the dipstick is positive for nitrites and leukocytes, treat for UTI. If it is positive for nitrites alone, treat but also send a sample for MC&amp;S. If the dipstick is either positive only for leukocytes or negative, then <em>refer</em> to the doctor.</p>\\r\\n<p>Treat children with amoxicillin 30 mg/kg (max 500 mg) TDS for 3 days. Tell the carer to bring the child back if they do not improve with this treatment. <em>Refer</em> all returning children to the doctor.</p>\\r\\n<p><strong><span class=\\\"underline\\\">Refer to the Doctor in OPD if:</span></strong></p>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>patients with signs of pyelonephritis: fever, back pain or flank pain.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>women with vaginal itch or discharge.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>elderly patients where the diagnosis is not clear.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>all children under 3 months</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>children over 3 months and under 3 years where the diagnosis is not clear.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>children over 3 years whose urine dipstick is not positive for nitrites.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>all patients who return to the clinic because their symptoms have not resolved with first line treatment.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"management-in-opd\\\">Management in OPD</h2>\\r\\n<p><strong><span class=\\\"underline\\\">Children between 3 months and 3 years:</span></strong></p>\\r\\n<p>Treat UTI if either nitrite or leucocyte esterase is positive. Review with urine MC&amp;S.</p>\\r\\n<p><strong><span class=\\\"underline\\\">Children over 3 years with negative nitrite on dipstick</span></strong></p>\\r\\n<p>If leucocyte esterase is also negative, do not treat as UTI and do not send sample for urine MC&amp;S. Explore alternative diagnoses.</p>\\r\\n<p>If leucocyte esterase is positive, send a sample for urine MC&amp;S. Consider starting antibiotics only if the child also has definite and specific UTI symptoms.</p>\\r\\n<p><strong><span class=\\\"underline\\\">Pyelonephritis:</span></strong></p>\\r\\n<p>Commence antibiotics after sending samples for urine MC&amp;S. Oral antibiotics are preferred unless the patient cannot tolerate them or is severely ill.</p>\\r\\n<p>For non-pregnant women and men (16 years and older), give oral ciprofloxacin 500 mg BD for 7 days. Pregnant women should be admitted and given intravenous antibiotics initially.</p>\\r\\n<p><strong><span class=\\\"underline\\\">Patients returning without improvement:</span></strong></p>\\r\\n<p>Review results of urine MC&amp;S and alter antibiotic prescription accordingly if necessary. Consider alternative diagnosis if culture is negative.</p>\\r\\n<p><strong><span class=\\\"underline\\\">Children with recurrent UTI:</span></strong></p>\\r\\n<p>A child is considered to have recurrent UTI if they have had 2 UTIs where at least one episode was acute pyelonephritis. Children with 3 or more episodes of lower UTI are also considered as having recurrent UTI. Such patients should receive urinary tract ultrasonography within 6 weeks of resolution of last episode.</p>\\r\\n<h2 id=\\\"management-on-the-ward\\\">Management on the Ward</h2>\\r\\n<p>Patients should be admitted to the ward if any of the following is present :</p>\\r\\n<ul>\\r\\n<li><p>Acutely ill patient / signs of sepsis</p></li>\\r\\n<li><p>Signs of urinary obstruction or significant underlying disease (such as diabetes, heart failure, chronic lung disease, severe immunosuppression)</p></li>\\r\\n<li><p>Not tolerating oral fluids or medications</p></li>\\r\\n<li><p>Infants younger than 3 months with febrile UTI</p></li>\\r\\n</ul>\\r\\n<p><strong><span class=\\\"underline\\\">Children under 3 months of age</span></strong>:</p>\\r\\n<p>Samples should be sent for urine MC&amp;S and a full blood count. Blood culture and a lumbar puncture should be performed before starting on IV/IM Ampicillin and IV Gentamicin. Tailor antibiotic therapy to microbiology results. When the child is afebrile for at least 24 hours, oral antibiotics can then be given to complete 14 days of therapy.</p>\\r\\n<p><strong><span class=\\\"underline\\\">Pyelonephritis/ Complicated UTIs:</span></strong></p>\\r\\n<p>Send samples for blood culture, urine MC&amp;S and commence empirical parenteral antibiotics. Pregnant patients should receive IV ceftriaxone 1 – 2 g daily. Older children, men and non-pregnant women should be placed on IV Ampicillin 1 g 8 hourly plus IV Gentamicin 5-7.5 mg/kg once daily</p>\\r\\n<p>Antibiotic regimens should be reviewed using microbiology results. With clinical improvement, patients can be stepped down to oral therapy. Total duration of antibiotic therapy should be 14 days unless other complications occur.</p>\\r\\n<p>Patients who fail to improve after 48 hours (children) or 72 hours (adults) should receive a urinary tract ultrasound scan.</p>\\r\\n<h2 id=\\\"key-issues-for-nursing-care\\\">Key Issues for Nursing care</h2>\\r\\n<ul>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Catheter specimen samples are the best for urine MC&amp;S in children unable to understand instructions. However, where this is not feasible, sterile collection bags/pads can be used.</p>\\r\\n</div></li>\\r\\n<li><div data-custom-style=\\\"List Paragraph\\\">\\r\\n<p>Dipstick testing should not be used for detecting urinary tract infections in catheterized adults.</p>\\r\\n</div></li>\\r\\n</ul>\\r\\n<h2 id=\\\"references\\\">References</h2>\\r\\n<p>Tullus K. Difficulties in diagnosing urinary tract infections in small children. Pediatr nephrol 2011;26:1923-6.</p>\\r\\n<p>Salo J, Ikaheimo R, Tapiainen I Uhari M. Childhood urinary tract infection as a cause of chronic kidney disease. Pediatrics 2011;128:840-7.</p>\\r\\n<p>National Institute of Health and Care Excellence. Fever in under 5s: assessment and initial management. Available from: <a href=\\\"https://www.nice.org.uk/guidance/cg160\\\"><span data-custom-style=\\\"Hyperlink\\\">https://www.nice.org.uk/guidance/cg160</span></a> Accessed: 1<sup>st</sup> May, 2019</p>\\r\\n<p>National Institute of Health and Care Excellence. Urinary tract infection (lower): antimicrobial prescribing. Available from: <a href=\\\"https://www.nice.org.uk/guidance/ng109\\\"><span data-custom-style=\\\"Hyperlink\\\">https://www.nice.org.uk/guidance/ng109</span></a> Accessed: 1<sup>st</sup> May, 2019</p>\\r\\n<p>National Institute of Health and Care Excellence. Pyelonephritis (acute): antimicrobial prescribing Available from: <a href=\\\"https://www.nice.org.uk/guidance/ng111\\\"><span data-custom-style=\\\"Hyperlink\\\">https://www.nice.org.uk/guidance/ng111</span></a> Accessed: 1<sup>st</sup> May, 2019</p>\\r\\n<p>Ramakrishnan K, Scheid DC. Diagnosis and Management of Acute Pyelonephritis in Adults. Am Fam Physician. 2005 Mar 1;71(5):933-942.</p>\\r\\n<p>Colgan R, Williams M. Diagnosis and Treatment of Acute Pyelonephritis in Women. Am Fam Physician. 2011 Sep 1;84(5):519-526.</p>\\r\\n<table>\\r\\n<thead>\\r\\n<tr class=\\\"header\\\">\\r\\n<th><strong>Written by:</strong></th>\\r\\n<th>Name: Yorro Bah</th>\\r\\n<th>Date: 1<sup>st</sup> May 2019</th>\\r\\n</tr>\\r\\n</thead>\\r\\n<tbody>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td><strong>Reviewed by:</strong></td>\\r\\n<td>Name: Fatai Akemokwe</td>\\r\\n<td>Date: 1<sup>st</sup> May 2019</td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td><strong>Version:</strong></td>\\r\\n<td><strong>Change history:</strong></td>\\r\\n<td><strong>Review due date:</strong></td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>1.0</td>\\r\\n<td>New document</td>\\r\\n<td></td>\\r\\n</tr>\\r\\n<tr class=\\\"even\\\">\\r\\n<td>2.0</td>\\r\\n<td>Updated, scope broadened and transferred to new template</td>\\r\\n<td>31 May 2021</td>\\r\\n</tr>\\r\\n<tr class=\\\"odd\\\">\\r\\n<td>Review Comments (<em>if applicable)</em></td>\\r\\n<td></td>\\r\\n<td></td>\\r\\n</tr>\\r\\n</tbody>\\r\\n</table>\\r\\n</article>\\r\\n</body>\\r\\n</html>\\r\\n\",}","import React, { useState, useEffect } from 'react';\r\nimport { StyleSheet, ScrollView, Dimensions } from 'react-native';\r\nimport { MaterialBottomTabNavigationProp } from '@react-navigation/material-bottom-tabs';\r\nimport { useTheme } from 'react-native-paper';\r\nimport HTML from 'react-native-render-html';\r\nimport htmlFile from './data/output/filelist.js';\r\n\r\nimport overlay from './overlay';\r\n\r\ntype Props = {\r\n  navigation: MaterialBottomTabNavigationProp<{}>;\r\n};\r\n\r\nexport const Message = () => {\r\n  const theme = useTheme();\r\n\r\n  const backgroundColor = overlay(2, theme.colors.surface) as string;\r\n\r\n  const data = \"<h1>Please wait...</h1>\"\r\n  const [htmlString, setHtmlString] = useState(data);\r\n\r\n  useEffect(() => {\r\n    const index1 = \"047\";\r\n    const htmlString2 = htmlFile[index1];\r\n    setHtmlString(htmlString2);\r\n  }, );\r\n  \r\n  return (\r\n        <ScrollView contentContainerStyle={ styles.scrollViewContent }>\r\n\t\t\t<HTML html={htmlString} imagesMaxWidth= {Dimensions.get('window').width} />\r\n\t\t</ScrollView>\r\n  );\r\n\r\n};\r\n\r\nconst styles = StyleSheet.create({\r\n  scrollViewContent: {\r\n    paddingHorizontal: 10,\r\n  },\r\n});\r\n","import React from 'react';\r\nimport { StyleSheet, View } from 'react-native';\r\nimport { Surface, Text, Avatar, useTheme } from 'react-native-paper';\r\nimport { MaterialCommunityIcons } from '@expo/vector-icons';\r\nimport color from 'color';\r\n\r\ntype Props = {\r\n  id: string;\r\n  name: string;\r\n};\r\n\r\nexport const NotificationTwitt = (props: Props) => {\r\n  const theme = useTheme();\r\n\r\n  return (\r\n    <Surface style={styles.container}>\r\n      <View style={styles.leftColumn}>\r\n        <MaterialCommunityIcons\r\n          name=\"star-four-points\"\r\n          size={30}\r\n          color=\"#8d38e8\"\r\n        />\r\n      </View>\r\n      <View style={styles.rightColumn}>\r\n        <Text style={{ marginBottom: 10 }}>\r\n          {props.name}\r\n        </Text>\r\n      </View>\r\n    </Surface>\r\n  );\r\n};\r\n\r\nconst styles = StyleSheet.create({\r\n  container: {\r\n    flexDirection: 'row',\r\n    paddingTop: 15,\r\n    paddingRight: 15,\r\n    paddingBottom: 15,\r\n  },\r\n  leftColumn: {\r\n    width: 40,\r\n    marginRight: 10,\r\n    alignItems: 'flex-end',\r\n  },\r\n  rightColumn: {\r\n    flex: 1,\r\n  },\r\n  topRow: {\r\n    flexDirection: 'row',\r\n    alignItems: 'center',\r\n    marginBottom: 10,\r\n  },\r\n});\r\n","import React from 'react';\r\nimport { View, FlatList, StyleSheet } from 'react-native';\r\nimport { useTheme } from 'react-native-paper';\r\n\r\nimport { NotificationTwitt } from './components/notificationTwitt';\r\nimport { notificationTweets } from './data/index.ts';\r\n\r\ntype NotificationTwittProps = React.ComponentProps<typeof NotificationTwitt>;\r\n\r\nfunction renderItem({ item }: { item: NotificationTwittProps }) {\r\n  return <NotificationTwitt {...item} />;\r\n}\r\n\r\nfunction keyExtractor(item: NotificationTwittProps) {\r\n  return item.id;\r\n}\r\n\r\nexport const AllChanges = () => {\r\n  const theme = useTheme();\r\n\r\n  return (\r\n    <FlatList\r\n      contentContainerStyle={{ backgroundColor: theme.colors.background }}\r\n      style={{ backgroundColor: theme.colors.background }}\r\n      data={notificationTweets}\r\n      renderItem={renderItem}\r\n      keyExtractor={keyExtractor}\r\n      ItemSeparatorComponent={() => (\r\n        <View style={{ height: StyleSheet.hairlineWidth }} />\r\n      )}\r\n    />\r\n  );\r\n};\r\n","import React from 'react';\r\nimport { ScrollView, StyleSheet } from 'react-native';\r\nimport { Headline, Caption, useTheme, Button } from 'react-native-paper';\r\nimport * as Linking from 'expo-linking';\r\n\r\nimport overlay from './overlay';\r\n\r\nexport const AllNotifications = () => {\r\n  const theme = useTheme();\r\n\r\n  const backgroundColor = overlay(2, theme.colors.surface) as string;\r\n\r\n  const _handlePress = () => {\r\n    Linking.openURL('mailto: csdapp@mrc.gm');\r\n  };\r\n\r\n  return (\r\n    <ScrollView\r\n      style={{ backgroundColor }}\r\n      contentContainerStyle={[styles.scrollViewContent, { backgroundColor }]}\r\n    >\r\n      <Headline style={styles.centerText}>\r\n        Thanks for installing our guidelines app.\r\n      </Headline>\r\n      <Caption style={styles.centerText}>\r\n        This app is designed to provide doctors and nurses with quick offline access to the clinical guidelines of the Clinical Services Department of the MRC Unit The Gambia at LSHTM. {'\\n'}It does not need an internet connection to be used. An internet connection is needed for updates which will download automatically whenever new guidelines are published. {'\\n'}For feedback or support, click the button below:\r\n      </Caption>\r\n      <Button\r\n        onPress={_handlePress}\r\n        style={styles.button}\r\n        mode=\"contained\"\r\n        labelStyle={{ color: 'white' }}\r\n      >\r\n        Contact Us\r\n      </Button>\r\n    </ScrollView>\r\n  );\r\n};\r\n\r\nconst styles = StyleSheet.create({\r\n  scrollViewContent: {\r\n    flex: 1,\r\n    paddingHorizontal: 30,\r\n    justifyContent: 'center',\r\n    alignItems: 'center',\r\n  },\r\n  centerText: {\r\n    textAlign: 'center',\r\n  },\r\n  button: {\r\n    marginTop: 20,\r\n  },\r\n});","import React from 'react';\r\nimport color from 'color';\r\nimport { Dimensions } from 'react-native';\r\nimport { useTheme } from 'react-native-paper';\r\nimport { TabView, SceneMap, TabBar } from 'react-native-tab-view';\r\n\r\nimport overlay from './overlay';\r\nimport { AllChanges} from './changes.tsx';\r\nimport { AllNotifications } from './all';\r\n\r\nconst initialLayout = { width: Dimensions.get('window').width };\r\n\r\nconst All = () => <AllNotifications />;\r\n\r\nconst Mentions = () => <AllChanges />;\r\n\r\nexport const Notifications = () => {\r\n  const [index, setIndex] = React.useState(0);\r\n  const [routes] = React.useState([\r\n    { key: 'all', title: 'About' },\r\n    { key: 'mentions', title: \"What's New\" },\r\n  ]);\r\n\r\n  const theme = useTheme();\r\n\r\n  const renderScene = SceneMap({\r\n    all: All,\r\n    mentions: Mentions,\r\n  });\r\n\r\n  const tabBarColor = theme.dark\r\n    ? (overlay(4, theme.colors.surface) as string)\r\n    : theme.colors.surface;\r\n\r\n  const rippleColor = theme.dark\r\n    ? color(tabBarColor).lighten(0.5)\r\n    : color(tabBarColor).darken(0.2);\r\n\r\n  const renderTabBar = props => (\r\n    <TabBar\r\n      {...props}\r\n      indicatorStyle={{ backgroundColor: theme.colors.primary }}\r\n      style={{ backgroundColor: tabBarColor, shadowColor: theme.colors.text }}\r\n      labelStyle={{ color: theme.colors.primary }}\r\n      pressColor={rippleColor}\r\n    />\r\n  );\r\n\r\n  return (\r\n    <React.Fragment>\r\n      <TabView\r\n        navigationState={{ index, routes }}\r\n        renderScene={renderScene}\r\n        onIndexChange={setIndex}\r\n        initialLayout={initialLayout}\r\n        renderTabBar={renderTabBar}\r\n      />\r\n    </React.Fragment>\r\n  );\r\n};\r\n","import React from 'react';\r\nimport color from 'color';\r\nimport { createMaterialBottomTabNavigator } from '@react-navigation/material-bottom-tabs';\r\nimport { useTheme } from 'react-native-paper';\r\nimport { useSafeArea } from 'react-native-safe-area-context';\r\nimport { useIsFocused, RouteProp } from '@react-navigation/native';\r\n\r\nimport overlay from './overlay';\r\nimport { Feed } from './feed';\r\nimport { Message } from './message';\r\nimport { Notifications } from './notifications';\r\nimport { StackNavigatorParamlist } from './types';\r\n\r\nconst Tab = createMaterialBottomTabNavigator();\r\n\r\ntype Props = {\r\n  route: RouteProp<StackNavigatorParamlist, 'FeedList'>;\r\n};\r\n\r\nexport const BottomTabs = (props: Props) => {\r\n  const routeName = props.route.state\r\n    ? props.route.state.routes[props.route.state.index].name\r\n    : 'Feed';\r\n\r\n  const theme = useTheme();\r\n  const safeArea = useSafeArea();\r\n  const isFocused = useIsFocused();\r\n\r\n  const tabBarColor = theme.dark\r\n    ? (overlay(6, theme.colors.surface) as string)\r\n    : theme.colors.surface;\r\n\r\n  return (\r\n    <React.Fragment>\r\n      <Tab.Navigator\r\n        initialRouteName=\"Messages\"\r\n        backBehavior=\"initialRoute\"\r\n        shifting={true}\r\n        activeColor={theme.colors.primary}\r\n        inactiveColor={color(theme.colors.text)\r\n          .alpha(0.6)\r\n          .rgb()\r\n          .string()}\r\n        sceneAnimationEnabled={false}\r\n      >\r\n        <Tab.Screen\r\n          name=\"Messages\"\r\n          component={Message}\r\n          options={{\r\n            tabBarIcon: 'home-outline',\r\n            tabBarLabel: \"Home\",\r\n            tabBarColor,\r\n          }}\r\n        />\r\n        <Tab.Screen\r\n          name=\"Feed\"\r\n          component={Feed}\r\n          options={{\r\n            tabBarIcon: 'feature-search-outline',\r\n            tabBarLabel: \"Search\",\r\n            tabBarColor,\r\n          }}\r\n        />\r\n        <Tab.Screen\r\n          name=\"Notifications\"\r\n          component={Notifications}\r\n          options={{\r\n            tabBarIcon: 'information-outline',\r\n            tabBarLabel: \"Info\",\r\n            tabBarColor,\r\n          }}\r\n        />\r\n      </Tab.Navigator>\r\n    </React.Fragment>\r\n  );\r\n};\r\n","import React from 'react';\r\nimport { StyleSheet, ScrollView, Dimensions  } from 'react-native';\r\nimport {\r\n  useTheme,\r\n} from 'react-native-paper';\r\nimport color from 'color';\r\nimport fileList from '../data/output/filelist.js'\r\nimport HTML from 'react-native-render-html';\r\n\r\ntype Props = {\r\n  id: string;\r\n  name: string;\r\n};\r\n\r\nexport const DetailedTwitt = (props: Props) => {\r\n  const theme = useTheme();\r\n  const file = props.id;\r\n  const htmlString = fileList[file];\r\n  return (\r\n        <ScrollView contentContainerStyle={ styles.scrollViewContent }>\r\n\t\t\t<HTML html={htmlString} imagesMaxWidth= {Dimensions.get('window').width} />\r\n\t\t</ScrollView>\r\n  );\r\n};\r\n\r\nconst styles = StyleSheet.create({\r\n  scrollViewContent: {\r\n    paddingHorizontal: 10,\r\n  },\r\n});\r\n","import React from 'react';\r\nimport { RouteProp } from '@react-navigation/native';\r\n\r\nimport { DetailedTwitt } from './components/detailedTwitt';\r\nimport { StackNavigatorParamlist } from './types';\r\n\r\ntype Props = {\r\n  route: RouteProp<StackNavigatorParamlist, 'Details'>;\r\n};\r\n\r\nexport const Details = (props: Props) => {\r\n  return <DetailedTwitt {...props.route.params} />;\r\n};\r\n","import React from 'react';\r\nimport { TouchableOpacity } from 'react-native';\r\nimport { createStackNavigator } from '@react-navigation/stack';\r\nimport { DrawerNavigationProp } from '@react-navigation/drawer';\r\nimport { Appbar, Avatar, useTheme } from 'react-native-paper';\r\nimport { MaterialCommunityIcons } from '@expo/vector-icons';\r\n\r\nimport { BottomTabs } from './bottomTabs';\r\nimport { Details } from './details';\r\nimport { StackNavigatorParamlist } from './types';\r\n\r\nconst Stack = createStackNavigator<StackNavigatorParamlist>();\r\n\r\nexport const StackNavigator = () => {\r\n  const theme = useTheme();\r\n\r\n  return (\r\n    <Stack.Navigator\r\n      initialRouteName=\"FeedList\"\r\n      headerMode=\"screen\"\r\n      screenOptions={{\r\n        header: ({ scene, previous, navigation }) => {\r\n          const { options } = scene.descriptor;\r\n          const title =\r\n            options.headerTitle !== undefined\r\n              ? options.headerTitle\r\n              : options.title !== undefined\r\n              ? options.title\r\n              : scene.route.name;\r\n\r\n          return (\r\n            <Appbar.Header\r\n              theme={{ colors: { primary: theme.colors.surface } }}\r\n            >\r\n              {previous ? (\r\n                <Appbar.BackAction\r\n                  onPress={navigation.goBack}\r\n                  color={theme.colors.primary}\r\n                />\r\n              ) : (\r\n                <TouchableOpacity\r\n                  style={{ marginLeft: 10 }}\r\n                  onPress={() => {\r\n                    ((navigation as any) as DrawerNavigationProp<{}>).openDrawer();\r\n                  }}\r\n                >\r\n                  <Avatar.Image\r\n                    size={40}\r\n                    source={require('./icon.png')} \r\n                  />\r\n                </TouchableOpacity>\r\n              )}\r\n              <Appbar.Content\r\n                title={\r\n                    \"CSD Guidelines\"\r\n                }\r\n                subtitle={\r\n                    \"MRC Unit The Gambia at LSHTM\"\r\n                }\r\n                titleStyle={{\r\n                  fontSize: 18,\r\n                  fontWeight: 'bold',\r\n                  color: theme.colors.primary,\r\n                }}\r\n                subtitleStyle={{\r\n                  fontSize: 12,\r\n                  fontWeight: 'bold',\r\n                  color: theme.colors.text,\r\n                }}\r\n              />\r\n            </Appbar.Header>\r\n          );\r\n        },\r\n      }}\r\n    >\r\n      <Stack.Screen\r\n        name=\"FeedList\"\r\n        component={BottomTabs}\r\n        options={({ route }) => {\r\n          console.log('!@# options', { route });\r\n          const routeName = route.state\r\n            ? route.state.routes[route.state.index].name\r\n            : 'Feed';\r\n          return { headerTitle: routeName };\r\n        }}\r\n      />\r\n      <Stack.Screen\r\n        name=\"Details\"\r\n        component={Details}\r\n        options={{ headerTitle: 'Tweet' }}\r\n      />\r\n    </Stack.Navigator>\r\n  );\r\n};\r\n","import React from 'react';\r\n\r\ntype PreferencesContextType = {\r\n  theme: 'light' | 'dark';\r\n  rtl: 'left' | 'right';\r\n  toggleTheme: () => void;\r\n  toggleRTL: () => void;\r\n};\r\n\r\nexport const PreferencesContext = React.createContext<PreferencesContextType>({\r\n  rtl: 'left',\r\n  theme: 'light',\r\n  toggleTheme: () => {},\r\n  toggleRTL: () => {},\r\n});\r\n","import { MaterialCommunityIcons } from '@expo/vector-icons';\r\nimport {\r\n  DrawerContentComponentProps,\r\n  DrawerContentOptions,\r\n  DrawerContentScrollView,\r\n  DrawerItem,\r\n} from '@react-navigation/drawer';\r\nimport React from 'react';\r\nimport { StyleSheet, TouchableOpacity, View } from 'react-native';\r\nimport {\r\n  Avatar,\r\n  Caption,\r\n  Drawer,\r\n  Paragraph,\r\n  Switch,\r\n  Text,\r\n  Title,\r\n  TouchableRipple,\r\n  useTheme,\r\n} from 'react-native-paper';\r\nimport Animated from 'react-native-reanimated';\r\n\r\nimport { PreferencesContext } from './context/preferencesContext';\r\n\r\ntype Props = DrawerContentComponentProps<DrawerNavigationProp>;\r\n\r\nexport function DrawerContent(props: Props) {\r\n  const paperTheme = useTheme();\r\n  const { theme, toggleTheme } = React.useContext(\r\n    PreferencesContext\r\n  );\r\n\r\n  const translateX = Animated.interpolate(props.progress, {\r\n    inputRange: [0, 0.5, 0.7, 0.8, 1],\r\n    outputRange: [-100, -85, -70, -45, 0],\r\n  });\r\n\r\n  return (\r\n    <DrawerContentScrollView {...props}>\r\n      <Animated.View\r\n        //@ts-ignore\r\n        style={[\r\n          styles.drawerContent,\r\n          {\r\n            backgroundColor: paperTheme.colors.surface,\r\n            transform: [{ translateX }],\r\n          },\r\n        ]}\r\n      >\r\n        <View style={styles.userInfoSection}>\r\n          <TouchableOpacity\r\n            style={{ marginLeft: 10 }}\r\n            onPress={() => {\r\n              props.navigation.toggleDrawer();\r\n            }}\r\n          >\r\n            <Avatar.Image\r\n              source={require('./icon.png')} \r\n              size={80}\r\n            />\r\n          </TouchableOpacity>\r\n          <Title style={styles.title}>CSD Guidelines</Title>\r\n          <Caption style={styles.caption}>MRC Unit at the LSHTM </Caption>\r\n        </View>\r\n        <Drawer.Section title=\"Preferences\">\r\n          <TouchableRipple onPress={toggleTheme}>\r\n            <View style={styles.preference}>\r\n              <Text>Dark Theme</Text>\r\n              <View pointerEvents=\"none\">\r\n                <Switch value={theme === 'dark'} />\r\n              </View>\r\n            </View>\r\n          </TouchableRipple>\r\n        </Drawer.Section>\r\n      </Animated.View>\r\n    </DrawerContentScrollView>\r\n  );\r\n}\r\n\r\nconst styles = StyleSheet.create({\r\n  drawerContent: {\r\n    flex: 1,\r\n  },\r\n  userInfoSection: {\r\n    paddingLeft: 20,\r\n  },\r\n  title: {\r\n    marginTop: 20,\r\n    fontWeight: 'bold',\r\n  },\r\n  caption: {\r\n    fontSize: 14,\r\n    lineHeight: 14,\r\n  },\r\n  row: {\r\n    marginTop: 20,\r\n    flexDirection: 'row',\r\n    alignItems: 'center',\r\n  },\r\n  section: {\r\n    flexDirection: 'row',\r\n    alignItems: 'center',\r\n    marginRight: 15,\r\n  },\r\n  paragraph: {\r\n    fontWeight: 'bold',\r\n    marginRight: 3,\r\n  },\r\n  drawerSection: {\r\n    marginTop: 15,\r\n  },\r\n  preference: {\r\n    flexDirection: 'row',\r\n    justifyContent: 'space-between',\r\n    paddingVertical: 12,\r\n    paddingHorizontal: 16,\r\n  },\r\n});\r\n","import React from 'react';\r\nimport { NavigationContainer } from '@react-navigation/native';\r\nimport { createDrawerNavigator } from '@react-navigation/drawer';\r\nimport { DefaultTheme, DarkTheme } from '@react-navigation/native';\r\nimport { useTheme } from 'react-native-paper';\r\n\r\nimport { StackNavigator } from './stack';\r\nimport { DrawerContent } from './drawerContent';\r\n\r\nconst Drawer = createDrawerNavigator();\r\n\r\nexport const RootNavigator = () => {\r\n  const theme = useTheme();\r\n  const navigationTheme = theme.dark ? DarkTheme : DefaultTheme;\r\n\r\n  return (\r\n    <NavigationContainer theme={navigationTheme}>\r\n      <Drawer.Navigator drawerContent={props => <DrawerContent {...props} />}>\r\n        <Drawer.Screen name=\"Home\" component={StackNavigator} />\r\n      </Drawer.Navigator>\r\n    </NavigationContainer>\r\n  );\r\n};\r\n","import React from 'react';\r\nimport {\r\n  Provider as PaperProvider,\r\n  DefaultTheme,\r\n  DarkTheme,\r\n} from 'react-native-paper';\r\nimport { Updates } from 'expo';\r\nimport { useColorScheme } from 'react-native-appearance';\r\n\r\nimport { RootNavigator } from './rootNavigator';\r\nimport { PreferencesContext } from './context/preferencesContext';\r\n\r\nexport const Main = () => {\r\n  const colorScheme = useColorScheme();\r\n  const [theme, setTheme] = React.useState<'light' | 'dark'>(\r\n    colorScheme === 'dark' ? 'dark' : 'light'\r\n  );\r\n\r\n  function toggleTheme() {\r\n    setTheme(theme => (theme === 'light' ? 'dark' : 'light'));\r\n  }\r\n\r\n  const preferences = React.useMemo(\r\n    () => ({\r\n      toggleTheme,\r\n      theme\r\n    }),\r\n    [theme]\r\n  );\r\n\r\n  return (\r\n    <PreferencesContext.Provider value={preferences}>\r\n      <PaperProvider\r\n        theme={\r\n          theme === 'light'\r\n            ? {\r\n                ...DefaultTheme,\r\n                colors: { ...DefaultTheme.colors, primary: '#1ba1f2' },\r\n              }\r\n            : {\r\n                ...DarkTheme,\r\n                colors: { ...DarkTheme.colors, primary: '#1ba1f2' },\r\n              }\r\n        }\r\n      >\r\n        <RootNavigator />\r\n      </PaperProvider>\r\n    </PreferencesContext.Provider>\r\n  );\r\n};\r\n","import React from 'react';\r\nimport { SafeAreaProvider } from 'react-native-safe-area-context';\r\nimport { AppearanceProvider } from 'react-native-appearance';\r\n\r\nimport { Main } from './src/main';\r\n\r\nexport default function App() {\r\n  return (\r\n    <SafeAreaProvider>\r\n      <AppearanceProvider>\r\n        <Main />\r\n      </AppearanceProvider>\r\n    </SafeAreaProvider>\r\n  );\r\n}\r\n","/* eslint-env browser */\n\nif ('serviceWorker' in navigator) {\n  window.addEventListener('load', function () {\n    navigator.serviceWorker\n      .register('/expo-service-worker.js', { scope: '/' })\n      .then(function (info) {\n        // console.info('Registered service-worker', info);\n      })\n      .catch(function (error) {\n        console.info('Failed to register service-worker', error);\n      });\n  });\n}\n"],"sourceRoot":""}